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David L. Luke III 
(1923–2014)
 Fanny (Curtis) Luke
(1923–2014)
In 2014, we lost both David and Fanny Luke. Fanny passed on October 16, and David joined his 
beloved wife of nearly 60 years soon thereafter on December 13. Their lives began and ended in 
the same years.
In 1999, the Cold Spring Harbor Laboratory Board of Trustees and then President Jim Watson 
hosted a “Tribute to the Legacy of David L. Luke III.” David and Fanny had already done so much 
for the Laboratory. Their support and friendship continued strong into the new millennium. As 
we mourn their deaths, I write this remembrance of their transformative legacy at this institution.
Fanny graduated from the Westover School in 1941, and in 1943, she joined the U.S. Navy 
WAVES. She was involved in the fi nal modifi cation of combat aircraft for U.S. Naval Forces in the 
Pacifi c Theatre, including the planes her future husband David would fl y. She completed her military 
service in 1946 and then attended Radcliffe College, receiving a B.A. degree in 1951. Fanny worked 
briefl y for Houghton Miffl in and also for Harvard University before moving back to New York. In 
New York, she took courses at the Bank Street College of Education and then devoted nearly 12 years 
to teaching young children. From 1972 to 1980 she served on the Board of the Westover School. She 
was also a member of the Board of the City Gardens Club and served for 2 years as its president.
Having graduated from the Hotchkiss School, David entered Yale University in 1941, but left 
after Pearl Harbor for naval aviation fl ight training. He received his naval aviator’s wings and a 
commission in the Marine Corps in June 1943. He saw combat in the Pacifi c over the Marianas 
and Okinawa. After military service, Mr. Luke returned to graduate from Yale in 1948, and then 
he joined the American Research and Development Corporation. He went to New York City 
3 years later to begin a distinguished career with the Westvaco Corporation.
The Luke family established the Westvaco Corporation in 1888, and by the time David joined 
its corporate fi nancial staff in 1952, the company was thriving not merely as a producer of paper 
and packaging products but as a developer of new technologies for forestry, tree breeding, and 
manufacturing. David steadily advanced through the executive ranks to become President in 1962 
and also Chief Executive Offi cer in 1963. He became Chairman in 1980, retiring from that posi-
tion in 1996.
After purchasing a home in Locust Valley in 1971, David and Fanny almost naturally found 
themselves at Cold Spring Harbor Laboratory. To David, CSHL’s renowned reputation in plant 
biology and genetics was practically irresistible. After attending only a few meetings with long-
time family friend and soon-to-be CSHL Chairman Barney Clarkson, David joined the Board 
in 1986 and quickly rose to the position of treasurer. He became Chairman of CSHL’s Board of 
Trustees in 1992.
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When David came to the Board, the Laboratory’s plant genetics program was at a turning point 
as the need for modern infrastructure intersected with advances in genome sequencing technolo-
gies. He boldly chaired the Second Century Fund, raising more than $50 million to meet these 
challenges at the dawn of the Laboratory’s second century in 1990. The Second Century Fund 
initiative allowed CSHL to build the Beckman Neuroscience Center and powerfully enter the 
fi eld of neuroscience. These funds also expanded our education programs by allowing for more 
visiting scientists to attend conferences and courses.
With the success of the Second Century Fund behind him, Chairman Luke was eager to do more. 
Jim Watson remarked that “David was acutely aware that in order for any organization to be suc-
cessful in its endeavors—be it corporate or non-profi t—it needs to be fi nancially sound.” David saw 
opportunities to refocus the Laboratory’s policies on commercial relations and technology transfer. 
In 1992, he also spearheaded the establishment of a new component of the Laboratory’s endowment, 
the Science Fund. This is a pool into which the proceeds from commercialization of the Laboratory’s 
scientifi c research would be placed. I know he would be pleased by our current commercialization 
efforts that are sparking new companies and bringing our research more rapidly to the clinic.
Under David’s chairmanship, CSHL acquired 12 acres in Woodbury that would be the home 
of the Genome Center, the CSHL Press, and a state-of-the-art greenhouse. In 2015, the Preclini-
cal Experimental Therapeutics (PETx) facility will open at Woodbury to support advanced drug 
testing opportunities as part of the Cancer Therapeutics Initiative.
In 1997, the Board of Trustees made the historic decision to establish a Ph.D.-granting program 
at CSHL. David and Fanny showed great leadership in this effort, creating a fellowship that fully 
supports one student each year, in perpetuity. When David stepped down as board chairman in 
1998, he became an Honorary Trustee and assumed a new role as chairman of the Capital Cam-
paign for the Watson School of Biological Sciences.
Westvaco Corporation, now MeadWestvaco and led by David’s nephew, John A. Luke, Jr., has a 
signifi cant research program on plant science, and David was always interested in bringing our two 
research organizations together to think about ways to improve tree growth and yield per acre. David 
recognized the importance of our basic plant science, and he and Fanny continued to support this 
research up until their death. David was also fascinated by the telomere research by former CSHL 
scientist and Nobel laureate Carol Greider, intrigued by the possibility that telomeres would be the 
secret to longevity. David always took great pride in understanding the research at the Laboratory, 
asking probing and insightful questions as well as being proud of our accomplishments. David was 
one of our most active board chairs, and through his tenure on our board, the Laboratory went 
through signifi cant expansion and a key leadership change.
In recognition of David’s outstanding contributions to CSHL, the renovated Power House 
building that holds administrative offi ces was named the Luke Building. I enjoy my visits there, 
always passing by the beautiful portrait of David and Fanny that greets all building visitors.
Since the start of the new millennium, not a year has gone by without notes from David 
or Fanny accompanied by generous donations to the Laboratory’s research and education pro-
grams. We were grateful for this continued support that has recognized CSHL events including 
the Women’s Partnership Luncheons, the Double Helix Medals Dinner, and Jim Watson’s 80th 
birthday year, as well as campaigns to support the annual fund and larger initiatives such as the 
capital campaign for the Hillside Laboratory complex completed in 2009.
David and Fanny made many friends at the Laboratory over the last three decades and we all 
feel their loss deeply. They left so much of themselves with us personally and to the benefi t of our 
institution that I would like to think they will always be with us. Our deepest gratitude to them 
and their family who shared them with us.
Bruce Stillman
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In 2015, Cold Spring Harbor Laboratory marks the 125th anniversary of its founding. In 1890, 
our institutional ancestor, The Biological Laboratory, brought together a small group of biology 
teachers. A pristine tidal estuary off the Long Island Sound provided these men and women with 
a living laboratory in which to explore the principles of Darwinian evolution. This was, in retro-
spect, a wonderful anticipation of the “hands-on” principle of learning by doing that the contem-
porary DNA Learning Center (DNALC) has spread far and wide. Our institutional DNA also 
refl ects an investment made in the fi rst years of the twentieth century by the Carnegie Institution 
of Washington. It breathed life into a Field Station for evolutionary studies at Cold Spring Harbor, 
merging Gregor Mendel’s ideas on inheritable traits with Charles Darwin’s explanation of natural 
selection. Housed in the structure we now call the Carnegie Building, the Field Station conducted 
experiments inspired by the re-discovery of Mendel’s research on quantitative traits that he fi rst 
presented exactly 150 years ago.
I would like to take the occasion of our quasquicentennial not only to remember our rich his-
tory, but to look forward. The contemporary Laboratory is the product of an evolutionary process 
in which major capabilities have been continuously added—particularly since 1968, the year Jim 
Watson was named Director. For friends and supporters of the Laboratory, I want to start by re-
fl ecting on what I think is most extraordinary about what we are today and then suggest how this 
informs the path we intend to take in the years ahead, indicating the critical role of the Labora-
tory’s new Capital Campaign.
I cannot think of a contemporary institution, anywhere in the world, that does what Cold 
Spring Harbor Laboratory does. It is an institution like no other. We are not only a research 
institution of the highest caliber, we are also a major innovator in biology education. Dr. Francis 
 Collins, one of the prime movers in the Human Genome Project and for the last 5 years the 
 Director of the National Institutes of Health, had it right when he noted some years ago that 
“Cold Spring Harbor has placed itself at the center of great science and great education.”
The educational part of our mission, a legacy of our earliest days, is indeed singular. Our 
campus is a crossroads of professional activity in the biomedical and life sciences. That repu-
tation refl ects the richness of our Meetings program, which brings nearly 9000 scientists to 
Bungtown Road each year and another 3000 to our meetings center in Suzhou, China. In the 
lobby of Grace Auditorium between meeting sessions, you are likely to see distinguished profes-
sors mixing with postdoctoral fellows and graduate students, an experience I encountered when, 
as a second-year graduate student, I was fortunate to speak at the Symposium celebrating the 
25th anniversary of the discovery of the double helix structure. There is a kind of intellectual 
quickening that occurs in these situations that is priceless. The same can be said for what hap-
pens among those who participate in the over two dozen professional Courses we offer annually, 
which collectively serve to advance the entire fi eld’s capabilities in the latest technologies and 
methods.
The impact of our educational program further refl ects the excellence of our “think-tank”-
inspired programs at Banbury Center and the wide-ranging efforts of the Cold Spring Harbor 
Laboratory Press to publish high-impact research journals as well as lab handbooks and mono-
graphs on important subjects across the biological sciences. All this activity probably qualifi es our 
educational program as unusual, particularly for a research laboratory. But there are two critical 
components I have not yet mentioned. One is the DNA Learning Center. Its prodigious efforts 
over a quarter-century have brought the insight and plain fun of hands-on biological experimenta-
tion to hundreds of thousands of Long Island youths, most of them of middle- and high-school 
age, as well as thousands of their teachers. The DNALC also has educated millions globally, both 
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at centers established in many countries and through over two dozen educational websites that 
travel everywhere, instantly and for free, via the Internet.
The other critical component is our bold experiment in graduate education, the Watson 
School of Biological Sciences. Now in its 16th year, the school has performed as well as we had 
hoped in the 1990s. Watson School students, along with students from nearby Stony Brook 
University and nearly 200 postdoctoral fellows, add vibrancy to life on our campus. It is the 
combined breadth of our educational and basic research activities that makes Cold Spring Har-
bor Laboratory different. The graduate education program complements the long-standing ad-
vanced courses that we teach for scientists who come to learn new techniques and approaches 
to a fi eld of science.
How do we sustain and expand upon the excellence I have just described? We may be a singular 
kind of place, but we are facing the same challenges that other institutions face. Never in my 20-
year tenure in guiding our science have we been in an environment in which securing operational 
funds has been more challenging, mostly because of the dramatic reductions in federal funding of 
science—particularly of fundamental discovery science. In support of both our educational and 
research missions, therefore, the Laboratory is embarking on a “125th Capital Campaign.” It is 
one that looks to the future and seeks to secure the means that will enable us to continue playing 
the wide-ranging, truly unique role that I have described. The fact is that if Cold Spring Harbor 
is to remain “a Lab like no other,” it will have to signifi cantly add to its endowment. Our goal for 
the Campaign is to raise at least $250 million.
Some $50 million of this sum will enable our extraordinary educational offerings to continue 
to thrive. About $13 million will endow student fellowships at the Watson School. These are 
critical in sustaining one of the school’s key innovations. Every student accepted for the program 
knows that he or she, or their research mentor, is not going to have to worry about securing funds 
to support their stipend. Our primary goal is to bring the best students here and provide them the 
freedom to blossom as future leaders in the fi eld. The Meetings and Courses Program will also 
benefi t from an initial endowment because the pressures on federal funding no longer make it ob-
vious that we should receive support for training scientists. As we note each year in this  report, the 
excellence of our program has critically depended on corporate donations. Those funds have de-
clined, in part because of business consolidation among companies but also because of  diminished 
corporate and federal investments in education—hence the need for private support to sustain 
these highly infl uential courses. Another portion of the educational endowment will help provide 
much-needed funds for the DNA Learning Center, including our plans to build a fl agship site in 
Manhattan that will directly serve students in the nation’s largest public school system. I can think 
of no more important investment in America’s future.
The bulk of the Capital Campaign—some $200 million—will endow research at Cold Spring 
Harbor Laboratory, the excellence of which is the bedrock of our reputation. Two factors make 
the success of the Campaign essential. First, the cost of doing research has skyrocketed since the 
dawn of the genome era. Genome science is powerful, but costly to do—and those costs have risen 
steadily at a rate signifi cantly exceeding that of infl ation. As the pie chart on this page indicates, 
only about 40% of the Laboratory’s research operating budget is now supported by federal grants. 
Even as the government’s contribution has declined over the last decade, a second factor has come 
into play. Today, the amount of money an investigator can expect to receive from a typical “modu-
lar” government grant is frozen at $250,000. If these grants had kept up with infl ation in recent 
years, they would now amount to $340,000. Our investigators are receiving less money to perform 
work that costs much more to do. This is seriously eroding the ability of scientists at CSHL and 
elsewhere to plan ambitious and innovative programs of research. But we are not throwing our 
hands up in exasperation. Instead, we are seeking help from nongovernmental sources—private 
individuals, foundations, enlightened corporations—to endow operations critical for Cold Spring 
Harbor Laboratory’s continuing leadership in discovery science.
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In research, the Capital Campaign will endow programs that are a critical part of our ongoing 
Cancer Therapeutics Initiative (CTI), as well as the President’s Fund that will support the most 
basic science and the infrastructure to enable innovation. The CTI represents our effort to identify 
targets for better cancer drugs. For decades, CSHL has been a world leader in developing tools 
and methods to characterize the genetic changes that are among cancer’s hallmarks. Our under-
standing of cancer genetics and the interaction between cancer cells and the surrounding tissue 
cells now provides us with a realistic chance to reduce certain forms of cancer to at least chronic 
illnesses, manageable over long periods of time, if not attain true cures. Technologies developed at 
CSHL have made it possible to compare the genomic properties of cancerous versus healthy cells; 
to model human cancers with remarkable fi delity in mice; and to shut off genes one by one in 
animal models to dissect genetic and biochemical pathways that drive cancers. We are now at an 
infl ection point. Our next step—and one of the key goals of the Capital Campaign—is to inte-
grate cancer genetics with cancer cell metabolism and whole-organism physiology.
Our new thrust recognizes the importance of thinking about human health in organismal 
terms. By this I mean understanding disease—cancer, but other diseases as well—not just in terms 
of what goes wrong in specifi c cells or tissues, but in terms of the functioning of the entire human 
system. The biology of the whole affects what diseases we get. One example is the immune system. 
We are learning, through the work of faculty members including Mikala Egeblad, Douglas 
Fearon, and David Tuveson, about how stromal tissue—the environment in which cancers de-
velop and thrive—interacts with tumors to affect their course. Nicholas Tonks is exploring the 
relationship between metabolism and cancer. His recent work provides insights into linkages be-
tween the biology of nutrition and disease. Obesity is a state that has broad impacts on the human 
system; it plays a role in causing diseases, including cancer. Aging affects the entire human system; 
its processes impact disease susceptibility. Our scientists now have clues that other changes over 
the life span, for instance, pregnancy, appear to alter disease susceptibility, in this case for breast 
cancer. What causes ductal-cell precursors in breast tissue to be differentially responsive to onco-
genesis—but only if a woman has had a baby before a certain age? How is this effect sustained 
over many years?
Funds raised through the Capital Campaign will support our exploration of these kinds of 
questions. We will renovate the Demerec Laboratory, a research building dating from the 1950s 
where four Nobel laureates have worked, to provide state-of-the-art facilities supporting a Cen-
ter for Therapeutics Research. As part of this new initiative, we will integrate studies on cancer 
metabolism and nutrition into CSHL’s already strong cancer program. Building on our ability 
to examine cancer cells and tissue at the single-cell level and employing advanced genomics de-
veloped here, the new core facilities will enable our scientists to identify metabolic and oxidative 
vulnerabilities of cancers that have heretofore remained resistant to therapy.
The Capital Campaign will also add to the capabilities of our Preclinical Experimental Thera-
peutics (PETX) facility, which will open on our Woodbury campus in 2015. We hope that PETX 
will enable Cold Spring Harbor Laboratory to deliver well-validated drug candidates to industry. 
The PETX facility encompasses two core facilities. One enables us to conduct drug testing in 
animal models for cancer that recapitulate cancer in patients. In particular, we look forward to 
testing novel drug combinations in these models, which is hard to do in human trials. The other 
core function in the PETX facility is advanced imaging. Our scientists will be able to look in real 
time at the progression of different cancers, particularly cancers being treated with experimental 
therapeutics. We want to assess not only whether particular drugs are working in our models, but 
also how they are working. About 40 years of fundamental cancer research has brought us to the 
stage where rational approaches to cancer therapy are now possible. I look forward to the day, in 
the not-too-distant future, when our neuroscientists will likewise apply their knowledge of how 
the brain works to use the PETX facility to advance treatments of the numerous neurological and 
psychiatric disorders.
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Cold Spring Harbor Laboratory has had a very important impact on science over its 125-year 
history. The mix of basic research and education comes together in a model that is well proven. 
The Capital Campaign will ensure that the Laboratory continues to be an innovator and a world 
leader in fundamental discovery science—which is critical to our future, even in times of restrict-
ed federal support of such science. I hope you will support it.
Bruce Stillman, Ph.D., F.R.S.
President and Chief Executive Officer
5Highlights of the Year
Research
Cold Spring Harbor Laboratory is a world-renowned center of research in Cancer, Neuroscience, Plant Genet-
ics, Quantitative Biology, and Genomics. The research environment is highly collaborative. Scientists at the 
Laboratory work together, frequently across disciplines, to solve biology’s most challenging problems. One goal 
is to apply this research on basic biological mechanisms to improve the diagnosis and treatment of cancer, neu-
rological disorders, and other diseases; another is to provide insights that will speed the development of food and 
energy supplies of the future. The scope of the faculty’s interests is suggested in this summary of several of the 
past year’s important fi ndings.
New View of NMDA Receptor Will Guide Drug Developers
Associate Professor Hiro Furukawa’s team this year obtained a full-length view of an 
important brain cell receptor that previously had been mapped only in segments. The 
receptor is called the N-methyl-d-aspartate (NMDA) receptor, and it is important for 
several reasons. When the receptor is functioning properly, it is essential in learning and 
memory. But both overactivity and underactivity of the receptor have been linked with 
a wide range of disorders, including depression, schizophrenia, and Alzheimer’s and 
 Parkinson’s diseases. The NMDA receptor is a popular target for candidate drugs to 
treat these problems. But it is a large and complex multisubunit protein, and, until now, 
its full-length structure had never been imaged at the atomic level. Early in the year, 
Furukawa’s team provided new detail of how one of the receptor’s subunits interacts with 
various compounds known to inhibit the receptor’s activity. These were fi rsts and will aid 
drug development. Then later in the year, the team published the fi rst view of all the subunits operating together. 
It identifi ed numerous interactions among the subunits and offered new insight into how the whole is regulated. 
In rough terms, the receptor looks like a hot air balloon. The “basket” sits in the membrane of the neuron and 
provides a passageway for entering and exiting ions. The large “balloon” section sits outside the membrane. One 
domain in the “balloon” portion called the amino-terminal domain directly regulates the “basket,” or ion chan-
nel. This function distinguishes the NMDA receptor from other receptors that are found in excitatory neurons 
throughout the brain. It is an important piece of information that will guide the design of new drugs to specifi -
cally and selectively regulate the receptor.
An Orchestrator of Developmental Timing
Development has often been likened to a symphony—a complex series of events that 
unfolds in time and space, culminating in the emergence of a viable organism. This past 
year, Assistant Professor Chris Hammell and his team identifi ed the gene lin-42 as a 
key regulator of developmental timing. Hammell was working in Caenorhabditis elegans, 
the roundworm that is the subject of so many basic science investigations. But lin-42 is 
found in creatures of all kinds, throughout the tree of life. Roundworms are very simple 
creatures, and thus make perfect models for studying not only what genes do at critical 
points but also when they are active and for how long. Hammell’s team likens lin-42 to 
the genes in people that control circadian rhythms. In the simple worm, lin-42 orches-
trates key events during development by regulating the activity of literally hundreds of 
other genes. Levels of the protein encoded by lin-42 were observed to oscillate in a char-
acteristic manner, suggesting that it is a kind of developmental clock. It provides the organism with a temporal 
memory that enables it to “remember” that it has completed one developmental step before moving on to the 
H. Furukawa
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next. Without such coordination, events would occur out of sequence or overlap, causing serious, 
irreversible developmental errors.
Our Clearest View Yet of Spontaneous Mutations in Autism
CSHL scientists published an important genetic study this year of families affected by 
autism—2500 “simplex” families in a collection curated by the Simons Foundation. 
These families have only one child with autism spectrum disorder (ASD); neither sib-
lings nor parents are affected. The study, led by quantitative biologist Ivan Iossifov, a 
CSHL Assistant Professor, provides our clearest view to date of what is, in its totality, 
a very complicated picture. The team looked for de novo mutations—variations in 
genes occurring spontaneously in the affected child and not in either parent. Further, 
they tried to pinpoint which de novo mutations might be devastating ones—that is, 
mutations in genes whose function is so vital in early development that an error might 
be serious enough to derail normal brain development, giving rise to ASD. Iossifov 
and colleagues now estimate that at least 30% of all ASD is caused by de novo muta-
tions. A related fi nding was the parsing of this set of mutations into those called “missense” 
mutations and “likely gene-disrupting” (LGD) mutations. Missense mutations are more com-
mon, but less often devastating (1 in 7, on average); LGDs, as their name implies, are often 
devastating (43%), but much less common. The team, which included Professors Mike Wigler 
and Dick McCombie as well as faculty members Dan Levy and Michael Schatz, estimated 
that the total pool of spontaneously mutated genes contributing to ASD numbers around 400, 
and that these appear to segregate into two risk classes. One portion is found in comparatively 
high-IQ males; the other in males with low IQ and in nearly all affected females. Females are 
thought to have a protective factor against the impact of ASD-linked mutations, but when 
females do develop ASD they tend to have the devastating, gene-disrupting mutations found 
in this second class.
A Way to Objectively Measure Conﬁ dence
Associate Professor Adam Kepecs and colleagues carried out a series of experiments this 
year that demonstrated something extraordinary: that confi dence is not just a feeling or 
emotion, but something that we can measure objectively in the laboratory. The team 
worked with rats, which were given a diffi cult choice of discrimination. To obtain a re-
ward, they needed to correctly assess which of two similar paired odors was dominant. 
Kepecs hypothesized that the amount of time an animal was willing to wait for its reward 
was directly related to its degree of confi dence in the choice it made in a given trial. In 
fact, the team found that the time a rat was willing to wait enabled them to predict the 
likelihood of the decision being correct. This is an objective way to measure confi dence 
and should also apply in humans. Kepecs’ team separately used optogenetics to inactivate 
neurons in a part of the rat brain called the orbitofrontal cortex (OFC), known to be 
involved in making decisions. They were surprised to fi nd that an inactive OFC did not impair 
the rats’ ability to make correct decisions. The only thing affected was how long the animals were 
willing to wait for a reward. Wait time ceased to correlate with confi dence; animals often waited 
a long time even when they had chosen incorrectly. Thus, inactivating the OFC impaired not 
decision-making but confi dence.
Elucidating Fear and Depression Mechanisms in the Mouse Brain
Associate Professor Bo Li and colleagues continued this year to explore pathways in the mam-
malian brain that are activated in two often disabling conditions: depression and acute fear. 
A. Kepecs
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In tracing the fear response, the team identifi ed a group of neurons in the central amyg-
dala that send long-range projections to a part of the brainstem called the midbrain peri-
aqueductal gray (PAG). When they conditioned mice to associate a particular sound with 
a shock, the team was able to see that activity of these neurons in the central amygdala 
was enhanced. They had traced a specifi c pathway used by the brain to translate fear into 
action. In their work on depression, Li and his team confi rmed in mice modeling symp-
toms of the illness that neurons in the medial prefrontal cortex (mPFC) are abnormally 
active. Using chemical genetics techniques, they artifi cially enhanced activity in mPFC 
neurons in mice that were not only not depressed but better able than most mice to re-
main unperturbed by stress. These resilient animals quickly became helpless, showing all 
of the classic signs of depression. This could help account for the often dramatic thera-
peutic effect of the experimental therapy called deep brain stimulation (DBS), which suppresses 
the activity of neurons in a small portion of the brain called area 25. Li’s work has the potential to 
make DBS even more targeted and powerful.
How Gene Expression Patterns Are Carried across Generations
Cells in our bodies are specialized. Heart cells, blood cells, and liver cells all attain their 
specifi city as they develop out of stem-like precursor cells. Although all our cells carry 
the full complement of human genes, only certain of these will be expressed as a cell of a 
given type differentiates. A team led by Professor Rob Martienssen this year showed how 
even the slightest variations in a class of code-carrying proteins called histones can dra-
matically alter the way a cell’s genes are expressed. Histones come together to form spools 
around which our DNA is wound, part of the remarkable process through which 6 feet 
of genetic material is compressed inside the nucleus of each human cell. Histone proteins 
are marked with chemical tags, such as methyl groups. The histone code consists of the 
patterns formed by these epigenetic marks across the genome. There are many kinds of 
histones. One, called H3, comes in two subtypes, H3.1 and H3.3. The former is found 
only where genes are silent; the latter, only where they are active. Martienssen and colleagues have 
now fi gured out why these histones segregate in this manner. Remarkably, they found that a single 
amino acid difference in the structure of histone H3.3 enables it to serve as a kind of memory 
device for cells, indicating genes that need to remain active. The amino acid in question is one 
that cannot be modifi ed with an epigenetic mark. This becomes extremely important when cells 
divide. Cells need to preserve epigenetic marks that delineate active and inactive genes. Martiens-
sen’s work shows how gene-silencing machinery deposits epigenetic marks on histone H3.1 during 
cell replication but not on H3.3, thus enabling cells to “remember” critical information across 
generations.
A Program to Find Disease-Related “Cuts” in the Human Genome
There are three billion DNA “letters” in the human genome—more than enough to fi ll 
a thousand books the length of Melville’s Moby-Dick. Remarkably, we have learned that 
adding or removing a single DNA base can have dramatic impacts on biological function. 
Devastating insertions and deletions—called “indels”—are quite rare, but when they 
do occur they can affect a person’s chances of getting a disease such as autism. Genome 
sequencing technology has made it possible to spot very large indels spanning thou-
sands of DNA letters, but it has been poor at fi nding tiny ones—indels of, say, a single 
letter. Because of the way our DNA encodes proteins—in groups consisting of three 
letters—single-letter indels can interfere with the production of essential proteins. This 
year Associate Professor Michael Schatz and colleagues published a computer algorithm 
R. Martienssen
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called SCALPEL that mines existing genome data sets for indel mutations. Schatz compares the 
effect of small indels with fi ne cuts in the genome and likens SCALPEL to a means of zeroing in 
on precisely where these “cuts” occur. With Assistant Professor Gholson Lyon, Schatz used 
SCALPEL to search for indels in samples from a patient with severe Tourette syndrome and 
obsessive-compulsive disorder. The team validated more than 1000 indels, demonstrating the ac-
curacy of the method.
Newly Discovered Variant of Tumor-Suppressor Protein May Control Metastasis
An intriguing discovery by Associate Professor Raffaella Sordella and colleagues was 
cited as one of 2014’s “signaling breakthroughs of the year” by the journal Science Signal-
ing. The team discovered a new variant of the very well-known protein p53, which they 
named p53Ψ (the Greek letter “psi”). p53 has often been called “the guardian of the 
genome.” It is a tumor-suppressing protein that comes to the fore when cells sense dam-
age to their DNA. When the damage is severe, p53 can cause cells to commit suicide, 
a process called apoptosis. Mutations of p53 are the most common genetic alterations 
seen in human tumors. Sordella’s team found that p53Ψ, in contrast to normal p53, has 
pro-growth and even pro-metastatic effects, which it produces by interacting with a pro-
tein at the membrane of the mitochondria, the cell’s ubiquitous energy factories. When 
expressed in cells, p53Ψ reduces the expression of a molecular glue called E-cadherin, 
which normally keeps cells in contact within epithelial tissue. Such tissue forms the lining of the 
lung and many other body organs. In fact, Sordella found elevated levels of p53Ψ in samples of 
early-stage lung tumors with poor prognosis. Normally, p53Ψ appears to play a role in wound 
healing. It is possible that mutant forms of p53, which play a key role in so many cancers, may 
have “hijacked” the ability to promote tumor growth and spread from the program used by p53Ψ 
to promote healing after tissue injury.
Mutant Protein Linked with Intellectual Disability Impairs Synaptic Plasticity
In recent years, Professor Linda Van Aelst has made a series of discoveries revealing the 
relationship of defects in a gene on the X chromosome called oligophrenin-1 (OPHN1) 
with various brain dysfunctions contributing to intellectual disability. (It is one form 
of so-called X-linked intellectual disability.) The OPHN1 protein is understood to help 
enable excitatory nerve transmission, particularly in cells that have receptors for the neu-
rotransmitter AMPA. This year Van Aelst and colleagues were able to demonstrate how 
defective forms of the OPHN protein, caused by defects in the gene of the same name, 
cause impairments in synaptic plasticity. This is the critical process through which our 
neurons are constantly adjusting the strength of their connections, a key to our ability to 
both remember and learn. Specifi cally, Van Aelst found that mutated OPHN1 proteins 
are not able to properly interact with another protein, called Homer1b/c. When this 
happens, AMPA “traffi cking” is impaired. The receptors, which after they are active normally 
are brought back inside neurons and pooled for later use, fail to recycle to the surface at synapses 
when OPHN1 and Homer1b/c are not interacting properly. This impairs neurons’ ability to 
synapse with one another and may be one of the mechanisms underlying X-linked intellectual 
disability.
Technology Transfer
Cold Spring Harbor Laboratory (CSHL) is engaged in technology transfer as one way of de-
livering important discoveries to the public. We continue to ramp up institutional support to 
R. Sordella
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CSHL scientists in partnering with companies, investors, and others to achieve their research-
related objectives and add value to the basic research that is the bedrock of science at Cold 
Spring Harbor. Our success can be measured in terms of dollars, transactions, and relation-
ships, but most importantly how these efforts eventually translate into applications that benefi t 
society. In 2014, CSHL had 561 active patent cases in progress for 133 technologies and 1627 
active technology transfer agreements. Net licensing revenue totaled $3,866,042. The return on 
commercialization efforts is reinvested in research and innovation at CSHL.
In June, CSHL announced the settlement of a long-running malpractice suit against law fi rm 
Ropes & Gray and attorney Matthew P. Vincent just days before the case was to go to a jury in 
Massachusetts state court. Malpractice impeded the timely issuance of a CSHL patent on short-
hairpin RNAs (shRNAs). These are engineered molecules that allow researchers to turn off 
expression of virtually any target gene or combination of genes in human and other mammalian 
cells. The shRNA technology at issue was developed by Professor and Howard Hughes Medi-
cal Institute Investigator Gregory Hannon, Ph.D. It rep-
resents a considerable advance over other technologies, 
including the RNA interference technology developed by 
Nobel Prize winners Drs. Andrew Fire and Craig Mello. 
The Hannon shRNA technology has had a powerful im-
pact across academic and industry medical research, in-
cluding its use to identify new drug targets and therapies 
for cancer.
Ultimately patented by CSHL in 2012 while the Laboratory simultaneously pursued the malprac-
tice suit, the proprietary shRNA technology is now a widely used biomedical research tool in cancer 
research and drug development. Many companies have already signed licenses for this technology 
with CSHL, and the Laboratory is pursuing additional licensing opportunities.
Cold Spring Harbor Laboratory Board of Trustees
The CSHL Board of Trustees elects members whose academic and professional accomplishments 
reach beyond the boundaries of science, providing well-informed governance in an in-
creasingly complex fi scal and regulatory environment. The Board welcomed Lalit Bahl, 
Ph.D., of Renaissance Technologies Corporation, David M. Knott of Knott Partners, 
and Elizabeth McCaul of Promontory Financial Group.
The Board congratulated retiring member Thomas Lehrman, who served from 2008 
to 2014 and was active on the Planning, Investment, and Academic Affairs committees.
James H. Simons was elected Honorary Trustee. Jim is the founder of Renaissance 
Technologies and Chairman of the  Simons Foundation. He and his wife, Marilyn, who 
serves as Vice Chairman of the CSHL Board of Trustees, are leaders in private funding of 
basic research at CSHL and throughout the country.
Trustees, faculty, students, and employees mourned the pass-
ing of long-time friends, former CSHL Chairman and Honorary 
Trustee David Luke and his wife Fanny.
With support from the CSHL Association, the Corporate Advi-
sory Board, foundations, and individuals, CSHL raised more than 
$6.6 million for the CSHL Annual Fund, which provides unre-
stricted support for research and education. The 9th Double Helix 
Medals Dinner, honoring Matthew Meselson, Marlo Thomas, 
and former CSHL trustee Andrew Solomon, raised a record $4 
million. Through his award-winning writings and lectures, An-
drew has promoted awareness and understanding of mental illness, 
shRNA, named for its hairpin shape
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including a number of disorders that have a genetic basis and are under active investigation at the 
Laboratory. Dr. Meselson is a legendary geneticist whose landmark experiment in 1958 with Frank-
lin Stahl revealed critical aspects of DNA replication, essentially proving Jim Watson and Francis 
Crick’s hypothesis as to how the double helix of DNA is copied. Marlo Thomas has raised the 
visibility of research in health care as National Outreach Director for St. Jude Children’s Research 
Hospital, spearheading national campaigns in support of the hospital’s mission to advance cures 
and prevent catastrophic pediatric diseases through research and treatment. In 1962, Marlo’s father, 
Danny Thomas, founded St. Jude Children’s Hospital in Memphis, Tennessee.
With generous support from Jim and Marilyn Simons, we established the Simons Center for 
Quantitative Biology in 2009. The Center brings together experts in applied mathematics, com-
puter science, physics, and engineering to further basic research and investigation into illnesses 
including cancer, autism, bipolar disorder, and depression. Thanks to Jim and Marilyn, this year 
we were able to recruit computational biologist Adam Siepel from Cornell University to be the 
inaugural Chair of the Simons Center.
We are grateful to all major donors who in 2014 supported research and education pro-
grams at the Laboratory. The Stanley Medical Research Institute contributed $10 million to 
support the Laboratory’s Stanley Institute for Cognitive Genomics. The G. Harold and Leila 
Y. Mathers Foundation continued its support of neuroscience research to map the mouse 
brain.
A gift from the Seraph Foundation will help sup-
port the Laboratory’s new state-of-the-art Genetic 
Screening Facility, named for John and Edna Daven-
port. The New York State Empire State Development 
Corporation awarded CSHL $1.5 million to equip a 
Center for Metabolomics, where researchers will as-
sess cell metabolism and oxidative vulnerabilities to 
develop new small- molecule inhibitors for treating 
cancers, autism, diabetes, and orphan diseases.
The Lustgarten Foundation contributed $5 mil-
lion to support pancreatic cancer researcher Douglas 
Fearon, M.D., who was recruited from the Univer-
sity of Cambridge, U.K., to continue his work on 
B. Stillman and Double Helix Medal winners M. Meselson, M. Thomas, and A. Solomon
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harnessing the immune system to fi ght cancer. This support is in addition to a similar amount 
that was previously given by the Lustgarten Foundation to support pancreas cancer research in 
David Tuveson’s laboratory.
The year’s outstanding additions to our Board, scientifi c staff, and community of supporters all 
bode well for a future of discovery and teaching innovation. All help CSHL maintain its leader-
ship position in both research and education in biology and the life sciences.
Research Faculty
Awards
The National Science Foundation (NSF) awarded Early Concept Grants for Exploratory Research 
(EAGER) to Assistant Professor Florin Albeanu and Professor Partha Mitra, who are working 
to develop new technologies that will provide insight into the structure and operation of neural 
circuits and address how complex behaviors emerge from them. The awards are part of President 
Barack Obama’s multiyear BRAIN Initiative that aims to answer fundamental questions about 
how the brain works.
The National Science Foundation (NSF) selected Assistant Professor Michael Schatz to re-
ceive its prestigious CAREER Award. The Faculty Early Career Development Program is tar-
geted for teacher-scholars who are most effective in integrating research and education. Mike 
was one of a small group selected from among more than 200 young scientists who were under 
consideration.
Assistant Professor Molly Hammell was one of seven 2014 Rita Allen Scholars. The award 
supports promising early-career investigators, and Molly received the Foundation’s highest honor: 
designation as the Milton E. Cassel Scholar, which pays tribute to a long-time president of the 
Rita Allen Foundation.
Assistant Professor Anne Churchland was named a Pew Scholar in the Biomedical Sciences by 
the Pew Charitable Trusts. She also received a Klingenstein-Simons Fellowship in the Neurosci-
ences from the Simons Foundation and the Esther A. and Joseph Klingenstein Fund.
Associate Professor Mikala Egeblad won an Era of Hope Scholar Award from the United States 
Department of Defense (DoD) Breast Cancer Research Program. This prestigious award supports 
early-career scientists who have demonstrated extraordinary creativity, vision, and leadership po-
tential within the fi eld of breast cancer research. Mikala is one of only two recipients of the award 
this year.
EMBO, founded 50 years ago as the European Molecular Biology Organization, elected Pro-
fessor David L. Spector, Ph.D., to its ranks. David, who is CSHL’s Director of Research, is one of 
50 outstanding researchers in the life sciences newly elected to membership. He was also elected 
to the American Academy of Arts and Sciences, joining some of the world’s most accomplished 
leaders from academia, business, public affairs, the humanities, and the arts.
The Pershing Square Sohn Cancer Research Alliance honored Lloyd Trotman, Associate Pro-
fessor, with one of six prizes for Young Investigators in Cancer Research. The prize seeks to fuel 
innovative scientifi c discoveries in the search for a cure.
I was honored to be selected as the 2014 recipient of the Herbert Tabor Research Award from 
the American Society for Biochemistry and Molecular Biology (ASBMB). The award is given for 
excellence in biological chemistry and molecular biology and for contributions to the community 
of scientists. It was my pleasure to give the opening lecture at this year’s ASBMB Annual meeting 
in San Diego, CA, in April.
New Faculty
Professor Douglas Fearon, who received his M.D. from Johns Hopkins University School of 
Medicine in 1968, joined us from the University of Cambridge to further study the interaction 
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between the immune system and tumors. With support from the Lustgarten Foundation, Doug’s 
goal is to develop an immunotherapy to treat cancer.
Thanks to the Simons Foundation, we welcomed Adam Siepel, Ph.D., Professor and Chair of 
the Simons Center for Quantitative Biology. Adam was previously Associate Professor at Cornell 
University, focused on comparative genomics and the development of statistical methods and 
software tools to identify evolutionarily conserved sequences and the complex processes by which 
genomes evolve over time. Dr. Siepel attended graduate school in computer science, receiving an 
M.S. from the University of New Mexico (2001) and a Ph.D. from the University of California, 
Santa Cruz (2005).
Je H. Lee, with an M.D., Ph.D. from Tufts School of Medicine (2002), is an Assistant Profes-
sor, joining CSHL from George Church’s laboratory at Harvard Medical School. Je studies how 
cells sense and remember timing, location, and history and how their surroundings infl uence 
their signals with other cells. He also develops imaging and molecular sequencing technologies for 
tracking genes, molecules, and cells.
A neuroscientist from the University of California, San Francisco, Assistant Professor Jessica 
Tolkuhn, received her Ph.D. from the University of California, San Diego, in 2006 and is study-
ing how estrogen and testosterone generate sex differences in the brain and behavior.
Promotions
Congratulations to newly promoted Associate Professors Anne Churchland, Mikala Egeblad, and 
Michael Schatz. Justin Kinney was named Assistant Professor, being promoted from his previous 
position of CSHL Quantitative Biology Fellow.
Education Programs
Banbury Center
More than 500 people took part in 16 by-invitation meetings at the Banbury Center this year. 
The  meetings included two that involved families of people affected by serious illnesses. Eliminat-
ing the  Stigma of Mental Illness was devoted to mobilization of a plan conceived by the founda-
tion BringChange2Mind, spearheaded by the actress Glenn Close, whose sister and nephew have 
 bipolar disorder.
Rhabdomyosarcoma: A Critical Review brought together world experts on this common, often 
fatal, soft-tissue sarcoma that affl icts children. In this meeting, too, urgency to initiate a course of 
action was spurred by advocacy on the part of affected families. The meeting resulted in the pub-
lication of a white paper outlining future research directions and marked the start of the Labora-
tory’s Sarcoma Research Project, funded by local, family-based nonprofi t organizations to support 
targeted research on specifi c sarcomas.
A. Siepel J. Lee J. TolkuhnD. Fearon
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Other important Banbury meetings in 2014 included Connections and Communications in the 
Brain; Defeating Ovarian Cancer; The Immune System and Cancer; Interpreting Personal Genomes; 
Reactive Oxygen Species in Biology and Cancer; and Epigenetics and Agriculture.
Unusually, in addition to the Rhabdomyosarcoma White Paper, this year’s Banbury meetings 
gave rise to two published papers, one on adolescent mental health (published in Science), the 
other on redefi ning the privacy of genomic data (published in PloS Biology).
DNA Learning Center
Operations of the DNALC in 2014 brought an additional 19,300 local students on fi eld trips 
to the Cold Spring Harbor, Lake Success, and Harlem, New York, locations. An additional 
9000 students were reached through in-school instruction by DNALC staff. During the sum-
mer months, 60 week-long biology and genetics summer camps were held in Cold Spring 
Harbor and eight other locations in the tristate area, involving 1300 students.
The Urban Barcode Project, in its third year, enjoyed continued success, with 145 students pre-
senting posters and talks at the American Museum of Natural History in the spring. The Urban 
Barcode Research Program, supported by the Pinkerton Foundation, made possible an extraordi-
nary opportunity for 38 students from the New York area to take part in summer barcoding work-
shops followed up with 100+ hours of research time spent with mentor-scientists at the Museum, 
CUNY, Columbia University, and the New York Botanical Garden. A new Barcode Long Island 
program was initiated.
The DNALC’s worldwide reach via the Internet was re-
fl ected in record-setting numbers: more than 5.2 million 
visits to 22 DNALC websites; 875,000 views of DNALC 
YouTube videos; and 668,000 downloads of popular 3D 
Brain, Weed to Wonder, and Gene Screen apps. Total multi-
media visits numbered 6.75 million, up 7.7% over the prior 
year.
Meetings and Courses Program
In 2014, just less than 7000 scientists attended meet-
ings held on the main campus. Attendance at each meet-
ing ranged from 100 participants to more than 500, and 
more than half of attendees are either graduate students or 
Eliminating the Stigma of Mental Illness Meeting. Glenn Close models 
Stigmasucks jacket.
Hands-on biology at the DNALC
2014 Meetings and Courses
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postdoctoral researchers. Nearly one-third of the attendees come from nations other than the 
United States. The Cold Spring Harbor Asia program, now in its fi fth year, included 20 confer-
ences and one summer school in 2014 and attracted more than 3400 participants.
2014 saw the continuation of many successful annual and biennial meetings and the introduc-
tion of several new ones: Avian Model Systems; the PARP Family & Friends; and Biological Data 
Science. The Courses program, meanwhile, drew about 600 trainees, including advanced graduate 
students, postdoctoral researchers, and faculty. A new offering in 2014 focused on the Genetics and 
Neurobiology of Language, and this meeting will be held biennially.
Strong backing of the Howard Hughes Medical Institute continues to sustain the Courses 
program. Courses also draw essential support from the National Institutes of Health and the 
National Science Foundation, and they rely on equipment and reagents loaned or donated by 
many companies. These partnerships enable CSHL to consistently offer training in the latest 
technologies.
Cold Spring Harbor Laboratory Press
2014 was another successful year for the Press. It maintained an output of high-quality pub-
lications, made a substantial fi nancial contribution to the Laboratory, introduced a promis-
ing new service, and laid the groundwork for a new research 
journal. Subscription and advertising revenue streams for its 
four research journals were stable or higher. Genes & Devel-
opment and Genome Research remain two of the world’s four 
most highly cited genetics journals. There was strong growth 
for the newer journals, Protocols, Perspectives in Biology, and 
Perspectives in Medicine, each of which represents a strategic 
online transformation of print manuals and monographs. 
Total downloads of Press journal articles worldwide reached a 
record level of 13 million.
Although only a year old, the preprint service bioRxiv made 
a signifi cant mark. More than 1000 draft research papers in 25 
subject categories were posted, and authors received much feed-
back through on-site comments, social media, and private email. 
More than 300 of the posted preprints have now been published, 
in over 100 journals.
The Press also published 21 new book titles in 2014, includ-
ing Jim Watson’s family memoir Father to Son.
Watson School of Biological Sciences
The Watson School welcomed its 16th incoming class and graduated its 11th class. The achieve-
ments of the graduate program continued to grow. The quality of scientifi c publications produced 
by school’s students remained highly impressive. Watson School students continued to graduate 
considerably faster than students in comparable Ph.D.-granting institutions and demonstrated an 
ability to secure excellent jobs. Nineteen WSBS graduates, or 27% of all graduates, have thus far 
secured tenure-track faculty positions, an impressive record since the fi rst graduates only left Cold 
Spring Harbor Laboratory in 2004.
Eleven WSBS students were awarded Ph.D. degrees, bringing the total since the school’s in-
ception to 71. We were pleased to award an Honorary Doctor of Science degree to Richard 
Burgess of the University of Wisconsin, Madison, who taught the protein biochemistry course 
here for many years and who has made major contributions to understanding gene transcription. 
During the year, scientifi c papers published by students of the school appeared in major jour-
nals, bringing the cumulative total of publications to nearly 300. Current and former students 
J. Watson’s family memoir.
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won prestigious and highly competi-
tive scholarships and fellowships, as 
in past years.
In August, the WSBS welcomed 
nine new students. Members of the 
Class of 2014 were selected from 
among 276 applicants and represent 
the United States, Canada, Germa-
ny, India, Lithuania, and the United 
Kingdom. Other new graduate stu-
dents entered as visitors from other 
institutions, including seven from 
Long Island’s Stony Brook Uni-
versity. Current visitors hail from 
more distant institutions, includ-
ing Cornell University and several 
from China, Germany, and France, 
among others.
During the summer, undergraduates from across the United States, as well as Austria, Bul-
garia, Canada, Greece, Mexico, Singapore, Syria, and the United Kingdom, took up residence 
at CSHL to take part in the historic Undergraduate Research Program. These “URPs” (chosen 
from among 819 applicants!) had the remarkable opportunity to perform advanced research in 
the laboratory of a CSHL faculty member.
Library and Archives
The Library and Archives organized a meeting in Grace Auditorium entitled “The History 
of mRNA” as part of a series held jointly with the Meetings and Courses division. This 
meeting brought together pioneers in the fi eld of RNA biology, including Jim Watson and 
Sydney Brenner—who were co-discoverers of messenger RNA (mRNA)—and those involved 
in the discovery of long heteronuclear RNA (hnRNA) and RNA splicing, which resulted in a 
Nobel Prize to former CSHL scientists Richard Roberts and Phillip Sharp. The meeting also 
included talks by contemporary scientists studying mRNA processing, splicing, and transla-
tion. This meeting is part of a series on the history of molecular biology and genetics held 
here each year.
Infrastructure
Preclinical Experimental Therapeutics Facility (PETx)
Construction on the 8000-square-foot addition to the 
Woodbury Genome Center that will open in 2015 as the 
Preclinical Experimental Therapeutics Facility (PETx) 
began in late 2013 and was delayed by a particularly harsh 
winter. When completed, the facility will house state-of-
the-art imaging equipment and a dedicated staff to allow 
for the discovery and development of novel therapeutics 
and diagnostics strategies. Equipment will include nonin-
vasive imaging such as PET/CT, ultrasound, and optical 
imaging equipment. The facility will have two surgical 
suites, necroscopy rooms, a pharmacy, and a diagnostic 
clinical laboratory.
WSBS class of 2014
Preclinical Experimental Therapeutics Facility
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Nicholls Biondi Hall
At the beginning of the year, we broke ground for construction of Nicholls Biondi Hall, a 
2000-square-foot poster pavilion space to enhance the Meetings and Courses Program and provide 
additional confi gurable space for conferences and seminars. The new building opened in June 2015, 
looking eastward over a great lawn bounded by the Carnegie Building and the recently constructed 
Hershey Laboratory. The 1904 Carnegie Building that was 
originally built as a laboratory building and now houses our 
Library and  Archives as a bookend to the new Hall.
The Laboratory this year also dealt with two signifi cant 
catastrophic system failures. One was the aging, 20-year 
old McClintock Laboratory chiller plant. Replacement of 
similarly aging systems have been scheduled beginning in 
early 2015. Another major event was fl ooding of the Her-
shey Laboratory caused by record low temperatures that 
contributed to the freezing of a fi re sprinkler line. Tens of 
thousands of gallons of water cascaded across the second 
fl oor of the building down to the fl oor below, causing major damage to the Flow Cytometry 
and Microscopy facilities and the total loss of a laser confocal microscope. Luckily, the Facilities 
Department responded immediately and the building was quickly dewatered. Flood damage was 
repaired and new equipment was procured in less than 60 days.
Community Outreach
Public Lectures
March 11–Mikala Egeblad, Ph.D., Assistant Professor, Cold Spring Harbor Laboratory;  Nicholas 
K. Tonks, Ph.D., F.R.S., Professor, Cold Spring Harbor Laboratory; Lora R.  Weiselberg, M.D., 
Clinical Associate Professor, Hofstra, North Shore–LIJ School of Medicine. Lecture: “Cold Spring 
Harbor Laboratory Breast Cancer Research Update.”
March 28–Siddhartha Mukherjee, author, The Emperor of All Maladies: A Biography of Cancer, 
2014 Roy J. Zuckerberg Lecture.
April 8–Craig Garner, Ph.D., Professor, Department of Psychiatry and Behavioral Sciences Stan-
ford University, Co-director Stanford Center for Research and Treatment of Down syndrome. Lec-
ture: “Developing Therapies to Improve Cognitive Abilities of Individuals with Down Syndrome.”
June 18–Michael Schatz, Ph.D., Assistant Professor, Simons Center for Quantitative Biology at 
Cold Spring Harbor Laboratory. Lecture: “Big Data: How Biological Data Science Can Improve 
Our Health, Foods, and Energy.”
June 24–Michael Ronemus, Ph.D., Research Assistant 
Professor Cold Spring Harbor Laboratory; Rebecca Sachs, 
Ph.D., Staff Psychologist, Fay J. Linder Center for Autism 
and Developmental Disabilities. Lecture: “Understanding 
Autism Spectrum Disorder: Focus on the Facts.”
October 23–Bruce Adolphe, composer and Resident Lec-
turer and Director of Family Concerts for the Chamber 
Music Society of Lincoln Center; Alexis Gambis, Ph.D., 
founder, Science Films. Lecture: “Creativity in Music, 
Film, and Neuroscience.”
Nicholls Biondi Hall
Roy J. Zuckerberg Lecture
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November 4–Lynn Pasquerella, Ph.D., President, Mount Holyoke College. Lecture: 2014 Lor-
raine Grace Lecture on societal issues of biomedical research: “Is Death Un- American?”
Public Concerts
March 21: Igor Lovchinsky, piano
April 25: Cicely Parnas, cello
May 2: Jerome Lowenthal, piano
May 16: Ken Noda with Anthony Kalil, piano with tenor
August 15: Charlie Albright, piano
September 12: Ji, piano
September 19: Yun-Chin Zhou, piano
October 2: Andrey Tchekmazov, cello
October 10: Einav Yarden, piano
March 27, 2015: Martin Kasik, Piano
April 17, 2015: Jiayin Shen and Alan Woo, piano duo
May 1, 2015: Julia Bullock, soprano
May 15, 2015: Trio Solisti, violin, cello, and piano
We thank our team of enthusiastic graduate students and postdoctoral fel-
lows who staff CSHL’s public tour program. They conducted 57 campus tours 
for more than 800 participants during the course of the year.
Local families enjoyed a day exploring the history of Cold Spring Harbor 
Village and DNA on April 26 as part of the DNA Day Scavenger Hunt. Local 
institutions including the Cold Spring Harbor Library, the Cold Spring Harbor 
Whaling Museum, the Firehouse Museum, and CSHL’s DNA Learning Center 
took part. DNA Day is celebrated across the country, commemorating the com-
pletion of the Human Genome Project in April 2003 and the discovery of the 
DNA double helix by Chancellor Emeritus James D. Watson and Francis Crick.
In April, fi rst graders from Goosehill Primary and Friends Academy partici-
pated in a science fair on the CSHL campus. With graduate students and DNA 
Learning Center instructors manning interactive stations, more than 100 local 
children, teachers, and parents explored the brain, seaweed, rainbows, and their 
own fi ngerprints.
C. Albright
Thank you from student visitor
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In December, Maria Nattestad, a WSBS Graduate Student, led a community event called 
“Hour of Code.” Part of a global effort to introduce children to computer coding at early ages, the 
event brought local families to the Laboratory. Maria also leads a “Girls Who Code” club for girls 
in grades 7–12 together with the DNA Learning Center Assistant Director Amanda McBrien.
Congressman Steve Israel (D-NY) joined CSHL in congratulating Long Island high school 
students recognized as Intel Science Prize Semifi nalists. Two of the 40 local semifi nalists were 
part of CSHL’s Partners for the Future Program, working in the laboratories of Mikala Egeblad 
and Leemor Joshua-Tor.
CSHL participated in the 11th Long Island 2-Day Walk that raised more than $22,800 for 
breast cancer in the lab of Mikala Egeblad, whose research is aimed at developing new strategies 
to treat breast cancer. Rather than attacking tumor cells directly, Mikala’s group is investigating 
whether it is possible to target immune cells in the tumor microenvironment that act to promote 
cancer metastasis and suppress the response to chemotherapy.
The LI2DAY Walk also awards six $2500 scholarships to Long Island high school seniors who 
have a parent or guardian with breast or other women’s cancer. CSHL is proud to participate in 
the scholarship committee.
Interacting with the public through lectures, tours, and special events is important in our ef-
forts to raise visibility about the signifi cance of basic research and science education. The under-
standing and support of the general public is critical to CSHL and other independent research in-
stitutions that rely on taxpayer funding and private philanthropic giving. We continue to expand 
our efforts to communicate with the public through use of the latest digital technologies. Follow 
us on Facebook and Twitter!
Looking Forward
We look forward to our 125th anniversary year and the future beyond it with excitement and opti-
mism, poised for even bigger breakthroughs that will undoubtedly change the world for the better.
Bruce Stillman, Ph.D., F.R.S.
President and Chief Executive Ofﬁ cer
Hour of Code @ CSHL
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CHIEF OPERATING OFFICER’S REPORT
In his President’s message, Bruce Stillman makes a compelling case for support of Cold Spring 
Harbor Laboratory’s 125th Anniversary Capital Campaign. He cites not only the Laboratory’s rich 
and productive record of achievement in research and education, but the unprecedented promise 
and opportunity that lies before us in the postgenomic era.
A well-documented decline in federal research funding, combined with dramatic increases in 
the cost of doing cutting-edge science and recruiting world-class faculty, requires a level of private 
philanthropic support that we would not have anticipated a decade ago. A primary role of the 
Chief Operating Offi cer, in this environment, is to ensure that the institution is worthy of such 
investment from the perspective of operational and fi scal management. In fact, there are many 
successes in these areas to which we can point.
Operating expense management has been an ongoing priority for the last decade. Although 
this has been diffi cult, at times, for our loyal staff who have endured years of minimal salary in-
creases as well as recent increases in employee contributions to our healthcare plan, such measures 
have been necessary. These efforts have accomplished their critical objectives of keeping operating 
expenses relatively fl at and conserving cash over the past 5 years, even in the face of absorbing a 
campus expansion and a substantial rise in the information technology costs associated with data-
driven science.
Our balance sheet, with $800 million in total assets, is strong. We carry a comfortable level of 
long-term debt ($97 million), the cost of which is synthetically fi xed at a reasonable level for 30 
years. The ratings agencies, Moody’s and Standard & Poor’s, concur, having recently reaffi rmed, 
respectively, our Aa3 and AA ratings. In fact, the Moody’s review included a “positive outlook,” 
stating that “it refl ects our expectation of continued strong growth in fi nancial resources that 
outpaces the growth of similarly-rated peers.” Moody’s added: “Our rating incorporates CSHL’s 
position as a leading not-for-profi t research institute, consistently positive operating performance, 
and healthy and growing fi nancial reserves that provide signifi cant operating fl exibility.”
In this milestone anniversary year, as we work to meet our fi nancial challenges, we recognize 
that endowment funds are the key to securing the Laboratory’s future as a leading and enduring 
independent research and education institution. It is imperative that we continue to grow the 
endowment “organically” through prudent investment management and “inorganically” through 
vigorous fund-raising. We have had good success in both. Since the original endowment gift of 
$8 million was received from the Charles Robertson family in 1975, the total fund has grown to 
a high-water mark of $444 million at year-end 2014. The goal of our Investment Committee is to 
maintain a diversifi ed portfolio designed to achieve healthy risk-adjusted returns while preserving 
capital and maintaining a reasonable level of liquidity. At the same time, we hold to a disciplined 
policy of spending no more than 5% of the fund, annually, on a 12-quarter moving average of 
year-end market value.
As we rely more heavily, over time, on private philanthropic support to sustain the Laboratory’s 
mission and secure its future, we are profoundly grateful for our generous donors. Cold Spring 
Harbor Laboratory does important work that we believe is worthy of your investment in us, and 
we work hard every day to earn and preserve your confi dence.
Here’s to the next 125 years!
W. Dillaway Ayres, Jr.
Chief Operating Ofﬁ cer
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Long-Term Service
The following employees celebrated milestone anniversaries in 2014:
35 years Maureen Berejka, James Hope, Bruce Stillman
30 years  Carmelita Bautista, Dessie Carter, Robert Gensel, Mary Ellen Goldstein, 
 Daniel Miller, Steven Tang
25 years  Sharon Bense, Charlene De Poto, Robert Martienssen, Alison McDermott, 
Spencer Teplin
20 years  Leslie Allen, Janet Argentine, Susan De Angelo, Carol DuPree, Diane Esposito, 
Philip Lembo, Idee Mallardi, Andrew Mendelsohn, Jennifer Troge
Front row (left to right): Susan De Angelo, Sharon Bense, Alison McDermott, Diane Esposito, Carmelita Bautista, Mary Ellen 
Goldstein, Dessie Carter; back row (left to right): David Spector, Daniel Miller, Philip Lembo, Idee Mallardi, Dill Ayres, James 
Watson, Bruce Stillman, Jennifer Troge, Spencer Teplin, Andrew Mendelsohn, Janet Argentine, Maureen Berejka, James Hope.
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Long-Term Service: 15 Years
15 years  Jeannette Amato, Maureen Bell, Karine Boyce, Kevin Donohue, Alexander Gann, 
Inessa Hakker, Pierre Jean-Baptiste, Frederik Munter, Jonathan Parsons, 
 Ludmila Pollock, John Sundman, David Trimboli, Jenna Williams, Chun-hua Yang, 
Anthony Zador
Front row (left to right): Karine Boyce, Ludmila Pollock, Pierre Jean-Baptiste, Jonathan Parsons; back row (left to right): James Watson, 
Chun-hua Yang, Bruce Stillman, Inessa Hakker, Maureen Bell, Kevin Donohue, Alexander Gann, Dill Ayres.
RESEARCH
See previous page for photos of the following scientifi c staff.
Row 1:    K. Weber (Mitra Lab); C. Hammell, K. Doerfel (C. Hammell Lab); A. Stenlund, 
S. Schuck (Stenlund Lab); Y. Jin (M. Hammell Lab)
Row 2:    A. Pommier, D. Fearon (Fearon Lab); Y. Tai (Van Aelst Lab); A. Ambrico 
(Trotman Lab); K. Rivera (Pappin Lab)
Row 3:    M. Moissidis (Huang Lab); C. Zepeda-Mendoza, D. Spector (Spector Lab); E. Olund, 
D. Filippini (Tuveson Lab); P. Mocombe (McCombie Lab)
Row 4:    M. Wu, J. Tollkuhn (Tollkuhn Lab); A. Scavelli (Gingeras Lab); M. Kaufman 
(Churchland Lab); T. Forcier (Wigler Lab)
Row 5:    T. Hige, M. Brill, M. Modi (Turner Lab); M. Regan (Furukawa Lab); B. Lau (Shea Lab); 
J. Gillis, S. Ballouz, W. Verleyen (Gillis Lab)
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CANCER: GENE REGULATION AND 
CELL PROLIFERATION
Many of the best cancer drugs are highly toxic chemotherapeutics that kill normal and malignant 
cells alike. In contrast, targeted compounds that recognize cancer-specifi c pathways represent a 
kind of silver bullet that would be able to distinguish tumor cells from their healthy counterparts. 
A few targeted drugs have been identifi ed, such as the BRAF inhibitor vemurafenib for melanoma, 
and initially these agents were highly promising. But patients rapidly relapsed as their cancers 
became resistant to treatment. Molly Hammell is working to tackle this problem, known as “ac-
quired resistance,” in melanoma. Her lab, in collaboration with the Wistar Institute, combines 
the power of systems-level, high-throughput data analysis with patient-derived tumor samples. 
Hammell has developed computational algorithms for the integration of multiple types of high-
throughput sequencing data into gene regulatory circuits. She is now applying these methods to 
explore the global changes in gene regulation that enable melanoma cells to bypass inhibitors of 
the BRAF signaling pathway, including DNA mutations and epigenetic modifi cations. Her work 
will identify the most clinically relevant pathways of interest for additional therapeutic approaches 
to inhibit tumor growth in melanoma. In addition to her work on melanoma, Hammell is using 
her expertise in bioinformatics in collaboration with other members of the CSHL community 
(including Marja Timmermans, Josh Dubnau, and Greg Hannon) to understand gene regulation 
in diverse systems, from maize to Drosophila.
In Leemor Joshua-Tor’s lab, researchers study the molecular basis of nucleic acid regulatory pro-
cesses, using the tools of structural biology and biochemistry. One such regulatory process is 
RNA interference (RNAi), in which a small double-stranded RNA triggers gene silencing. Joshua-
Tor and her team offered critical insight when they solved the crystal structure of the Argonaute 
protein and identifi ed it as the long-sought Slicer. They then went on to explore the mechanism of 
the slicing event. The structure of human Argonaute 2 (hAgo2) bound to a microRNA (miRNA) 
guide allowed Joshua-Tor and her colleagues to understand how mRNA is cleaved during RNAi. 
More recently, members of the Joshua-Tor lab explored the function of a very similar protein, 
called Argonaute 1, that has no slicing ability, even though it is almost identical in structure to 
the slicing hAgo2. Using biochemical methods and mutational analysis, they were able to identify 
key parts of the protein that are required for slicing activity. The lab also studies the generation 
of PIWI-interacting RNAs (piRNAs), which serve to protect the genome of germ cells. With 
colleagues in the Hannon lab, Joshua-Tor’s team also determined the structure and function of 
Zucchini, a key nuclease in the initial generation of piRNAs in fruit fl ies. In other work, the lab is 
exploring the mechanisms of heterochromatin formation and gene silencing, through the study of 
a protein complex called RNA-induced initiation of transcriptional gene silencing (RITS). Joshua-
Tor is also well known for her work on the E1 helicase enzyme, which acts to unwind DNA 
strands during the DNA replication process.
Adrian Krainer’s lab studies the mechanisms of RNA splicing, ways in which they go awry in 
disease, and the means by which faulty splicing can be corrected. In particular, they study splic-
ing in spinal muscular atrophy (SMA), a neuromuscular disease that is the leading genetic cause 
of death in infants. In SMA, a gene called SMN2 is spliced incorrectly, making it only partially 
functional. The Krainer lab is able to correct this defect using a potentially powerful therapeutic 
approach. It is possible to stimulate protein production by altering mRNA splicing through the 
introduction of chemically modifi ed pieces of RNA called antisense oligonucleotides (ASOs) into 
the spinal cords of mice. A drug based on this technology is now in late-stage human trials. Using 
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ASOs in mice carrying a transgene of human SMN2, Krainer’s team has developed a model for 
SMA using a technique they called TSUNAMI (shorthand for targeting-splicing using negative 
ASOs to model illness). They have developed a mouse model for adult-onset SMA and they are 
working to develop models for the study of other diseases caused by splicing defects, including 
familial dysautonomia. The Krainer lab has also worked to shed light on the role of splicing proteins 
in cancer. They have found that the splicing factor SRSF1 functions as an oncogene stimulating 
the proliferation of immortal cells. They have discovered that SRSF1 can actually stop cell growth 
by stabilizing a powerful tumor suppressor protein, called p53, suggesting that the cell is responding 
to the aberrant SRSF1 activity. This discovery offers insight into how tumors arise and the path-
ways that lead to transformation.
David L. Spector’s laboratory studies the spatial organization and regulation of gene expression. 
Their recent studies have demonstrated an increase in random monoallelic gene expression upon 
the differentiation of mouse embryonic stem cells (ESCs) to neural progenitor cells (NPCs). These 
data support a model where stochastic gene regulation during differentiation results in monoallelic 
gene expression, and for some genes, the cell is able to compensate transcriptionally to maintain 
the required transcriptional output of these genes. Therefore, random monoallelic gene expres-
sion exemplifi es the stochastic and plastic nature of gene expression in single cells. In addition, 
the Spector lab is characterizing long nuclear retained noncoding RNAs (lncRNAs) that exhibit 
altered levels of expression as mESCs transition from the pluripotent state to neural progenitor 
cells, and they are studying lncRNAs that are misregulated in cancer. Their efforts have focused 
on Malat1 lncRNA, one of the most abundant noncoding RNAs. The Spector lab previously 
identifi ed a novel mechanism of 3′-end processing of this RNA. Current studies have revealed 
that altered levels of Malat1 lncRNA impact breast cancer initiation and progression. Studies are 
currently under way to elucidate the mechanism of action of this abundant nuclear retained RNA.
Arne Stenlund and colleagues have obtained a detailed understanding of processes required for 
initiation of DNA replication from the papillomavirus, using this system to gain a general bio-
chemical understanding applicable in other systems. Papillomaviruses are a large viral family that 
induces cell proliferation at the site of infection, usually giving rise to benign tumors. But cer-
tain types of human papillomaviruses (HPVs) generate tumors that progress toward malignancy. 
Among these are HPVs that cause most cervical cancers. Members of the Stenlund lab also pursue 
studies aimed at developing an effective small-molecule inhibitor of HPVs that might someday be 
used by women who do not receive the preventive anti-HPV vaccine now available or those already 
infected with HPV who would not be helped by the vaccine.
Bruce Stillman’s lab studies the process by which DNA is copied within cells before they divide in 
two. Working with yeast and human cells, Stillman and colleagues have identifi ed many of the cel-
lular proteins that function at the DNA replication fork during the S phase, the portion of the cell- 
division cycle when DNA synthesis occurs. Among these proteins are those that facilitate the assembly 
of chromatin, the protein–DNA complexes that form the chromosomes. Current research focuses 
on the mechanism that initiates the entire process of DNA replication in eukaryotic cells. At the 
heart of this mechanism is a protein that binds to “start” sites on the chromosomes, called the 
origin recognition complex, ORC. The Stillman lab is part of an ongoing collaboration that de-
termined the cryo-EM structure of ORC proteins in complex with a group of proteins, called a he-
licase, that unwind DNA during replication. These images offer molecular insights into how the 
helicase is loaded onto DNA. Stillman’s research also focuses on the process by which duplicated 
chromosomes are segregated during mitosis. They found ORC at centrosomes and centromeres, 
structures that orchestrate chromosome separation during mitosis. At centromeres, ORC subunits 
monitor the attachment of duplicated chromosomes to the mitotic spindle that pulls the chromo-
somes apart when they are correctly aligned. Stillman’s team has discovered that mutations in the 
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Orc1 protein alter the ability of ORC to regulate both DNA replication and centrosome duplica-
tion. These mutations have been linked to Meier–Gorlin syndrome, a condition that results in 
people with extreme dwarfi sm and small brain size, but normal intelligence.
Acute myeloid leukemia (AML) is a particularly devastating and aggressive blood cancer that is 
currently incurable in 70% of patients. Research in Chris Vakoc’s lab seeks to understand this dis-
ease as well as others, such as lymphoid leukemias and epithelial tumors, by studying them at the 
level of genomic regulation. He is particularly interested in the proteins that regulate chromatin in 
the nucleus of the cell. To identify proteins involved in AML, which may also be targets for drug 
therapy, he deploys large-scale genetic screens using RNA interference (RNAi) as well as geneti-
cally engineered mouse models that display the hallmarks of human cancer. In collaboration with 
Jay Bradner at the Dana-Farber Cancer Institute, Vakoc has shown that the small-molecule drug 
candidate JQ1 has potent anti-AML activity. It works by suppressing the protein BRD4, which is 
a critical regulator of the potent oncogene c-Myc. JQ1 is currently in clinical trials as a therapeu-
tic strategy for AML. Vakoc’s team identifi ed other chromatin regulators, including PRC2 and 
RNF20, that if blocked with small-molecule inhibitors may halt AML. Vakoc’s lab has gained 
new insights into the mechanism behind these drug targets, fi nding that Brd4 and other proteins 
required for AML bind to enhancers, short stretches of DNA more than a million bases away from 
the oncogene c-Myc. When Brd4 binds to the enhancer, it bends the DNA within the nucleus so 
that it touches the c-Myc region of the genome and activates it, causing cells to proliferate without 
restraint. Understanding how these proteins function in AML will allow researchers to design 
more effective and safer therapies to treat this intractable cancer.
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INTEGRATING GENOMIC DATA SETS TO UNDERSTAND 
GENE REGULATION IN DEVELOPMENT AND DISEASE
M. Hammell Y. Hao Y. Jin E. Paniagua J. Regalado Perez
 Y.-J. Ho D. Molik A. Patel O. Tam
Human development requires the regulated expres-
sion of thousands of genes in hundreds of distinct 
cell types throughout life. One requirement for this 
process is that each cell must contain an intact, func-
tional genome. Furthermore, there is a set of rules 
for how the genes in our genomes coordinate their 
activities, and these rules are encoded within gene 
regulatory networks. Many human diseases occur 
when these basic processes are altered, either through 
altering the genome itself (as in the mutations seen in 
cancers) or through altering the way in which genes 
interact within gene networks. The focus of our lab is 
to understand how mutations in our genomes lead to 
alterations in the function of the mutated gene itself 
and also the repercussion of these alterations on the 
hundreds of other neighboring genes within the net-
work. To this end, we use computational algorithms 
to integrate multiple types of genomic and transcrip-
tomic profi ling data into models of regulatory rewir-
ing events in human disease. This includes an empha-
sis on developing novel tools for the statistical analysis 
of high-throughput data, developing novel algorithms 
for modeling the fl ow of signals through genetic path-
ways, and importantly, testing these models using the 
tools of molecular genetics. The ultimate goal is to 
understand how human diseases like cancer take ad-
vantage of the cell’s ability to rewire its own regulatory 
networks into programs that serve the needs of the 
cancer cells.
Much of this work involves tight collaborations with 
other experimental groups at CSHL. One example in-
volves a collaboration with Marja Timmermans’ lab to 
understand the diversity of small RNA regulators in 
the maize genome and how these small RNAs dictate 
leaf patterning in development. Another collaboration, 
with Josh Dubnau’s lab, is exploring the contribution 
of transposons to human neurodegenerative diseases 
such as amyotrophic lateral sclerosis (ALS) and fronto-
temporal dementia (FTD). A collaboration with Greg 
Hannon’s lab probes the molecular mechanisms of 
transposon control more generally. A separate project 
with Greg Hannon’s lab aims to understand the chang-
es that occur during early breast cancer development 
so that we can better predict which patients are most 
likely to progress to invasive malignant cancers. An in-
dependent project in the M. Hammell lab combines 
both computational and experimental techniques to 
understand how melanoma cells develop resistance to 
targeted inhibitors of the melanoma cell growth path-
ways. Although the experimental systems for each of 
these projects vary greatly, each project seeks to under-
stand how gene regulation contributes to maintaining 
cellular function.
Mechanisms of Acquired Drug Resistance 
in Melanoma
A. Patel, J. Regalado Perez
The genetic basis of melanoma development is fairly 
well understood, with activating mutations in the on-
cogene BRAF occurring in a majority of melanoma pa-
tients (Hodis et al. 2012). Specifi c inhibitors that tar-
get activated BRAF as well as the downstream MAP/
ERK (mitogen-activated protein kinase/extracellular 
signal-related kinase) signaling pathway have been de-
veloped that dramatically reduce the growth of mela-
noma cells in patients. However, the effects of these 
drugs typically extend patient life span for 6 mo or 
less, as the tumors rapidly develop resistance to these 
targeted therapies (Villanueva et al. 2011). Although 
some tumors resistant to BRAF inhibitors acquire ad-
ditional genetic lesions that elevate ERK or AKT sig-
naling (Alcala et al. 2012), an astounding number of 
therapy-resistant cell lines establish resistance without 
signifi cant alteration of the genome (M. Herlyn, pers. 
comm.). Furthermore, serial passage of some of these 
cell lines in drug-free media results in the re-acqui-
sition of sensitivity to the targeted therapeutics, sug-
gesting that the resistance mechanism in these cases is 
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likely to be due to changes in gene regulation rather 
than secondary acquired mutations. Many factors 
could be mediating this reversible acquired resistance 
phenotype, the most likely of which would involve 
 alterations in the expression of small RNAs, alternative 
splicing of key transcripts in the MEK/ERK or AKT 
signaling pathways, or chromatin-modifying enzymes 
that alter DNA methylation or histone modifi cation. 
Members of our lab are using genomic and transcrip-
tomic profi ling studies to identify the gene regulatory 
factors that accompany acquired resistance to BRAF 
inhibitors. These experimental data sets are fed into 
custom algorithms designed to integrate these dispa-
rate data types into a systems-level view of the cellular 
signaling pathways that underlie melanoma growth 
and BRAF inhibitor resistance.
The Progression from Ductal Carcinoma 
In Situ to Invasive Ductal Carcinoma 
in Early Breast Cancer
Y.-J. Ho, O. Tam [in collaboration with G. Hannon, 
Cold Spring Harbor Laboratory]
Ductal carcinoma in situ (DCIS) is currently believed 
to be the precursor of invasive ductal carcinoma 
(IDC), the most common form of breast cancer, ac-
counting for 80% of all breast cancers (DeSantis et al. 
2014). It has been estimated that more than 50% of 
all patients diagnosed with DCIS would never pro-
gress to invasive cancer in the patient’s lifetime (Cow-
ell et al. 2013), yet nearly all patients opt for treat-
ment to avoid that risk. This refl ects an urgent need 
for understanding the pathway for progression from 
relatively benign DCIS to the mortality-causing IDC. 
Adequately characterizing DCIS lesions, however, re-
quires new experimental and computational tools that 
can handle the extremely small cell counts typically 
seen—on the order of 10–100 cells per biopsy section. 
We seek to develop tools that are suitable for single-
cell and low-input (1–100 cells) differential expres-
sion analysis by improving gene abundance normal-
ization methods, better formulating the relationship 
between abundance and variance in high-variance 
samples, and adjusting the standard statistical models 
currently used to model the sequence counts distri-
bution. Application of these tools to DCIS transcrip-
tome samples will enable us to probe the small popu-
lations of cells within early DCIS lesions, understand 
the heterogeneity that exists both within and between 
individual DCIS lesions, understand the changes that 
occur as benign DCIS lesions develop aggressive and 
invasive characteristics, and fi nd molecular markers 
that can be used to predict which DCIS lesions will 
eventually progress to IDC tumors.
This project will be aided by thousands of tis-
sue samples available from the Duke Breast SPORE 
bank. Fresh frozen DCIS biopsy samples are available 
for 159 lesions from 85 patients, with many patient 
samples exhibiting co-occurring DCIS and IDC tu-
mors. In addition, 3000 DCIS samples are available 
as formalin-fi xed paraffi n-embedded (FFPE) tissue 
blocks from the Duke surgical pathology archives. Al-
though these FFPE samples are much more degraded 
than the freshly frozen samples, this archive includes a 
crucial set of biopsies from 25 patients originally diag-
nosed with DCIS who later developed IDC tumors in 
the same breast. These cases can be compared to a set 
of 50 samples with extended clinical follow-up, where 
the patients are known not to have progressed to IDC 
within 10 years of the initial DCIS diagnosis. Taken 
together, these samples present an excellent resource 
for surveying the range of variance in DCIS tran-
scriptomes, for asking questions about the progression 
from DCIS to IDC, and for validating any prognos-
tic markers determined from the larger case-control 
using the smaller longitudinal cohort.
Small RNA Pathways in Maize
O. Tam [in collaboration with M. Timmermans, 
Cold Spring Harbor Laboratory]
The maize genome has remained relatively unexplored 
despite the importance of maize as one of the early 
genetic model organisms. Preliminary characteriza-
tions of the maize genome and transcriptome suggest 
that substantial differences exist, between both maize 
ecotypes and the well-characterized plant model Ara-
bidopsis (Springer et al. 2009; Eveland et al. 2010). 
Furthermore, these maize inbreds exhibit dramatic 
phenotypic differences in response to mutations in 
small RNA biogenesis factors, suggesting extensive 
evolution in both small RNA function and activity. 
In collaboration with the Timmermans lab, my group 
has undertaken a project to characterize the dynamics 
of small RNA expression and activity in a variety of 
maize tissues and inbreds. The focus of this project 
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is to determine the small RNA-mediated regulatory 
circuits that give rise to inbred-specifi c phenotypic 
diversity both within the maize species and within 
the larger group of grasses. Our analysis of maize 
trans-acting small interfering RNAs (tasiRNAs), a 
group of mobile endogenous 21-nucleotide siRNAs, 
has revealed that in maize shoots, tasiRNAs are 
generated through just a single genetic pathway and 
function solely in leaf development. In contrast, the 
many tasiRNAs found in Arabidopsis are processed via 
several distinct biogenesis pathways and function in 
development as well as pathogen defense. This same 
analysis also identifi ed a new class of 22-nucleotide 
phased siRNAs, produced by an unidentifi ed pathway 
that does not overlap with the tasiRNA biogenesis 
pathway. This class of small RNAs is entirely novel, 
with no homologs in other sequenced plants and no 
defi ned mechanism for biogenesis or activity. Finally, 
only 25% of the known microRNAs (miRNAs) from 
Arabidopsis are conserved in maize, leaving a wealth 
of novel miRNAs to explore. Members of our lab are 
collaborating to provide computational analysis of the 
profi les of small RNAs and their targets across maize 
ecotypes. Our lab has developed novel algorithms for 
the identifi cation of phased small RNAs, for miRNA 
gene identifi cation, and for miRNA target interaction 
analysis. These algorithms are being applied to deep-
sequencing data sets of small RNAs and mRNAs iso-
lated from developing maize tissues.
Transposon Control Systems in Animals
Y. Jin, O. Tam [in collaboration with G. Hannon and 
J. Dubnau, Cold Spring Harbor Laboratory]
TDP-43 is an RNA-binding protein that is known to 
control proper splicing and translation of many RNA 
targets in neurons. Mutation of TDP-43 has been as-
sociated with a variety of neurodegenerative diseases 
including amyotrophic lateral sclerosis (ALS), fronto-
temporal lobar degeneration (FTLD), and Alzhei-
mer’s disease (AD) (Cohen et al. 2011). However, the 
normal function of TDP-43 in neuronal development 
and maintenance has not been fully characterized, and 
few of its mRNA targets have been defi nitively asso-
ciated with the neurodegenerative diseases that result 
from loss of TDP-43 function (Da Cruz et al. 2011). 
In collaboration with the Dubnau lab, my group has 
explored the novel hypothesis that TDP-43 normally 
plays a large and hitherto uncharacterized role in reg-
ulating the expression of transposable elements (TEs), 
mobile genetic elements whose unregulated expression 
leads to genetic instability as well as cellular toxicity. 
Members of our lab have shown that TE transcripts 
are elevated upon expression of mutant, aggregate-
prone forms of human TDP-43 in the fl y brain and 
that neurodegeneration results from expression of this 
human TDP-43 protein. Members of my group have 
shown that TDP-43 binds widely to TE transcripts 
in mammals and that TDP-43 binding to TEs is lost 
in human patients diagnosed with FTLD (Li et al. 
2012), a disease characterized by TDP-43 proteinopa-
thy. Although these studies support a role for TDP-
43 in regulating TE expression, our future goals are 
centered on defi ning a causal role for TDP-43- mediated 
regulation of TEs in neurodegenerative disease. One 
important element of this project will be to identify 
how TDP-43 interacts with the small RNA regulators 
of TE expression known to be involved in controlling 
TE mobility. We are currently exploring the molecular 
mechanism behind TDP-43 function in the fl y and 
mouse model organisms, where many genetic mutants 
are available, to carefully describe the factors that medi-
ate TDP-43 involvement in TE regulation, biogenesis, 
and activity. My group is pursuing a parallel approach in 
close collaboration with the Dubnau lab to quantify the 
extent to which TDP-43 contributes to TE regulation as 
compared to its other mRNA targets and the potential 
contribution of each function to clinical outcomes.
In a separate collaboration, we work closely with 
members of the G. Hannon lab to better understand 
the biological mechanisms of transposon control 
in animals. This basic research into the factors that 
regulate transposon activity sets the foundation for 
understanding disease processes affected by transpo-
son misregulation. Most families of TEs are highly 
distinct at the primary sequence level and use differ-
ent strategies for their propagation, challenging the 
ability of host genomes to discriminate transposons 
from endogenous genes (Levin and Moran 2011). Sev-
eral recent studies have indicated that a small RNA-
based innate immune system, the Piwi-interacting 
RNA (piRNA) pathway, addresses the challenge of 
transposon recognition and silencing. In germ cells, 
primary piRNAs are loaded into Piwi and Aubergine 
to control transposons through a posttranscriptional 
mechanism. However, several factors, including Piwi’s 
nuclear localization, have suggested that Piwi might 
Cancer: Gene Regulation and Cell Proliferation  31
also regulate its targets by controlling their transcrip-
tion. We therefore probed the contributions of Piwi to 
transposon silencing in germ cells and in their somatic 
support cells using tissue-specifi c piwi knockdowns.
Integrated analyses of steady-state RNA levels by 
RNA sequencing (RNA-Seq), and measurements of 
nascent RNA synthesis using global run-on sequenc-
ing (GRO-Seq), chromatin marks by chromatin im-
munoprecipitation combined with deep sequencing 
(ChIP-Seq), and small RNA levels indicated multi-
ple roles for Piwi in the piRNA pathway in both the 
germline and the soma. In the soma, our data sup-
port a model where Piwi silences the transcription of 
targeted elements, such that transcriptional gene si-
lencing (TGS) is the dominant form of Piwi activity. 
In germ cells, our data revealed that Piwi both acts 
via TGS and exerts unexpected impacts on piRNAs 
that occupy Aubergine and Ago3, indirectly reducing 
the capacity of the entire piRNA pathway to silence 
transposons via posttranscriptional gene silencing 
(PTGS). These data sets add new complexity to our 
understanding of Piwi function, which has primar-
ily been studied for its direct role in PTGS. Ongoing 
experiments will seek to understand the mechanisms 
by which Piwi contributes to TGS and how Piwi indi-
rectly affects other moderators of PTGS.
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STRUCTURAL BIOLOGY OF NUCLEIC ACID 
REGULATORY PROCESSES
L. Joshua-Tor E. Elkayam C. Faehnle J. Ipsaro S.-J. Lee A. Tocilj
 A. Epstein S. Goldsmith C. Kuhn K. On J. Walleshauser
We study the molecular basis of nucleic acid regula-
tory processes, RNA interference (RNAi) and DNA 
replication in particular. We use the tools of struc-
tural biology, biochemistry, and biophysics to study 
proteins and protein complexes associated with these 
processes to elucidate how they work. X-ray crystal-
lography and other structural techniques enable us to 
obtain the three-dimensional structures of these mo-
lecular machines. Biochemistry, biophysics, and mo-
lecular biology allow us to study properties that can be 
correlated with their function and biology.
Mechanisms of RNAi and Noncoding RNAs
RNAi has made an enormous impact on biology in a 
very short period of time. Not only are we still discov-
ering new cellular pathways for the regulation of gene 
expression that use these pathways, but RNAi has also 
become an extraordinarily useful and simple tool for 
gene silencing. Almost from its beginnings, people 
have used genetics, biochemistry, molecular biology, 
and bioinformatics to study the mechanism of RNAi 
and related pathways. We argued, however, that in 
order to get a true mechanistic understanding of these 
pathways, we must understand how the components 
of the RNAi machinery work at a molecular level.
The let-7 Pathway
C. Faehnle, J. Walleshauser
let-7 is among the fi rst microRNAs (miRNAs) discov-
ered, and it is involved in controlling cell fate dur-
ing late-stage larval development in Caenorhabditis 
elegans. Functionally conserved in humans, the let-7 
family is broadly expressed in somatic cells and regu-
lates cellular proliferation and differentiation, as well 
as the repression of several oncogenes and key regu-
lators of mitogenic pathways. Humans have 12 let-7 
variants expressed from eight independent chromo-
somal loci, and many tumors are associated with the 
coordinated down-regulation of multiple let-7 family 
members. In contrast to differentiated cells, mature 
let-7 levels are undetectable in stem cells, but primary 
and precursor let-7s remain high. Similarly, human 
tumors generally express the primary transcripts but 
not the mature form, which was the fi rst indication 
that a mechanism of posttranscriptional regulation of 
let-7 biogenesis is at play. The Lin28 protein was dis-
covered to be the posttranscriptional regulator of let-7 
biogenesis. Lin28 is highly expressed in embryonic 
stem cells and is naturally active in early development, 
where it suppresses the expression of mature let-7 to 
maintain the pluripotent state. Lin28 has a number of 
important biological roles, including the maintenance 
of pluripotency, the reprograming of cellular metabo-
lism, and the promotion of tissue regeneration. The 
Lin28–let-7 pathway has been described as a bistable 
switch. Either Lin28 or mature let-7 is expressed, but 
not both. Each molecule represses expression of the 
other, and once the cell changes its state, the result is 
differentiation or if the switch is reversed, cancer.
In differentiated cells, TUT4 and TUT7 uridylate 
certain let-7 precursors (pre-let-7) that carry a single 
3′-nucleotide overhang, rather than the more Dicer-
ready two-nucleotide overhang pre-miRNAs. In this 
case, in the absence of Lin28, only a single uridine 
is added to convert the pre-let-7s to better substrates 
for Dicer and promote the production of mature let-7. 
In stem cells, Lin28 binds to pre-let-7, triggering its 
3′ oligouridylation by TUT4/7. The oligoU tail serves 
as a decay signal, as it is rapidly degraded by Dis3L2, 
a homolog of the catalytic subunit of the exosome. We 
determined the structure of mouse Dis3L2 in complex 
with an oligoU RNA to mimic the uridylated tail of 
pre-let-7 (Fig. 1). The RNA-binding domains form an 
open funnel on one face of the catalytic domain that 
allows RNA to navigate a path to the active site. An 
extensive network of uracil-specifi c interactions spans 
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the fi rst 12 nucleotides of the oligoU-tailed RNA, ex-
plaining how Dis3L2 recognizes, binds, and processes 
uridylated pre-let-7 in the fi nal step of the Lin28-let-7 
pathway.
Small RNA and tRNA Surveillance 
by the CCA-Adding Enzyme
C. Kuhn [in collaboration with J. Wilusz, University of 
Pennsylvania; P. Beal, University of California, Davis]
Transcription in eukaryotes produces a number of 
long noncoding RNAs (lncRNAs). Two of these, 
MALAT1 and Menβ, which are well-characterized 
long nuclear-retained noncoding transcripts that are 
involved in cancer progression and paraspeckle for-
mation, generate a tRNA-like small RNA in addition 
to the mature lncRNA. The stability of these tRNA-
like small RNAs as well as that of bona fi de tRNAs 
are monitored by the CCA-adding enzyme. Just as 
for bona fi de tRNAs, the trinucleotide CCA is post-
transcriptionally added to the 3′-end of mascRNA 
(MALAT1-associated small cytoplasmic RNA), the 
tRNA-like transcript originating from the 3′-end of 
MALAT1. Unlike the acceptor stems of canonical 
tRNAs and mascRNA, the Menβ acceptor stem is de-
stabilized through mismatches or wobble base pairs, 
somehow prompting the CCA-adding enzyme to re-
peat its catalytic cycle and thereby add tandem CCA 
motifs. The CCACCA tail then serves as a degradation 
signal for the cellular RNA decay machinery. It appears 
now that many bona fi de tRNAs that are destabilized 
through mutations or the lack of proper modifi cations 
are subjected to a similar CCACCA addition. Thus, 
the CCA-adding enzyme is not only critical for gen-
erating functional tRNAs, but also likely has a uni-
versal and central role in tRNA and tRNA-like small 
RNA surveillance and quality control.
We investigated how the CCA-adding enzyme 
distinguishes structurally stable RNAs from unsta-
ble RNAs so as to only mark unstable RNAs with 
CCACCA. We unraveled how a second CCA cycle 
can occur despite the enzyme possessing a unique 
mechanism that normally ensures a single cycle of 
CCA synthesis. We found that after the fi rst CCA 
cycle, nucleotide binding to the active site induces 
the enzyme to apply torque on the RNA. A clockwise 
screw motion of the enzyme’s catalytic domain leads 
to RNA compression and overwinding. This causes 
unstable RNAs to extrude a distinctively positioned 
bulge from the acceptor stem while still bound to 
the enzyme (Fig. 2). The bulge does not perturb the 
double-helical nature of the substrate and all other 
Figure 1. The structure of mouse Dis3L2 in complex with oligoU 
RNA.
Figure 2. Structure of the CCA-adding enzyme from Archaeo-
globos fulgidus in complex with a tRNA minihelix (containing 
the acceptor stem and the TΨC stem-loop) with added CCAC, 
and CTP.
34  Research
structural determinants near the active site remain 
in place. The catalytic mechanism is thus preserved 
between the fi rst and second cycles of CCA addi-
tion. In total, we found that tandem CCA addition 
is not the result of a modifi ed enzymatic activity that 
is particular to unstable RNAs. Rather, it is a con-
sequence of the natural activity of the CCA-adding 
enzyme on a substrate with increased conformational 
fl exibility. By exploiting the versatility of RNA struc-
ture, the CCA-adding enzyme is able to trigger the 
degradation of potentially detrimental small RNAs 
and tRNAs (Fig. 3).
RNAi and Heterochromatin Formation
C. Kuscu, T. Schalch [in collaboration with 
R.A. Martienssen, Cold Spring Harbor Laboratory; 
J. Partridge, St. Jude Children’s Research Hospital]
RNAi pathways are also used to repress genes at the 
transcriptional level by guiding heterochromatin 
formation. Although we are just beginning to dis-
cover how metazoans use this type of mechanism for 
transcriptional silencing, these pathways are much 
better characterized in plants and fungi, in particu-
lar in Schizosaccharomyces pombe, where heterochro-
matin is essential for kinetochore assembly required 
for proper segregation of chromosomes during cell 
division. The complexes involved in heterochroma-
tization in S. pombe are fairly well defi ned, and in 
most cases, only one version of each component ex-
ists. However, our understanding of this pathway has 
not gone much beyond the “blobology” stage either. 
Assembly of centromeric heterochromatin requires 
the RITS (RNA-induced transcriptional silencing) 
complex, a specialized RISC (RNA-induced silenc-
ing complex), which physically anchors small RNAs 
to chromatin. It consists of the Argonaute protein, 
Ago1, the chromodomain protein Chp1, a GW-like 
protein Tas3, and small interfering RNAs (siRNAs) 
derived from centromeric repeats. We previously char-
acterized Chp1’s high-affi nity binding to chromatin 
and showed it to be critical for the establishment 
of centromeric heterochromatin. In addition, apart 
from the chromodomain, Chp1 had no recognizable 
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domains. Our structure of the carboxy-terminal half 
of Chp1 with the Tas3 amino-terminal domain re-
vealed the presence of a PIN domain in Chp1, which 
contributes to posttranscriptional gene silencing of 
subtelomeric transcripts independent of RNAi. We 
also realized that Chp1 and Tas3 form a tight com-
plex and that Argonaute appears to bind more loosely. 
We suggested that Chp1–Tas3 provides a solid and 
versatile platform to recruit both RNAi-dependent 
and RNAi-independent gene-silencing pathways for 
locus-specifi c regulation of heterochromatin and that 
the reach of long and fl exible regions in these two 
proteins might be important for contacting other nu-
cleosomes at these loci.
The RITS complex recruits the H3K9 methylase, 
Clr4, which is part of a large complex called CLRC. 
CLRC also contains the cullin Cul4 and its interact-
ing protein Pip1, the adaptor Rik1, a WD repeat pro-
tein Dos1, and Dos2. Curiously, CLRC is an active 
E3 ligase in vitro, and this activity is necessary for 
heterochromatin assembly in vivo. Yet the role of this 
E3 ligase activity is still unknown. We performed a 
pairwise interaction screen of the CLRC components 
revealing a subunit arrangement that is reminiscent 
of CRL4, a different cullin ring ligase complex for 
which a crystal structure is available. Both complex-
es contain the ubiquitin ligase Cul4, and sequence 
similarities between two other subunits were already 
noted. We have begun delineating structural and 
functional similarities. In particular the placement 
of Dos1 indicated that it might have a role similar to 
that of DDB2 in CRL4, as a target-binding factor for 
the E3 ligase. We solved the structure of Dos1 and 
found it to be an eight-bladed β-propeller with one 
face mediating interaction with the adaptor protein 
Rik1. We made a series of mutations on the opposite 
surface and found several regions that are required 
for heterochromatin silencing, underscoring the no-
tion that Dos1 is the specifi city factor for the ligase.
The Different Faces of E1: A Replicative 
Hexameric Helicase
S.-J. Lee [in collaboration with A. Stenlund, 
Cold Spring Harbor Laboratory: T. Ha, University 
of Illinois, Urbana-Champaign]
Precise replication of the genome is essential for main-
taining the integrity of genomic information. As a 
prerequisite for DNA replication, two complemen-
tary DNA strands are separated and each becomes 
a template for the synthesis of a new complementary 
strand. Strand separation is mediated by a helicase 
enzyme, a molecular machine that uses the energy 
derived from ATP hydrolysis while moving along the 
DNA. Our crystal structures of the double-stranded 
DNA (dsDNA)-binding domain (DBD) of the rep-
licative helicase E1 from papillomavirus in various 
stages of assembly led us to propose a model in which 
the transition from the dimer to the ultimate dou-
ble hexamer results in strand separation. The load-
ing and assembly of this protein separate the double 
helix, such that each hexameric helicase encircles one 
strand of DNA. Once assembled, the helicase uses 
its ATP-driven motor to translocate on the DNA or 
“pump” the single-stranded DNA (ssDNA) through 
the hexameric ring. Several competing mechanisms 
for helicase unwinding were proposed. Having de-
termined a structure of hexameric E1 with ssDNA 
discretely bound in the central channel and nucleo-
tides at the subunit interfaces, we showed that only 
one DNA strand passes through the hexamer chan-
nel and that the DNA-binding hairpins of each sub-
unit form a spiral staircase that sequentially tracks 
the DNA backbone. The nucleotide confi gurations 
at the subunit interfaces indicate that each subunit 
sequentially progresses through ATP, ADP, and apo 
states, whereas its associated DNA-binding hairpin 
travels from the top to the bottom of the staircase, 
each escorting one nucleotide of ssDNA through 
the channel, as if six hands grab the DNA and upon 
ATP hydrolysis and ADP release pull it through the 
channel. With this unique look into the mechanism 
of translocation of this molecular machine along 
DNA, we have focused on mechanistic aspects of the 
enzyme in solution.
By taking a multifaceted approach including 
single- molecule and ensemble FRET (Förster reso-
nance energy transfer) methods, we have found that 
E1 is oriented with the amino-terminal side of heli-
case facing the replication fork, consistent with the 
crystal structure. We also showed that E1 generates 
strikingly heterogeneous unwinding patterns stem-
ming from varying degrees of repetitive movements 
that are modulated by the DNA-binding domain. 
Furthermore, our studies found that the DNA-bind-
ing domain promotes the assembly of E1 helicase 
onto a forked DNA substrate, acting as an allosteric 
effector of the helicase. Taken together, our studies 
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reveal previously unrecognized dynamic facets of 
replicative helicase unwinding mechanisms, add-
ing another layer of complexity in the workings and 
regulation of DNA replication.
PUBLICATIONS
Faehnle CR, Walleshauser J, Joshua-Tor L. 2014. Mechanism of 
Dis3L2 substrate recognition in the Lin28/let-pathway. Nature 
514: 252–256.
Kuscu C, Zaratiegui M, Kim HS, Wah DA, Martienssen RA, 
Schalch T, Joshua-Tor L. 2014. The CRL4-like Clr4 Complex 
in S. pombe depends on an exposed surface of Dos1 for hetero-
chromatin silencing. Proc Natl Acad Sci 111: 1795–1800.
Lee SJ, Syed S, Enemark EJ, Schuck S, Stenlund A, Ha T, Joshua-Tor 
L. 2014. Dynamic look at DNA unwinding by a replicative heli-
case. Proc Natl Acad Sci 111: E827–E835.
In Press
Ipsaro JJ, Joshua-Tor L. 2015. From guide to target: Molecular in-
sights into eukaryotic RNAi machinery. Nat Struct Mol Biol 22: 
20–28.
Kuhn CD, Wilusz JE, Zheng Y, Beal PA, Joshua-Tor L. 2015. On-
enzyme refolding permits small RNA and tRNA surveillance by 
the CCA-adding enzyme. Cell 160: 644–658.
37
RNA SPLICING
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Mechanisms of Constitutive and Alternative 
Pre-mRNA Splicing
RNA splicing is required for expression of most eu-
karyotic protein-coding genes. The spliceosome selects 
authentic splice sites with very high fi delity, relying on 
limited sequence information present throughout in-
trons and exons. In humans, >90% of genes are ex-
pressed via alternative splicing, giving rise to multiple 
protein isoforms. The choice of alternative splice sites 
is commonly regulated to alter gene expression, either 
tissue-specifi cally or in response to a developmental 
program or to signaling pathways. The fact that mul-
tiple protein isoforms can be expressed from individu-
al genes demonstrates that the classical “one gene–one 
enzyme” paradigm is no longer valid and provides an 
explanation for the unexpectedly small number of 
protein-coding genes uncovered by genome-sequenc-
ing projects.
Both constitutive and alternative splicing mecha-
nisms involve numerous protein components, as well 
as fi ve noncoding RNA components that are part of 
small nuclear ribonucleoprotein (snRNP) particles. 
The work in our lab focuses on the identifi cation and 
molecular characterization of protein factors and se-
quence elements that are necessary for the catalysis 
and fi delity of splicing and/or for the regulation of 
alternative splice-site selection. We are interested in 
how the spliceosome correctly identifi es the exons on 
pre-mRNA, and how certain point mutations in ei-
ther exon or intron sequences cause aberrant splicing, 
leading to various human genetic diseases. Related 
areas of interest include the remodeling of mRNP ar-
chitecture as a consequence of splicing, which infl u-
ences downstream events, such as nonsense-mediated 
mRNA decay (NMD); the various roles of alternative 
splicing misregulation in cancer; and the development 
of effective methods to correct defective splicing or 
modulate alternative splicing, especially in a disease 
context. A summary of some of our recently published 
studies is provided below.
Alternative Splicing and Cancer
Alternative splicing has an important role in cancer, 
partly by modulating the expression of many onco-
genes and tumor suppressors, and also because inac-
tivating mutations that affect alternative splicing of 
various tumor suppressor genes account for some of 
the inherited and sporadic susceptibility to cancer. 
In addition, alternative splicing controls a metabolic 
switch characteristic of all cancer cells, known as the 
Warburg effect. We have continued to analyze the 
roles of individual members of the SR protein family 
of splicing factors in cancer.
We studied the SR protein SRSF6 and identifi ed it 
as a regulator of wound healing and tissue homeostasis 
in skin (in collaboration with John Erby Wilkinson, 
University of Michigan, Ann Arbor). We found that 
SRSF6 is a proto-oncogene frequently overexpressed 
in human skin cancer, including malignant melano-
mas and basal-cell and squamous-cell carcinomas. 
Overexpressing doxycycline-inducible SRSF6 cDNA 
in transgenic mice induced epithelial hyperplasia of 
sensitized skin (e.g., by shaving or hair plucking) and 
promoted aberrant alternative splicing. We observed 
severe epidermal thickening and hair-follicle lesions, 
which were reversible upon withdrawal of the doxy-
cycline inducer. Skin transplantation experiments to 
nontransgenic donor mice showed that the inducible 
SRSF6 effects are cell-autonomous.
Microarray analysis identifi ed 139 target genes with 
SRSF6-induced alternative-splicing changes in skin, 
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including many genes associated with wound healing. 
Focusing on the Tnc gene coding for the extracellu-
lar-matrix protein tenascin C, we demonstrated that 
SRSF6 binds to alternative exons in its pre-mRNA 
and promotes the expression of isoforms characteristic 
of invasive and metastatic cancer, although this par-
ticular regulatory event is independent of cell type. 
SRSF6 overexpression additionally resulted in deple-
tion of LGR6+ stem cells and excessive keratinocyte 
proliferation and response to injury. Furthermore, we 
showed that the effects of SRSF6 on wound healing 
assayed in vitro depend on the TNC isoforms. Thus, 
abnormal expression of this SR protein splicing factor 
can perturb tissue homeostasis in skin.
Targeted Antisense Modulation of 
Alternative Splicing for Therapy and 
Investigation of Pathogenesis Mechanisms
Spinal muscular atrophy (SMA) is a common, auto-
somal-recessive motor-neuron degeneration disorder 
caused by homozygous deletion or mutation of the 
survival-of-motor-neuron gene, SMN1. A closely re-
lated SMN1 paralog, SMN2, is present in all patients 
and differs from SMN1 by a C to T transition in exon 
7 that causes substantial skipping of this exon, such 
that SMN2 expresses only low levels of functional, 
full-length SMN protein. SMN2 decreases the sever-
ity of SMA in a copy-number-dependent manner. We 
previously developed an antisense oligonucleotide 
(ASO) that effi ciently increases the extent of exon 7 
inclusion during splicing of SMN2 transcripts, for 
therapeutic use in SMA. This translational research 
was done in collaboration with Isis Pharmaceuticals. 
After extensive preclinical testing, and phase I and 
phase II open-label clinical trials, phase III random-
ized, double-blind, sham-procedure-controlled clini-
cal trials with the ASO compound, ISIS-SMNRx, are 
well under way. The drug, which is administered to 
SMA infants and children by lumbar puncture, has 
been well tolerated at all doses tested, and dose- and 
time-dependent improvements in motor function have 
already been observed in the open-label studies.
Although it is clear that SMN defi ciency causes 
SMA, the pathogenesis mechanisms remain elusive. 
SMN is ubiquitously expressed and is an essential 
protein, but its reduction appears to selectively affect 
motor neurons, for unknown reasons. However, selec-
tively restoring SMN in motor neurons only partially 
rescues SMA in mouse models. We addressed the rela-
tive importance of SMN restoration in the central ner-
vous system (CNS) versus peripheral tissues in mouse 
models using a systemically administered therapeutic 
splice-switching ASO to broadly restore SMN, and an 
intracerebroventricularly administered complemen-
tary decoy oligonucleotide to neutralize the effects 
of the therapeutic ASO within the CNS. This pro-
cedure effectively cancels out the effect of ASO that 
crosses the immature blood-brain barrier in neonate 
mice. Increasing SMN exclusively in peripheral tis-
sues completely rescued necrosis in mild SMA mice 
and robustly extended survival in severe SMA mice, 
with signifi cant improvements in vulnerable tissues 
and motor function along with preservation of spinal 
motor neuron counts and neuromuscular-junction 
integrity. Our data demonstrate a critical role of pe-
ripheral pathology in the mortality of SMA mice and 
indicate that peripheral SMN restoration compensates 
for its defi ciency in the CNS and preserves motor neu-
rons. Thus, SMA is not a cell-autonomous defect of 
motor neurons in SMA mice.
Spliceosomal Protein-Interaction Network
During spliceosome assembly, protein–protein inter-
actions (PPI) are sequentially formed and disrupted to 
accommodate the spatial requirements of pre-mRNA 
substrate recognition and catalysis. Splicing activators 
and repressors, such as SR proteins and heterogeneous 
nuclear RNPs (hnRNPs), modulate spliceosome as-
sembly and regulate alternative splicing. However, it 
remains unclear how they differentially interact with 
the core spliceosome to perform their functions.
We investigated the protein connectivity of SR 
and hnRNP proteins to the core spliceosome using 
probabilistic network reconstruction based on the 
integration of interactome and gene-expression data. 
We validated our model by immunoprecipitation 
and mass spectrometry of the prototypical splicing 
factors SRSF1 and hnRNPA1. Network analysis re-
vealed that a splicing factor’s properties as an activa-
tor or repressor can be predicted from its overall con-
nectivity to the rest of the spliceosome. In addition, 
we discovered and experimentally validated PPIs 
between the oncoprotein SRSF1 and members of 
the SF3 subcomplex of U2 snRNP that are targeted 
by spliceostatin, pladienolide, and related antitumor 
drugs. Our fi ndings suggest that activators promote 
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the formation of PPIs between spliceosomal subcom-
plexes, whereas repressors mostly operate through 
protein-RNA interactions.
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CELL BIOLOGY OF THE NUCLEUS
D.L. Spector G. Arun S. Diermeier R.I. Kumaran
 J. Bergmann M. Eckersley-Maslin J. Li
 M.S. Bodnar S. Hearn A. Yu
 K.-C. Chang M. Hübner C. Zepeda-Mendoza
Most cellular processes can trace their beginnings to 
the nucleus, where gene activation results in the pro-
duction of an RNA molecule, some of which encode 
for proteins, whereas others are functional in the form 
of RNA. Although much biochemical information is 
available regarding many of the factors involved in 
gene expression, the spatial and temporal parameters 
that infl uence gene expression and the role of non-
coding RNAs in regulating this multifaceted process 
are just beginning to be elucidated. During the past 
year, our research has continued to focus on elucidat-
ing various mechanisms of regulating gene expression 
and DNA repair and the role of long nuclear retained 
noncoding RNAs in development and cancer pro-
gression. The following is an overview of some of our 
major accomplishments over the past year.
Expression of lncRNAs in Mouse 
Embryonic Stem Cells and Neural 
Progenitor Cells
J. Bergmann, A. Yu, M. Eckersley-Maslin, J. Li 
[in collaboration with F. Rigo and S. Freier, 
Isis Pharmaceuticals]
Long noncoding RNAs (lncRNAs) (>200 nucleotides 
in length) represent a relatively recently studied class 
of RNAs that have been implicated in numerous cel-
lular functions, including modulating transcriptional 
patterns, regulating protein activities, serving struc-
tural or organizational roles, altering RNA processing 
events, and serving as precursors to small RNAs. The 
majority of lncRNAs are expressed at very low levels, 
and these RNAs generally exhibit poor primary se-
quence conservation over evolution.
We performed high-depth poly(A)+ RNA se-
quencing across multiple clonal populations of 
mouse embryonic stem cells (ESCs) and neural pro-
genitor cells (NPCs) to comprehensively identify 
differentially regulated intergenic lncRNAs. Of the 
3506 genes annotated in Gencode M3 as “lincRNA” 
or “processed transcript” (Ensembl 76; referred to as 
“lncRNA” for the remainder of this study), we de-
tected 958 lncRNAs expressed at ≥ 0.1 FPKM (frag-
ments per kilobases of exons for per million mapped 
reads) in the union of our ESC and NPC data sets. 
This set of lncRNAs contained well over 800 that are 
largely uncharacterized on the molecular level. Of 
the 800 lncRNAs identifi ed, 508 (64%) displayed 
a signifi cant change in expression level upon differ-
entiation of ESCs to NPCs (DESeq2, FDR < 0.01), 
with 439 lncRNAs being exclusively detected in ei-
ther cell type. We also used ab initio transcript as-
sembly using Cuffl inks to assess the completeness 
of the Gencode annotation. From our analyses, we 
prioritized 50 lncRNA candidates that exhibited ex-
pression in ESCs, thus potentially implicating them 
in the coregulation of self-renewal or pluripotency-
related networks. Because we are interested in iden-
tifying lncRNAs whose expression is strongly as-
sociated with the ESC state, we also analyzed raw 
poly(A)+ RNA-Seq data from 22 mouse tissues (in-
cluding fetal liver and neural tissues of embryonic 
origin) recently released by the ENCODE project. 
Gene-level analysis of this matrix demonstrated that 
the majority of the 50 lncRNAs most specifi cally 
expressed in ESCs displayed exclusive expression in 
this cell type, rendering them viable candidates as 
pluripotency biomarkers.
We have initiated studies to assess the functional 
role of these lncRNA candidates. Among our top 
candidates, we have been able to demonstrate that 
acute depletion of PAT-14 using antisense oligonu-
cleotide technology impacts the differentiation- and 
development-associated gene expression program 
of ESCs. Furthermore, we demonstrate that Firre, 
an lncRNA highly enriched in the nucleoplasm and 
 previously reported to mediate chromosomal con-
tacts in ESCs, controls a network of genes related to 
RNA processing. Ongoing studies will further analyze 
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the functional associations of these and other ESC-
specifi c lncRNAs.
Probing the Role of the lncRNA 
Malat1 in Breast Cancer Progression
G. Arun, S. Diermeier, K.-C. Chang [in collaboration with 
M. Egeblad, M. Akerman, S. Hearn, and A. Krainer, Cold 
Spring Harbor Laboratory; J.E. Wilkinson, University of 
Michigan Medical School; Y. Kim and A.R. MacLeod, 
Isis Pharmaceuticals; L. Norton and E. Brogi, Memorial 
Sloan-Kettering Cancer Center]
MALAT1 (metastasis-associated lung adenocarcinoma 
transcript 1) is among the most abundant and highly 
conserved nucleus-restricted lncRNAs whose expres-
sion is misregulated in many cancers, including breast 
cancer. We have used the MMTV-PyMT mouse model 
of luminal-B breast cancer to characterize the role of 
Malat1 in primary breast cancer and its subsequent 
metastasis. Malat1 lncRNA was knocked down via 
subcutaneous administration of antisense oligonucle-
otides (ASOs) over a period of 7 wk, after which ani-
mals were sacrifi ced, and primary tumors and lungs 
were removed for molecular and histological analyses. 
Malat1 ASO treatment resulted in ~60% knockdown 
in the primary tumor concomitant with a signifi cant 
reduction in tumor progression rate, as well as a change 
in the differentiation status. Detailed histopathologi-
cal analysis of ASO-treated tumors showed an increase 
in well-differentiated ductular tumors, whereas scram-
bled ASO-treated tumors progressed to solid carcino-
mas. Most interestingly, a marked decrease was ob-
served in the incidence of lung metastases: ~70% fewer 
metastatic nodules in Malat1 ASO-treated animals 
than in scrambled ASO-treated animals. Furthermore, 
Malat1 ASO-treated ex-vivo-generated mammary 
gland organoids from MMTV-PyMT mice resulted 
in an inhibition of branching morphogenesis, which 
recapitulates the invasive process that initiates metas-
tases in vivo. RNA-Seq analysis of the primary tumors 
and tumor-derived organoids treated with Malat1 
ASO showed up-regulation of genes involved in dif-
ferentiation and down-regulation of genes involved 
in migration and proliferation. Furthermore, Malat1 
knockdown also resulted in altered pre-mRNA splic-
ing of many genes including critical transcription fac-
tors. Together, our data indicate that Malat1 lncRNA 
regulates critical processes in breast cancer pathogen-
esis and represents a promising therapeutic target.
Identiﬁ cation of lncRNAs Involved in 
Breast Cancer Progression
S. Diermeier, K.-C. Chang [in collaboration with S.M. 
Freier, F. Rigo, and C. Frank Bennett, Isis Pharmaceuticals]
Recent fi ndings of the ENCODE consortium re-
vealed that as much as ~80% of the human genome 
can be transcribed, in contrast to only 2% being 
translated into proteins. The noncoding RNA tran-
scripts can be subdivided into several groups, with 
lncRNAs representing the largest and most diverse 
class. With breast cancer being the most frequent 
malignancy in women worldwide, we set out to in-
vestigate the role of lncRNAs as potential prognostic 
and therapeutic targets in mammary tumor forma-
tion, progression and metastasis. Here, we focus 
on the luminal-B and the HER2/neu-positive sub-
types of breast cancer, as both are associated with 
high prevalence and bad prognosis. To identify the 
complement of lncRNAs with altered expression 
levels, we extracted carcinomas from mouse mam-
mary tumor virus–polyomavirus middle-T antigen 
(MMTV-PyMT) and MMTV-Neu-NDL mice and 
performed a comparative RNA-Seq screen. The 
transcriptome of wild-type, nulliparous mammary 
glands served as control. We isolated RNA either di-
rectly from cryosections of the tumor tissue or from 
organotypic epithelial cultures that have been grown 
in a three-dimensional extracellular matrix. Our 
RNA-Seq results reveal drastic changes in both the 
coding and the lncRNA transcriptome. To narrow 
down the candidate list of lncRNAs with the highest 
therapeutic potential, we sorted the data computa-
tionally according to expression fold-change, inter-
genic genome location, and lncRNA size. Following 
these criteria, we identifi ed a number of lncRNAs 
that are up-regulated in both the PyMT and the 
HER2/neu model, as well as some that are subtype-
specifi c transcripts. These lncRNAs represent a di-
verse group in terms of expression levels, genomic 
locations, length, and biotypes. ASOs were designed 
that independently target several of the newly identi-
fi ed lncRNAs. Knockdown assays were performed in 
primary mammary tumor cells and organotypic epi-
thelial cultures, resulting in a knockdown effi ciency 
of 45%–99% for the tested transcripts. Within 6 
days of ASO-mediated knockdown of several of the 
lncRNAs, we observed phenotypic changes of the 
organoids such as reduced cell migration and/or cell 
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growth. Future studies will focus on the molecular 
characterization of these lncRNAs and elucidation of 
their potential role(s) in mammary tumor progres-
sion and metastasis.
Quantitative Analysis of Chromatin 
Interactions upon Copy-Number 
Variation at Mouse 4E2
C. Zepeda-Mendoza, M. Eckersley-Maslin [in collaboration 
with S. Mukhopadhyay and A. Mills, Cold Spring Harbor 
Laboratory; E.S. Wong and P. Flicek, EMBL-EBI; N. Harder, 
R. Eils, and K. Rohr, University of Heidelberg; E. Splinter, 
E. de Wit, and W. de Laat, Hubrecht Institute; T. Ried, 
National Cancer Institute; A.M. Sengupta, Rutgers 
University]
Circular chromosome conformation capture (4C) 
has provided important insights into three-dimen-
sional (3D) genome organization and its critical 
impact on the regulation of gene expression. We 
developed a new quantitative framework based on 
polymer physics for the analysis of paired-end high-
throughput sequencing 4C (PE-4C-Seq) data. Our 
pipeline corrects for PE-4C-Seq data biases, nor-
malizes data, and computes the contact probability 
between a viewpoint fragment and all other frag-
ments in the chromosome, allowing the quantita-
tive testing of differences in chromatin contacts and 
chromatin compaction. In particular, this method 
is especially suited for the analysis of complex chro-
mosome modifi cations such as copy-number vari-
ants (CNVs). We applied this new approach to 
study chromatin interactions within and around a 
4.3-Mb engineered deletion in mouse region 4E2, 
which is orthologous to human 1p36. Allele- specifi c 
PE-4C-Seq experiments of deletion and wild-type 
(WT) chromosomes revealed several local and 
long- range differentially interacting regions (DIRs) 
in the deletion-containing chromosome (Df ). A 
surprising reduction of local chromatin compaction 
was identifi ed for viewpoints located near the telo-
meric end in the Df chromosome. This result points 
to a new higher-order architectural change upon the 
occurrence of the 4.3-Mb deletion, affecting more 
than 1 Mb of the terminal part of the Df chromo-
some. Additional experiments will test the hypoth-
esis that chromatin-tethering points exist within or 
neighboring the CNV region (such as LADs), which 
could cause the intervening chromatin to extend upon 
the occurrence of the 4.3-Mb deletion. Interestingly, 
DIRs were enriched in differentially expressed (DE) 
genes as detected by RNA-Seq, as well as CTCF- and 
Smc1-binding sites—proteins that had been previous-
ly characterized as structural determinants of chroma-
tin organization. Selected DIRs were validated by 3D 
DNA fl uorescence in situ hybridization (FISH), dem-
onstrating the robustness of our analysis framework. 
Together, these data revealed the complex effects that 
CNVs can exert on chromatin structure and function.
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MOLECULAR BIOLOGY OF PAPILLOMAVIRUSES
A. Stenlund S. Schuck
The papillomaviruses are a group of viruses that infect 
and transform the basal epithelium, inducing prolif-
eration of the cells at the site of infection. The result-
ing tumors (warts) are in most cases benign and will 
usually regress after some time, but certain types of 
human papillomaviruses (HPVs) give rise to tumors 
that are prone to progress toward malignancy, espe-
cially frequently cervical carcinoma. Indeed, HPV 
infection appears to be a necessary cause of invasive 
cervical carcinoma and thus represents one of the few 
fi rmly established links between viral infections and 
the development of cancer.
An impediment to the study of papillomaviruses 
has been the inability to defi ne simple in vitro cell cul-
ture systems for analysis of the viral life cycle. These 
viruses normally require specialized differentiating 
cells that only with diffi culty can be generated in 
cell culture. However, for a bovine papillomavirus 
(BPV-1), a convenient cell culture system exists where 
viral gene expression, oncogenic transformation, and 
viral DNA replication can be studied. Thus, BPV has 
become a useful model for these aspects of the viral 
life cycle. The DNA replication properties of the 
papillomaviruses show some unique and interesting 
characteristics. As part of their normal life cycle, these 
 viruses can exist in a state of latency, which is charac-
terized by maintenance of the viral DNA as a multi-
copy plasmid in infected cells. The copy number of the 
viral DNA is tightly controlled, and the viral DNA is 
stably inherited under these conditions. Papillomavi-
ruses therefore provide a unique opportunity to study 
plasmid replication in mammalian cells. In addition, 
the viral DNA replication machinery represents one of 
the most promising targets for antiviral therapy.
In previous years, we have reported the character-
ization of the papillomavirus replicon and the identi-
fi cation of the viral components that are required for 
viral DNA replication. In recent years, we have direct-
ed our attention toward the biochemical events that 
are associated with initiation of DNA replication. We 
are studying the biochemical properties of the viral E1 
and E2 proteins and how these two proteins interact 
with the viral origin of DNA replication and with the 
cellular replication machinery to generate initiation 
complexes. Our studies demonstrate that the E1 pro-
tein has all the characteristics of an initiator protein, 
including ori recognition, DNA-dependent ATPase 
activity, and DNA helicase activity. The transcription 
factor E2, whose precise function has remained more 
elusive, appears to serve largely as a loading factor for 
E1. Through direct physical interactions with both E1 
and the ori, E2 provides sequence specifi city for the 
formation of the initiation complex.
We are currently attempting to elucidate how the 
E1 and E2 proteins orchestrate the precise biochemi-
cal events that precede initiation of DNA replication 
at the viral ori. These events include binding of the 
initiator to the ori, the initial opening of the DNA du-
plex (melting), and the assembly and loading of the E1 
replicative helicase at the replication fork. Our studies 
so far indicate that these activities are generated in an 
ordered process that involves the sequential assembly 
of E1 molecules on the ori. This sequential assembly 
generates different complexes with different properties 
that in turn recognize ori, destabilize the double helix, 
and function as the replicative DNA helicase.
A Conserved Regulatory Module at the 
Carboxyl Terminus of the E1 Helicase 
Domain Controls E1 Helicase Assembly
The papillomavirus E1 protein is a representative of a 
subgroup of hexameric helicases. However, E1 is not a 
dedicated helicase but serves several additional func-
tions in the viral life cycle. E1 takes part in initiation 
of viral DNA replication in several different ways: 
The E1 DNA-binding domain provides sequence-
specifi c binding to the viral origin of replication (ori); 
a particular form of E1, a double trimer, can then gen-
erate local melting of the viral ori. Once the DNA is 
melted locally, an E1 double hexamer is formed on the 
melted DNA and unwinds the DNA in front of the 
replication fork.
Obviously, the utilization of a single polypeptide to 
provide multiple functions presents many challenges. 
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In addition to accommodating multiple different ac-
tivities in one polypeptide, mechanisms have to exist 
that allow switching between the different activities, 
as well as mechanisms that prevent the different ac-
tivities from interfering with each other. For example, 
in the DT to DH transition, E1 switches from site-
specifi c DNA binding and complex formation dic-
tated by E1-binding sites in the ori, to formation of 
hexamers dictated by the oligomerization domain and 
binding to single-stranded DNA (ssDNA). How this 
feat is accomplished is very poorly understood.
We were interested in identifying parts of the E1 
protein that control the critical transition from DT 
to DH. We were intrigued by a fairly well-conserved 
25–30-residue-long peptide at the carboxyl termi-
nus of E1, which according to structural studies does 
not constitute a part of the AAA+ helicase domain 
structural unit, although it is attached to the helicase 
domain. We performed a mutational analysis of this 
peptide in the context of the carboxy-terminal half of 
the E1 protein (E1308–605). This fragment contains the 
oligomerization and helicase domains that have been 
structurally characterized.
We made several interesting observations using 
mutations in the carboxy-terminal peptide. When the 
entire peptide was removed, the resulting protein had 
wild-type activity for hexamer formation on ssDNA, 
ATPase, and DNA helicase activities, demonstrating 
that the peptide is not required for these processes. 
However, point mutations affecting the peptide had 
dramatic phenotypes. On the basis of the sequence 
content, we divided the carboxy-terminal peptide into 
two components, an acidic region and a C-tail. Point 
mutations or deletions of the C-tail resulted in the loss 
of hexamer formation, ATPase activity, and DNA heli-
case activity, whereas further deletion of the acidic re-
gion resulted in restoration of wild-type activity. These 
results demonstrated that the acidic region functions as 
a negative regulator of hexamer formation, whereas the 
C-tail can counteract this negative effect.
Because these results demonstrated that the car-
boxy-terminal peptide is not required for the activities 
of the helicase and oligomerization domain fragment, 
we tested the activity of the carboxy-terminal peptide 
in the context of full-length E1. Interestingly, muta-
tions in the acidic region resulted in the failure to form 
the E1 DT complex, indicating that the formation of 
the DT complex requires that the acidic region blocks 
hexamer formation. Although the DT can form in the 
absence of C-tail, the transition from the DT to the 
DH does take place unless the C-tail is present. These 
results strikingly defi ne the carboxy-terminal peptide 
as having two specifi c functions: The acidic region is 
specifi cally required for the formation of a DT com-
plex, and the acidic region is specifi cally required for 
the formation of the DH complex.
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DNA REPLICATION AND CHROMATIN INHERITANCE
B. Stillman W. Gao J. Jansen S. Ni
 M. Hossain A. Mazurek Y.-J. Sheu
 N. Kara S. Nandi P. Wendel
The process of replicating the DNA each time a cell 
divides is fundamental to all living organisms and re-
mains the main focus of our studies. Using the yeast 
Saccharomyces cerevisiae system that has long been a 
mainstay of our research, we continue to study how 
pre-replicative complexes (pre-RCs) are established at 
origins of DNA replication before they are used for 
the initiation of DNA synthesis during the S phase of 
the cell division cycle. These studies were made possi-
ble with the ability to reconstitute pre-RC assembly in 
vitro with purifi ed proteins, but increasingly we have 
focused on structural studies of assembly intermedi-
ates in collaboration with Dr. Huilin Li at Brookhaven 
National Laboratory and Stony Brook University and 
Dr. Christian Speck at Imperial College in London. 
However, the yeast system is not the perfect paradigm 
for understanding DNA replication in all eukaryotes 
because we have found that there are considerable dif-
ferences between yeast and human cells. Therefore, 
we have continued our detailed studies of pre-RC 
assembly in human cells, as well as the surprisingly 
diverse activities of the subunits of the human origin 
recognition complex (ORC), one of the critical pre-
RC assembly proteins.
Studies on the Assembly of the 
Pre-Replicative Complex
A number of years ago, we reconstituted the pre-RC 
that assembles at all origins of DNA replication prior 
to entry into S phase of the cell division cycle and ini-
tiation of DNA replication. In a continuing collabora-
tion with Dr. Huilin Li and Dr. Christian Speck, we 
have investigated the structures of pre-RC assembly 
intermediates using the yeast S. cerevisiae system as a 
model for other eukaryotes. ORC, which in yeast is a 
stable six-subunit complex that exists throughout the 
entire cell division cycle, fi rst binds to defi ned origins 
of DNA replication and recruits the Cdc6 protein 
that is related in structure to the largest subunit of 
ORC, the Orc1 subunit. The ORC-Cdc6-DNA com-
plex assembly involves signifi cant re-arrangement of 
ORC subunits. This complex then recruits the hexa-
meric Mcm2-7 proteins that are bound to the chap-
erone Cdt1, forming the ORC-Cdc6-Cdt1-Mcm2-7 
(OCCM) complex on DNA. This protein complex is 
assembled in the presence of an analog of ATP that 
cannot be easily hydrolyzed so as to prevent ATPase 
activity and recruitment of the second Mcm2-7 hex-
amer, to form a double Mcm2-7 hexamer that is 
loaded onto the DNA and constitutes with ORC the 
pre-RC. Cryo-electron microscopy of the OCCM 
showed that it has one ORC-Cdc6 complex that sits 
on top of the Mcm2-7 hexamer with Cdt1 still bound 
to Mcm2-7. ORC-Cdc6 undergoes a substantial re-ar-
rangement compared to the ORC-Cdc6-DNA com-
plex. The ORC-Cdc6, when bound in the absence of 
Mcm2-7-Cdc1, is a fl at ring of the six AAA+ proteins 
(Orc1, Orc2, Orc3, Orc4, Orc5, and Cdc6) formed 
with DNA going through the center. When the com-
plex engages the Mcm2-7-Cdt1 complex, it distorts to 
form a slightly concave, spiral structure that encircles 
the DNA with a pitch of ~34 Å—the same as the pitch 
of the helix of double-stranded DNA. The structure 
is reminiscent of the structure of replication factor C 
(RFC) loading PCNA (proliferating cell nuclear anti-
gen) that was determined by John Kuriyan, Michael 
O’Donnell, and colleagues, proteins that we discov-
ered as components of the DNA replication fork in 
eukaryotes. The similarity of AAA+ protein loading 
ring-shaped protein onto DNA suggests a common 
mechanism whereby ATP-dependent proteins change 
the shape of other proteins and arrange them to sur-
round the DNA double helix.
The product of the pre-RC assembly process is a 
double hexamer of Mcm2-7 proteins that surround 
the double helix and is the precursor of assembly 
of two active DNA-unwinding helicases that move 
with each DNA replication fork. Cryo-electron 
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microscopy (cryo-EM) analysis of the Mcm2-7 
double hexamer shows that each hexamer assembles 
head to head with the double-stranded DNA pass-
ing through the middle of the barrel-shaped struc-
ture. One Mcm2-7 hexamer is twisted relative to the 
other, showing that the two gates between the Mcm2 
and Mcm5 subunits of each hexamer are not aligned; 
this creates a lock that does not allow the DNA to exit 
the middle of the structure. The juxtaposition of the 
two hexamers in a head-to-head confi guration brings 
together the amino termini of the Mcm2, Mcm4, and 
Mcm5 proteins that form the binding site of the DDK 
kinase that consists of two subunits, Cdc7 and Dbf4, 
that we have shown control, along with cyclin-depen-
dent protein kinase (CDK), the initiation of DNA rep-
lication and assembly of the active helicase. The DDK 
kinase phosphorylates the Mcm4 subunit and relieves 
repression of the initiation of DNA replication by an 
amino-terminal fragment of the Mcm4 protein.
The Origin Recognition Complex 
in Human Cells
ORC in human cells is far more complicated than the 
yeast paradigm suggests because it is not a single, six-
subunit complex that is stable throughout the cell di-
vision cycle. We have shown previously that the large 
subunit of ORC, ORC1, is degraded at the G1- to 
S-phase boundary by an SKP2-dependent ubiquitin 
ligase-mediated process and that assembly of ORC 
occurs during the G1 phase of the cell division cycle. 
Recent studies using time-lapse microscopy have 
shown that in human cells expressing fl uorescently 
tagged ORC1, the ORC1 binds to chromatin as cells 
enter into mitosis with the breakdown of the nuclear 
envelope. The chromatin-bound protein is inherited 
into the two daughter cells bound to chromatin and 
is present as the cell nucleus reassembles. ORC1 then 
displays dynamic nuclear localization patterns as 
cells progress through G1 phase, and the ORC1 pro-
tein displays a punctate pattern late in G1 phase with 
late-replicating regions of the genome. ORC1 binds 
the other ORC subunits in early- to mid-G1 phase. 
The initial binding of Orc1 to mitotic chromosomes 
requires two regions of the carboxy-terminal domain 
of ORC1, sequences that show similarity to the mi-
totic chromosome binding domain within the tran-
scriptional pioneer protein FOXA1. Two separate 
motifs within the ORC1 sequence that has similar-
ity to FOXA1 are suffi cient to bind mitotic chromo-
somes. Depletion of ORC1 prevents the assembly of 
the minichromosome maintenance (Mcm2-7) heli-
case proteins on chromatin in G1 phase. These re-
cent studies suggest that ORC1 acts as a nucleating 
center for ORC assembly and then pre-RC assem-
bly by binding to mitotic chromosomes, followed by 
gradual removal from chromatin during G1 phase. 
Because FOXA1 is a pioneer transcription factor that 
is inherited into daughter cells and is required for ac-
tivation of gene transcription in the newly born cells, 
we suggest that, analogously, ORC1 is a pioneer fac-
tor for DNA replication. Because we have shown that 
ORC1 is also required for maintenance of hetero-
chromatin and binds to the HP1 heterochromatin 
protein, it is possible that ORC1 binding to mitotic 
chromosomes also helps establish repressive chroma-
tin in newly born daughter cells—a hypothesis we 
are testing.
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Figure 1. Cryo-EM structure of the Mcm2-7 double hexamer 
(A) and models of how the structure locks on DNA (B) and how 
the DDK kinase binds (C,D). (From Sun et al 2014.)
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CHROMATIN REGULATORS AS CANCER DEPENDENCIES
C.R. Vakoc A. Bhagwat F. Mercan J. Minder C. Shen E. Wang
 A. Hohmann J. Milazzo J. Roe J. Shi Y. Xu
A universal attribute of cancer cells is an aberrant tran-
scriptional program that supports a malignant pheno-
type. To initiate and thereafter maintain such oncogenic 
patterns of gene expression requires a diverse ensemble 
of regulatory factors, which includes sequence-specifi c 
transcription factors, chromatin-modifying enzymes, 
and various other cofactors. Our research directly eval-
uates the hypothesis that cancer cells can be eliminated 
by targeting certain transcriptional regulators, with an 
emphasis on the factors that modify chromatin. We 
utilize genetic screening strategies to reveal vulnera-
bilities in various forms of cancer and pursue detailed 
mechanistic analysis to reveal opportunities for thera-
peutic intervention.
Mechanistic Studies of Brd4 in Acute 
Myeloid Leukemia Maintenance
A. Bhagwat, J. Roe, C. Shen [in collaboration with 
L. Joshua-Tor and D. Pappin, Cold Spring Harbor 
Laboratory]
Original studies from our laboratory in 2011 identifi ed 
the BET bromodomain protein Brd4 (bromodomain 
containing protein 4) as a leukemia dependency and 
drug target in acute myeloid leukemia. In 2013, Brd4 
inhibitors entered Phase 1 clinical trials in leukemia pa-
tients, and in 2014, the fi rst complete responses were 
reported in leukemia patients receiving these agents. A 
major focus of our current work is to defi ne the disease-
relevant molecular mechanism of Brd4 function in 
leukemia. We have pursued this question using a host 
of genetic and biochemical approaches and have made 
substantial progress in defi ning a “Brd4 pathway” 
composed of critical cis- and trans-acting components 
that fuel uncontrolled cell growth in leukemia.
One area of initial focus has been to defi ne the 
key cis elements used by Brd4 to regulate its impor-
tant target genes in leukemia cells. Using chromatin 
immunoprecipitation followed by next-generation se-
quencing, we have completed a genome-wide survey of 
Brd4-occupied sites along the leukemia genome. One 
remarkable observation from these studies has been 
the realization that a number of Brd4-dependent genes 
possess large clusters of distal enhancer elements that 
exhibit profound occupancy of Brd4. These large clus-
ters of enhancers, recently termed superenhancers, ap-
pear to be the functionally relevant mode of regulation 
by Brd4 for a subset of its target genes. For example, 
Myc is among the most Brd4-dependent genes for its 
expression and Myc is located near one of the most 
profoundly Brd4-occupied enhancers in the leukemia 
genome. Interestingly, the Myc enhancers closely corre-
spond to a region found previously as a site of recurrent 
focal amplifi cation in leukemia patients, which has 
clarifi ed the mechanism of transcriptional regulation 
performed by Brd4 to support leukemia maintenance.
An additional area of investigation has been to 
defi ne the recruitment mechanism that directs Brd4 
recruitment to specifi c cis elements in the leukemia ge-
nome. Through an epigenomic analysis of Brd4-occu-
pied sites, we have uncovered a suite of hematopoietic 
transcription factors (PU.1, Fli1, Erg, Myb, C/EBPα, 
C/EBPβ) that determine the locations of Brd4 oc-
cupancy. Remarkably, introducing these transcrip-
tion factors into fi broblast cells can reprogram Brd4 
occupancy into its leukemia-specifi c confi guration. 
This effect occurs through an ability of the transcrip-
tion factors to recruit the lysine acetyltransferase pro-
teins p300/CBP to their occupied sites, which in turn 
acetylates various protein substrates at enhancers and 
promoters to promote bromodomain-dependent Brd4 
recruitment. One of the key substrates of p300/CBP 
is likely to be histone H3 and H4; however, we have 
also derived evidence that Erg acetylation might also 
facilitate Brd4 recruitment. Collectively, this work re-
veals a chromatin-based signaling cascade composed 
of hematopoietic transcription factors, p300/CBP, 
and Brd4, which supports leukemia maintenance and 
is suppressed by BET bromodomain inhibition.
Another area of mechanistic investigation has been 
to identify candidate effectors of Brd4 in facilitating 
transcriptional activation. Through immunoprecipita-
tion coupled with mass-spectrometry analysis, we have 
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identifi ed several Brd4-associated proteins. By fi ltering 
of candidates through genetic criteria of having critical 
roles in leukemia maintenance, we have initiated stud-
ies of Nsd3, which is a SET domain-containing his-
tone H3K36 methyltransferase that has not been well 
characterized previously. In ongoing studies, we have 
found that Nsd3 functions as a bona fi de effector for 
Brd4 in supporting leukemia maintenance. We fi nd 
that the genome-wide localization of Nsd3 matches 
that of Brd4 and that chemical inhibition of BET 
bromodomains leads to displacement of Nsd3 at pro-
moter and enhancer regions. Unexpectedly, we have 
discovered that Nsd3 performs its essential function 
in leukemia cells independently of its SET domain, 
and we are currently investigating how Nsd3 pro-
motes transcriptional activation independently of its 
catalytic domains.
We have also found that Brd4 utilizes the multisub-
unit Mediator complex as an effector at a subset of its 
occupied sites, which includes the Myc enhancers. Re-
markably, a short treatment with BET inhibitors causes 
a large-scale displacement of several Mediator subunits 
from the Myc enhancers and from various other regula-
tory sites in the genome. In addition, we fi nd the ge-
netic perturbation of several Mediator subunits leads to 
leukemia cell differentiation, which mimics the effects 
of targeting Brd4. Collectively, these studies suggest 
that Brd4 facilitates Mediator recruitment to promote 
transcriptional activation of certain target genes. This 
represents progress in defi ning downstream compo-
nents of Brd4 function that are functionally suppressed 
by BET bromodomain inhibition.
Chemical Inhibition of SWI/SNF 
as a Therapeutic Approach in 
Acute Myeloid Leukemia
A. Hohmann, J. Minder, F. Mercan [in collaboration with 
L. Joshua-Tor, Cold Spring Harbor Laboratory]
Prior research from our laboratory has implicated the 
SWI/SNF complex as a unique vulnerability in acute 
myeloid leukemia. In the absence of any available drugs 
that target SWI/SNF, we have pursued the identifi ca-
tion of therapeutic approaches that would be capable of 
modulating SWI/SNF function in leukemia cells. On 
the basis of proteomic and genetic evidence, we have 
identifi ed one SWI/SNF subunit, called Brd9 (bromo-
domain containing protein 9) as an attractive target 
for chemical inhibition. More specifi cally, our genetic 
evidence has implicated the bromodomain pocket of 
Brd9 as supporting leukemia maintenance and, based 
on this fi nding, chemistry collaborators have initiated 
the development of selective small-molecule inhibitors 
of Brd9. Notably, these inhibitors limit leukemia cell 
proliferation and mimic many of the cellular effects of 
RNA interference (RNAi)-based Brd9 inhibition. Fur-
thermore, we have engineered a mutant Brd9 cDNA 
that no longer binds to the small molecule but retains 
functionality. Using this novel reagent, we have shown 
that Brd9 is the sole cellular target of this novel inhibitor 
that is responsible for antileukemia effects. Having es-
tablished genetic and chemical evidence to support Brd9 
as a drug target in leukemia, we now seek to advance 
Brd9 inhibition as a therapeutic strategy in leukemia. 
To this end, we are pursuing experiments that defi ne 
the molecular function of Brd9 in leukemia cells, thus 
revealing how Brd9 contributes to the overall function-
ality of the SWI/SNF complex and to the maintenance 
of a leukemia-supporting gene regulatory network. In 
addition, we are investigating the genetic basis for pri-
mary sensitivity and resistance to Brd9 inhibition using 
existing human acute myeloid leukemia cell lines. These 
experiments will likely be complemented by CRISPR-
based genetic screens that seek to identify genes that, 
when mutated, confer resistance to Brd9 inhibition, 
thus providing critical insight into the adaptive resis-
tance mechanism. Finally, we will perform preclinical 
trials of Brd9 inhibitors in genetically engineered mice 
and in human xenograft models of disseminated acute 
myeloid leukemia. This research holds great promise 
in revealing basic mechanisms for an unstudied chro-
matin reader protein as well as a strong translational 
potential for exploring Brd9 inhibition as an epigenetic 
therapy in acute myeloid leukemia.
TRIM33 Allows the Survival of 
B Lymphoblastic Leukemia Cells by 
Deactivating a Single Enhancer Element
E. Wang [in collaboration with J. Kinney, Cold Spring 
Harbor Laboratory]
We have recently extended our epigenetic screening 
platform into the high-risk blood cancer acute lym-
phoblastic leukemia of B-cell origin (B-ALL). This 
disease model is driven by the BCR-ABL oncogene and 
is associated with a dismal prognosis. We evaluated 
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the role of all chromatin regulators in the prolifera-
tion of these leukemia cells and have pinpointed a 
TRIM domain containing protein (TRIM33) in the 
pathogenesis of this disease. TRIM33 protein acts to 
support survival of B-ALL cells largely by repressing 
tissue-specifi c enhancer function. Notably, knock-
ing down expression of TRIM33 has minimal ef-
fects on heterologous cell types. We have recently 
completed genome-wide studies evaluating chroma-
tin occupancy of TRIM33 in B-ALL and are ex-
panding these studies into other cell lineages. From 
this work, we hope to gain a general model for how 
TRIM33 governs leukemia-specifi c transcriptional 
regulation.
A remarkable attribute of TRIM33 in B-ALL is that 
it preferentially occupies a small number of cis elements 
across the genome. Two discrete regions are heavily oc-
cupied by TRIM33, which includes a distal upstream 
enhancer located 117 kb upstream of the Bim promot-
er. We fi nd that TRIM33 is recruited by a dense cluster 
of PU.1, a hematopoietic transcription factor, which in 
turn deactivates the underlying enhancer. A stunning 
observation in this study is that CRISPR-based deletion 
of the Bim 117-kb element renders TRIM33 dispens-
able for B-ALL survival. This indicates that TRIM33 
performs an essential function through a single ge-
nomic binding site. To our knowledge, this indicates a 
level of regulatory precision not observed previously for 
a mammalian regulator of transcription. Finally, our 
fi ndings also nominate TRIM33 inhibition as a thera-
peutic strategy in B lymphoid malignancies.
TFIID Complex as an Oncogenic 
Regulatory Hub in Leukemia
Y. Xu
A major theme in our research investigating chromatin 
regulators as cancer dependencies is that major regula-
tory hubs in transcriptional control can be perturbed 
in a selective manner to eradicate cancer cells, which 
refl ects the essential role of such machineries to im-
plement oncogenic transcriptional programs. On the 
basis of this rationale, we have begun to probe the re-
quirement of TFIID in cancer maintenance. TFIID is 
a multisubunit complex composed of the TATA-bind-
ing protein (TBP) as well as various TBP-associated 
factors (TAFs) that function in promoter sequence 
recognition and as a coactivator for DNA-binding 
transcription factors. We have hypothesized that spe-
cifi c cancers might be hypersensitive to perturbation 
of certain TAF subunits of TFIID to elicit selective 
transcriptional effects on cancer-relevant genes. Cus-
tom short hairpin RNA (shRNA) libraries have been 
constructed targeting each TFIID subunit and have 
been introduced broadly into an assortment of differ-
ent cancer cell lines. Out of this comparative screen-
ing has come the identifi cation of a submodule of 
TFIID that uniquely supports the biology of leuke-
mia. In future experiments, we will defi ne genetically 
and biochemically how this submodule drives leuke-
mia pathogenesis.
A Domain-Focused CRISPR Strategy 
for Cancer Drug Target Discovery
J. Shi, J. Milazzo, E. Wang [in collaboration with 
J. Kinney, Cold Spring Harbor Laboratory]
CRISPR-Cas9 technology holds great promise for ge-
netic screening and for the discovery of therapeutic 
targets. To achieve optimal performance in negative 
selection screens, it is critical for CRISPR to generate 
homozygous loss-of-function mutations in a highly 
effi cient manner. We have developed a CRISPR strat-
egy that exploits this principle and simultaneously 
reveals protein domains that support cancer main-
tenance. By targeting CRISPR-mediated mutagen-
esis to exons encoding functional protein domains, 
negative selection phenotypes are achieved that are 
an order of magnitude stronger than those observed 
through mutagenesis of 5′ exons. We have also de-
veloped a deep sequencing-based method for target 
validation that effectively excludes off-target effects. 
This approach has been benchmarked by mutageniz-
ing lysine methyltransferase, lysine demethylase, bro-
modomain, ATPase, lysine deacetylase, and lysine 
acetyltransferase domains in MLL-AF9 leukemia 
cells, which has confi rmed known dependencies and 
identifi ed additional disease requirements. A broad 
application of these procedures may allow a compre-
hensive annotation of targetable protein domains that 
sustain cancer cell viability.
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Christopher Hammell’s lab is interested in understanding gene regulatory processes that give rise 
to robust phenotypes associated with normal development in animals (specifi cally, how the tim-
ing of developmental processes is controlled) as well as the alterations in these pathways that give 
rise to diseases such as cancer (as in the alterations in mitogenic pathways in melanoma). Ham-
mell and colleagues approach this elemental problem by using a variety of model organisms and 
patient-derived cancer cell lines. To identify the components that function in controlling normal 
developmental timing, they use the small nematode Caenorhabditis elegans, applying forward and 
reverse genetic approaches. This past year, the team identifi ed the gene LIN-42 as a key regulator 
of developmental timing. In contrast to the extreme robustness of cell-fate lineage in C. elegans, in 
which specifi cation of developmental programs is hard-wired, mutations that alter conserved sig-
naling pathways in melanoma create relatively plastic developmental landscapes that allow these 
lesions to become aggressive tumors. Notably, the gene regulatory architecture of melanoma cells 
allows them to acquire resistance to therapeutic agents. Hammell’s team is interested in epigenetic 
mechanisms that contribute to resistance—specifi cally, dramatic changes in gene expression pat-
terns and intracellular signaling pathways. They are performing high-throughput screens to iden-
tify cellular factors that allow these re-wiring events to occur, with the idea that these components 
would make ideal therapeutic targets to complement existing clinical strategies.
Gregory Hannon is a pioneer in the study of RNA interference (RNAi), a process in which 
double-stranded RNA molecules induce gene silencing. Hannon and colleagues have elucidated 
key elements of the RNAi machinery. During the past several years, the Hannon lab has focused 
on roles of small RNAs in germ cells, which tend to have the most elaborate set of small RNA 
pathways of any cell type. They have discovered an essential role for small RNAs, called Piwi- 
interacting RNAs (piRNAs), that are critical for proper oocyte development and guard the ge-
nome against transposable elements. The lab has conducted screens, one in the fruit fl y germ line 
and another in somatic cells, to search for new components of the pathway that generates piRNAs. 
They have identifi ed dozens of genes that are required for piRNA production, offering insight into 
how germ cells ensure genomic integrity. The Hannon lab also strives to understand the biology 
of cancer cells, with a focus on breast and pancreatic cancer. They have led the way in using RNAi 
to study cancer biology and genetics, generating libraries of short-hairpin RNAs that have been 
widely applied in gene silencing studies. These libraries can then be used to identify new therapeu-
tic targets for specifi c disease subtypes. In addition, they are exploring the roles of small RNAs as 
oncogenes and tumor suppressors and are using genetic approaches to understand the biology of 
resistance to currently used cancer therapies. Another research thrust of Hannon’s team exploits 
the power of next-generation sequencing to understand the biology of the mammalian genome. 
Their efforts range from the identifi cation of new classes of small RNAs to understanding human 
evolution and diversity, including an emphasis on the evolution of the epigenome and its role in 
driving cell-fate specifi cation.
Alea Mills is studying genetic pathways important in cancer, aging, and autism, identifying the 
genetic players and determining how aberrations in their functions culminate in human disease. 
Through use of a technique called “chromosome engineering,” the Mills group discovered that 
one of the most common genetic alterations in autism—deletion of a 27-gene cluster on chromo-
some 16—causes autism-like features in mice. These autism-like movement impairments can be 
identifi ed just days after birth, suggesting that these features could be used to diagnose autism. 
Mills has also used chromosome engineering to identify a tumor suppressor gene that had eluded 
investigators for three decades. The gene, called Chd5, was shown by Mills to regulate an extensive 
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cancer-preventing network. The Mills lab has uncovered how Chd5 acts as a tumor suppressor: It 
binds to a protein found within chromatin to turn specifi c genes on or off, halting cancer progres-
sion. The epigenetic role of Chd5 in development, cancer, and stem-cell maintenance is currently 
being investigated. This past year, the team identifi ed the Chd5 protein as a key regulator of 
chromatin remodeling during sperm development. The lab is also studying p63 proteins, which 
regulate development, tumorigenesis, cellular senescence, and aging in vivo. They succeeded in 
halting the growth of malignant tumors by turning on production of one of the proteins encoded 
by the p63 gene, called TAp63. TAp63 also exerts other protective effects. The Mills lab has 
generated a mouse model which allowed them to fi nd that TAp63 is required to prevent a genetic 
disorder, known as EEC (ectrodactyly–ectodermal dysplasia cleft lip/palate syndrome), which is 
characterized by a cleft palate and major deformities of the skin and limbs in infants. In addition, 
they recently discovered that a different version of p63, called ΔNp63, reprograms stem cells of the 
skin to cause carcinoma development—the most prevalent form of human cancer. Modulation of 
these proteins may offer new ways to treat human malignancies in the future.
Scott Powers’ work focuses on gene alterations that cause cancer and factors that infl uence re-
sponses to specifi c anticancer drugs. His lab uses technologies that probe the entire genome to 
identify candidate cancer genes and evaluate their functional role in cell transformation and 
tumor biology. They also use whole-genome technologies to guide development of novel cancer di-
agnostics and therapeutics. Using DNA copy-number analysis, the Powers group pinpoints novel 
amplifi ed oncogenes and then applies functional studies to address the mechanisms by which they 
are implicated in oncogenesis. They have successfully applied this approach in breast, liver, colon, 
and lung cancers. Powers has also had an important role in the development of a distinctive CSHL 
approach to functional study of cancer genes. Called integrative oncogenomics, it is a rapid, large-
scale screen for genes that are deleted or amplifi ed in human cancers and suspected of being tumor 
suppressors, in the case of deletions, or oncogenes, in the case of amplifi cations.
Michael Wigler’s work provides a new paradigm for understanding and exploring human disease. 
The Wigler lab studies human cancer and the contribution of new mutation to genetic disorders. 
The cancer effort (with James Hicks, Alex Krasnitz, and Lloyd Trotman) focuses on breast and 
prostate cancers. It involves collaborative clinical studies to discover mutational patterns predict-
ing treatment response and outcome, and the development of diagnostics to detect cancer cells in 
bodily fl uids such as blood and urine. The major tools are single-cell DNA and RNA analysis. The 
single-cell methods, which are in development, are also being applied to problems in neurobiol-
ogy (with Josh Huang and Pavel Osten) to characterize neuronal subtypes, somatic mutation, and 
monoallelic expression. The Wigler lab’s genetic efforts are a collaboration with Ivan Iossifov and 
Dan Levy, and this team focuses on determining the role of new mutations in pediatric disorders. 
In a large-scale population sequencing project with W. Richard McCombie and the Genome 
 Sequencing Center at Washington University in St. Louis, and supported by the Simons Founda-
tion, the team has proven the contribution of this mechanism to autism. The work further suggests 
a relationship between the mutational targets in autism and the process of neuroplasticity that lies 
at the heart of learning. Smaller-scale population studies of congenital heart disease and pediat-
ric cancer (collaborations with scientists at Columbia University and Memorial Sloan- Kettering 
 Cancer Center, respectively) also point to new mutation as a causal factor in these disorders.
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GENE REGULATION IN DISEASE AND DEVELOPMENT
C.M. Hammell C. Aguirre-Chen C. Carlston K. Doerfel
The major focus of our lab is to use the model organ-
ism Caenorhabditis elegans to understand how normal 
gene regulation contributes to proper development 
and how misregulation of expression leads to dis-
ease. Using forward genetics, we have made strides 
in identifying several novel genes and mechanisms 
that coordinate the specifi c timing of gene expression 
with the elaboration of normal temporal patterning. 
These include the identifi cation of the blmp-1 gene, 
encoding a ZnF transcription factor, which promotes 
the pulsatile expression of many C. elegans genes that 
control temporal cell fate. In addition, in the last 
year, we have initiated very fruitful collaborations 
with the McCombie and Wigler laboratories here at 
CSHL to develop an in vivo model for studying the 
roles of genes implicated in neuropsychiatric disor-
ders in establishing and maintaining normal neuro-
nal architecture.
Oscillatory Gene Expression and 
Developmental Patterning
K. Doerfel, C.M. Hammell, C. Carlston
In normal development, the identity, behavior, and 
biological function of individual cells are coordinated 
with its neighbors from distinct tissues. The defi ned 
structure and specifi cation of tissues endows them 
with unique functional and physiological properties 
that exceed the capabilities of individual cells. Setting 
up these architectures is an incredibly complex pro-
cess and requires aspects of spatial and temporal gene 
regulation to be coordinated to control facets of cell 
proliferation and cell fate determination. Although 
the last few decades have illuminated a variety of con-
served regulatory mechanisms that mediate spatial 
gene regulation, our understanding of how temporal 
patterning is set up lags behind. From what we do 
know, the genes and mechanisms that control devel-
opmental timing are very well conserved—and dis-
ruptions in this regulation result in a variety of human 
diseases, including cancer.
To identify genes that control temporal pattern-
ing, we have taken advantage of the model organism, 
C. elegans, which displays an essentially invariant cell 
lineage and is amenable to genetic studies. In the last 
year we have developed a variety of genetic strate-
gies to identify regulatory components that modulate 
gene expression levels throughout development. Dur-
ing these studies, we found that many of the genes 
that control normal temporal patterning (including 
microRNAs [miRNAs]) are expressed in highly dy-
namic patterns. These expression patterns are repeti-
tive and are correlated with the normal growth and 
behavior of developing animals; disruption of these 
patterns of expression leads to alterations in temporal 
cell fate.
The major fi nding from these studies has revealed 
that C. elegans encodes a developmental clock that 
demarcates both absolute and relative time and coor-
dinates temporal gene expression with cell fate speci-
fi cation. One of the central components of this clock 
is lin-42, the C. elegans homolog of the human and 
Drosophila Period gene implicated in controlling circa-
dian gene regulation. We found that a major function 
of lin-42 during larval development is to maintain 
normal miRNA expression. Specifi cally, lin-42 is re-
quired to dampen the oscillatory expression patterns 
of these genes at the transcriptional level, and lin-42 
mutants display precocious heterochronic phenotypes 
as a consequence of this defect. These fi ndings were 
published in PLoS Genetics.
In an effort to identify the regulatory architecture 
required to generate oscillatory patterns of gene ex-
pression and additional components of this develop-
mental clock, we identifi ed the regulatory elements 
required for this pattern of transcription and initiated 
a candidate-based screen to identify lin-42 suppres-
sors. These efforts demonstrated that the oscillatory 
patterns of heterochronic miRNA expression required 
conserved cis-acting elements present in the promoters 
of oscillating genes, and we also identifi ed the con-
served ZnF transcription factor, BLMP-1, as a novel 
component of the heterochronic pathway (Fig. 1). 
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blmp-1 mutant animals display mild heterochronic 
phenotypes and underaccumulate mature miRNAs 
during development. The cis-regulatory elements that 
are essential for oscillatory transcription are bound by 
BLMP-1 in vitro, and these elements are suffi cient to 
generate oscillatory expression patterns of a heterolo-
gous gene (Fig. 2).
These results suggest that the transcriptional acti-
vation of heterochronic genes requires two modes of 
transcriptional activation: (1) a system that drives a 
low level of constitutive transcription and (2) a system 
that is dependent of BLMP-1 activation to drive high-
ly pulsatile expression that is coupled to growth and 
nutritional status of developing animals. Finally, we 
determined that the BLMP-1-dependent activation of 
heterochronic genes is essential for animals to recover 
normal temporal patterning after developmental dia-
pause.
In Vivo Screening of Genes Implicated in 
Human Neuropsychiatric Disorders to Identify 
Genes Required for the Establishment or 
Maintenance of Neuronal Architecture
C. Aguirre-Chen
High-throughput sequencing and genome-wide as-
sociation studies of DNA derived from patients with 
Figure 1. BLMP-1 and cis-regulatory DNA elements in miRNA promoters are required for oscillatory gene expres-
sion. (A) A schematic of the lin-4 and let-7 transcriptional reporters. (B) Transgenic animals containing the lin-4::GFP-
pest transgene were synchronized at the L1 stage, allowed to begin postembryonic development, and monitored 
for GFP expression. (C) Micrographs of transgenic animals from b demonstrating that the wild-type lin-4 promoter 
is sufﬁ cient for driving pulsatile transcription and that this activity requires promoter elements and the BLMP-1 ZnF 
transcription factor. (D,E) Oscillatory transcription of the let-7::GFP-pest reporter in intestine does not require blmp-1 
activity, but pulsatile expression patterns in hypodermal tissues do.
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various neuropsychiatric disorders have led to the 
identifi cation of hundreds of separate mutations that 
are potentially causal. This rapid advance in the iden-
tifi cation of inherited and de novo mutations for com-
plex diseases such as autism and schizophrenia has 
created a huge bottleneck for understanding the roles 
of these candidate genes in normal and disease pro-
cesses. This is in part due to the sheer number of genes 
that have already been identifi ed, the complexity of 
the nervous system itself, and the expense of initiating 
model organism-based strategies for understanding 
the disease process.
We, in collaboration with the McCombie and 
Wigler laboratories, hypothesized that one of many 
potential mechanisms that may tie these neuropa-
thologies together would be one in which the dis-
ease phenotype is caused by alterations in neuronal 
wiring. To test this hypothesis, we developed a rapid 
screening protocol to discover roles for the genes 
identifi ed in the sequence-based family approaches 
in the establishment or maintenance or neuronal 
 architecture.
This model takes advantage of the genetic and ex-
perimental tractability of C. elegans and allows gene 
function to be assayed in living animals. Our model 
incorporates transgenic animals that express green 
fl uorescent protein (GFP) in two neurons: the PVD, 
located on the lateral sides of the animal. These neu-
rons display highly elaborate and specifi c dendritic 
arbors that are both developmentally regulated and 
amenable to RNA interference (RNAi) (Fig. 3). To 
determine if mutation or inactivation of genes previ-
ously implicated in schizophrenia or autism results in 
structural defects of dendritic arbors, we depleted the 
C. elegans homologs of these genes in transgenic ani-
mals via RNAi. Working from a list of 50 candidates 
of which 34 had clear C. elegans homologs, knock 
down of four control genes produced clear dendrit-
ic arborization phenotypes (Figs. 3 and 4). When 
compared to an unbiased screen of C. elegans genes 
from chromosome IV, this candidate-based screen 
Figure 2.  BLMP-1 binds to a conserved sequence found in 
the promoters of many genes that display pulsatile expression 
patterns, and these elements are sufﬁ cient for oscillatory tran-
scription. (A) The experimentally derived BLMP-1 consensus 
sequence (PCE; pulse control element) and the three essential 
versions of PCE elements contained within the lin-4 promoter. 
(B) The recombinant zinc ﬁ nger domains of BLMP-1 directly 
bind the three lin-4 elements in in vitro. (C) A schematic of the 
gst-5::GFP-pest and the (2xPCE)gst-5::GFP-pest reporters. (D) 
Transgenic animals containing these reporters were monitored 
in a manner similar to that of the GFP-pest reporters in Figure 1B. 
(E) The 2xPCE element is also sufﬁ cient to drive pulsatile tran-
scription in the hypodermis of later larval staged animals, and 
this activity requires BLMP-1.
Figure 3. An experimental assay to identify genes required for 
normal dendritic arborization. (A) Animals expressing the wdIs52 
transgene express GFP speciﬁ cally in the PVD neurons. (B) The 
dendritic arbors of the PVD neuron display a highly repetitive 
and developmentally regulated “menorah” structure that is 
formed throughout postembryonic development. (C) Depletion 
of the C. elegans orthologs of several candidate genes results in 
speciﬁ c disruptions in dendritic architecture. (Closed light grey 
arrowheads) Hyper-branching of the 4° dendrites; (grey line ar-
rowheads) Hyper-branching of the 2° branches of the menorah 
structure.
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is enriched for positive hits by at least 10-fold. Most 
of the phenotypes produced by RNAi were recapitu-
lated in animals that harbor loss of function alleles 
of the indicated genes. We are currently exploring 
other novel uses of this model, including using this 
system to establish epistasis between genes that alter 
dendritic arborization.
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Figure 4.  A summary of the neuropsychiatric candidate gene 
screen using the C. elegans PVD reporter. (A) A bar graph de-
picting the average percentage of animals displaying abnormal 
dendritic arborization in the RNAi screen. (B) A comparison 
of the results from our screen and an unbiased screen of the 
C. elegans genes found on chromosome IV.
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RNA INTERFERENCE MECHANISMS AND APPLICATIONS
G. Hannon G. Battistoni C. dos Santos W.S. Goh M. Kudla E. Rozhkova X. Zhou
 S. Boettcher O. El Demerdash P. Guzzardo E. Lee L. Sabin 
 D. Bressan N. Erard A. Haase F. Muerdter E. Wagenblast 
 K. Chang D. Fagegaltier E. Harrison J. Preall V. Vagin 
 B. Czech I. Falciatori E. Hodges C. Rebbeck K. Wasik 
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Our lab continues to work along three major lines of 
enquiry. First, we study small RNA biology with a 
particular focus on the roles of small RNAs in germ 
cells. Second, we work toward an understanding of 
unsolved mysteries in cancer, with a particular focus 
on breast and pancreatic cancer. Third, we continue 
to work to break technological barriers through the 
development of new approaches.
This has been a year of transition in the lab. Post-
doctoral fellows John Preall and Vasily Vagin left for 
positions at Pfi zer and CSHL, respectively. Students 
Marek Kudla, Paloma Guzzardo, and Felix Muerdter 
began postdoctoral positions, and Felix and Paloma 
also started life together as a married couple. With 
a great deal of sadness, we said goodbye to Jo Leo-
nardo, who has worked alongside me as my PA for the 
past decade. Momma Jo, as she was often called, was 
a large part of the glue that held the lab together. She 
will be greatly missed, and we all wish her well in her 
new position at the California Institute of Technol-
ogy, where at least she will fi nd familiar faces in lab 
alumni.
We had a number of visiting students this year, as 
do we always. Eugene Jun Wen, Martin Fabry, Sara 
Gutierrez Angel, Annika Gable, Stephen Dickopf, 
Mar del Soto, and Jiaqui Gu all made important con-
tributions to our work.
This year also marked the start of the transition of 
my laboratory to the University of Cambridge, after 
nearly 23 years at CSHL. Clare Rebbeck, Ben Czech, 
Ilaria Falciatori, Eugene Jun Wen, Nic Erard, Joaqui-
na Delas Vives, Dario Bressan, Giorgia Battistoni, and 
Megan Keane have all come to join me in this new 
adventure, although Giorgia and Joaquina will remain 
students at CSHL.
Examples of ongoing work by members of the labo-
ratory are presented below.
Development of a Sequencing Protocol 
to Achieve Single-Base Resolution
G. Battistoni
DNA methylation is one of the best-studied epige-
netic marks. RNA species are similarly methylated, 
but the functional role of this modifi cation is largely 
unknown. Recent evidence suggests that N6-methyl-
adenosine (m6A), one such RNA modifi cation, has a 
pivotal role in gene expression regulation. The currently 
available sequencing techniques are not able to achieve 
single-base resolution. My project aims at the develop-
ment of a sequencing protocol that could achieve such 
resolution. Analogously to bisulfi te sequencing, where 
methylcytosine is chemically converted to uracil, our 
technique is based on the enzymatic conversion of m6A 
to inosine, which leads to an A > C transversion in the 
resulting cDNA and sequencing reads. During my time 
in the Hannon laboratory, I have purifi ed the enzyme 
required for this protocol and optimized the conditions 
for the enzymatic conversion on single nucleosides. I 
have also produced some preliminary results using a 
methylated RNA oligonucleotide.
Development of a Suite of Optogenetic Tools
D. Bressan
During the past year, we started the development 
of a suite of optogenetic tools to read, modify, and 
write the genetic and epigenetic status of a cell, which 
we named “laserTAG.” The project originated from 
the work I did during my thesis research to develop 
a light-dependent method for the space-specifi c pu-
rifi cation of biomolecules. In this technique, a small 
light-sensitive molecule can be specifi cally bound to 
a target protein in vivo by a pulse of focused laser 
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light. The “tagged” protein can then be recovered and 
analyzed in several ways, merging the advantages of 
high-resolution in vivo analysis (i.e., microscopy) with 
those of a high-throughput technique such as DNA 
sequencing.
In the past year, we have expanded this technique 
to allow not only the recovery of proteins, but also 
their manipulation. We plan to use small chemical 
linkers to trigger protein interactions and drive cel-
lular processes such as gene expression and to build 
a “photosensitive viral vector” able to introduce new 
genes into cells following light activation. This suite 
of tools would be transformative for several fi elds of 
science, most notably neuroscience.
Our project benefi ts from funding by the National 
Institutes of Health through both an R21 technology 
development grant and a major “B.R.A.I.N” initiative 
grant for transformative technologies in neuroscience.
Target Discovery to Overcome Drug 
Resistance in Her2-Positive Breast Cancer
K. Chang
Breast cancers currently fall into three broad therapeutic 
categories: tumors positive for estrogen receptor (ER) 
expression, tumors positive for the HER2 (erB2/neu) re-
ceptor tyrosine kinase oncogene, and tumors lacking ER 
and progesterone receptors as well as the HER2 altera-
tion (also referred to as “triple-negative” tumors). Tar-
geted therapies exist for both ER- and HER2-positive 
diseases. These are effective in many appropriately clas-
sifi ed patients; however, some tumors fail to respond, 
and in many initially responsive patients, treatments 
eventually lose potency (acquired resistance).
HER2 is amplifi ed and overexpressed in 20%–
25% of human breast cancers. Patients whose breast 
cancers contain this alteration typically have an ag-
gressive form of the disease with signifi cantly short-
ened disease-free and overall survival. Trastuzumab-
targeted therapy to block HER2 function is effi ca-
cious in both metastatic and early HER2-amplifi ed 
breast cancers. Not all patients whose tumors contain 
the HER2 alteration respond to trastuzumab. Less 
than 35% of the patients with HER2-positive meta-
static breast cancer respond to trastuzumab as a single 
agent, and a number of those that initially respond 
will acquire drug resistance within 24 to 36 months. 
Drug resistance has been correlated with genetic and/or 
epigenetic alterations that activate pathways which re-
duce the dependence on established drivers observed 
in responsive tumors. Our objective is to use RNA in-
terference (RNAi) as a path to breast cancer therapy.
We have carried out more than 24 genome-wide 
short hairpin RNA (shRNA) screens to fi nd essential 
genes in tumor-derived cell lines representing all three 
therapeutic treatment groups of breast cancer (ER-
positive, HER2-positive, and triple-negative disease) 
and to identify genetic determinants of therapy resis-
tance for trastuzumab. Our goal is to mine this large 
data set of genome-wide breast cancer vulnerabilities 
to discover therapeutic targets to combat acquired 
trastuzumab resistance for HER2-driven breast can-
cer. To identify genes conferring secondary (acquired) 
resistance to trastuzumab from the data sets, we set 
a stringent statistical cutoff and fi ltered for shRNAs 
that depleted only upon trastuzumab treatment in 
the drug-resistant line, SKTR, but not in either of 
the two drug-sensitive lines, SKBR3 and EFM192A. 
This produced a list of 25 genes, which included those 
from phosphoinositol-3 kinase–mammalian target of 
rapamycin (PI3K-mTOR) signaling (PI4K2A, Rap-
tor, insulin receptor, and EIF4A), RNA processing 
(PRPF8, U2AF1, and LSM6), mitotic checkpoint 
(BUB1B), and genes of unknown function. Identi-
fi cation of the insulin receptor and members of the 
PI3K-mTOR signaling pathway fulfi lls our expecta-
tion of fi nding these genes in this screen because they 
are known to be functionally associated with trastuzu-
mab resistance. All 25 genes were validated to confer 
drug sensitivity in trastuzumab-resistant cells in vitro. 
TNFSF11/RANKL (ligand of the receptor activator 
of nuclear factor κB), a gene of signifi cant relevance 
to breast cancer, was one of two most highly depleted 
hits. Denosumab is a humanized monoclonal anti-
body designed to inhibit RANKL for treating vari-
ous bone-related conditions. This drug was approved 
to treat giant cell tumors of the bone, breast cancer 
patients on adjuvant aromatase inhibitor therapy, and 
postmenopausal women with risk of osteoporosis, 
and to prevent skeletal-related events in patients with 
bone metastases from solid tumors. The dysregulation 
of the RANKL-RANK system is the major cause of 
osteoporosis in postmenopausal women. Appropriate 
RANKL signaling is also required for the formation 
of a lactating mammary gland, and both RANKL 
and RANK are expressed under the control of pro-
gesterone, prolactin, and the parathyroid hormone 
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protein-related peptide (PTHrP). Recent data impli-
cate RANKL and RANK in the control of metastasis 
of breast cancer cells to the bone. We are currently 
expanding our validation studies to test the effi cacy 
of this strategy to overcome trastuzumab resistance 
using a panel of drug-resistant/sensitive breast tumor 
cells in vivo. We will also use patient tumor-derived 
xenograft mouse models of trastuzumab resistance to 
functionally validate RANKL and other target genes 
to fi nd the best strategy to overcome this disease.
Molecular Characterization of piRNA 
Biogenesis in Drosophila
B. Czech
The Piwi-interacting RNA (piRNA) pathway pro-
vides an elegant defense mechanism that protects the 
genetic information of animal germ cells from the del-
eterious effects of molecular parasites known as trans-
posable elements. This conserved small RNA silenc-
ing system consists of Piwi-clade Argonaute proteins 
and their associated 24- to 28-nucleotide RNA-bind-
ing partners, the piRNAs. piRNAs typically descend 
from acute transposon mobilization events and from 
piRNA clusters, which provide a genomic memory of 
ancestral transposon activity, through the coordinated 
activity of several processing factors. Although a can-
didate nuclease, called Zucchini, and its putative part-
ner protein Minotaur have been identifi ed, the precise 
molecular mechanism that converts transposon and 
cluster transcripts—but not coding mRNAs—into 
mature piRNAs remains largely elusive.
We have recently carried out a reverse genetic 
screen aimed at identifying the full repertoire of genes 
that participate in piRNA-mediated genome defense. 
Follow-up experiments have revealed a number of pre-
viously unknown factors that are crucial for piRNA 
biogenesis. Through genetic experiments combined 
with high-throughput sequencing, we identifi ed two 
proteins, GASZ and PIMP, that are essential for the 
production of piRNAs from cluster transcripts. Inter-
estingly, both proteins share their cellular localization 
on the outer surface of mitochondria with Zucchini 
and Minotaur. Using a combination of molecular, 
structural, genetic, and biochemical approaches, we 
are currently dissecting the specifi c roles of each of 
these factors individually, as well as their interplay, in 
order to understand piRNA processing in full detail.
Mouse Mammary Glands
C.O. dos Santos
During the past year, we have focused on understand-
ing the effects of pregnancy on the mammary gland 
epigenome. We performed whole-genome bisulfi te 
sequencing of purifi ed mouse mammary gland cell 
types before (nulliparous) and after pregnancy (par-
ous). Analysis of nulliparous and parous methylomes 
revealed localized, but substantial, changes in DNA 
methylation. Many of these changes were localized 
near genes with known roles in milk production, 
cell proliferation, and apoptosis. In addition, we saw 
enrichment for STAT DNA motifs in regions that 
lost methylation during pregnancy. Further analy-
ses demonstrated a great overlap of Stat5a ChIP-Seq 
(chromatin immunoprecipitation–high-throughput 
sequencing) peaks with parous-specifi c regions, sug-
gesting that Stat activity heavily infl uenced the parous 
epigenome. Finally, we associated pregnancy-induced 
changes in DNA methylation with the kinetics of gene 
reactivation in a subsequent pregnancy, implying that 
the mammary gland harbors a long-term epigenetic 
memory of prior pregnancy cycles. We are currently 
investigating the correlation of these pregnancy- 
induced modifi cations with the risk of developing 
breast cancer, with the long-term goal of devising 
strategies to target these areas for cancer prevention 
and treatment.
Combinatorial Drug Discovery through 
Two-Dimensional RNAi Screens
N. Erard
Loss-of-function RNAi screens are a powerful tool 
used to discover the oncogenic factors that allow can-
cer cells to thrive. These screens are driven by the 
premise that oncogenic changes alter the dependen-
cies of cells, making them vulnerable to the loss of 
driving oncogenes and to addictions that their trans-
formed state creates. Although this paradigm has 
proven fruitful in identifying some drug targets, there 
are patients who inevitably fail to respond or who ac-
quire resistance to single-target therapies. Acquired 
resistance can be explained by the redundancy and 
plasticity of cellular pathways: Cells can rely on paral-
lel pathways to escape a targeted therapy and continue 
their growth unimpeded.
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To overcome the shortfalls of single-target therapy, 
it is necessary to turn toward combinational agents 
targeting critical nodes of multiple pathways. We have 
developed multiplexed multidimensional shRNA 
screens, where two genes are knocked down simul-
taneously in each cell. This strategy will allow us to 
identify gene pairs that could be targeted together to 
maximize therapeutic benefi ts.
As a proof of concept, a gene set of approximately 120 
highly expressed druggable genes was targeted in four 
melanoma cell lines. The pairwise combinatorial library 
has a total complexity of ~150,000, making a pooled 
screen feasible. Hits in this depletion screen will be lethal 
pairs of genes that are consistently depleted across all cell 
lines. Such gene pairs will be validated in vitro, and a 
short list of most lethal pairs will be studied in vivo.
Germline Genes and Functional 
Piwi/piRNAs in Drosophila Primary 
Cultures Relevant to Cancer
D. Fagegaltier
In a STARR Cancer Consortium collaboration, we 
have derived a large collection of immortalized cell 
lines from Drosophila embryos expressing an activated 
oncogene or mutant for a tumor suppressor gene.
High-content information contained in time series 
profi ling, as opposed to single static measurements, 
potentially allows the detection of coregulated sets of 
genes that are functionally related. To evaluate the 
power of this approach in a multicellular organism, 
we generated transcriptome time series during the im-
mortalization process of seven independent cell lines 
expressing an activated form of Ras. Stabilization of the 
cultures over time is associated with up-regulation of 
genes involved in cell cycle regulation, epigenetic state, 
and enrichment of neurogenic and myogenic tissue 
types. Using correlation analysis of the expression of the 
Twist muscle master transcription factor profi le in the 
time series, we deconvoluted a transcriptional profi le 
signature reminiscent of adult muscle progenitor cells 
(AMPs) and identifi ed several candidate genes we fur-
ther validated with potential roles in myogenesis/myo-
blast proliferation/self-maintenance. Our study dem-
onstrates the power of RNA-Seq time series of evolving 
cell populations to identify functionally related genes.
In addition, we use these cells lines to uncover 
the role of germline PIWI proteins and piRNAs in 
cancer: PIWI proteins are detected in several human 
and mouse tumors, yet no direct link has been estab-
lished between cancer and a piRNA response to ge-
nome instability. We have identifi ed and characterized 
in detail cell lines expressing a complete piRNA ma-
chinery including Aubergine (AUB) and Argonaute3 
(AGO3), proteins known to amplify the piRNA re-
sponse exclusively in ovarian germ cells. We demon-
strated that the piRNA pathway in these tumorigenic 
cell lines of somatic origin is fully functional and 
fulfi lls a crucial role in regulating not only transpos-
able elements (TEs) in the context of carcinogenesis, 
but numerous genes relevant to cancer as well. This 
work provides the fi rst evidence of a functional role 
for the piRNA pathway in cancer and identifi es Ras 
and SHW as two major signaling pathways upstream 
of the response. This in vitro system represents an in-
valuable tool to allow the identifi cation in the long 
term of novel therapeutic targets.
Role of piRNAs in Mouse Spermatogenesis
I. Falciatori
The piRNAs are a class of very diverse small noncod-
ing RNAs present in the germline of all the organisms 
studied so far. They work in association with PIWI 
proteins and they are essential for fertility. In the 
mouse, dysregulation of the piRNA pathway invari-
ably leads to male sterility, with slightly different phe-
notypes depending on the exact components that are 
perturbed. During mouse embryonic development, 
premeiotic piRNAs associate with PIWI proteins to 
form an RNA-based innate immune system able to 
defend the genome from the attack of genomic para-
sites such as transposable elements. This function in-
volves both the direct cleavage of transposable element 
transcripts and the transcriptional silencing of trans-
posons mediated by DNA methylation. Although it 
is well established that DNA methylation of certain 
young transposable elements is dependent on the Piwi 
protein MIWI2 and its associated piRNAs, the exact 
molecular mechanism by which this occurs has yet to 
be fully elucidated. We seek to identify protein part-
ners or downstream targets of MIWI2 that can par-
ticipate to this process.
MIWI2 is only expressed during a very short 
window of embryonic development, coinciding with 
a wave of de novo DNA methylation that occurs in 
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germ cells. The low number of germ cells at this stage 
poses quite a challenge to further understanding the 
molecular mechanisms behind the MIWI2-induced 
DNA methylation. To overcome this hurdle, we are 
optimizing the differentiation of mouse or human 
embryonic stem cells (ESCs) into germ cells. This 
will allow us to collect a higher number of germ cells 
at the right stage and to confi rm or exclude the role 
of possible candidates in this process using shRNA 
technologies. As an alternative strategy, we produced 
transgenic mouse lines in which a MIWI2-GFP 
(green fl uorescent protein) fusion is expressed under 
the control of the Miwi promoter. MIWI is expressed 
starting at meiosis, and it is associated with a class of 
piRNAs (meiotic piRNAs) that differs in origin and 
sequence from those usually associated with MIWI2. 
We thought that the ectopic expression of MIWI2 in 
meiotic and postmeiotic germ cells could have pro-
vided some insight into the targeting mechanism for 
DNA methylation because MIWI2 should now be di-
rected to ectopic locations by its association with the 
meiotic piRNA. Unfortunately, although MIWI2 was 
expressed in the expected MIWI-positive cell types, 
the expression was rather low, and we confi rmed that 
MIWI2 in this context was not loaded with pachy-
tene piRNAs. We believe that this is due to the ab-
sence of proteins that are present during embryonic 
development and are necessary to direct the loading of 
piRNAs into MIWI2.
Exploiting RNAi to Identify a Putative Target 
for Pancreatic Cancer Treatment
S. Fenoglio, M. Hemann, G. Hannon
Although pancreatic cancer occurs at low incidence 
in the United States, it is nevertheless currently the 
fourth leading cause of cancer-related death in the 
country. The high mortality rate is the result of poor 
diagnostic tools and ineffective treatment: In fact, 
most of the patients present at diagnosis with an ad-
vanced and metastatic disease. For this reason, resec-
tion of the tumor mass is impractical in the majority 
of cases, leaving chemotherapy and radiotherapy as 
the only options, which are applied with very low suc-
cess rate as the improvement in survival achieved by 
any treatment is minimal.
Few therapeutic options are currently available for 
the treatment of pancreatic cancer: Gemcitabine is 
administered as standard care; alternatively, a combi-
nation of four different drugs (folfi rinox) can be used 
as fi rst-line therapy for those patients who can tolerate 
the high toxicity of the treatment. Finally, the FDA 
recently approved the combination therapy of albu-
min-conjugated paclitaxel with gemcitabine. This last 
approach to pancreatic cancer treatment aims to im-
prove drug delivery to the tumor and represents only 
one of the multiple formulations under clinical evalu-
ation.
Because of the lethality of pancreatic cancer, it is 
crucial to achieve a better understanding of the dis-
ease in order to increase therapeutic effi cacy. To ad-
dress this urgent clinical need, we performed an in 
vivo RNAi screening in a model system of pancreatic 
cancer to identify genetic dependencies that could be 
exploited for the treatment of the disease. The technol-
ogy of RNAi is a powerful tool to discover the factors 
necessary for tumor growth by specifi cally knocking 
down one protein per cell, revealing the phenotypic 
consequences of the loss of gene function.
The model system we adopted is a cancer cell line 
derived from a genetically engineered mouse model of 
pancreatic cancer, and it carries molecular alterations 
that are relevant to the disease. The oncogenic driver 
is mutant kras, which is present in >95% of patients, 
and the cells lack tp53, a gene that is altered in ~60% 
of cases. This cell line can be transplanted orthotopi-
cally in the pancreas of syngeneic immunocompetent 
mice, which allows for the evaluation of the immune 
system contribution to gene dependencies. We believe 
that it is necessary to include the tumor microenviron-
ment as a variable in the experiments, because the in-
teractions with the environment shape the behavior of 
cancer cells in response to treatment, here replicated 
by RNAi-mediated knockdown of genes. Accordingly, 
in our model, the tumors are resistant to gemcitabine 
in vivo, although we observe sensitivity when the cells 
are cultured in vitro.
We identifi ed one gene, cyclinE2, that is required 
for tumor growth exclusively in vivo, and we are now 
investigating the mechanism responsible for this effect. 
Upon loss of cyclinE2, we observed changes in prolif-
eration and induction of cellular senescence, a program 
that results in permanent cell cycle arrest. The phe-
notypes are a consequence of the role of cyclinE2 in 
cell cycle regulation; what is surprising is the exclusive 
dependency on its function for a cellular process, the 
cell cycle, which has remarkable redundancy.
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piRNA-Directed Cleavage of Meiotic 
Transcripts Regulates Spermatogenesis
W.S. Goh
MIWI catalytic activity is required for spermatogen-
esis, indicating that piRNA-guided cleavage is critical 
for germ cell development. To identify meiotic piRNA 
targets, we augmented the mouse piRNA repertoire 
by introducing a human meiotic piRNA cluster. This 
triggered a spermatogenesis defect by inappropriately 
targeting the piRNA machinery to mouse mRNAs 
essential for germ cell development. Through analy-
sis of such de novo targets, we derived a signature for 
pachytene piRNA target recognition. This enabled 
identifi cation of both transposable elements and mei-
otically expressed protein-coding genes as targets of 
native piRNAs. Cleavage of genic targets began at the 
pachytene stage and resulted in progressive repression 
through meiosis. We also fi nd evidence that pachy-
tene piRNAs undergo the ping-pong cycle to drive 
the silencing of mRNA targets. Our data support the 
idea that meiotic piRNA populations must be strong-
ly selected to enable successful spermatogenesis, both 
driving the response away from essential genes and 
directing the pathway toward mRNA targets that are 
regulated by small RNAs in meiotic cells.
Optimization of shRNA Efﬁ cacy and the 
Creation of Fifth-Generation shRNA Reagents 
Targeting Human and Mouse Genomes
S. Knott
We have published our version-4 and version-5 builds 
of genome-wide shRNA libraries. As mentioned in pre-
vious reports, we performed the shRNA “sensor assay” 
(Fellmann et al., Mol. Cell 41: 733 [2011]) to develop 
a data set of 250,000 shRNA effi cacy data points. Using 
standard linear regression tools, we then determined 
what pairs and triplets of nucleotides within the shRNA 
guide were most predictive of shRNA strength. These 
variables were then included during machine learning 
to develop a computational algorithm that could predict 
well on a set of withheld data points (predicted scores 
showed 0.72 correlation with true scores; Fig. 1).
To benchmark the algorithm (which we call 
shERWOOD), we designed shRNAs (10 per gene) 
targeting a set of genes that, based on their gene on-
tology annotations, were likely to be essential for cell 
proliferation in vitro. We also included in this set 
the olfactory genes that are not expressed in cancer 
cells and could thus serve as negative controls. We also 
 developed libraries targeting these genes using the cur-
rent Broad TRC collection and our version-3 collec-
tion. These three libraries were then used to perform 
multiplexed shRNA screens in the pancreatic cancer 
cell line A385. To develop a set of essential genes, we 
identifi ed all genes for which at least two hairpins per 
library “hit” in the screen. We then assessed library 
quality based on the percentage of shRNAs targeting 
these genes hit for each library and also the rate of de-
pletion that was achieved on average for each of these 
genes. We found that the shERWOOD shRNAs tar-
geting these genes had a higher hit rate and a greater 
level of depletion than the other two libraries (Fig. 2).
For many genes, it is diffi cult to predict potent 
 shRNAs due to their length or GC content. Shorter 
genes provide a lesser search space and potent  shRNAs 
are typically A/T-rich. On the basis of our current 
knowledge, the 5′ bases of RISC (RNA- induced silenc-
ing complex)-loaded shRNA guides are inaccessible 
and do not contact the target sequence. Furthermore, 
Figure 1. Predicted scores as compared to true scores for shRNAs included in the Fellmann et al. (2011) data set. Nine 
separate algorithms were trained, each time eliminating from the training set one of the nine genes in the data set. The 
plots indicate the predicted scores for each gene when it was withheld from training. Data points are separated based 
on the ﬁ rst base of the shRNA guide.
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it is well known that shRNAs with a uracil at this po-
sition tend to be the most potent. Thus, we hypoth-
esized that for any target sequence, we could alter the 
endogenous guide to have a 5′ U and that this would 
allow for potent shRNAs to be identifi ed for short or 
GC-rich genes. To test this hypothesis, we performed 
a sensor assay using constructs that contained a 5′ U 
endogenous and artifi cial guides and only endogenous 
targets. To our surprise, when the scores of these 
shRNAs were stratifi ed based on their fi rst base, the 
endogenous 5′ U guides were most potent (Fig. 3). 
However, some of the nonendogenous 5′ U shRNAs 
did provide potent knockdown.
On the basis of the above fi ndings, we trained a 
machine learning algorithm to discern which of the 
5′ U shRNAs were most effi cacious. We then applied 
this algorithm to an shRNA screen performed with 
only 5′ U shRNAs (containing both endogenous and 
nonendogenous shRNAs) and to the screen described 
above. From this analysis, it was discovered that by 
applying this additional fi lter step, one can achieve a 
higher rate of shRNAs that “hit” and a greater degree 
of depletion (Fig. 4).
Finally, recent studies into microRNA (miRNA) 
sequence conservation have indicated that the place-
ment of the restriction sites in the altered miR30 
scaffold that we use to clone shRNAs with might be 
deleterious to their processing. To determine if this 
was the case, we developed a method by which shR-
NAs could be placed into the endogenous scaffold 
and named this setup UltramiR. To test if small RNA 
processing was improved with this altered scaffold, we 
performed small RNA sequencing on cells that had 
been infected with two different shRNAs, where each 
was harbored within the original miR30 scaffold or 
the new UltramiR scaffold. Processing was assessed 
as the log ratio of the shRNA guide count as com-
pared to the 66th quantile of the endogenous miRNA 
counts. This analysis determined that the placement 
of shRNAs into the UltramiR scaffold results in a 
roughly twofold increase in processing (Fig. 5).
To better ascertain what advantage one has by using 
the UltramiR scaffold, we placed the shERWOOD 
Figure 2.  Percent shRNAs per essential gene depleted (left) and 
average level of depletion (right) for essential genes for each of 
the TRC, V3, and shERWOOD shRNA libraries.
Figure 3.  Sensor scores for endogenous 5′ U shRNAs (1U) and 
for nonendogenous 5′ U shRNAs (1A, 1C, and 1G). Also includ-
ed in the plot are the average scores of benchmark shRNAs that 
were found to be bad, medium, good, and very good.
Figure 4.  Percent shRNAs that were signiﬁ cantly depleted in the 
initial shERWOOD shRNA screen and in a screen combining 
this initial screen, a full 1U strategy, and the additional algorith-
mic ﬁ lter. Average depletion of shRNAs targeting essential genes 
is also plotted on the left.
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shRNA libraries mentioned above into the altered 
scaffold and performed the shRNA screens again. 
Following screening, the 1U fi lter was applied and 
the results of the UltramiR were compared with the 
corresponding miR30 results. This analysis showed 
that when the shRNAs were placed into the UltramiR 
scaffold, a greater percentage of shRNAs per essential 
gene signifi cantly depleted and the average rate of de-
pletion was greater (Fig. 6).
Finally, to assess how the increased processing 
achieved with the UltramiR scaffold affects off- targeting, 
we performed RNA-Seq on cells that had been infected 
with potent shERWOOD-UltramiR shRNAs tar-
geting mouse Serpine2 and Slpi and with U6-driven 
TRC (The RNAi Consortium) shRNAs targeting the 
same genes. By comparing libraries from cells with 
the same genes targeted, we were able to distinguish 
between on-target and off-target effects by looking 
at the median profi les. shRNAs that had the most 
off-target effects would have corresponding libraries 
that were most distant from the median. Inter-library 
comparison determined that the cells infected with 
shERWOO-UltramiR shRNAs differed by about 20 
differentially expressed genes. In comparison, the U6-
driven TRC constructs differed greatly from these 
profi les, with more than 100 genes differentially ex-
pressed (Fig. 7).
In summary, we have developed an shRNA selec-
tion strategy that produces potent shRNAs with low 
off-targeting effects. We have produced individually 
Figure 5. Measurement of the small RNA levels of processed 
shRNAs targeting Renilla Luciferase and mouse Rpa3 when they 
are placed in the altered miR30 scaffold or when they are placed 
into UltramiR. Counts were normalized by the average counts 
of endogenous miRNAs in the 66th quantile (based on counts).
Figure 6.  Percent shRNAs that were signiﬁ cantly depleted in the 
initial screen 1U + ﬁ lter shRNA screen and corresponding Ul-
tramiR shRNA screen. Average depletion of shRNAs targeting 
essential genes is also plotted on the left.
Figure 7. The number of differentially expressed genes (more than 
twofold change and FDR < 0.05) identiﬁ ed through pairwise 
comparisons of the cell lines corresponding to Mgp and Slpi 
knockdown by the shERWOOD-1U selected shRNAs and TRC 
shRNAs 88943 and 66708.
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arrayed sequence-verifi ed versions of these libraries. 
The current human library contains ~50K molecules 
and the current mouse library contains ~35K mole-
cules. They are housed within retroviral vectors where 
the shRNA is expressed from the LTR. The vectors 
also constitutively express neomycin and zsGreen. 
This work has been published by Knott et al. (2014).
The Role of miRNAs in Mouse Embryonic 
Stem Cell Differentiation
M. Kudla
miRNAs are part of the posttranscriptional mecha-
nism of gene expression that modulates protein trans-
lation. Despite multiple investigations of miRNAs 
taking part in development, the global image is still 
elusive. Using a genome-wide, next-generation se-
quencing HITS-CLIP (high-throughput sequencing– 
cross-linking immunoprecipitation) technique, we 
have generated snapshots of miRNA inhibition in the 
differentiation of embryonic stem (ES) cells to neuro-
nal progenitor cells. Our data confi rm that during this 
differentiation, miRNA increasingly targets brain-
specifi c genes as the cells assume neuronal progenitor 
identity. This may be an indication of the involvement 
of miRNAs in the complex feedback mechanism re-
quired for establishing and maintaining neuronal 
identity. During differentiation, several miRNA fam-
ilies become up-regulated, a fact that is emphasized 
particularly by poor diversity of ES cell miRNAs that 
are dominated primarily by the miR-290 family. In 
particular, we observe up-regulation of miR-19 and 
miR-367 and observe the corresponding up-regula-
tion of binding of those miRNAs to the transcripts, 
as indicated by the CLIP data. The subset of miR-19- 
and miR-367-targeted transcripts is also rich in genes 
involved in neuronal functions. This study is unique 
in its capacity for investigating both cause and effect 
in miRNA regulation, because we can track both 
miRNA level increase and the corresponding increase 
of binding to the matching transcripts.
DCIS Project
C. Rebbeck
This past year, we have been working on building the 
foundations toward a long-term project on early-stage 
breast cancer (ductal carcinoma in situ [DCIS]). In 
addition to securing a large grant for this project, we 
have almost completed a pilot study looking at DCIS 
lesions in 30 patients (as part of a collaboration with 
Duke University Medical Center). We are comparing 
their expression profi les and copy-number variations 
with other areas and cell types from the same patient 
and also across patients. Among these patients, some 
have progressed to invasive breast cancer and we have 
taken data from these invasive areas also. During this 
pilot study, we have developed and improved tissue-
staining methods, clinical annotation collaborations, 
laser-capture microscopy methods, and sequencing 
techniques.
In addition, we have been working on a project 
involving dormant cancer; we have spent the past 
year working on low-input sequencing of fi xed cells 
(1–10) and methods for identifying and isolating 
dormant cells. Part of this project has involved ini-
tiating and developing nanobodies, small antibodies 
made in alpacas, for the purpose of improved anti-
body staining.
I have also been working on tumor-associated mac-
rophages, comparing gene expression profi les across 
these cells taken from in vivo tumors. I have identi-
fi ed the gene targets and have then proceeded to do in 
vitro knockdown experiments with shRNAs.
A Molecular Characterization of Breast 
Cancer Progression and Metastasis
E. Wagenblast, S. Knott
Breast cancer is one of the most common cancers 
among women. About one in eight women will de-
velop invasive breast cancer during their lifetime. 
Despite recent advances in treatment of advanced 
breast cancer, the majority of patients with meta-
static disease will succumb to their disease. During 
metastasis, primary tumor cells evolve the capacity 
to intravasate into the lymphatic or vascular systems, 
extravasate into a target organ such as the lung, and 
colonize secondary sites. Previous studies have dem-
onstrated that individual cells within complex popu-
lations show heterogeneity in their capacity to form 
metastatic lesions. However, no model system has 
yet emerged that allows genetically modifi ed cells to 
be followed in a polyclonal context throughout each 
stage of  metastatic disease progression. We developed a 
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mouse model of breast tumor heterogeneity and found 
that distinct clones within a mixed population display 
 specialization—for example, dominating the prima-
ry tumor, contributing to metastatic populations, or 
showing tropism for entering the lymphatic or vascular 
systems. We correlated these stable properties to dis-
tinct gene expression profi les. Those clones that effi -
ciently entered the vasculature expressed two secreted 
proteins, Serpine2 and Slpi, which were necessary and 
suffi cient to program these cells for vascular mimicry. 
Vascular mimicry is a phenomenon wherein highly ag-
gressive tumor cells form channels to distribute blood 
to hypoxic (lacking oxygen) regions of the tumor. Our 
data indicate that Serpine2 and Slpi drive the forma-
tion of extravascular networks, which ultimately lead 
to the formation of distant metastases. Thus, these two 
secreted proteins, and the phenotype they promote, 
may be broadly relevant as drivers of metastatic pro-
gression in human cancer.
RNF17 Blocks Promiscuous Activity 
of PIWI Proteins in Mouse Testes
K. Wasik
PIWI proteins and their associated piRNAs pro-
tect germ cells from the activity of mobile genetic 
elements. Two classes of piRNAs—primary and sec-
ondary—are defi ned by their mechanisms of biogen-
esis. Primary piRNAs are processed directly from 
transcripts of piRNA cluster loci, whereas second-
ary  piRNAs are generated in an adaptive amplifi ca-
tion loop termed the ping-pong cycle. In mammals, 
piRNA populations are dynamic, shifting as male 
germ cells develop. Embryonic piRNAs consist of 
both primary and secondary species and are mainly 
directed toward transposons. In meiotic cells, the 
piRNA population is transposon-poor and largely re-
stricted to primary piRNAs derived from pachytene 
piRNA clusters. The transition from the embryonic to 
the adult piRNA pathway is not well understood. We 
have shown that RNF17 shapes adult meiotic piRNA 
content by suppressing the production of secondary 
piRNAs. In the absence of RNF17, ping-pong occurs 
inappropriately in meiotic cells. Ping-pong initiates 
piRNA responses not only against transposons, but 
also against protein-coding genes and long noncod-
ing RNAs (lncRNAs), including genes essential for 
germ cell development. Thus, the sterility of Rnf17 
mutants may be a manifestation of a small-RNA-based 
autoimmune reaction.
Macrostomum lignano: Building a Toolbox 
for a New Model Species
K. Wasik
Flatworms, such as Macrostomum lignano, have at-
tracted scientifi c attention for centuries due to their 
astonishing, almost unheard of in the animal king-
dom, regenerative abilities. Most fl atworms can re-
generate their entire body, or at least a large majority 
of damaged or amputated organs, thanks to an abun-
dance of somatic stem cells, termed neoblasts. This 
regenerative potential is a rare occurrence among bi-
laterally symmetrical animals. To contribute to the 
understanding of the impressive regenerative abilities 
of fl atworms, we, in collaboration with the Schatz 
lab here at CSHL, have generated and analyzed a 
reference genome sequence for M. lignano. Our as-
sembly incorporates a 100× coverage of PacBio data, 
making it the most complete genome assembly in the 
Loprotrochozon clade. We have also generated and 
annotated a Macrostomum transcriptome from intact 
and regenerating worms. Both will serve as a refer-
ence for future studies of this fascinating clade and 
as a resource to help advance the fi eld of regenera-
tive research, where the choice of model organisms 
is widely restricted by the fact that only a few organ-
isms are able to regenerate multiple tissues in vivo. 
Stem cells possess great therapeutic potential and 
neoblasts provide a very accessible model to study 
somatic pluripotency.
Piwi-Mediated Transcriptional 
Gene Silencing
Y. Yu
I have focused on understanding the mechanism of 
 Piwi-mediated transcriptional gene silencing. In brief, 
we took advantage of a λN/BoxB tethering system to 
mimic piRNA targeting. Surprisingly, artifi cial tether-
ing of λN-Piwi to a luciferase reporter containing BoxB 
sites failed to silence the expression of the reporter. 
Moreover, the reporter remained actively transcribed 
even when Piwi was tethered simultaneously with an-
other piRNA silencing effector, Asterix/DmGTSF1. 
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This is in direct contrast with the observation that 
guiding Piwi complexes via artifi cial  piRNAs can lead 
to repression of their complementary targets. Taken to-
gether, our data suggest that additional factor(s) and/
or conformation changes are required to license Piwi 
complexes to repress transcription.
Through mining the data from several indepen-
dent genome-wide RNAi screens for factors required 
for transposon silencing, we identifi ed a novel protein-
coding gene that can infl uence global transposon ex-
pression in a fashion similar to Piwi when knocked 
down by RNAi. The effect is not due to the defects of 
piRNA biogenesis because levels of piRNAs remained 
unchanged and Piwi maintained its nuclear localiza-
tion. Strikingly, enforced tethering of this protein to 
nascent mRNA transcripts causes cotranscriptional 
silencing of the source locus and the deposition of re-
pressive chromatin marks. Because of its function in 
the piRNA pathway and relationship to Asterix, we 
have named this protein Panoramix, the mentor who 
empowers Asterix to perform his feats of strength. 
Importantly, we found that both Eggless, an H3K9 
methyltransferase, and HP1a, an H3K9me2/3 binder, 
are required for Panoramix-mediated transcriptional 
silencing. Finally, we demonstrated that Panoramix 
binds to genomic loci that harbor transposon sequenc-
es in a manner that depends upon Asterix. We propose 
that Panoramix forms one of the missing links between 
the piRNA pathway and the general silencing machin-
ery that it recruits to enforce transcriptional repression 
to protect germline from deleterious transposons.
Functional Characterization of PIWI 
Proteins and piRNAs in the Flatworm 
Macrostomum lignano
X. Zhou
The Argonaute/PIWI family of proteins is the essen-
tial component of RNAi pathways in eukaryotes. The 
PIWI subfamily is predominantly expressed in the 
germline and interacts with a class of small noncoding 
RNA known as piRNA in multiple species. piRNA 
pathways have crucial roles in germline development 
and maintenance of genomic integrity. However, in 
fl atworms such as M. lignano, the germline is not the 
only cell type that expresses PIWI proteins. A PIWI 
protein, Macpiwi1, has been shown to be predomi-
nantly expressed in both germline and somatic stem 
cells in M. lignano. The stem cells in fl atworms, 
known as neoblasts, are the only proliferating cells 
in the organisms. They are crucial for postembryonic 
development, adult homeostasis, and the remarkable 
regeneration ability of fl atworms. The previous study 
of Macpiwi1 has shed light on PIWI’s importance in 
stem cell and germline maintenance. Knockdown of 
Macpiwi1 has been shown to lead to elimination of 
neoblasts, collapse of the germline, and death of the 
worms. However, the molecular mechanism of PIWI 
and piRNA pathways in fl atworms remains unclear. 
First, we identifi ed another PIWI protein, Macpiwi2. 
Like Macpiwi1, Macpiwi2 is predominantly expressed 
in the germline and somatic neoblasts. Knockdown 
of Macpiwi2 caused the death of worms, whereas 
the germline remained unaffected, indicating differ-
ent mechanisms between Macpiwi1 and Macpiwi2. 
Macpiwi1 knockdown induced a global decrease of 
piRNA production, and interestingly, Macpiwi2 knock-
down led to a global elevation of piRNAs.  Repression 
of piRNA production from transposable element (TE)-
related transcripts resulted in up-regulation of TEs, 
whereas the opposite trend was observed in Macpiwi2 
knockdown. These results imply the importance of 
piRNA pathways and TE regulation in germline and 
stem cell functions in M. lignano.
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TRACKING DOWN CANCER CELL BY CELL
J. Hicks N. Anaparthy H. Qi 
 T. Baslan M. Riggs 
 H. Cox A. Stepansky 
 S. Li 
Our laboratory is focused on further developing high-
throughput applications for the single-cell genomic 
technologies developed at Cold Spring Harbor during 
the last several years in the Wigler and Hicks research 
groups. This technology permits the rapid molecular 
profi ling of clinical cancer samples, with the primary 
goal of understanding the cellular complexity of cancer 
initiation and progression, and, through these studies, 
to discover and implement molecular biomarkers into 
clinical practice.
A core motivation for our work on single-cell genomic 
analysis is the now accepted understanding that tumors 
and their resulting metastases are nearly always hetero-
geneous in both phenotype and genotype. The distinct 
genotypes defi ne populations of cells, each potentially 
exhibiting a different response to anticancer therapy as 
well as the potential to follow novel evolutionary paths 
as the cancer progresses. Although “bulk” DNA se-
quencing of tumor tissue can provide important infor-
mation about the gross makeup of a tumor, novel sub-
populations will often be obscured. Single-cell genom-
ics provides a means to resolve the complex mixtures of 
cells within a tumor and enable us to identify otherwise 
cryptic cell types that may emerge as treatment-resistant 
lineages as the patient undergoes therapy. The goal is to 
characterize the specifi c genetic changes as “biomarkers” 
that can provide prognostic information for the patient 
and establish guideposts that can help direct treatment 
decisions for the physician.
The ultimate goal of this work is the achievement 
of “precision medicine”: matching the right therapies 
with the right patients at the right time. To this end, 
our group has established collaborations with on-
cologists and pathologists at clinical cancer centers 
in order to apply molecular analysis—in particular, 
next-generation DNA sequencing (NGS) and copy-
number variation (CNV) analysis—to profi le cancer 
at its most fundamental level, the single cell.
Single-Cell Proﬁ ling of Circulating 
Tumor Cells
H. Cox, M. Riggs, N. Anaparthy [in collaboration 
with P. Kuhn, University of Southern California]
Most patients being treated for advanced cancer have 
a small number of epithelial cells in their blood-
stream that are apparently shed from the primary or 
metastatic sites. These so-called “circulating tumor 
cells” can be identifi ed among tens of millions of 
white blood cells by immunohistochemical staining 
for specifi c protein markers and provide a potential 
window into the deep recesses of metastatic cancer. 
During the last year, we have optimized a method 
for genomic analysis of both cells and free DNA 
captured from blood samples using a novel approach 
developed by our collaborator, Dr. Peter Kuhn of the 
University of Southern California, that permits the 
observation of every single cell, including both epi-
thelial and mesenchymal “stem-like” cells, in an un-
selected manner from an entire blood sample, along 
with so-called “cell-free” DNA. The combination of 
Dr. Kuhn’s blood sampling technology with our sin-
gle genome technology constitutes a breakthrough in 
the analysis of cancer from blood samples.
In collaboration with the group at the Univer-
sity of Southern California, we have analyzed 800 
blood samples from more than 500 patients in vari-
ous stages of breast, prostate, melanoma, and ovar-
ian cancer. In many cases, we have been able to 
document the progress of disease and the response 
to treatment over time during the course of treat-
ment and are building up a database of treatment 
responses associated with biomarkers extracted from 
the genomic profi les. Two of these data sets for pros-
tate (Dago et al. 2014) and melanoma (Ruiz et al. 
2015) have been published recently and several more 
are papers are in preparation.
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Single-Cell Technology: Analysis 
of Archived FFPE Pathology Samples
T. Baslan, H. Cox [in collaboration with L. Martelotto and 
J. Reis-Filho, Memorial Sloan-Kettering Cancer Center]
Up to now, for reasons associated with preparation 
methods, single-cell profi ling has been limited to 
cultured cells and fresh or fresh-frozen specimens. 
However, in clinical practice, surgical specimens and 
biopsy “cores” taken during diagnostic procedures 
are not preserved by freezing but by formaldehyde 
fi xation and paraffi n embedding (FFPE). This stan-
dard method preserves tissue for routine histopathol-
ogy, but it causes enough chemical damage to DNA 
and RNA to make archived tissue inaccessible to our 
single-cell approach. This limitation made huge col-
lections of archived cancer samples inaccessible to 
our methods for identifying tumor heterogeneity. 
However, as part of our biomarker discovery work 
in collaboration with the Reis-Filho laboratory in 
the Dept. of Pathology at Memorial Sloan-Kettering 
Cancer Center in New York, Dr. Luciano Martelotto 
used DNA-modifying enzymes to repair the DNA of 
3–5-year-old FFPE samples to a level where isolated 
nuclei could be individually sorted into 96-well plates 
and the DNA amplifi ed for sequencing. The method 
now yields results comparable to our previous data 
from frozen cells and opens up the entire archive of 
clinical trial samples to our method of analysis. The 
research was accepted for presentation at the 2015 
Annual Meeting of the American Association of Can-
cer Research (AACR).
Methods for Optimizing Single-Cell 
Genomic Proﬁ ling
T. Baslan, H. Cox
Single-cell genomic profi ling has many valuable ap-
plications in cancer research, from analyzing the re-
sults of mouse model experiments to tracking patient 
response to drugs in clinical trials. However, one limit 
to this utility is in the cost of preparing cells and se-
quencing the DNA and RNA. With support from the 
Breast Cancer Research Foundation, Timour Baslan 
has pursued a project designed to signifi cantly reduce 
the cost of single-cell copy-number profi ling. In the 
course of this project, he has developed a new meth-
od that combines DNA amplifi cation with Illumina 
sequencing library preparation into a two-step process 
that cuts the time for preparing 96 single cells in half. 
He has applied this method to cancer cell lines and to 
breast tumor biopsy tissue, showing that it is superior 
to our previously used methods. Furthermore, he has 
performed analytical experiments to determine the 
exact minimum levels of DNA-sequencing depth that 
are required to permit the elucidation of useful copy-
number profi les. Reducing DNA sequencing depth to 
the minimum necessary allows us to profi le 96 cells 
on one sequencing lane, thereby tripling our data out-
put for less cost overall.
An article describing these methods has been ac-
cepted for publication in Genome Research and will 
appear early in 2015.
Biomarker Discovery: Retrospective 
CNV Analysis of Matched DCIS and 
Invasive Breast Cancer
With support from a 3-year grant from the Susan G. 
Komen Foundation, we have embarked upon a new 
breast cancer project in collaboration with Drs. Jorge 
Reis-Filho, Britta Weigel, and Tari King in the De-
partment of Pathology at Memorial Sloan-Kettering 
Cancer Center. Many breast lesions discovered during 
mammographic screening fall into the precancerous 
category of ductal carcinoma in situ, or DCIS, most of 
which do not progress to invasive disease. This diag-
nosis leaves many patients with the agonizing choices 
that fall between no treatment and drastic treatment. 
The goal of this work is to identify biomarkers that 
would be able to distinguish indolent from malig-
nant cancers at a very early stage, thereby saving both 
human and fi nancial costs involved in treating growth 
that would not turn into life threatening disease.
We hypothesized that if DCIS is composed of mo-
saics of genetically diverse tumor cell clones and that 
the process of invasion is an evolutionary bottleneck, 
then examination of the subclones in invasive breast 
cancer (IBC) could reveal genetic events that may re-
sult in the acquisition of invasive behavior. To test 
this hypothesis and search for genetic biomarkers, we 
began a study of 50 DCIS and matched IBC collect-
ed by Dr. King and macrodissected in the Reis-Filho 
laboratory. These are being analyzed by a combina-
tion of comparative exome sequencing and single-cell 
profi ling to determine whether there are mutations or 
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copy-number variants that are associated with inva-
sive  behavior.
We next focused on the mutational landscape of the 
six DCIS–IBC pairs. In the DCIS samples, a median 
of 41 nonsynonymous mutations (range 25–114), and 
in the IBC samples, a median of 47 nonsynonymous 
mutations (range 19–105) were found (Table 1).
In all six DCIS–IBC pairs analyzed, we identifi ed so-
matic mutations that were present in both the DCIS and 
the adjacent IBC components. These encompassed so-
matic mutations affecting known “driver” breast cancer 
genes (Mansson et al. 1990), including an AKT1 E17K 
mutation (case SK01), PIK3CA H1047R hot-spot muta-
tions (cases SK02 and SK05), a GATA3 S407fs muta-
tion (SK03), a MAP2K4 splice-site mutation (SK06), 
and a TP53 G245S mutation (SK04). Interestingly, 
however, we have also identifi ed mutations that were re-
stricted either to the DCIS or to the IBC. For example, 
in case SK03, we found an ATRX S1154* truncating 
mutation in the IBC, which could not be identifi ed in 
the matched DCIS of the same patient. In case SK05, 
an ALK S928fs frameshift mutation and a PKD2 R872* 
mutation were restricted to the IBC, whereas an ESR1 
F461V mutation was only found in the DCIS.
These initial results indicate that the invasive and 
noninvasive forms of the disease separate early in the 
evolution of the lesion and support the notion that 
the change from indolent to invasive may be due to 
a genetic progression and that certain mutations may 
be genetic markers for progression. We are therefore 
encouraged to continue this study through the entire 
set of available tissue samples.
Bioinformatics of Single-Cell Genomics
H. Qi, S. Li [in collaboration with J. Kendall (Wigler Lab), 
Cold Spring Harbor Laboratory]
A natural fallout from our efforts to reduce the cost of 
single-cell sequencing is the general problem of trying 
to maximize the biological information that can be ex-
tracted from a limited amount of sequence data. Our 
single-cell method for copy-number profi ling uses in-
formatically created “bins” across the genome to aggre-
gate sparse sequencing reads into a statistically useful 
number for each locus. Our resolution for copy-num-
ber breakpoints is thus limited to a range of 3–5 bin 
positions, depending on read count. Huan Qi, work-
ing with Jude Kendall, has attacked the problem of 
using a Bayesian statistics approach that can effectively 
assign a probability measure for the location of a break-
point relative to any gene in the reference genome, in-
dependent of previously established bin boundaries. 
This work is being written up for publication.
In a separate project, Shanshan Li is working on 
ways to call single-nucleotide variant (SNV) muta-
tions in DNA isolated from patient blood samples. 
Blood from cancer patients contains small amounts of 
tumor DNA mixed with variable amounts of normal 
DNA routinely shed from cells. The goal is to deter-
mine the amount of tumor DNA in any sample from 
sparse sequencing and use that value to determine the 
depth of sequencing that will be necessary to identify 
a potential novel mutation arising from the tumor at 
any desired confi dence level. This project is just get-
ting under way and is supported by a grant from the 
Breast Cancer Research Foundation.
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Table 1. Mutations identiﬁ ed in the DCIS and matched IBC.
ID DCIS IBC Shared DCIS-IBC
Nonsynonymous Indel Nonsynonymous Indel Nonsynonymous Indel
SK01 40 0 73 3 31 0
SK02 59 1 59 1 43 1
SK03 25 1 35 1 17 1
SK04 114 1 105 1 25 1
SK05 42 3 28 4 17 3
SK06 37 0 19 0 8 0
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MAMMALIAN FUNCTIONAL GENOMICS
A. Mills Y. Chang A. Jaganathan
 D.-W. Hwang Y.E. Son
Our research is focused on elucidating the genetic/
epigenetic basis of neurodevelopmental syndromes 
and cancer. We have discovered new genes that impact 
these ailments, have revealed mechanisms for how the 
encoded proteins normally work, and determined 
what goes wrong during the disease process. These 
fi ndings have had a major impact in the scientifi c 
community and have affected how clinicians analyze 
and treat patients with these syndromes.
Major discoveries:
• Identifying p63 as a gene affecting development, 
aging, and cancer.
• Defi ning the genetic basis of autism.
• Discovering CHD5 as a gene that prevents cancer.
• Determining that Chd5 loss causes male infertility.
Identifying p63 as a Gene Affecting 
Development, Cancer, and Aging
We discovered p63, a gene that looked very similar 
to p53—a well-studied gene known to be defective in 
over half of all human cancers. Besides looking similar 
to p53, it was not clear how p63 worked. We found 
that a lack of p63 leads to aging. We discovered that 
p63 is needed for stem cell renewal and that when 
p63 is depleted, rapid aging features take place, in-
cluding curvature of the spine, hair loss, and severe 
skin lesions. Yet there is a fi ne balance, as an excess of 
one version of p63 (ΔNp63α) causes carcinoma—the 
most prevalent type of human cancer. In contrast, we 
found that a different version of p63 (TAp63) pre-
vents cancer. We showed that TAp63 inhibits tumor 
growth and that it can do so even when p53 is absent. 
This work was surprising, as it had always been be-
lieved that p53 was absolutely essential for inhibiting 
cancer. Instead, we found that TAp63 can do the job 
alone. We are currently working on strategies to turn 
p63 on, which might be useful in the clinic.
When we fi rst identifi ed p63, we found that it was 
needed for development, as its loss in mice causes 
malformations of the limbs, skin, and palate. This 
work provided a clue to clinicians searching for the 
cause of human syndromes in which children have 
birth defects, including anomalies of the hands and 
feet, abnormal skin, and severe cleft palate. Our dis-
covery that p63 is needed for development led to the 
discovery that p63 mutations cause seven different 
human syndromes involving birth defects affecting 
the limbs, skin, and palate. We generated the fi rst 
mouse models for one of these syndromes, called ec-
trodactyly, ectodermal dysplasia, clefting (EEC) syn-
drome. These models yielded new insight into why 
some children with EEC syndrome have symptoms 
that are very severe and even life threatening, whereas 
other children with EEC—even those in the same 
family with the same p63 mutation—have symptoms 
that are barely noticeable. We are currently working 
to understand how p63 regulates stem cell biology and 
how its perturbation leads to cancer.
Discovering CHD5 as a New 
Cancer-Preventing Gene
We discovered CHD5 as a tumor suppressor mapping 
to human 1p36—a region of our genomes that is often 
deleted in cancer cells. 1p36 deletions occur in many 
different types of human cancers, including those of 
the epithelia, brain, and blood. Although this sug-
gested that a cancer-suppressing gene resided in this 
region, its identity remained a mystery. To tackle this 
problem, we generated mice with deletions and dupli-
cations of the genomic region corresponding to 1p36. 
Using chromosome engineering technology—a strat-
egy with which we can generate precise chromosome 
rearrangements in the mouse—we pinpointed a region 
of the genome with potent tumor suppressive activity. 
Using genetic and molecular approaches, we identifi ed 
CHD5 as the tumor suppressor gene in the region and 
found that its product worked as a “circuit breaker” 
for a cancer-preventing network. In addition, we dis-
covered that CHD5 was frequently deleted in human 
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glioma. We found that CHD5 uses its plant homeodo-
mains to bind histone 3 and that this interaction is 
essential for Chd5 to function as a tumor suppressor. 
Our work paved the way for further discoveries, and it 
is now known that CHD5 is mutated in human can-
cers of the breast, ovary, and prostate, as well as in 
melanoma, glioma, and neuroblastoma. Furthermore, 
recent reports indicate that CHD5 status predicts 
whether anticancer therapy will be effective; indeed, 
patients with high levels of CHD5 have much better 
overall survival than those with low levels. Within 
the past year, we have shown that Chd5 is essential 
for packaging DNA and that loss of Chd5 causes im-
properly packaged DNA that is prone to DNA dam-
age (Li et al. 2014). Intriguingly, Chd5’s absence is 
particularly important during the process of sperm 
maturation—an event in which the DNA is fi rst un-
packaged and then repackaged using an elaborate se-
ries of steps—and that defi ciency of Chd5 causes male 
infertility (Li et al. 2014; Li and Mills 2014). We also 
discovered that Chd5 is expressed highly in neurons 
and that Chd5 plays a pivotal role in the brain, sug-
gesting that inappropriate DNA packaging contrib-
utes to neurodevelopmental syndromes such as autism 
(Li and Mills 2014b). We are currently delving deeper 
into the mechanisms whereby Chd5-mediated regu-
lation of chromatin affects gene expression cascades 
that regulate neuronal stem cells and how deregula-
tion of this process sets the stage for neurodevelopmen-
tal syndromes and cancer.
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CANCER GENES
S. Powers J. Li A. Mofunanya M. Rao
Our main focus has been to use genome-wide DNA 
copy-number profi ling to identify recurrent amplifi ed 
driver genes and to perform in vitro and in vivo analy-
sis to validate their functional role in oncogenesis. Our 
discoveries in this area include gene amplifi cation of 
PPM1D and ACK1 in breast and prostate adenocar-
cinomas and more recently activation of FGF19 and 
POFUT1 by genomic amplifi cation and overexpression 
in hepatocellular carcinoma. During the last few years, 
we have become increasingly interested in the emerging 
possibilities for developing new genome-based methods 
for cancer detection and diagnostics. To enable initia-
tives along these lines, our base of operations is now at 
Stony Brook Medicine, where we have developed col-
laborations with pathologists and oncologists to test ge-
nomic methods for early detection of cancer. Currently, 
there are three ongoing research projects in our laborato-
ry, each being spearheaded by an individual lab member.
Oncogenomic Screening for Linked Driver 
Dependencies in Breast Cancer
A. Mofunanya [in collaboration with K. Scott, Baylor 
University; B. Hahn, Broad Institute; and M. Hemann, 
Massachusetts Institute of Technology]
We are part of a network of laboratories (CTD2; https://
ocg.cancer.gov/programs/ctd2) that are funded by the 
National Cancer Institute to work individually and col-
laboratively to use cancer genome data for the discovery 
and development of human cancer therapeutics. Many 
of the best targets for cancer treatment are encoded by 
the genes that when altered drive cancer progression 
and that when inhibited selectively block the survival 
of cancer cells with that particular alteration (linked 
driver-dependency, e.g., amplifi cation of HER2 drives 
breast cancer development; amplifi ed HER2 tumors are 
selectively dependent upon HER2 function). Following 
this paradigm, I have performed functional genomic 
screening of aberrantly expressed candidate breast can-
cer genes along with controls (102 in total) and am now 
validating hits to determine which gene(s) to focus on 
for in-depth characterization.
Two driver screens were performed: one using 
human breast epithelial cells (MCF10A; screened in 
three-dimensional culture) and the other using murine 
breast epithelial cells (NMuMG; screened in vivo). Ap-
proximately one-half of the genes signifi cantly affected 
growth of MCF10A, most of them negatively and a 
smaller set positively, with IL19 and WWTR being the 
highest-ranked. Surprisingly, although one-half of the 
genes also signifi cantly affected the tumorigenicity 
of NMuMG cells, almost all did so negatively; only 
three increased tumorigenicity, including ALDHB2, 
NKX2.1 (which negatively affected MCF10A), and 
WWTR. The small overlap of hits between the two 
systems as well as the opposite effects of NKX2.1 may 
refl ect the ductal, ER+ status of MCF10A and the 
basal, ER– status of NMuMG. Dependency screens 
were performed with custom-synthesized short hair-
pin RNA (shRNA) libraries with eight independent 
shRNAs designed to target each of the 102 genes. 
The libraries were transfected as pools into four dif-
ferent breast cancer cell lines and assayed for effects 
on both growth under normal cell culture conditions 
and anchorage-independent growth. Next-generation 
sequencing of the bar-coded shRNAs were used to es-
timate biological effects. To convert individual shRNA 
results into a gene-score, Stouffer’s weighted Z-score 
was computed. WWTR1 showed the highest depen-
dency overall and is the strongest dependency in the 
triple-negative cell line CAL-120.
Comparative Analysis Using FLLat Reveals 
Oncogenomic Properties of Individual 
DNA Copy-Number Features
J. Li [in collaboration with J. Pollack and R. Tibshirani, 
Stanford University; and W. Zhao and G. Mills, MD 
Anderson Cancer Center]
The ability to translate complex cancer genome data sets 
to improved diagnosis and treatment strategies remains 
challenging, particularly for acquired copy-number 
 alterations (CNAs). We have been collaborating with 
R. Tibshirani on extending his FLLat modeling of 
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DNA copy-number alterations to identify oncogenomic 
properties of specifi c DNA copy-number alterations (a 
fused lasso latent feature model for analyzing multi-
sample aCGH data; Nowak et al. Biostatistics 12: 776 
[2011]). The purpose of FLLat is to increase the inter-
pretability of massive DNA copy-number data sets by 
modeling them as a much smaller set of copy-number 
features. This modeling accurately preserves the impor-
tant details of DNA copy-number profi les. One of our 
goals in using FLLat has been to develop auxiliary com-
putational tools that would allow us to do comparative 
biology of closely matched tumors that differ only with 
regard to a single DNA copy-number feature. To test the 
method we developed, we applied it to the HER2 ampli-
con which is probably the best understood copy-number 
feature in breast cancer (Fig. 1). These results suggest 
that comparative biology can lead to a deeper under-
standing of poorly understood copy number alterations.
Genomic Test for Early Detection 
of High-Grade Serous Ovarian Cancer
M. Rao [in collaboration with M. Pearl and K. Shroyer, 
Stony Brook University]
We aim to develop a genomic test that can fi nd high-
grade serous ovarian cancer (HGS-OVCA) cells that 
are shedding from the suspected precursor serous 
tubal intraepithelial carcinoma located at fallopian 
tube fi mbriae into the uterine cavity. These precursors 
have been shown to have already undergone the two 
key features of high-grade serous ovarian cancer, dom-
inant TP53 mutations and DNA copy-number altera-
tions (Hunter et al., Am J Pathol 184: 1871 [2014]). 
We are basing our test on the most up-to-date char-
acterization of the genomic features of HGS-OVCA 
that distinguish it from normal, healthy tissue. HGS-
OVCA is unusual among human cancer types in that 
virtually every tumor has undergone extensive copy-
number alterations. Despite the extensive heterogene-
ity of copy-number breakpoints, there is uniformity in 
terms of peak regions amplifi ed or deleted. By model-
ing and simulation studies, we have chosen 10 DNA 
probes that detect different chromosomal abnormali-
ties, each of which distinguishes HGS-OVCA from 
normal tissue. Together, this panel of 10 probes is pre-
dicted to detect >99% of HGS-OVCA cases, using 
digital polymerase chain reaction (PCR). Our plan is 
to develop a test that would involve gentle rinsing of 
the uterine cavity with saline at the time of collection 
of a routine cervical Pap test specimen. Cells collected 
by this approach would subsequently be analyzed for 
genomic aberrations using highly sensitive single-mol-
ecule DNA tests with our panel of 10 probes. Because 
Figure 1. Comparison of closely matched tumors that differ only with regard to the HER2 amplicon. Using linked 
proteomic and gene expression data, comparative analysis indicated that the types of changes associated with HER2 
overexpression in model systems are also found in human cancers using the comparative approach we developed.
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TIC cells are shed from the fallopian tube into the 
uterine cavity, developing very sensitive methods to 
detect and subsequently treat these lesions should pre-
vent most cases of HGS-OVCA.
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CANCER AND HUMAN GENETICS
M. Wigler R. Aboukhalil D. Esposito J. Kendall J. McIndoo J. Troge
 J. Alexander T. Forcier Y.-H. Lee S. Mukhopadhyay Z. Wang
 J. Allen E. Grabowska A. Leotta L. Rodgers B. Yamrom
 P. Andrews I. Hakker B. Ma M. Ronemus C. Yoon
 M. Bekritsky R. Kandasamy S. Marks J. Rosenbaum L. Zhang
Our lab studies human cancer and genetic disorders 
from a genomics perspective, mainly in collabora-
tive efforts with Dan Levy and Ivan Iossifov here at 
CSHL. The cancer effort focuses on breast and pros-
tate cancer and involves collaborative clinical studies 
to discover mutational patterns predicting treatment 
response and outcome. The lab also develops meth-
odologies for single-cell DNA and RNA analysis to 
detect cancer cells in tissues and bodily fl uids. This 
has major potential applications to the early detec-
tion of cancer, monitoring recurrence, and response 
to therapy during and after treatment. Single-cell 
analysis has led to insights about the clonal evolution 
and heterogeneity of cancers and may lead to a better 
understanding of initiation, progression, and metasta-
sis. These single-cell methods are also being applied to 
problems in neurobiology.
The research on genetic disease is aimed at deter-
mining the role of de novo mutation in pediatric dis-
orders. The work has mainly involved participation 
in a large study of autism organized by the Simons 
Foundation Autism Research Initiative. Recently pub-
lished work has confi rmed and extended the team’s 
earlier observations on the role of de novo copy-num-
ber variation in autism, with similar results in other 
disorders such as congenital heart disease. The large-
scale whole-exome sequencing project was done in 
collaboration with W. Richard McCombie at CSHL, 
as well as Evan Eichler and Jay Shendure (University 
of Washington, Seattle) and Matthew State (Univer-
sity of California, San Francisco).
The Molecular Genetics of Autism
We are examining the genetic basis of autism spectrum 
disorders (ASDs) by studying de novo (DN) mutations 
occurring in affected individuals. We have combined 
the efforts of three teams that analyzed 2517 fami-
lies from the Simons Simplex Collection (SSC). This 
collection consists of families with only one affected 
child (simplex) and is therefore not depleted for causal 
DN mutations. These data were published in Iossi-
fov et al. (2014). By comparing affected to unaffected 
siblings, we estimate that 13% of DN missense muta-
tions (that change protein sequences) and 42% of DN 
likely gene-disrupting (LGD) mutations contributed 
to 12% and 9% of diagnoses, respectively. Including 
large-scale copy-number changes, coding DN muta-
tions contributed to ~30% of diagnosis  simplex and 
45% of female diagnoses. Virtually all LGD mutations 
occurred opposite normal alleles. LGD targets in af-
fected females signifi cantly overlapped the targets in 
males of lower IQ, but neither overlapped signifi cant-
ly with targets in males of higher IQ. We estimate 
that LGD mutation in about 400 genes can contrib-
ute to the “joint” class of affected females and males 
of lower IQ, with an overlapping and similar number 
of genes vulnerable to causative missense mutation. 
LGD targets in the joint class overlap with published 
targets for intellectual disability and schizophre-
nia and are enriched for chromatin modifi ers, genes 
bound by the Fragile X mental retardation protein 
(FMRP), and genes expressed during embryonic 
development.
Genetic Models for Autism
A limitation in studying the genetics of autism has been 
the lack of accurate models. Many genetic mechanisms 
have been proposed for autism, including transmitted 
and DN mutation, incorporating both small and large 
effects. On the basis of data from our genomics efforts, 
we have built a theoretical population genetic model 
and computational framework that can incorporate 
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various high-level epidemiological and genetic obser-
vations, such as incidence, gender bias, recurrence rate 
in families with one or multiply affected children, twin 
concordance, DN mutation rate, and other factors. We 
have developed the simplest model that successfully 
captures much of the epidemiology of autism, involv-
ing a single class of genes and three parameters: pen-
etrance for males (i.e., the likelihood that an individual 
carrying a mutation will have the disorder), penetrance 
for females, and rate of new mutation. By constraining 
male incidence to an exact value, this model has just 
two free parameters. We are in the process of refi ning 
this model to take into account all observations from 
our data as well as our published data sets, allowing 
variants of small effect.
We observed in our molecular genetic study of the 
SSC that strong purifying selection—evidenced by 
a surprising lack of deleterious variants—was acting 
on many genes implicated in autism. We term such 
genes “vulnerable” to mutation. Taking advantage of 
our large data set, as well as those from other studies, 
we have expanded our observations. From the known 
rates of DN mutation, it is evident that only half of 
the targets of DN LGD mutation in autistic children 
are likely to be causal. On the basis of our analysis, 
we can use vulnerability to mutation to prioritize the 
list of autism candidate genes, because those that are 
depleted for rare LGDs in unaffected individuals are 
more likely to be related to autism.
De Novo Mutation in Sporadic Human 
Disease
Congenital heart disease (CHD) is one of the most 
common malformations in humans—found in nearly 
1% of live births—and is largely sporadic, with evi-
dence of a signifi cant genetic component. Utilizing 
the same approach as in our autism study, we stud-
ied 213 families in collaboration with Drs. Dorothy 
Warburton and Wendy Chung at Columbia Univer-
sity Medical Center. As in the other studies, we found 
strong evidence that DN CNVs may cause CHD, with 
greater than 10% of affected children having a germ-
line variant—a rate fi ve times higher than was seen 
in a control population. This study is now published 
(Warburton et al. 2014), and it suggests that rare DN 
mutation of high risk may contribute to many types of 
sporadic disorders in humans.
Algorithms for Genomic Analysis
In collaboration with Dan Levy, Ivan Iossifov, and 
Mike Schatz, we developed tools for genome analysis 
by refi ning existing methods and creating novel algo-
rithms when “off-the-shelf” software is inadequate. 
Insertions and deletions (indels), as well as other ge-
nome rearrangements, contribute signifi cantly to ge-
netic variation and disease. Many small indels can be 
detected by existing software, but in some genomic 
contexts—such as within microsatellites—indels can 
be diffi cult to discern. We have developed “Scalpel” 
based on local reference-free assembly, and a “split-
read” method called “Mumdel” to fi nd almost-unique 
matches to align sequence reads to the genome. Fur-
ther development has allowed us to create a database 
of all discontinuities observed in samples. Within this 
population-based database, we can readily distinguish 
rare events of signifi cance. We are now refi ning this 
algorithm to make it more generally applicable to dif-
ferent types of sequencing data.
Molecular Methods
We have continuously worked on developing methods 
to perform measurements with greater resolution, or 
more effi ciently, or to make new types of measure-
ments. In the area of genomics, this includes algo-
rithm development as described above as well as bench 
methods. In this regard, we have two ongoing projects. 
First, we are developing a method to maximize the ge-
nomic “real estate” available on the current generation 
of sequencing instruments. Termed SMASH sequenc-
ing, this consists of making genomic copy-number 
measurements based on sequencing and lowering ex-
perimental costs using sample barcodes, pooled sam-
ples, and DNA fragmentation. In combination, we use 
a custom algorithm to map and count sequence tags. 
Our results suggest that SMASH performs equally as 
well as whole-genome sequencing and is a dramatically 
cheaper option than any other method for accurately 
determining copy-number variation. In addition, it 
allows genome-wide coverage on a scale not available 
using hybridization-based technologies, such as micro-
arrays.
Second, we have developed a bench protocol 
for mutational tagging using random deamination 
of cytosine at a tunable conversion rate—MuSeq. 
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DNA templates are imbued with a unique muta-
tional identifi er that allows individual molecules to 
be discerned and larger contigs to be constructed 
by matching unique patterns. This addresses some 
of the prominent shortcomings of existing short-
read technology, namely, errors in sequencing and 
polymerase chain reaction (PCR), which limit util-
ity in many applications. We have been able to cre-
ate a stable and reproducible protocol, as well as 
algorithms that can successfully perform assembly. 
Potential applications range from single-cell tran-
scriptome isoform profi ling, precise measurements 
of copy number, error-free DNA sequencing, sensi-
tive detection of rare populations, haplotype phas-
ing, to long-range genome assembly. The latter is 
of particular interest, as it will allow us to uncover 
structure in genomic regions that are currently dif-
fi cult to resolve, such as the 16p11.2 locus, the HLA 
region, and the Y chromosome.
Single-Cell Analysis of Human Neurons
Neuronal cells of the brain are the most function-
ally diverse of any organ in the human body, but 
the totality of that diversity is not fully understood. 
Moreover, the diversity of neurons in the brain may 
be increased by somatic mutational mechanisms oc-
curring during the last few cycles of neuronal dif-
ferentiation—before neuronal fate is fi xed. With 
recent advances in single-cell sequencing technol-
ogy, it is possible to sequence DNA and RNA from 
single neurons in the brain. In collaboration with 
Dan  Geschwind at the University of California, Los 
 Angeles, we are exploring the roles of somatic mu-
tation in neurons derived from embryonic human 
brains, categorizing subtypes and specifi c tran-
scription patterns, and exploring the contribution 
of monoallelic expression to neuronal diversity and 
cognitive-behavioral variation. With Josh Huang 
here at CSHL, we are conducting a similar study 
with special focus on GABAergic interneurons.
Genomic Landscape of Prostate Cancer
Prostate cancer (PCa) is the most common genito-
urinary malignancy among men. It often presents 
as a multifocal disease characterized by tremendous 
biologic heterogeneity with a variable clinical course 
ranging from indolent to lethal disease. Current guide-
lines for prognostication and treatment strategies rely 
on clinic pathological parameters such as serum PSA 
levels and histological appearance. Developing genom-
ic parameters such as copy-number variation, genome 
instability, and clonality will enhance current methods 
for prognostication and disease management. We are 
using a single-cell DNA (scDNA) genomics approach 
to obtain high-resolution profi les of the genetic altera-
tions that occur in single prostatic cancer cells. Our 
methods are very general and are applicable to many 
kinds of cancer and many types of biological sampling.
In collaboration with Drs. Ashutosh Tewari of 
 Weill Cornell Medical College and Herbert Lepor at 
New York University Medical School, we have shown 
that analysis of the genomes of just a few hundred cells 
can provide a landscape of the evolution of prostatic 
neoplasia. A comparison to Gleason scores suggests 
that early stages of the disease comprise cells with 
unstable genotypes, with little if any clustering into 
emergent clones with consensus genotypic markers. 
In contrast, advanced-stage disease displays not only 
cells with divergent and unstable genotypes, but also 
emergent clones of cells with common chromosomal 
deletions and amplifi cations that spread throughout 
the organ. Efforts are under way to determine if ge-
nome scores derived from single-cell genomic analysis 
may improve risk stratifi cation in PCa. This study has 
continued from last year with a doubling of samples 
and confi rmation of earlier results.
We are working out a new scDNA protocol that 
will be less expensive and also give us nucleotide-level 
information from each cell, with the aim of using 
rates of mutation to aid in prognostication and stag-
ing as well as phylogenetic mapping. In collaboration 
with Alex Krasnitz here at CSHL, we are developing 
a single-cell “viewer” that integrates scalable single-
cell profi le data with phylogeny, sector of origin, and 
histopathology. A prototype is already written and is 
being used routinely to observe and analyze data.
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CANCER: SIGNAL TRANSDUCTION
Mikala Egeblad and colleagues study tumors and, in particular, the contributions of the microen-
vironment in which the cancer cells arise and live. Solid tumors are abnormally organized tissues 
that contain not only cancer cells, but also various stromal cell types and the extracellular matrix, 
and these latter components constitute the microenvironment. Communications between the dif-
ferent components of the tumor infl uence its growth, its response to therapy, and its ability to 
metastasize. Among the tumor-associated stromal cells, the lab’s main focus is on  myeloid-derived 
immune cells, a diverse group of cells that can enhance angiogenesis and metastasis and  suppress 
the cytotoxic immune response against tumors. Egeblad is interested in how different types of 
myeloid cells are recruited to tumors and how their behaviors—for example, their physical interac-
tions with cancer cells and other immune cells, infl uence cancer progression, including metastasis. 
The Egeblad lab studies the importance of the myeloid cells using mouse models of breast and 
pancreatic cancer and real-time imaging of cells in tumors in live mice. This enables them to fol-
low the behaviors of and the interactions between cancer and myeloid cells in tumors during pro-
gression or treatment. This technique was instrumental when the lab recently showed that cancer 
drug therapy can be boosted by altering components of the tumor microenvironments, specifi cally 
reducing either matrix metalloproteinases (enzymes secreted by myeloid cells) or  chemokine recep-
tors (signal receptors on myeloid cells). The Egeblad lab has collaborated with Scott Powers’ group 
to understand how normal cells surrounding a tumor promote cancer growth. They have found 
that normal cells signal to tumors through multiple pathways, and blocking these signals together 
has the greatest effect on inhibiting tumor growth—offering a new strategy to fi ght cancer.
Darryl Pappin’s lab develops chemical and computational methods for analysis of proteins and 
peptides. These are fundamental tools for proteomics, and they are vital in many fi elds of biologi-
cal investigation. Proteins and peptides are typically analyzed via mass spectrometry, a method 
that involves fragmenting samples by colliding them with gas atoms in a vacuum. Masses of the 
resulting fragments are measured, and computer algorithms match the results with known or pre-
dicted molecules whose amino acid sequences are either known or inferred. Pappin has developed 
search engines for mass spectrometry data that enable investigators to sift hundreds of thousands 
of experimental spectra at a time for database matches. He also seeks to reduce sample complexity 
via an approach he calls chemical sorting. This includes the use of chelation to enrich phospho-
peptides from the total peptide pool and the use of specifi c affi nity-tagged small-molecule inhibi-
tors to segregate classes of kinases or phosphatases for more specifi c mass spectroscopic analysis.
Despite their large variety of genetic abnormalities, cancer cells have been found to be extremely 
sensitive to the reversal of certain mutations. Raffaella Sordella and colleagues study why cells 
in certain cancers are responsive to the inhibition of one particular gene or gene product. Why, 
for instance, do non-small-cell lung cancer (NSCLC) cells that have a particular mutation in 
the EGFR (epidermal growth factor receptor) respond dramatically to its inhibition by the drug 
Tarceva? This occurs in 15%–20% of patients, the great majority of whom, within 1–3 years, 
develop resistance. Various mutations have been implicated in about half of resistant patients. Sor-
della and colleagues have discovered a new resistance mechanism in a subpopulation of NSCLC 
cells that are intrinsically resistant to Tarceva. These tumor cells were observed to secrete elevated 
amounts of a growth factor called transforming growth factor-β (TGF-β), which in turn increases 
secretion of interleukin-6 (IL-6), an immune signaling molecule. Signifi cantly, these effects were 
independent of the EGFR pathway. The team therefore hypothesizes that infl ammation is one of 
the factors that can render a tumor cell resistant to treatment with Tarceva. In other work, Sordella 
collaborates with the Krainer lab to study whether alternative splicing has a role in the failure of 
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p53-mediated senescence to halt oncogenesis in certain lung cancers. In a discovery cited as one 
of 2014’s “signaling breakthroughs of the year,” Sordella’s team discovered a new variant of p53, 
which they named p53Ψ. In contrast to normal p53, this splice variant has pro-growth and even 
pro-metastatic effects, which it produces by interacting with a protein at the membrane of the 
mitochondria.
Nicholas Tonks and colleagues study a family of enzymes called protein tyrosine phosphatases, or 
PTPs, which remove phosphate groups from proteins and other signaling molecules, such as lipids, 
in cells. Disruption of PTP function is a cause of major human diseases, and several of the PTPs 
are potential therapeutic targets for such diseases. Tonks’ group seeks to fully characterize the PTP 
family, understanding how PTP activity is controlled and how PTPs modify signaling pathways. 
In addition, they are working to determine how those pathways are abrogated in serious illnesses, 
including cancer, diabetes, and Parkinson’s disease. The overall goal is to identify new targets and 
strategies for therapeutic intervention in human disease. Tonks and colleagues have defi ned new 
roles for PTPs in regulating signaling events in breast cancer, identifying three PTPs as novel 
potential tumor suppressors. They have characterized the regulation of PTP1B by reversible oxi-
dation, demonstrating that it is regulated by covalent modifi cation of the active site by hydrogen 
sulfi de (H2S) under conditions of ER stress that are linked to protein-folding-related pathologies, 
such as Parkinson’s and Alzheimer’s. In addition, they have generated recombinant antibodies that 
selectively recognize the oxidized conformation of PTP1B; these antibodies display the ability to 
promote insulin signaling in cells and suggest novel approaches to therapy for diabetes. Finally, 
they have also discovered a novel mechanism for allosteric regulation of PTP1B activity, offering 
the possibility of developing small-molecule drugs that could inhibit the phosphatase and thereby 
modulate signaling by insulin and the oncoprotein tyrosine kinase HER2, potentially offering 
new ways to treat insulin resistance in type-2 diabetes and breast cancer.
Lloyd Trotman’s recent research path begins at his discovery some years ago that the loss of a 
single copy of a master tumor suppressing gene called PTEN is suffi cient to permit tumors to 
develop in animal models of prostate cancer. His team later found that complete loss of PTEN 
paradoxically triggers senescence, an arrested state that delays or blocks cancer development in 
affected cells. These fi ndings explained why many patients only display partial loss of this tumor 
suppressor when diagnosed with prostate cancer. Now the team is researching ways to restore the 
PTEN protein levels in these patients. This therapeutic approach could slow disease progression 
and thus greatly reduce the need for surgical removal of the prostate or of similar drastic inter-
ventions that carry the risks of incontinence and impotence. Their second approach to combat 
prostate cancer is to model the lethal metastatic disease in genetically engineered mice. They are 
developing a novel approach, RapidCaP, that allows for quick generation and visualization of 
metastatic disease. The effi cacy of existing and novel late-stage therapies, such as antihormonal 
therapy, can then be tested and optimized in these animals. At the same time, the Trotman lab is 
exploring the genome alterations associated with metastatic disease and with resistance to therapy. 
To this end, they use single- and multicell genome sequencing techniques developed at CSHL by 
Drs. Wigler and Hicks.
David Tuveson’s lab uses mouse and human tissue models of neoplasia to explore the funda-
mental biology of these diseases and thereby identify new diagnostic and treatment strategies. 
His team’s main focus is pancreatic cancer, a lethal malignancy that has eluded clinical solutions 
despite intensive study. The lab’s approaches at CSHL run the gamut from designing new model 
systems of disease to inventing new therapeutic and diagnostic platforms for rapid evaluation in 
preclinical and clinical settings. For example, they have adopted a new method of culturing tissue 
fragments indefi nitely in cell culture, enabling deep analysis with genetic and pharmacological 
probes. In addition, therapeutic experiments in mouse models have revealed an important role of 
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redox metabolism and stromal interactions on infl uencing therapeutic response. They have used 
the mouse model system to identify the mechanism of a promising drug treatment for pancreatic 
cancer. The lab found that using the drug in combination with more standard chemotherapeutic 
drugs stopped the tumor growth and lengthened life span for the mice, suggesting that the com-
binatorial therapy may help overcome the drug resistance that is so commonly found in cancers. 
Tuveson’s lab also has a strong link to clinical trials locally and internationally, with confi rmation 
in early phase trials the ultimate goal. Collectively, their strategy in the preclinical and clinical 
arena is codifi ed as the “Cancer Therapeutics Initiative,” and this initiative will provide these same 
approaches to the entire CSHL cancer community.
Linda Van Aelst’s lab studies how aberrations in intracellular signaling involving enzymes 
called small GTPases can result in disease. They are particularly interested in Ras and Rho 
 GTPases, which help control cellular growth, differentiation, and morphogenesis. Alterations affect-
ing Ras and Rho functions are involved in cancer and various neurodevelopmental disorders. 
Van Aelst’s team has extended its prior study of mutations in a Rho-linked gene called oligo-
phrenin-1 (OPHN1), part of an effort to connect the genetic abnormalities associated with mental 
retardation to biological processes that establish and modify the function of neuronal circuits. In 
addition to a role for OPHN1 in activity-driven glutamatergic synapse development, lab members 
have obtained evidence that OPHN1 has a critical role in mediating mGluR-LTD, a form of long-
term synaptic plasticity, in CA1 hippocampal neurons. Their fi ndings provide novel insight not 
only into the mechanism and function of mGluR-dependent LTD, but also into the cellular basis 
by which mutations in OPHN1 could contribute to the cognitive defi cits observed in patients. 
This year, the team demonstrated that OPHN1 is involved in AMPAR traffi cking; when it is 
mutated or missing, long-term potentiation is impaired. Defects in cortical neurogenesis have 
been associated with cerebral malformations and disorders of cortical organization. The Van Aelst 
team discovered that interfering with the function of the Rho activator DOCK7 in neuronal pro-
genitors in embryonic cerebral cortices results in an increase in the number of proliferating neuro-
nal progenitors and defects in the genesis of neurons. The team has also shown that DOCK7 has 
a central regulatory role in the process that determines how and when a radial glial cell progenitor 
“decides” to either proliferate or give rise to cells that will differentiate into pyramidal neurons. 
They recently discovered that DOCK7 activation of ErbB4 is essential for normal chandelier cell 
development. These lines of research provide novel insight into mechanisms that coordinate the 
maintenance of the neural progenitor pool and neurogenesis.
Hongwu Zheng’s lab aims to defi ne the complex biology of malignant glioma pathogenesis, with 
the ultimate goal of translating the developed knowledge into patient benefi ts. Although eerily 
similar in terms of their self-renewal capacity and distinct phenotypic plasticity, malignant glioma 
cells conspicuously lack the terminal differentiation traits possessed by their normal counter-
parts—neural progenitors. With the use of multiple approaches combining human cancer genom-
ics, animal modeling, and stem cell biology, Zheng has unraveled the causal relationship between 
aberrant differentiation and ensuing gliomagenesis. Perhaps more importantly, his team has dem-
onstrated that forced restoration of differentiation capacity within glioma cells can drastically 
attenuate their tumorigenic potential. This fi nding fi ts well with the team’s overall strategy, which 
is to target differentiation control pathways as a novel avenue for malignant glioma treatment. To 
this end, they have sought (1) to develop various animal models to recapitulate the human glioma 
pathogenesis and utilize them to trace and investigate in vivo tumor initiation/progression and (2) 
to identify key pathways/players controlling normal and neoplastic neural progenitor cell renewal 
and fate determination.
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THE INFLUENCE OF THE TUMOR MICROENVIRONMENT 
ON DRUG RESISTANCE AND METASTASIS
M. Egeblad A. Almeida M. Fein V. Kuettner J. Park R. Wysocki
 J. Cappellani Y. Jia L. Maiorino M. Shields
Solid tumors are aberrant tissues, and like organs, they 
are composed of cancer cells and stroma. The stroma 
is the supportive framework of the organs and in-
cludes the extracellular matrix (ECM) and fi broblasts, 
adipocytes, cells of the vascular system, and immune 
cells. Interactions between epithelium and stroma are 
essential for normal organ development as well as for 
tumor progression. In solid tumors, the stroma is also 
known as the tumor microenvironment.
We study how the tumor microenvironment infl u-
ences cancer cells in the context of drug resistance and 
metastasis. We use mouse models of breast and pan-
creatic cancer together with real-time spinning-disk 
microscopy in living mice (intravital imaging). This 
allows us to study how cancer cell proliferation, mi-
gration, and survival are infl uenced by stromal com-
ponents in real time.
The Inﬂ uence of the Tumor 
Microenvironment on Response to Therapy
J. Jia, R. Wysocki, M. Fein, J. Cappellani
Breast cancer will recur in 20% of patients within 10 
years after apparently successful treatment with che-
motherapy. When resistance to chemotherapy devel-
ops, no other effective treatment options are available. 
How resistance develops is still an open question with 
three main theories proposed for the origin of the re-
sistant cells: (1) from subpopulations of cells already 
within the tumor, (2) from cells with stem-cell-like 
properties, or (3) through mutations or epigenetic 
changes. Understanding which of these mechanisms 
drive resistance is critical to reducing recurrence.
Surprisingly, little is known about how cancer cells 
in intact tumors respond to classical chemotherapy, al-
though these drugs have been used for decades. Most 
knowledge of the responses has been obtained from 
cell culture or xenograft animal experiments, but such 
experiments are often not predictive of drug responses 
in patients. We previously used intravital imaging to 
show that monocytes are recruited to tumors ~30 h 
after chemotherapeutic treatment with doxorubicin, 
after cancer cell death was observed. We determined 
that monocytes were recruited to tumors through ac-
tivation of the chemokine receptor CCR2. We further 
determined that the infi ltration of these monocytes 
contributed to chemoresistance, as the effect of doxo-
rubicin and cisplatin on tumors transplanted to mice 
lacking CCR2 was signifi cantly better than that of 
tumors in normal mice.
We noted that when tumors recurred in mice lack-
ing CCR2, they were of lower histological grade than 
tumors relapsing in wild-type mice. We have now 
found that the tumors relapsing in mice where host 
cells lack CCR2 are more differentiated toward a lu-
minal epithelial cell type than the rapidly relapsing 
tumors in wild-type mice. We are currently investigat-
ing how activation and expression of transcription fac-
tors involved in breast epithelial cell differentiation are 
altered during response to chemotherapy. To identify 
the cellular and molecular mechanisms, we are also 
using lineage tracing combined with intravital imag-
ing over weeks, using mammary imaging windows, 
together with microgenomics approaches.
Effects of Myeloid Cells on Breast Cancer 
Metastasis
J. Park, R. Wysocki, M. Fein
The prognosis of metastatic breast cancer is poor. 
More than a century ago, Dr. Stephen Paget observed 
that metastases develop preferentially in certain or-
gans, suggesting that factors external to cancer cells 
infl uence metastasis and that targeting such factors 
might reduce the ability of cancer cells to take seed. It 
is now recognized that communications between can-
cer cells through growth factors and cytokines have an 
important role in the process of metastasis.
Traditionally, studies of metastasis have relied pri-
marily on measurements made at the endpoint of the 
86  Research
process, the establishment of micro- or macrometas-
tases. However, the metastatic process is dynamic and 
characterized by the ability of cancer cells to move 
from one part of the body to another: Cells exit the 
primary tumor, invade the local tissue, enter blood or 
lymphatic vessels, and are transported to a distant site 
where they exit the vessels and move into the tissue. 
Thus, a different level of understanding of metastasis 
might be achieved using technologies that can follow 
these dynamic processes in vivo.
We use intravital imaging with mouse models of 
breast cancer and classical genetic manipulation to 
determine how interactions between cancer cells and 
stromal cells infl uence metastasis. We have compared 
the microenvironment of tumors formed from the 
metastatic 4T1 and the nonmetastatic 4T07 cell lines, 
isolated from the same breast tumor. We have identi-
fi ed signifi cant differences in the types and amount of 
chemokines that are secreted by the cancer cells and 
in the nature of the myeloid cell infi ltrate between 
the metastatic and nonmetastatic tumors. Strik-
ingly, tumors grow slower and metastasis is greatly 
reduced in mice that lack the receptor for one of the 
chemokines that specifi cally is secreted by metastatic 
cancer cells and acts on neutrophils, one of the least 
studied infl ammatory cell types in cancer metastasis. 
Ongoing studies are addressing how the chemokine– 
chemokine receptor signaling axis regulates invasion 
and promotes metastasis. Preliminary data strongly 
suggest that cancer cells activate an unusual cell-
death mechanism in the neutrophils, leading to the 
release of strong proteolytic enzymes. We have deter-
mined that pharmacological inhibitors blocking the 
neutrophil cell death pathway are effective at reducing 
neutrophil-promoted invasion in vitro and metastasis 
in vivo.
Collagen Architecture in Pancreatic 
Cancer Progression
M. Shields, L. Maiorino, J. Cappellani
Tumors are often discovered as nodules that are harder 
than the surrounding tissue. This refl ects the changes 
in ECM stiffening and architecture. The interstitial 
ECM consists of macromolecules such as fi brillar col-
lagens, fi bronectin, and proteoglycans. Type I colla-
gen is the major fi brillar collagen in many tissues and 
forms a scaffold that provides stability. Type I collagen 
also has signaling functions mediated by, for example, 
integrins and discoidin domain receptors. The syn-
thesis and proteolytic remodeling of the fi brillar type 
I collagen increases in many tumors, most notably in 
pancreatic tumors.
Collagen cross-linking in mouse models of mam-
mary carcinoma delays tumor onset and slows tumor 
progression. We also found that the collagen archi-
tectural structure became abnormal with progression 
of breast cancer: Whereas collagen fi bers are curly 
and oriented in parallel to normal or hyperplastic epi-
thelium, there is a progressive change in the fi bers so 
that they are straighter and mostly perpendicular to 
the tumor border in the late stages. This changed ar-
chitecture promotes cell invasion by enabling cells to 
migrate along the collagen fi bers or by enhancing in-
tegrin signaling. Enzymes of the lysyl oxidase (LOX) 
family are important for the collagen cross-linking 
that results in straighter fi bers, and these enzymes 
have been shown to promote cancer progression and 
metastasis of breast cancer.
Pancreatic cancer has higher levels of type I col-
lagen and of the LOX-like 2 enzyme than breast 
cancer, and we therefore hypothesized that collagen 
cross-linking would have a signifi cant effect on reduc-
ing tumor initiation and metastatic spread. However, 
using both pharmacological inhibitors and genetic ap-
proaches, we instead found an increase in the growth 
of pancreatic tumors and in metastatic spread. Intra-
vital imaging in mice showed that pancreatic cancer 
cells also migrate along collagen fi bers and that col-
lagen architecture is altered by cross-linking inhibi-
tors in pancreatic cancer. This suggests that collagen 
architecture or the cancer cells’ response to collagen 
is fundamentally different between breast and pan-
creatic cancer. In addition, we have determined that 
intracellular signaling pathways, downstream from 
integrins, are up-regulated after inhibition of LOX in 
pancreatic cancer cells.
Coactivating Innate and Adaptive 
Immune Cells
A. Almeida [in collaboration with S. Adams, 
New York University]
Innate and adaptive immune cells (e.g., macrophages 
and T cells, respectively) infi ltrate breast tumors. Acti-
vated, cytotoxic T cells can eliminate cancer cells, but 
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cancer cells counteract T-cell activation and killing by 
engaging inhibitory receptors. Checkpoint blockade 
immunotherapeutics target these inhibitory receptors, 
leading to durable clinical responses in several meta-
static malignancies, especially those with tumor infi l-
trating lymphocytes (TILs). In triple-negative breast 
cancer, high levels of TILs are an independent predic-
tor of survival. Consistently, durable responses were 
recently reported with checkpoint inhibitors for this 
breast cancer subtype. However, in hormone receptor 
(HR)-positive breast cancer, TILs do not predict posi-
tive outcomes, and checkpoint inhibitors have no ef-
fect. Instead, macrophage infi ltration correlates with 
poor prognosis and such macrophages suppress T-cell 
activation. Together, these data suggest that approach-
es that target macrophages are needed for HR-positive 
breast cancers.
Our preliminary data show that in vitro, macro-
phages activated by lipopolysaccharide (LPS, a Toll-
like receptor [TLR] agonist) and interferon-γ (IFN-γ) 
effi ciently kill ~90% of cancer cells within 48 h. Im-
portantly, they also potently activate T cells. LPS can-
not be used in humans due to severe side effects, but 
other synthetic TLR agonists can be used clinically.
To dissect the pathways regulating macrophage/T 
cell/cancer cell interaction and to defi ne the optimal 
conditions for coactivation of macrophages and T 
cells, we have established an immune coculture assay 
(ICCA). To interrogate immune cell/cancer interac-
tions in tumors, we have developed a sophisticated 
intravital imaging approach: confocal, time-lapse 
microscopy of cancer cells, macrophages, and T cells 
in vivo, using a metastatic mouse model of luminal 
B breast cancer, mouse mammary tumor virus– 
polyomavirus medium T (MMTV-PyMT)-mCherry-
OVA. Ovalbumin (OVA) antigen serves as an artifi -
cial tumor antigen, and OVA-recognizing T cells infi l-
trate the tumors, but are suppressed by macrophages.
The immunotherapeutic strategy of stimulating 
macrophages’ and T cells’ tumoricidal activities in 
parallel has the potential to (1) overcome the immune 
suppressive environment of HR-positive breast can-
cer and (2) eradicate metastasized breast cancer cells 
while sparing normal cells.
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PROTEOMICS AND MASS SPECTROMETRY LABORATORY
D. Pappin S. Bencze K. Rivera
 C.M. Gauss J. Snider
 T. Hassan N.S. Turna
 S. Peacock J. Wilson
A Software Tool to Evaluate Correspondence 
between Extracted Ion Chromatographic 
Peaks and Peptide-Spectrum Matches in 
Shotgun Proteomics
P. Leopold, D. Pappin, S. Peacock, K. Rivera, C. Ruse
Chromatographed peptide signals form the basis of 
additional data processing that produces functional 
information derived from data-dependent bottom-up 
proteomics experiments. We fi rst ranked LC/MS (liq-
uid chromatography/mass spectrometry) parent ions 
by the quality of their extracted ion chromatograms. 
Ranked extracted ion chromatograms were then used 
as a fi lter to improve the quality of MS/MS spectra 
submitted for database searches. In trial experiments, 
we initially identifi ed approximately 5000 proteins 
when considering detector shifts of <7 ppm in the fi rst 
pass of database searching. High-quality parent ions 
for which the database search yielded no hits were then 
used as candidates for subsequent unrestricted analy-
sis for searching for posttranslational modifi cations 
(PTMs). Following this rational approach, we were 
able to identify more than 5000 additional spectrum 
matches from modifi ed peptides and even confi rmed 
the presence of acetylaldehyde-modifi ed His/Lys resi-
dues. We have developed a logical workfl ow that scores 
data-dependent selected ion chromatograms and lever-
ages information about semianalytical LC/LC dimen-
sions prior to MS. The method can be successfully used 
to identify unexpected modifi cations in peptides with 
excellent chromatography characteristics, independent 
of fragmentation pattern and activation methods.
Biochemical Characterization of a 
Lys/Arg-N Protease for MS Applications
J. Wilson, D. Pappin
Directed in vacuo peptide fragmentation using MS 
can generate specifi c ion fragment series that simplify 
MS/MS collision spectra. Put simply, this is most 
readily achieved by controlling where charge is located 
on the peptide, either enzymatically or by chemical 
modifi cation. To produce predominantly amino-
terminal ions, the charge must be placed at or near 
the amino termini of peptides. This can be elegantly 
achieved using a proteolytic enzyme with amino-ter-
minal cleavage specifi city at basic amino acids, and 
we have discovered a novel thermostable protease with 
amino-terminal arginine and lysine specifi city. The 
enzyme can be used as a substitute for trypsin, gen-
erates predominantly amino-terminal ions, and com-
pletes digestions in 1–2 h at 60°C.
The enzyme exhibits a temperature optimum of 
∼60°C and broad pH specifi city centered at pH 8.5, 
with at least 50% activity remaining at pH 5 and pH 
11. The protease is most active in low-ionic-strength 
MS-compatible acetate buffers, and it requires both 
calcium and zinc. Specifi city for amino-terminal 
cleavage at arginine and lysine was ∼ >95%, with the 
remaining 5% amino-terminal to larger aliphatic resi-
dues. In whole-cell lysates, the numbers of identifi ed 
peptides and proteins were similar to those of trypsin, 
yet generated in approximately 20 times shorter diges-
tion times; 80% of the enzyme activity was retained 
in 0.5% SDS, and specifi city was equal for both lysine 
and arginine residues. As expected, the b-ion series in 
MS/MS spectra were signifi cantly more intense than 
y-ions, and relative b/y ion intensities were almost 
exactly reversed compared to trypsin. In complex 
mixtures, a shift to lower peptide charge states was 
also observed. This tendency was partly reversed by 
modifi cation with iTRAQ (isobaric tags for relative 
and absolute quantitation), probably due to increased 
distance between charges, although iTRAQ labeling 
effi ciency was unchanged.
This active metalloprotease is suitable for extremely 
rapid (1–2-h) digestion of samples for high-through-
put MS analysis. The peptides produced by this en-
zyme always have major basic centers at the peptide 
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amino termini, producing more easily interpretable 
MS/MS fragmentation spectra by generating a domi-
nant b-ion series. In contrast to trypsin, ion current 
is not spread between b- and y-ions, also increasing 
detection sensitivity.
p53 Mutations Change Phosphatidylinositol 
Acyl Chain Composition
S. Bencze [in collaboration with A. Naguib, G. Bencze, 
D. Engle, C. Chio, D. Tuveson, and L. Trotman, 
Cold Spring Harbor Laboratory]
Phosphatidylinositol phosphate (PIP) second mes-
sengers relay extracellular growth signals through the 
phosphorylation status of the inositol sugar, a signal 
transduction system that is known to be deregulated 
in cancer. In stark contrast to PIP inositol head-group 
phosphorylation, changes in phosphatidylinositol (PI) 
lipid acyl chains in cancer have remained ill-defi ned. 
In collaboration with the Trotman and Tuveson labo-
ratories, we applied an MS-based method capable of 
unbiased high-throughput identifi cation and quanti-
fi cation of 20 different cellular PIs that vary in acyl 
chain composition. Using this multiple reaction 
monitoring (MRM) approach, we found that PI lipid 
chains represent a cell-specifi c fi ngerprint and are un-
perturbed by serum-mediated signaling. This is in 
complete contrast to the inositol head group. We also 
found that mutation of Trp53 results in PIs containing 
reduced-length fatty acid moieties, from 38- to 36- 
and 34-carbon acyl chains. Our results suggest that 
the anchoring tails of lipid second messengers form an 
additional layer of PIP signaling in cancer that oper-
ates independently of PTEN/PI3-kinase activity but 
is instead linked to p53.
Function of N-Acetyltransferases in 
Neurological Disorders
This work was done in collaboration with M. Doerfel and 
G. Lyon (Cold Spring Harbor Laboratory).
The large majority (>85%) of human proteins are 
acetylated at their amino-terminal amino acids, mak-
ing N(α)-terminal acetylation the most abundant 
protein posttranslational modifi cation (PTM). De-
spite this, very little is known about the cellular ef-
fects or functions of this modifi cation. In humans, 
six distinct amino-terminal amino-acetyltransferases 
(NATs) catalyze the transfer of an acetyl group from 
acetyl-CoA to the N(α)-terminal amino group of 
their specifi c target proteins.
The major human acetyltransferase, NatA, consists 
of an auxiliary subunit, Naa15, and a catalytically ac-
tive subunit, Naa10. Recently, the Lyon laboratory de-
scribed two families with a lethal X-linked disorder of 
infancy called Ogden syndrome. This disorder com-
prises a distinct combination of an aged appearance, 
craniofacial anomalies, hypotonia, global develop-
mental delays, cryptorchidism, and cardiac arrhyth-
mias. Using X-chromosome exon sequencing and a 
recently developed variant annotation, analysis, and 
selection tool (VAAST), they identifi ed a c.109T > C 
(p.Ser37Pro) variant in Naa10 as the probable disease-
causing variant.
To characterize the effects of this mutation on 
complex formation of NatA and to identify new in-
teraction partners, Naa10 wild-type or S37P mutants 
were immunoprecipitated from HEK293 cells. The 
isolated complexes were labeled with distinct iTRAQ 
reagents and analyzed by LC/MS. The data revealed 
a strong interaction of Naa10 with ribosomal compo-
nents, supporting the idea that NTA occurs cotransla-
tionally on newly synthesized proteins as they emerge 
from the ribosome. Furthermore, the interaction of 
the S37P mutant toward specifi c interaction partners 
was found to be strongly reduced, which remains to be 
confi rmed in future in vitro experiments.
Dephosphorylation of Tyrosine 393 
in Ago2 by PTP1B Regulates Gene 
Silencing in RAS-Induced Senescence
This work was done in collaboration with M. Yang and 
N. Tonks (Cold Spring Harbor Laboratory).
Oncogenic RAS (H-RAS(V12)) induces premature 
senescence in primary cells by triggering production 
of reactive oxygen species (ROS), but the molecu-
lar mechanism was unclear. The Tonks laboratory 
investigated whether inhibition of protein tyrosine 
phosphatases by ROS contributed to H-RAS(V12)-
induced senescence. They identifi ed protein tyro-
sine phosphatase 1B (PTP1B) as a major target of 
H-RAS(V12)-induced ROS. Inactivation of PTP1B 
was both necessary and suffi cient to induce premature 
senescence in H-RAS(V12)-expressing IMR90 fi bro-
blasts. We identifi ed phospho-Tyr 393 of argonaute 2 
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(Ago2) as a direct substrate of PTP1B using a trap-
ping mutant and MS. Phosphorylation of Ago2 at 
Tyr 393 inhibited loading of microRNAs (miRNAs) 
and thus inhibited miRNA-mediated gene silencing, 
which counteracted the function of H-RAS(V12)-
induced oncogenic miRNAs. The data illustrated that 
premature senescence in H-RAS(V12)-transformed 
primary cells was a consequence of oxidative inacti-
vation of PTP1B and inhibition of miRNA-mediated 
gene silencing.
Role of Nrf2 in Pancreatic Cancer
This work was done in collaboration with C. Chio and 
D. Tuveson (Cold Spring Harbor Laboratory).
Drug resistance is a major cause of lethality in pan-
creatic cancer. This has been ascribed to augmented 
cell survival pathways and poor drug delivery. Nrf2 is 
a transcription factor that promotes both pancreatic 
ductal adenocarcinoma (PDAC) progression and drug 
resistance, so antagonizing the Nrf2 pathway may be 
clinically advantageous. Because transcription fac-
tors are diffi cult to target therapeutically, the Tuveson 
laboratory has sought to comprehensively characterize 
the mechanisms used by Nrf2 to promote PDAC so 
that more feasible approaches to counter the effects of 
Nrf2 in PDA may be developed.
Activation of the Nrf2 program is known to elicit 
a more reducing intracellular environment. Because 
protein oxidation can infl uence protein activity and 
stability, one hypothesis is that certain mediators of 
Nrf2 function may be “redox sensor” proteins that 
contain labile cysteine thiol groups. Accordingly, we 
used pancreatic ductal organoids to develop a highly 
sensitive proteomic method that identifi es proteins 
containing cysteines that undergo selective reduction 
because of the Nrf2 antioxidant program.
We previously developed a novel proteomics work-
fl ow that uses selective capture of cysteine peptides in 
conjunction with iTRAQ isobaric labeling to deter-
mine quantitative changes in free (reduced) cysteine 
residues on a proteome-wide scale that also normal-
izes these changes to expression levels of the respective 
proteins. A proof-of-concept experiment was per-
formed using mouse embryonic fi broblasts treated 
with BSO or DEM (two oxidizing agents known to 
induce Nrf2 target genes); 98% of isotope-enriched 
affi nity tag (ICAT)-enriched peptides contained 
cysteines, demonstrating the specifi city of the ICAT-
labeling reagent. We found 349 cysteine-containing 
peptides modifi ed by both of these two treatments 
from a total of 3662 proteins and 4572 cysteine-
containing peptides, showing that the approach was 
effective in quantifying free cysteine changes upon 
redox alterations. Proteins oxidized by both agents 
included those previously reported to contain redox 
sensitive sites, such as Pkm1 and Pkm2, thioredoxin, 
and  galectin-1.
To identify key Nrf2-dependent, redox-sensitive ef-
fector proteins/pathways, three pairs of N (normal), P 
(preneoplastic) and T (tumor) organoids bearing the 
wild-type or knockout Nrf2 allele were then analyzed 
to evaluate differences in the total and reactive cys-
teine proteomes. The analysis yielded 3416 cysteine 
labeled peptides. To identify key Nrf2-dependent, re-
dox-sensitive pathways, the total proteome (iTRAQ) 
and cysteine proteome (ICAT) in N, P, and T organ-
oids with or without Nrf2 were analyzed using gene 
set enrichment analysis (GSEA). Eight of 10 of the 
most enriched pathways encompassed highly oxidized 
proteins that were involved in translational control. 
These included core translational machinery compo-
nents, such as ribosomal subunits, as well as numerous 
regulatory factors that control translation effi ciency 
(GSEA p values range from p < 0.04 to p < 0.1 for the 
top 10 enriched pathways). Individual targets are cur-
rently being assessed by model-remodel (MRM) ap-
proaches to evaluate the oxidative states of the redox-
sensitive cysteines.
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ROLE OF CROSS-TALK BETWEEN INTERLEUKIN-6 AND TRANSFORMING 
GROWTH FACTOR-β1 IN CHEMORESISTANCE
R. Sordella D. Pal N. Shirole
 S. Senturk Z. Yao
Cancers are largely a consequence of accumulating ge-
nomic damage during life. Because some of the same 
mutations that are driving the onset and the progres-
sion of tumors could be druggable, we can design 
therapies that will spare normal cells and specifi cally 
target only the cancer cells. This approach is usually 
referred to as “targeted therapy” or “precision medi-
cine.” Many targeted therapies have been and current-
ly are being developed. Yet their success in the clinic 
has been hampered by the development of resistance. 
Many studies in fact have shown that despite initial 
responses, targeted therapies overall are failing.
To better understand the mechanism of resistance 
to targeted therapy, we used as a paradigm lung can-
cer tumors harboring oncogenic mutations in the en-
hanced epidermal growth factor (EGFR) genes. Pre-
viously, we showed that although tumors with these 
mutations are initially highly sensitive to the inactiva-
tion of EGFR by small-molecule inhibitors such as er-
lotinib and gefi tinib, these same tumors soon become 
refractory to the effect of the drug treatment. In re-
cent years, we and other investigators have identifi ed 
multiple mechanisms of resistance to EGFR small-
molecule inhibitors. These comprise secondary EGFR 
mutations (T790M) that block the binding of EGFR 
inhibitors to their targets, amplifi cation of c-Met, and 
the acquisition of mesenchymal-like properties. In the 
latter case, we showed that resistance to inhibition 
of EGFR is due to the activation of a transforming 
growth factor-β/interleukin-6 (TGF-β/IL-6) axis. In 
the past year, we have focused our effort in trying to 
understand how TGF-β regulates IL-6 expression and 
how TGF-β protects cells from apoptosis.
ZC3H12A Down-Regulation by TGF-β 
Is Critical for Increasing IL-6 Expression 
and Chemoresistance
TGF-β family members are secreted proteins that con-
trol many cellular functions, including proliferation 
and cellular differentiation. They have a role in can-
cer, immunity, fi brosis, heart disease, diabetes, and 
degenerative diseases such as Parkinson’s disease and 
multiple sclerosis. TGF-β1, TGF-β2, and TGF-β3 
ligands function as the primary mediators of TGF-β 
signaling. These ligands bind to the type-2 TGF-β 
receptor (TGFBR2), which causes recruitment and 
phosphorylation of TGFBR1 (also known as ALK5), 
resulting in downstream signaling activation through 
the phosphorylation of R-SMAD proteins (SMAD2 or 
SMAD3). This ultimately leads to transcriptional acti-
vation or transcriptional repression of several genes via 
oligomerization of R-SMAD proteins with a  variety of 
transcription cofactors including SMAD4. In addition 
to this signaling cascade, often referred to as “canoni-
cal” TGF-β signaling, stimulation of cells with TGF-β 
can induce the activation of alternative signaling mod-
ules such as the NF-κB, PI3K/AKT, RHOA, and 
MAPK pathways in a SMAD-independent manner.
The outcome of the activation of these signaling 
pathways in cancer cells is highly contextual and can 
result in either suppression of cell proliferation or in-
duction of cellular migration and invasion. In prema-
lignant stages, for example, the TGF-β pathway has 
been shown to have tumor-preventive roles by induc-
tion of apoptosis as well as senescence. On the other 
hand, during malignant transformation, many of these 
tumor suppressive functions are instead lost, and the 
TGF-β pathway eventually promotes tumor growth, 
invasion, and metastatic dissemination of cancer cells 
and importantly drives resistance to standard and tar-
geted chemotherapy.
One key component of TGF-β-driven resistance is 
the expression of the cytokine IL-6. Given the impor-
tance of this axis in our studies, we investigated the 
molecular insights underlying the regulation of IL-6 
expression by TGF-β. A better understanding of this 
mechanism could aid in the development of novel and 
more effective cancer therapies.
Although initial studies indicated that TGF-β could 
induce the expression of IL-6 via JunD homodimers 
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in lung fi broblasts, we found that this mechanism has 
a minimal role in cancer cells. In particular, we dem-
onstrated that transcriptional repression of ZC3H12A 
(also known as MCPIP1 or Regnase-1) by TGF-β was 
critical. In fact, we found that TGF-β inhibition of 
ZC3H12A transcription increased IL-6 expression via 
a bimodal mechanism encompassing increased mRNA 
stability and/or NF-κB-mediated mRNA transcrip-
tion. Interestingly, we observed that the activation of 
this signal transduction mechanism could also have a 
role in mediating primary resistance to EGFR inhibi-
tion in tumors harboring oncogenic EGFR mutations. 
Our fi ndings imply that co-inhibition of the NF-κB 
and IL-6 axes could improve current cancer therapies 
in lung cancer patients harboring EGFR mutations. 
Excitingly, a clinical trial has been recently opened to 
evaluate this hypothesis.
NF-κB is a sequence-specifi c transcription factor 
that is best known as a major regulator of infl am-
matory and innate immune responses. Hence, the 
repression of ZC3H12A by TGF-β not only could 
have a key role in regulating intrinsic/cell autono-
mous mechanisms of resistance to targeted therapy, 
but could also be important in fi ne-tuning the dialog 
between malignant cells and their microenvironment.
TGF-β Down-Regulation of β-TRCP 
Is Required for Chemoresistance 
and Metastasis
We have previously shown that the induced expres-
sion of IL-6 by TGF-β is required and suffi cient for 
antagonizing anti-apoptotic pathways activated as a 
consequence of EGFR inhibition in cells addicted to 
oncogenic EGFR mutations.
To better understand the molecular mechanisms 
underpinning the protection of cells from apoptosis 
by TGF-β/IL-6, we examined the expression of Bcl-2 
family members in cells in response to TGF-β treat-
ment. So far, 15 mammalian Bcl-2 family members 
have been identifi ed, which can be divided into three 
subfamilies: the Bcl-2 pro-survival subfamily (Bcl-2, 
Bcl-XL, Bcl-w, Mcl-1, and A1); the pro-apoptotic Bax 
subfamily (Bax, Bak, and Bok); and the BH3 pro-
apoptotic subfamily (Bad, Bid, Bik, Blk, Hrk, BNIP3, 
PUMA, NOXA, and BimL).
We initially examined expression of this family of 
proteins in A549 cells, an NSCLC-derived cell line in 
which TGF-β has been previously shown to induce 
epithelial-to-mesenchymal transition. We found in-
creased expression of the pro-apoptotic proteins BAX, 
BAD, and BIM-EL and of the anti-apoptotic protein 
MCL-1.
To test whether mcl-1 was required for the survival 
of cells in TGF-β treatment, we silenced mcl-1 expres-
sion via small interfering (siRNA)-mediated knock-
down and analyzed the effect on viability in A549 cells 
upon treatment with TGF-β. Although knockdown 
of mcl1 had minimal effect in control cells (scramble 
siRNA) or in TGF-β-naïve cells, it resulted in a no-
table decrease of viable cells in populations exposed to 
TGF-β. Consistent with a role of mcl-1 in antagoniz-
ing pro-apoptotic stimuli, we observed a large sub-G1 
fraction in cells treated with TGF-β and increased ex-
pression of cleaved caspase 3 upon mcl-1 knockdown.
Given the central role of mcl-1 in opposing TGF-
β-induced apoptosis, we next undertook studies aimed 
at understanding the regulation of mcl-1 expression by 
TGF-β. Differently from the pro-apoptotic Blc-2 fam-
ily members Bax, Bad, and BImEL, we did not observe 
increased expression of mcl-1 mRNA in cells treated 
with TGF-β. In principle, this could indicate an alter-
native transcriptional-independent regulation of mcl-1 
by TGF-β. Hence, we investigated whether TGF-β, 
rather than regulating the transcription of mcl-1, could 
instead infl uence the stability of the MCL-1 protein. 
Levels of MCL-1 and of EGFR were analyzed fol-
lowing inhibition of the translational machinery with 
cycloheximide. Western blot analysis of MCL-1 levels 
from lysates of cells treated for 15, 30, and 60 min 
with cycloheximide demonstrated striking differences 
in the abundance of MCL-1 in cells in the presence of 
TGF-β when compared to the untreated cells. Because 
no difference in the expression of EGFR was observed, 
this implies that TGF-β did not affect the translational 
machinery but rather that MCL-1 protein is inherently 
more stable in TGF-β-treated cells.
The ubiquitin proteasome system (UPS) is a major 
regulator of protein abundance in cells. In general, the 
transfer of ubiquitin molecules onto target proteins con-
stitutes a signal that results in the targeting of the modi-
fi ed proteins for proteolysis by the proteasome system. 
Thus, we asked whether the increased stability of mcl-1 
that we observed in cells was mediated by impaired 
ubiquitination/degradation. We found that TGF-β 
regulation of Mcl-1 occurs mainly at the level of protein 
stability by halting mcl-1 degradation via the UPS.
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More specifi cally, we observed that TGF-β control 
of MCL-1 stability was mediated by the down-regu-
lation of β-TRCP expression. β-TRCP has important 
roles in regulating cell cycle checkpoints, in protein 
translation, in cell growth, and in multiple tran-
scriptional programs by regulating, for example, the 
NF-κB and WNT pathways. In light of the current 
literature, our fi ndings were particularly interesting 
because they suggest a potential role for the inhibition 
of β-TRCP in mediating some of the biological effects 
of TGF-β such as EMT cell cycle control beyond the 
expression of MCL-1.
94
PROTEIN TYROSINE PHOSPHATASES AND THE CONTROL 
OF SIGNAL TRANSDUCTION
N.K. Tonks S. Akshinthala F. Chaudhary N. Krishnan M. Ramesh D. Song S. Zhang
 G. Bencze G. Fang L. Li I. Rus M. Yang W. Zheng
An important aspect of the work of the Tonks lab is to 
devise creative new approaches to exploiting the pro-
tein tyrosine phosphatase (PTP) family of enzymes as 
targets for therapeutic intervention in major human 
diseases, including diabetes, obesity, and cancer. At 
the core of this effort is the study of PTP1B, the proto-
typic protein tyrosine phosphatase, which Nick Tonks 
fi rst discovered 25 years ago. It is now established that 
PTP1B not only plays a role in attenuating insulin 
signaling, but also plays a positive role in promoting 
signaling events associated with breast tumorigenesis. 
This suggests that inhibition of PTP1B function may 
represent a novel therapeutic strategy to address not 
only diabetes and obesity, but also mammary tumori-
genesis and malignancy.
The reversible addition and removal of phosphate 
to proteins, which is termed protein phosphoryla-
tion, is the central feature of the mechanism of sig-
nal transduction—the process by which cells respond 
to stimuli in their environment. The activities of the 
enzymes that mediate the addition (kinases) and re-
moval (phosphatases) of phosphate groups are coordi-
nated in signal transduction pathways to mediate the 
cellular response to environmental stimuli, and the 
function of these enzymes is frequently disrupted in 
human diseases, including diabetes and cancer. The 
ability to modulate such signal transduction path-
ways selectively with drugs holds enormous therapeu-
tic potential. Drugs that target the protein kinases 
represent breakthroughs in cancer therapy. For ex-
ample, HER2 is a member of the family of kinases 
and is amplifi ed and/or overexpressed in several can-
cers, in particular in ~25% of breast cancer, where 
it is associated with poor prognosis. The humanized 
HER2-directed antibody Herceptin (trastuzumab) is 
an example of a “rational cancer therapy” for treat-
ment of HER2-positive metastatic breast tumors. It 
targets HER2 as a unique marker of the cancer cell. 
Although Herceptin is used frequently and is being 
presented as a treatment of choice, the overall success 
rate is low and patients develop resistance to the ther-
apy. The problem of acquired resistance has become 
an obstacle to the successful application of kinase-
directed therapies in general. Therefore, despite the 
obvious potential, it is anticipated that new alterna-
tive therapies, administered alone or in combination 
with kinase-directed drugs, will represent the way 
forward. The challenge is to identify such alterna-
tive therapies. Considering the intimate cooperation 
between kinases and phosphatases in the regulation 
of signal transduction under normal and pathophysi-
ological conditions, the Tonks lab focuses on the 
PTPs, which have been garnering attention as poten-
tial therapeutic targets, but remain a largely untapped 
resource for drug development.
In following established approaches to developing 
small-molecule drugs that bind to the active site of 
an enzyme, industry has found PTPs to be challeng-
ing targets for therapeutic development. Although it 
was possible to generate potent, specifi c, and revers-
ible inhibitors of PTP1B, such molecules were highly 
charged, due to the chemistry underlying PTP-medi-
ated catalysis, and thus of limited drug development 
potential. Consequently, new approaches are required 
to exploit this important target effectively and reinvig-
orate drug discovery efforts. One strategy that would 
avoid targeting the active site of PTP1B would be to 
look for allosteric inhibitors, which bind at a site re-
mote from the catalytic center, but induce conforma-
tional changes in the enzyme that result in inhibition. 
The Tonks lab has characterized a small-molecule 
natural product, TRODUSQUEMINE, as such an 
allosteric inhibitor of PTP1B. This is a unique mecha-
nism of inhibition that will have been missed in the 
efforts to target PTP1B that have been conducted to 
date in industry. They have demonstrated that this in-
hibitor antagonizes the function of HER2 in cell and 
animal models of breast cancer. In particular, it essen-
tially abrogates metastasis of HER2-positive tumor 
cells in the NDL2 mouse model of breast cancer.
Cancer: Signal Transduction  95
It is important also to note that TRODUSQUE-
MINE (also known as MSI-1436) has already been 
tested in a Phase 1 study that involved 88 obese patients 
and was found to be extremely well tolerated. Of par-
ticular signifi cance is the fact that the effects observed 
in mice by the Tonks lab were achieved at ~20% of the 
maximum dose that has been administered to patients. 
During the last year, discussions have been initiated 
with the FDA, and a collaboration between the Tonks 
lab and the Monter Cancer Center at North Shore 
LIJ has been set up to take TRODUSQUEMINE/
MSI-1436 into clinical trials for HER2-positive can-
cer. In an initial meeting with the FDA, it was indi-
cated that a Phase 1 study of safety and tolerability of 
TRODUSQUEMINE/MSI-1436 as a single agent in 
metastatic breast cancer patients would have to be per-
formed. The preparations for this clinical trial are now 
under way and will represent a focus of effort in 2014.
Although TRODUSQUEMINE/MSI-1436 dem-
onstrates effi cacy in an injectable format, it also has 
limited oral bioavailability. Industry has set oral bio-
availability as a hurdle for the next generation of ther-
apies for diabetes. During the last year, the Tonks lab 
has identifi ed a derivative of TRODUSQUEMINE/
MSI-1436 for which they have demonstrated oral bio-
availability in a weight loss study in a high-fat diet-
induced mouse model of obesity. At this time, they 
are defi ning the mechanism of action of this inhibi-
tor. Furthermore, they have identifi ed novel chemi-
cal entities that display properties similar to those of 
TRODUSQUEMINE/MSI-1436, which are current-
ly being validated as inhibitors of PTP1B to identify 
further new drug candidates.
The Tonks lab is also trying to harness a physi-
ological mechanism for regulation of PTP1B func-
tion as a distinct approach to development of thera-
peutics, particularly in the context of diabetes and 
obesity. PTP1B is a major regulator of the signaling 
pathways initiated by insulin and leptin, which con-
trols appetite. Gene-targeting studies demonstrated 
that PTP1B-null mice are healthy, display enhanced 
insulin sensitivity, do not develop type-2 diabetes, and 
are resistant to obesity when fed with a high-fat diet. 
Furthermore, depletion of PTP1B expression with an-
tisense oligonucleotides elicits anti-diabetic and anti-
obesity effects in rodents, as well as human subjects. 
The Tonks lab discovered that the activity of PTP1B 
is attenuated by reversible oxidation of an essential 
cysteinyl residue at the active site of the enzyme. The 
architecture of the PTP active site is such that this 
essential cysteinyl residue displays unique properties 
that favor its role in catalysis but also render it prone 
to oxidation. Insulin stimulation of mammalian cells 
leads to enhanced production of intracellular H2O2, 
which causes reversible oxidation of PTP1B and in-
hibition of its enzymatic activity, which in turn con-
comitantly promotes the signaling response to insulin. 
They have shown that mild oxidation of PTP1B, such 
as occurs in response to insulin, results in profound 
conformational changes in the active site of the en-
zyme that transiently inhibit substrate binding and 
catalysis. These structural changes, however, are re-
versible and the enzyme can be reduced back to its 
active state. Therefore, reversible oxidation of PTP1B 
in response to insulin provides a mechanism for fi ne-
tuning the signaling response to the hormone. They 
hypothesized that a conformation-sensor antibody 
that recognizes the reversibly oxidized form of PTP1B 
selectively may stabilize the inactive state, inhibit its 
reactivation by reducing agent, and thereby inhibit 
phosphatase activity. Using antibody phage display, 
they generated such conformation-sensor antibodies 
and demonstrated that expression of these antibodies 
in cells enhanced insulin-induced signal transduc-
tion. Their data provide proof-of-concept that stabi-
lization of the oxidized, inactive form of PTP1B with 
appropriate therapeutic molecules may offer a novel 
paradigm for phosphatase drug development. This 
has the additional advantage that, if one assumes that 
in responding to insulin the cell targets for oxidation 
the pool of PTP1B that is important for physiological 
regulation of the signaling response, then this strategy 
Figure 1. Structure model for PTP1B (residues 1–405) with two 
molecules of the allosteric inhibitor MSI-1436 (marked with 
arrows) docked to the two putative binding sites. Important 
structural features within PTP1B are highlighted.
96  Research
will target that pool specifi cally, possibly also reducing 
complications of side effects that may accompany in-
hibition of the native enzyme as a whole. The antibod-
ies themselves are unlikely to be of use as therapeutics; 
however, the Tonks lab has now developed an assay 
that will permit screening of a small-molecule library 
on an industrial scale to identify drug-like molecules 
that mimic the effects of the antibodies. A pilot-scale 
screen has already been completed, demonstrating the 
feasibility of this strategy and identifying candidate 
small molecules that stabilize specifi cally the oxidized 
form of PTP1B. During the last year, this approach 
has led to the initiation of a collaboration with a large 
pharmaceutical company. Studies are under way to 
test the potential for conformation-sensor antibodies 
that recognize selectively the oxidized form of PTP1B 
to promote the signaling response to leptin. If these 
antibodies are shown also to potentiate leptin sig-
naling, it is anticipated that a full-scale screen of the 
company’s small-molecule collection will be initiated 
to exploit fully this unique approach to development 
of PTP inhibitors, thereby opening up a new strategy 
for therapeutic intervention in a major disease.
Efforts in the Tonks lab to defi ne PTP function, 
and wherever possible establish links to human dis-
ease, are not restricted to PTP1B. Examples of prog-
ress in additional areas include the following.
Characterization of PTP Function in the 
Control of Migration and Invasion of 
Mammary Epithelial Cells
The Tonks lab has characterized missing in metasta-
sis (MIM), which is a scaffold protein that is down-
regulated in multiple metastatic cancer cell lines com-
pared to nonmetastatic counterparts. MIM regulates 
cytoskeletal dynamics and actin polymerization, and 
it has been implicated in the control of cell motility 
and invasion. MIM has also been shown to bind to a 
receptor PTP, PTPδ, an interaction that may provide 
a link between tyrosine-phosphorylation-dependent 
signaling and metastasis. They used small hairpin 
RNA (shRNA)-mediated gene silencing to investigate 
the consequences of loss of MIM on the migration 
and invasion of the MCF10A mammary epithelial cell 
model of breast cancer. They observed that suppres-
sion of MIM by RNA interference (RNAi) enhanced 
migration and invasion of MCF10A cells, effects that 
were mediated by enhancing the stability and quan-
tity of PTPδ. Furthermore, analysis of human clinical 
data indicated that PTPδ was elevated in breast cancer 
samples when compared to normal tissue. They dem-
onstrated that SRC is a direct substrate of PTPδ and, 
upon suppression of MIM, they observed changes in 
the phosphorylation status of the SRC protein tyro-
sine kinase—the inhibitory site (Y527) was hypophos-
phorylated, whereas the activating autophosphoryla-
tion site (Y416) was hyperphosphorylated. Thus, the 
absence of MIM led to PTPδ-mediated activation of 
SRC. Finally, the SRC inhibitor SU6656 counteracted 
the effects of MIM suppression on cell motility and 
invasion. This demonstration of PTPδ-dependent ac-
tivation of SRC in cells depleted of MIM suggests a 
new therapeutic strategy for targeting metastasis.
Investigation of the Role of Thioredoxin 
in Reversible PTP Oxidation
Despite great progress in defi ning the mechanism of 
reactive oxygen species (ROS) production, the con-
trols over the levels of ROS in cells and the scope of 
potential targets of this modifi cation, the mechanisms 
underlying reduction and reactivation of the oxidized 
PTPs have remained relatively underexplored. It is es-
sential that PTPs recover their active form when ROS 
concentrations decrease so as to limit the response to 
growth factors/hormones and prevent uncontrolled 
stimulation of signaling pathways. For the PTPs, 
redox-active enzymes and small molecules, such as 
thioredoxin (TRX), glutaredoxin, or glutathione, 
have been implicated in reduction and reactivation. 
In a collaborative study with Arne Östman’s lab, they 
demonstrated that TRX was important for reduction 
and reactivation of PTP1B in the context of PDGF 
signaling. In a separate study, they used a combina-
tion of biochemical analysis, mechanism-based trap-
ping, and RNAi-induced suppression to demonstrate 
the importance of TRX1 for the reduction and reac-
tivation of PTP1B and PTEN. Although TRX is best 
known as a disulfi de reductase, they demonstrated 
that it plays an important role in the reduction and 
reactivation of the oxidized form of PTP1B, which 
features a cyclic sulphenamide modifi cation of the 
active-site cysteine residue. Furthermore, they have 
shown that these effects of TRX have the potential 
to fi ne-tune the signaling response to insulin. Finally, 
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in addition to highlighting the important role of TRX 
in reduction and reactivation of PTPs, the TRX trap-
ping mutants illustrate another approach to defi ning 
the importance of reversible oxidation in the regula-
tion of PTP function in general and tyrosine-phos-
phorylation-dependent signaling in a broad array of 
signaling contexts.
Identiﬁ cation of the Anti-Inﬂ ammatory 
Compound BAY 11-7082 as a Potent 
Inhibitor of PTPs
BAY 11-7082 is an anti-infl ammatory compound that 
has been reported to inhibit IκB kinase activity. The 
compound has an α,β-unsaturated electrophilic cen-
ter, which confers the property of being a Michael 
acceptor; this suggests that it may react with nucleo-
philic cysteine-containing proteins, such as PTPs. 
In this study, the Tonks lab demonstrated that BAY 
11-7082 was a potent, irreversible inhibitor of PTPs. 
Using mass spectrometry, they demonstrated that 
BAY 11-7082 inactivated PTPs by forming a covalent 
adduct with the active-site cysteine. Administration of 
the compound caused an increase in protein tyrosine 
phosphorylation in RAW 264 macrophages, similar 
to the effects of the generic PTP inhibitor sodium or-
thovanadate. These data illustrate that BAY 11-7082 
is an effective pan-PTP inhibitor with cell permeabil-
ity, revealing its potential as a new probe for chemi-
cal biology approaches to the study of PTP function. 
Furthermore, the data suggest that inhibition of PTP 
function may contribute to the many biological effects 
of BAY 11-7082 that have been reported to date.
Investigation of the Regulation and Function 
of Receptor PTPα in Breast Cancer Models
HER2/ERBB2 is a member of the epidermal growth 
factor (EGF) receptor family of protein tyrosine ki-
nases (PTKs), which is amplifi ed and/or overexpressed 
in ~25% of breast cancer and associated with poor 
prognosis. Using MCF10A mammary epithelial cells 
that ectopically express an “activatable” ErbB2 chime-
ra as a model, they demonstrated that NOX-depen-
dent production of hydrogen peroxide occurs rapidly 
following ERBB2 activation, leading to reversible oxi-
dation of the transmembrane receptor phosphatase 
PTPα. This inhibited the activity of PTPα, contrib-
uting to increased ERBB2 signaling. Furthermore, 
the suppression of PTPα by shRNA led to ERBB2-
dependent increased cell migration, which was char-
acterized by prolonged interaction of GRB7 with 
ERBB2, increased association of ERBB2 with a β1 
integrin-rich complex, and was dependent on GRB7-
SH2 domain interactions. Interestingly, the human 
GRB7 gene is commonly co-amplifi ed with ERBB2 
in breast cancer, and GRB7 has been implicated in 
cell migration. Supporting this concept, the ERBB2-
dependent migration in PTPα-knockdown cells was 
suppressed by a GRB7-SH2 domain inhibitor. They 
demonstrated that PTPα dephosphorylated FAK spe-
cifi cally on Tyr407, and FAK Tyr407 phosphorylation 
was enhanced in cells following ERBB2 activation 
when PTPα was suppressed, which contributed to the 
recruitment of vinculin to FAK. Collectively, these 
data support a role for PTPα in regulating motility of 
mammary epithelial cells in response to ERBB2 sig-
naling, consistent with a role for the phosphatase in 
breast cancer.
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UNDERSTANDING PROSTATE CANCER METASTASIS
L. Trotman A. Ambrico D. Nowak
 H. Cho C. Stahlhut
 T. Herzka K. Watrud
 A. Naguib
Resistance to therapy of metastatic prostate cancer 
(CRPC) is responsible for the annual deaths of about 
250,000 U.S. men. Although there is considerable 
progress in the development of improved antihor-
mone therapy for treatment of metastatic disease, this 
standard of care approach will invariably fail at some 
point.
Our focus is to understand the mechanisms driving 
human prostate cancer in its most lethal form: meta-
static disease. We have studied the human genetics be-
hind the transition from indolent to lethal metastatic 
prostate cancer and combined it with viral transgene 
delivery into prostate. With this approach, we have 
succeeded in generating a unique, fast, and faithful 
mouse model for metastatic prostate cancer. We have 
termed this system RapidCaP because it allows us to 
generate any genetically mutant mouse prostate can-
cer with a much accelerated time frame compared to 
breeding-based approaches. We now use RapidCaP 
for analysis and therapy of metastatic disease. At the 
same time, we aim to better defi ne PTEN/PI3 kinase 
signaling and derive new types of markers that indi-
cate high metastatic potential of disease.
The RapidCaP GEM Model for 
Metastatic Prostate Cancer
H. Cho, D. Nowak, T. Herzka, K. Watrud, A. Ambrico, 
C. Stahlhut [in collaboration with J. Wilkinson, 
University of Michigan; J. Bradner, Dana Farber Cancer 
Center; B. Robinson, Weill Cornell Medical College; 
M. Castillo-Martin and C. Cordon-Cardo, Mt. Sinai 
School of Medicine]
We previously identifi ed the loss of the p53 senescence 
program as a critical barrier to metastatic progres-
sion of PTEN/PHLPP mutant prostate cancer. On 
the basis of these fi ndings, we were able to transform 
GEM modeling of prostate cancer by developing the 
RapidCaP system for analysis and therapy of endog-
enous metastatic prostate cancer.
Although considerable progress has been made 
in the development of improved drugs for treatment 
of metastatic disease, it remains a huge challenge to 
predict which patients will best respond to a given ap-
proach. The RapidCaP system is highly versatile as 
genetic alterations are introduced by infection of the 
mouse prostate through a transgene-carrying virus. 
In a fi rst approach, we used RapidCaP to model loss 
of the Pten and p53 genes, a signature that has been 
found in 50% of human castration-resistant metastatic 
prostate cancer. In contrast to the classic approaches of 
studying (human) tumors in a mouse, our approach 
allows us to study prostate cancer of a mouse. Rapid-
CaP makes use of existing genetic engineering tools 
with conditional tumor suppressor alleles. We trigger 
disease by viral Cre delivery and monitor progression 
of disease by integration of the luciferase transgene and 
noninvasive visualization using bioluminescence imag-
ing. It exceeds current GEM prostate models by pro-
ducing focal disease that retains intact histopathology 
of surrounding stroma and normal tissue. In contrast, 
traditional conditional knockout of the entire prostatic 
epithelium, and targeting the same genes, results in le-
thal primary disease burden within months. This arti-
fi cial scenario is without a human counterpart and has 
so far hampered analysis of progression phenotypes.
The innovative RapidCaP system is important 
in four areas: (1) it matches the high speed at which 
human candidate cancer genes are discovered because 
mutant animals are generated by viral infection, not 
by breeding; (2) it allows us to trace disease progres-
sion and therapy in live animals without the need for 
costly high-tech imaging modalities such as magnetic 
resonance imaging (MRI) or positron emission to-
mography (PET); (3) primary and secondary lesions 
arise natively and in situ in fully immune-competent 
mice and entirely native tissue microenvironments; 
and (4) most pertinent to our future work, it allows us 
to test the causality of genetic mutations in the endog-
enous metastatic process.
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RapidCaP recapitulates the therapy failure seen 
in patients, as shown by emergence of refractory 
metastatic disease after castration. We have used the 
RapidCaP system to defi ne new mechanisms behind 
lethal CRPC2, specifi cally identifying Myc as a driver 
of Pten mutant metastasis. This fi nding has opened 
up novel rational approaches for CRPC therapy using 
MYC-suppressing bromodomain inhibitors. Further 
demonstrating the power of the new model system, 
we showed using in vivo RNA interference (RNAi) 
technology that the RNA-regulating protein SHQ1, 
a human genomics-derived candidate cancer gene re-
siding in a common deleted chromosomal region, is 
a driver of Pten mutant prostate metastasis. To gain 
further insights, we studied the mechanisms behind 
activation of the Myc oncogene after Pten loss.
The system now affords us new insights into lethal 
cancer evolution. We also use it to test whether and 
how novel therapies can enhance or even outperform 
the 80-year-old standard of care—hormone depriva-
tion therapy—and turn lethal prostate cancer into a 
curable disease.
The PTEN/PI3 Kinase Pathway in Action
A. Naguib, T. Herzka, W. Zheng [in collaboration with 
D. Pappin and L. Joshua-Tor, Cold Spring Harbor Laboratory]
PTEN is the major negative regulator of phosphoino-
sitol-3 kinase (PI3K) signaling with cell-specifi c func-
tions that go beyond tumor suppression. We aim 
to better defi ne PTEN/PI3K signaling at its most 
fundamental level. This has led us to probe PTEN 
function in the cytoplasm, where the vast majority 
of PTEN resides. We use live imaging, super resolu-
tion microscopy, and fl uorescence photobleaching to 
map and capture PTEN/PI3K signaling in motion. 
To better understand modifi cation of the lipid second 
messengers that communicate PI3K signaling, we use 
mass spectrometry. Our approaches are geared to-
ward rapid analysis in tissues, with the goal in mind 
of detecting aberrant growth signals on a time scale 
that is much faster than standard genomics-based 
 approaches.
Finally, our analysis of phosphatidylinositol-based 
signaling has shown that the lipid tails of these mol-
ecules reveal information on the p53 mutation status 
of a cell. This fi nding is of particular interest as we de-
veloped a mass-spectrometry-based detection protocol 
that yields results within minutes. Thus, our success-
ful analysis is based on a technology that is much fast-
er than sequencing-based mutation analysis and thus 
could be used to guide the defi nition of margins of a 
patient’s cancer during surgery.
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D. Tuveson B. Alagesan D. Engle E. Lee H. Tiriac
 L. Baker E. Elyada M. Ludwig K. Wright
 G. Bifﬁ  M. Feigin E. Olund G. Yordanov
 D. Cheng D. Filippini T. Oni K. Yu
 I.I. Chio A. Handly-Santana Y. Park
 V. Corbo C.-I. Hwang M. Ponz-Sarvise
The lethality of pancreatic ductal adenocarcinoma 
(PDAC) is due to the advanced stage of disease at the 
time of diagnosis and the poor effi cacy of current ther-
apies. During the past 12 years, our lab has pioneered 
preclinical model systems to investigate both of these 
problems, and we have translated this information to 
clinical investigation. Most recently, we codeveloped 
primary tissue models of both human and murine 
pancreatic cancer, termed “organoids.” We expect that 
over the next several years, organoids will reveal fun-
damental insights into pancreatic cancer progression 
and the tumor microenvironment while also serving as 
a useful platform and renewable biorepository for the 
discovery of novel diagnostic and therapeutic targets. 
Accordingly, organoids are currently being evaluated 
as a transformative technology for our new Preclinical 
Experimental Therapeutics-X Facility (PETx), with an 
immediate task of determining whether organoids can 
facilitate early-stage human trials.
Organoid Models of Pancreatic Cancer
This work was done in collaboration with H. Clevers 
(Utrecht, The Netherlands); D. Pappin, M. Hammell, and 
J. Hicks (Cold Spring Harbor Laboratory)
Organoids are three-dimensional primary epithelial 
cell cultures formed from benign and malignant mu-
rine and human pancreatic tissues (Boj SF, et al., in 
press). Organoids can be generated from small human 
tissue samples such as endoscopic needle biopsies. Bi-
opsies are more easily and commonly obtained in the 
clinic than resected tumors, so the ability to study 
cells taken from biopsies provides a feasible route to 
infl uence patient management. With our panel of 
organoids, we can perform diverse global molecular 
analyses. Our own transcriptomic, genomic, metab-
olomic, and proteomic analyses have identifi ed new 
pathways that are altered in pancreatic cancer, includ-
ing pathways involved in lipid metabolism. Addition-
ally, analysis of our initial set of human pancreatic 
cancer organoids has revealed marked interpatient 
genetic diversity, which we are now able to study ex 
vivo. Strikingly, single-cell assessment of our human 
organoids has also uncovered intrapatient subclonal 
diversity. To determine the extent of interpatient and 
intrapatient heterogeneity, we have initiated a project 
with multiple international sites to collect and charac-
terize 300 human organoids. Single-cell analyses will 
be performed on some of these specimens to determine 
the pattern of co-occurring genetic alterations. Using 
this information, we can defi ne distinct genetic sub-
types of pancreatic cancer that may represent unique 
therapeutic vulnerabilities. By deriving new organoid 
cultures from individual cells isolated from those mul-
ticlonal, heterogeneous organoids, we will be able to 
further study individual subclones within a tumor.
Using our mouse organoid system, we discov-
ered that primary pancreatic ductal adenocarcinoma 
(PDAC) in the classic Kras+/LSL-G12D; Trp53+/LSL-R172H; 
Pdx1-Cre (KPC) mouse model of pancreatic cancer did 
not harbor loss of heterozygosity (LOH) of the wild-
type Trp53 allele and maintained normal karyotypes. 
In contrast, organoids derived from metastases and 
two-dimensional, monolayer cell lines generated from 
primary-tumor-derived organoids did undergo Trp53 
LOH and displayed abnormal karyotypes. Impor-
tantly, human organoids derived from primary PDAC 
all had abnormal karyotypes. This demonstrates that 
prior work from our laboratory and others using the 
KPC mouse system may best model the biology and 
therapeutic response of early cancers, a fi nding which 
prompts us to develop more advanced mouse models of 
PDAC for current and future work.
Intriguingly, following orthotopic transplantation, 
organoids recapitulated the stages of pancreatic tumor 
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progression, forming structures resembling early pre-
invasive carcinomas, which eventually progressed to 
invasive carcinomas. Thus, organoids represent the 
fi rst robust, transplantable model of human pancre-
atic cancer progression (Fig. 1). Remarkably, within 
tumors derived from transplanted organoids, both the 
neoplastic and tumor microenvironment composition 
evolved simultaneously. We are currently determin-
ing whether these orthotopically engrafted organoid 
(OGO) models accurately refl ect therapeutic re-
sponses. We expect that the OGO models will be a 
rich resource for studying the fundamental biology of 
PDAC, discovering new biomarkers, and identifying 
new treatment strategies.
To determine whether organoids are more predic-
tive of therapeutic response than standard models of 
human pancreatic cancer, we are comparing organ-
oids to monolayer cultures, patient-derived-xenograft 
models (PDXs), and patient-derived circulating 
tumor cells (CTCs). As part of our work to investi-
gate treatment response, we have translated one of 
our fi ndings into a clinical trial at Memorial Sloan 
Kettering Cancer Center (PI, Kenneth Yu). This trial 
is evaluating the ability of pegylated hyaluronidase 
(PEGPH20) to enhance the delivery of cetuximab. In 
addition to evaluating patient response and drug de-
livery, we will prepare human organoids from resected 
tumors obtained from patients enrolled in this trial 
for follow-up studies. In the future, we plan to gener-
ate organoid cultures from pretreatment biopsies, as 
well as serial biopsies from patients under therapy, to 
explore mechanisms of primary and acquired drug re-
sistance that will inform new treatment strategies.
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Figure 1. Following orthotopic transplantation of human tumor organoids into Nu/Nu mice, human tumor organoids 
recapitulated the full progression of pancreatic cancer. Early-stage preinvasive lesions are initially formed and later 
progress to invasive carcinomas. Tumor sections are stained with hematoxylin and eosin. Higher magniﬁ cation im-
ages of insets are shown below. Bar, 50 μm.
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RAS AND RHO GTPASES AND THE CONTROL 
OF SIGNAL TRANSDUCTION
L. Van Aelst B. Elmer M. Wang
 Y. Tai Y.-T. Yang
 C.-L. Wang J.-R. Yu
Research in my laboratory is focused on the role of 
Ras and Rho GTPase family members in signal trans-
duction. Ras and Rho family members have key roles 
in cellular activities controlling cell growth control, 
differentiation, and morphogenesis. Alterations in Ras 
and Rho functions have been causally linked to both 
cancer and brain disorders, including mental retarda-
tion, schizophrenia, and epilepsy. Our interests lie in 
understanding how defects in Ras- and Rho-linked 
proteins contribute to the development of these dis-
ease processes. Toward this end, my lab has contin-
ued to defi ne the functions of selected GTPases and 
their regulators and effectors in models of cancer and 
neurodevelopmental disorders. Below are highlighted 
selected key projects that have been carried out during 
the past year.
Multifunctional Role of the X-linked 
Intellectual Disability Protein OPHN1 
at the Hippocampal CA1 Synapse
Oligophrenin-1 (OPHN1), which encodes a Rho- 
GTPase activating protein, was the fi rst identifi ed Rho-
linked intellectual disability (ID) gene. It was initially 
identifi ed by the analysis of a balanced translocation 
t(X;12) observed in a female patient with mild ID. 
Subsequent studies revealed the presence of OPHN1 
mutations in families with ID associated with cerebel-
lar hypoplasia, lateral ventricle enlargement, and/or ep-
ilepsy. Most of the OPHN1 mutations identifi ed to date 
have been shown, or predicted, to result in OPHN1 
loss of function; however, the pathophysiological role of 
OPHN1 has remained poorly understood.
We have begun to unveil the function of OPHN1 
at both the presynaptic site and postsynaptic site of 
the hippocampal CA3-CA1 synapse. We previously 
described how during early development, presynaptic 
OPHN1 is important for effi cient retrieval of synap-
tic vesicles, whereas postsynaptic OPHN1 has a key 
role in activity-dependent maturation and plasticity 
of excitatory synapses, suggesting the involvement 
of OPHN1 in normal activity-driven glutamatergic 
synapse development. Interestingly, we more recently 
found that postsynaptic OPHN1 also has a critical 
role in mediating a form of plasticity (mGluR-LTD 
[long-term depression]) that relies on the activation 
of group I metabotropic glutamate receptors, which 
consist of mGluR1 and mGluR5 in CA1 hippocam-
pal neurons. Alterations in this form of plasticity have 
been linked to drug addiction and cognitive disorders. 
A key characteristic of mGluR-LTD is its dependence 
on rapid protein synthesis; however, the identities of 
the proteins mediating LTD have remained largely 
elusive. We obtained evidence that OPHN1 expres-
sion is translationally induced in dendrites of CA1 
neurons within 10 min of mGluR activation and that 
this response is essential for mGluR-dependent LTD. 
Specifi cally, acute blockade of new OPHN1 synthesis 
impedes mGluR-LTD and the associated long-term 
decreases in surface AMPARs (α-amino-3-hydroxy-
5-methyl-4-isoxazole propionic acid receptors). Inter-
estingly, the rapid induction of OPHN1 expression 
is primarily dependent on mGluR1 activation and is 
independent of fragile-X intellectual disability protein 
(FMRP).
We further demonstrated that OPHN1’s role in 
mediating mGluR-LTD is dissociable from its role in 
basal synaptic transmission. mGluR-LTD and the as-
sociated long-term decreases in surface AMPARs are 
dependent on OPHN1’s interaction with Endophilin 
A2/3, whereas regulation of basal synaptic strength 
requires OPHN1’s Rho-GAP activity and association 
with Homer 1b/c proteins. As to how OPHN1 could 
mediate the strengthening of synapses via interactions 
with Homer 1b/c and RhoA, we previously showed 
that OPHN1 becomes enriched in spines in response 
to synaptic activity and NMDAR (N-methyl-d-aspar-
tate receptor) activation, where by locally modulating 
RhoA/Rho kinase activities (i.e., in the proximity of 
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AMPARs), it contributes to the stabilization of AM-
PARs. Homer 1b/c proteins, on the other hand, were 
shown to participate in the positioning of the endo-
cytic zone (EZ) near the postsynaptic density (PSD). 
The close juxtaposition of the EZ and the PSD en-
ables localized endocytosis and recycling of AMPARs 
that serves to maintain a mobile pool of surface AM-
PARs required for synaptic potentiation. Interest-
ingly, we recently found that a physical interaction 
between OPHN1 and Homer 1b/c is crucial for the 
positioning of the EZ adjacent to the PSD, and we 
obtained evidence that this interaction is important 
for OPHN1’s role in controlling activity-dependent 
strengthening of excitatory synapses. Disruption of 
the OPHN1–Homer 1b/c interaction caused a dis-
placement of EZs from the PSD, along with impaired 
AMPAR recycling and reduced AMPAR accumula-
tion at synapses, under both basal conditions and con-
ditions that can induce synaptic potentiation. Thus, 
these data indicate that OPHN1 exerts its effects on 
synapse strengthening by serving at least two distinct 
roles. Via its interaction with Homer 1b/c, OPHN1 
facilitates the recycling and thereby maintenance of a 
mobile pool of surface AMPARs, whereas via its Rho-
GAP activity, OPHN1 contributes to the stabilization 
of synaptic AMPARs.
Collectively, our fi ndings point to a multifunctional 
role for OPHN1 at CA1 synapses. Independent of its 
role in activity-driven glutamatergic synapse develop-
ment, regulated OPHN1 synthesis has a critical role in 
mGluR-dependent LTD. Thus, it is conceivable that, 
on one hand, OPHN1 might have an important role in 
synapse maturation and circuit wiring during early de-
velopment. On the other hand, the regulated OPHN1 
synthesis could operate during adulthood to weaken 
synapses in response to behaviorally relevant stimuli.
Regulation of Chandelier Cell Cartridge 
and Bouton Development via DOCK7-
Mediated ErbB4 Activation
DOCK7 is a member of the evolutionarily con-
served DOCK180-related protein superfamily. The 
DOCK180 family, of which in total 11 mammalian 
members have been identifi ed (termed DOCK1/
DOCK180 to DOCK11), emerged as a distinct class 
of Rac and/or Cdc42 GTPase guanine nucleotide ex-
change factors (GEFs). This class of proteins has been 
implicated in diverse cell-type-specifi c processes. We 
initially identifi ed DOCK7 as a novel activator of Rac, 
which is highly expressed in the developing brain. Sig-
nifi cantly, mutations in DOCK7 have been reported 
in individuals with epileptic encephalopathy and cor-
tical blindness; however, the role(s) of DOCK7 in 
neuronal development and/or function has remained 
largely elusive.
We previously described how DOCK7 has a critical 
role in the polarization and genesis of newborn pyra-
midal neurons and how it does so by promoting Rac 
activity and antagonizing TACC3 (transforming acidic 
coiled-coil-containing protein 3) function, respec-
tively. Interestingly, in more recent studies examining 
the expression patterns of members of the DOCK180 
family in GABAergic interneurons, we intriguingly 
observed the presence of DOCK7, among other par-
valbumin (PV)-expressing interneurons, in chande-
lier cells (ChCs) of adolescent/adult mouse brains. 
ChCs, typifi ed by their unique axonal morphology, 
are the most distinct interneurons present in cortical 
circuits. Through their distinctive axonal terminals, 
called cartridges, these cells selectively target the axon 
initial segment of pyramidal cells and control action 
potential initiation; yet, the mechanisms that govern 
the characteristic ChC axonal structure have remained 
elusive. The main obstacles have been a lack of unique 
biochemical ChC markers and versatile methods to 
target and manipulate gene expression in these cells. 
This prompted us to develop a method to manipulate 
gene expression in ChCs so that DOCK7’s role in their 
development could be assessed. On the basis of recent 
evidence indicating that progenitors in the ventral me-
dial ganglionic eminence (vMGE) provide a source of 
ChCs, we reasoned it should be possible to target gene 
expression in nascent ChCs by means of in utero elec-
troporation directed toward the vMGE, and we found 
that this is indeed the case. Using this technique, we 
demonstrated a critical role for DOCK7 in ChC car-
tridge/bouton development. In particular, knockdown 
of DOCK7 caused a disorganization of ChC cartridges 
and a decrease in the density and size of ChC boutons. 
DOCK7 overexpression elicited essentially the opposite 
phenotypes. An organized network of ChC cartridges 
was formed, and both the density and size of boutons 
were increased. We further found that DOCK7 func-
tions as a cytoplasmic activator of the schizophrenia-as-
sociated ErbB4 receptor tyrosine kinase and important-
ly that DOCK7 modulates ErbB4 activity to control 
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ChC cartridge/bouton development. Indeed, an ErbB4 
mutant with enhanced kinase activity was able to over-
come the phenotypes associated with DOCK7 knock-
down, whereas silencing of ErbB4 prevented the phe-
notypes elicited by DOCK7 overexpression. Thus, our 
fi ndings defi ne DOCK7 and ErbB4 as key components 
of a pathway that controls the morphological differen-
tiation of ChCs, with implications for the pathogenesis 
of schizophrenia.
TGF-β/Smad Signaling through DOCK4 
Facilitates Lung Adenocarcinoma Metastasis
The cytokine transforming growth factor-β (TGF-
β) has an important, albeit complex, role in epithe-
lial tumorigenesis. During early stages of tumorigen-
esis, TGF-β typically functions as a tumor suppres-
sor; however, at later stages, it can act as a potent 
promoter of multiple steps of the metastatic process, 
which comprise local motility/invasion, entry of can-
cer cells into the blood stream (intravasation), exit 
from the blood vessels (extravasation), and coloniza-
tion of distant organs. The relevance of TGF-β sig-
naling for disease progression has been particularly 
recognized in tumors where cancer cells retain the 
core TGF-β-signaling components, as is frequently 
the case in breast and lung cancers. However, a major 
remaining challenge is the identifi cation of TGF-β 
target genes that drive the different steps of metas-
tasis, especially since TGF-β modulates gene expres-
sion in a highly cell- and context-specifi c manner. 
Although some progress to this end has been made in 
the context of breast cancer metastasis, the genes and 
mechanisms that mediate the prometastatic effects 
of TGF-β in lung adenocarcinoma (ADC) remain 
largely unknown.
To explore the molecular mechanisms that could 
mediate the prometastatic effects of TGF-β in lung 
ADC, we took a candidate gene approach and started 
off by scrutinizing members of the DOCK180-related 
protein superfamily. We found that in lung ADC cells, 
expression of DOCK4, but not other DOCK180-
family members, is rapidly and robustly induced by 
TGF-β in a Smad-dependent manner. Moreover, we 
found that DOCK4 is a direct TGF-β/Smad target 
gene and, importantly, that high DOCK4 expres-
sion correlates with activated TGF-β signaling and 
poor prognosis in human lung ADC. These fi ndings 
prompted us to assess the role of DOCK4 in mediat-
ing the prometastatic effects of TGF-β in lung ADC 
in vivo in a mouse model. We found that DOCK4 
induction is essential for TGF-β-driven lung ADC 
metastasis. Specifi cally, we observed that blockade 
of TGF-β-induced DOCK4 attenuates the ability of 
lung ADC cells to extravasate into distant organ sites, 
resulting in a marked reduction in metastatic burden 
in mice. At a cellular level, we obtained evidence that 
TGF-β-induced DOCK4 signaling facilitates extrava-
sation by stimulating lung ADC cell protrusive activi-
ty, motility, and invasion, without affecting epithelial-
to-mesenchymal transition (EMT), and, intriguingly, 
that it does so by driving Rac1 activation. So far, Rac1 
has only been linked to TGF-β via a noncanonical 
pathway. Thus, our fi ndings identifi ed the atypical 
Rac1 activator DOCK4 as a novel, key component of 
the TGF-β/Smad pathway that promotes lung ADC 
cell extravasation and metastasis.
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UNDERSTANDING MALIGNANT GLIOMA PATHOGENESIS
H. Zheng S. Klingler C. Wu
 F. Li L. Zhang
Our laboratory studies the molecular and developmen-
tal programs that control initiation and progression 
of malignant glioma, the most common and lethal 
type of brain tumor. Our long-term goal is to defi ne 
the complex biology of malignant glioma pathogen-
esis with the aim of identifying novel therapeutic and 
pharmacological opportunities that will improve treat-
ment options for glioma patients. During the past year, 
we have continued to focus our research around two 
major areas.
1. We are developing genetically engineered animal 
models to recapitulate the process of human glio-
ma pathogenesis and utilizing these animal mod-
els as tools to investigate in vivo tumor initiation 
and progression, as well as their response to vari-
ous therapeutic treatments.
2. We are also identifying the genetic and epigenetic 
pathways governing normal and neoplastic neural 
stem and glioma cell-fate determination.
EGFR-Dependent and -Independent 
Mechanisms Underlie EGFR-Targeted 
Therapeutic Resistance in Malignant Glioma
The epidermal growth factor receptor (EGFR) belongs 
to a family of receptor tyrosine kinases, and it is highly 
amplifi ed, mutated, and overexpressed in human ma-
lignant gliomas, making it a compelling candidate for 
targeted therapies. Despite the prevalence and growth-
promoting functions of EGFR, therapeutic strategies 
including EGFR tyrosine kinase inhibitors (TKIs) to 
target its kinase activity have not been translated into 
profound benefi cial effects in glioma clinical trials. 
The glioma patient’s poor response to EGFR TKIs is in 
contrast to the remarkable therapeutic benefi ts of these 
inhibitors in lung cancer patients carrying EGFR mu-
tations. The reason behind these differential responses 
has remained poorly understood.
We have begun to uncover the mechanisms un-
derlying the EGFR-targeted therapeutic resistance in 
malignant gliomas. Notably, although glioma and lung 
cancer EGFR mutants both exhibit ligand-independent 
autophosphorylation and activation, one major differ-
ence between them is the distribution of mutations 
within the EGFR-coding sequence; lung cancer muta-
tions generally reside in the EGFR intracellular kinase 
domain, whereas glioma mutations mainly cluster in the 
extracellular domain. These tumor-type-specifi c EGFR 
mutational patterns likely refl ect different functional re-
quirements during tumor initiation and progression. In 
our studies to defi ne their response to EGFR TKIs, we 
demonstrated that the kinase activities of glioma-spe-
cifi c EGFR mutants can be effi ciently inhibited just like 
those of the lung cancer. These observations prompted 
us to reason that the poor response of glioma patients 
to EGFR TKIs might be due to ineffi cient drug pen-
etration through the blood-brain barrier or that EGFR 
might not be required for glioma cell survival and 
propagation. To address these questions, we collaborat-
ed with scientists from Columbia University and Weill 
Cornell Medical College to develop a novel malignant 
glioma mouse model driven by the inducible expression 
of a glioma-specifi c mutant EGFR. Using an approach 
combining genetic and pharmacological interventions, 
we further demonstrated that oncogenic EGFR indeed 
serves a tumor-maintenance role in EGFR-driven ma-
lignant gliomas. Genetic suppression of mutant EGFR 
expression led to signifi cant tumor regression. This is in 
contrast to the meager effect of EGFR TKI treatment 
despite the fact that the inhibitors can effi ciently inhibit 
mutant EGFR kinase activity within the gliomas. Our 
fi ndings suggest that the poor response to EGFR TKIs 
in glioma clinical trials was not due to the inhibitors’ 
inability to suppress EGFR phosphorylation but rather 
that glioma was less dependent on EGFR kinase activ-
ity. To achieve optimal effi cacy against EGFR-driven 
glioma, the next generation of targeted therapeutics 
will need to consider other EGFR functional domains 
as well as its kinase activity.
In addition to the EGFR-dependent resistance 
mechanism, our studies further uncovered an EGFR-
 independent mechanism responsible for glioma relapse 
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following genetic ablation of mutant EGFR expression. 
In collaboration with scientists from the University of 
Texas M.D. Anderson Cancer Center, we demonstrated 
that a subpopulation of glioma cells that survived onco-
genic EGFR ablation and were responsible for relapse 
existed prior to treatment. Interestingly, we found that 
the EGFR-independent relapsed tumors were strongly 
enriched for mesenchymal features. Addition of a phos-
phoinositol-3 kinase/mammalian target of rapamycin 
(PI3K/mTOR) inhibitor could signifi cantly delay the 
relapse and prolong survival. Together, our research re-
veals important mechanistic insights into glioma thera-
peutic resistance development and provides a platform 
for testing therapies targeting EGFR signaling-driven 
malignant gliomas.
Characterization of the Function 
of ATRX during Glioma Pathogenesis
α-thalassemia/mental retardation syndrome X-linked 
(ATRX ), encoding a Rad54-like ATP-driven DNA 
translocase, belongs to the SWI/SNF family of chro-
matin remodulators. ATRX was initially identifi ed to 
be the gene involved in the X-linked α-thalassemia/
mental retardation syndrome. Its germline mutation 
causes a form of syndromal mental retardation with 
multiple developmental abnormalities. The fi rst link 
of ATRX with cancer came from the observation that 
a cohort of patients presenting with myelodysplastic 
syndrome (MDS) concurrently harbor ATRX muta-
tion. More recently, frequent somatic loss-of-function 
ATRX mutations have been identifi ed in human pe-
diatric and adult gliomas, pancreatic neuroendocrine 
tumors (PanNETs), osteosarcomas, and others, indi-
cating the tumor suppressor roles of ATRX. Function-
ally, it has been shown that ATRX, in combination 
with its interaction partner Death domain-associated 
protein 6 (DAXX), can facilitate replication-indepen-
dent histone variant H3.3 incorporation into pericen-
tric, telomeric, and other heterochromatin regions 
with high repeat sequences; however, its link to tu-
morigenesis has remained poorly understood.
In collaboration with Scott Lowe and Chris 
 Vakoc’s groups here at CSHL, we previously initiated 
a project to probe the epigenetic networks controlling 
neural stem and/or glioma cell self-renewal and dif-
ferentiation. By conducting a comprehensive screen 
of a customized small hairpin RNA (shRNA) library 
targeting epigenetic regulators, we identifi ed mul-
tiple chromatin modulators including ATRX whose 
suppression attenuates the differentiation capacity of 
neural stem and glioma cells. Suppression of Atrx pro-
tein expression strongly promotes glioma formation 
from a mouse neural stem cell inactivated of p53 and 
Pten tumor suppressor genes. More recently, we dem-
onstrated that deletion of Atrx in neural stem cells 
could block the neuronal lineage terminal differentia-
tion but had minimal impact on glial lineages. This is 
consistent with our studies examining Atrx expression 
pattern in adult mouse brains, in which we found that 
Atrx protein levels increase upon neuronal differen-
tiation with strongest expression confi ned to postmi-
totic neuron cells. Our fi ndings therefore indicate that 
ATRX has a critical role controlling neuronal matura-
tion, and its inactivation may facilitate lineage rever-
sion and glioma formation.
It is well known that cancer cells must overcome 
the progressive telomere attrition that occurs with each 
cell division in order to grow indefi nitely. Unlike the 
majority of cancer cells that circumvent the replicative 
mortality through reactivation of telomerase, ATRX 
mutant tumors seemingly rely on a telomerase-indepen-
dent mechanism termed the alternative lengthening of 
telomeres (ALT) pathway for telomere maintenance. In 
collaboration with scientists from the Wistar Institute 
in Philadelphia, we obtained evidence that ATRX is 
involved in telomere maintenance by regulating telom-
erase activity. Deletion of ATRX expression in human 
glioma cells leads to progressive cellular senescence or 
crisis that can be rescued by introduction of exogenous 
telomerase expression. Additionally, we found that 
ATRX functions to repress aberrant telomeric recom-
bination and has a key role in telomere homeostasis. 
Collectively, our fi ndings point to a multifunctional 
role for ATRX during glioma pathogenesis.
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How does the brain encode stimuli from the outside world, within and across sensory modali-
ties, to generate specifi c perceptions that trigger complex behaviors? How is the brain shaped by 
sensory experience and contextual information, and what modifi cations occur in neuronal circuits 
that allow us to adapt to unexpected changes in our environment? These are the questions guiding 
the work of Florin Albeanu, who is searching for neuronal mechanisms underlying behavior by 
investigating circuit dynamics in the olfactory bulb, the olfactory cortex, and the corresponding 
premotor areas of mice. Advances in optical imaging, patterned illumination, and optogenetics, 
combined with electrophysiological recordings, enable Albeanu and colleagues to monitor and/
or alter patterns of activity at unprecedented synaptic and millisecond resolution, in real time, as 
animals are engaged in various behaviors. For survival, rodents need to identify the smells of objects 
of interest such as food, mates, and predators, across their recurring appearances in the surroundings, 
despite apparent variations in their features. Furthermore, animals aptly extract relevant information 
about the environment across different sensory modalities, combining olfactory, visual, or auditory 
cues. By recording neuronal activity in the input and output layers of the olfactory bulb and cortex, 
as well as feedback from cortical areas and neuromodulatory signals, Albeanu and his team aim 
to understand computations these circuits perform and how this information is decoded deeper in 
the brain and leads to action.
The study of decision making provides a window into the family of brain functions that constitute 
cognition. It intervenes between perception and action and can link one to the other. Although 
much is known about sensory processing and motor control, much less is known about the cir-
cuitry connecting them. Some of the most interesting circuits are those that make it possible to de-
liberate among different interpretations of sensory information before making a choice about what 
to do. Anne Churchland’s lab investigates the neural machinery underlying decision making. Lab 
members use carefully designed paradigms that encourage experimental subjects to deliberate over 
incoming sensory evidence before making a decision. Recent results show that rats and humans 
have a statistically similar decision-making ability. To connect this behavior to its underlying 
neural circuitry, they measure electrophysiological responses of cortical neurons in rodents as they 
perform designated tasks. The lab’s current focus is on the parietal cortex, which appears to be at 
the midpoint between sensory processing and motor planning. Churchland and colleagues also 
use theoretical models of varying complexity to further constrain how observed neural responses 
might drive behavior. This approach generates insights into sensory processing, motor planning, 
and complex cognitive function.
Research in Josh Dubnau’s lab is concentrated on two different questions. First, Dubnau and his 
team are investigating mechanisms of memory using Drosophila as a model system. A second area 
of research is focused on uncovering mechanisms of neurodegeneration that underlie amyotrophic 
lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). Work in the Dubnau lab 
has suggested a novel hypothesis to explain neurodegeneration in these disorders. They discovered 
that awakening retrotransposons in the genome of some brain cells might be responsible for caus-
ing cell death. Retrotransposons are virus-like repetitive elements that are encoded in the genome 
and are capable of replicating and inserting into new chromosomal positions. This can lead to 
DNA damage and cell death by a process known as apoptosis. The lab is investigating this hy-
pothesis for ALS/FTLD using a multidisciplinary approach that includes experimental work with 
fl y, mouse, cell culture, and human postmortem tissue. Computational analyses of genomic data 
are performed in collaboration with Molly Hammell’s group. If the retrotransposon hypothesis is 
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correct, it will change the trajectory of neurodegeneration research and have obvious clinical im-
pact. Retrotransposon RNAs and proteins are promising new diagnostic markers and potentially 
important therapeutic targets.
Grigori Enikolopov and colleagues study stem cells in the adult brain. They have generated several 
models to account for how stem cells give rise to progenitors and, ultimately, to neurons, and they 
are using these models to determine the targets of antidepressant therapies, to identify signaling 
pathways that control generation of new neurons, and to search for neuronal and neuroendocrine 
circuits involved in mood regulation. Recent experiments suggest a new model of how stem cells 
are regulated in the adult brain, with a focus on stem cells’ decision on whether to divide—and 
embark on a path of differentiation—or remain quiescent. This model explains why the number 
of new neurons decreases with advancing age—potentially leading to impairments in memory 
and depressed mood. It also explains why multiple brain trauma and prolonged neurodegenera-
tive disease may lead to accelerated decrease of cognitive abilities. In other research, the team has 
identifi ed stem cell targets of various therapies used for treating depression and developed a gen-
eral platform to determine the effect of drugs and therapies and predict their action. The team 
is now focusing on the signaling landscape of neural stem cells and on their interaction with the 
surrounding niche. Enikolopov’s group is also focusing on other types of stem cells in the organ-
ism. Their latest discovery, with a team at Cornell University, relates to a new type of stem cell in 
the ovary that normally heals the ovarian tissue after an oocyte is released, but easily transforms 
to become malignant and generate tumors. The team is now using these discoveries to reveal how 
stem cells relate to neural and oncological disorders.
Hiro Furukawa’s lab studies receptor molecules involved in neurotransmission. Its members main-
ly focus on the structure and function of NMDA (N-methyl-d-aspartate) receptors, ion channels 
that mediate excitatory transmission. Dysfunctional NMDA receptors cause neurological disor-
ders and diseases including Alzheimer’s disease, Parkinson’s disease, schizophrenia, depression, 
and stroke-related ischemic injuries. The Furukawa lab is working to solve the three-dimensional 
structure of the very large NMDA receptor by dividing it into several domains. They seek to 
understand the pharmacological specifi city of neurotransmitter ligands and allosteric modula-
tors in different subtypes of NMDA receptors at the molecular level. Toward this end, they use 
cutting-edge techniques in X-ray crystallography to obtain crystal structures of the NMDA recep-
tor domains and validate structure-based functional hypotheses by a combination of biophysical 
techniques including electrophysiology, fl uorescence analysis, isothermal titration calorimetry, 
and analytical centrifugation. Crystal structures of NMDA receptors serve as a blueprint for cre-
ating and improving the design of therapeutic compounds with minimal side effects for treating 
neurological disorders and diseases. During the last several years, the team has unraveled the over-
all architecture and discovered and mapped several regulatory sites in specifi c classes of NMDA 
receptors—progress that now opens the way to the development of a potentially new class of drugs 
to modulate the receptor’s activity.
Josh Huang and colleagues study the assembly and function of neural circuits in the neocortex 
of the mouse. The neocortex comprises a constellation of functional areas that form a representa-
tional map of the external (sensory, social) and internal (visceral, emotional) world. These areas 
are strategically interconnected into elaborate networks which support dynamic operations that 
process information and guide intelligent behavior. The group’s overarching hypothesis is that, at 
the cellular level, cortical processing streams and output channels are mediated by a large set of 
distinct glutamatergic pyramidal neurons (PyNs), and functional PyN ensembles are regulated by 
a diverse yet distinct set of GABAergic interneurons (INs). The Huang lab systematically builds 
cell-type genetic tools that integrate a full set of modern techniques for exploring neural circuits. 
Building on their success in genetic targeting of GABA INs, they have recently extended this 
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effort to PyNs. Their current research program is beginning to integrate studies of GABA INs and 
PyNs toward understanding the development and function of specifi c cortical circuits underlying 
behavior. Among GABA interneurons, the chandelier cell is one of the most distinctive cell types 
that controls PyN fi ring at the axon initial segment. Huang and colleagues are studying the devel-
opmental specifi cation of chandelier cells, their activity-dependent circuit integration, and their 
functional connectivity. Regarding pyramidal neurons, they are systematically characterizing the 
developmental origin, axon projection, and input connectivity of multiple classes of genetically 
defi ned PyN types, focusing on the forelimb motor cortex. They combine a range of approaches 
that include genetic and viral engineering, cell-type gene expression, genetic fate mapping, imag-
ing, electrophysiology, and behavior analysis. With this progress, they are beginning to integrate 
their studies in the context of the motor cortex control of volitional forelimb movements and 
motor learning.
Adam Kepecs and colleagues are interested in identifying the neurobiological principles underly-
ing cognition and decision making. They use a reductionist approach, distilling behavioral ques-
tions to quantitative behavioral tasks for rats and mice that enable the monitoring and manipula-
tion of neural circuits supporting behavior. Using state-of-the-art electrophysiological techniques, 
they fi rst seek to establish the neural correlates of behavior and then use molecular and optoge-
netic manipulations to systematically dissect the underlying neural circuits. Given the complexity 
of animal behavior and the dynamics of neural networks that produce it, their studies require 
quantitative analysis and make regular use of computational models. The team also has begun 
to incorporate human psychophysics to validate its behavioral observations in rodents by linking 
them with analogous behaviors in human subjects. Currently, the team’s research encompasses 
study of (1) the roles of uncertainty in decision making, (2) the division of labor among cell types 
in prefrontal cortex, (3) how the cholinergic system supports learning and attention, and (4) 
social decisions that rely on stereotyped circuits. A unifying theme is the use of precisely timed 
cell-type- and pathway-specifi c perturbations to effect gain and loss of function for specifi c be-
havioral abilities. This past year, Kepecs and colleagues discovered in experiments with rats that 
confi dence is a measurable quantity; they identifi ed a brain region, the orbitofrontal cortex, whose 
function is required for the animals to express confi dence in their decisions. In other notable work, 
the lab has identifi ed a class of inhibitory neurons that specializes in inhibiting other inhibitory 
neurons in cerebral cortex and is recruited during behavior when rewards and punishment are 
delivered. Through manipulations of genetically and anatomically defi ned neuronal elements, the 
team hopes to identify fundamental principles of neural circuit function that will be useful for 
developing therapies for diseases such as schizophrenia, Alzheimer’s disease, and autism spectrum 
disorder.
Alexei Koulakov and colleagues are trying to determine the mathematical rules by which the 
brain assembles itself, with particular focus on the formation of sensory circuits such as those in-
volved in visual perception and olfaction. The visual system of the mouse was chosen for study in 
part because its components, in neuroanatomical terms, are well understood. What is not known 
is how projections are generated that lead from the eye through the thalamus and into the visual 
cortex, how an individual’s experience infl uences the confi guration of the network, and what 
parameters for the process are set by genetic factors. Even less is known about the assembly of the 
neural net within the mouse olfactory system, which, in the end, enables the individual to distin-
guish one smell from another with astonishing specifi city and to remember such distinctions over 
time. These are among the challenges that engage Koulakov and his team.
Dysfunction of synapses in the brain is believed to have an important role in the pathogenesis 
of major psychiatric disorders, including depression, anxiety, and schizophrenia. But what are 
the causes? Where in the brain does the dysfunction occur? How does it result in the behavioral 
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symptoms of illness? To address these issues, Bo Li and colleagues are studying, in animals, nor-
mal synaptic plasticity underlying adaptive behaviors and synaptic aberrations responsible for 
maladaptive behaviors that are related to depression, anxiety, and schizophrenia. Their long-term 
goal is to develop methods allowing the manipulation of activity in specifi c brain circuits in 
order to change disease-related behaviors. Li’s group uses a variety of methodologies, including 
patch-clamp recording and calcium imaging of labeled neurons, two-photon imaging of spine 
morphology and tagged receptors, in vivo stereotaxic virus injection, RNA interference (RNAi)-
based gene silencing, activation of specifi c axon terminals using light-gated cation channels, ac-
tivation or silencing of specifi c brain regions using transgenes, and assessment of the behavioral 
consequences of certain manipulations. A project focusing initially on a gene called ErbB4 seeks 
to determine the genetic causes of attention defi cit, a cognitive impairment that is consistently 
observed in schizophrenia. During the last two years, Li and his lab members demonstrated that 
neurons in a tiny area of the mammalian brain called the central amygdala encode fear memory 
and control fear expression. These and related fi ndings lay the foundation for future work aimed 
at understanding the circuit mechanisms of anxiety disorders, particularly post-traumatic stress 
disorder (PTSD). The team has also identifi ed a group of neurons in the medial prefrontal cortex 
(mPFC) that determines how mice respond to stress. These neurons, hyperactive in the depressed 
brain, are weakened in mice with natural stress resilience.
Partha Mitra’s group studies complex neurobiological systems using a combination of experimen-
tal and computational approaches. The primary experimental focus continues to be the Mouse 
Brain Architecture (MBA) project, with a goal to generate a mesoscale connectivity map. The 
approach is to microinject anterograde and retrograde neuronal tracer substances at target loca-
tions systematically selected on a grid in the brain and then histologically process, image, and 
digitally reconstruct whole brains and visualize all labeled connections. Currently, more than 
800 tracer-injected mouse brains are viewable via the on-line digital microscope on the MBA 
project web portal. Mitra’s neuroinformatics research involves the development of analytical tools 
and  informatics infrastructures to process, analyze, and integrate large volumes (totaling about a 
petabyte) of neurobiological data in various brain connectivity projects. In collaborative studies, 
the team applies methods of whole-brain digital neuroanatomy developed for the MBA project 
to normal and disease model brains in various species. A joint study with Josh Huang to obtain a 
brain-wide census of genetically targeted GABAergic interneurons in the mouse brain during de-
velopment and in genetic models of autism is drawing to a conclusion. New work with Pavel Osten 
seeks to obtain an accurate whole-brain census of neuron classes in cell-type-specifi c reporter 
mice and to develop neuroinformatics infrastructure to analyze and integrate such data. With 
Sacha Nelson (Brandeis University), the team is engaged in a cross-species study of neuronal cell 
types in transgenic strains of rats and mice. The lab also has collaborations with Marcello Rosa 
(Monash University, Australia) and Hideyuki Okan (RIKEN, Japan) on a project to develop the 
fi rst atlas of the brain of a New World primate, the marmoset. In collaboration with Balaraman 
Ravindran, Mitra has initiated a Center for Computational Brain Research at the Indian Institute 
of Technology (IIT), Madras. In parallel, Mitra is undertaking theoretical work at the interface 
among physics, engineering, and biology. In this line of investigation, Mitra and his collaborators 
bring methods from statistical physics and control theory to bear on problems in complex inter-
connected biological systems, including whole-brain connectivity.
Pavel Osten’s lab works on identifi cation and analysis of brain regions, neural circuits, and con-
nectivity pathways that are disrupted in genetic mouse models of autism and schizophrenia. Osten 
hypothesizes that (1) systematic comparison of multiple genetic mouse models will allow deter-
mination of overlaps in pathology—neural circuit endophenotypes—responsible for the mani-
festation of neuropsychiatric disorders and (2) neural circuit-based classifi cation of autism and 
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schizophrenia will provide key circuit targets for detailed mechanistic studies and therapeutic 
development. Osten and colleagues have developed the fi rst systematic approach to the study 
of neural circuits in mouse models of psychiatric diseases, based on a pipeline of anatomical 
and functional methods for analysis of mouse brain circuits. An important part of this pipeline 
is high-throughput microscopy for whole-mouse brain imaging, called serial two-photon (STP) 
 tomography. They have used this method to describe the fi rst whole-brain activation map rep-
resenting social behavior in normal mice. They are currently focusing on using this approach to 
study brain activation changes in two mouse models of autism, the 16p11.2 df/+ mouse model, 
which shows an increased propensity to seizures and hyperactivity, and the CNTNAP2 knockout 
mouse model, which shows abnormal social behavior.
Stephen Shea’s lab studies the neural circuitry underlying social communication and decisions. 
He uses natural social communication behavior in mice as a model to understand circuits and pro-
cesses that are evolutionarily conserved and therefore shared broadly across species, likely contrib-
uting to disorders such as autism. Shea and colleagues have examined how emotion and arousal 
enable mice, via their olfactory systems, to store memories of other individuals and of related 
social signals. The team has exploited the intimate relationship between memory and emotion to 
effectively create memories in anesthetized mice, allowing them unprecedented access to neuro-
biological processes that typically only occur during behavior. The lab has been making a detailed 
analysis of the changes in neural connections that underlie odor memory. The team is particularly 
focused on an enigmatic cell type (granule cells or GCs) that has long been hypothesized to be 
crucial for memories but has resisted direct study. They have developed methods for recording 
that are giving them the fi rst glimpse of the dynamics of these cells while the animal is learning 
an odor. The results show unexpectedly complex population dynamics among the GCs that were 
independently predicted by a model of odor learning developed in Alexei Koulakov’s lab. The two 
labs are collaborating to discern how GC population activity gets integrated by olfactory bulb 
output neurons and to pinpoint the synaptic circuit that underlies this form of learning. In paral-
lel, another member of the lab is using imaging techniques to determine how memories are stored 
among broad neuronal ensembles, at a different level of the system. Recently, the lab made a key 
breakthrough, developing the ability to record from GCs in awake animals and discovering that 
their activity is dramatically modulated by state of consciousness. Finally, the Shea lab completed a 
series of studies of a different form of social recognition: auditory recognition of pup vocalizations 
by their mothers. Through this research, they have shown that a mouse model of Rett syndrome 
exhibits defi cits in communication and learning not unlike those in human patients. Grants from 
the Simons and Whitehall Foundations are allowing the lab to extend this work by directly link-
ing these defi cits to the action of the gene MeCP2 in the auditory cortex.
What is a memory? When we learn an association, information from two different sensory streams 
somehow becomes linked together. What is this link in terms of neural activity? For example, after 
a few bad experiences, we learn that the “green” smell of an unripe banana predicts its starchy 
taste. How has the neural response to that green smell changed so it becomes linked to that taste? 
What are the underlying mechanisms—what synapses change strength, what ion channel proper-
ties change? These are the questions that drive research in Glenn Turner’s laboratory. His team 
addresses these questions by tracking neural activity using a combination of different techniques. 
Using electrophysiological methods, they can examine individual neurons with very high reso-
lution, monitoring synaptic strength and spiking output. They have also developed functional 
imaging techniques to monitor the activity of the entire set of cells in the learning and memory 
center of the fl y brain. This comprehensive view of neural activity patterns enables them to actu-
ally predict the accuracy of memory formation in separate behavioral experiments. This year, the 
Turner lab was able to map the activity of a particular region of the brain that is associated with 
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learning and memory. They found that a remarkably small number of neurons are required for 
fl ies to distinguish between odors. The Turner lab also studied the role of a specifi c type of cells 
known as Kenyon cells, which receive input via several large claw-like protrusions. These neurons 
use their claws to recognize multiple individual chemicals in combination in order to remember 
a single scent. By examining the effects of learning-related genes on these processes, they can in 
the future connect their network-level view of memory formation to the underlying molecular 
mechanisms that govern the basic cellular and synaptic changes that drive learning.
Anthony Zador and colleagues study how brain circuitry gives rise to complex behavior. Work 
in the lab is focused on two main areas. First, they ask how the cortex processes sound, how that 
processing is modulated by attention, and how it is disrupted in neuropsychiatric disorders such 
as autism. Recently, the lab found that when a rat makes a decision about a sound, the informa-
tion needed to make the decision is passed to a particular subset of neurons in the auditory cortex 
whose axons project to a structure called the striatum. In the second major line of work in the 
Zador lab, they are developing new methods for determining the complete wiring instructions of 
the mouse brain at single-neuron resolution, which they term the “Connectome.” In contrast to 
previous methods, which make use of microscopy, these methods exploit high-throughput DNA 
sequencing. Because the costs of DNA sequencing are plummeting so rapidly, these methods have 
the potential to yield the complete wiring diagram of an entire brain for just thousands of dollars.
Yi Zhong’s lab studies the neural basis of learning and memory. The team works with fruit fl y 
models to study genes involved in human cognitive disorders, including neurofi bromatosis, Noon-
an syndrome (NS), and Alzheimer’s disease. Mutations leading to a lack of function of the neuro-
fi bromatosis 1 (NF1) gene cause noncancerous tumors of the peripheral nervous system as well as 
learning defects. The lab’s analyses of Drosophila NF1 mutants have revealed how expression of the 
mutant gene affects a pathway crucial for learning and memory formation. The NF1 gene and a 
gene called corkscrew, implicated in NS, share a biochemical pathway. Recently, the lab succeeded 
in linking changes in this pathway due to specifi c genetic defects in NS with long-term memory 
defi ciencies. In fl y models, they discovered the molecular underpinnings of the “spacing effect”—
the fact that memory is improved when learning sessions are spaced out between rest intervals. 
Zhong’s team also has succeeded in reversing memory defi cits in mutant fl ies, work suggesting 
that longer resting intervals for Noonan’s patients might reverse their memory defi cits. They also 
identifi ed a means of reversing memory loss in fruit fl ies while suppressing brain plaques similar to 
those implicated in Alzheimer’s disease by blocking epidermal growth factor receptor (EGFR) sig-
naling, a pathway commonly targeted in cancer. Separately, having discovered that memory decay 
is an active process regulated by the Rac protein, the team has proposed that Rac’s role in erasing 
memory is related to its infl uence on downstream cytoskeleton remodeling agents. This year, the 
Zhong lab explored how neurons control our response to different scents, offering insight into how 
the brain distinguishes between food odors that are attractive and repulsive. They determined that 
neurons expressing a particular peptide were only activated by food odors and that the amount of 
activation predicted how strongly a fl y was attracted to a particular odor.
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UNDERSTANDING NEURONAL CIRCUITS IN THE 
MAMMALIAN OLFACTORY BULB
D. Albeanu F. Anselmi H.G. Chae P. Alexandre Garcia Da Silva M. Koh G. Otazu 
 A. Banerjee M. Davis P. Gupta F. Marbach B. Rebouillat
The focus of our research group is to understand how 
neuronal circuits encode and interpret inputs from 
the environment across different contexts, senses, 
and brain states to generate meaningful behaviors. 
Toward this end, we use optogenetic methods (such 
as fast multiphoton laser-scanning imaging of geneti-
cally encoded neuronal activity reporters or patterned 
illumination of light-gated neuronal activity switches) 
coupled with electrophysiological measurements (ex-
tracellular and intracellular recordings). We want to 
understand (1) how inputs get processed at different 
synapses of the underlying neuronal circuits, (2) how 
these representations change with the state of the sys-
tem and its circuits (awake vs. anesthetized, naïve vs. 
behaving, learning), and (3) what changes in the ac-
tivity patterns of well-defi ned neuronal circuits con-
tribute to specifi c behaviors. The broad scope of this 
effort is observing how perceptions arise.
We use the rodent olfactory system as a model and 
monitor neuronal inputs, outputs, and feedback loops 
across different layers of the circuit. We modulate 
activity of select neuronal populations in a reversible 
manner in awake animals to understand how funda-
mental sensory encoding problems are solved by the 
olfactory bulb (OB) and olfactory (piriform) cortex 
networks.
Characterizing the Input–Output 
Transform of the Olfactory Bulb
In the OB, sensory neurons expressing the same type 
of olfactory receptor converge in tight focus, form-
ing ~2000 clusters of synapses called glomeruli. The 
layout of glomeruli on the bulb is highly reproduc-
ible across individuals with a precision of 1 part in 
1000. However, nearby glomeruli are as diverse in 
their responses to odors as distant ones, lacking an 
apparent chemotopic arrangement (Soucy et al., Nat 
Neurosci 12: 210 [2009]). From each glomerulus, a 
few dozen mitral cells (principal output neurons of 
the OB) carry the output further to the olfactory cor-
tex and several other brain areas. Such “sister” mitral 
cells typically have only one primary dendrite that 
projects to a single glomerulus, but they can sample 
inputs on their primary and secondary dendrites from 
functionally diverse glomeruli via several types of 
interneurons. Using optogenetic manipulations and 
digital micro-mirror device (DMD)-based patterned 
photostimulation, we found that sister cells carry dif-
ferent information to the cortex: average activity rep-
resenting shared glomerular input, and phase-specifi c 
information that refi nes odor representations and is 
substantially independent across sister cells (Dhawale 
et al., Nat  Neurosci 13: 1404 [2010]).
Activity in the bulb is a rich mix of excitation and 
inhibition, via both direct inputs and feedback connec-
tions. Many different classes of interneurons interact 
with the sensory afferents and/or the output neurons 
via both short- and long-range connections. Their 
connectivity patterns and roles in olfactory processing, 
however, remain largely unknown. We use a Cre/loxP 
approach to express reporters (i.e., synaptopHluorin, 
GCaMP6) and light-gated switches of neuronal activ-
ity (ChR2, Halorhodopsin, Arch) in different bulbar 
neuronal types. We monitor the inputs (glomerular 
activity patterns) and the outputs (mitral cell fi ring) 
in response to numerous odorants across a wide range 
of concentrations (three orders of magnitude) as we 
systematically perturb the activity of the input nodes 
(glomeruli) and of different interneuron types. Pat-
terned photostimulation allows us to bypass odor stim-
ulation and gain precise spatiotemporal control over 
the inputs by directly activating glomerular patterns 
of choice. We record bulbar outputs via multitetrode 
recordings and patch clamp, or we use optical imaging 
readouts via multiphoton microscopy in vivo to under-
stand what computations the olfactory bulb performs.
We are currently investigating the roles of two 
classes of interneurons: dopaminergic/GABAergic cells 
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(DAT+) that broadcast long-range signals in the glo-
merular layer and granule cells (GCs) that establish 
reciprocal synapses with mitral/tufted cells and receive 
rich cortical feedback input.
Long-Range Interactions between DAT+ 
Cells and External Tufted Cells Implement 
Gain Control and Gate the Output of the 
Glomerular Layer of the OB
Odors elicit distributed activation of input nodes 
(glomeruli) on the OB. This necessitates long-range 
interactions between coactive glomeruli. Long-range 
projecting DAT+ cells provide the earliest opportunity 
for such cross-talk. DAT+ cells, in the glomerular layer, 
receive inputs from olfactory sensory neurons and/or 
external tufted (ET) cells and release both GABA and 
dopamine, synapsing onto ET cells as far as tens of 
glomeruli away (Kiyokage et al., J Neurosci 30: 1185 
[2010]). Computational models (Cleland et al., Trends 
Neurosci 33: 130 [2007]) have suggested that these cells 
may be involved in long-range normalization of bulb 
outputs, but to date, their function in the intact brain 
has not been investigated. We fi nd that DAT+ cells con-
vey concentration-dependent odor signals by broadcast-
ing focal glomerular inputs throughout the OB. Using 
optogenetic and pharmacogenetic approaches, we fi nd 
that DAT+ cells infl uence distant mitral/tufted (M/T) 
cells by modulating local excitatory interneurons (ET 
cells). Synaptic action of DAT+ cells enables long-range 
suppression of ET cells. In addition, we fi nd electrical 
coupling between DAT+ and ET cells, which may fa-
cilitate local synchronization of ET cell responses. Our 
results indicate that ET cells are essential gatekeepers 
of glomerular output and prime determinants of M/T 
responsiveness. Furthermore, using a cell-specifi c abla-
tion approach, we show that long-range DAT + -to-ET 
action implements gain control and contrast enhance-
ment via M/T cell odor response decorrelation, by al-
lowing multiple coactive inputs to alter the output of 
any given glomerulus (Fig. 1).
Characterization of Granule Cell Odor 
Responses in Awake Head-Fixed Mice
GCs mediate both lateral and recurrent inhibition by 
forming reciprocal synapses with M/T, the principal 
output neurons of the OB. GCs receive glutamatergic 
inputs both from M/T cells and from feedback axons 
originating in the olfactory cortex. GCs are the most 
numerous cells in the OB (~90%), outnumbering the 
M/T cells by two orders of magnitude, and further 
represent the main target of direct feedback from the 
olfactory cortex.
Computational models and behavioral studies have 
suggested critical roles for these cells in olfactory pro-
cessing and learning. However, very little is known 
about their response properties in vivo, because of 
technical diffi culties in electrophysiological record-
ings from these small-sized neurons.
To begin characterizing the odor response proper-
ties of GCs, we used a genetically encoded calcium 
indicator (GCaMP6f) in the GCs (CST-Cre) and 
multiphoton imaging to monitor the odor-evoked re-
sponses of GCs (250–350 μm deep) in awake head-
fi xed mice (Fig. 2). GCs showed robust spontaneous 
activity and were sparsely activated upon odor pre-
sentation, displaying a diverse range of enhanced and 
suppressed, ON, OFF, and ON–OFF responses. En-
hanced responses were more common than suppressed 
responses (65% vs. 35%). Furthermore, a signifi cant 
fraction (~25%) of GCs exhibited characteristic en-
hanced OFF responses, independent of stimulus dura-
tion. Pairwise analysis of GCs monitored simultane-
ously indicates that neighboring GCs are as diverse in 
their odor responses as pairs of distant cells. No spatial 
clustering of similarly odor-responding GCs was ap-
parent within a 350-μm range. Enhanced responsive 
GCs increased monotonically in number across con-
centrations. Suppressed and OFF responsive GCs var-
ied in a complex fashion with concentration.
To dissect the contribution of the corticobulbar 
feedback to GC activity, we are using pharmacological 
and optogenetic manipulations of the cortical input in 
tandem with multiphoton imaging of GCs and MTs. 
Furthermore, we are currently monitoring how GC 
responses evolve during learning and performing of 
olfactory detection and discrimination tasks.
Dissecting the Spatial and Temporal 
Features of the Glomerular Code 
in Awake Behaving Animals via 
Optogenetic Strategies
Odorants activate precise spatiotemporal glomerular 
activity patterns on the OB surface. These patterns 
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Figure 1. DAT+ cells implement gain control and decorrelate mitral cell odor responses. (A) TH+ immunohistochem-
istry in the olfactory bulb (OB) of a DAT-Cre × Thyl-GCaMP3.0 mouse injected with AAV2.9-FLEX-DTR-GFP virus on 
the dorsal aspect of the OB followed by diphtheria toxin (DT) intraperitoneal injection. Confocal images of the TH+ 
signal in two representative ﬁ eld of views (FOVs) on the ventral (left) and dorsal (right) aspect of a given slice. Average 
counts of TH+ cells from all dorsal FOVs and from all ventral FOVs in DTR-injected mice, normalized by the number 
of visible glomeruli (100% for control and 8.3% for +DT, n = 1259 cells, eight FOVs, two mice). Residual signals mostly 
consisted of neuropil. (B) Baseline-subtracted, normalized GCaMP3.0 ensemble mitral cell responses to increasing 
concentrations of Allyl tiglate. (Top) Day 0 before injection of DT (control, n = 33 cells). (Bottom) Different FOVs in 
the same OB on Day 7 after DT injection (+DT, n = 44 cells). Each row represents an individual mitral cell (ROI) in the 
same FOV. Gray color indicates (dF/F). Dotted lines indicate odor presentation (4 s). (C) (i) Distribution of onset laten-
cies of mitral cell odor responses for control (1.55s ± 1.51s, n = 3660 cell-odor pairs) and +DT condition (1.2s ± 1.39s, 
n = 3000 cell-odor pairs). Numbers denote mean and standard deviation. Both the mean (two-sample t-test, p < 10−18) 
and the variance (F-test, p < 10−5) are signiﬁ cantly smaller under the +DT condition. (ii) Odor-evoked response (dF/F) 
of four example mitral cells from B, as a function of odor concentration. (iii) Mean odor-evoked response (dF/F) of all 
mitral cells from B as a function of odor concentration for Allyl tiglate on Day 0 (black, n = 33 cells) and Day 7 after 
+DT administration (gray, n = 44 cells). (D) Mean odor-evoked response (dF/F) of all mitral cells pooled across experi-
ments as a function of odor concentration for Allyl tiglate and Ethyl valerate. Concentration response curves are shown 
for control (black, n = 168 cells, seven FOVs, seven mice) and +DT conditions (light gray, n = 150 cells, seven FOVs, 
three mice). (E) Cumulative distribution of odor response strength of all mitral cells pooled across experiments, to ﬁ ve 
odors as a function of concentration under the control condition (n = 168 × 5 cell-odor pairs for each concentration) 
and after +DT injection (n = 150 × 5 cell-odor pairs for each concentration). (F) Cumulative distribution of slopes of the 
ensemble mitral cell concentration response curves separately ﬁ tted for each FOV and odor, under the control and +DT 
conditions (n = 35, seven FOVs × ﬁ ve odors). (G) Populations sparseness of mitral cell odor representations for each 
concentration under the control (black, n = 168 cells, seven FOVs) and +DT conditions (gray n = 150 cells, seven FOVs). 
Each bar denotes the mean population sparseness for ﬁ ve odors at each concentration. (H) (i) Matrix of correlation 
coefﬁ cients between the neural response spectra (length of vector = number of recorded neurons) for each odor pair 
at 1:100 dilution under the control and +DT conditions. (ii) Distribution of pairwise correlation coefﬁ cients between all 
stimulus pairs (n = 190 pairs, ﬁ ve odors at four concentrations) under the control and +DT conditions.
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constitute the fi rst representation of odor input into 
the olfactory system and hence must contain all 
meaningful attributes of the incoming odor stimulus, 
such as odor identity, intensity, and temporal dynam-
ics. Different odors activate distinct overlapping and 
nonoverlapping glomerular maps. In principle, these 
odor maps can vary in several possible features, such 
as number (how many glomeruli are activated), space 
(which glomeruli), intensity (absolute and relative 
levels of activity of individual glomeruli), and timing 
(onset with respect to each other and the order of their 
activation). Previous experiments suggest that present-
ing different odorants (A vs. B), mixtures (A and B), or 
different concentrations of the same odorant (A) may 
all result in modulation of odor maps along many (if 
not all) features. It is unknown how the downstream 
circuitry (M/T cells, olfactory cortex) interprets these 
variations and assigns meaning to them, in order to 
segregate odor identity from changes in concentration 
or components within/from a mixture.
One way to understand how the circuit makes sense 
of changes in the glomerular activity patterns to ex-
tract relevant information is to systematically alter fea-
tures of odor maps and study the concurrent changes 
in neuronal outputs and olfactory behavior. Hitherto, 
however, this has not been possible, primarily because 
of the inability to activate and modulate individual 
glomeruli in a controlled manner using odorants. We 
are using optogenetic tools to bypass odorant stimula-
tion and simulate odor-like glomerular activity pat-
terns, or alter them, by directly activating/inhibiting 
glomeruli using light in transgenic mice that express 
ChR2 or Arch in all olfactory sensory neurons (OSNs) 
or in a single type of OSN (Olf151). Furthermore, 
using patterned illumination, we are activating/inhib-
iting select subsets of glomeruli with single-glomerulus 
precision in terms of intensity, onset time, or duration. 
This approach confers unprecedented ability to effect 
feature-specifi c perturbations in a glomerular pat-
tern of choice. We aim to understand which features 
of an odor map are used by a behaving mouse under 
naturalistic conditions to identify odors and their at-
tributes such as concentration, temporal fl uctuations, 
or spatial location. Furthermore, we are testing the 
resolution at which mice can in principle detect varia-
tions within specifi c features of odor maps in a strictly 
controlled artifi cial regime. While doing so, we will 
also monitor neuronal responses at multiple layers in 
the olfactory system to compare the behavioral and 
neuronal detection thresholds and to understand the 
neuronal correlates of olfactory behavior.
To this end, we are training head-fi xed and water-
restricted mice to identify a target stimulus (“A”) as 
being unique from other nontarget (“not A”) stimuli 
by licking a “Left” versus “Right” water reward port 
placed on either side of the mouth. Animals are re-
inforced with water reward for correct choices and a 
mild air puff as punishment upon licking of the wrong 
port. We are using wide-fi eld imaging (intrinsic, fl uo-
rescence) and two-photon microscopy to monitor the 
glomerular input maps evoked by the target (“A”) and 
the non-target stimuli (“not A”) as mice learn and 
perform the task. These activity patterns are further 
used as templates to design photostimulation masks 
for perturbation of stimulus-induced activity patterns 
during behavior. Once the task has been learned to 
>85% accuracy, we reversibly perturb the stimulus 
“A” activity pattern and determine the behavioral 
Figure 2.  Cortical feedback and granule cell dynamics (A) Multiphoton imaging of cortical feedback boutons labeled with 
GCaMP5, 250 μm deep from OB surface. (B) Example odor responses from individual boutons selected in A in an awake animal. 
(C) GCs in an awake head-ﬁ xed CST-Cre mouse expressing GCaMP6f in the OB. (Right) Odor response types and their frequency 
in GC population. (From top left) Types are enhanced ON, suppressed ON, enhanced OFF, enhanced ON–OFF, suppressed ON – 
enhanced OFF.
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threshold at which an altered activity pattern is clas-
sifi ed as “not A”.
OB Coding of Puffs, Mixtures, and Sniffs
The olfactory system receives intermittent and fl uc-
tuating inputs arising from dispersion of odor plumes 
and active exploration by the animal. The highly non-
linear olfactory transduction machinery, and complex 
excitatory–inhibitory circuitry, is believed to generate 
a nonlinear population trajectory of neuronal activity 
that distinguishes odorants. In contrast, we recently 
showed (Gupta et al., 2015) that individual M/T cells 
linearly sum inputs across odors and time. By decou-
pling odor sampling from respiration, we showed that 
M/T cell responses to arbitrary odor waveforms are 
well described by an odor-specifi c impulse response 
convolved with the odorant’s temporal profi le (Fig. 
3). This linear convolution applied to respiratory 
airfl ow predicts the classical inhalation-locked fi ring 
of OB neurons and several other reported response 
properties of M/T cells. This raises interest in further 
understanding how this linear transform is achieved 
given the complexity of local microcircuits in the OB 
and feedback from other brain areas. These results 
suggest that the OB linearly processes fl uctuating 
odor inputs, thus simplifying downstream decoding 
of stimulus identity and temporal dynamics.
Investigating the Roles of Cortical Feedback 
in Invariant Odor Perception
Invariant perception refers to the identifi cation of a sen-
sory stimulus or an object of interest in a generalized 
fashion across its variable and recurring presentations. 
This is a common feature across all sensory modalities 
and becomes particularly preeminent in olfaction. Natu-
ral odor scenes are composed of odor plumes originat-
ing from multiple sources and traveling at fl uctuating 
intensities that span several orders of magnitude. Despite 
this turbulent nature of the stimulus, rodents readily 
identify odors essential for their survival against varying 
Figure 3.  Schematic of the linear model. (A) The M/T cell response is calculated by convolving the odor kernel with 
the odor waveform (measured via PID). Negative ﬁ ring rates are rectiﬁ ed after addition of the pre-odor baseline. 
Vertical bars mark odor ON periods. (B) Estimated odor kernels of three example M/T cells. Odors used are indicated 
at the left of each kernel. Odors were delivered at 1% saturation. (C) Comparison of model predictions and observed 
responses of the M/T cells in B to various time-varying odor stimuli. Vertical gray bars mark odor ON periods. Black 
lines show the observed mean ﬁ ring rate across 12 trials. Gray bands indicate S.E.M. Red lines show the nonrectiﬁ ed 
prediction from the model using the estimated kernels shown in B.
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odor-rich backgrounds and faithfully track a fl uctuating 
odor stream to its source. Several models have attempted 
to explain invariant perception in different sensory mo-
dalities. Some of these models are based on the conven-
tional view of sensory processing that relies solely on 
feed-forward information fl ow, whereas others argue that 
feed-forward mechanisms are insuffi cient and suggest 
the involvement of feedback between different neuronal 
layers. Anatomical studies show massive feedback projec-
tions from higher brain areas to the sensory periphery 
that often outnumber direct sensory inputs. The inter-
play of feed-forward and feedback signals has been pro-
posed to be fundamental for learning and memory recall.
The OB receives rich glutamatergic projections 
from the piriform cortex. However, the dynamics and 
importance of these feedback signals remain unknown. 
We use multiphoton calcium imaging to monitor cor-
tical feedback in the OB of awake mice and further 
probe its impact on bulb output. We found that the 
responses of feedback boutons are sparse, odor-specifi c, 
and often outlasted stimuli by several seconds. Odor 
presentation both enhanced and suppressed the activ-
ity of boutons. However, any given bouton responded 
with stereotypic polarity across multiple odors, pre-
ferring either enhancement or suppression. Feedback 
representations were locally diverse and differed in 
dynamics across bulb layers. Pharmacological inacti-
vation of the piriform cortex increased odor respon-
siveness and pairwise similarity of mitral cells, but had 
little impact on tufted cells (Fig. 4). We propose that 
cortical feedback differentially impacts the two out-
put channels of the bulb by specifi cally decorrelating 
mitral cell responses to enable odor separation.
We further aim to understand the role of corticobul-
bar feedback (Fig. 4) in the identifi cation of an odor, 
invariant of fl uctuations in its concentration, and/or 
timing and presence of background odors. We are tak-
ing advantage of optogenetic tools and patterned illumi-
nation techniques recently developed by our group to 
reversibly manipulate the activity of cortical feedback 
fi bers and their targets in awake head-fi xed mice, as they 
learn and perform invariant odor perception tasks. To 
mimic naturalistic odor conditions, we are making use 
of custom-designed odor delivery systems that reproduc-
ibly deliver arbitrary time-varying patterns of individual 
odors and mixtures. To understand the underlying neu-
ronal mechanisms, we monitor the activity of feedback 
inputs and their targets via high-speed scanning multi-
photon microscopy and multitetrode recordings.
Monitoring Cholinergic Input in the 
OB in Mice Engaged in Attention Tasks
Cholinergic inputs from the basal forebrain have been 
shown to enhance encoding and discrimination of vi-
sual, auditory, and somatosensory cues by modulat-
ing attention and learning processes. Although rich 
cholinergic projections innervate the mouse olfac-
tory bulb (MOB), to date, little is known about their 
contribution to olfactory behaviors. Pharmacological 
blockade of ACh action has been shown to impair 
olfactory behavior, whereas augmenting acetylcholine 
(ACh) levels improved odor discrimination. A clear 
understanding of the underlying mechanisms of ACh 
action and their spatiotemporal statistics, however, 
has been limited by the low yield of recordings from 
the basal forebrain, as well as diffi culties in ascertain-
ing the downstream targets of the recorded neurons, 
given the wide-spread and long-range nature of cho-
linergic projections.
To circumvent these issues, we are taking advan-
tage of genetically engineered mice (Chat-Cre) and 
viral strategies to target expression of calcium indica-
tors (GCaMP6) in cholinergic neurons and to opti-
cally monitor the activity patterns of the projection fi -
bers to the MOB in behaving animals (Fig. 5). We are 
pursuing two complementary strategies to gain access 
to the activity of ensembles of cholinergic neurons: (1) 
multiphoton imaging in awake head-fi xed mice (Fig. 
5C,D), which allows observation of large number of 
cholinergic projections in the MOB, with axonal reso-
lution, enabling precise spatiotemporal characteriza-
tion of their activity patterns within, as well as across, 
different circuit layers (glomerular vs. mitral cell 
layer), and (2) fi ber optic imaging in freely moving 
mice (Fig. 5E–G). Although limited to assessment of 
average population activity of cholinergic inputs, this 
approach can be easily coupled with electrophysiologi-
cal means to simultaneously monitor the OB output 
(mitral/tufted cells). Combining insights obtained via 
these two approaches will reveal how ACh action in 
the OB is linked to the timing and nature of olfac-
tory stimuli across different behavioral states. We are 
investigating how cholinergic surges in the OB dur-
ing odor detection, discrimination, and multimodal 
reversal learning tasks (switching reward contingen-
cies between olfactory and auditory stimuli) modulate 
the output of the OB and relate to behavioral perfor-
mance (Fig. 5).
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Implementing DMD-Based and Digital 
Holography Methods to Investigate in a 
Closed-Loop Fashion the Spatiotemporal 
Integration Rules in the OB and Cortex
We are implementing strategies that will enable non-
invasive, functional dissection of neuronal networks, 
with cellular resolution, in behaving animals. This 
will be brought about via a closed-loop strategy in-
volving real-time control of activity of select neurons 
with simultaneous monitoring of the concomitant 
effects of these manipulations on neuronal out-
puts within the circuit and elsewhere in the brain. 
Briefl y, we are using digital holography methods via 
spatial light modulators to optogenetically control 
neurons of interest at single-cell level and DMD-
based methods to control cell-type-specifi c popula-
tions across large brain regions (Fig. 6). This allows 
us to both replicate and systematically manipulate 
stimulus-evoked activity patterns in a circuit. We are 
Figure 4.  Cortical-bulbar feedback decorrelates the OB output. (A) Olfactory bulb (OB) circuit and neuronal types; 
OSN, olfactory sensory neurons; PG, periglomerular cells; SA, superﬁ cial short axon cells; ET, external tufted cells; 
TC, tufted cells; MC, mitral cells; dSA, deep short axon cells; GC, granule cells; CFB, cortical feedback ﬁ bers synaps-
ing onto inhibitory interneurons across the OB. (B, Top left) Average resting ﬂ uorescence of an example ﬁ eld of view 
in the MC layer (~220 μm from surface). (Bottom) Gray map showing average ﬂ uorescence change in response to γ 
terpinene in the ﬁ eld of view before (left) and after (right) muscimol injection (injected in anterior piriform cortex to 
suppress cortical activity and thus disable cortical feedback). (Top right) Histogram of the number of odors individual 
mitral cells responded to before (black bars) and after (gray trace) muscimol injection; Asterisks indicate signiﬁ cance 
level (p < 0.001, Wilcoxon-signed rank test). (C) Schematic exemplifying pairwise cell similarity and pairwise odor 
similarity calculations for a given ﬁ eld of view. (Left) Cartoon showing responses of six identiﬁ ed regions of inter-
est (ROIs) (gray outlines) within a given ﬁ eld of view across three odors; degrees of grayness indicates the average 
response amplitude (dF/F) for each ROI. (Center) An odor response spectrum (ORS) is calculated for each ROI (cell) 
as the vector containing the average dF/F for each odor; pairwise cell similarity is calculated as the uncentered cor-
relation between the ORS vectors for each pair of cells (indicated by dotted lines). (Right) A cell response spectrum 
(CRS) is calculated for each odor as the vector containing the average dF/F for each cell upon presentation of the given 
odor; pairwise odor similarity is calculated as the uncentered correlation between the CRS vectors for each pair of 
odors. (D–G) Histogram of pairwise cell (left) and odor (right) similarity of mitral cells (MC) and tufted cells (TC) before 
(black, baseline) and after (gray) muscimol injection; asterisks indicate signiﬁ cance level (p < 0.001, Wilcoxon signed 
rank test); dotted lines indicate the median.
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simultaneously using two-photon calcium imaging 
and electrophysiology within the same and differ-
ent brain regions (OB vs. olfactory cortex) to dissect 
how the alteration of select circuit elements, or their 
specifi c properties, affects the output of the network. 
This closed-loop approach will make it possible to 
determine the spatiotemporal integration rules with-
in the OB and the olfactory cortex, investigate the 
relevance of spike-time codes, and reveal underlying 
decoding schemes.
Mapping Odor Space onto Neuronal 
Representations in the Olfactory System
Unlike many other sensory systems, low-dimension-
al metrics for characterizing stimuli have remained 
elusive for olfaction, and it is unclear what features 
of chemical stimuli are represented by neurons. We 
would like to relate neural activity in the early olfac-
tory system of mice to the physicochemical proper-
ties of odorants. We imaged odor-evoked responses 
Figure 6.  Combined imaging and photostimulation setup. (Left) 
Experimental conﬁ guration, combining scanning two-photon 
imaging, DMD photostimulation, and holographic photostimula-
tion. (Right) Schematic of the experimental microscope. DMD 
stimulation is used to create spatial-temporal light patterns on the 
surface (<100 μm). Digital holography is used to photostimulate 
deeper (<500 μm) into the brain with cellular resolution. Calcium 
activity is monitored in an independent optical plane by two-
photon imaging and by electrodes in downstream brain regions. 
BE, Beam expander; SM, scan mirrors; O, objective; PMT, photo-
multiplier; SLR, camera lens; DMD, digital micromirror device; 
SLM, spatial light modulator; CCD, charge coupled device.
Figure 5. (A) Sustained attention (i) and selective attention (ii) tasks. (B) 1-mo-old cranial window over MOB; cho-
linergic axons expressing GCaMP5 imaged at 100-μm depth (150 × 150 μm ﬁ eld of view). (C) Recorded traces of 
spontaneous activity of cholinergic axons form three different ROIs (4 min, mean dF/F0 = 200%). (D) Two examples 
of cue-evoked (white lines) transients of cholinergic axon activity in awake animals. Rows represent different axon 
boutons. (Bottom) Mean (black line) and standard deviation (gray line) of all responsive axon boutons (mean dF/F for 
transients = 200%). (E) Spread of cholinergic axons expressing GCaMP5 in different layers of the MOB; injection site 
showing cholinergic cell bodies. (F) Diagram of the ﬁ ber optic imaging setup. (G) Two proofs of principle odor-evoked 
responses acquired with optical ﬁ bers from cortical feedback axons expressing GCaMP3 (left, 6-sec odor; (black bar) 
mean dF/F0 = 3%, four repeats each) recorded in the main OB. 
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in identifi ed tufted and mitral cells in awake mice 
using multiphoton microscopy. Similarity of odors 
computed through a comprehensive set of 1664 
physicochemical features was a poor predictor of 
similarity of the corresponding neuronal represen-
tation by mitral or tufted cells. Dimension reduc-
tion revealed that fewer dimensions (~12) in the 
combined neurochemical space than in neural space 
alone (~22) were required to explain 90% of vari-
ance in neural responses across the population, sug-
gesting that factors other than the physicochemical 
properties we considered are required to fully explain 
the neural responses (Fig. 7). Responsive mitral and 
tufted cells were spatially dispersed, and cells within 
a local region were functionally heterogeneous, with 
only limited and variable dependence of M/T cell 
position on odorant characteristics. Our data indi-
cate that novel descriptors are needed to link chemi-
cal space to neuronal representations and that odor 
information leaves the OB in a mosaic pattern, with 
substantial local diversity (in collaboration with the 
Koulakov lab here at CSHL).
Figure 7.  Mapping odor space on mitral cell activity patterns (A) Average resting ﬂ uorescence multiphoton image 
in the mitral cell layer. (B) Numbers indicate the relative positions of 112 mitral cell bodies in the imaged ﬁ eld of 
view. (C) Example odor response spectra of mitral cell bodies within an arbitrarily picked 75-μm diameter region in 
A, sorted according to functional chemical groups (tiglates, thiazoles, ethyl esters, aldehydes, ketones, alcohols, and 
acids). (D) Scatter plots showing odor-induced change in tufted (left) and mitral (right) cells with increasing odor con-
centration. (E) Dimensionality of odorant properties; M/T neuronal responses and M/T receptive ﬁ elds (properties 
response strength, PRS, Φ). (F) A LASSO/jackknife predictor yields a set of AP and ML cell positions that are weakly 
correlated with observed values. (G) Odor pairwise similarity across a set of 1660 physicochemical properties versus 
neuronal responses.
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Other Collaborative Projects with 
CSHL Groups
We are collaborating with other CSHL scientists on the 
following projects: DLP-based patterned stimulation 
to functionally map the motor cortex (Z.J. Huang); 
sequencing the OB—bridging the gap between glo-
merular odors responses and odor receptor sequences 
by identifying the molecular identity of glomeruli 
(A. Koulakov, J. Lee, A. Zador); fi ber-optic-based ap-
proach to monitor neuronal activity in punishment 
and reward neuronal circuits during behavior (B. Lee) 
(we are focusing on monitoring and manipulating ac-
tivity in the lateral division of the central amygdala 
and the insula cortex); developing light-sheet-based 
approaches for fast optical reconstruction of neuronal 
circuits (P. Osten); optical monitoring and manipula-
tion of neuronal activity in genetically and anatomi-
cally defi ned cortical circuits in animal models of cog-
nition (A. Zador).
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INVESTIGATING NEURAL CIRCUITS FOR SENSORY 
INTEGRATION AND DECISION MAKING
A. Churchland A. Brown A. Licata D. Nunes Raposo 
 L. Chartarifsky F. Najaﬁ  O. Odoemene
 M. Kaufman H. Nguyen M. Ryan
Making use of sensory information requires more 
than simply relaying incoming signals from the sen-
sory organs. It requires interpreting information clas-
sifying it, drawing inferences, and ultimately using 
the context of behavioral goals to make a decision 
about its meaning. A decision is a commitment to a 
particular choice or proposition at the expense of com-
peting alternatives. In some situations, decisions in-
volve integration of evidence—that is, they make use 
of multiple pieces of information from the environ-
ment or from memory. These decisions can provide a 
framework in which to investigate complex cognitive 
processes and open a window into higher brain func-
tion in general.
Although previous experiments have begun to re-
veal how neural systems combine evidence to make 
decisions, they have left a critical gap in our under-
standing. Specifi cally, very little is currently known 
about the neural mechanisms that make it possible to 
combine information from multiple sensory modali-
ties for decisions. The gap is apparent, although it is 
clear from behavioral observations that neural sys-
tems can combine multisensory information: When 
parsing speech in a crowded room, for example, the 
listener makes use of both auditory information (the 
speaker’s vocal sounds) and visual information (the 
speaker’s lip movements). Understanding the neural 
mechanisms of multisensory integration is critical 
for two reasons. First, it is essential for a complete 
understanding of sensory perception because real-
world stimuli rarely affect a single sense in isolation. 
Therefore, understanding how the brain interprets 
incoming information requires understanding how 
the brain merges information from different sens-
es. Second, it is likely of clinical importance that 
several developmental abnormalities appear to be 
related to diffi culties in integrating sensory infor-
mation. For example, abnormalities in multisensory 
processing are a hallmark of subjects with autism 
spectrum disorder. Impairments in multisensory 
processing are also observed in subjects with a col-
lection of sensory abnormalities known together as 
sensory processing disorder and may also be evident 
in patients with Rett syndrome and dyslexia. Un-
derstanding the neural mechanisms of multisensory 
integration could inform treatment of those condi-
tions. Our long-term goal is to understand how the 
brain can make decisions that integrate inputs from 
our multiple senses, stored memories, and innate 
impulses. Our projects in previous years constituted 
the very fi rst steps toward achieving this goal: We 
developed a multisensory behavior that could be 
carefully measured in both humans and rodents 
(Raposo et al., J Neurosci 32: 3726 [2012]; Shep-
pard et al., J Vision 13: 1 [2013]). In addition, we 
built on the foundation by measuring the responses 
of neurons in rodents engaged in the behavior, af-
fording insight into the neural circuits underlying 
multisensory decisions.
The Role of Parietal Cortex in 
Multisensory Decision Making
M. Ryan, A. Licata [in collaboration with D. Raposo, 
Champalimaud Neuroscience Program, Lisbon, Portugal; 
M. Kaufman, Stanford University]
The goal of this project is to gain a deeper under-
standing of the neural circuits that enable integration 
of visual and auditory inputs for decision making. 
David Raposo has been a leader in the lab in two 
techniques this year: He measures electrophysiologi-
cal responses from neurons in the posterior parietal 
cortex (PPC) of rats engaged in decision-making 
behavior. He presented this work at two conferences 
(Raposo et al. 2013). In addition, David inactivated 
124  Research
those same neurons and measured the effect on be-
havior (Raposo and Churchland, Soc Neurosci Abs 
2013). Matt Kaufman has worked alongside David to 
develop sophisticated analyses of the data. John Shep-
pard has also contributed to the project by recording 
additional neurons that are included in our grow-
ing population of cells. John, David, and Matt are 
working as a group; their main fi nding is that PPC 
neurons refl ect random combinations of stimulus 
features, but they can be decoded at the population 
level to provide the animal with ongoing estimates 
of incoming sensory stimuli. The three are working 
collectively to write up the exciting results from these 
experiments for publication.
Population Dynamics across Cortex
This work was done in collaboration with M. Kaufman 
(Stanford University)
The goal of this project is to understand how popu-
lation activity changes from one neural structure to 
the next to support behavior. To tackle this ques-
tion, Matt has brought a new technique to the lab: 
two-photon imaging. Using this technique, we can 
measure the responses of 80–100 neurons simulta-
neously. This approach will revolutionize the kinds 
of questions we can address about decision making, 
especially when used in conjunctions with emerging 
mathematical techniques for analysis. We have ben-
efi ted greatly in this project from technical support 
from the Albeanu lab, our neighbors in the Marks 
building, and valued collaborators. This year, Matt 
was supported by a grant from the Swartz Founda-
tion. He presented data from our Nature Neuroscience 
paper (on which he was the co-fi rst author) at the An-
nual Meeting of the Swartz Foundation in Seattle, 
Washington.
Multisensory Integration Mechanisms
This work was done in collaboration with L. Chartarifsky 
(Watson School of Biological Sciences)
The goal of this project is to understand how the 
brain estimates the reliability of sensory stimuli and 
uses that estimate to guide decision making. To re-
veal mechanisms that support this behavior, Lital 
Chartarifsky will use multisensory stimuli (called 
“confl ict stimuli”) in which information from the 
two modalities differ. In Lital’s experiments, these 
will be auditory and visual stimuli that differ in their 
number. She will leverage a large body of human lit-
erature that has explored these behaviors and will 
bring them to a powerful rodent model to elucidate 
neural mechanisms.
Decision Making in Mice
H. Nguyen [in collaboration with F. Najaﬁ , University of 
Pennsylvania; O. Odoemene, Watson School of 
Biological Sciences]
We have developed a decision-making paradigm 
using mice that will allow us to take advantage of 
genetic tools. These tools will also allow us to probe 
the neural circuitry that underlies decision making. 
In the past year, Onyekachi Odoemene has sought 
to establish which neural structures in mice are crit-
ical for decision making. He is using cutting-edge 
techniques to inactivate different structures and 
examine the effect on behavior. By using different 
strains of transgenic mice, Onyekachi is able to tar-
get particular cell types within each area and exam-
ine how they contribute to behavior. This project 
had benefi ted greatly from our collaborator Dr. Z. 
Josh Huang, who has provided us with materials for 
experiments and also with invaluable advice on un-
derstanding inhibitory circuitry. Support has been 
provided by a new research technician, Hien Nguy-
en, who has developed new training paradigms for 
mice and designed new devices for measuring neural 
responses.
A new postdoctoral fellow in the lab, Farzaneh 
 Najafi , is the newest member of the team studying 
decision making in mice. Her expertise is in imaging 
neurons in animals during behavior and connect-
ing the two using advanced analyses. She will bring 
these skills to the decision-making paradigms we use 
here, with an emphasis on understanding animal’s 
strategies and how they infl uence behavior and neu-
ral  responses.
Bayesian Number Estimation
A. Brown
This project aims to understand whether humans 
use a probabilistic approach to number estimation, 
and it is part of an international collaboration with 
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Dr. Alexandre Pouget (University of Geneva). This 
work challenges a long-standing assumption about 
human number estimation—that numbers are esti-
mated as scalar quantities. Our experiments suggest 
that the assumption is not correct. Instead, humans 
appear to represent numbers probabilistically, and a 
signature of this representation is evident when they 
combine number estimates from two modalities. 
We completed the project this year and have submit-
ted a manuscript for publication.
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MECHANISMS OF NEURODEGENERATION AND 
MEMORY FORMATION
J. Dubnau R. Borges Monroy W. Li M.F. Shih
 L. Krug L. Prazak 
There are two main areas of research in my lab. First, 
we are using neurogenetic and genomics approaches to 
investigate a novel hypothesis to explain neurodegen-
erative disorders such as frontotemporal lobar degen-
eration and amyotrophic lateral sclerosis. Second, we 
are investigating genetic and neuronal mechanisms of 
memory formation using Drosophila as a model system.
Impact of Retrotransposons on Aging 
and Neurodegeneration Underlying 
Frontotemporal Lobar Degeneration 
and Amyotrophic Lateral Sclerosis
R. Borges, L. Krug, L. Prazak, J. Dubnau [In collaboration 
with M. Hammell and Y. Jin, Cold Spring Harbor 
Laboratory]
Transposable elements (TEs) are mobile genetic ele-
ments that provide a massive reservoir of potential 
genetic instability and toxicity. We have advanced the 
novel hypothesis that deregulated TE/ERV (endog-
enous retrovirus) expression may contribute to TDP-
43-mediated neurodegenerative disorders (Li et al. 
2013). We have found that TE transcripts are dere-
pressed during the normal aging process and that this 
leads to active mobilization of transposons, resulting 
in new insertions in the genome of neurons. We used 
mutations in Drosophila Argonaute 2 (dAgo2) to cre-
ate a situation in which TEs are derepressed in the 
brain. Such mutants exhibit precocious TE elevation 
in young animals and exacerbated age-dependent dere-
pression. This is accompanied by rapid age-dependent 
memory impairment and shortened life span. These 
fi ndings support the hypothesis that protracted loss of 
TE silencing contributes to age-dependent decline in 
neuronal physiological function.
To investigate the hypothesis that TE derepression 
contributes to neurodegenerative disorders, we fo-
cused (in collaboration with Molly Hammell and Ying 
Jin) on TDP-43, an RNA-binding protein involved 
in a broad spectrum of neurodegenerative disorders 
including amyotrophic lateral sclerosis (ALS) and 
frontotemporal lobar degeneration (FTLD). As a 
fi rst foray into the role of TDP-43 in transposon con-
trol, we mined a series of deep sequencing data sets 
of protein–RNA interactions and of gene expression 
profi les and uncovered broad and extensive binding 
of TE transcripts to TDP-43 (Li et al., PLoS One 7: 
e44099 [2012]). We also found that association be-
tween TDP-43 and many of its TE targets is reduced 
in FTLD patients. Finally, we discovered that a large 
fraction of the TEs to which TDP-43 binds become 
derepressed in mouse TDP-43 disease models. On the 
basis of these fi ndings, we propose the hypothesis that 
TE misregulation contributes to TDP-43-related neu-
rodegenerative disease. This hypothesis is now being 
tested using a Drosophila model and examining post-
mortem human tissue from ALS patients.
We have used an established Drosophila model of 
TDP-43 neurodegeneration to test the hypothesis that 
transposons contribute to the underlying pathology. 
On the basis of the bioinformatics analyses of sequenc-
ing studies in mouse, rat, and human (see above), we 
predict that aggregation pathology of the TDP-43 pro-
tein will disrupt the normal mechanisms of transposon 
silencing, leading to a storm of awakened transposons. 
Indeed, we fi nd that overexpression of human TDP-43 
in Drosophila leads to activation of gypsy transposon 
expression (L. Krug et al., in prep.). Interestingly, the 
TDP-43 pathology in glial cells shows more dramatic 
gypsy expression than manipulation solely in neurons. 
This is accompanied by apoptotic cell death, progressive 
defects in locomotion, and shortened life span. More-
over, using reporter systems, we have established that 
TDP-43 expression leads to a disruption of the normal 
cellular systems to silence transposons. Together, these 
fi ndings support the idea that a storm of unregulated 
transposons contributes to TDP-43-mediated neurode-
generation. This idea is now being tested using post-
mortem tissue from ALS and FTLD patients.
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Age-Dependent Cognitive Decline 
and Retrotransposon Activation
L. Prazak
On the basis of our observation that certain ret-
rotransposons become highly active during normal 
brain aging, we are investigating the hypothesis that 
retrotransposon-generated DNA damage contributes 
to age-related neuronal decline. Using the toolbox for 
genetic manipulations that are available in Drosophila, 
we are (1) investigating the normal mechanisms of ret-
rotransposon silencing in the brain, (2) testing the im-
pacts of age and stress on these cellular mechanisms, 
and (3) testing whether retrotransposon activation has 
a causal role in age-related cognitive impairment.
Neurogenetic Mechanisms of 
Olfactory Memory
M.F. Shih
An understanding of memory, indeed of all behav-
ioral phenotypes, will require a multidisciplinary ap-
proach to forge conceptual links between the relevant 
genetic/cell signaling pathways and neural circuits. 
Work in genetic model systems such as Drosophila can 
contribute to our understanding in several ways. First, 
by enabling discovery of genes and genetic pathways 
underlying normal memory as well as pathological or 
degenerative cognitive disorders, model systems pro-
vide entry points for dissection of cellular mechanisms 
that are often conserved. Second, systematic manipu-
lation of gene function within relevant anatomical cir-
cuits allows a conceptual integration of fi ndings from 
cellular, neuroanatomical, and behavioral levels.
Our current work on this topic is focused on forg-
ing links between gene function and neural circuitry. 
We are using cell-type-specifi c genomic approaches 
to identify memory-induced transcriptional chang-
es within each of the neuronal cell types that form 
part of the circuit for olfactory memory processing in 
 Drosophila.
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STEM CELLS, SIGNAL TRANSDUCTION, AND BRAIN FUNCTION
G. Enikolopov T. Michurina J.H. Park N. Peunova
Our main focus is on stem cells in the adult organism 
and on signals controlling their maintenance, divi-
sion, and fate. Most of our effort is directed at stem 
cells of the adult brain and on the signaling landscape 
of the neural stem cell niche. We are also interested 
in stem cells in nonneural tissues, with a particular 
focus on those tissues and organs that are involved in 
complex physiological circuits and major physiologi-
cal and behavioral responses of the organism. We also 
study how diffusible signaling molecules affect stem 
cell maintenance, differentiation, and interactions 
with their local environment. Furthermore, we work 
to generate new genetic tools that would allow track-
ing multiple signaling events in a cell or a tissue. Be-
sides the main goal of elucidating the molecular logic 
of stem cell control, we consider these studies as an 
entry point for designing therapeutic interventions to 
ameliorate the effects of aging or disease.
Neural Stem Cells
The key focus of our group is on adult neurogenesis. 
Production of new neurons is important for behav-
ior, pathophysiology, aging, and neural tissue repair 
in adult humans and animals. New neurons are born 
from neural stem cells that are maintained at specifi c 
locations in the adult brain. Continuous drive toward 
a differentiated state starts as soon as an activated stem 
cell produces progeny destined to become a neuron. 
Neural stem cells are the only source of new neurons 
in the adult brain (in contrast to the situation in a 
number of tissues, e.g., liver and pancreas, where fully 
differentiated cells can be activated to produce simi-
lar differentiated cells). Therefore, our understanding 
of the features and the role of new neurons depends 
on the ability to identify adult stem cells, trace their 
lineage, and reveal basic mechanisms governing their 
maintenance, division, differentiation, and death.
Our main approach is generating animal models 
that would enable visualization of stem cells and their 
environment and monitoring of their signaling land-
scape. The use of such model reporter mouse lines 
allowed us to develop a new model for the quiescence, 
maintenance, and division of the adult hippocampal 
stem cells (Cell Stem Cell, 2011). Our results indicate 
that adult neural stem cells may remain quiescent for 
their entire postnatal life; however, when activated, 
they rapidly divide several times in quick succession 
to bud off daughter cells that eventually yield neu-
rons, while the remaining stem cell differentiates into 
a mature astrocyte, thus leaving the stem cell pool. 
Hence, most hippocampal stem cells can be described 
as a “single-use” or a “disposable” unit, used in adult-
hood only once and then abandoned in its stem cell 
capacity. We also found that astrocytic differentiation 
of hippocampal stem cells is tightly coupled to their di-
vision, that all dividing stem cells of the hippocampus 
convert into astrocytes, and that new astrocytes of the 
dentate gyrus (DG) derive from these stem cells. We 
found that the decrease in the number of new neurons 
that accompanies aging is driven by the disappearance 
of stem cells via their division-coupled astrocytic differ-
entiation. This continuous loss of stem cells underlies 
age-dependent diminished production of new neurons 
and may contribute to age-related cognitive impairment.
During the last several years, we have applied our 
model and our reporter lines to determine the classes 
of stem and progenitor cells that are affected by vari-
ous pro- and antineurogenic factors. We found that in 
the adult brain, stem cell output can be increased in 
different ways and that various pro- and antineuro-
genic stimuli affect defi ned targets in the neurogen-
esis cascade. Importantly, we found that each mode 
of augmented production of new neurons may have 
different effects on the pool of stem cells, with impor-
tant implications. For instance, some antidepressant 
treatments (e.g., fl uoxetine or deep brain stimulation) 
do not affect stem cells, but instead target rapidly am-
plifying progenitor population. Another antidepres-
sant therapy (electroconvulsive shock) increases the 
number of asymmetric divisions of stem cells without 
recruiting additional stem cells (and therefore leads to 
an increased number of new neurons without addi-
tional loss of stem cells). Some clinically used com-
pounds increase recruitment of normally quiescent 
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stem cells in division, potentially leading to an in-
crease in new neurons at the expense of premature 
exhaustion of the stem cell pool. These fi ndings high-
light the potential clinical relevance of our studies and 
may have direct implications for human therapy. Our 
results warn that any drug or therapeutic treatment 
that involves changes in neurogenesis should be inves-
tigated for the precise mechanisms of those changes, 
because seemingly identical outcomes may be induced 
by very different mechanisms and with very different 
long-term consequences.
Complementing our investigation of the basic mech-
anisms of stem cell regulation, much of our current ef-
fort focuses on developing new methods to study adult 
neurogenesis. These approaches include the  following:
1. Triple S phase labeling of dividing stem cells. We have 
developed a new method for analyzing the division 
of stem and progenitor cells. This method is based 
on sequential labeling with three different nucleotide 
analogs on the background of green fl uorescent pro-
tein (GFP)-labeled cells (i.e., quadruple labeling). Our 
method brings a qualitative improvement to the analy-
sis of kinetics of cell division and to the tracing of mul-
tiple cell populations. We are currently applying this 
new approach to determine the changes in neural stem 
cell division and differentiation upon aging, physical 
activity, neuronal damage, and response to drugs.
2. Serial two-photon tomography: Three-dimensional 
representation of neural stem cells. We are applying a 
new method of serial two-photon tomography to our 
reporter mouse lines to produce quantitative three-
dimensional representations of changes in stem and 
progenitor cell populations in the adult brain (in 
collaboration with Dr. Pavel Osten, CSHL). We 
can visualize and quantify the entire complement of 
stem and progenitor cells, as well as cells with a stem 
cell potential, in the major neurogenic zones and in 
less-studied regions of the adult brain (e.g., the cir-
cumventricular organs). We are now applying serial 
two-photon tomography to reveal changes due to age 
or treatment with neurogenesis-related drugs.
3. Metabolic profi ling of dividing cells by MRS (PLoS One, 
2014). In collaboration with Dr. Helene Benveniste 
(Stony Brook University), we have applied proton 
magnetic resonance spectroscopy (1HMRS) and a 
widely used spectral fi tting algorithm (LCModel) to 
characterize the metabolic changes in the live rodent 
brain after electroconvulsive shock or in glioblastomas 
with actively dividing cells, paralleling these changes 
to postmortem histology. LCModel processing reveals 
 elevated signals related to the division of stem cells 
in glioblastomas, suggesting that a higher density of 
actively dividing cells is necessary for the LCModel 
suite to reliably detect corresponding metabolic profi les.
4. Using MIMS to study stem cell division and turnover. 
We have collaborated with Dr. Claude Lechene 
(Harvard Medical School), who has developed the 
multi-isotope imaging mass spectrometry (MIMS) 
approach for biological studies, to investigate division 
and maintenance of stem cells in the adult brain. Our 
results with long-term labeling of stem cells and their 
progeny with stable isotope 15N-labeled thymidine are 
fully compatible with our proposed model of “dispos-
able” adult stem cells (but not with the conventional 
model of recurrent stem cell quiescence). A similar 
approach can be used to detect the turnover of other 
macromolecules, and we are currently using combina-
tions of stable isotopes to label both DNA and protein 
and follow metabolic changes in adult stem cells.
5. Computational modeling and cell-counting algorithms. In 
collaboration with Dr. Alex Koulakov here at CSHL, 
we continue to develop a general framework for compu-
tational modeling of stem and progenitor division and 
differentiation in the adult brain. This model incorpo-
rates several key kinetics parameters that can be inde-
pendently manipulated to cover most of the complex 
interconversion schemes for dividing and differentiat-
ing cell populations. We use this model to determine 
age-related changes in specifi c subpopulations of qui-
escent and amplifying progenitor, astrocytes, neuro-
blasts, and neurons. Furthermore, we developed a new 
algorithm for counting labeled nuclei in sections and 
three-dimensional images of the developing and adult 
brain. This protocol is faster and more precise than 
most of the available commercial suites for cell count-
ing and will accelerate analysis of adult neurogenesis.
Stem Cells in Nonneural Tissues
We began engineering reporter mouse lines to visual-
ize, track, and isolate neural stem cells more than 15 
years ago and some of our reporter lines (e.g., Nestin-
GFP mice, J Comp Neurol, 2004) became widely used 
genetic tools. These lines were originally designed to 
identify stem cells in the nervous system; however, 
we soon found the same reporter lines (Nestin-GFP, 
Nestin-CFPnuc, or Nestin-mCherry) help to discover 
stem and progenitor cells in a range of other tissues 
as diverse as anterior pituitary, skeletal muscle, testis, 
hair follicles, liver, pancreas, retina, or bone marrow. 
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We identifi ed some of those nonneuronal stem cell 
species in our group, while other types were studied in 
collaboration with other research groups. Of the fi nd-
ings with nonneural stem cells, we will mention most 
recent results with subtypes of pericytes in the skeletal 
muscle, liver oval cells (Cell, 2014), and stem cells in 
the adult adrenal medulla (Stem Cells, 2015).
NO, Development, and Differentiation
During the last two decades, we have investigated the 
diversity of biological functions mediated by nitric oxide 
(NO) and discovered the essential role that NO has in 
development, differentiation, and stem cell regulation. 
NO potentiates weak calcium signals (Nature, 1993), 
mediates neuronal differentiation (Nature, 1995), regu-
lates Drosophila imaginal disk development (Cell, 1996), 
controls brain development (J Neurosci, 2001) and adult 
neurogenesis (Proc Natl Acad Sci, 2003), and coordi-
nates cell proliferation and cell movements during early 
development (Cell Cycle, 2007). We have uncovered a 
novel function of NO and thus our current focus is on 
the role it plays in the development and function of cilia 
in multiciliated cells of the mucociliary epithelium. We 
found that in such diverse settings as mouse trachea 
and embryonic frog skin, NO synthase is crucial for the 
main function of the motile cilia: to beat in concert and 
generate directed fl ow of fl uid across tissue. In the tra-
chea and bronchi, this fl ow helps to clear pathogens, for-
eign particles, and toxic chemicals from the airways. We 
identifi ed evolutionary conserved signaling pathways 
controlling cilia distribution, polarity, and function and 
found that genetic defects in cilia function can be res-
cued by NO-releasing compounds. Our recent results 
suggest that NO may similarly contribute to cilia func-
tion in other types of ciliary epithelium; furthermore, 
they suggest that certain inborn and acquired human 
ciliopathies and related disorders may also be associated 
with decreased availability of NO and may benefi t from 
NO-based therapies.
Genetically Encoded Sensors
We have recently launched a new direction, aimed at vi-
sualizing multiple signaling fl uxes in real time using ge-
netically encoded sensors and elucidating the signaling 
landscape of the neural stem cell niche. Our particular 
focus is on reactive oxygen species (ROS), because redox 
signaling emerges as a regulatory network that is criti-
cal for supporting metabolism and homeostasis of stem 
cells and contributing to aging and disease. To that end, 
we are developing a new platform for genetically en-
coded redox sensors characterized by greatly improved 
quantum yield, contrast, sensitivity, and expanded 
palette. Our system reports changes in redox status in 
various cell compartments using four separate channels, 
as well as changes in redox signals in parallel to other 
types of signals (e.g., calcium, pH, or NAD(H)), thus 
approaching our goal of multiparametric monitoring of 
signal fl uxes and cell activity. Currently accomplished 
projects (performed in collaboration with Dr. Vsevolod 
Belousov, a Visiting Scientist in the group) related to 
genetically encoded sensors include the following:
1. Genetically encoded fl uorescent indicator for imaging 
NAD+/NADH ratio (BBA, 2014). The ratio of NAD+ to 
NADH is a key indicator that refl ects the overall redox 
state of the cells. We developed and validated a new 
genetically encoded probe for NAD(H) using redox-
sensitive protein domains from Thermus aquaticus. Our 
RexYFP sensor has several advantages over existing sen-
sors such as small size and optimal affi nity for differ-
ent compartments. We demonstrated that the affi nity 
of the probe enables comparison of NAD+/NADH in 
compartments with low (cytoplasm) and high (mito-
chondria) NADH concentration. Thus, RexYFP is an 
effi cient sensor, suitable for detecting the NAD(H) 
redox states in different cellular compartments.
2. Sensor-generator pairs to evaluate redox production and 
signaling (ARS, 2014). Yeast D-amino acid oxidase 
(DAO), activated by externally added D amino acids 
(e.g., D-alanine), can serve as a genetically encoded 
producer of ROS. We found that DAO, fused to or 
cotransfected with a genetically encoded H2O2 indi-
cator (HyPer), can be used for controlled production 
and detection of ROS in living eukaryotic cells. Our 
results show the utility of the HyPer-DAO genetically 
encoded system for redox signaling studies, indicate 
profound heterogeneity in ROS  production dynamics 
between individual cells, and suggest that H2O2 pro-
duced by DAO in the cytoplasm acts locally in close 
proximity to the enzyme.
3. Red fl uorescent genetically encoded indicator for intracel-
lular hydrogen peroxide (Nat Comm, 2014). Currently 
available recombinant redox sensors have green emission, 
which overlaps with the spectra of many other probes. 
Expanding the spectral range of recombinant ROS 
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probes would enable multiparametric in vivo ROS 
detection. We generated a genetically encoded red 
fl uorescent sensor for H2O2 detection, HyPerRed, and 
demonstrated the utility of the sensor by tracing low 
concentrations of H2O2 produced in the cytoplasm of 
cultured cells upon growth factor stimulation. More-
over, using HyPerRed, we were able to detect local 
and transient H2O2 production in the mitochondrial 
matrix upon inhibition of endoplasmic reticulum 
Ca2+ uptake.
We are now applying our multicolor redox sensor plat-
form for multiparametric imaging of signaling events 
in stem cells and transgenic animals.
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MOLECULAR ANALYSIS OF NEURONAL RECEPTORS 
AND ION CHANNELS
H. Furukawa E. Karakas A. Romero Hernandez
 T. Malinauskas N. Simorowski
 M. Regan N. Tajima
The research program in our lab attempts to under-
stand the molecular basis for the functions of recep-
tors and ion channels at the cellular membrane that 
initiate cellular signal transductions involved in neu-
rotransmission in the mammalian brain and in the 
process of neurological diseases and disorders includ-
ing schizophrenia, depression, stroke, and Alzheimer’s 
disease. Toward achieving our goals, we have been 
focusing on understanding various functional aspects 
of ion channels called N-methyl-d-aspartate receptors 
(NMDARs) that control intracellular calcium signaling 
upon stimulation by voltage and/or neurotransmitters. 
NMDARs are ligand-gated ion channels that regulate 
neurotransmission, the fundamental process whereby 
multiple neurons communicate with one another. Dys-
function of the NMDAR ion channels has a strong link 
to the neurotoxicity that results in various neurological 
disorders and diseases described above. We use X-ray 
crystallography and cryo-electron microscopy to de-
termine three-dimensional atomic structures and test 
structure-based mechanistic hypotheses by site-direct-
ed mutagenesis in combination with biochemical and 
biophysical techniques. We also use structural informa-
tion to develop compounds with therapeutic potential 
for treating the neurological disorders described above. 
Our main accomplishment in 2014 was to establish an 
effective heterologous expression method suitable for 
assembling heteromeric membrane protein complexes 
such as NMDARs and the completion of the fi rst crys-
tal structure of the intact heterotetrameric NMDAR 
that contains the entire extracellular domain and the 
transmembrane ion channel pore domain.
Production and Biochemical 
Characterization of Heteromultimeric 
NMDAR Complexes
We have established a novel expression system that 
facilitates the assembly of heteromeric membrane pro-
teins such as NMDARs. In achieving this, we con-
ducted various constructs of NMDARs that contain 
the GluN2B subunit, which is carboxy-terminally 
truncated, and the GluN1 subunit, which is carboxy-
terminally fused to enhanced green fl uorescent protein 
(EGFP), to allow (1) screening of host cells including 
Sf9 and High Five insect cells, HEK293, CHO, and 
Cos7 mammalian cells; (2) screening of expression 
systems including transient transfection, production 
of stable cell line, and baculovirus-mediated protein 
production; and (3) screening of promoters including 
CMV, IE1 and IE2, WSSV, and Hsp70 promoters. 
Expression, subunit assembly, and size homogeneity 
were assessed by fl uorescence-coupled size-exclusion 
chromatography that detects the proteins of interest 
by fl uorescence (in this case, the EGFP signal derived 
from the GluN1-EGFP fusion protein). Of all com-
binations tested, the following produced the fully 
assembled NMDARs: (1) HEK293 in combination 
with the CMV promoter and with either transient 
transfection or baculovirus-mediated DNA incorpo-
ration and (2) Sf9 or High Five cells in combination 
with the CMV or Hsp70 promoter and with baculo-
virus-mediated DNA incorporation. Of all host cell/
promoter/expression system combinations, expression 
in Sf9 cells in combination with the baculovirus har-
boring the Hsp70 promoter gave the highest level of 
expression (~0.1 mg of purifi ed proteins per liter Sf9 
culture). This expression system has been instrumen-
tal to successful structural studies outlined in Aim 2. 
In addition, this expression system is now distributed 
to approximately 20 laboratories interested in express-
ing membrane proteins.
Structural and Functional Studies on Intact 
Heteromultimeric NMDARs
By taking full advantage of the protein production 
system we established above, we have completed the 
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work showing the fi rst crystal structure of heterotetra-
meric NMDARs, which contains the entire extracel-
lular domain including an amino-terminal domain 
(ATD), ligand-binding domain (LBD), and the trans-
membrane domain (TMD). In general, this study 
marked the fi rst crystal structure of the heteromeric 
ion channel or of the eukaryotic heteromeric mem-
brane proteins reconstituted in a recombinant expres-
sion system. Toward solving the crystal structure of 
NMDAR, we have optimized the construct to im-
prove protein stability and crystallizability. This led 
to the construct GluN1a/2Bcryst, which contains a 
number of point mutations that reduce the number 
of free cysteine residues and N-linked glycosylations, 
and truncations that eliminate the carboxy-terminal 
domain (CTD) and the linker between the ATD and 
the LBD in GluN2B.
The GluN1a/2Bcryst construct was crystallized 
in the presence of the GluN1 agonist, glycine; the 
GluN2 agonist, glutamate; and an ATD-binding allo-
steric inhibitor, ifenprodil. The structure was initially 
solved at 5.7 Å by molecular replacement using the 
structures of the ATD and LBD as search probes. To 
improve the diffraction power of these crystals, we 
stabilized the heterotetrameric subunit interactions by 
forming intersubunit disulfi de cross-links at the ex-
tracellular and juxtamembrane regions based on the 
5.7-Å structure above. These construct manipulations 
improved the diffraction limit to beyond 4 Å, which 
resulted in electron density suffi cient to build most of 
the GluN1a/2B NMDAR including all the extracellu-
lar domains, TMD, linkers between ATD and LBD, 
and linkers between LBD and TMD.
The GluN1a/GluN2B NMDAR bound to gly-
cine, l-glutamate, and ifenprodil is shaped like a 
“hot-air balloon” where a balloon and a basket cor-
respond to the entire extracellular domains and the 
TMD, respectively. The structure has a clear bound-
ary between the layers of LBD and TMD, whereas 
ATD and LBD appear as a single unit. Both ATD 
and LBD form two GluN1a-GluN2B heterodimers 
that are assembled as a GluN1-GluN2-GluN1-
GluN2 (1-2-1-2) heterotetramer where the twofold 
symmetry axis runs across the center of the molecule 
through the interface between the two GluN2B 
ATDs to the middle of the ion channel pore (Fig. 1). 
The overall shape of GluN1a/GluN2B NMDAR 
is highly distinct from that of the homotetrameric 
GluA2 AMPAR (α-amino-3-hydroxy-5-methyl-4-
isoxazole propionic acid receptor), another member 
Figure 1. First crystal structure of heterotetrameric NMDARs. We crystallized the GluN1a/GluN2B NMDARs without 
CTD. The heterotetramers are formed as a dimer of heterodimers in the GluN1-GluN2B-GluN1-GluN2B arrange-
ment in each domain layer. Interestingly, dimer pairs are swapped between ATD and LBD.
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of the iGluR family, which has an overall “Y” shape. 
This difference in the overall architecture is attrib-
uted to the fact that ATD and LBD pack tightly 
through numbers of well-defi ned interdomain inter-
faces in GluN1a/GluN2B NMDARs, whereas ATD 
and LBD interact minimally in GluA2 AMPARs. 
This surprisingly “compact” architecture of GluN1a/
GluN2B NMDAR stems from the intersubunit and 
interdomain interactions over large surface areas that 
are unique to NMDARs.
The TMD of GluN1a/GluN2B NMDAR forms 
the heterotetrameric ion channel with pseudo four-
fold symmetry. The ion channel of GluN1a/GluN2B 
NMDAR is similar to the closed state of GluA2 
AMPARs and KcsA bacterial potassium channels. 
In this plausible allosterically inhibited state, the ion 
channel is closed to an extent similar to the closed 
channels of AMPAR and KcsA. One of the key func-
tions of NMDARs is their high permeation of cal-
cium ions, which has a major role in neuronal plas-
ticity as well as excitotoxicity. The crystal structure 
complexed with holmium, a lanthanide known to 
recognize calcium-binding sites in many biological 
macromolecules, shows the binding in between the 
LBD-TMD linkers of GluN1 right above the center 
of the ion channel (Fig. 2). A set of acidic residues 
in GluN1 (DRPEER motif ) located in this region 
has been shown previously to be a critical part of 
high calcium fl ux characteristic of NMDARs. Thus, 
the lanthanide-binding site along with the previ-
ous electrophysiological study further confi rms the 
physiological relevance of the current crystal struc-
ture. However, despite extensive efforts, the region 
of TMD that determines voltage-dependent Mg2+ 
block and Ca2+ permeation was not clearly resolved 
in this crystal structure. A structure-based under-
standing of ion selectivity and fl ux regulation thus 
remains to be achieved.
The current work on GluN1a-GluN2B NMDARs 
marks the fi rst crystal structure of a heteromeric 
ion channel. The structure will serve as a template 
for designing experiments that further address the 
complex function of NMDARs. Furthermore, the 
defi ned subunit and domain interfaces should serve 
as an invaluable blueprint for binding sites for po-
tential compounds leading to design of therapeutic 
compounds, an example of which is described in the 
next section.
Locating Novel Compound Binding Site 
in NMDAR
The crystal structure of the intact heterotetrameric 
NMDAR now provides a solid foundation for predicting 
compound binding sites—especially the those located at 
the subunit or domain interface. In collaboration with 
James Snyder and Stephen Traynelis at Emory Univer-
sity, we have used the crystal structure described above 
to predict the binding site of a novel compound called 
PYD-106 that binds GluN2C- containing NMDAR. 
A homology model for GluN2C was built using the 
above crystal structure with the program Modeler. On 
the basis of knowledge gained from electrophysiological 
data that binding of the compound may involve residues 
from both ATD and LBD of GluN2C, the molecular 
model of PYD-106 was docked to the ATD-LBD 
interface of the GluN1/GluN2C homology model. 
Figure 2. Plausible calcium binding site at the juxtamembrane 
site. Shown here is an anomalous difference Fourier map ob-
tained from diffraction data of crystals soaked against holmium. 
Holmium has been previously shown to bind calcium-binding 
site.
Figure 3. Prediction of novel compound binding site. Homol-
ogy model of GluN1/GluN2C NMDAR built based on the crystal 
structure of GluN1/GluN2B NMDAR. Docking study shows that 
PYD-106 may be binding at the domain interface between ATD 
and LBD.
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The binding site residues were energy-minimized to 
obtain the most likely mode of compound binding 
(Fig. 3), which is consistent with electrophysiology 
data.
Overall, our work has provided an important foun-
dation for understanding the structural and function-
al mechanism of NMDARs in unprecedented detail. 
We are continuing our effort to provide structural 
understanding of subtype specifi city in NMDARs to 
further support development of therapeutic agents.
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ASSEMBLY AND FUNCTION OF NEURAL CIRCUITS 
IN THE NEOCORTEX
Z.J. Huang X. An S. Kelly J. Levine M. Moissidis J. Tucciarone
 D. Huilgol K. Krishnan J. Lu A. Paul P. Wu
We aim to understand the developmental assembly 
and functional organization of neural circuits in the 
cerebral cortex. The neocortex consists of a constella-
tion of functional areas that form a representational 
map of the external (sensory, social) and internal (vis-
ceral, emotional) world. These areas are strategically 
interconnected into elaborate networks that support 
dynamic operations that process information and 
guide intelligent behavior. Our overarching hypothesis 
is that, at the cellular level, cortical processing streams 
and output channels are mediated by a large set of dis-
tinct glutamatergic pyramidal neurons (PyNs), and 
functional PyN ensembles are regulated by a diverse 
yet distinct set of GABAergic interneurons (INs). We 
systematically build cell-type genetic tools that in-
tegrate a full set of modern techniques for exploring 
neural circuits. Building on our success in genetic tar-
geting of GABA INs, we have recently extended this 
effort to PyNs. We combine a range of approaches that 
include genetic and viral engineering, cell-type gene 
expression, genetic fate mapping, imaging, electro-
physiology, and behavior analysis. This progress allows 
us to integrate our studies in the context of the motor 
cortex control of volitional forelimb movements and 
motor learning.
Genetic Targeting of Pyramidal Neuron 
Subtypes in the Mouse Neocortex
A key obstacle to studying the development, organiza-
tion, and function of neural circuits in the cerebral cor-
tex is the stunning diversity of neuron types and a lack 
of comprehensive knowledge about their basic biology. 
The problem of neuronal diversity and identity in the 
cortex is fundamental, transcending developmental and 
systems neuroscience, and lies at the heart of defi ning 
the biology of cognition and psychiatric disorders. PyNs 
constitute ~80% of cortical neurons, are endowed with 
a large capacity for information coding, storage, and 
plasticity, and carry the output of cortical computation. 
PyNs consist of diverse subtypes based on their specifi c 
laminar locations, axonal projection patterns, and gene 
expression profi les. Subsets of PyNs form multiple and 
hierarchical subnetworks of information processing, 
with distinct output channels to cortical and subcorti-
cal targets that subserve sensory, motor, cognitive, and 
emotional functions. Importantly, PyN subtypes are 
differentially affected in various neuropsychiatric and 
neurodegenerative disorders. However, the severe lack 
of specifi c and effective genetic tools for studying PyNs 
has hampered progress in understanding cortical cir-
cuits. We have begun to build a comprehensive genetic 
tool set for major PyN subtypes in the mouse in collab-
oration with Dr. Paola Arlotta at Harvard University. 
We have discovered a set of specifi c and combinatorial 
markers that distinguish major PyN subtypes. We are 
using intersection, subtraction, and inducible strategies 
to target PyN subtypes. We have already generated 10 
knockin driver lines that target restricted populations 
of corticothalamic, corticofugal, corticostriatal, and 
corticocortical PyNs.
The Progenitor Origin of Chandelier Cells
Diverse GABAergic INs regulate the functional orga-
nization of cortical circuits and derive from multiple 
embryonic sources. It remains unclear to what extent 
embryonic origin infl uences interneuron specifi cation 
and cortical integration due to diffi culties in tracking 
defi ned cell types. Using genetic fate mapping, we fol-
lowed the developmental trajectory of chandelier cells 
(ChCs), the most distinct interneurons that innervate 
the axon initial segment of pyramidal neurons and 
control action potential initiation. We recently dis-
covered that the specifi cation of ChC identity is me-
diated through lineage and birth timing mechanisms 
in the embryonic subpallium, and young ChCs navi-
gate over long distances with stereotyped routes and 
schedules to achieve characteristic laminar and areal 
distribution in the cortex by the end of fi rst postnatal 
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week. We have been using combinatorial genetic fate 
mapping to explore whether there are designated ChC 
progenitor pools that give rise to these distinct cell 
types. Results in the past year suggest that there are 
fate-restricted progenitors that give rise to L5/6 or L2 
ChCs, respectively.
Activity-Regulated Pruning and 
Circuit Integration
We have discovered a massive and neural activity-regu-
lated pruning of ChCs during their postnatal integra-
tion into the cortical network. Upon fate specifi cation 
at cell birth, young ChCs migrate over long distances 
following stereotyped routes and schedules and settle 
mainly in cortical layers 2, 5, and 6 by the end of the 
fi rst postnatal week. In the following week (from ~P7 to 
P14), ~60% of L2 ChCs undergo cell death throughout 
the cortex through the Bax-Bak apoptosis pathway. At 
the primary (V1) and secondary (V2) visual cortex bor-
der region, ChC apoptosis and density are regulated by 
contralateral callosal axons in an activity- and retina-
dependent manner. Blocking activity of contralateral 
callosal PyNs leads to reduction of ChC pruning at 
V1-V2 border, and removing retinal input by neonatal 
monocular enucleation leads to ectopic callosal projec-
tions and reduction of ChC pruning in V1 regions that 
correlated with ectopic callosal axons. Our working hy-
pothesis is that patterned retinal activities before vision 
onset coordinate the wiring of bilateral callosal PyNs, 
in part through eliminating inappropriately connected 
young ChCs. This might allow retinotopically matched 
callosal PyN axons to establish fast bihemispheric sig-
naling and contribute to the fusion of left-right visual 
fi eld. Such activity-regulated ChC pruning may repre-
sent a general mechanism that shapes interhemisphere 
and interarea processing pathways.
Connectivity and Function of Chandelier 
Cells in a Medial Prefrontal Cortex Fear 
Circuit
Although the amygdala is central in mediating innate 
and learned fear, the prelimbic area (PL) of the ro-
dent medial prefrontal cortex (mPFC) has been impli-
cated in the regulation of fear responses in part through 
modulating amygdala activities. PL may integrate mul-
tiple inputs that convey contextual, internal state, and 
mnemonic information in regulating the activity of 
basolateral amygdala (BLA), thereby achieving fl ex-
ibility in fear response to changing cues, but the un-
derlying circuitry mechanism is unclear. The supra-
granular layers of PL contain multiple populations 
of pyramidal neurons (PyNs) that project to several 
target areas such as striatum (STRp), contralateral PL 
(CCp), and BLA (BLAp). Among these, BLAp fi ring 
directly drives BLA fear neurons, but the inhibitory 
control of BLAp is not understood. Among diverse 
cortical GABA inhibitory neurons, the ChCs inner-
vate the axon initial segment (AIS) of PyNs and likely 
exert a decisive control over their fi ring. Using cell-
lineage-dependent genetic targeting, we examined 
the connectivity and function of ChCs in PL. Layer 
2 (L2) ChCs preferentially control BLAp over CCp in 
PL, even when these PyNs are intermingled, suggest-
ing a role of ChCs in regulating BLA activity. Paired 
recordings and retrograde rabies tracings indicate 
that L2 ChCs do not receive signifi cant glutamatergic 
inputs from local PyNs, but they do receive multiple 
long-range inputs from the mediodorsal thalamus, 
ventral hippocampus, BLA, diagonal band (acetylcho-
line), and ventral tegmental area (dopamine), which 
may carry contextual, emotional, and brain state in-
formation. Importantly, chemical genetic suppression 
of PL L2 ChCs resulted in enhanced fear expression. 
Together, these results suggest that prelimbic ChCs 
may integrate multiple contextual, emotional, and 
motivational information to modify BLAp fi ring and 
achieve fl exible regulation of fear expression.
Input-Speciﬁ c Maturation of Synaptic 
Recruitment of Parvalbumin Interneurons 
in the Primary Visual Cortex
Cortical networks consist of local recurrent circuits 
and long-range pathways from other brain areas. Parv-
albumin inhibitory interneurons (PVNs) regulate the 
dynamic operation of local ensembles as well as the 
temporal precision of afferent signals. The synaptic 
recruitment of PVNs that support these circuit op-
erations is not well understood. Here, we demonstrate 
that the synaptic dynamics of PVN recruitment in the 
mouse visual cortex are customized according to input 
source with distinct maturation profi les. Although the 
long-range inputs to PVNs show strong short-term 
depression throughout postnatal maturation, local 
inputs from nearby pyramidal neurons progressively 
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lose such depression. This enhanced local recruitment 
depends on PVN-mediated reciprocal inhibition and 
results from both pre- and postsynaptic mechanisms, 
including calcium-permeable AMPA (α-amino-3-
hydroxy-5-methyl-4-isoxazole propionic acid) recep-
tors at PVN postsynaptic sites. Although short-term 
depression of long-range inputs is well-suited for af-
ferent signal detection, the robust dynamics of local 
inputs may facilitate rapid and proportional PVN re-
cruitment in regulating local circuit operations.
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NEUROBIOLOGY OF COGNITION AND DECISION MAKING
A. Kepecs N. Bobrowski-Khoury M. Lorenc J. Sanders
 E. Demir P. Masset T. Sikkens
 B. Hangya H.J. Pi A. Vaughan
 J. Hirokawa J.L. Pie
 D. Kvitsiani S. Ranade 
Understanding the mysteries of cognition has been 
an age-old aspiration of humankind. Our laboratory 
engages this question by studying the neurobiological 
basis of cognitive tasks in rodents. We use a reduction-
ist approach to translate psychological questions into 
the language of neuroscience by developing quantifi -
able, well-controlled behavioral tasks for rodents. We 
then couple these tasks with targeted, high-resolution, 
and high-throughput monitoring and manipulation of 
neural circuits mediating cognitive behaviors. Given 
the complexity of animal behavior and the dynam-
ics of neural networks producing it, our studies rely 
on computational models to guide and sharpen the 
neurobiological questions. Finally, we use human 
psychophysics to validate our behavioral observations 
in rodents by linking them to analogous behaviors in 
humans. Behavioral links to humans can also serve to 
identify behavioral dimensions that are predictive of 
disordered mental states, and our goal is to bridge our 
studies in animals with psychiatric disorders. Using 
this integrated approach, our long-term goal is to “re-
verse engineer” the computational and neurobiological 
principles underlying cognition and decision  making.
In terms of topics, our approach is multifaceted: We 
study (1) the roles of uncertainty and confi dence in 
 decision making, (2) foraging decisions about whether 
to stay or to switch, (3) the division of labor between 
different cell types in the prefrontal cortex, (4) how the 
cholinergic system supports sustained attention, and 
(5) social decisions that rely on shallow, stereotyped 
circuits. A unifying theme is the use of cell-type- and 
pathway-specifi c perturbations to effect gain and loss 
of function for specifi c behavioral abilities. Through 
such manipulations of genetically and anatomically 
defi ned neuronal elements, we hope to identify funda-
mental principles of neural circuit function that will be 
ultimately useful for developing therapies for diseases 
such as addiction, major depression, schizophrenia, 
 Alzheimer’s disease, and autism spectrum disorder.
Neural Basis of Decision Conﬁ dence
J. Hirokawa, P. Masset [in collaboration with A. Lak, 
University of Cambridge; G. Costa, and Z.F. Mainen, 
Champalimaud Neuroscience Program, Portugal; 
A. Koulakov, Cold Spring Harbor Laboratory]
Natural events in the world, and the likely conse-
quences of our actions, are both fraught with ambigu-
ity. In face of pervasive uncertainty, one’s degree of 
confi dence in a belief is a critical component of cogni-
tion. This can confer benefi ts for a broad range of ac-
tivities from the sophisticated to the mundane to the 
essential: managing a stock portfolio, deciding wheth-
er to carry an umbrella, or deciding between fi ght and 
fl ight. An essential use of confi dence estimates is to 
guide information-seeking behaviors, learning, and 
attention so as to reduce the level of uncertainty. Con-
versely, the pathological misevaluation of confi dence 
can contribute to a wide range of neuropsychiatric 
conditions, including anxiety, obsessive-compulsive 
disorder, and addiction.
What is the neural basis for such judgments? Pre-
viously, we discovered neurons in the orbitofrontal 
cortex (OFC) that signal decision confi dence, and 
we are pursuing these observations by trying to es-
tablish the causal neural circuit basis for estimating 
and acting on decision confi dence. We designed a 
new behavioral task for rats, in which we could mea-
sure confi dence behaviorally on a trial-by-trial basis. 
Briefl y, rats are trained on a simple olfactory decision 
task, and by delaying reward, we found that the time 
they are willing to wait for an uncertain reward is 
proportional to decision confi dence, as predicted by 
theory. To further refi ne the role OFC in confi dence, 
we are trying to “read out” confi dence reports (i.e., 
predict the timing of leaving decisions on a trial-by-
trial basis based on neural activity [establish corre-
lation]). To demonstrate that OFC is necessary for 
confi dence reports, we used both excitotoxic lesions 
140  Research
and pharmacological inactivation techniques and 
found that confi dence reports were disrupted with-
out changing decision accuracy. To establish the suf-
fi ciency of OFC for confi dence reporting, we are pre-
paring gain-of-function experiments. Because there is 
no obvious map in prefrontal cortex, we cannot use 
electrical microstimulation. Instead, we will use op-
togenetic activation of neurons defi ned by projection 
target using retrograde viruses and attempt to inject 
extra “uncertainty” into the brain by activating the 
appropriate population of neurons. Currently, we are 
mapping the projections into and out of OFC to de-
fi ne a precise neural circuit for computing and using 
decision confi dence.
From Metacognition to Statistics: 
Conﬁ dence Judgments in Humans
J. Sanders, B. Hangya, P. Masset
In our rodent studies of confi dence, we use a com-
putational framework to interpret behavioral and 
neural data. We are also interested in understanding 
the degree to which the statistical concept of decision 
confi dence corresponds to the human notion of sub-
jective confi dence. Human confi dence judgments are 
thought to originate from metacognitive processes 
that provide a subjective assessment about one’s be-
liefs. Confi dence can be alternatively framed as an 
objective statistical quantity, an estimate of the prob-
ability that a chosen hypothesis was correct. Despite 
similar usage of this term, it remains unclear whether 
the objective, statistical notion of confi dence is related 
to the subjective human feeling of confi dence.
To address this issue, we developed a normative sta-
tistical framework to mathematically derive predictions 
relating a statistical measure of decision confi dence 
to observable measures of decisions. We found that 
human confi dence reports in both sensory and general 
knowledge decision tasks followed the normative statis-
tical predictions, defying several naïve intuitions about 
confi dence. In addition, by fi tting a model to choice be-
havior within this framework, we could quantitatively 
predict confi dence reports. On the basis of these results, 
we suggest that the computation underlying the human 
sense of confi dence is consistent with a mental imple-
mentation of statistical decision confi dence.
Next, we developed a new confi dence-reporting task 
that provides both implicit and explicit measures of deci-
sion confi dence and is suitable for both rodents and hu-
mans in order to make direct comparisons. We designed 
a perceptual discrimination task where subjects choose 
which of two Poisson click streams is clicking faster and 
rate their confi dence in their choices. On each trial, we 
store the precise time of each click the subject heard in 
each ear and acquire three measures: a reaction time 
(how long the subject collected evidence before choos-
ing), a choice (which side they thought was faster), and 
a confi dence report (how much they believe in the hy-
pothesis that their choice was correct). Using several pre-
viously described models of choice and confi dence, we 
tried to design a computer program that could “listen” to 
the same click trains and respond with the same reaction 
time, choice, and confi dence. To our surprise, we discov-
ered that standard models of perceptual decision making 
failed to reproduce the basic patterns from our normative 
model, that confi dence refl ects the strength of perceived 
evidence. Currently, we are examining a broader range of 
models to fi t our psychophysical data.
We fi nd that all of these confi dence-reporting tasks 
share the basic patterns of confi dence that is predicted 
by statistical confi dence. On the basis of these results, 
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Figure 1. A canonical cortical circuit for disinhibition. Vasointestinal peptide (VIP) interneurons receive inputs from 
local neurons, long-range afferents from other cortical areas, as well as serotonergic and cholinergic neuromodula-
tory input. VIP interneurons generate disinhibition by inhibiting two other major inhibitory neuron types, somatosta-
tin (SST) and to a smaller degree parvalbumin (PV) interneurons.
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we are now in a position to use these quantitative 
measures of decision confi dence in humans, through 
collaborations and with neuroimaging and genetic ap-
proaches. Moreover, by showing that a single confi -
dence measure is applicable to humans and rodents, 
our results strengthen the case for using the rat as a 
model system for studying decision confi dence.
The Representational Content of the OFC 
during Outcome Anticipation
J. Hirokawa, A. Vaughan, J.L. Pie
OFC is strongly implicated in decision making under 
uncertainty, especially when decisions require the 
evaluation of predicted outcomes. Neurophysiological 
studies conceptualize OFC as a hub for the integra-
tion of different variables into unifi ed value signals. 
Using model-based approaches, previous studies have 
identifi ed a number of critical outcome-related vari-
ables in OFC, such as reward value, risk, and con-
fi dence. However, such model-based approaches are 
limited in their ability to characterize neuronal repre-
sentations because it is diffi cult to address all poten-
tially encoded variables. Here, we address the repre-
sentational content of OFC using both model-based 
and model-free (i.e., unsupervised) approaches. First, 
we assessed whether and how different decision vari-
ables are integrated in OFC using a model-based ap-
proach. Second, we sought to uncover the content of 
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Figure 2. Network effects and behavioral correlates of identiﬁ ed interneuron classes. (A,B,C) (Top) Spike raster and 
peri stimulus time histogram (PSTH) of PV (A), SOM (B), and VIP (C) interneurons aligned to light onset. (Bottom) 
PSTH of three simultaneously recorded unidentiﬁ ed neurons (PV pairs, SOM pairs, and VIP pairs). (D,F) Cartoon 
of mouse performing the reward foraging task. (D) Mouse is leaving the rewarded zone. (E, Top two panels) Spike 
raster and peri-event time histogram (PETH) for an identiﬁ ed PV interneuron aligned to time of reward zone exit 
(bottom), mean z-scored response of 14 PV neurons (shaded area indicates S.E.M.). (F) Mouse is approaching a 
rewarded zone. (G, Top panels) Spike raster and PETH for an NS-SOM interneuron aligned to the time of reward 
zone entry. (Bottom) Mean responses for 10 NS-SOM neurons (shaded area represents S.E.M.). (H) Schematic of be-
havioral setup and auditory discrimination task. (I) (Top two panels) Raster plots and PETH of example VIP neuron. 
Neural activity was aligned to reinforcement (reward/punishment; dark gray). (Bottom panel) PETHs of VIP neurons 
(n = 10). All VIP neurons showed a strong increase in ﬁ ring rate after punishment.
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OFC representations using unsupervised techniques 
to assess whether decision variables arise naturally, 
and whether they are represented separately or as a 
continuum.
To address this, we trained rats in a task that combines 
two classic decision paradigms, one based on sensory un-
certainty (perceptual decision) and one based on reward 
uncertainty (value-based decision) to engage OFC. We 
recorded neural activity and focused our analysis on the 
period after choice/before feedback (i.e., while the animal 
is anticipating the outcome of its choice). First, we con-
structed a normative model to account for the behavioral 
data. Our model combines reward value and perceptual 
decision confi dence in a Bayesian way to yield integrated 
value, which is then used to make choices. The model 
correctly predicted the behavioral choices and reaction 
times observed in each animal. From neuronal data, 
analysis of single units revealed that individual OFC 
neurons can represent identifi able decision variables sep-
arately, including reward size and confi dence, as well as 
their combination into integrated reward value. Second, 
we used an unsupervised clustering method to uncover a 
more complete representational structure of task-related 
activity in a model-free way. This analysis revealed non-
random, structured representations of these decision 
variables in OFC. Taken together, we demonstrated that 
OFC representations of task variables are fundamentally 
linked to model-based decision variables such as reward 
value and decision confi dence.
Computational Psychiatry: Quantitative 
Behavioral Phenotyping in Rodents 
and Humans
P. Masset, J. Hirokawa [in collaboration with D. Rubinow, 
University of North Carolina, Chapel Hill]
At present, the classifi cation of mental disorders is 
based on clinical criteria and self-reports of symptoms. 
Objective and reliable diagnoses are a prerequisite for 
meaningful progress in establishing genetic and neu-
ral etiologies and eventually new treatments. Although 
the promise of a dimensional approach to characterize 
behavior and its dysfunctions is widely appreciated, we 
do not know how to identify appropriate “behavioral 
dimensions” that are predictive of disordered mental 
states. Our goal is to develop behavioral tasks that 
isolate specifi c mental computations, such as decision 
confi dence, and use computational models to quantita-
tively characterize the behavioral data. We have begun 
this work in rodents and healthy humans with the goal 
of applying them to genetic models of psychiatric dis-
eases in rodents and patient populations.
Usually, animal models are validated mainly on the 
basis of genetic insights and simple behavioral mea-
sures. However, in the case of cognitive diseases, this 
has become challenging because it is unclear how to 
map human behavioral defi cits to animal models. To 
overcome these issues, we focus on microtraits that can 
be easily quantifi ed using psychometric tasks and be di-
rectly related to humans (e.g., reward sensitivity, learn-
ing rate, and decision confi dence). We attempted to use 
such a dimensional approach to identify microtraits 
that may be quantitatively different between our model 
rats and their controls. We studied major depressive dis-
order (MDD), a heterogeneous condition whose patho-
physiology remains unclear, with a commonly used ro-
dent model, the congenital learned-helplessness (cLH) 
rat. Using different behavioral paradigms, we tested two 
major hypotheses about depression: anhedonia, a blunt-
ed sensitivity to reinforcers, and depressive realism, the 
improved calibration of the sense of confi dence. We 
fi rst manipulated reward contingencies by introducing 
a bias in either reward size or reward probability. Our 
results showed no signifi cant difference between cLH 
and cNLH rats, which suggested that cLH rats did not 
display any imbalance in reward evaluation. We then 
assessed confi dence based on the rat’s willingness to in-
vest waiting time for uncertain outcomes. When they 
were most confi dent, the optimal strategy was to wait 
longer, and indeed this is what we observed. Moreover, 
we observed greater differences in cLHs’ waiting times 
with confi dence, suggesting that they had more insight 
into their choices than controls during the task. These 
preliminary results highlight how a computational phe-
notyping approach can be used to relate animal models 
of psychopathologies to human behavior.
Impact of Drugs of Abuse on 
Decision Making and OFC
J.L. Pie, J. Hirokawa
Drug abuse and addiction result in and are compound-
ed by compromised decision-making processes. OFC 
has emerged as one important region for structural and 
functional alterations resulting from chronic drug ex-
posure. Although opioids are widely used for treatment 
of chronic pain conditions, their long-term effects on 
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cognitive functions have not been well characterized. 
Morphine is a potent opiate drug that has been shown 
to directly affect OFC, along with other prefrontal 
regions with strong dopaminergic projections. Addic-
tion to morphine renders subjects unable to make good 
judgments and fl exible choices, which mimics the ef-
fects of OFC lesions. Therefore, we sought to fi nd out 
whether the previously unexplained behavioral aspects 
of drug addiction could be due to defects in integration 
of decision confi dence and reward value in the decision-
making process. Specifi cally, we seek to identify the im-
pact of morphine self-administration protocol on opti-
mal decision making in the reward-biased 2AFC task.
We trained rats in the 2AFC task and exposed them 
to ~2 wk morphine self-administration followed by 
2 wk withdrawal. These rats reliably evoked morphine 
self-administration, and following withdrawal, we 
tested for disruption of the decision-making processes 
as deviations in two types of choice biases. Reward 
size bias that changes choices modulated the propen-
sity to choose toward the larger reward and previous 
outcome bias that generated changes in choice behav-
ior based on the immediately preceding outcome. We 
observed distinct changes in choice bias: Reward size 
bias was signifi cantly reduced, whereas previous out-
come bias was not by morphine exposure. This result 
suggests that chronic morphine administration alters 
decision making selectively, disrupting either a circuit- 
or cell-type-specifi c representation of choice bias. On 
the basis of this evidence, we are pursuing the hypoth-
esis that morphine self-administration leads to subop-
timal decision making by disrupting integration and 
distribution of decision variables in OFC.
Foraging Decisions, Anterior Cingulate 
Cortex and Inhibitory Neuron Types
D. Kvitsiani, S. Ranade, B. Hangya, M. Lorenc 
[in collaboration with Z.J. Huang, Cold Spring 
Harbor Laboratory]
Making decisions about when to engage with options 
as they are encountered and when to disengage and 
switch behavior is a fundamental problem for all deci-
sion makers. Such decisions about whether to stay and 
exploit an opportunity or leave and explore alterna-
tives, presented in the language of behavioral ecology, 
are called foraging decisions. It is critical to appreciate 
that foraging decisions are not binary ones between 
currently available options (such as two-alternative 
forced choice), but are instead decisions about when 
and how to engage with the available options.
We have been studying the anterior cingulate cor-
tex (ACC) during a simple foraging task. In humans 
and rodents, ACC has been implicated in a variety of 
goal-directed behaviors including reward processing, 
inhibitory response control, and confl ict monitoring. 
Electrophysiological recordings from ACC show great 
diversity of neuronal responses to a range of behav-
ioral variables. To address this issue, we used optoge-
netics as a means to identify extracellularly recorded 
neurons in freely moving mice, focusing on inhibitory 
interneurons, which exhibit the largest diversity of cell 
types in cortex. We demonstrated that parvalbumin 
(Pv)-expressing neurons and a subtype of somatostatin 
(Som)-expressing neurons form functionally homo-
geneous populations, showing a double dissociation 
between both their inhibitory impact and behavioral 
correlates. Of a number of events pertaining to behav-
ior, a subtype of Som neurons selectively responded at 
reward approach, whereas Pv neurons responded at re-
ward leaving, encoding preceding stay duration. These 
behavioral correlates of Pv and Som neurons defi ned a 
behavioral epoch and a decision variable important for 
foraging (whether to stay or to leave), a crucial func-
tion attributed to ACC. Our results also point to a new 
view of inhibition, according to which interneurons 
encode behaviorally relevant variables and serve to con-
trol the fl ow of information and behavioral timescales.
Cortical VIP Interneurons and 
Disinhibitory Control
H.J. Pi, B. Hangya, A. Vaughan, T. Sikkens [in collaboration 
with Z.J. Huang, Cold Spring Harbor Laboratory; B. Rozsa, 
KOKI, Hungary]
We are interested in understanding how the diversity 
of cortical inhibitory interneurons underlies distinct 
neural circuit dynamics that direct perception and 
behavior. We have recently identifi ed a disinhibitory 
cortical circuit motif that appears to be a conduit for 
fast neuromodulatory action in cortex. This circuit 
is controlled by a class of inhibitory interneurons 
that express vasoactive intestinal polypeptide (VIP), 
which inhibits other interneurons and thereby dis-
inhibits a subpopulation of principal neurons. VIP 
neurons express ionotropic nicotinic acetylcholine 
and serotonergic 5-HT3A receptors. Functionally, we 
showed that VIP interneurons in the auditory cortex 
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are recruited in response to specifi c reinforcement 
signals such as reward and punishment. Although 
these observations raise the possibility that VIP neu-
rons transform neuromodulatory signals to cortical 
output, the exact neuromodulatory signals that are 
involved remain unknown.
What are the mechanisms by which VIP neurons 
are recruited at specifi c moments in behavior? Previous 
studies suggest that VIP neurons may act as a conduit 
for fast neuromodulatory control and thereby acquire 
behaviorally relevant responses. To identify which 
neuromodulatory systems recruit a VIP- controlled 
disinhibitory circuit, we took advantage of a rabies- 
virus-assisted retrograde tracing system that labels only 
monosynaptic input neurons fl uorescently. We identi-
fi ed direct projections from cholinergic neurons in the 
basal forebrain and serotonergic neurons in the raphe 
nuclei. On the basis of these results, we are pursuing 
the hypothesis that VIP neurons transform fast neuro-
modulatory signals into cortical disinhibitory output.
Neural Representation of Social Decisions 
and Rewards
E. Demir, N. Bobrowski-Khoury [in collaboration with 
R. Axel, Columbia University]
Social behavior is integral to animals’ survival and re-
production. Social defi cits are at the heart of cognitive 
disorders such as autism spectrum disorder that have 
proven profoundly diffi cult to study in model organ-
isms. Mice, like humans, are social animals. To inter-
act, cooperate, and compete with others, mice must 
collect information about each other’s identity, fertil-
ity, and likely intent. We would like to understand 
how social information is represented, computed, and 
used by mice. In rodents, a main source of informa-
tion for social decision making and reward valuation 
is the chemosensory system. The neural circuits sup-
porting these tend to be shallow, from sensory input 
to motor actions, and highly stereotyped, enabling the 
systematic dissection of this system.
We started our studies by recording from part of 
the amygdala that processes information from the 
vomeronasal system, detecting behaviorally signifi -
cant chemical cues such as pheromones. We have 
designed a behavioral task that presents different 
urinary proteins to our mice while we are perform-
ing electrophysiology in medial amygdala. Moreover, 
we characterized molecular markers that enable us to 
further dissect social amygdalar circuit. Currently, 
we are carrying out optogenetic experiments as well 
as electrophysiological recordings to map behavioral 
relevance onto specifi c medial amygdala neurons.
We are also interested in understanding the basic 
rules that mice use to choose their partners. For this 
purpose, we have developed a psychophysical social 
behavior task, the “social carousel,” inspired by per-
ceptual psychophysics and game theoretic traditions 
that have been instrumental in studying other facets 
of cognition. Our task enables the reliable, quantita-
tive, and high-throughput analysis of social interac-
tions in mice. This task contrasts appetitive rewards 
with opportunities for social interaction. Water-
deprived animals are trained to alternate between 
two platforms: One platform provides a small water 
reward, and the other allows for social interaction 
with caged mice drawn at random from a revolving 
magazine. Subjects can engage in extended social in-
teractions with these mice, but at the expense of de-
laying the water reward. This task allows us to infer 
the “social value” of a mouse based on the trade-off 
between social interactions and appetitive rewards. 
In addition, this task is compatible with our electro-
physiological studies because it is devised for precise 
stimulus delivery and reproducible behavioral con-
tingencies. Currently, we are characterizing social 
preferences of individual mice of different strains 
and subspecies.
Optogenetic Dissection of Nucleus 
Basalis during Sustained Attention 
and Reinforcement
B. Hangya, S. Ranade, M. Lorenc
The nucleus basalis (NB) is a vitally important yet 
poorly understood neuromodulatory system that is 
thought to have signifi cant roles in cognitive func-
tions, including learning, memory, and attention. 
Cognitive defi cits in Alzheimer’s disease, Parkinson’s 
dementia, age-related dementias, and normal aging 
are correlated with the extent of deterioration of NB 
cholinergic neurons. Yet, despite the association of 
NB with higher cognitive functions and a host of dis-
ease states in humans, it is surprising how little we 
understand about its function during behavior. Pre-
vious research, mostly using lesions, pharmacology, 
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and microdialysis, revealed that NB can have strong 
and confusingly diverse effects on downstream targets 
and behavior. However, there are no functional stud-
ies that reveal what NB neurons actually do during 
behavior.
To overcome these challenges, we combine opto-
genetic and electrophysiological approaches to record 
from identifi ed cholinergic projection neurons in two 
distinct nuclei of NB during behavior: The caudal re-
gion projecting to the auditory cortex and the hori-
zontal diagonal band that projects to the prefrontal 
cortex. We have successfully developed visual and au-
ditory versions of sustained attention tasks for mice. 
In these tasks, mice report target stimuli occurring at 
uncertain times. Performance and reaction time are 
used as indicators of attention. We manipulate tempo-
ral expectancy by using specifi c distributions for stim-
ulus timing, thus modulating attention in a tempo-
rally precise, graded manner, also refl ected in the reac-
tion times of the animals. We recorded single-neuron 
activity from the NB while mice were performing the 
auditory sustained attention task and identifi ed cho-
linergic neurons by using an optogenetic approach. 
We found that central cholinergic neurons responded 
to primary reward and punishment with remarkable 
speed and precision (18 ± 3 msec), unexpected for a 
neuromodulatory system. Responses to reward were 
scaled by reinforcement surprise, indicating that the 
cholinergic system also conveys cognitive information. 
These results reveal that cholinergic neurons provide a 
rapid, reliable, and temporally precise signaling route 
for reinforcement feedback that can mediate fast cor-
tical activation and plasticity. Such fast responses of 
cholinergic neurons have not been reported and cast 
into doubt the prevailing notion that neuromodula-
tors are slow-acting. These data also provide support 
to the idea that acetylcholine is a “broadcast signal” 
involved in identifying salient events, possibly mediat-
ing cortical plasticity and learning.
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THEORETICAL AND COMPUTATIONAL NEUROSCIENCE
A. Koulakov D. Ferrante Y. Wei
Our laboratory develops theories of neural compu-
tation. We work in parallel on three topics. First, 
we formulate mathematical models for combining 
genetic information and experience (nature and 
nurture) during formation of connections between 
neurons. Our models describe how genes can help 
build neural networks and how neural activity adds 
a layer of plasticity to the network topology that re-
fl ects learning and experience. These models have 
been tested on circuits that are formed in the visual 
system and can be rewired through genetic, surgi-
cal, and pharmacological manipulations. Second, 
we have been developing the neural network theory 
for olfactory processing. We previously argued that 
information about smells can be represented in the 
olfactory system in the form of temporal sequences. 
We develop network models that can interpret these 
sequences. With these models, we hope to under-
stand the function of olfactory cortex. Finally, we 
are working on computational models of decision 
making and related processes such as confi dence esti-
mation within cortical networks forming perceptual 
decision.
A Network That Performs Brute-Force 
Conversion of a Temporal Sequence to 
a Spatial Pattern: Relevance to Odor 
Recognition
H. Sanders, B. Kolterman, J. Lisman, D. Rinberg, 
A. Koulakov
A classic problem in neuroscience is how temporal 
sequences can be recognized. This problem is ex-
emplifi ed in the olfactory system, where an odor is 
defi ned by the temporal sequence of olfactory bulb 
output that occurs during a sniff. This sequence is 
discrete because the output is subdivided by gamma 
frequency oscillations. We proposed a new class of 
“brute-force” solutions to recognition of discrete se-
quences. We demonstrated a network architecture in 
which there are a small number of modules, each of 
which provides a persistent snapshot of what occurs 
in a different gamma cycle. The collection of these 
snapshots forms a spatial pattern that can be recog-
nized by standard attractor-based network mecha-
nisms. This strategy has implications for recognizing 
odor-specifi c sequences generated by the olfactory 
bulb.
Orbitofrontal Cortex Is Required for 
Optimal Waiting Based on Decision 
Conﬁ dence
A. Lak, G. Costa, E. Romberg, A. Koulakov, 
[in collaboration with Z. Mainen; A. Kepecs, 
Cold Spring Harbor Laboratory]
Confi dence judgments are a central example of 
metacognition—knowledge about one’s own cogni-
tive processes. According to this metacognitive view, 
confi dence reports are generated by a second-order 
monitoring process based on the quality of inter-
nal representations about beliefs. Although neural 
correlates of decision confi dence have been recently 
identifi ed in humans and other animals, it is not 
well understood whether there are brain areas spe-
cifi cally important for confi dence monitoring. To 
address this issue, we designed a postdecision tem-
poral wagering task in which rats expressed choice 
confi dence by the amount of time they were willing 
to wait for reward. We found that orbitofrontal cor-
tex inactivation disrupts waiting-based confi dence 
reports without affecting decision accuracy. To ad-
dress this data, we have developed a computational 
model that both accounts for the results of the tem-
poral wagering task and provides a statistical basis 
for confi dence measurement. We show that the nor-
mative model can quantitatively account for waiting 
times based on the computation of decision confi -
dence. These results establish an anatomical locus 
for a metacognitive report, confi dence judgment, 
distinct from the processes required for perceptual 
decisions.
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Statistical Model of Evolution of Brain Regions
D. Ferrante, Y. Wei, A. Koulakov
We study the distribution of brain and cortical area 
sizes—parcellation units (PUs; Fig. 1)—obtained for 
three species: mouse, macaque, and human. We fi nd 
that the distribution of PU sizes is close to lognormal. 
We analyze the mathematical model of evolution of 
brain parcellation based on iterative fragmentation 
and specialization. In this model, each existing PU 
has a probability of splitting that depends on PU size 
only. This model shows that the same evolutionary 
process may have led to brain parcellation in these 
three species. Our model suggests that region-to-re-
gion (macro) connectivity is given by the outer prod-
uct form. We show that most experimental data on 
non-zero macaque cortex macroconnectivity (62% 
for area V1) can be explained by the outer product 
power-law form suggested by our model. We propose 
a multiplicative Hebbian learning rule for the mac-
roconnectome that could yield the correct scaling of 
connection strengths between areas.
Long-Term Memory Stabilized 
by Noise-Induced Rehearsal
Y. Wei, A. Koulakov
Cortical networks can maintain memories for decades 
despite the short lifetime of synaptic strengths. Can 
a neural network store long-lasting memories in un-
stable synapses? We have studied the effects of ongo-
ing spike-timing-dependent plasticity (STDP) on the 
stability of memory patterns stored in synapses of an 
attractor neural network. We show that certain classes 
of STDP rules can stabilize all stored memory pat-
terns despite a short lifetime of synapses. In our model, 
unstructured neural noise, after passing through the 
recurrent network connections, carries the imprint of 
all memory patterns in temporal correlations. STDP, 
combined with these correlations, leads to reinforce-
ment of all stored patterns, even those that are never 
explicitly visited. Our fi ndings may provide the func-
tional reason for irregular spiking displayed by cor-
tical neurons and justify models of system memory 
consolidation. Therefore, we propose that irregular 
Figure 1. Mouse brain parcellation tree. Each brain region (PU) is represented by a node. PUs farther from the root 
are parts of upstream PUs.
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neural activity is the feature that helps cortical net-
works maintain stable connections.
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THE FUNCTION AND PLASTICITY OF CENTRAL SYNAPSES 
IN ADAPTIVE AND MALADAPTIVE BEHAVIORS RELATED 
TO PSYCHIATRIC DISORDERS
B. Li S. Ahrens L. Mejia M. Stephenson-Jones
 K. Delevich M. Penzo K. Yu
 G. Hwang H. Schiff X. Zhang
Understanding the relationship among synapse, cir-
cuit, and behavior has been the focus of research in 
our lab. We are particularly interested in understand-
ing the synaptic and circuit mechanisms underlying 
cognitive functions, as well as synaptic and circuit 
dysfunction that may underlie mental disorders, in-
cluding anxiety, depression, schizophrenia and au-
tism. To address these questions, we use in vitro and 
in vivo electrophysiology, two-photon imaging, mo-
lecular, genetic, optogenetic, and chemical-genetic 
methodologies to probe and manipulate the function 
of specifi c neural circuits in the rodent brain and to 
determine their role in behaviors, such as learning and 
expression of fear, learned helplessness, and attention. 
We are currently undertaking the following major 
lines of research, which are summarized below.
The Paraventricular Thalamus Controls 
a Central Amygdala Fear Circuit
Appropriate responses to an imminent threat brace us 
for adversities. The ability to sense and predict threat-
ening or stressful events is essential for such adaptive 
behavior. In the mammalian brain, one putative stress 
sensor is the paraventricular nucleus of the thalamus 
(PVT), an area that is readily activated by both physi-
cal and psychological stressors. However, the role of 
the PVT in the establishment of adaptive behavioral 
responses remains unclear. Here, we demonstrate in 
mice that the PVT regulates fear processing in the 
lateral division of the central amygdala (CeL), a struc-
ture that orchestrates fear learning and expression. 
Selective inactivation of CeL-projecting PVT neurons 
prevented fear conditioning, an effect that can be ac-
counted for by an impairment in fear-conditioning-
induced synaptic potentiation onto somatostatin-
expressing (SOM+) CeL neurons, which has previ-
ously been shown to store fear memory. Consistently, 
we found that PVT neurons preferentially innervate 
SOM+ neurons in the CeL, and stimulation of PVT 
afferents facilitated SOM+ neuron activity and pro-
moted intra-CeL inhibition, two processes that are 
critical for fear learning and expression. Notably, 
PVT modulation of SOM+ CeL neurons was medi-
ated by activation of the brain-derived neurotrophic 
factor (BDNF) receptor tropomysin-related kinase B 
(TrkB). As a result, selective deletion of either Bdnf 
in the PVT or Trkb in SOM+ CeL neurons impaired 
fear conditioning, whereas infusion of BDNF into 
the CeL enhanced fear learning and elicited uncon-
ditioned fear responses. Our results demonstrate that 
the PVT–CeL pathway constitutes a novel circuit es-
sential for both the establishment of fear memory and 
the expression of fear responses. Additionally, we have 
uncovered mechanisms linking stress detection in 
PVT with the emergence of adaptive behavior.
Synaptic Modiﬁ cations in the Medial 
Prefrontal Cortex in Susceptibility and 
Resilience to Stress
When facing stress, most individuals are resilient, 
whereas others are prone to developing mood disor-
ders. The brain mechanisms underlying such diver-
gent behavioral responses remain unclear. We used the 
learned helplessness procedure in mice to examine the 
role of the medial prefrontal cortex (mPFC), a brain 
region highly implicated in both clinical and animal 
models of depression, in adaptive and maladaptive be-
havioral responses to stress. We found that uncontrol-
lable and inescapable stress induced behavioral state-
dependent changes in the excitatory synapses onto a 
subset of mPFC neurons: those that were activated 
during behavioral responses as indicated by their ex-
pression of the activity reporter c-Fos. Whereas syn-
aptic potentiation was linked to learned helplessness, 
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a depression-like behavior, synaptic weakening, was 
associated with resilience to stress. Notably, enhanc-
ing the activity of mPFC neurons using a chemical-
genetic method was suffi cient to convert the resilient 
behavior into helplessness. Our results provide direct 
evidence that mPFC dysfunction is linked to mal-
adaptive behavioral responses to stress and suggest 
that enhanced excitatory synaptic drive onto mPFC 
neurons may underlie the previously reported hyper-
activity of this brain region in depression.
Depression of Excitatory Synapses onto 
Parvalbumin Interneurons in the Medial 
Prefrontal Cortex in Susceptibility to 
Stress
In response to extreme stress, individuals either show 
resilience or succumb to despair. The PFC is required 
for coping with stress, and PFC dysfunction has been 
implicated in stress-related mental disorders, includ-
ing depression. Nevertheless, the mechanisms by 
which the PFC participates in stress responses re-
main unclear. Here, we investigate the role of parv-
albumin (PV) interneurons in the mPFC in shaping 
behavioral responses to stress induced by the learned 
helplessness procedure, in which animals are subject-
ed to an unpredictable and inescapable stressor. PV 
interneurons in the mPFC were probed and manipu-
lated in knock-in mice expressing the Cre recombi-
nase under the endogenous PV promoter. Notably, 
we found that excitatory synaptic transmission onto 
these neurons was decreased in mice showing help-
lessness, a behavioral state that is thought to resemble 
features of human depression. Furthermore, selective 
suppression of PV interneurons in the mPFC using 
hM4Di, a DREADD (designer receptor exclusively 
activated by designer drug), promoted helplessness, 
indicating that activation of these neurons during 
stress promotes the establishment of resilient behav-
ior. Our results reveal a cellular mechanism of mPFC 
dysfunction that may contribute to the emergence of 
maladaptive behavioral responses in the face of ad-
verse life events.
The Schizophrenia-Linked Gene ErbB4 
Regulates a Thalamic Reticular Nucleus 
Circuit for Sensory Selection
Selective processing of behaviorally relevant sensory 
inputs against irrelevant inputs is a fundamental cog-
nitive function whose impairment has been implicat-
ed in major psychiatric disorders. It is known that the 
thalamic reticular nucleus (TRN) gates sensory in-
formation en route to the cortex, but the underlying 
mechanisms remain unclear. We show in mice that 
defi ciency of Erbb4, a gene linked to schizophrenia, 
in somatostatin-expressing TRN neurons markedly 
alters behaviors that are dependent on sensory selec-
tion. Whereas the performance of the Erbb4-defi cient 
mice in identifying targets from distractors was im-
proved, their ability to switch attention between con-
fl icting sensory cues was impaired. These behavioral 
changes were mediated by an enhanced cortical drive 
onto the TRN that promotes the TRN-mediated 
cortical feedback inhibition of thalamic neurons. 
Our results uncover a previously unknown role of 
ErbB4 in regulating cortico-TRN-thalamic circuit 
function. We propose that ErbB4 sets the sensitiv-
ity of the TRN to cortical inputs at levels that can 
support sensory  selection while allowing behavioral 
fl exibility.
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INTEGRATIVE SYSTEMS NEUROBIOLOGY
P. Mitra N. Baltera A. Field-Pollatou G. Havkin  S. Michelsen V. Pinskiy A. Tolpygo
 D. Ferrante N. Franciotti  F. Mechler A. Mukherjee S. Savoia K. Weber
We study complex neurobiological systems using a 
combination of experimental and computational ap-
proaches. The primary area of experimental work in 
our laboratory continues to be the Mouse Brain Ar-
chitecture (MBA) project, with a goal of generating 
a mesoscale connectivity map. Our neuroinformatics 
research involves the development of analytical tools 
and informatics infrastructures to process, analyze, 
and integrate large volumes of neurobiological data in 
various brain connectivity projects.
In collaborative studies, we apply the methods de-
veloped for the MBA project to the zebra fi nch, mar-
moset, macaque monkey, and human; here we name 
the major ones. A joint study with Josh Huang at 
CSHL (supported by the Simons Foundation) to ob-
tain a brain-wide census of GABAergic interneurons 
in the mouse brain during development and in genetic 
models of autism is drawing to a conclusion this year. 
With funding from the National Institutes of Health 
awarded through the BRAIN Initiative program 
starting in 2014, we joined forces with Pavel Osten 
at CSHL to obtain an accurate whole-brain census of 
neuron classes in cell-type-specifi c reporter mice and 
develop neuroinformatics infrastructure to analyze 
and integrate such data. On a separate BRAIN-I grant, 
we join a team effort led by Sacha Nelson (Brandeis 
University) on a cross-species study of neuronal cell 
types in transgenic strains of rats and mice. We also 
have ongoing collaborations with Marcello Rosa 
(Monash University, Australia) and Hideyuki Okan 
(RIKEN, Japan) on a project to develop the fi rst atlas 
of the marmoset brain; with Harvey Karten (Univer-
sity of California, San Diego) to map the zebra fi nch 
brain; and with Bijan Pesaran (New York University) 
to study anatomical and functional connectivity of vi-
sual areas in the macaque brain.
I have recently been appointed distinguished (visit-
ing) professor at the Indian Institute of Technology 
(IIT), Madras. In collaboration with Professor Balara-
man Ravindran and his team at the Department of 
Computer Science and Engineering at IIT, I have 
initiated a Center for Computational Brain Research. 
Work at the Center will be devoted to the analysis 
of neuroanatomical data sets from whole-brain light 
microscopy, including those from our projects. Com-
puter scientists from IIT Madras and students will 
be visiting CSHL in summer 2015 to further this 
collaborative work. Continuing in our laboratory in 
2014 are Sandra Michelsen (Administrator), Alex Tol-
pygo (Laboratory Manager), Kevin Weber (Labora-
tory Technician), Neil Franciotti (Laboratory Tech-
nician), Nicholas Baltera (Laboratory Technician), 
Stephen Savoia (Laboratory Technician), Angeliki 
Field-Pollatou (Visiting Graduate Student), Gregor 
Havkin (Computational Science Manager), and Fe-
renc Mechler (Computational Science Analyst, Proj-
ect Manager). Amit Mukherjee (Postdoctoral Fellow) 
and Vadim Pinskiy (Computational Science Analyst) 
have recently left in pursuit of their careers in indus-
try. Daniel Ferrante (Computational Science Man-
ager) joined in 2015.
Mouse Brain Architecture Project
V. Pinskiy, A. Tolpygo, K. Weber, N. Franciotti, N. Baltera, 
S. Savoia, G. Havkin, A. Mukherjee, D. Ferrante, F. Mechler
The MBA project, now in its fi fth year, aims to con-
struct a comprehensive mesoscale wiring map of the 
adult mouse brain using a classical neuroanatomical 
approach that we scaled to a high-throughput data 
acquisition pipeline. Using computer-guided stereo-
taxic targeting, we microinject neurotracer substances 
(two anterograde or two retrograde) in one of the 390 
predetermined sites systematically mapped on a three-
dimensional grid that covers the entire brain vol-
ume. The sample brains are sectioned, histologically 
processed, and digitally scanned. Labeled somata or 
axonal projections are detected and analyzed in reg-
istered, annotated, high-resolution whole-brain image 
stacks, and the mesoscale connectivity matrix is as-
sembled from the analyzed sample brains. The MBA 
data enjoys critical advantages over the current alter-
native mouse brain connectivity mapping projects 
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(including the Allen Institute’s), including higher spa-
tial resolution and high-specifi city retrograde tracing.
Registered project brains and metadata are released 
to the public on the MBA web portal (http://mouse
.brainarchitecture.org). The portal interface and user 
experience itself have continued to improve with the 
new addition of a rotating three-dimensional injection 
browser (Fig. 1). To date, we have processed and re-
leased ~800 brains (Fig. 2). With continued support 
from the Mathers Foundation and with the current 
processing and publishing rate at approximately one 
to two brains per day, our expectation is to be able to 
complete data acquisition with at least one anterograde 
(AAV) and one retrograde (CTB) tracer by year end.
Figure 1.  The new three-dimensional injection viewer and brain tree navigator on the MBA portal.
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Outreach. We continue to work to highlight the 
MBA project to the scientifi c public. I have published 
a perspectives paper on mesoscale circuit mapping in 
the brain (Mitra 2014) and have been involved in or-
ganizational activity with the National Science Foun-
dation for BRAIN-I workshops. The MBA project has 
been represented in talks, posters, panel discussions, 
and a demonstration booth at the major annual scien-
tifi c forums for the fi eld (Max Planck/HHMI Con-
nectomics Conference Berlin 2014; Annual Meeting 
of the Society for Neuroscience, Washington, DC).
Alterations in Brain-Wide GABAergic 
Neuroanatomy in Autism Mouse Models
V. Pinskiy, A. Tolpygo, A. Mukherjee, F. Mechler
In our collaboration with Josh Huang, funded by 
the Simons Foundation Autism Research Initiative 
(SFARI), we address the developmental neuroanato-
my of dysfunctional inhibition implicated in autism 
spectrum disorders (ASD). In a systematic brain-
wide approach, we generate whole-brain maps of ge-
netically targeted key subpopulations of inhibitory 
neurons that have specialized cellular morphology 
refl ecting distinct physiological function. We quan-
tify the cell distribution and long-range axonal pro-
jections of these GABAergic neurons and compare 
them in an ASD mouse model (the 16p(df/+) heterozy-
gous copy-number-defi cit mutant) and the “wild type” 
(C57BL/6). Last year, we reported on the distribu-
tion of somatostatin-expressing (SOM+)  GABAergic 
bitufted neurons. Here, we report on data collected 
since then for a comparative analysis of the density 
distribution of the corticotropin-releasing hormone-
positive (CRH+) subtype of GABAergic neurons 
during development (Fig. 3). The data acquisition is 
drawing to completion, and we have started the anal-
ysis phase. Software tools are being developed for the 
rigorous quantitative analysis of these data sets. In 
this process, aligned whole-brain image stacks are 
registered to a reference atlas, and the normalized cell 
counts obtained with automatic cell detection within 
annotated anatomical compartments are compared 
across genotypes. Data sets and analysis results will 
be released to the public on a dedicated portal.
A Mesoscale Circuit Map of the 
Marmoset Brain
A. Tolpygo, N. Franciotti, D. Ferrante
The common marmoset (Callithrix jacchus) is a small 
New World primate with accelerated development 
and is the fi rst primate with established stable trans-
genic lines. For neuroscientists, the species is impor-
tant for being the simplest organism that shares many 
of the features that make primate brains special. Sev-
eral years ago, Dr. Mitra joined world-renowned mar-
moset expert Dr. Marcello Rosa (Monash University, 
Australia) and several other international collabora-
tors to create the fi rst digital marmoset brain con-
nectivity atlas. This project was seeded with existing 
cortical connectivity data originally collected by Dr. 
Rosa, and it currently focuses on new data acquisition 
and web portal development. More recently, Professor 
Mitra was invited to join a parallel international col-
laborative effort centered at RIKEN Brain Science In-
stitute (Japan) to map the anatomical and functional 
connectivity of the marmoset brain, with Dr. Mitra’s 
efforts contributing toward a comprehensive meso-
scale circuit map of the marmoset brain. The project 
is modeled after the MBA project at CSHL: It will be 
using injections of neuronal tracer substances, includ-
ing viral vectors, placed on a systematic grid designed 
to cover one hemisphere of the brain and will use a 
Figure 2.  Injection data sets published to date, arranged in a 
common reference frame, separated by tracer. AAV n = 390; 
CTB n = 190; BDA n = 80; RV n = 120.
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newly built high-throughput neurohistology pipeline. 
The raw digitized image data will be made publicly 
available through a data portal, as well as subjected to 
computational neuroanatomical analysis and circuit 
reconstruction.
The Cavity Method for Phase Transitions 
in Sparse Reconstruction Algorithms
P. Mitra [in collaboration with A. Sengupta, 
Rutgers University]
Compressed sensing relies on sparse reconstruction 
algorithms to retrieve high-dimensional sparse sig-
nals from a limited amount of measurements under 
suitable conditions. These algorithms exhibit sharp 
phase transition boundaries where signal retrieval 
breaks down as the number of variables goes to infi n-
ity. A common approach to predict these algorithmic 
breakdown boundaries uses mean fi eld approxima-
tion of associated statistical mechanical model sys-
tems at a fi nite temperature and subsequently taking 
a zero-temperature limit. Despite the success of this 
approach, the nontrivial last step obscures the rea-
sons for the algorithmic breakdown. We present an 
alternative approach for the derivation of the phase 
transition boundaries that uses the “cavity method,” 
working directly in the zero-temperature limit. The 
method has the advantage of naturally generating 
a susceptibility that provides insight into different 
phases in this system, and it can be generalized for 
analysis of a broader class of sparse reconstruction 
 algorithms.
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Figure 3.  The distribution of CRH+ subtype of GABAergic neurons in the ASD model 16p(df/+) mutant mouse (left) 
and its wild-type littermate (right) at the postnatal age of p8, p21, and p56 (top to bottom rows, respectively). Overall 
distribution and local CRH+ densities are qualitatively similar in ASD model and wild type at all developmental stages.
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IDENTIFICATION OF DISRUPTED BRAIN CIRCUITS IN MOUSE MODELS 
OF AUTISM AND SCHIZOPHRENIA
P. Osten G. Fitzgerald C. Mende R. Palaniswamy J. Taranda
 Y. Kim A. Narasimhan E. Szelenyi K.U. Venkataraju
We are interested in studying how brain circuits as-
semble during development and give rise to behavior 
in the juvenile and adult mouse, both under normal 
conditions and in genetic mouse models of autism.
Mapping Mouse Brain Activation
For the past several years, we have been developing 
a largely automated and highly quantitative approach 
to mapping neuronal activation in the mouse brain at 
cellular resolution. We have introduced a novel mi-
croscopy, called serial two-photon (STP) tomography, 
which achieves high-throughput fl uorescence imaging 
of whole mouse brains by integrating two-photon mi-
croscopy and tissue sectioning (Ragan et al., Nat Meth-
ods 9: 255 [2012]; Osten and Margrie, Nat Methods 
10: 515 [2013]). More recently, we have established a 
computational pipeline that allows the visualization of 
the immediate-early gene c-fos, a molecular marker of 
neuronal activation, by STP tomography in transgen-
ic c-fos-GFP mice. The c-fos-GFP-positive neurons are 
computationally detected, their distribution is warped 
to a reference brain registered to the Allen Mouse 
Brain Atlas (ABA), and the activated brain regions are 
identifi ed by rigorous statistical tests comparing c-fos-
GFP cell counts in more than 600 anatomical ABA 
regions (Fig. 1). We have demonstrated the power of 
these methods by generating whole-brain activation 
maps for two complex behaviors: a brief social interac-
tion between a male and either a female mouse (sexual 
behavior) or another male mouse (agonistic behavior) 
(Kim et al. 2014). The result uncovered many novel 
fi ndings including dorsoventral separation in activa-
tion patterns from olfactory cortices based on the two 
different social stimuli (Fig. 2). We anticipate that our 
methods will enable routine quantitative generation 
of whole-brain activation maps representing different 
complex behaviors, including other innate behaviors 
(e.g., sex, aggression, or fear) and higher cognitive be-
haviors (e.g., decision making). We predict that such 
maps will become a valuable resource for the systems 
neuroscience community. Furthermore, the applica-
tion of our methods to the screening of brain activa-
tion in genetic mouse models of autism may reveal 
brain circuit defi cits common to multiple suscepti-
bility genes, which could serve as clinically relevant 
brain-circuit-based targets (or biomarkers) for the 
 development of novel therapeutics.
Toward Quantitative Cell-Type-Based 
Mapping of the Mouse Brain
The mouse brain comprises approximately 70 million 
neurons and approximately 30 million glia and other 
cells. In addition to the method for mapping brain acti-
vation described above, we have developed an assay for 
Figure 1.  Mapping mouse brain activation by STP tomography. (A) Brain activation causes the induction of c-fos-
GFP. (B) The brain is imaged by STP tomography. (C) c-fos-GFP cells are computationally detected. (D) The data sets 
are warped to a “reference” brain and Allen Mouse Brain Atlas. (E) The distribution of c-fos-GFP cells is compared 
by statistical analyses and the results are tabulated in a spreadsheet of brain regions.
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quantitative mapping of the many neuronal and glial 
cell types present in the mouse brain. This work aims 
to provide a complete picture of cell type distribution 
in the mouse brain during development, in the adult, 
and during aging. The study of the developing brain 
will shed light on the temporal sequence of cell-type- 
and region-specifi c circuit assemblies that give rise to 
emerging motor, sensory-perceptual, and cognitive 
specializations in the young brain. The experiments 
in the adult brain will focus primarily on the ques-
tions of gender differences in cell numbers that have 
been described for several brain areas, but have not 
been examined at a whole-brain level. As a fi rst step 
toward this goal, we applied our mapping method to 
quantify expression of three major cortical interneu-
rons throughout the whole brain (Fig. 3). In addition, 
we further developed a computational way to measure 
volumes of anatomical regions. The result provides 
complete cell counting and density measurement of 
genetically labeled cells. The established method will 
be applied to gain quantitative understanding of dif-
ferent cell types in the context of neurodevelopment 
and disease models.
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Figure 3. Whole-brain PV, SST, and VIP+ interneuron distribution. 
(A–C) Quantitative spatial cell type mapping of PV-IRES-cre (A), 
SST-IRES-cre (B), and VIP-IRES-cre (C) crossed with LoxP-Stop-
LoxP-H2B-GFP reporter mice. The heat map represents the 
number of cells per voxel. (D–F) Virtual overlay of signals from 
three different cell types in the same space (D) and over the 
reference STP brain (E,F).
Figure 2.  Social brain circuit: Dorsoventral separation in the mouse olfactory bulb (MOB) downstream circuitry. 
(A,B) The male–female (A) and male–male groups (B) are compared to the handling group and signiﬁ cantly activated 
ROIs downstream from the MOB are displayed. Note similar activation in piriform (PIR) and entorhinal cortices 
(ENTl). Numbers in A  represent bregma A/P coordinates. (C–E) Voxel-based analysis revealed activation patterns 
 selective for the female stimulus, the male stimulus, and shared by both stimuli. Dorsoventral separation was detected 
between the male- and female-evoked activation in the PIR (C) and ENT (D). Such a pattern is clearly visualized by 
a three-dimensional side view (E).
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NEURAL CIRCUITRY FOR SOCIAL COMMUNICATION
S. Shea B. Cazakoff D. Eckmeier
 M. Dinh B. Lau
The overarching research goal in our laboratory is to 
understand how processing in specifi c brain circuits 
works to support natural communication behaviors. 
We aim to reveal neural mechanisms that allow or-
ganisms to detect and recognize familiar individuals, 
to gather information about their identity and social 
status, and to select appropriate behaviors. Mice are 
capable of acquiring detailed profi les on one another 
from the smells and sounds experienced during their 
social encounters. These dossiers may include infor-
mation on a mouse’s sex, genetic identity, reproduc-
tive state, levels of distress or sexual interest, or even 
recently consumed foods—details that are indispens-
able for survival and mating success. Initially, we are 
working to understand the neuronal activities and 
mechanisms in primary sensory brain areas that sup-
port these forms of communication. In the future, we 
anticipate moving deeper into the brain to ascertain 
where the sensory data from those regions are col-
lected and integrated into hormonal and electrical 
signals that promote appropriate behavioral choices. 
We are particularly interested in how all stages of this 
decision arc are fl exible according to experience and 
behavioral state.
The scientifi c benefi t of this approach is twofold. 
First, we want to identify fundamental principles 
for how the circuitry of the brain adaptively controls 
complex behavior. In our pursuit of this goal, innate 
social behaviors are advantageous because they allow 
us to study neural circuits in light of problems they 
are exquisitely adapted to solve. Second, it is also our 
goal to pinpoint disturbances in the circuits that im-
pair appropriate use of social information. Diffi culty 
with social perception and cognition are core features 
of the autism spectrum disorders (ASD); for example, 
patients may have trouble perceiving and interpret-
ing communication gestures such as speech, facial 
expressions, and “body language.” This broad feature 
is recapitulated in many mouse models of ASD that 
carry genetic variants identifi ed in human ASD popu-
lations. Therefore, if we can ascertain the neural cir-
cuit substrates of social behavior in normal mice, we 
can make and test predictions for how the circuitry is 
affected in the mouse models. The results are likely 
to tell us more about the synaptic modifi cations that 
occur in human autism.
State-Dependent Neuronal Coding 
in Granule Cells of the Olfactory Bulb
B. Cazakoff, B. Lau, K. Crump, H. Demmer
Arguably, the most critical and fi nely tuned instru-
ment providing a mouse with information about its 
social world is its sense of smell. Detection and inter-
pretation of olfactory stimuli in the brain begins at 
the olfactory bulb. Odor signals passing through the 
olfactory bulb are subject to processing and modifi ca-
tion by the intrinsic neuronal circuitry of the bulb. 
Among these intrinsic neurons, inhibitory granule 
cells are certainly the most numerous, arguably the 
most important, and yet somehow the most mysteri-
ous. These cells are the primary conduit for the olfac-
tory bulb to integrate odor information with signals 
originating deep in the brain. Furthermore, granule 
cell anatomy along with a handful of functional stud-
ies suggests that they are crucial for olfactory dis-
crimination and learning. Nonetheless, their activity 
patterns in vivo are poorly understood, and their elec-
trophysiological properties in awake animals are com-
pletely unknown. This is because granule cells do not 
yield to conventional recording techniques. Former 
lab postdoc Dr. Heike Demmer therefore developed 
reliable methods for recording and labeling olfactory 
bulb granule cells. In a tour de force series of experi-
ments, Watson School of Biological Sciences student 
Brittany Cazakoff, postdoctoral fellow Dr. Billy Lau, 
and CSHL Undergraduate Research Program student 
Kerensa Crump applied these methods to mice that 
were awake with their heads fi xed, but running freely 
on a foam ball and receiving water rewards from a 
lick tube. Their recordings represent the fi rst reported 
view of the activity of this important cell type dur-
ing wakeful behavior. The team’s results conclusively 
Neuroscience  159
show that granule cells become much more active dur-
ing wakefulness and surprisingly uncouple from the 
animal’s breathing and sniffi ng pattern. This seems 
to suggest that upon waking, granule cell activity be-
comes dominated by internal signals from the brain 
rather than the sensory properties of odors. If so, we 
have functionally identifi ed a pathway central to the 
remarkably labile processing of odor stimuli. In April 
of this year, we published our fi rst study of this system 
in Nature Neuroscience (Cazakoff et al. 2014).
Since then, Brittany Cazakoff has been extending 
her recordings of granule cells into mice that are not 
only awake, but actively learning new associations of 
odor stimuli with reward (water) and punishment (bit-
ter taste). She has developed a behavioral paradigm in 
which mice learn that two new odors each signal ei-
ther impending reward or the bitter taste,  respectively. 
They are also asked to learn that the odor associations 
have switched. The mice show that they have learned 
by licking when reward is signaled and withholding 
licks when the odor portends bitter taste. This learn-
ing develops in a timeframe that allows us to monitor 
activity in individual granule cells throughout. Such 
recordings are ongoing.
Noradrenaline Stores Olfactory Memories 
through Dynamic Regulation of Inhibition
H. Demmer, D. Eckmeier, B. Cazakoff [in collaboration 
with A. Koulakov, Cold Spring Harbor Laboratory]
How do we remember individuals that we have previ-
ously encountered? Substantial evidence indicates that 
many animals remember each other based on olfac-
tory cues. Memories are especially strong for individu-
als encountered during key life events such as mating 
with a new partner or the birth of a litter of young. 
These important events typically evoke massive re-
lease of the neurochemical noradrenaline (NA), initi-
ating a heightened state of emotion and arousal. This 
surge appears to cause long-lasting modifi cations to 
the responses to odorants in the olfactory bulb, which 
is the fi rst processing station for scent in the mam-
malian brain. Indeed, it was hypothesized that the 
coincidence of an odor stimulus with a surge of NA is 
minimally suffi cient to store a memory. We have been 
exploiting the intimate relationship between NA, 
olfactory bulb activity, and behavior to trigger and 
observe olfactory memories in mice. We discovered 
that indeed, when NA release is evoked by stimulat-
ing locus coeruleus, the source of most NA, while the 
sleeping mouse sniffed an odorant, neural responses 
to that odor underwent specifi c long-term alterations. 
Remarkably, once awake, the mouse’s subsequent be-
havior toward the odorant was also changed. In other 
words, the mouse seemed to remember the odor and 
treat it as though it were familiar. This fi nding has 
motivated several of our studies into how NA causes 
lasting changes to odor processing circuitry.
Using several experimental approaches, we are ac-
tively pursuing the following question: How are olfac-
tory memories for individuals stored mechanistically 
among the specifi c synaptic connections of the various 
neuronal types in the olfactory bulb? Dr. Heike Dem-
mer made recordings from granule cells to observe their 
activity during the induction of NA-dependent plas-
ticity. She found that stimulation of NA release like 
that which occurs during social encounters suppresses 
granule cells. Suppression of granule cells transiently in-
creases the excitability of mitral cells by relieving them 
from inhibition. This transient release of mitral cells 
from granule cell control is a key trigger for the synaptic 
plasticity that likely underlies memory. Indeed, this dis-
inhibitory event triggers selective long-term changes to 
mitral cells that signal the presence of the learned odor. 
We have therefore pinpointed the synaptic connections 
between granule cells and mitral cells as an important 
synaptic substrate of individual recognition memories.
Dr. Dennis Eckmeier took a different approach 
to observe population mechanisms of NA-dependent 
memory formation with functional neural imaging. 
He used a technique in which the sensory neurons 
that provide input to the olfactory bulb are labeled 
with a fl uorescent activity sensor that allows him 
to monitor the strength of activation in foci called 
“glomeruli.” By comparing the response strength of 
each of these glomeruli before and after NA release, 
Dr. Eckmeier showed that NA weakens the response 
to paired odors. This effect is only observed in cases 
where NA is released during the odor by stimulation 
of a brainstem structure called locus coeruleus. These 
data establish the synaptic input to the mouse olfac-
tory bulb as a target of noradrenergic modulation, 
thus revealing that the effects of learning and plastic-
ity in the olfactory system extend to remarkably early 
sensory signaling events. We published these fi nd-
ings in  November 2014 in The Journal of Neuroscience 
( Eckmeier and Shea 2014).
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Auditory Plasticity Is Impaired in a 
Mouse Model of Rett Syndrome
B. Lau, G. Ewall [in collaboration with J. Huang and 
K. Krishnan, Cold Spring Harbor Laboratory]
Far outside the range of our hearing, in the ultrasound 
range, mice are constantly holding conversations with 
one another in a language that is poorly understood 
at best. Many types of vocalizations are emitted by 
males and females, juveniles and adults, in a variety 
of behavioral contexts. We would like to better un-
derstand the perceptual signifi cance of these calls to 
the mice and how they are used to guide behavioral 
choices. One form of vocalization that is reasonably 
well understood is the ultrasonic distress vocalization 
(USV). Young mice prior to vision and full mobil-
ity will occasionally become separated from the nest. 
This is stressful for them and they will therefore call 
out to their mother with a very high frequency peep. 
New mothers develop sensitivity to these cries and re-
spond by moving toward their source (phonotaxis) to 
retrieve the pup. Moreover, females who have never 
given birth do not innately show approach responses 
to pups or their calls; however, they can learn to per-
form the behavior with experience.
Dr. Billy Lau is collaborating with CSHL profes-
sor Dr. Josh Huang and his postdoctoral fellow Dr. 
Keerthi Krishnan to examine how vocal perception of 
pup calls is affected in mice that are missing one copy 
of a gene called MeCP2. Impairments in the function of 
this gene are understood to cause the autism spectrum 
disorder Rett syndrome, and the Huang lab’s fi ndings 
regarding mutations in MeCP2 suggest that they may 
affect inhibitory networks in the auditory cortex im-
portant for development of pup call sensitivity. Indeed, 
we fi nd that females that possess only a single copy of 
MeCP2 are not able to develop profi ciency at gathering 
pups. This is an important fi nding because we describe 
the fi rst robust behavioral phenotype to be observed 
in mice that most closely genetically resemble humans 
with Rett syndrome. It is also signifi cant that this phe-
notype is a social communication defi cit.
This year, we completed our initial study the effects 
of MeCP2 mutation on auditory cortical circuitry and 
plasticity. Using a viral genetic strategy, we were able 
to knock down expression of MeCP2 selectively in the 
auditory cortex of adult females and impaired retrieval 
behavior. This indicates that MeCP2 has a critical role 
in maintenance and plasticity of the auditory cortex 
in support of this maternal behavior. Further experi-
ments revealed abnormalities in the response of audi-
tory cortical inhibitory networks to maternal learn-
ing in mutant mice. In a particularly exciting set of 
experiments, we were able to repair inhibitory func-
tion with genetic and pharmacological manipulations, 
thereby restoring maternal gathering behavior. We are 
hopeful that these fi ndings will open new therapeutic 
avenues for Rett syndrome.
Neural Activity during Social Encounters
D. Eckmeier
We have begun experiments that are ultimately aimed 
at recording individual neurons during social encoun-
ters and other behavioral assays involving the percep-
tion of social and nonsocial information. There are two 
broad related goals to this approach. The fi rst goal is 
to examine the encoding of social information such as 
body odors and vocalizations in primary sensory struc-
tures of awake animals. We hypothesize that activity 
in response to these signals may be labile to associative 
learning, attention, and arousal, which we may be able 
to manipulate in the context of social encounters. The 
second goal is to record from neurons in deep brain 
neuromodulatory centers during these encounters as 
well. Neurons that release noradrenaline and dopamine 
are likely responsive to social signals and may modulate 
encoding of sensory data and associative plasticity. Un-
derstanding the context-dependent activity patterns of 
these neurotransmitters is therefore critical to develop-
ing models for how they affect behavior.
Olfactory and Auditory Interactions
M. Dinh, J. Shen
Social encounters are multisensory events that include 
smells and sounds. Increasingly, we are interested in 
neural mechanisms that integrate olfactory and audi-
tory signals into a coherent perception of the social 
world. For example, how does the smell of a male 
mouse interact the sounds he makes in the brain of 
the female mouse? As a fi rst step, this year, Michael 
Dinh and Jia Shen performed experiments in which 
they activated olfactory projections to the auditory 
cortex using optogenetic tools. The preliminary data 
from these experiments strongly suggest that regions 
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carrying social olfactory cues can modify responses to 
auditory stimuli in a complex manner.
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NEURAL CODING AND MEMORY FORMATION 
IN THE DROSOPHILA OLFACTORY SYSTEM
G. Turner M. Brill T. Hige M. Modi
The brain has a tremendous capacity to form differ-
ent memories. These memories are, under normal cir-
cumstances, highly accurate for particular stimuli and 
situations. This is precisely the facility that is lost in 
diseases such as Alzheimer’s and other dementias. Our 
overall goal is to understand how the brain forms such 
precise memories: How does the specifi city arise, and 
how does the brain derive such a tremendous capacity 
for forming different memories?
We address these questions by studying olfactory 
memory formation in Drosophila. Just like Pavlov’s 
dogs, Drosophila learn to form associations between 
smells and reward or punishment. A specifi c area of the 
fl y brain, known as the mushroom body (MB), is es-
sential for the fl ies to form olfactory memories. We are 
investigating how the neural activity patterns in this 
brain area are used to form specifi c olfactory memories. 
To achieve this, we monitor activity using both electro-
physiological and functional imaging techniques. We 
have found that individual MB neurons exhibit highly 
odor-specifi c responses; at the population level, this 
translates into sparse activity patterns that are distinct 
for different odors. This specifi city is thought to un-
derlie the accuracy of memory; modifying the synapses 
of highly odor-specifi c neurons would lead to relatively 
precise memories. Sparse representations by highly 
stimulus-specifi c neurons are a general feature of brain 
areas involved in learning and memory, including the 
hippocampus and cerebellum in humans.
Using the simplicity and genetic manipulability of 
Drosophila, our goal is to understand several funda-
mental properties of neural responses in learning and 
memory-related brain areas: What mechanisms give 
rise to the stimulus specifi city? What exactly is mean-
ingful about the activity patterns? Is it simply which 
cells respond, or does the precise timing of activity mat-
ter? How are these response patterns modifi ed by learn-
ing? And ultimately, what are the roles of the many 
genes implicated in learning on network level activity 
in the brain?
Is the Timing of Spikes Important for the 
Neural Code in the Olfactory System?
M. Brill
Neuronal signals propagate from one cell to the next 
via electrical impulses, or spikes, that evoke neu-
rotransmitter release. These trains of spikes are like 
the ones and zeros of the binary code of a computer. 
Spike trains have many different features that could 
potentially carry information: the rate of spikes, the 
timing of the onset, and the relative timing of fi ring 
across neurons. Although spike rate is widely recog-
nized as important, other features of those spike trains 
more related to spike timing could also be important 
signaling factors. Understanding what features of 
these spike trains convey information is a fundamen-
tal aspect of understanding the brain. It is a little like 
fi nding the key to a computer’s binary code.
We have begun to investigate this fundamental 
question by constructing artifi cial spike trains with 
these different features (spike rate vs. spike timing) 
under our experimental control. Using optogenetic 
techniques, we can manipulate the activity patterns at 
an early layer of the olfactory system. By then moni-
toring downstream layers of the circuit using in vivo 
imaging techniques, we can assess what features of 
those artifi cial spike trains are effectively transmit-
ted to those downstream neurons, i.e., what features 
of the code are relevant. We are currently focusing 
on the importance of the onset of spiking activity. If 
downstream decoder neurons receive inhibition that is 
slow and takes time to develop, early-onset spikes could 
potentially be more effective at driving downstream 
circuitry than those arriving late. By combining this 
optogenetic control of spike trains with measures of the 
impact on behavior, we plan to reveal which spike train 
features are important for the perception of the animal, 
getting to the core features of the neural code in this 
system.
Neuroscience  163
Dopamine Controls the Signal-to-Noise Ratio 
of Transmission through the Mushroom Body
T. Hige, M. Modi
Neuromodulators such as dopamine and octopamine 
are essential for learning, but how they act and what 
their precise role is during the learning process have 
not been established. We examined the effects of these 
neuromodulators on activity in the MB. Surprisingly, 
we found that dopamine affects the signal-to-noise 
ratio of odor representations in the MB. Preliminary 
results suggest that dopamine increases the reliability 
of MB responses. Reliability is diffi cult to achieve in 
sparse representations because neurons typically re-
spond with small numbers of spikes. Thus, it seems 
particularly useful for the circuit to use neuromodula-
tors to increase signal-to-noise ratio depending on the 
behavioral context the animal is in; essentially dopa-
mine could control the salience of a stimulus.
Additionally, we have shown that dopamine di-
minishes odor responses in the neurons that are down-
stream of the MB, the MB output neurons. Together, 
these results suggest a model where the dopamine acts 
to make the circuit a selective fi lter, increasing the 
signal-to-noise ratio of responses in the MB while de-
creasing signal transmission through the MB. These 
results may be an excellent entry point for studying 
the fundamental cognitive process of attention, which 
is essentially a process of fi ltering out distracting in-
formation to focus on pertinent inputs. We are now 
testing this possibility and investigating the precise 
mechanisms of the dopamine effects.
Mushroom Body Output Neurons and 
Flexible Odor Categorization
T. Hige
Almost no studies have examined what happens to 
sensory information downstream from areas with 
sparse representations. So what happens to odor infor-
mation after it leaves the MB? In collaboration with 
Gerry Rubin’s lab at the Janelia Research Campus, 
we have functionally characterized odor coding in the 
complete set of 34 MB output neurons (MBONs). 
The following are our main fi ndings.
1. Synaptic plasticity diversifi es MBON tuning prop-
erties. We found that uniquely identifi able MBONs 
have strikingly different odor response properties 
across different fl ies. To test whether these individ-
ual differences are experience-dependent, we exam-
ined odor tuning of the same neuron across the 
two hemispheres of the brain. Identical MBONs 
in the two hemispheres have identical odor tuning 
properties; however, the tuning of that neuron is 
very different across different individual fl ies. This 
result suggested that MBON tuning in each fl y is 
partly a product of that individual’s developmental 
and experimental history. We tested this by show-
ing that a central gene in learning and memory, 
rutabaga, is required for these individual differ-
ences to arise. This experiment is one of the fi rst to 
show that the odor tuning properties of MBONs 
are shaped by synaptic plasticity.
2. MBONs represent categories/groups of odors. We 
examined odor responses across the entire population 
of MBONs. We found that MBONs do a poor job of 
representing odor identity, especially in comparison 
to the upstream neurons that constitute the MB itself. 
This is because certain odors evoke extremely similar 
patterns of response across the MBON population. 
In fact, only three main groups of odors were identi-
fi ed based on the pattern of activity in the MBONs. 
Interestingly, one group was composed of odors that 
are repellent to fl ies, whereas another group contains 
food-based odors. This is an exciting result because 
few investigators have considered how different 
sensory inputs can be categorized into behaviorally 
meaningful classes. We may be seeing olfactory infor-
mation shaped into behaviorally relevant neuronal 
signals at this layer, fi nding the connection between 
sensory input and motor output
These two results indicate that MBON odor re-
sponses are highly plastic and that the MBON re-
sponse pattern signals the positive or negative quality 
of an odor. Together, these fi ndings suggest that the 
MB represents odors categorically and that experience 
could potentially shift a neutral odor into either a pos-
itive or negative category, depending on the fl y’s past 
experience with that odor. This work has now been 
through two rounds of reviews at Nature and the out-
look is positive, although it has not yet been accepted.
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CIRCUITRY UNDERLYING CORTICAL PROCESSING 
AND DECISION MAKING 
A. Zador B. Burbach S. Koh A. Reid
 D. Gizatullina U. Livneh V. Vasily
 S. Ghosh F. Marbach Q. Xiong
 S. Jaramillo H. Oyibo P. Znamenskiy
 J. Kebschull I. Peikon
My laboratory is interested in how neural circuits un-
derlie cognition, with a focus on the cortical circuits 
underlying auditory processing and decision making. 
To address these questions, we use a combination of 
molecular, electrophysiological, imaging, and behavior-
al approaches. In addition, we are developing a method 
that will allow us to use high-throughput DNA se-
quencing to determine the wiring diagram of the brain 
at single-neuron resolution rapidly and effi ciently, at 
low cost.
Role of Corticostriatal Plasticity 
in Auditory Decisions
Q. Xiong, P. Znamenskiy
Corticostriatal plasticity has a key role in reinforce-
ment learning, but how associations between stimuli 
and motor responses are established remains unclear. 
Recent work from our group demonstrated a causal 
role of corticostriatal neurons in driving choices dur-
ing an auditory discrimination task, inspired by the 
classic random dot motion task used by Newsome 
and colleagues in macaques, in which subjects were 
required to choose the left or the right response port 
depending on the perceived frequency of a sound. We 
are testing the hypothesis that changes in the strength 
of corticostriatal synapses underlie the association be-
tween sound and action required to perform this task. 
Our results indicate that changes in the strength of a 
specifi c subset of corticostriatal synapses encode the 
arbitrary association between stimulus and motor re-
sponse. Because all sensory cortical areas send projec-
tions to the striatum, our fi ndings suggest a general 
mechanism for the formation of arbitrary sensorimo-
tor transformations.
In Vivo Two-Photon Imaging of Cortical 
Activity in Mice Performing an Auditory 
Discrimination Task
U. Livneh, F. Marbach
We are studying how activity in the auditory cortex is 
used to guide behavior. To address this, we have de-
veloped a suitable behavioral paradigm in mice that is 
compatible with two-photon imaging of behaviorally 
evoked neural activity. This task is modifi ed from one 
we previously used in freely moving rats (Znamenskiy 
and Zador, Nature 497: 482 [2013]). This paradigm 
will allow us to identify the pathways important for 
the fl exible association of sensory stimuli with desired 
actions, a critical function of higher nervous systems.
Sequencing the Connectome
I. Peikon, D. Gizatullina, J. Kebschull, H. Oyibo, V. Vasily
We are developing an entirely novel approach to map-
ping neural connectivity that harnesses the high-
throughput power of next-generation sequencing. We 
have engineered a suite of molecular tools to barcode 
individual neuronal connections (BOINC) for read-
out via DNA sequencing. By mapping neural con-
nectivity onto DNA sequencing, we have rendered 
neural circuit reconstruction tractable with current 
techniques.
Sequencing the Projectome
J. Kebschull, I. Peikon, D. Gizatullina
Understanding the brain requires knowledge of its 
anatomy. Recently, much progress has been made in 
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mapping out “mesoscale” (area-to-area) connectivity 
in the mouse brain. However, most current approaches 
rely solely on bulk mapping of projections and can-
not resolve the projection patterns of single neurons; 
techniques with the resolution needed to resolve single-
neuron connectivity suffer from very low throughput. 
We are developing a high-throughput, multiplexable 
method to determine long-range projections in the 
mouse brain at single-cell resolution. To do so, we are 
leveraging the vast combinatorial space of nucleic acid 
barcodes to uniquely label individual neurons. We then 
use the power of modern high-throughput sequencing 
technology to reliably, quickly, and inexpensively read 
out these labels at projection target sites.
Proximity Ligation Assay for 
Synapse Detection
J. Kebschull, D. Gizatullina
We are developing a novel method to label synapses 
between two genetically identifi ed neural populations 
based on the proximity ligation assay (PLA). PLA uses 
antibodies to detect the close (<40-nm) apposition of 
two proteins. By targeting a pre- and postsynaptic 
protein, we can identify synapses with high reliability. 
This method has the potential to multiplex synapse 
detection to several pathways through labeling with 
orthogonal proximity probes.
Role of Corticostriatal Plasticity 
in Stimulus-Motor Association
S. Ghosh
Previous work from our lab has shown that corticostri-
atal projections have a causal role in decision making 
in a complex auditory discrimination task (Znamen-
skiy and Zador, Nature 497: 482 [2013]; Xiong et al. 
2015). Moreover, learning of this discriminatory task 
results in a specifi c pattern of plasticity in this path-
way, which is determined by the frequency tuning of 
the neurons and the corresponding motor movement. 
Nevertheless, how this pattern of plasticity overlays 
onto the complex striatal circuitry remains unknown. 
We are therefore testing the hypothesis that differen-
tial patterns of plasticity in specifi c subtypes of corti-
costriatal synapses underlie the ability to associate a 
particular auditory cue with a given motor action in 
the “tone cloud” task.
Circuits Underlying Auditory 
Representations and Decisions
S. Jaramillo, U. Livneh, F. Marbach
We are studying the circuits underlying auditory rep-
resentations and how these representations give rise 
to decisions. We train rats and mice to perform well-
controlled auditory tasks and then use electrical and 
optogenetic methods to monitor and perturb neural 
activity. We use this approach to study the role of the 
auditory thalamus, cortex, and striatum in these be-
havioral processes. Using tasks in which the stimulus-
action associations vary within a behavioral session, we 
have uncovered striking similarities in how thalamic 
and cortical neurons are modulated by the animals’ 
choices.
Interhemispheric Connections 
in the Auditory Cortex
S. Koh
The callosal projection is a long-range connection be-
tween the left and right auditory cortex, and it is one 
of the major corticocortical projections in the auditory 
cortex. However, its role in auditory coding is unclear. 
We are studying how manipulating the callosal pro-
jection affects auditory representations in the cortex. 
We found that silencing the auditory cortex in one 
hemisphere suppresses sound-evoked activity in the 
other hemisphere. The suppression effect was stronger 
for late response with latency longer than 40 msec and 
also for the response to sound coming from ipsilateral 
locations. Our results suggest that the callosal projec-
tion is well suited for slow interhemispheric integra-
tion of location-relevant information.
Using Rci Recombinase to Generate 
Cellular Barcodes In Vivo
I. Peikon, D. Gizatullina
Heterogeneity is a ubiquitous feature of biological 
systems. A complete understanding of such systems 
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requires a method for uniquely identifying and track-
ing individual components and their interactions 
with each other. We have developed a novel method of 
uniquely tagging individual cells in vivo with a genetic 
“barcode” that can be recovered by DNA sequencing. 
Our method is a two-component system composed of 
a genetic barcode cassette whose fragments are shuf-
fl ed by Rci, a site-specifi c DNA invertase. The system 
is highly scalable, with the potential to generate theo-
retical diversities in the billions. Currently, this meth-
od could be used to track the dynamics of populations 
of microbes through various bottlenecks. Advances of 
this method should prove useful in tracking interac-
tions of cells within a network and/or heterogeneity 
within complex biological samples. The barcoding 
method developed here represents a major fi rst step 
toward our goal of uncovering the connectivity of 
neural circuits using DNA sequencing.
Role of Inhibitory Interneurons 
in Auditory Cortex Function
A. Reid
Fast synaptic inputs to neurons in the auditory 
cortex are either inhibitory or excitatory. Cortical 
interneurons are tremendously diverse. One inhibi-
tory interneuron subclass, defi ned molecularly by 
the expression of parvalbumin (“PV+”), seems to 
be ideally positioned to mediate the fast component 
of the characteristic barrage of inhibition elicited 
by a sound. We are testing the hypothesis that PV+ 
inhibitory interneurons mediate fast sound-evoked 
inhibitory synaptic currents in the auditory cortex. 
We seek to establish a causal link between a physi-
ological property—the fast sound-evoked inhibition 
that contributes to receptive fi eld dynamics—and 
a component of the underlying cortical circuitry. 
We approach the problem at three different levels, 
from brain slices through in vivo physiology to be-
havior. Although we are currently focusing on the 
role of one particular interneuron subclass (PV+), 
our approach combining electrophysiological and 
molecular tools can readily be generalized to other 
subclasses and can be extended to probe the circuit-
ry underlying other behavior- and sensory-elicited 
neuronal responses.
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NEURAL BASIS OF BEHAVIOR IN DROSOPHILA
Y. Zhong J. Beshel Y. Shuai M. Zhang
Multiple Neural Pathways Mediate 
Active Forgetting in Drosophila
Y. Shuai
Evidence exists that short-term memories are removed 
by active forgetting processes, which involve the ac-
tivation of signal transduction pathways independent 
of those for learning. To investigate the neural basis 
of such active forgetting, we performed a neural-si-
lencing screen targeting extrinsic neurons connected 
to the Drosophila olfactory memory site, the mush-
room body (MB). We identifi ed two populations of 
neurons that are not involved in learning, but that 
function in parallel to drive forgetting (i.e., stimulat-
ing their activity induces memory loss), whereas si-
lencing their functions preserves labile memory. These 
neurons include a cluster of dopamine neurons termed 
PAM-β′1 and a pair of glutamate neurons termed 
MBON-γ4 > γ1γ2. The identifi ed neurons are re-
quired for time-dependent memory decay specifi cally, 
but not for acute forgetting during reversal learning. 
The differential requirement suggests the presence of 
diversifi ed forgetting circuits that may be recruited in 
a context-dependent manner.
Mapping the Food-Odor Circuit 
Anatomically and Functionally
J. Beshel
We have previously reported that the range of attrac-
tion fl ies display to food odors can be accounted for by 
looking at the odor-evoked activity of neurons immu-
nopositive for the Drosophila homolog of mammalian 
neuropeptide Y or Drosophila neuropeptide F (dNPF). 
These dNPF neurons are both necessary and suffi cient 
to promote food-odor-attraction behavior. They reside 
within the central brain and demonstrate the possibil-
ity of one of perhaps several discrete brain sites that 
explicitly encodes odor value. We continue to map the 
food-odor circuit anatomically and functionally and 
have made signifi cant progress in the isolation of sin-
gle dNPF-positive neurons using multiple genetically 
based techniques. Single-cell isolation considered in 
combination with visualization of pre- and postsyn-
aptic marker proteins has allowed us to further refi ne 
proposed dNPF-upstream and -downstream brain 
regions. We continue to study loss/gain-of-function 
phenotypes through a combination of RNA interfer-
ence and acute genetic manipulation on neuronal sub-
sets determined to be part of the dNPF circuitry.
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David Jackson and colleagues study genes and signals that regulate plant growth and architecture. 
They are investigating a unique way in which plant cells communicate, by transporting regula-
tory proteins via small channels called plasmodesmata. These channels, which direct the fl ow of 
nutrients and signals through growing tissues, are regulated during development. The team dis-
covered a gene encoding a chaperonin, CCT8, that controls the transport of a transcription factor 
SHOOTMERISTEMLESS (STM) between cells in the plant stem cell niche, or meristem. STM 
is critical for stem cell maintenance, and studies in this past year have identifi ed additional factors 
that are required for transport of this important regulator. The lab also continues to identify addi-
tional genes that control plant architecture through effects on stem cell maintenance and identity, 
and their work has implications for crop yields. Recent examples include discovery of a subunit 
of a heterotrimeric G protein that is conserved throughout animals and plants, and their studies 
indicate that this gene controls stem cell proliferation. They have found that in plants, the G pro-
tein interacts with a class of receptors completely different from those in animals. Their discovery 
helps to explain how signaling from diverse receptors is achieved in plants. This year, they also 
discovered a fundamentally new mechanism of stem cell control that involves signaling from dif-
ferentiating cells back to the stem cell niche. Several studies in plants and animals have hinted at 
such a mechanism, but their work has for the fi rst time identifi ed the receptor and signals involved. 
They are applying this work to agriculture by fi nding weak mutations in some of these genes and 
are fi nding in some cases that they can enhance seed production in maize, which could lead to 
yield increases. Separately, the lab has characterized system-wide networks of gene expression, 
using “next-gen” profi ling and chromatin immunoprecipitation methods that have revealed many 
new hypotheses in developmental networks controlling infl orescence development. They are also 
developing a collection of maize lines that can drive expression of any reporter or experimental 
gene in any tissue type—tools of great interest to maize researchers that are being made available 
to the broader scientifi c community, enabling experiments never before possible in crop plants.
Zachary Lippman’s research focuses on the process of fl owering and fl ower production, which is 
a major contributor to plant reproductive success and agricultural yield. By identifying genes that 
control how tomato plants produce their fl owers in their characteristic repeated zigzag arrange-
ment (e.g., tomatoes on a vine), Lippman’s lab is addressing when and how fl owering branches 
known as infl orescences develop on plants, particularly fruit-bearing plants. Of particular interest 
is how these “reproductive phase transitions” have contributed to the evolution of diverse infl o-
rescence branching patterns in tomato’s larger Solanaceae family, which includes plants that make 
just one fl ower, such as pepper and petunia, in each infl orescence, to plants whose infl orescences 
produce dozens of branches and hundreds of fl owers, such as many wild species of tomato. Using 
a combination of genetic, genomic, and molecular approaches, Lippman is dissecting the gene 
networks that are responsible for the variation in infl orescence branching found in nature. He 
hopes to leverage these discoveries to improve crop yields. Already, his work on genes that are re-
sponsible for the production and activity of a universal fl owering hormone known as fl origen has 
resulted in novel approaches to fi ne-tune plant architecture and fl ower production, boosting yield 
beyond leading commercial varieties. To continue hunting for new genes, Lippman has adopted 
a systems-biology approach and next-generation sequencing technology to capture those genes 
that are active as stem cells mature from a vegetative to a reproductive state. Nearly 4000 genes 
were found to refl ect the existence of a “maturation clock,” and one of the clock genes known as 
Terminating Flower acts as a key regulator to maintain a progressive pace to fl owering—which in 
turn dictates how many fl owers are produced on each tomato infl orescence. Finally, the Lippman 
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lab determined the genome sequence of the “currant tomato,” the wild ancestor of larger-fruited 
cultivated tomatoes, in order to better understand how fl ower and fruit production changed dur-
ing the process of crop domestication.
Epigenetic mechanisms of gene regulation—chemical and conformational changes to DNA and 
the chromatin that bundles it—have had an important impact on genome organization and in-
heritance and on cell fate. These mechanisms are conserved in eukaryotes and provide an addi-
tional layer of information superimposed on the genetic code. Robert Martienssen, a pioneer in 
the study of epigenetics, investigates mechanisms involved in gene regulation and stem cell fate in 
yeast and model plants including Arabidopsis and maize. He and colleagues have shed light 
on a phenomenon called position-effect variegation, caused by inactivation of a gene positioned 
near densely packed chromosomal material called heterochromatin. They have discovered that 
small RNA molecules arising from repeating genetic sequences program that heterochromatin. 
Martienssen and colleagues have described a remarkable process by which “companion cells” to 
sperm in plant pollen grains provide them with instructions that protect sperm DNA from trans-
poson damage. They found that some of these instructions, or epigenetic marks, could be inher-
ited in the next generation. With collaborators in Mexico, Martienssen has also coaxed Arabidop-
sis, a fl owering plant, to produce egg cells without meiosis, an important step toward a long-time 
goal of plant breeding: generating clonal offspring to perpetuate hybrid vigor. The lab has also 
showed that when RNA polymerase II has transcribed a stretch of DNA, the RNA interference 
mechanism causes the enzyme to release its hold on the DNA and fall away. This allows the repli-
cation fork to progress smoothly and the DNA strands to be copied; histone-modifying proteins, 
which follow right along, establish heterochromatin. Martienssen’s group also continues to work 
on problems related to the creation of plant-based biofuels. This year, as part of a collaborative 
project to generate a high-quality full genome map of the oil palm plant, Martienssen and his col-
leagues identifi ed a single gene that controls the yield of oil palm trees. This discovery will increase 
yields and should lessen the environmental burden of oil palm production, which often threatens 
already endangered rainforest lands.
The growing tips of plants, called meristems, contain a population of stem cells that serve as a 
persistent source of daughter cells from which new organs, such as leaves, arise. Marja Timmer-
mans and colleagues are studying the genetic networks that regulate plant stem cell activity. Using 
genomic approaches, they have defi ned gene expression signatures that distinguish indeterminate 
stem cells from their differentiating derivatives. They have also worked out the mechanism that 
suppresses stem-cell fate to allow cells to differentiate and have shown that this process requires 
a highly conserved epigenetic gene silencing mechanism. In particular, Timmermans’ group has 
shown that specifi c DNA-binding proteins mediate the recruitment of Polycomb repressive com-
plexes to stem cell factors, an action that stably represses their expression in differentiating organs. 
This work addresses a major unresolved question in the fi eld of epigenetics: how Polycomb pro-
teins, which do not bind DNA themselves, recognize defi ned targets. Plant stem cells also produce 
signals important for the patterning of lateral organs. The lab has discovered that small RNAs can 
traffi c from cell to cell and are among the stem-cell-derived signals. They have found that polarity 
in leaves is established via opposing gradients of mobile small RNAs that act as morphogen-like 
signals. Their most recent fi ndings identifi ed a third small RNA gradient involved in maintenance 
of organ polarity. These fi ndings illustrate the complexity with which small RNAs generate devel-
opmental patterns. Currently, they are investigating parameters of small RNA mobility and the 
unique patterning properties of resulting small RNA gradients. Mathematical modeling predicts 
that gradients might serve to generate robustness during development.
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DEVELOPMENTAL BIOLOGY: STEM CELLS, SIGNALING, 
AND CROP PLANT ARCHITECTURE
D. Jackson R. Balkunde M. Fuchs M. Shen
 H.T. Bui B.I. Je K. Vera
 H. Claeys T. Lau Q. Wu
 E. Demesa-Arevalo I. Liao T. Zadrozny
 A. Eveland M. Rutigliano
The ultimate goal of our research is to improve crop 
plant growth and yield. More specifi cally, we aim to 
identify genes, signals, and pathways that regulate 
plant architecture and development. All higher or-
ganisms develop by carefully controlling the fl ow of 
information that passes between cells and tissues. We 
are interested in discovering the signals that carry this 
information, in fi nding out how the signals are trans-
mitted, and in determining how they function.
A major focus has been identifi cation of genes that 
control development through effects on stem cell 
maintenance and identity. Examples from the past 
year include discovery of a redox enzyme that controls 
shoot architecture and its interacting partner, a DNA-
binding transcription factor. We used “next-gen” pro-
fi ling methods to identify system-wide networks of 
gene expression in infl orescence development, and the 
genes that function downstream from the redox en-
zyme transcription factor complex. We also continue 
to characterize the role of G proteins in stem cells, 
identifying candidate upstream receptors, as well as 
mutations in partner proteins, using CRISPR. Our 
discoveries help explain how signaling from diverse 
receptors is achieved in plants. This work could help 
improve crop yields, because we previously demon-
strated that weak mutations in one of the receptor 
genes enhance seed production in maize.
In another project, we are investigating a unique 
way in which plant cells communicate, by transport-
ing regulatory proteins via small channels called plas-
modesmata. These channels, which direct the fl ow 
of nutrients and signals through growing tissues, are 
regulated during development. We are using genetic 
screens to identify novel factors that control the trans-
port of transcription factors between cells in the plant 
stem cell niche. Finally, we aslo made a major con-
tribution to the maize genetics toolbox by creating 
a collection of lines that can drive expression of any 
reporter or experimental gene in any tissue type. Such 
tools are of great interest to researchers and are being 
made available to the broader scientifi c community, 
enabling experiments never before possible in crop 
plants.
Regulation of Cell-To-Cell Trafﬁ cking 
of the KNOTTED1 Transcription Factor
R. Balkunde, H. Bui, K. Vera, M. Shen
Cell-to-cell communication functions to specify cell 
fate and coordinate development in all multicellular 
organisms. However, unlike animal cells, plant cells 
have cell walls that could limit exchange of signal mol-
ecules between neighboring cells. Plants have therefore 
developed direct connections using special structures 
called plasmodesmata (PD). These channels allow the 
selective traffi cking of signaling macromolecules, such 
as transcription factors and RNAs, between cells. In 
addition to cell fate specifi cation, they are involved in 
viral movement, transport of metabolites, and cell-to-
cell spread of RNA interference (RNAi), which points 
to their fundamental importance in coordinating plant 
defense, metabolism, and development. Despite the 
discovery of PD more than 100 years ago, the underly-
ing components and mechanisms of PD traffi cking re-
main poorly understood. Hence, we are implementing 
an unbiased genetic strategy to dissect these molecular 
mechanisms, using a reporter system involving Arabi-
dopsis leaf trichomes as an easily scorable phenotype 
and the developmentally important mobile proteins 
KNOTTED1 (KN1) from maize and its Arabidopsis 
homolog SHOOTMERISTEMLESS (STM).
The trichome rescue system designed by our lab is 
widely used to characterize protein mobility. Briefl y, 
GLABRA1 (GL1) protein is cell-autonomous and is 
required for trichome formation in the leaf epidermis. 
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Therefore, GL1, when expressed in mesophyll in gl1 mu-
tants, does not rescue trichomes. However, when fused 
to KN1 (GL1-KN1), it now results in trichome rescue, 
as the mobile KN1 brings GL1 into the epidermis. Eth-
ylmethane sulfate (EMS) mutagenesis screening using 
this system, followed by Illumina high-throughput se-
quencing, resulted in identifi cation of a mutation in a 
gene encoding CCT8 (chaperone containing tailless-
complex 8). This led to the exciting proposal that chap-
eronins facilitate cell-to-cell traffi cking and stem cell 
maintenance in Arabidopsis, supporting the functional 
relevance of chaperonin-mediated traffi cking through 
PD. These results highlight the importance of protein 
conformational changes for PD traffi cking.
Current efforts are focused on understanding the 
mechanism of CCT8 action and on identifying new 
traffi cking regulators. Our efforts have identifi ed mu-
tants with interesting developmental defects, in addi-
tion to loss of trichome rescue. For example, mutant 
1058 has leaf shape and fl oral organ defects, and mu-
tant 1066 has narrow and elongated leaves, enlarged 
vegetative meristems, and fasciated shoots. Using a 
combination of marker-based mapping and Illumina 
high-throughput sequencing, we mapped these muta-
tions to candidate genes. Next, using transformable 
bacteria artifi cial chromosomes (TACs) for comple-
mentation, we identifi ed the causal mutations in 
NUCLEOSTEMIN (NSN1) and ASPARTYL tRNA 
SYNTHETASE (AspRS) genes for mutants 1058 and 
1066, respectively. We further confi rmed these genes 
by crossing to T-DNA knockout lines. NSN1 encodes 
a GTPase that localizes to the nucleolus and nucleo-
plasm. The exact molecular function of NSN1 is not 
clear; however, studies in mammalian cells suggest 
that NSN1 is required for cell proliferation, rRNA bio-
genesis, and ribosome assembly, and its GTPase activ-
ity is required for traffi cking from the nucleoplasm to 
the nucleolus. Interestingly, the Drosophila NSN1 ho-
molog was shown to function non-cell-autonomously. 
The second candidate, AspRS, is a nuclear gene, but the 
protein is targeted to the chloroplast and mitochon-
dria. Aminoacyl-tRNA synthetases (AARSs) catalyze 
the attachment of an amino acid to its cognate transfer 
RNA molecule. AARSs have also been shown to be re-
quired for the gametogenesis and embryo development 
and for organ patterning. An example of a non-cell- 
autonomous function for tRNA synthetases was shown 
for the SYCO gene, which encodes a cysteinyl tRNA 
synthetase. During female gametophyte development 
in Arabidopsis, SYCO is expressed and is localized to 
the mitochondria of central gametic cells, but it is ab-
sent in the antipodal cells. However, it controls the life 
span of antipodal cells, by nonautonomous signaling.
Interestingly, both NSN1 and AspRS proteins have 
been reported in the PD proteome, suggesting that 
these proteins may have a direct role in PD regula-
tion and protein traffi cking. Currently, we are inves-
tigating protein localization to PD using fusions to 
mCherry or YPET. We will next perform a detailed 
characterization of the mechanism by which these 
candidates regulate protein traffi cking. In an effort 
to identify additional regulators of PDs, we are also 
screening additional EMS-mutagenized M2 families.
Role of SHOOTMERISTEMLESS Trafﬁ cking 
in the Shoot Apical Meristem
R. Balkunde
STM encodes a homeodomain transcription factor 
and is required for the maintenance of pluripotent 
stem cells in the shoot. STM is expressed throughout 
the meristem and is down-regulated in developing 
organ primordia. STM protein moves between cells, 
but the signifi cance of this is not well understood. 
A common approach to prevent cell-to-cell move-
ment is to add nuclear localization sequences (NLSs) 
to sequester the protein in the nucleus. We made an 
STM native expression construct with yellow fl uo-
rescent protein (YFP) fused at the amino terminus, 
and a second construct that also contained 2xNLS 
sequences at the amino terminus, to promote nuclear 
import. We found that the native pSTM::YFP~STM 
construct fully rescued stm phenotypes; however, the 
pSTM::2xNLS~YFP~STM construct did not. The 
2xNLS~YFP~STM plants had axillary shoots in the 
axils of the cotyledons and smaller SAMs (shoot apical 
meristems) with fewer YFP~STM expressing cells 
(Fig. 1). We interpret the results as evidence that STM 
traffi cking is important for proper SAM development. 
For example, having a smaller or “less potent” SAM 
could lead to axillary bud formation in the axils of 
cotyledons by a loss of apical dominance. This phe-
notype also suggested a possible defect in defi ning a 
correct organ boundary. It is known that STM and 
organ boundary genes CUP SHAPED COTYLE-
DON1/2/(CUC1/2) reinforce each other, and thus we 
are checking the expression of boundary genes. Subtle 
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differences in the localization of STM and 2xNLS-
STM at the organ boundary region may infl uence the 
levels of boundary gene expression, which may explain 
the developmental differences between the lines ex-
pressing STM and those expressing 2xNLS-STM.
Generation of a pOp-LhG4 trans-Activation 
System for High-Throughput Protein 
Localization and Functional Studies in Maize
E. Demesa-Arevalo, Q. Wu, T. Zadrozny [in collaboration 
with A. Chan, J. Craig Venter Institute; A. Sylvester, 
University of Wyoming]
Despite the growing abundance of resources available 
for the study of various model organisms, the classi-
cal approach of characterizing a single gene mutant 
still provides invaluable information regarding gene 
function. We previously generated transgenic lines by 
tagging various genes with fl uorescent markers, using 
their endogenous promoters to provide visual infor-
mation with respect to time and location of expres-
sion as well as the ability to study the gene products 
at the protein level. Using our experience in promoter 
analysis, we are currently establishing tools for com-
plex analysis at cellular, tissue, or organ level. We 
have developed a pOp-LhG4 trans-activation system 
in maize that allows us to express proteins in specifi c 
tissues and/or transient developmental stages. The 
pOp-LhG4 system includes (1) a transcription activa-
tor, LhG4, which is a fusion between a high-affi nity 
DNA-binding mutant of lac repressor, LacIHis17, and 
transcription-activation domain II of GAL4 from 
Saccharomyces cerevisiae, and (2) a chimeric promoter, 
pOp, that consists of lac operators cloned upstream 
of a minimal CaMV (caulifl ower mosaic virus) pro-
moter, not activated in the reporter lines until crossed 
with the LhG4 activator line. We have already gen-
erated several LhG4 drivers, as well as four pOp re-
sponder lines, including Zea mays FON2-LIKE CLE 
PROTEIN1 (pOp::FCP1) and the FLOWERING 
LOCUS T-like Zea mays CENTRORADIALIS 8 
(pOp::ZCN8). By crossing pOp::ZCN8 plants with 
a constitutive promoter line, pEF1A::LhG4, we found 
that neither the driver plants, pEF1a::LhG4, nor the 
responder plants, pOp::ZCN8-YFP, showed an early 
fl owering phenotype; whereas the F1 plants containing 
both pEF1A::LhG4 and pOp::ZCN8-YFP showed 
early fl owering. We are now analyzing additional tis-
sue-specifi c LhG4 driver lines expressing pOp::FCP1. 
pYABBY14-LhG4 is expressed in young leaf primor-
dia, but not in the SAM. Overexpression of ZmFCP1 
specifi cally in the leaf using this promoter reduces 
seedling size, possibly by affecting meristem size non-
cell-autonomously (Fig. 2, upper panel). Currently, 20 
LhG4 driver constructs have been generated, and our 
goal is to produce a comprehensive array of cell and 
tissue-specifi c lines (Fig 2, lower panel), which we will 
use to (1) isolate specifi c cell types by fl uorescence-
activated cell sorting (FACS) for transcriptional pro-
fi ling and (2) drive the misexpression of developmen-
tally regulated genes in order to better understand the 
function of stem cell niches during development. Data 
on the characterization of our FP and LhG4 trans-
genic lines, including confocal micrographs, movies, 
and recent publications, can be found on our website, 
http://maize.jcvi.org/cellgenomics.
The Regulation of Meristem Size in Maize
B.I. Je, Q. Wu, M. Fuchs, A. Eveland [in collaboration with 
M. Komatsu and H. Sakai, Dupont Crop Genetics]
All plant organs derive from populations of stem cells 
called meristems. These stem cells have two purposes: to 
divide to replace themselves, and to give rise to daughter 
cells, which will differentiate into lateral organs. Conse-
quently, meristems must precisely control the size of the 
Figure 1.  Blocking STM movement causes SAM phenotypes. (A) 
stm11 seedling complemented by pSTM::YFP-gSTM. (B) stm11 
seedling complemented by pSTM::2xNLS-YFP-gSTM, showing 
abnormal axillary shoot in the axils of cotyledon. These seed-
lings also have a smaller SAM (D, compared to control, C).
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stem cell niche via a network of positive and negative 
feedback signals. A loss of function in a negative regula-
tor of stem cell fate can result in an enlarged or fasciated 
meristem phenotype and a dramatic alteration in the 
morphology of the maize ear and tassel.
Maize is an excellent genetic model system because 
of a large collection of developmental mutants and a 
sequenced reference genome. Our lab has undertaken 
a forward genetic approach to identify key regulators 
of stem cell homeostasis and meristem size. Two pre-
viously cloned mutants, fasciated ear2 and thick-tassel 
dwarf1, encode orthologs of the Arabidopsis thaliana 
genes CLAVATA1 and CLAVATA2, indicating that 
the well-known CLAVATA-WUSCHEL regulatory 
feedback loop is conserved from dicots to monocots. 
However, little else is known about the control of this 
important developmental process in maize. Here, we 
describe our progress in identifying additional genes 
contributing to stem cell niche homeostasis.
Recently, we have shown that the maize COM-
PACT PLANT2 (CT2) gene, which encodes the pre-
dicted α subunit of a heterotrimeric GTPase (Gα), 
functions in the CLAVATA pathway to control meri-
stem size through its interaction with FEA2. Genetic 
data indicate that ct2 and fea2 are in a common path-
way, and co-immunoprecipitation (Co-IP) and gel-
fi ltration data further suggest that FEA2 and CT2 
are in the same complex. Interestingly, our Co-IP 
experiments in Nicotiana benthamiana suggested that 
scrambling the intracellular tail of the FEA2 receptor 
did not affect the FEA2-CT2 interaction, suggesting 
their interaction may require additional mediators. 
Furthermore, fl uorescence resonance energy transfer 
(FRET) and bimolecular fl uorescence complementa-
tion (BiFC) data also suggested that FEA2 and CT2 
do not directly associate with each other and that 
other proteins may bridge their interaction. To fi nd 
the bridging protein(s), we used IP-mass spectrom-
etry to fi nd proteins that can be pulled down by both 
FEA2 and CT2. We identifi ed an uncharacterized 
leucine-rich repeat receptor-like kinase (LRR-RLK) 
that interacted with both FEA2 and CT2, and these 
results were confi rmed by Co-IP experiments using 
a tobacco transient expression system. Furthermore, 
BiFC results suggested that the LRR-RLK protein di-
rectly associates with CT2, but a kinase domain trun-
cated version did not, suggesting that the kinase do-
main is required for this interaction. This LRR-RLK 
Figure 2. A maize trans-activation system. (Upper panel) pYABBY14-LhG4//pOp-TagRFPt is speciﬁ cally expressed 
in leaf primordia (P, white dots = nuclei), plants containing both constructs pYABBY14-LhG4 and pOp-ZmFCP1 
are reduced in size, but the seedlings containing only pYABBY14-LhG4 or pOp-FCP1 were normal. (Lower panel) 
pGLB1-LhG4//pOp-GUS, pAbph2-LhG4//pOp-TagRFPt and pTsh1-LhG4//pOp-TagRFPt are speciﬁ c promoter drivers 
for embryo, young leaf (arrow) and young bracts, respectively.
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is preferentially expressed in meristems, and we are 
now searching for phenotypes to illuminate its bio-
logical function in meristem development.
To further explore G-protein signaling, we gener-
ated a constitutively active form (CA-CT2), using a 
point mutation to abolish the GTPase activity, and 
tagged this protein with mTFP1. We are introgress-
ing CA-CT2-mTFP1 into ct2 and fea2 mutant back-
grounds to study how constitutive G-protein signal-
ing affects maize development. We also knocked out 
the only Gβ subunit of maize using CRISPR-Cas 
genome editing and will study the role of Gβ in mer-
istem regulation. All of these studies will facilitate 
our understanding of G-protein signaling in maize 
development.
Another fasciated ear mutant that we have cloned 
is fasciated ear 3 ( fea3), which was derived from irra-
diation mutagenesis. fea3 shows an overproliferation 
of the infl orescence meristems, leading to enlarged or 
fasciated ears and thick tassels. Double mutants of fea3 
with td1 or fea2 have additive and synergistic fasciated 
phenotypes, indicating that they act in independent 
pathways that converge on the same downstream tar-
get to control meristem size. We cloned the fea3 gene 
using a map-based cloning approach, and the mutant 
results from an insertion of a partial retrotransposon 
into an exon of the fea3 locus. We confi rmed this 
identity by isolation of three additional alleles of fea3 
from a targeted EMS mutagenesis. FEA3 encodes a 
predicted leucine-rich repeat receptor-like protein re-
lated to FEA2. In-situ hybridization and imaging of 
red fl uorescent protein (RFP)-tagged transgenic plants 
show that FEA3 is expressed in the organizing center 
of the SAM and in leaf primordia (Fig. 3), as well as 
in the root apical meristem. Remarkably, expression of 
maize WUSCHEL, a marker for the stem cell niche 
organizing cells, spreads downward in fea3 mutants, 
which is strikingly different from its response in the 
known CLAVATA stem cell mutants.
FEA3 is localized in the plasma membrane, and to 
see if it responds to a CLV3-related (CLE) peptide, we 
tested its sensitivity to different peptides. fea3 mutants 
showed reduced peptide sensitivity, but interestingly, 
they responded to a different CLE peptide, ZmFCP1 
(FLORAL ORGAN NUMBER2-like CLE protein 
1), compared to FEA2. ZmFCP1 is expressed in leaf 
primordia (Fig. 3), suggesting that it serves as a signal 
from differentiating cells to repress meristem growth 
via the FEA3 receptor. Our results suggest that the 
FEA3 receptor function is in a new pathway for stem 
cell control that is spatially distinct from the known 
CLV receptors and uses a different peptide signal. 
This signaling system appears to be universal, as we 
have also found orthologs in Arabidopsis with similar 
properties.
In addition to these advances, we are in the pro-
cess of mapping additional fasciated ear mutants from 
EMS mutagenesis screens. We have determined candi-
date map positions for several of these mutants and are 
proceeding with fi ne mapping and molecular cloning.
Control of Branching and Determinacy 
in Plant Shoots
H. Claeys, E. Demesa-Arevalo, T. Zadrozny, A. Eveland 
[in collaboration with M. Komatsu and H. Sakai, Dupont 
Crop Genetics]
The RAMOSA (RA) genes in maize function to im-
pose determinacy on axillary meristem growth; con-
sequently, ra loss-of-function mutants (ra1, ra2, and 
ra3) have more highly branched infl orescences. RA3 
encodes a trehalose phosphate phosphatase, which 
catalyzes the conversion of trehalose-6-phosphate 
(T6P) to trehalose. T6P was shown to be an impor-
tant regulatory metabolite that connects sucrose lev-
els, and thus the sugar status, to plant growth and 
development, but its mode of action is still unclear. 
RA3 is expressed in a localized domain at the base 
of axillary infl orescence meristems, and it localizes 
to distinct puncta in both nuclear and cytoplasmic 
compartments, suggesting that its effect on develop-
ment may not be simply metabolic. The RAMOSA 
genes defi ne a boundary domain that surrounds the 
developing branch meristem, rather than being de-
ployed in the meristem itself. These data support 
Figure 3.  In-situ hybridization of FEA3 and ZmFCP1. FEA3 is 
expressed in the organizing center of the SAM and in leaf pri-
mordia (A). ZmFCP1 is expressed in the leaf primordia (B).
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the hypothesis that RA genes may serve as media-
tors of signals, maybe a sugar signal, originated at the 
boundary domain and regulating determinacy. RA3 
itself may have a transcriptional regulatory function, 
since it affects the expression of specifi c genes.
We are taking genetic approaches to identify fac-
tors that act in the same pathway with RA3 to control 
spikelet pair meristem determinancy by screening for 
enhancers of the ra3 phenotype. Typically, ra3 mutants 
in a B73 background have three to eight branches only 
at the base of the ear, and thus we mutagenized ra3 
mutants and looked for plants that have more branches 
and/or have branches in the upper part of the ear (Fig. 
4). Notably, ra3 in the Mo17 background was also mu-
tagenized. In this background, ra3 is suppressed, so the 
presence of branches also indicates that an enhancer 
mutation has been found. Combining both back-
grounds, about 20 mutants have been isolated so far. 
Mapping of a subset of these mutants is currently under 
way. So far, two independent mutant alleles of REL3 
(RAMOSA ENHANCER LOCUS 3), an RA3 paralog, 
were identifi ed. Both contain amino acid substitutions, 
and we are currently trying to understand how these 
mutations affect protein activity.
As a third approach to better understand how RA3 
functions, we are looking for interacting proteins. To 
this end, a yeast two-hybrid screen was performed, 
and a number of predominantly nuclear proteins were 
found to interact with RA3, which fi ts with its partial-
ly nuclear localization. In parallel, meristematic ear tis-
sue from plants expressing an HA-tagged RA3 protein 
was used for IP-mass spectrometry, revealing a number 
of potential in vivo interactors. The biological roles of 
a number of these interactors in ear development are 
currently being studied using insertional mutants and 
mutant alleles generated using CRISPR-Cas9.
Natural Variation in Inﬂ orescence 
Architecture
H. Claeys, S. Vi, I. Liao, T. Lau, M. Rutigliano
Maize infl orescence architecture has been a target 
for extensive selection by breeders since domestica-
tion; hence, different maize inbreds vary greatly in 
these traits. The genetic basis underlying this diver-
sity is largely unknown, but it is of great interest for 
both fundamental and applied science. Now with the 
wealth of genomic data, we are equipped to study 
them. To identify natural variation relevant to infl o-
rescence traits, we looked for inbred backgrounds that 
can enhance or suppress the phenotypes of different 
mutants. We focused on the 25 NAM (nested associa-
tion mapping) founder inbreds because they were se-
lected to capture the diversity of maize germplasm and 
because of the genetic tools available for these inbreds. 
We have crossed these 25 inbreds to our collection of 
mutants (in a B73 background) and screened the F2 
for plants with suppressed or enhanced phenotypes 
compared to the mutant in the B73 background.
We identifi ed a suppressor of ramosa3 (ra3) from the 
Mo17 inbred, an enhancer from the Ki11 inbred, and 
an enhancer of fea2 from NC350. Segregation ratios 
suggest one semidominant locus for the Mo17-derived 
suppressor, two or more loci for the Ki11-derived en-
hancer, and one recessive locus for the NC350-derived 
enhancer. We are now in the process of rough mapping 
by bulked segregant analysis. Additionally, because 
the natural modifi ers are often the results of quanti-
tative trait loci (QTL) rather than single-gene effects, 
we crossed the mutants to the corresponding NAM-
founder/B73 recombinant inbred lines (RILs), in 
order to identify and map potential modifying QTL. 
Using this approach, we successfully mapped the fea2 
Figure 4.  SEM of young ears of B73, the ra3 mutant in a B73 background, and ra3 combined with a rel3 mutant allele. B73 
ears do not have branches, whereas ra3 ears form branches at the base of the ear. In contrast, ra3; rel3 ears have a signiﬁ -
cantly increased number of branches that are not conﬁ ned to the base of the ear.
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enhancer from NC350 to a region that colocalizes 
with a previously identifi ed kernel row number (KRN) 
QTL. This fi ts with our lab’s recent fi nding that hypo-
morphic alleles of fea2 lead to increased KRN, linking 
fasciation and KRN. Fine mapping of this locus to iso-
late one or more candidate genes is ongoing.
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PLANT DEVELOPMENTAL BIOLOGY, STEM CELLS, AND FLORAL 
BRANCHING SYSTEMS
Z. Lippman C. Brooks K.L. Liberatore S.J. Park S. Thomain
 K. Jiang C.A. MacAlister S. Soyk C. Xu
Research in our laboratory is aimed at revealing, under-
standing, and manipulating the genetic and molecular 
networks that control when, where, and how fl owers 
are produced on plants. Flowers form on infl orescences, 
the reproductive branches that originate from stem cell 
populations at the growing tips of shoots called meri-
stems. The number of infl orescences produced on a 
plant, as well as how many branches and fl owers form 
on each infl orescence, can vary dramatically both with-
in and between species. At the center of this diversity 
lie two critical processes of meristem growth and regu-
lation: (1) meristem maturation, during which stem 
cell populations transition from a vegetative growth 
program to a reproductive fl ower-promoting program, 
and (2) meristem maintenance, which modulates stem 
cell proliferation and meristem size. Our research takes 
advantage of natural and mutant variation in infl ores-
cence production and architecture in tomato and re-
lated Solanaceae species to explore the hypothesis that 
differences in meristem maturation and size explain the 
remarkable diversity in infl orescence branching, fl ower 
production, and reproductive success observed in na-
ture and agriculture.
Meristems typically start growing as small fl at 
structures that give rise to leaves before maturing into 
large domes that develop into infl orescences. This ge-
neric description, however, fails to capture that species-
specifi c variation in this fl owering transition underlies 
the remarkable diversity in infl orescence architecture. 
For example, both within and between species, not 
all doming meristems become fl owers, and for some 
meristems, maturing into a fl ower can be sudden, 
like a switch. We use the infl orescence of tomato as a 
model to investigate the mechanisms controlling meri-
stem maturation and size in sympodial plants, which 
comprise half of all fl owering plants and display some 
of the most impressive diversity in shoot complex-
ity. This is because, compared to monopodial plants 
like Arabidopsis, in which meristems persist after the 
transition to reproductive growth, meristems in sym-
podial plants terminate in fl owers, and new growth 
continuously arises from specialized axillary (sympo-
dial) meristems to produce compound shoots. The 
tomato infl orescence is an excellent system for study-
ing meristem maturation and size, because meristems 
are easily accessed for morphological and molecular 
analyses, and genetic perturbations have provided 
a foundation to build a molecular understanding of 
how these two processes are regulated.
Gene Editing in Tomato Using 
CRISPR/Cas9 Technology
C. Brooks
In the last decade, rapid advances in technology for 
genome editing have made it possible to engineer mu-
tations in genes in a sequence-specifi c manner. Two 
of these strategies, zinc fi nger nucleases (ZFNs) and 
transcription activator-like nucleases (TALENs), are 
based on protein–DNA interactions, whereas a third 
technology, clustered regularly interspaced short pal-
indromic repeats (CRISPR)/Cas9, is an RNA-guided 
DNA endonuclease system. CRISPR/Cas9 has seen a 
meteoric rise in the last 2 years, in large part due to a 
number of advantages of CRISPR/Cas9 over ZFNs 
and TALENs, including simple construct design and 
assembly and a high degree of success in multiple ani-
mal and plant systems.
This year, we tested the CRISPR/Cas9 system for 
gene editing in tomato. In CRISPR/Cas9, an engi-
neered single guide RNA (sgRNA) targets the Cas9 
DNA endonuclease to a specifi c chromosomal region 
to create double-strand breaks. Imprecise repair re-
sults in mutations, typically insertions and deletions 
(indels). Specifi c deletions can be created using two 
sgRNAs separated by a spacer region. We tested the 
effi cacy of CRISPR/Cas9 in tomato by targeting the 
ARGONAUTE7 (SlAGO7) gene (Fig. 1). SlAGO7 is 
required for the biogenesis of trans-acting short inter-
fering RNAs (tasiRNAs), which regulate organ polar-
ity through posttranscriptional silencing of AUXIN 
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RESPONSE FACTOR (ARF) genes. The fi rst leaves of 
loss-of-function mutations in SlAGO7 produce leafl ets 
without petioles, and later-formed leaves lack laminae, 
providing distinctive recessive “wiry” leaf phenotypes 
that are easily recognized.
We designed a CRISPR/Cas9 construct contain-
ing two sgRNAs with the goal of creating large, de-
fi ned deletions. Working with our collaborator Joyce 
Van Eck at the Boyce Thompson Institute Center for 
Plant Biotechnology, we generated 29 independent 
transgenic tomato plants and confi rmed by poly-
merase chain reaction (PCR) that each carried an in-
tegrated CRISPR/Cas9 transfer DNA. Remarkably, 
nearly half of these plants were indistinguishable from 
a known strong slago7 allele (wiry2-1), indicating a 
high effi ciency of CRISPR/Cas9-mediated muta-
genesis (Fig. 1). We evaluated the types of mutations 
generated using PCR and found one plant homozy-
gous for the expected deletion. The remaining plants 
were chimeric, having the expected deletion and/
or indels of various sizes. Importantly, we also dem-
onstrated that an induced indel mutation could be 
transmitted through the germ line, and we targeted 
additional genes, including simultaneous induction 
of homozygous deletions in two closely related ho-
mologs. Our fi ndings demonstrated the power of the 
CRISPR/Cas9 system to create targeted mutations in 
tomato and likely many other dicot crops, providing 
a superior alternative to RNA interference (RNAi) for 
reverse genetics studies and crop genome engineering.
Arabinosyltransferases Control Shoot 
Meristem Size in Tomato
K. Liberatore, C. Xu, C. MacAlister, S. Thomain
Despite its importance in agriculture, surprisingly 
little is known about the control of meristem size in 
plants beyond knowledge gained during the last two 
decades in Arabidopsis and the cereal crops maize and 
rice. Meristem size is controlled through a mainte-
nance mechanism, in which stem cells lost to lateral 
organ formation are replenished through a feedback 
circuit involving the stem-cell-promoting WUSCHEL 
homeobox gene and its repression by the CLAVATA 
(CLV ) signaling pathway. In CLV signaling, a cell 
surface receptor complex containing the leucine-
rich repeat (LRR) receptor kinase CLV1 and related 
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Figure 1. CRISPR/Cas9-mediated gene editing in stable transgenic tomato plants. (A) A wild-type (WT) tomato 
plant at 9 weeks of age, and the fourth produced leaf from the primary shoot (inset). (B) The strong wiry2-1 allele 
of slago7. First-formed leaves have leaﬂ ets lacking petioles and later-formed leaves are radialized. (C,D) A repre-
sentative CRISPR/Cas9-slago7 (CR-slago7) plant (C) and its ﬁ rst ﬁ ve leaves showing the distinctive loss-of-function 
recessive wiry syndrome (D). Scale bar, 1 cm. (E,F) PCR genotyping of eight representative CR-slago7 plants 
showing the type of DNA lesions generated (E), including homozygosity for the expected 90-base-pair deletion 
in plant #1 (F).
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receptors is bound by CLV3, a secreted peptide that is 
modifi ed with a chain of three arabinose sugars. How-
ever, the pathway responsible for modifying CLV3, 
and its importance in controlling meristem size, is 
unknown.
By screening a large tomato mutagenesis population, 
we identifi ed novel mutants that develop branched in-
fl orescences that produce fasciated fl owers with extra 
fl oral organs. Molecular analyses showed that these 
phenotypes resulted from a broken CLV-WUS circuit, 
which causes stem cells to overproliferate and meri-
stems to enlarge. The fi rst mutant was weakly fasciated 
and was found to be defective in the homolog of CLV1. 
However, surprisingly, a much more extreme mutant, 
fasciated infl orescence (fi n), was defective in a hydroxy-
proline O-arabinosyltransferase (HPAT), which cata-
lyzes the addition of arabinose to diverse plant proteins, 
including peptides related to CLV3. Chemically in-
duced and CRISPR/Cas9-engineered mutations in the 
FASCIATED AND BRANCHED 2 (FAB2/XEG113) 
and REDUCED RESIDUAL ARABINOSE 3 (RRA3) 
genes, encoding arabinosyltransferases predicted to 
extend arabinose chains, resulted in plants resembling 
fi n mutants, but they were less severely fasciated while 
having additional defects. We also used CRISPR/
Cas9 to mutate all homologs of the CLV pathway in 
tomato, including CLV3 and a second receptor gene, 
CLV2, that functions redundantly with CLV1. All of 
these mutants were also fasciated like the arabinosyl-
transferase mutants. Through a series of genetic, ex-
pression, and functional assays, we found that CLV3 
and related CLE peptides must be fully arabinosylated 
for normal activity, demonstrating that a cascade of ara-
binosyltransferase activity is required to fully activate 
the CLV-WUS circuit. These fi ndings have exposed 
arabinosyltransferase genes as critical new components 
of the CLV signaling pathway, revealing a new layer of 
complexity in the control of stem cell homeostasis and 
meristem size during plant development.
Diverse Developmental Roles for 
Arabinosyltransferases in Other Plants
C. MacAlister
The FIN/HPAT, FAB2/XEG113, and RRA3 arabino-
syltransferase genes are all members of the plant and ani-
mal glycosyltransferase (GT) superfamily, several mem-
bers of which have recently been reported to function 
in diverse developmental processes, including pollen 
tube growth and root hair elongation in Arabidopsis 
and nodule formation in pea and clover. Yet, surpris-
ingly, no meristem phenotypes for any of the available 
arabinosyltransferase mutants have been reported. That 
our analysis of extreme fasciated mutants in tomato un-
covered a crucial role for arabinosyltransferase genes in 
stem cell homeostasis suggested that members of dif-
ferent arabinosyltransferase families might have been 
co-opted to target distinct sets of proteins and signaling 
peptides in different species and developmental con-
texts. To compare developmental roles of FIN/HPAT 
genes in diverse species, we analyzed mutations in the 
three HPAT family members in Arabidopsis. Surpris-
ingly, we observed no phenotypes beyond pollen tube 
growth defects in any hpat mutant combination. In ho-
mozygous hpat double mutants, we found that pollen 
grains can germinate; however, tube growth arrests in 
the transmitting tract of the ovary, resulting in a failure 
to target ovules and poor seed set. Data from our lab 
and others’ suggest that these phenotypes might be due 
to loss of arabinosylation on extensin proteins, which 
are critical for cell wall assembly.
To further explore the diverse, and potentially an-
cient, roles of the FIN/HPAT family, we created muta-
tions in two homologs in the moss Physcomitrella pat-
ens. Moss development involves germination of a hap-
loid spore followed by formation of a vegetative body 
(colony) composed of fi lamentous protonemal network 
containing two cell types: slower-growing chloronema 
for photosynthesis and faster-growing caulonema to 
colonize the surrounding substrate. We found that 
knocking out the more highly expressed FIN homolog 
(PpFINLa) results in larger and faster colonizing colo-
nies, because of the enhanced caulonema production 
relative to chloronema. Notably, although pollen tubes 
and caulonema are both tip-growing cells, the process 
of tip growth itself is unaffected in both systems. We 
are currently investigating the molecular basis for the 
fi lament growth defects in moss Ppfi nla mutants, and 
preliminary data suggest that a distinct protein fam-
ily is targeted for arabinosylation compared to tomato 
and Arabidopsis.
A New Mechanism Controlling 
Meristem Maturation in Tomato
C. Xu, C. MacAlister
Several years ago, we found that mutations in the 
genes COMPOUND INFLORESCENCE (S, homolog 
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of WUSCHEL HOMEOBOX 9), ANANTHA (AN, 
homolog of UNUSUAL FLORAL ORGANS), and 
FALSIFLORA (FA, homolog of LEAFY ) cause more 
branches and fl owers to develop, because meristem ter-
mination is delayed (s mutants) or never achieved (an, 
fa). S is expressed late in maturation just before acti-
vation of AN, which encodes an F-box protein. From 
work in petunia, we understand how an ortholog of 
AN promotes the fi nal stage of maturation; upon its 
late activation, the AN protein interacts with FA to 
form a fl ower specifi cation complex, which activates 
fl oral identity genes. In tomato, the rate of maturation 
promoted by S and AN-FA permits only one lateral 
meristem to form in each sympodial cycle, resulting in 
a multifl owered, unbranched infl orescence.
To investigate whether a mechanism also exists to 
repress maturation, we studied the tmf mutant, which 
fl owers early and produces a single fl ower infl orescence 
on the primary shoot. We found that the TMF gene 
encodes a member of the ALOG (Arabidopsis LSH1 
and Oryza G1) protein family. ALOGs contain a DNA-
binding domain, suggesting transcription factor func-
tion. Consistent with this, TMF is in the nucleus and 
can activate transcription in yeast. ALOGs have de-
velopmental roles in Arabidopsis and rice fl oral organ 
identity and, like TMF, rice infl orescence architecture.
In a yeast two-hybrid (Y2H) screen using TMF 
as bait, we identifi ed several transcriptional regula-
tors, the most interesting to us being homologs of the 
Arabidopsis BTB/POZ domain-containing BOP fam-
ily and the APETALA2/ethylene responsive factor 
(AP2/ERF) family. These genes have diverse devel-
opmental functions in Arabidopsis, including in fl oral 
meristem determinacy; however, nothing is known 
about these genes in tomato. Tomato has three BOP 
genes (SlBOP1/2/3), and we used bimolecular fl uo-
rescence complementation (BiFC) to show that all 
three SlBOP proteins interact with TMF in tomato 
nuclei. Using RNAi, we knocked down expression of 
the SlBOP genes. RNAi of SlBOP1 (slbop1-RNAi) re-
sulted in increased leaf complexity and loss of fl oral 
organ abscission, similar to Arabidopsis bop1/2 mu-
tants. RNAi of SlBOP2/3 together (slbop2/3-RNAi) 
causes not only the same phenotypes, but also infl o-
rescences with architectural defects. To further study 
the SlBOPs and their roles in infl orescence archi-
tecture, we are taking advantage of CRISPR/Cas9 
technology and have engineered deletion mutations 
in each SlBOP (CR-slbop). We have also engineered 
mutations in AP2/ERF family members. In the com-
ing year, these mutants will be studied for their effects 
on fl owering time and infl orescence development as it 
relates to meristem maturation. We have also devel-
oped biochemical tools to begin identifying transcrip-
tional targets of TMF and S.
Improving Tomato Productivity Using 
Mutations in the Florigen Pathway
S.J. Park, K. Jiang
By studying novel meristem maturation mutants of 
tomato, we uncovered a new way to customize and 
optimize plant architecture and yield using genes in 
the universal fl origen fl owering pathway. A major 
driver of crop domestication was the modifi cation 
of wild-plant architectures into new architectural 
forms that improved fl ower, fruit, and seed produc-
tion. In tomato, selection during domestication was 
for exceptionally large fruits, and shoot architecture 
underwent a radical change 85 years ago with the 
discovery of the self pruning (sp) mutation, which 
transformed “indeterminate” plants into a new “de-
terminate” form that spawned the processing tomato 
industry. SP is the homolog of Antirrhinum CEN-
TRORADIALIS (CEN ) and Arabidopsis TERMI-
NAL FLOWER1 (TFL1), and it encodes a repressor 
of fl owering in the CETS family of proteins, which 
includes the generic fl owering hormone fl origen. All 
wild tomatoes and classical cultivated varieties are in-
determinate, a refl ection of their sympodial growth 
program, which is regulated by the opposing activi-
ties of SP and fl origen. The regularity and perpetua-
tion of sympodial cycling are made possible by a bal-
ance of fl ower promoting and repressing signals: SP 
is produced in meristems to counterbalance fl origen, 
encoded by SINGLE FLOWER TRUSS (SFT ), but in 
sp mutants, fl origen is no longer inhibited, causing 
shoots to terminate progressively faster until cycling 
eventually stops. The result is a burst of infl orescence 
production and nearly synchronous fruit ripening 
on compact bushy plants that can be grown at high 
density and harvested mechanically, providing major 
advantages for large-scale open fi eld production.
Homologs of SP and SFT were repeatedly target-
ed for agricultural adaptations in many crops. Yet, 
the limited number and types of alleles provided by 
nature may not be providing optimal balances of 
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fl owering signals to allow maximum productivity. 
In a telling example from our prior work, we found 
that induced mutations in SFT can increase yield in 
determinate plants. In sft mutants, a loss of fl origen 
impedes initiation of sympodial growth, resulting in 
highly vegetative plants with few fl owers and fruits. 
However, when sft mutations are heterozygous, a par-
tial dose-dependent reduction of fl origen modifi es the 
balance of fl owering signals, causing a weak suppres-
sion of sp that results in more sympodial shoots and 
infl orescences.
We reasoned that other mutants that suppress de-
terminacy might provide new ways to modify tomato 
fl owering, meristem maturation, and fl ower produc-
tion. Several years ago, we identifi ed three suppressor 
of sp (ssp) mutants that restored indeterminate growth. 
We cloned the SSP genes and found that they were 
defective in genes encoding components of a fl origen 
activation complex, originally described in rice. Nota-
bly, ssp-1906 was a weak mutation in SFT, whereas the 
other two ssp mutants were defective in a basic leucine 
zipper (bZIP) transcription factor component of the 
fl origen complex. By combining these mutations in 
heterozygous states in hybrid plants, we pinpointed 
an optimal balance of fl owering signals, which result-
ed in a new partially determinate architecture that 
doubled the yields of sp plants and surpassed the yield 
gain of sft heterozygotes by 15% (Fig. 2). These fi nd-
ings indicate that harnessing mutations in the highly 
conserved fl origen pathway to customize plant archi-
tecture and fl ower production offers a broad tool kit 
to maximize productivity in many crops.
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Figure 2. Exploiting dosage sensitivity of the ﬂ origen pathway 
leads to a new optimum for tomato yield. (A) Representative plant 
and yield from an M82 control plant, an sft-1906/+ sp single het-
erozygote, the previous highest-yielding sft-4537/+ sp genotype, 
and the new highest-yielding sft-1906/+ ssp-2129/+ sp double het-
erozygote. (B,C) Statistical comparisons of mean values (± s.e.m.) 
for total fruit yields (B), and Brix-yield (C) between sp plants (white 
bar), ssp-2129 sp indeterminate plants (black bar), and the single 
(light gray) and double (dark gray) heterozygous genotypes. Aster-
isks indicate signiﬁ cantly different yields from sp (Dunnett’s “com-
pare with control,” *P < 0.05, **P < 0.01). (D) Model of tomato 
yield with respect to shoot determinacy and the shifting ratios 
of ﬂ ower promoting and repressing signals. The ratio in nature 
provides typical indeterminate growth. When ﬂ ower-promoting 
signals are extremely high (e.g., 35S:SFT sp) or extremely low (e.g., 
strong sft mutants), yields are low, because of rapid termination or 
failure to initiate sympodial growth, respectively. In sp mutants, 
ﬂ ower-repressing signals are reduced, resulting in classical deter-
minate growth. As ﬂ ower-promoting signals are progressively re-
duced, determinacy is gradually relieved, and yields reach a new 
maximum before a further loss of ﬂ ower-promoting signals results 
in a new balance that approaches WT, resulting in a switch to 
indeterminate growth and a drop in yield. H, high; L, low.
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EPIGENETIC INHERITANCE IN PLANTS AND FISSION YEAST
R. Martienssen S. Bhattacharjee R. Herridge B. Roche
 S. Castel Y. Jacob A. Schorn
 A.-Y. Chang H.S. Kim A. Shimada
 K. Creasey C. LeBlanc J. Simorowski
 F. de Sousa Borges S.C. Lee R. Tirado-Magallanes
 M. Donoghue A. Molla-Morales R. Umamaheswari
 E. Ernst J.-S. Parent C. Underwood
 M. Gutbrod M. Regulski 
 J.-J. Han J. Ren 
Plants and fi ssion yeast provide excellent models for 
epigenetic mechanisms of transposon regulation, het-
erochromatic silencing, and gene imprinting, impor-
tant both for plant breeding and for human health. 
We are investigating the role of RNA interference 
(RNAi) in heterochromatic silencing in the fi ssion 
yeast Schizosaccharomyces pombe and in the model 
plant Arabidopsis thaliana, as well as continuing our 
work on Zea mays. In fi ssion yeast, we have found 
that RNAi promotes DNA replication and repair 
by releasing RNA polymerase II (Pol II). In plants, 
we have found that the genome undergoes limited 
reprogramming of DNA methylation in pollen, 
guided by DNA glycosylases and small RNA. Using 
mutants defi cient in histone and DNA methylation, 
we have found that histone variants and microRNA 
(miRNA) contribute to reprogramming by target-
ing transposons and determining the specifi city of 
epigenetic histone modifi cations. Our results suggest 
a model for imprinting, transposon control and the 
origin of epialleles. We continue to develop duck-
weeds as a source of biofuel and have developed an 
effi cient transformation and gene control system in 
the clonally propagated aquatic macrophyte Lemna 
minor. Sequencing of the duckweed, oil palm, and 
sugarcane genomes has provided important clues as 
to how to increase biofuel yields and reduce tropical 
deforestation.
This year, we said good-bye to Roberto Tirado-
Magallanes, who has started his Ph.D. at Ecole Nor-
male Superieure in Paris, and Stephane Castel, who 
started a postdoc at the New York Genome Center. 
We welcomed Watson School of Biological Sciences 
student Michael Gutbrod.
Dicer Promotes Transcription Termination 
at Sites of Replication Stress to Maintain 
Genome Stability
S.E. Castel, J. Ren, S. Bhattacharjee, A.-Y. Chang, 
R. Martienssen [In collaboration with F. Antequera, 
CSIC/Universidad de Salamanca, Salamanca, Spain; 
and B. Arcangioli, Insitut Pasteur, Paris France]
Nuclear RNAi is an important regulator of transcrip-
tion and epigenetic modifi cation, but the underlying 
mechanisms remain elusive. Using a genome-wide ap-
proach in the fi ssion yeast S. pombe, we have found that 
Dcr1, but not other components of the canonical RNAi 
pathway, promotes the release of Pol II from the 3′ end 
of highly transcribed genes, and, surprisingly, from an-
tisense transcription of rRNA and tRNA genes, which 
are normally transcribed by Pol I and Pol III. These 
Dcr1-terminated loci correspond to sites of replication 
stress and DNA damage, likely resulting from tran-
scription-replication collisions. At the rDNA loci, re-
lease of Pol II facilitates DNA replication and prevents 
homologous recombination, which would otherwise 
lead to loss of rDNA repeats especially during meiosis. 
Our results reveal a novel role for Dcr1-mediated tran-
scription termination in genome maintenance and may 
account for widespread regulation of genome stability 
by nuclear RNAi in higher eukaryotes.
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Chromosome Conformation Maps in 
Fission Yeast Reveal Cell-Cycle-Dependent 
Subnuclear Structure
R. Martienssen [In collaboration with R.S. Grand, J. O’Sullivan 
Liggins Institute, University of Auckland, New Zealand; 
J.R. Allison, Massey University, Auckland, New Zealand]
Successful progression through the cell cycle requires 
spatial and temporal regulation of gene transcript lev-
els and the number, positions, and condensation levels 
of chromosomes. We have performed a high-resolu-
tion survey of genome interactions in S. pombe using 
synchronized cells to investigate cell-cycle-dependent 
changes in genome organization and transcription. 
Cell-cycle-dependent interactions were captured be-
tween and within S. pombe chromosomes. The clus-
tering of telomeres and retrotransposon long terminal 
repeats (LTRs) was observed throughout the cell cycle. 
There were clear correlations between transcript levels 
and chromosomal interactions between genes, consis-
tent with a role for interactions in transcriptional regu-
lation at specifi c stages of the cell cycle. In silico recon-
structions of chromosome organization were made by 
polymer modeling. These models suggest that groups 
of genes with high and low or differentially regulated 
transcript levels have preferred positions within the nu-
cleus. The observation that chromosomal interactions 
are maintained even when chromosomes are fully con-
densed in M phase implicates genome organization in 
epigenetic inheritance and bookmarking.
RNAi Acts in Essential Novel Mechanisms in 
Quiescence in the Fission Yeast S. pombe
B. Roche, R. Martienssen [in collaboration with 
B. Arcangioli, Institute Pasteur, Paris]
Quiescence is defi ned as the state of a nondividing cell 
(G0), which is still metabolically active and is able to 
return to the cell cycle with full viability. Quiescent 
cells have a predominant role in unicellular organisms 
and in multicellular organisms, in which they are es-
sential, for example, in humans (in stem cell niches 
and memory B cells). However, the mechanisms gov-
erning the transition between the cell cycle and quies-
cence, and quiescence maintenance, are not well un-
derstood. In S. pombe, cells can be induced into G0 by 
nitrogen starvation of a heterothallic strain and keep 
full viability for a long period (>3 wk). We found that 
RNAi mutants (Δdcr1, Δrdp1, Δago1) are predominant-
ly impaired specifi cally in quiescence and lose viability 
rapidly. Intriguingly, heterochromatin mutants (Δclr4, 
Δswi6, Δchp2) do not show this phenotype, suggesting 
that RNAi functions in quiescence independently of its 
role in heterochromatin assembly, which we have previ-
ously shown to occur in S phase. In accordance with 
this model, we found that centromeric small RNAs are 
not detectable in G0 in wild type. However, the Dicer 
catalytic mutant dcr1–5 has the Δdcr1 G0 phenotype, 
which suggests the involvement of cryptic new small 
RNAs. To uncover the novel pathways involved, we es-
tablished a genetic screen for G0-specifi c suppressors of 
RNAi mutants. This screen allowed us to isolate >30 
independent suppressors of Δdcr1 in the absence of a 
mutagen, potentially indicating a role in DNA repair.
DNA Demethylation in Arabidopsis Pollen 
and Consequences for Transgenerational 
Epigenetic Inheritance
M. Donoghue, F. de Sousa Borges, Y. Jacob, C. LeBlanc, 
R. Martienssen [in collaboration with D.l. Bouyer and 
V. Colot, Ecole Normale Superieure, Paris]
Genome reprogramming of DNA methylation is im-
portant for transposon regulation and epigenetic in-
heritance. In Arabidopsis thaliana, dynamic changes 
of DNA methylation occur in the male gametophyte, 
where two sperm cells (SCs) and a vegetative cell dif-
ferentiate from a precursor microspore after postmeiotic 
cell divisions. One pathway toward epigenetic variation 
in plants comes from the activity of DNA glycosylases/
demethylases in the pollen vegetative cell nucleus (VN). 
We have found that previously identifi ed variable epial-
leles and imprinted genes are specifi cally demethylated 
in the VN, by combined activity of the DNA glyco-
sylases ROS1 and DME. In contrast, heterochromatic 
CHH methylation, where H is A, C, or T, is almost 
completely lost during or after meiosis, and restored in 
the VN, but not in the gametes that remain hypometh-
ylated at the mature pollen stage. The role of targeted 
demethylation in the VN is important for pollen devel-
opment and fertility, as well as for stable repression of 
transposable elements in the germline and subsequent 
generations. We analyzed genome-wide methylomes 
of fl uorescence-activated cell sorting (FACS)-purifi ed 
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dme/ + , ros1 and dme/ + , ros1 mutant sperm and VN 
and showed that DME is responsible for demethylation 
of DNA transposons that are found in regulatory re-
gions near imprinted genes and epialleles. Strikingly, 
the double-mutant dme/ + , ros1 showed a cumulative 
effect, indicating that DNA demethylation in the VN 
involves combined activity of DME and ROS1.
Selective Methylation of Histone H3 Variant 
H3.1 Regulates Heterochromatin Replication
Y. Jacob, M. Donoghue, C. LeBlanc, C. Underwood, 
R. Martienssen [in collaboration with S. Michaels, 
Indiana University; D. Reinberg, New York University 
Medical School; and J.-F. Couture, University of Ottawa]
Histone variants have been proposed to act as determi-
nants for posttranslational modifi cations (PTM) with 
widespread regulatory functions. We have found a his-
tone-modifying enzyme that selectively methylates the 
replication-dependent histone H3 variant H3.1. The 
crystal structure of the SET domain of the histone H3 
lysine 27 (H3K27) methyltransferase ARABIDOPSIS 
TRITHORAX-RELATED PROTEIN 5 (ATXR5) 
in complex with an H3.1 peptide shows that ATXR5 
contains a bipartite catalytic domain that specifi cally 
“reads” alanine 31 of H3.1. Variation at position 31 be-
tween H3.1 and replication-independent H3.3 is con-
served in plants and animals, and threonine 31 in H3.3 
is responsible for inhibiting the activity of ATXR5 and 
its paralog ATXR6. Our results suggest a simple model 
for the mitotic inheritance of the heterochromatic mark 
H3K27me1 and the protection of H3.3-enriched genes 
against heterochromatization during DNA replication. 
Unmodifi ed histone H3.1 may trigger overreplication 
of heterochromatin and contribute to reprogramming 
in pollen, which lacks H3.1 in the VN.
miRNAs Trigger Widespread Epigenetically 
Activated siRNAs from Transposons 
in Arabidopsis
K. Creasey, M. Regulski, F. de Sousa Borges, A. Shimada, 
R. Martienssen [In collaboration with B.C. Meyers, 
University of Delaware]
Transposons in Arabidopsis give rise to abundant 21-nt 
“epigenetically activated” small interfering RNAs 
(easiRNAs) in DECREASE IN DNA METHYLAT-
ION1 (ddm1) and DNA METHYLTRANSFERASE1 
(met1) mutants, as well as in pollen from wild-type 
plants, in which heterochromatin is lost during repro-
gramming. easiRNA biogenesis is dependent on AR-
GONAUTE1 (AGO1), DICER-LIKE4 (DCL4) and 
RNA-DEPENDENT RNA POLYMERASE6 (RDR6 ), 
resembling 21-nt trans-acting (ta)siRNAs and other 
secondary siRNA in this respect. However, the fac-
tor that triggers easiRNA biogenesis from transposons 
has remained elusive. We have found that specifi city is 
provided by targeted cleavage of thousands of transpo-
son transcripts by at least fi fty micro (mi)RNAs, some 
of which are themselves encoded by transposons, but 
most of which are highly conserved with well known 
roles in plant development. Interestingly, the loss of 
easiRNAs in ddm1 rdr6 is compensated by the gain of 
24-nt heterochromatic (het)siRNAs which can guide 
RNA-directed DNA methylation (RdDM). This sug-
gests that RDR6-directed easiRNA production acts an-
tagonistically to RDR2-directed hetsiRNA production, 
thereby inhibiting transcriptional gene silencing. Wide-
spread targeting of transposons may refl ect the evolu-
tionary origin of microRNA in genome surveillance.
Efﬁ cient Transformation and Artiﬁ cial 
miRNA Gene Silencing in Lemna minor
A. Molla-Morales, E. Ernst, R. Martienssen [in collaboration 
with J. Shanklin, Brookhaven National Laboratory, New York; 
and B. Meyers, University of Delaware]
Despite rapid doubling time, simple architecture, and ease 
of metabolic labelling, a lack of genetic tools in the Lem-
naceae (duckweed) has impeded the full implementation 
of this organism as a model for biological research. We 
Figure 1. Phenotype of L. minor duckweed expressing an artiﬁ cial 
miRNA targeting chlorophyll biosynthesis and green ﬂ uorescent 
protein (GFP). Wild-type Lemna minor (A,B) and transformed 
amiR_CH42 (C,D) fronds observed under bright-ﬁ eld (A,C) and 
ﬂ uorescence (B,D) light. Quantiﬁ cation of the chlorophyll content 
in L. minor and amiR_CH42 (E). The S.D. values are shown. n = 3. 
Stars indicate signiﬁ cance in two-tailed z-test, ***P < 0.0001.
Plant Biology  185
have developed technologies to facilitate high-through-
put genetic studies in duckweed. We developed a fast 
and effi cient method for producing Lemna minor stable 
transgenic fronds via Agrobacterium-mediated transfor-
mation and regeneration from tissue culture. Addition-
ally, we engineered an artifi cial miRNA (amiRNA) gene 
silencing system (Fig. 1). We identifi ed a Lemna gibba 
endogenous miR166 precursor and used it as a backbone 
to produce amiRNAs. As a proof of concept, we induced 
the silencing of CH42, a magnesium chelatase subunit, 
using our amiRNA platform. Expression of CH42 in 
transgenic L. minor fronds was signifi cantly reduced, 
which resulted in reduction of chlorophyll pigmentation. 
These techniques will enable us to tackle future chal-
lenges in the biology and biotechnology of Lemnaceae.
Duckweeds: Aquatic Macrophytes for 
Biofuel Production
E. Ernst, A. Molla-Morales, S.C. Lee [in collaboration 
with J. Shanklin and J. Schwender, Brookhaven National 
Laboratories; D. Pappin, Cold Spring Harbor Laboratory]
Petroleum availability and atmospheric carbon accumu-
lation are some of the main concerns of our era: Cur-
rently, biofuels produced from corn grain and sugarcane 
are predominant alternatives, but they directly compete 
for land, with food production raising sustainability 
concerns. Lemnaceae species (aquatic duckweeds) in-
clude the smallest fl owering plants, and they have con-
siderable potential as biofuel feedstocks because of their 
extreme growth rates and clonal propagation. Our goal 
is to engineer duckweeds to increase their oil levels for 
biofuel production. To do so, we aim to increase the ex-
pression of genes related to the production of triacylg-
lycerol (TAG), silence the genes that have a role in the 
oxidation of lipid bodies, or redirect the starch metabo-
lism to oil production by silencing the key genes that 
lead to starch accumulation. We have sequenced the ge-
nome of Lemna gibba DWC131, as well as the tetraploid 
L. minor. These genome sequences will enable tackling 
future challenges in the biology and biotechnology of 
Lemnaceae. For example, nitrogen defi ciency is an en-
vironmental stress that can enhance biosynthesis and 
storage of starch and TAG in vegetative tissues of model 
plant species such as tobacco, and TAG is a precursor of 
biodiesel. L. gibba grown on nitrate-lacking media had 
increased numbers of lipid droplets in the chloroplast 
and increases in saturated and monounsaturated fatty 
acids such as palmitic acid (16:0) and palmitoleic acid 
(16:10). Transcriptome analysis is under way to identify 
the genes responsible, and we are using our transforma-
tion system to enhance oil yields further via CRISPR 
 genome editing technology.
Sugarcane Genome Sequencing by 
Methylation Filtration
M. Regulski, R. Martienssen [In collaboration with 
A.S. Hemerly and P.C. Ferreira, Universidade Federal do 
Rio de Janeiro, Brazil; and W. McCombie, Cold Spring 
Harbor Laboratory]
Large tracts of methylated repeats occur in plant ge-
nomes that are interspersed by hypomethylated gene-
rich regions, reaching an extreme in the polyaneuploid 
hybrid sugarcane, a relative of sorghum and one of the 
most effi cient biofuel crops. Gene-enrichment strate-
gies based on methylation profi les offer an alternative to 
sequencing repetitive genomes. We have applied methyl 
fi ltration with McrBC endonuclease digestion to enrich 
for euchromatic regions in the sugarcane genome. The 
use of methyl fi ltration fi ltered out 35% of the sugarcane 
genome and produced 1.5× more scaffolds and 1.7× 
more assembled sequences compared with unfi ltered. 
The coverage of sorghum-coding sequences (CDS) by 
MF scaffolds was at least 36% higher, and we increased 
by 134× the coverage of gene regions of the monoploid 
sugarcane genome. The MF reads assembled into scaf-
folds that covered 100% of genes on existing sugarcane 
bacterial artifi cial chromosomes (BACs), 97.2% of 
sugarcane expressed sequence tags (ESTs), 92.7% of 
sugarcane RNA-Seq reads, and 98.4% of sorghum pro-
tein sequences. A large number of miRNA genes were 
also identifi ed in the MF scaffolds. The information 
achieved by the MF data set provides a valuable tool 
for genomic research in the genus Saccharum and for 
improvement of sugarcane as a biofuel crop.
The Oil Palm VIRESCENS Gene Controls 
Fruit Color and Encodes a R2R3-MYB 
Transcription Factor
R. Martienssen [In collaboration with R. Singh, E.T. Low, 
R. Nookiah, and R. Sambanthamurthi, Malaysian Palm 
Oil Board, Selangor, Malaysia; N. Lakey, S.W. Smith, 
J.M. Ordway, Orion Genomics, St. Louis, Missouri]
Oil palm, a plantation crop of major economic impor-
tance in Southeast Asia, is the predominant source of 
edible oil worldwide. We identifi ed the virescens (VIR) 
186  Research
gene, which controls fruit exocarp color and is an in-
dicator of ripeness. VIR is a R2R3-MYB transcription 
factor that has homology with Lily LhMYB12 and 
similarity with Arabidopsis production of anthocyanin 
pigment 1 (PAP1). We identifi ed fi ve independent mu-
tant alleles of VIR in more than 400 accessions from 
sub-Saharan Africa that account for the dominant-
negative VIR phenotype. Each mutation results in pre-
mature termination of the carboxy-terminal domain 
of VIR, resembling McClintock’s C1-I allele in maize. 
The abundance of alleles likely refl ects cultural prac-
tices, by which fruits were venerated for magical and 
medicinal properties. The identifi cation of VIR will 
allow selection of the trait at the seed or early-nursery 
stage, 3–6 years before fruits are produced, greatly ad-
vancing introgression into elite breeding material.
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PLANT DEVELOPMENTAL GENETICS
M. Timmermans A. Benkovics C. Fernandez-Marco S. Knauer D. Skopelitis
 M. Dotto A. Husbands K. Petsch
Specifi cation of adaxial–abaxial (upper/lower) po-
larity in the developing leaf drives the fl attened out-
growth of the leaf blade and directs the differentiation 
of distinct cell types within the leaf ’s adaxial/top and 
abaxial/bottom domains. Both are important innova-
tions in the evolution of land plants that maximize 
photosynthesis while minimizing water loss to the 
environment. In addition to being a key developmen-
tal process, adaxial–abaxial patterning is of particu-
lar interest from a mechanistic point of view and has 
proven to be an excellent model to study small RNA-
mediated gene regulation. We previously showed that 
patterning of this developmental axis involves a cas-
cade of opposing small RNAs, in which microRNA 
(miRNA) miR390 triggers the biogenesis of the TAS3-
derived 21-nucleotide tasiR-ARF on the adaxial side of 
developing leaves. These confi ne the accumulation of 
abaxial determinants, including AUXIN RESPONSE 
FACTOR3 (ARF3) and miR166, to the lower side of 
leaves. miR166, in turn, demarcates the abaxial side 
by repressing expression of class III homeodomain 
leucine zipper (HD-ZIPIII) transcription factors that 
specify adaxial fate.
Importantly, our analysis of the TAS3 trans-acting 
short interfering RNA (tasiRNA) pathway in Arabi-
dopsis demonstrated that tasiR-ARF functions as a 
mobile positional signal in adaxial–abaxial pattern-
ing. Movement of this small RNA from its defi ned 
source of biogenesis in the two uppermost cell lay-
ers of leaves creates a gradient of accumulation that 
dissipates abaxially. The tasiR-ARF gradient gener-
ates a sharply defi ned expression domain of the ab-
axial determinant ARF3 on the bottom side of leaf 
primordia, suggesting that small RNAs can establish 
pattern through a morphogen-like activity. This work 
provided the fi rst direct evidence that small RNAs are 
mobile and can function as instructive signals in de-
velopment, thereby revealing a novel patterning activ-
ity of small RNAs. We are currently studying the role 
of this specifi c small RNA pathway and the properties 
of mobile small RNAs in general in maize, Arabidop-
sis, and the moss Physcomitrella patens.
Small RNA Gradients Create Stable 
Developmental Boundaries
A. Benkovics, D. Skopelitis, C. Fernandez-Marco
Mathematical modeling of the tasiR-ARF–ARF3 inter-
action predicts that small RNA gradients resulting from 
mobility are uniquely suited to generate sharply defi ned 
boundaries of target gene expression. To test this, we are 
taking advantage of the pARF3:ARF3-GUS reporter 
generated previously. In an rdr6 mutant background, 
which blocks tasiR-ARF production, this reporter 
is expressed throughout the developing leaf. In this 
background, we express an artifi cial miRNA targeting 
ARF3 (miRARF) from different leaf-specifi c promot-
ers to modulate the position, direction, and steepness 
of this small RNA gradient. Target gene expression is 
being monitored by GUS histochemistry and miRARF 
expression patterns will be determined by in situ hy-
bridizations. Our results strongly support the idea that 
small RNA gradients have the inherent ability to gener-
ate sharply defi ned domains of target gene expression.
Patterning via small RNA gradients is also being ad-
dressed using a reporter system that monitors the read-
out of a miR166 gradient. A miR166-insensitive HD-
ZIPIII reporter (PHB*-YFP) that is active throughout 
the leaf induces an adaxialized leaf phenotype. In this 
background, we express a modifi ed version of miR166 
(miR166*) that specifi cally cleaves the PHB*-YFP 
transcripts. Our results show that miR166* expres-
sion from the abaxial epidermis is suffi cient to suppress 
the PHB*-YFP leaf defects, indicative of movement of 
this small RNA. Visualization of PHB*-YFP expres-
sion patterns by confocal microscopy indicates that 
similar to results obtained via our miR-ARF3–ARF3-
GUS system, miR166* gradients generated in different 
directions in the leaf create a sharp on-off expression 
pattern of target expression, suggesting that this is a 
general patterning property of small RNA gradients.
Considering that patterning of the adaxial–ab-
axial axis involves two opposing small RNA gradi-
ents, these might serve to confer robustness onto the 
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leaf development program by stabilizing the adaxial– 
abaxial boundary throughout organogenesis and under 
a range of environmental conditions. We are comparing 
variability in leaf parameters under normal and mild 
stress conditions between wild-type plants and plants 
in which either small RNA gradient is perturbed. We 
are also analyzing the expression patterns of adaxial and 
abaxial reporters in these lines to monitor the effect of 
perturbing small RNA gradients on the position and 
uniformity of the adaxial–abaxial cell fate boundary 
under normal and stress conditions. The outcome of 
these experiments will reveal whether small RNA gra-
dients provide robustness to the leaf developmental pro-
gram under a range of environmental conditions.
Dissecting Small RNA Mobility in Plants
D. Skopelitis, C. Fernandez-Marco
Given the scope of miRNA-regulated gene networks, 
the cell-to-cell movement of small RNAs has impor-
tant implications with respect to their potential as 
instructive signals in development or in response to 
physiological and stress stimuli. We are using artifi -
cial miRNAs targeting easy-to-score reporter genes to 
study parameters of miRNA movement, such as tissue 
specifi city, directionality, dose-dependence, and the 
kinetics of movement. To investigate miRNA mobil-
ity in multiple distinct developmental contexts, we 
are expressing an artifi cial miRNA targeting a cell-
autonomous green fl uorescent protein (GFP) reporter 
(miR-GFP) from a number of promoters with distinct 
spatiotemporal patterns of expression. Expression of 
miR-GFP from the epidermis-specifi c ATML1 pro-
moter, mesophyll-specifi c RBCS promoter, or vascula-
ture companion cell-specifi c SUC2 promoter showed 
that miRNAs move bidirectionally between all three 
cell layers and that the number of cells across which a 
small RNA moves is determined in part by its abun-
dance. Moreover, analysis of GFP fl uorescence in the 
vasculature supports the idea that miRNA-mediated 
gene regulation is a dose-dependent process and de-
pends on the relative abundance of the miRNA versus 
the target mRNA. No GFP silencing was observed in 
the symplastically isolated stomata, suggesting that 
miRNA movement occurs via plasmodesmata, small 
channels that connect most plant cells.
Interestingly, production of miR-GFP in young 
leaf primordia surrounding the shoot apical meristem 
(SAM) resulted in silencing of GFP inside the SAM, 
demonstrating that miRNAs traffi c from determi-
nate organs into the shoot-stem-cell niche. In addi-
tion, miR-GFP was able to move from the vascula-
ture below the SAM into the niche. These fi ndings 
suggest that miRNAs may function as mobile signals 
between differentiated tissues and stem cells, possi-
bly integrating environmental/physiological cues and 
plant development. Analyses of miRNA mobility in 
other developmental contexts are still ongoing, but 
the data obtained thus far suggest that small RNA 
mobility is developmentally regulated and follows 
rules that are distinct from those that govern pro-
tein traffi cking. In addition, with the knowledge that 
miRNAs can traffi c from the epidermis into underly-
ing tissue layers, we are carrying out forward genetic 
screens to identify factors infl uencing this process.
The START Domain Regulates HD-ZIPIII 
Activity and Organ Polarity
A. Husbands [in collaboration with V. Yong and 
H. Djaballah, Memorial Sloan-Kettering Cancer Center, 
New York]
On the basis of our previous observations regarding 
the expression and function of miR166 and tasiR-
ARF, it is evident that adaxial–abaxial patterning 
involves a cascade of positional signals. The mobile 
signals that pattern the newly formed leaf are distinct 
from those that maintain polarity during subsequent 
development. This project aims to identify additional 
signals in adaxial–abaxial patterning. The adaxial 
promoting HD-ZIPIII transcription factors contain 
a predicted START lipid-binding domain (Fig. 1). 
Modeling of the START domain of the HD-ZIPIII 
member PHABULOSA (PHB) suggests a structural 
similarity to human PC-TP, a phosphatidylcholine-
binding START domain. This model and sequence 
conservation with other START domains was used to 
predict amino acids in PHB critical for START do-
main ligand binding. Analysis of Arabidopsis lines that 
express PHB-YFP fusion proteins with mutations in 
key residues lining the START ligand-binding pock-
et indicates that the START domain is required for 
proper HD-ZIPIII function. Such mutations block 
PHB-mediated target gene expression, indicating pos-
itive regulation of HD-ZIPIII activity by an unknown 
ligand.
Plant Biology  189
Experiments to determine the mechanism through 
which the START domain controls HD-ZIPIII func-
tion are ongoing. Ligand binding does not appear to 
affect the subcellular localization of these transcrip-
tion factors, as confocal imaging showed that the 
PHB-YFP derivatives correctly localize to the nucle-
us. Likewise, ligand binding is not essential for PHB 
dimerization. However, ligand binding does affect 
PHB’s ability to bind DNA and possibly the interac-
tion with protein partners. As part of these analyses, 
we developed a yeast-based assay and conducted a 
high-throughput screen for chemical compounds that 
bind the HD-ZIPIII START domain and modulate 
protein activity. Using yeast growth as readout, we 
identifi ed compounds that reduced yeast growth (an-
tagonists) and others that promoted growth (agonists). 
Validation experiments in yeast and plants are under 
way to eliminate false positives and demonstrate that 
these chemicals act via modulation of HD-ZIPIII ac-
tivity. In a parallel approach, we have generated plants 
expressing a biotin-tagged form of the START do-
main and will be performing immunoprecipitations 
and mass spectrometry to identify the endogenous 
ligand bound by HD-ZIPIII proteins. These latter 
experiments are under way in collaboration with the 
CSHL proteomics facility.
tasiRNA Pathways in Maize and 
New Players in Leaf Polarity
M. Dotto [in collaboration with M. Hammell, Cold 
Spring Harbor Laboratory; M. Aukerman, M. Beatty, 
and R. Meeley, DuPont-Pioneer]
tasiRNAs are 21-nucleotide small RNAs that regulate 
the activity of key genes involved in plant growth and 
development. Mutations in maize leafbladeless1 (lbl1) 
that disrupt tasiRNA biogenesis give rise to plants 
with thread-like leaves that have lost top/bottom po-
larity. We used genomic approaches to identify lbl1-
dependent small RNAs and their targets to determine 
the basis for these polarity defects. This revealed sub-
stantial diversity in small RNA pathways across plant 
species and identifi ed unexpected roles for LBL1 in 
the regulation of repetitive elements within the maize 
genome. We further showed that only tasiRNA loci 
belonging to the TAS3 family function in the maize 
vegetative apex. The TAS3-derived tasiR-ARFs are 
the main tasiRNA active in the apex, and misregu-
lation of their ARF3 targets emerges as the basis for 
the lbl1 leaf polarity defects. Supporting this, we show 
that plants expressing arf3a transcripts insensitive to 
tasiR-ARF-directed cleavage recapitulate the pheno-
types observed in lbl1. The TAS3 tasiRNA pathway, 
including the regulation of ARF3 genes, is conserved 
throughout land plant evolution, yet the phenotypes 
of plants defective for tasiRNA biogenesis are strik-
ingly different. Our data lead us to propose that di-
vergence in the processes regulated by the ARF3 tran-
scription factors or the spatiotemporal pattern during 
development in which these proteins act underlies 
the diverse developmental contributions of this small 
RNA pathway across plants.
In a separate approach, we are working to iden-
tify additional small RNAs with a role in maize 
Figure 1. Novel DCL1-dependent 22-nucleotide siRNAs bypass 
the loss of DCL4 in development. (A) In wild type, the 21-nu-
cleotide tasiR-ARFs are generated via the two-hit TAS3 tasiRNA 
pathway. Biogenesis of these small RNAs is conﬁ ned to the ad-
axial/upper side of leaf primordia via the localized accumulation 
of miR390. tasiR-ARFs target arf3 transcripts, limiting expression 
of these abaxial determinants to the lower side of developing 
leaves. (B) In dcl4, targeting of TAS3 transcripts by miR390-
AGO7 complexes proceeds on the adaxial side of leaf primordia 
as in wild type. However, upon loss of DCL4 activity, the dou-
ble-stranded TAS3 precursors are processed by DCL2/3 and this 
leads to the accumulation of 22-nucleotide tasiR-ARF variants 
rather than the normal 21-nucleotide species. The 22-nucleotide 
tasiR-ARFs trigger a unique one-hit mechanism of secondary 
siRNA biogenesis at the arf3a and arf3d transcripts speciﬁ cally, 
leading to the processing of arf3a/d transcripts into 22-nucle-
otide siRNAs by DCL1. As a result, expression for both ARF3 
abaxial determinants remains largely unaffected and the phe-
notype of dcl4 mutants is suppressed in comparison to that of 
similar mutations in other TAS3 tasiRNA pathway components.
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development. Small RNAs associate with specifi c 
AGO proteins to form an RNA-induced silenc-
ing complex (RISC) that directs the cleavage and 
degradation of complementary mRNA targets. In 
Arabidopsis, AGO10 (AtAGO10) exclusively binds 
miR166, and this interaction is required for shoot 
apical meristem maintenance. However, interest-
ingly, deep sequencing of immunoprecipitates of 
maize AGO10 (ZmAGO10), obtained using a 
peptide antibody that recognizes both AGO10 ho-
mologs, demonstrated that these AGO proteins 
bind both miR166 and miR394. In situ hybridiza-
tion and laser microdissection–RNA-Seq analyses 
showed that miR394 accumulates in a gradient on 
the adaxial side of developing maize leaves, whereas 
its F-box targets accumulate in the complementary 
abaxial domain. This presents the possibility that 
organ polarity is regulated also by a fourth small 
RNA signal. Indeed, maize ago10 double mutants 
display a downward-curled leaf phenotype, consis-
tent with a role for this pathway in leaf development. 
We are currently characterizing single and double 
mutants for the remaining components of this path-
way, zma-miR394a and zma-miR394b, as well as the 
two F-box protein targets. We are also analyzing 
how structural differences between these miRNA 
precursors and the AGO10 proteins in Arabidopsis 
and maize may account for the differential loading 
of miR394 in these species.
Effects of Natural Variation Present in 
Maize Inbreds on the tasiRNA Pathway
K. Petsch [in collaboration with former postdoc Marie 
Javelle and M. Scanlon, Cornell University, Ithaca, 
New York; G. Muehlbauer, University of Minnesota, 
Minneapolis; J. Yu, Kansas State University, Manhattan; 
P. Schnable, Iowa State University, Ames]
Mutants that disrupt tasiRNA biogenesis exhibit de-
fects in adaxial–abaxial patterning. Interestingly, the 
severity of these phenotypes is greatly dependent on 
the inbred background. tasiRNA pathway mutants, 
as well as other small RNA biogenesis mutants, typi-
cally exhibit weaker phenotypes when introgressed 
into B73 as opposed to other inbred backgrounds, 
such as W22, Mo17, and A619. To understand how 
inbred background infl uences expressivity of tasiRNA 
pathway mutants, we are using the severe ragged1 
allele of leafbladeless1 (lbl1-rgd1). In the B73 inbred 
background, lbl1-rgd1 conditions a classical leaf po-
larity phenotype with most leaves developing as ra-
dial, abaxialized organs. In W22, however, lbl1-rgd1 
embryos lack a shoot meristem and germinate with 
just a root. We have generated an F2 population to 
map loci that contribute to the variable expressivity of 
lbl1-rgd1 in the two inbreds. This identifi ed a major 
modifi er locus on chromosome 8, which we have 
now fi ne-mapped to a region containing ~140 genes. 
In addition, we performed transcriptome analysis of 
lbl1-rgd1 embryos and nonmutant siblings in B73 and 
W22. This identifi ed 214 genes that are differentially 
expressed in lbl1-rgd1 embryos in both backgrounds. 
These include known tasiRNA targets and genes 
showing differential expression across the adaxial–ab-
axial axis, as well as genes predicted to function in the 
embryonic shoot meristem. Most notably, ~30% of 
genes down-regulated in W22 mutant embryos have 
“meristem-associated” functions. Further investiga-
tion into specifi c genes is ongoing. Importantly, this 
study identifi ed 40 genes within the chromosome 8 
modifi er region that are expressed in the developing 
embryo and show differential expression between the 
inbreds or between lbl1-rgd1 and nonmutant siblings. 
And fi nally, this resource identifi ed genes that are 
polymorphic between B73 and W22. By combining 
these approaches, we hope to gain a better under-
standing of the factors contributing to natural varia-
tion in tasiRNA pathway function.
Novel DICER-LIKE1 siRNAs Bypass 
the Requirement for DICER-LIKE4 
in Development
K. Petsch [in collaboration with O. Tam and M. Hammell, 
Cold Spring Harbor Laboratory; R. Meeley, DuPont-
Pioneer; P. Manzotti and G. Consonni, University of Milan, 
Italy]
Dicer enzymes function at the core of RNA silencing 
to defend against exogenous RNA, or as an endog-
enous mechanism of gene regulation. Plant DICER-
LIKE4 (DCL4) performs dual functions, acting in 
antiviral defense, as well as in development via the 
biogenesis of tasiR-ARFs. These small RNAs have 
an essential role in the grasses and act to spatially de-
fi ne the expression domain of AUXIN RESPONSE 
FACTOR3 (ARF3) transcription factors. However, 
contrary to tasiR-ARFs’ essential function in devel-
opment, DCL4 proteins exhibit strong evidence of 
Plant Biology  191
recurrent adaptation typical of host factors involved 
in antiviral immunity. Here, we address how DCL4 
balances its role in development with pressures to di-
versify in response to viral attack. We show that in 
contrast to other tasiR-ARF biogenesis mutants, dcl4 
null alleles condition an uncharacteristically mild 
phenotype, correlated with normal expression of select 
arf3 targets. Loss of DCL4 activity yields a class of 
22-nucleotide tasiR-ARF variants associated with the 
processing of arf3 transcripts into 22-nucleotide sec-
ondary siRNAs by DCL1. Our fi ndings uncover the 
presence of a novel DCL1-dependent siRNA pathway 
that bypasses the otherwise adverse developmental ef-
fects of DCL4 mutations (Fig. 1). This novel path-
way is predicted to have important implications for 
DCL4’s role in antiviral defense by reducing the selec-
tive constraints on DCL4 and allowing it to diversify 
in response to viral suppressors.
High-Resolution Gene Expression Atlas 
for the Maize Shoot Apex
S. Knauer [in collaboration with former postdoc Marie 
Javelle, and M. Scanlon, Cornell University, Ithaca, 
New York; G. Muehlbauer, University of Minnesota, 
Minneapolis; J. Yu, Kansas State University, Manhattan; 
P. Schnable, Iowa State University, Ames]
Plants have the distinctive ability to form new organs 
throughout their lifetime, which can span hundreds 
or even thousands of years. The growing tip of a plant 
contains a population of stem cells that are located 
within a specialized niche, termed the shoot apical 
meristem (SAM). These stem cells divide to main-
tain the SAM and to generate daughter cells from 
which lateral organs, such as leaves and fl owers, arise. 
The gene regulatory networks controlling meristem 
indeterminacy and organogenesis remain largely ob-
scure. To gain insight into such networks, we have 
generated a high-resolution gene expression atlas for 
the maize shoot apex. Functional domains of the 
meristem were isolated by laser microdissection and 
analyzed by RNA deep sequencing. These include 
the whole meristem, the stem cell–containing SAM 
tip, the newly initiating leaf (P0), the epidermal layer 
of the SAM (L1), and the subepidermal region (L2). 
Because gene networks controlling meristem main-
tenance and leaf development are largely intercon-
nected, we further compared expression profi les in an 
ontogenic series of leaf primordia, P1, P2, and P3. 
Using this extensive data set, we were able to identify 
genes that mark specifi c cell types or are differentially 
expressed between distinct tissue types. Using CAST 
clustering, we further identifi ed genes that show dy-
namic expression profi les during the transition from 
a stem cell to an organ primordium. For instance, we 
identifi ed numerous genes that specifi cally mark the 
stem cell domain of the meristem and several genes 
that mark the presumptive organizing center. Most 
notably, our analysis identifi ed unique transcription 
factor signatures that, next to the interplay of hor-
mones, distinguish stem cells from their differentiat-
ing descendants within the SAM. Reverse genetic re-
sources available for maize are being used to directly 
test the function of select genes in these processes. 
This has identifi ed several new mutants affecting 
meristem maintenance and leaf morphology. Overall, 
our fi ndings present a novel approach to modulating 
plant architecture by manipulating master regulators 
of cell identity.
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There has been a growing appreciation in recent years that gene function is frequently context-
dependent, with a large part of that context provided by the activities of other genes. But trying to 
understand how genes interact to produce function is a hugely complicated problem and one that 
appears likely to become more so as genomic information becomes more detailed. Jesse Gillis and 
colleagues are computational biologists who are presently challenging an oft-taken approach to the 
problem in which the functions of genes are interpreted in the context of networks derived from 
gene association data. Such networks consist of millions of interactions across thousands of genes, 
derived from protein-binding assays, RNA coexpression analysis, and other sources.  Historically, 
many attempts to understand gene function through networks have leveraged a  biological prin-
ciple known as “guilt by association.” It suggests that genes with related functions tend to share 
properties (e.g., physical interactions). In the past decade, this approach has been scaled up for 
application to large gene networks, becoming a favored way to grapple with the complex interde-
pendencies of gene functions in the face of fl oods of genomics and proteomics data. Gillis’ work 
centers on identifying the limits of the approach and making fundamental improvements to its 
operation, as well as applying those improvements to neuropsychiatric gene network data.
Thomas Gingeras and colleagues study where and how functional information is stored in ge-
nomes. These efforts help explain the biological and clinical effects of disease-causing gene mu-
tations in humans and other organisms. Gingeras is a leader of the ENCODE (ENCyclopedia 
of DNA Elements) and the mouseENCODE and modENCODE (model genome ENCODE) 
projects of the National Institutes of Health. His research has altered our understanding of the 
traditional boundaries of genes, revealing that almost the entire lengths of genomes in organisms 
ranging from bacteria to humans can be transcribed into RNA (pervasive transcription) and that 
most RNA products made by a cell are not destined to be translated into proteins (noncoding, or 
ncRNAs). In fact, ncRNAs are proving to be involved in a variety of other important biological 
functions. Some have been shown to be critical components in the pre- and posttranscriptional 
and translational processes, as scaffolds upon which large protein complexes are assembled and as 
extracellular signals. The initial studies that led to these observations have been extended to cover 
the entire human genome.
Gholson Lyon’s lab focuses on analyzing human genetic variation and its role in severe neuropsy-
chiatric disorders and rare diseases, including intellectual disability, autism, and schizophrenia. By 
recruiting large groups of related individuals living in the same geographic location (e.g., Utah), 
Lyon’s lab can study the breadth and depth of genetic variants in a similar environmental back-
ground. Using the exome—the parts of the genome that code for protein—and whole-genome 
sequencing, his lab looks for mutations that segregate with syndromes in the various populations. 
A second focus of the Lyon lab is to study the mechanistic basis of a new rare disease that they 
described in 2011. This is the fi rst human disease involving a defect in the amino-terminal acety-
lation of proteins, a common modifi cation of eukaryotic proteins carried out by amino-terminal 
acetyltransferases (NATs). The team has been using several different cellular model systems to 
better understand the disease pathophysiology and the basic process of amino-terminal acetylation.
The insights of W. Richard McCombie and colleagues have led to the introduction and optimi-
zation of novel methods of high-throughput genome sequencing. His team has made it possible 
to catalog variation among individual organisms in a way that would have been unthinkable 10 
years ago. They have brought online a new generation of Illumina sequencers and optimized 
their function to a level at which eight to 10 trillion DNA bases can be sequenced in a month. 
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McCombie’s team has been involved in international efforts culminating in genome sequences for 
maize, rice, and bread wheat—three of the world’s most important food crops. They have also had 
an important role in projects to sequence the fl owering plant Arabidopsis thaliana (the fi rst plant 
genome sequence), the fi ssion yeast Schizosaccharomyces pombe, as well as the human genome and 
other important genomes. McCombie’s group is currently involved in several important projects 
to resequence genes in patient samples that are of special interest to human health, including 
DISC1 (a strong candidate gene for schizophrenia), looking for genetic variants implicated in 
bipolar illness and major recurrent depression. They are also looking for genes that contribute to 
cancer progression using whole-genome sequencing or a method called exome sequencing, which 
they developed with Greg Hannon to look at mutations in the regions of the genome that code 
for proteins.
Using multidisciplinary approaches that combine computational analysis, modeling, and predic-
tion with experimental verifi cation, Doreen Ware’s lab seeks a deeper understanding of the evo-
lution of genome sequences in plants and their implications for agricultural improvement. By 
looking comparatively across the genomes of plants in the same lineage, they seek answers to the 
following questions: How are genes conserved and lost over time? What are the fates of duplicated 
genes? What is the impact of structural variation on phenotypic variation? Ware’s team also stud-
ies gene regulation in plants, focusing on gene regulatory networks, targeting transcription factors 
and microRNA genes with the objective of understanding how these parts of the plant genome 
work together in determining spatial and temporal expression of genes. The lab had an important 
role in the project to produce a haplotype map reference genome of maize, spearheading the most 
comprehensive analysis of the crop yet. This has provided important information on the variation 
of the reference genome, as well as comparative data showing changes in the genome acquired 
through domestication and breeding. They have devoted special attention to examining diversity 
within maize, grape, and tomato, aiming to accelerate the development of strategies to introduce 
new germplasm that is needed to meet demands of increasing population and a changing environ-
ment. The lab also has brought fully sequenced genomes into an integrated data framework, to 
enhance the power of their comparative studies. This past year, Ware was named as its principal 
investigator for the National Science Foundation-funded Gramene project, a comparative genom-
ics resource for agriculturally important crops and models to support sustainable food and fuel 
production. Ware, as principal investigator for plants, has also helped lead an effort funded by 
the Department of Energy to create—out of many separate streams of biological information— 
a single, integrated cyber-“knowledgebase” for plants and microbial life.
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GENE NETWORK ANALYSIS
J. Gillis S. Ballouz W. Verleyen
Research in our lab centers on using computational 
methods to understand gene function. Computa-
tional biology has taken up the challenge of deter-
mining gene function mainly by attempting to in-
terpret the activities of genes in the context of net-
works derived from gene association data. As data 
sets characterizing genes grow in size and complex-
ity, it seems self-evident that computation can as-
sist in inference as to gene function. Gene network 
analysis intended to provide insight into complex 
disorders is a dominant interest in the fi eld. Gene 
associations (of various sorts) are believed to en-
code functional interaction, and this interaction is 
frequently shown to be able to substantially predict 
gene function across all functions. This approach, 
commonly called “Guilt by Association,” is embed-
ded in everything from prioritization of de novo 
variants to uncovering novel molecular phenotypes 
or mechanisms of disease. Our research focuses on 
identifying limitations in gene network analysis and 
making fundamental improvements to its operation 
for the interpretation of neuropsychiatric genomics 
data. We are developing gene network resources that 
improve both the sophistication and breadth of data 
available for determining functional convergence 
among disease-causal genes. We develop carefully 
calibrated networks from data that are specifi c to 
age, species, sex, tissue, and disease state, as well 
as machine learning tools customized to their use 
for neuropsychiatric analysis. In addition to post-
docs Wim Verleyen and Sara Ballouz, Maggie Crow 
joined us in 2015.
Machine Learning Functional Properties 
of Genes
Increasingly, biologists have turned to computational 
methods to sift through the vast array of preexisting 
genomics data for validation that a candidate vari-
ant has a molecular role in the phenotype of interest 
or to prioritize a candidate as disease-causal. These 
computational methods usually fi t under the rubric 
of “machine learning,” using network data that repre-
sent the interaction of genes or their products.
The use of our burgeoning genomics data to 
characterize gene function has been one of the cen-
tral research objectives of computational biology 
in the postgenomics era. Despite this intense focus, 
the abundance of public data, and methods develop-
ment in machine learning and “big data” analysis, 
progress has been surprisingly uncertain. Attaching 
novel functions to genes based on prior data remains 
diffi cult, and a large number of genes still have com-
paratively little information attached to them. This is 
a critically important problem in evaluating disease 
candidate variants, many of which involve otherwise 
unstudied genes. To better understand the forces 
driving algorithmic and data performance, develop-
ers have focused on comparative assessment. Despite 
some important progress enabled by these assess-
ments, the underlying mechanisms driving methods 
performance are poorly understood. Each developer 
may use separate data resources, different algorithms, 
and quite specifi c means for parsing the data, making 
it quite hard to explore factors affecting performance. 
Field-wide progress is hampered by our inability to 
know why a specifi c algorithm worked on a particular 
data set for a potentially narrow task.
To overcome this lack of detail in assessment, we 
developed a computational infrastructure that allows 
us to implement representative samples of cutting-
edge machine learning algorithms. These algorithms 
can then be customized to specifi c biological problems 
and, when benchmarked against prior data, obtain 
very high levels of performance. Moreover, we learn 
more by combining them through meta-analysis than 
we do from their individual results, as is often the case 
in machine learning. Because we now have in-house 
versions of multiple algorithms, we can explore vari-
ance and data dependencies in a way not typically 
possible, leading to several useful heuristics for me-
ta-analysis that we have recently published (Verleyen 
et al. 2014).
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We have focused on data based on networks de-
rived from protein–protein interaction, sequence 
similarity, aggregated coexpression, and semantic 
similarity to study underlying patterns of perfor-
mance. Our infrastructure allows us to characterize 
in detail why aggregation improves performance, 
where results are robust and reproducible, and what 
artifacts are potentially problematic in data inter-
pretation. We plan to make this replication across 
methods available as a public resource, allowing ge-
neticists using function prediction methods to bet-
ter assess reproducibility and data dependencies in 
target genes of interest.
Condition-Speciﬁ c RNA-Seq 
Coexpression Networks
The idea of condition-specifi c networks exists in a 
number of forms within the fi eld of systems biology, 
most prominently as a way of capturing network 
dynamics; creating multiple condition-specifi c net-
works is a way of capturing how interactions between 
genes or their products change. Network construc-
tion depends on data type, but it usually takes the 
form of profi les of genes across a range of condi-
tions. Our interest in such data is in determining 
not only that disease genes interact, but also under 
what conditions they do so. To assess this, we  exploit 
RNA-Seq measures of expression activity from 
 diverse prior data.
RNA-Seq offers profound biological and techni-
cal advantages over microarray technologies, such as 
detecting the whole transcriptome and an improved 
dynamic range. However, as was once the case for 
microarrays, RNA-Seq’s utility is hobbled by our in-
ability to determine sound consensus standards. One 
major reason is that RNA-Seq data have quite dif-
ferent statistical properties from those of microarray 
data, and thus the same principles do not apply for 
differential expression. Important questions about 
data quality, such as the role of biological noise in 
experimental design, are not readily addressed. A 
broader characterization of RNA-Seq data through 
meta-analysis offers one avenue to investigate prob-
lems of this nature.
Although differential expression analysis is a more 
common means for interpreting transcriptomic data, 
coexpression analysis is far more routine in the con-
text of meta-analysis, with thousands of expression 
profi les aggregated to generate robust signatures 
using repurposed data. One advantage of coexpres-
sion methods is that it already tends to require meta-
analysis of disparate data sets with quite different 
properties, so approaches for aggregating across data 
are already common. We have developed a series of 
methods appropriate for RNA-Seq meta-analysis as 
well as producing reference networks for general use. 
RNA-Seq coexpression poses novel statistical and 
bioinformatics challenges; we have identifi ed major 
confounds and developed appropriate control experi-
ments necessary for network construction, laying the 
groundwork for functional analyses into RNA-Seq 
coexpression. Our analysis platform allows us to 
easily repurpose preexisting raw data, to construct 
large-scale aggregate coexpression networks from a 
variety of conditions, and to use both RNA-Seq and 
microarray data.
Bias Tradeoffs in the Creation and Analysis 
of Protein–Protein Interaction Networks
Networks constructed from aggregated protein– 
protein interaction data are commonplace in  biology. 
But the studies from which these data are  derived 
were conducted with their own hypotheses and foci. 
Focusing on data from budding yeast present in 
BioGRID, we determined that many of the down-
stream signals present in network data are signifi -
cantly impacted by biases in the original data. We 
determined the degree to which selection bias in favor 
of biologically interesting bait proteins goes down 
with study size, and we also fi nd that promiscuity in 
prey contributes more substantially in larger studies. 
We analyze interaction studies over time with respect 
to data in the Gene Ontology and fi nd that repro-
ducibly observed interactions are less likely to favor 
multifunctional proteins. We fi nd that strong align-
ment between coexpression and protein–protein in-
teraction data occurs only for extreme coexpression 
values, and we use these data to suggest candidates 
for targets likely to reveal novel biology in follow-up 
studies (Gillis et al. 2014).
Ligand-Binding Networks
With the development of large-scale target-ligand 
 databases, and new chemoinformatics metrics, it is 
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now feasible to directly correlate ligand similarities 
between proteins to their bioinformatic or proteomic 
similarities. We hoped that by investigating this al-
ternate source of network data, new bridging ligands 
may be found for targets whose activity is perturbed 
in disease. In collaboration with the Shoichet lab at 
the University of California, San Francisco, we calcu-
lated similarities for 1131 proteins, each of which had 
known ligands, and compared ligand-based similarities 
to those derived from sequences, from protein–protein 
interaction networks, and from coexpression networks. 
Surprisingly, the proteomic associations were often or-
thogonal to the ligand-based associations; two targets 
that were intensely related by protein–protein interac-
tion or by coexpression only rarely recognized similar 
ligands, and most pairs of targets that bound similar 
ligands were unrelated proteomically. Even sequence 
similarity was an unreliable predictor of shared li-
gand recognition among targets: Most related se-
quences had only a 55% chance of sharing similar 
ligands, and 29% of the targets that recognized sim-
ilar ligands had no signifi cant sequence similarity. 
Still, there were regions of high proteomic similarity 
that overlapped with high ligand similarity and that 
were coannotated for diseases. We sought single li-
gands that could bridge disease-linked targets, where 
no such bridging ligand was known. On experimen-
tal testing, we found such bridging ligands for seven 
pairs of targets, previously unknown to share li-
gands but linked proteomically in neuropsychiatric 
diseases.
Improved Quality Control for RNA-Seq
Recent analyses of RNA-Seq have emphasized the 
value added by experimental designs with more sam-
ples, permitting better estimation of biological and 
technical variability. Unfortunately, this does not 
automatically translate into an experimental design 
decision for more replicates (biological or technical), 
largely because of the relatively high cost of RNA-
Seq. Study design is further complicated by complex 
dependencies on the platform chosen, library prepa-
ration, and normalization methods. All of these fac-
tors affect the concordance of downstream differen-
tial expression analysis. Although researchers must be 
aware of the pitfalls that can arise when designing 
their experiment, they receive only modest feedback 
in the experimental data itself as to whether their 
choices were successful. Many optimized protocols 
or best practices exist, but there are few means for 
assessing the quality of a given transcriptomic study, 
particularly outside of purely technical concerns and 
where focusing on novel biology.
In our recent work, we have demonstrated a 
straightforward but surprisingly powerful method 
to measure replicability by modeling the effects of 
noise within observed coexpression. Because of the 
breadth and extent of coexpression, it provides a 
sensitive, yet general means of performing a quality 
control. We begin our analysis by performing some 
sample and replicate-based analyses of RNA-Seq 
quality to establish general properties, then we show 
how common heuristics for quality control appear 
in a coexpression-based framework, and fi nally we 
provide a means of directly quantifying this by dis-
ruption of known coexpression pairs. By providing 
a direct quality control measure, we hope to make it 
straightforward to customize experiments to do bet-
ter than a general heuristic—such as discarding all 
low-expressing genes—would normally permit. We 
plan to make our software available in a convenient 
form for bioinformatic use.
De Novo Variant Network Analysis
One of the principal applications to which we put 
machine learning and coexpression networks is in 
looking for functional convergence among de novo 
variants. For the last several months, we have been 
relying on the recently published Simons simplex 
collection autism variant list to determine features 
that predict disease properties among genes. The 
key to our approach is to look for features that dis-
tinguish not only the disease candidates from other 
genes, but also high-quality disease candidates from 
low-quality ones. It is important to acknowledge that 
even these high-quality gene sets have false positives 
(perhaps as many as 50% of the total) with char-
acteristic features; thus, it is not suffi cient simply 
to look for points of convergence, because the false 
positives, too, have overlapping features. Instead, as 
our coexpression data have expanded, we have found 
that we can predict which candidates will recur in 
the population (true positives) based on their coex-
pression patterns.
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GENOME ORGANIZATION AND REGULATION AND 
FUNCTIONAL ROLES OF NONCODING RNAs
T.R. Gingeras P. Batut J. Drenkow F. Schlesinger
 S. Chakrabortty G. Nechooshtan L.-H. See
 C. Davis A. Prakash H. Xue
 A. Dobin A. Scavelli C. Zaleski
Human ENCODE Project
P. Batut, C. Davis, A. Dobin, J. Drenkow, A. Scavelli, 
L.-H. See, C. Zaleski
A total of 173 human primary cell line and tis-
sue samples (done in replica) have been analyzed for 
long RNA (>200 nucleotides), short RNA (<200 
nucleotides), and RAMPAGE (5′ cap sites) this year. 
These and all generated for this phase of ENCODE 
data are available at (https://www.encodeproject.org/
search/?type=experiment&lab.title=Thomas%20
Gingeras,%20CSHL). As part of the model genomes 
ENCODE (mod-ENCODE), we and our collabora-
tors from the University of Connecticut, University of 
California, Berkeley, University of Indiana, RIKEN, 
Harvard University, and the Rockefeller University 
have identifi ed new genes, transcripts, and proteins 
using poly(A)+ isolated from cultured cell lines and 
dissected organ systems from Drosophila melanogaster. 
We found that a small set of mostly neuron-specifi c 
genes has the potential to encode thousands of tran-
scripts each through extensive alternative promoter 
usage and RNA splicing. The magnitudes of splicing 
changes were seen to be larger between tissues than 
between developmental stages, and most sex-specifi c 
splicing is gonad-specifi c. Gonads expressed hundreds 
of previously unknown coding and long noncoding 
RNAs (lncRNAs), some of which are antisense to pro-
tein-coding genes and produce short regulatory RNAs. 
Furthermore, previously identifi ed pervasive intergenic 
transcription occurs primarily within newly identifi ed 
introns. The fl y transcriptome is substantially more 
complex than previously recognized, with this com-
plexity arising from combinatorial usage of promot-
ers, splice sites, and polyadenylation sites. Using these 
and other data consisting of matched RNA-sequenc-
ing data from human, worm, and fl y that we and our 
collaborators in the ENCODE and mod-ENCODE 
consortia have generated has allowed comparison 
across metazoan phyla, extending beyond earlier with-
in-phylum transcriptome comparisons and revealing 
ancient conserved features. Specifi cally, we discovered 
coexpression modules shared across animals, many of 
which are enriched in developmental genes. Moreover, 
we used expression patterns to align the stages in worm 
and fl y development and fi nd a novel pairing between 
worm embryo and fl y pupae, in addition to the embryo-
to-embryo and larvae-to-larvae pairings. Furthermore, 
we found that the extent of noncanonical, noncoding 
transcription is similar in each organism, per base pair. 
Finally, we fi nd in all three organisms that the gene-
expression levels, both coding and noncoding, can be 
quantitatively predicted from chromatin features at the 
promoter using a “universal model” based on a single 
set of organism-independent parameters.
Comparisons of Transcriptomes 
of Human and Mouse
C. Davis, A. Dobin, C. Zaleski
The laboratory mouse shares the majority of its pro-
tein-coding genes with humans, making it the pre-
mier model organism in biomedical research—yet 
the two mammals differ in signifi cant ways. To gain 
greater insight into both shared and species-specifi c 
transcriptional and cellular regulatory programs in 
the mouse, the Mouse ENCODE Consortium has 
mapped transcription, DNase I hypersensitivity, tran-
scription factor binding, chromatin modifi cations, 
and replication domains throughout the mouse ge-
nome in diverse cell and tissue types. By comparing 
with the human genome, we not only confi rmed sub-
stantial conservation in the newly annotated potential 
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functional sequences, but also found a large degree 
of divergence of sequences involved in transcriptional 
regulation, chromatin state, and higher-order chroma-
tin organization. To better understand these two spe-
cies on a molecular level, we and our Mouse ENCODE 
collaborators performed a comparison of the expres-
sion profi les of 15 tissues by deep RNA sequencing 
and examined the similarities and differences in the 
transcriptome for both protein-coding and -noncoding 
transcripts. Although commonalities are evident in the 
expression of tissue-specifi c genes between the two spe-
cies, the expression for many sets of genes was found 
to be more similar in different tissues within the same 
species than between species. However, comparison 
with transcriptome profi les in human cell lines also 
revealed substantial conservation of transcriptional 
programs and uncovered a distinct class of genes with 
levels of expression that have been constrained early 
in vertebrate evolution. This core set of genes captures 
a substantial fraction of the transcriptional output of 
mammalian cells and participates in basic functional 
and structural housekeeping processes common to all 
cell types. Perturbation of these constrained genes was 
associated with signifi cant phenotypes including em-
bryonic lethality and cancer. Evolutionary constraint 
in gene expression levels was not refl ected in the con-
servation of the genomic sequences, but it was asso-
ciated with conserved epigenetic marking, as well as 
with the characteristic posttranscriptional regulatory 
program, in which subcellular localization and alter-
native splicing have comparatively large roles.
Database and Software Development
A. Dobin, C. Zaleski
The infrastructure of our laboratory’s analysis pro-
grams is used for the continued development and main-
tenance of the large databases collected as part of the 
human, mouse, and model genome (mod) ENCODE 
projects. The notable achievements in this area include 
the following:
Database Development
• Continued management and organization of se-
quencing data consisting of raw fastq fi les and 
genome-mapped data fi les. These include bam, 
bigwig, and other formats in a growing repository 
almost 30 TB in size.
• Continued execution of a sequencing production 
pipeline. This consists of sequence mapping into 
multiple formats, multiple QC steps, and fi le trans-
fer to outside locations.
• Began implementation of new software tools for 
annotation–agnostic analysis of sequencing data. 
Completed part 1, consisting of a program that 
uses a recursive algorithm to generate “intervals” or 
“regions” of expression from RNA-Seq data.
• Managed our primary storage hardware to accom-
modate >40 TB (terabytes) of data that were mi-
grated to a new hardware system and connected to 
the shared computing cluster as well as our own 
lab’s servers.
• Established an archival storage tier that organized 
and migrated almost 25 TB of data to the archive 
tier. Also implemented a shared storage tracking 
system to monitor usage of live and archived data.
Software Development
• Developed standardized RNA-Seq pipelines for 
the ENCODE consortium. The long and small 
RNA-Seq, as well as RAMPAGE, pipelines have 
been transferred to the ENCODE DCC and are 
ready for uniform processing of the RNA-Seq data.
• Developed and supported the STAR RNA-Seq 
aligner. STAR’s popularity is rising: The paper has 
been cited ~230 times in the 2 years since publi-
cation in 2013, with hundreds of users using the 
software (~700 unique users in GitHub repository).
• Developed comprehensive RNA-Seq analysis soft-
ware STARtools. Although numerous tools have 
been developed for performing separate analysis 
tasks, linking them into a processing pipeline is a 
demanding job due to peculiarities of the fi le for-
mats, necessity of maintaining an assortment of 
executables, and the wide range of required com-
putational resources. To resolve these diffi culties, 
we have developed STARtools, a software suite for 
comprehensive analysis of RNA-Seq data, which 
can perform a variety of common analysis tasks in 
a single pass. STARtools is based on our RNA-Seq 
mapper STAR, which is gaining popularity because 
of its high mapping speed and precision. Conver-
sion tool converts alignments into various output 
formats, which can be visualized in genome brows-
ers. Quantifi cation tool quantifi es gene and iso-
form expression using highly effi cient and accurate 
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algorithms, allowing for differential expression 
assessment. In addition, it outputs the alignments 
in the transcriptomic coordinates, which can be 
input into popular quantifi cation software such as 
RSEM or eXpress. Chimeric detection tool discov-
ers and quantifi es chimeric (fusion) transcripts, and 
it is also capable of discovering circular RNAs and 
shuffl ed exons. Long read tool is used for extracting 
full-length transcripts from Pacifi c Biosciences and 
Oxford Nanopore data. We will show that combin-
ing mapping of the RNA-Seq data with the down-
stream processing results in a substantial reduction 
of required computational resources as compared to 
the consecutive implementation, and at the same, it 
yields same or better accuracy as the existing tools.
• Developed a pipeline for mapping and annotating 
PacBio Circular Consensus reads. The full-length 
transcript reconstruction from data obtained from 
Pacifi c Biosciences and Oxford Nanopore tech-
nologies has been a key goal of this year’s efforts. 
Because of the high error rate, Oxford Nanopore 
reads require a signifi cantly revised mapping strat-
egy, which is currently under development. Using 
long reads allows for improvements of existing an-
notations and predicting novel genes and isoforms 
in hundreds of human genome loci.
Evolutionary Dynamics of the Genomic 
Elements That Regulate Gene Expression
P. Batut, A. Dobin
Animal development is orchestrated by the unfolding 
of regulatory programs that dynamically specify the 
expression patterns of thousands of protein-coding 
genes and noncoding transcripts. It has long been 
thought that changes to these regulatory programs 
drove the evolution of metazoans, and yet little is 
known about the evolutionary dynamics of the ge-
nomic elements that regulate gene expression. To 
experimentally study the evolution of transcriptional 
promoters, we generated genome-wide profi les of pro-
moter activity throughout embryonic development in 
fi ve Drosophila species spanning ~25 million years of 
divergence (D. melanogaster, D. simulans, D. erecta, 
D. ananassae, D. pseudoobscura). We found that pro-
moter gain and loss have been very active processes 
throughout the evolutionary history of these species. 
Developmental gene expression profi les tend to be 
tightly conserved, and regulatory divergence is shaped 
by systems-level constraints on gene function and de-
velopmental stages. We detected extremely prevalent 
noncoding transcription throughout embryogenesis: 
4050 lncRNA promoters, most of which have never 
been described before, are dynamically expressed dur-
ing that critical period. We identifi ed a Drosophila core 
set of more than 1000 lncRNA promoters conserved 
over 25 million years and showed that they are under 
substantial purifying selection at the levels of promoter 
sequence and expression specifi city. This suggests that 
noncoding transcription in Drosophila not only is prev-
alent, but also fulfi lls essential functions during em-
bryonic development. lncRNA promoters do, however, 
evolve substantially faster than their protein-coding 
gene counterparts. The observation that lineage-specifi c 
lncRNA promoters have recently come under strong 
purifying selection suggests that noncoding transcrip-
tion is a major driving force behind the adaptive evolu-
tion of Drosophila species. We are currently conducting 
functional studies on the FBgn0264479 locus, which 
harbors an lncRNA that is expressed extremely highly, 
and in a spatially restricted fashion, during a 3–4-h 
period around the onset of gastrulation.
Extracellular Vesicles Containing Processed 
Forms of RNY5 Potentially Contribute to 
Tumor Microenvironment
S. Chakrabortty, A. Prakash
Tumor microenvironments are critical to the estab-
lishment and growth of tumors. Extracellular vesicles 
(EVs) have been hypothesized as a means to establish 
and shape such environments. Explorations of the 
diversity of extracellular vesicles were conducted to 
evaluate their biological functionalities. EVs can be 
loosely grouped based on their size distributions into 
exosomes, microvesicles, and apoptotic bodies. To im-
prove our ability to isolate and enrich for various types 
of EVs, we tested and developed more viable meth-
ods of exosome isolation for small RNA-sequencing 
experiments. Through small RNA sequencing of their 
respective RNA cargo, we explored the activity of cells 
sending out signifi cantly conserved messages as RNA 
using any of these types of vesicles as a carrier. Evi-
dence for the biological relevance of the EV-mediated 
communication of RNAs was observed when cultured 
human primary cells were exposed to EVs from each 
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of fi ve human cancer cell lines of distinct lineages. 
Rapid apoptosis of the primary cells is seen as a result, 
whereas cancer cells treated with EVs from primary or 
cancer cells do not trigger this response. Analysis of 
the RNA cargos highlighted the prominence of RNY5 
and its fragments. Clearly distinct expression pat-
terns within and outside cancer and primary cells of 
the RNY5 RNAs and their fragments were observed. 
Overrepresentation and pathway analysis were devel-
oped to understand the pathways triggered leading to 
the apoptotic phenotype in primary cells. Results from 
these studies are being assembled for publication.
In Vitro Processing of RNY5
G. Nechooshtan
Full-length fragments of the RNY5 transcript are seen 
in EVs. Verifi cation of the in vivo steady-state levels 
of the full-length form of RNY5 found in cells and 
EVs was established, as was the relative abundance of 
processed forms of the transcript by northern hybrid-
ization analysis. EVs were found to be enriched for the 
processed forms, whereas whole cells harbor exclusive-
ly the full-length transcript. Using whole-cell and EV 
protein extracts for in vitro processing of a synthetic 
full transcript revealed that although the whole-cell 
extract is able to protect the transcript from degrada-
tion by ribonucleases, EV protein extracts effi ciently 
process the full-length RNY5 into typical shorter spe-
cies found in vivo. These shorter species then remain 
protected from further degradation. To identify the 
cellular factors that have a role in the phenotype ex-
erted by RNY5 in recipient cells and in its processing 
and targeting to EVs, proteomic analysis of binding 
partners of RNY5 were carried out by RNA–protein 
pulldowns with complete and processed forms of 
RNY5 acting as bait. In addition to known binding 
counterparts of Y5 RNA, this analysis revealed several 
other candidate factors that will be further explored.
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HUMAN GENETICS AND GENOMIC MEDICINE
G. Lyon M. Doerfel J. O’Rawe
 P. Kota Y. Wu
Our lab focuses on analyzing human genetic variation 
and its role in severe neuropsychiatric disorders and 
rare diseases, including intellectual disability, autism, 
and schizophrenia. By recruiting large groups of related 
individuals living in the same geographic location (e.g., 
Utah), we can study the breadth and depth of genetic 
variants in a similar environmental background. Using 
the exome—the parts of the genome that code for pro-
tein—and whole-genome sequencing, we look for mu-
tations that segregate with syndromes in the various 
populations and undertake comprehensive functional 
studies of many of the newly identifi ed mutations.
Ogden Syndrome and the Amino-Terminal 
Acetylation of Proteins
M. Doerfel, Y. Wu [in collaboration with R. Marmorstein, 
Philadelphia, Pennsylvania; T. Arnesen and N. Reuter, 
Norway; and P. van Damme, Belgium]
More than 85% of human proteins are acetylated at 
their amino-terminal amino group; hence, amino-
terminal acetylation (NTA) is one of the most abun-
dant modifi cations of eukaryotic proteins. Despite its 
discovery more than 30 years ago, very little is known 
about the cellular effects/functions of this modifi ca-
tion. In humans, six distinct amino-terminal amino-
acetyltransferases (NATs) catalyze the transfer of an 
acetyl group from acetyl-CoA to the amino-terminal 
amino group of their specifi c target proteins. The 
major human acetyltransferase, NatA, consists of 
an auxiliary subunit, Naa15, and a catalytic active 
subunit, Naa10. We have previously described two 
families with a lethal X-linked disorder of infancy 
called Ogden syndrome. This disorder comprises a 
distinct combination of an aged appearance, cranio-
facial anomalies, hypotonia, global developmental 
delays, cryptorchidism, and cardiac arrhythmias. 
Using X-chromosome exon sequencing, we identi-
fi ed a c.109T > C (p.Ser37Pro) variant in Naa10 as 
contributing to this disease. Biochemical analysis 
and immunoprecipitation assays in combination with 
liquid chromatography/mass spectrometry (LC/MS) 
demonstrated a reduced catalytic capacity and re-
vealed an impaired binding of the S37P mutant to-
ward specifi c interaction partners, including Naa15 
and Naa50. Analysis of the amino-terminal acetylome 
of patient cells revealed a decreased acetylation of a 
subset of NatA substrates, indicating that a reduced 
binding capability and an affected enzymatic activity 
of the Naa10 S37P mutation is a prominent feature 
in Ogden syndrome. Characterization of NAA10/
NAA15 knockout yeast strains revealed various phe-
notypes, including growth defects at elevated temper-
atures and altered sensitivity toward cytotoxic stress-
es. These effects could be rescued by overexpressing 
human wild-type Naa15/Naa10 from plasmids; how-
ever, overexpressing mutant Naa15/Naa10 S37P only 
partially rescues these effects. Interestingly, introduc-
tion of both a human Naa15/Naa10 wild type and 
S37P mutant into the endogenous locus of the cor-
responding yeast genes failed to reverse the effects. We 
also continued our efforts with establishing induced 
pluripotent stem cells (iPSCs) from skin fi broblasts 
from one of the boys with Ogden syndrome, and we 
are also establishing knock-in mice containing the 
mutation of interest in NAA10. Ongoing work will 
focus on characterizing the cells and mice.
RykDax Syndrome: Characterization 
and Analysis of an Idiopathic Intellectual 
Disability Syndrome
J. O’Rawe, Y. Wu [in collaboration with H. Fang, L. Jimenez 
Barron, Cold Spring Harbor Laboratory; E. Yang, Boston; 
A. Rope, Oregon; J. Swensen, Arizona; R. Robison, Utah; 
and K. Wang, California]
We worked on the discovery of a new genetic syndrome, 
RykDax syndrome, driven by a whole-genome sequenc-
ing (WGS) study for one family from Utah. This family 
had two affected brothers presenting with severe intellec-
tual disability (ID), a characteristic intergluteal crease, 
and very distinctive facial features, including a broad, 
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upturned nose, sagging cheeks, downward sloping palpe-
bral fi ssures, prominent periorbital ridges, deep-set eyes, 
relative hypertelorism, thin upper lip, a high-arched pal-
ate, prominent ears with thickened helices, and a pointed 
chin. Illumina-based WGS was performed on 10 mem-
bers of this Caucasian family, with additional complete 
genomics-based WGS performed on the nuclear por-
tion of the family (mother, father, and the two affected 
males). Using WGS data sets from 10 members of this 
family, we could increase the reliability of the biological 
inferences with an integrative bioinformatic pipeline. In 
combination with insights from clinical evaluations and 
medical diagnostic analyses, the DNA sequencing data 
were used in the study of three plausible genetic disease 
models that might uncover genetic contribution to the 
syndrome. We found a two- to fi vefold difference in the 
number of variants detected as being relevant for various 
disease models when using different sets of sequencing 
data and analysis pipelines. We derived greater accuracy 
when more pipelines were used in conjunction with data 
encompassing a larger portion of the family, with the 
number of putative de novo mutations being reduced 
by 80%, because of false-negative calls in the parents. 
The boys carry a maternally inherited missense variant 
in the X-chromosomal gene TAF1, which we consider as 
disease relevant. We took a “genotype-fi rst” approach to 
fi nd other families with variants in TAF1 and containing 
individuals having a remarkably similar clinical presen-
tation. TAF1 is the largest subunit of the general tran-
scription factor IID (TFIID) multiprotein transcription 
complex, and our results have implicated mutations in 
TAF1 as having a critical role in the development of this 
new intellectual disability syndrome. We published the 
mutation as part of a paper developing SeqHBase, de-
scribed below, and we also posted a preprint with much 
more detailed clinical description to the BioRxiv pre-
print server while we continue searching for mutations 
in TAF1 in additional families.
Development of Comprehensive 
Whole-Genome Sequencing Analysis 
Pipelines
J. O’Rawe, Y. Wu [in collaboration with H. Fang, 
L. Jimenez Barron, M. Schatz, and G. Narzisi, 
Cold Spring Harbor Laboratory; K. Wang, California; 
and M. He, Wisconsin]
We continued developing various bioinformatics ap-
proaches for the analysis of exome and whole-genome 
sequencing data. For example, in one project, we 
showed that the accuracy of detection of small inser-
tions and deletions (INDELs) is greater when using 
WGS versus exon capture and sequencing. We also 
calculated that 60× WGS depth of coverage from the 
Illumina HiSeq platform is needed to recover 95% of 
INDELs detected by Scalpel. Although this is higher 
than current sequencing practices, we proposed that 
the deeper coverage may save total project costs be-
cause of the greater accuracy and sensitivity. Finally, 
we investigated sources of INDEL errors (e.g., capture 
defi ciency, polymerase chain reaction [PCR] amplifi -
cation, homopolymers). During the past 12 months, 
we reported the results of several other ongoing bio-
informatics projects as well, as shown in the below 
publications. For example, we developed SeqHBase, 
a big data-based tool set for analyzing family-based 
sequencing data to detect de novo, inherited homozy-
gous or compound heterozygous mutations that may 
be disease contributory. We demonstrated SeqHBase’s 
high effi ciency and scalability, which is necessary, as 
WGS and WES (whole exome sequencing) are rapidly 
becoming standard methods to study the genetics of 
familial disorders. We also recently published an opin-
ion piece regarding the current state of uncertainty 
quantifi cation in DNA-sequencing applications, and 
we proposed methods that can be used to account for 
propagation of errors and their uncertainties through 
subsequent calculations.
Summarizing the State of Human Genetics, 
Including the Genetic Architecture of 
Human Disease
J. O’Rawe
We prepared a comprehensive book chapter summa-
rizing the current state of human genetics, and we con-
tinue to expand upon this work. In brief, there are ~12 
billion nucleotides in every cell of the human body, 
and there are ~25–100 trillion cells in each human 
body. Given somatic mosaicism, epigenetic changes 
and environmental differences, no two human beings 
are the same, particularly as there are only ~7 billion 
people on the planet. One of the next great challenges 
for studying human genetics will be to acknowledge 
and embrace complexity. Every human is unique, and 
the study of human disease phenotypes (and pheno-
types in general) will be greatly enriched by moving 
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from a deterministic to a more stochastic/probabi-
listic model. The dichotomous distinction between 
“simple” and “complex” diseases is completely artifi -
cial, and we argue instead for a model that considers a 
spectrum of diseases that are variably manifesting in 
each person. The rapid adoption of WGS and the In-
ternet-mediated networking of people promise to yield 
more insight into this century-old debate. Compre-
hensive ancestry tracking and detailed family history 
data, when combined with WGS or at least cascade-
carrier screening, might eventually facilitate a degree 
of genetic prediction for some diseases in the context 
of their familial and ancestral etiologies. However, it 
is important to remain humble, as our current state of 
knowledge is not yet suffi cient, and in principle, any 
number of nucleotides in the genome, if mutated or 
modifi ed in a certain way and at a certain time and 
place, might infl uence some phenotype during em-
bryogenesis or postnatal life.
Expanding Collection and Sequencing 
of Other Rare Genetic Syndromes
J. O’Rawe, Y. Wu [in collaboration with H. Fang, L. 
Jimenez Barron, M. Yoon, I. Iossifov, Cold Spring Harbor 
Laboratory; R. Robison, Utah; K. Wang, California; 
A. Rope, Oregon; and others]
We continue to meet and collect many families in 
Utah and elsewhere with very rare, idiopathic genetic 
syndromes. The total number of DNA samples col-
lected to date is approaching 2000, and this includes 
detailed phenotyping information. Some of these 
samples have undergone exome or WGS, and we are 
currently analyzing 18 whole genomes and 35 exomes 
generated as part of this project. This includes the 
ongoing analysis of whole genomes from three fami-
lies with singleton cases of autism, being performed 
in collaboration with Ivan Iossifov at CSHL, and an 
analysis of nine whole genomes from a pedigree with 
Prader–Willi syndrome (PWS), hereditary hemochro-
matosis, familial dysautonomia (FD), and Tourette 
syndrome. We did publish about one case in China 
where two siblings both began to develop idiopathic 
progressive cognitive decline starting from age six and 
were suspected of having an undiagnosed neurological 
disease. Initial clinical assessments included review of 
medical history, comprehensive physical examination, 
genetic testing for metabolic diseases, blood tests, and 
brain imaging. We performed exome sequencing with 
Agilent SureSelect exon capture and the Illumina 
HiSeq2000 platform, followed by variant annotation 
and selection of rare, shared mutations that fi t a reces-
sive model of inheritance. To assess the functional im-
pact of candidate variants, we performed extensive bio-
chemical tests in blood and urine, and examined their 
possible roles by protein structure modeling. Exome 
sequencing identifi ed NAGLU as the most likely can-
didate gene with compound heterozygous mutations 
(chr17:40695717C > T and chr17:40693129A > G in 
hg19 coordinate). Sanger sequencing confi rmed the 
recessive patterns of inheritance, leading to a genetic 
diagnosis of Sanfi lippo syndrome (mucopolysacchari-
dosis IIIB). Biochemical tests confi rmed the complete 
loss of activity of α-N-acetylglucosaminidase (encod-
ed by NAGLU) in blood, as well as signifi cantly el-
evated dermatan sulfate and heparan sulfate in urine. 
Structure modeling revealed the mechanism whereby 
the two variants affect protein structural stability. 
This successful diagnosis of a rare genetic disorder 
with an atypical phenotypic presentation confi rmed 
that such “genotype-fi rst” approaches can particularly 
succeed in areas of the world with insuffi cient medical 
genetics expertise and with cost-prohibitive in-depth 
phenotyping.
Writing Policy and Opinion Pieces 
in Genomic Medicine
C. Barash, Cold Spring Harbor Laboratory; and others
The PI is an ongoing advocate for open access and data 
sharing, along with assisting with efforts at CSHL 
Press to roll out new initiatives, such as the BioRxiv 
preprint server and the new journal,  Molecular Case 
Studies, which is designed to make it easier to pub-
lish and share the underlying data from single cases, 
families, or small cohorts of human conditions.
Collaborating on Genetics of Tourette 
Syndrome
This work was done in collaboration with the Tourette 
Syndrome Association International Consortium for 
Genetics.
The PI continues to collaborate on this international 
effort to understand the genetics of Tourette syn-
drome (TS). Psychiatric comorbidity is common in 
TS; when present, these conditions typically cause 
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more distress and impairment than do tics. High rates 
of attention-defi cit/hyperactivity disorder (ADHD) 
and obsessive-compulsive disorder (OCD) are well 
documented and thought to be core components of 
the TS phenotype; however, few studies have fully 
characterized other comorbidities. We therefore char-
acterized the prevalence and impact of psychiatric 
comorbidity in a large sample of individuals with TS 
and their family members. The lifetime prevalence 
of comorbid psychiatric disorders, their heritabilities, 
and ages of risk was determined in participants with 
TS (N = 1374). The lifetime prevalence of any psychi-
atric comorbidity was 85.7%; 57.7% of participants 
had at least two psychiatric disorders. The mean num-
ber of lifetime comorbid diagnoses was 2.1. Prevalence 
of mood, anxiety, and disruptive behavior disorders 
was ~30%. The age of greatest risk for most psychi-
atric disorders was 4 to 10 years, except eating and 
substance use disorders, which begin in adolescence. 
TS was associated with increased risk of anxiety and 
decreased risk of substance use disorders; high rates of 
mood disorders among participants with TS may be 
accounted for by comorbid OCD. Parental history of 
ADHD was associated with a higher burden of non-
OCD, non-ADHD psychiatric disorders. Genetic 
correlations between TS and mood, anxiety, and dis-
ruptive behavior disorders were better accounted for 
by ADHD and, for mood disorders, by OCD. This 
study confi rmed that psychiatric comorbidities begin 
early in life and are extremely common among in-
dividuals with TS and demonstrates that some may 
be mediated by the presence of comorbid OCD or 
ADHD.
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DEVELOPMENT OF NEXT-GENERATION SEQUENCING TECHNOLOGY
W.R. McCombie E. Antoniou S.M. Eskipehlivan J. Lihm S. Teng
 N. Azamy E. Ghiban S. McCarthy 
 Y. Berstein S. Goodwin O. Mendivil Ramos 
 P. Deshpande M. Kramer S. Muller 
One of the great challenges remaining in biology is to 
understand how variation in the genome of an organ-
ism dictates its phenotype. This is of great theoretical 
interest as well and is also central to understanding the 
impact of genetic variation on susceptibility to disease. 
We are studying this phenomenon in a variety of con-
texts ranging from analyzing the variants that contrib-
ute to signifi cant human diseases such as psychiatric 
disorders and cancer, to understanding how variation 
contributes to the evolution of plant species. We are 
also looking at the impact of epigenetic variation (par-
ticularly in cancer) as well as identifying the de novo 
mutations contributing to psychiatric disorders. In this 
past year, we have found de novo variants that appear 
to be contributing to schizophrenia, which also overlap 
with genes involved in autism. To better understand 
these variants, we have developed, with the Hammell 
lab here at CSHL, a high-throughput testing system to 
identify potential functions of genes that may be con-
tributing to psychiatric illnesses. We have also made 
substantial improvements to our understanding of the 
genes and the variants within them that contribute to 
evolution among plants.
Investigating Bipolar Disorder Using 
Exome Sequencing of Case, Control, 
and Family Samples
M. Kramer, S. Muller, E. Ghiban, W.R. McCombie [in 
collaboration with J. Potash, V.L. Willour, and E. Monson, 
University of Iowa; P. Zandi, M. Pirooznia, F. Goes, and 
A. Chakravarti, Johns Hopkins School of Medicine]
Bipolar disorder is a debilitating psychiatric disorder 
with complex genetic architecture. In 2010, we began 
a collaboration with Johns Hopkins University to apply 
exome sequencing to discover genetic variants associated 
with bipolar disorder. Our early work has been detailed 
in previous reports, including our efforts last year to 
dramatically increase throughput to double our study’s 
sample size. Building on our 2013 scale-up of sequencing 
efforts and the establishment of our informatics pipeline 
(details of which were published in the journal Human 
Genomics), as well as the previous analysis of the fam-
ily samples, in 2014, we turned our focus to the case-
control analysis of our enlarged data set. In an effort to 
generate more accurate calling across the entire data set, 
we used the updated version of GATK (genome analy-
sis toolkit) with multisample joint genotyping to repro-
cess the 1135 bipolar cases and 1142 control subjects. 
After stringent data quality assurance (QC), we called 
more than 883,000 variants, which were then annotat-
ed using ANNOVAR. The rare coding variants (with 
a minor allele frequency <5%) that were predicted to 
be damaging (nonsense, missense, splice, and frameshift 
variants) were then subjected to statistical analysis at the 
variant, gene, gene set, and pathway levels. Although 
several fi ndings rose to a suggestive level of signifi cance, 
no particular variant, gene, gene set, or pathway has 
risen to a genome-wide signifi cant value thus far. This 
is perhaps not unexpected considering that much larger 
sample sizes may be required to overcome the genetic 
heterogeneity in these disorders. The expanded capture 
target set we used in 2013 included more than 1400 
genes that encode proteins localized in the synapses of 
the brain, as well as promoter regions of those genes, and 
we will include these noncoding regions in our analysis. 
In addition, we will be performing a meta-analysis of 
our data to look for replication in other large data sets 
from the PGC. We plan to fi nalize all of the case-control 
and family analyses in 2015, and publish our fi ndings.
Comparative Genomics of Seed Evolution
E. Antoniou, M. Kramer, W.R. McCombie [in collaboration 
with R. Martienssen, Cold Spring Harbor Laboratory; 
D. Sasha, K. Varala, and G. Coruzzi, New York University; 
D. Stevenson, New York Botanical Gardens; R. DeSalle, 
American Museum National History]
The goal of this project is to exploit plant genome diver-
sity to discover new genes involved in the development 
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of seeds. Data (transcriptome, orthologs), resources 
(phylogenetic matrix and tree), informatics tools, and 
pipelines for phylogenomics and machine learning 
will be generated. It is envisioned that the data and 
software resources created will empower compara-
tive genomic researchers to exploit plant diversity to 
identify genes associated with any trait of interest or 
economic value. For example, a major event in seed 
crops was the shift from prefertilization storage tissue 
in gymnosperms to the postfertilization endosperm in 
angiosperms. Other seed traits of economic interest 
are onset dormancy, shift of fl eshy seeds to dry winged 
seeds, and evolution of de novo appendages such as 
arils, each of which have multiple origins within seed 
plants. By studying the sequence and expression of 
genes supporting nodes where these independent ori-
gins occur, we can test whether the same or different 
gene(s) give rise to the trait.
The fi rst aim is to generate RNA-Seq data for nodal 
species plus outgroups for analysis of leaf, ovule, and 
seed transcriptomes to fi ll in gaps in depth/breadth of 
taxa/ortholog coverage in phylogenetic analysis. The 
second aim is to generate deep transcriptome data to 
be used for unigene assembly, ortholog identifi cation, 
and expression data. Chip-Seq data will also be gener-
ated to elucidate relationships between gene expres-
sion and evolution of regulatory genes.
We have sequenced 306 RNA-Seq libraries and 68 
Chip-Seq libraries prepared at New York University in 
2014. Analysis of the data is ongoing.
Functional Screening in the PVD 
Neuron of Caenorhabditis elegans 
for Psychiatric Candidate Genes
O. Mendivil Ramos, C. Aguirre-Chen, S. McCarthy, 
M. Kramer, C. Hammell, W.R. McCombie
Despite the complex genetic heterogeneity of neuro-
psychiatric disorders, the development of large-scale 
genomic techniques has led to important advances 
in the identifi cation of genes and loci associated with 
schizophrenia, bipolar disorder, and major depressive 
disorder. However, the functional interpretation of 
genetic variation is the rate-limiting step in determin-
ing the impact of mutations on biological function 
and disease pathogenesis. Functional analyses have 
not kept up with our ability to detect variants, and 
interpretation relies on inconsistent computational 
methods. This speaks to the need for high-throughput 
functional validation of novel genes and variants. We 
propose a new strategy in which we would use a tiered 
approach in model organisms, using an inexpensive, 
high-throughput initial test in C. elegans that would 
feed into more expensive and time-consuming down-
stream analyses.
Late in 2013, we established a collaboration with 
the Hammell lab at CSHL. Using bacterial ingestion-
mediated RNA interference (RNAi) to knock down 
candidate gene orthologs, it was possible to detect al-
tered branching of the PVD neuron in a subset of psy-
chiatric candidate genes we had identifi ed. Building 
on that pilot work, we expanded this research line in 
2014 by extending this list of homologs to additional 
candidates, as well as doing positive control studies to 
better estimate the effi cacy of this model in assessing 
the large numbers of genetic variants being identifi ed 
for major psychiatric disorders. The genes assayed in 
this extended experiment cover the gamut of candi-
dates identifi ed from large-scale genetic studies on 
schizophrenia and autism as well as genes harboring 
damaging mutations present in healthy individuals. 
From previously published data of candidate genes for 
autism and schizophrenia, we identifi ed 34 homologs 
of human–C. elegans, four of which altered the PVD 
neuron—a success rate of ~12%. We compared our re-
sults to an unbiased PVD neuron assay on 2635 genes 
of chromosome IV of C. elegans. From these genes, 338 
are homologs in humans and fi ve of them had a dis-
rupted PVD neuron—a success rate of 1.5%. Thus, 
we show that the enrichment of this procedure was 
approximately eightfold. As arborization and neuronal 
migration are likely part of the molecular pathogenesis 
of psychiatric disorders in some patients, this assay is a 
useful tool to further validate at a functional level the 
genes contributing to these important illnesses.
The Epigenome of Fear
S. McCarthy, N. Azamy, P. Deshpande, W.R. McCombie 
[in collaboration with S. Ahrens, L. Sabin, and B. Li, 
Cold Spring Harbor Laboratory]
In 2014, the Li and McCombie labs initiated a col-
laboration to explore the hypothesis that critical epi-
genetic changes controlling gene expression in the 
amygdala underlie long-term fear memory formation 
and contribute to fear dysregulation in mental disor-
ders. This collaboration unites discoveries made by the 
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McCombie and Li groups which showed that damag-
ing mutations in genes important for chromatin orga-
nization may be strong risk factors for schizophrenia 
and that fear conditioning in mice induces robust 
memory formation through specifi c plasticity in the 
SOM+ and SOM– inhibitory neurons of central amyg-
dala, respectively. Fear dysregulation brought about 
by traumatic life experiences is implicated in many 
psychiatric disorders including depression, schizophre-
nia, and, in particular, posttraumatic stress disorder 
(PTSD). Therefore, both studies suggest that genetic 
and activity-dependent changes in gene expression 
converge on epigenetic regulation as a potentially im-
portant biological mechanism in the etiology of psy-
chiatric disorders.
We are combining the powers of genetic and be-
havioral techniques with cutting-edge genomic tech-
nologies to profi le the “Epigenome of Fear”: changes 
in structural features of the genome in SOM+ and 
SOM– neurons that regulate the molecular response 
of long-term fear memory formation. Using “assay for 
transposase-accessible chromatin” (ATAC-Seq), we 
are fi rst identifying differences in the open chromatin 
profi les of the murine cortex and blood as a proof of 
principle to develop bioinformatics tools that broadly 
distinguish non-specifi c tissue types. In parallel we are 
also gathering data on SOM+ nuclei to fi ne-tune our 
analysis pipeline to distinguish cell-type- and func-
tion-specifi c differences.
During 2014, we optimized nuclei extraction to 
overcome the problems caused by mitochondrial con-
tamination. Specifi cally, we used fl uorescence-acti-
vated cell sorting (FACS) to fl uorescently label nuclei 
from the cortex and the amygdala, thereby removing 
neuronal mitochondria and increasing the specifi city 
of neuronal nuclei for analysis by ATAC-Seq. Further-
more, we streamlined our analysis pipeline to identify 
tissue-specifi c open-chromatin profi les. First, ATAC-
Seq data are aligned to the mouse genome. Uniquely 
mapping reads are fi ltered to remove polymerase 
chain reaction (PCR) duplicates. Second, peaks of 
stacked reads representing regions of open chromatin 
tagmented by the Tn5 transposase are called using 
MACS2. ATAC-Seq peaks that overlap the transcrip-
tion start site of Ref-Seq genes are then identifi ed and 
fi ltered for uniqueness in either the cortex or blood. 
The clustering of genes into biological pathways and 
ontologies is then carried out using a number of differ-
ent analysis packages in R. Preliminary data analysis 
suggests that we can clearly identify patterns of open 
chromatin at transcriptional start sites of genes unique 
to the cortex and blood. For example, unique open 
chromatin profi les in the cortex are enriched in genes 
that function in neuronal projection, at the synapse, 
at the cell junction, in cell differentiation, and in syn-
aptic transmission. Conversely, unique open chromatin 
 profi les in blood are enriched in leukocyte activation, 
T-cell proliferation, and immunity. In addition, we have 
evidence of isoform-specifi c open chromatin profi les 
in the brain and blood at genes such as TIMELESS, 
which is critical in circadian rhythm, further exem-
plifying the power of ATAC-Seq to distinguish cell 
functions and high resolution.
Going forward in 2015, we will further refi ne our 
analysis to profi le open chromatin in the amygdala, 
laying the foundation for experience-dependent and 
genetic-dependent models of fear conditioning.
Targeted Resequencing of 264 DISC1 
Interactome Genes in 1543 Samples
S. Teng, S. McCarthy, M. Kramer, W.R. McCombie 
[in collaboration with D. Blackwood, D. Porteous, 
P. Thompson, and I. Deary, University of Edinburgh; 
A. McRae, University of Queensland]
Continuing our growing collaboration with the Uni-
versity of Edinburgh, to enhance our understanding 
of DISC1 genetics and biology, we strengthened our 
analysis of targeted and resequenced exons, promot-
ers, and conserved regions of 264 genes, which we call 
the DISC1 Interactome, that directly interact with 
DISC1 or are correlated with DISC1 expression and 
form functional biological pathways related to DISC1 
activity. We previously completed sequencing of 1543 
individuals comprising 241 schizophrenia patients, 
221 bipolar patients, 192 recurrent major depressive 
disorder patients, and 889 healthy controls.
In a quality fi ltered cohort of 1464 (95%) samples 
that had greater than 20× coverage for more than 
80% of the Interactome target, we discovered 226,953 
single-nucleotide variants (SNVs). We identifi ed 3146 
missense variants and reported 71 validated disrup-
tive variants, including 47 nonsense and 24 splice site 
variants. In 2014, we focused our attention on the pat-
terns of rare (MAF < 1%) but also common variants 
(MAF ≥ 1%) for their associations with psychiatric 
and cognitive conditions. We found an enrichment 
of rare disruptive SNVs in schizophrenia cases versus 
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controls (P = 0.0038), which is supported by previous 
fi ndings from other schizophrenia exome sequence 
studies demonstrating that the rare damaging muta-
tions were enriched in the genes involved in neural de-
velopment or synaptic function. Damaging mutations 
in schizophrenia and recurrent major depressive disor-
der patients were greatly enriched in a gene that indi-
rectly interacts with DISC1. Furthermore, we found 
an increased burden of damaging singleton variants 
associated with reduced cognitive ability measures 
such as the National Adult Reading Test and Moray 
House Test at age 11 and 70.
In our analysis of common variants, we identi-
fi ed an association between an SNP in a strong copy 
 number variant (CNV) candidate gene and the 
combined set of psychiatric disorders (OR = 0.56, 
P = 3E-6, Adjusted P = 0.047). In contrast to previ-
ous associations with CNV analysis, the effect we ob-
served is protective, suggesting complex roles for this 
gene in disease susceptibility.
Going forward in 2015, our objective is to prioritize 
variants and genes for functional follow-up in model 
systems such as Caenorhabditis elegans. In addition, we 
aim to use our data and fi ndings in the DISC1 Inter-
actome, the whole-genome sequencing of members of 
the DISC1 translocation family, as well as gene ex-
pression data to analyze epistatic interactions between 
genes that could lead to variable phenotype and in-
complete penetrance in the DISC1 t(1:11) family.
Colorectal Cancer Genomics
E. Antoniou, W.R. McCombie [in collaboration with 
X. Wang, X. Yu, E. Li, and J. Williams, Stony Brook University]
Colorectal cancer (CRC) is the third most com-
monly diagnosed cancer and is the second leading 
cause of cancer-related deaths in the Western world. 
The mortality from colorectal cancer in Caucasian 
Americans (CAs) has been declining, but, in con-
trast, it has been rising in African Americans (AAs). 
The response to chemopreventive agents differs, as 
do the biological/genetic heterogeneity of the tu-
mors of AAs and CAs. Because chemopreventive 
agents exert their effect through a molecular target, 
this disparity would suggest differences at the ge-
netic level. This project aims to determine the at-
tribution of genetic and epigenetic differences to the 
colon cancer racial/ethnic health disparity.
In previous years, we used RNA-Seq to obtain gene 
expression measurements on 18 tumor/normal paired 
AA tissue samples and as many samples from CA pa-
tients. We also prepared 57 reduced representational 
bisulfi te sequencing (RRBS) libraries, 52 of them 
from paired tumor/normal tissues.
In 2014, we worked with Dr. X. Wang from Stony 
Brook University to develop a new way to analyze 
RRBS sequences produced by the Illumina Next-
Seq500 sequencer. The new bioinformatic pipeline 
almost doubled the number of mapped CpG sites. Pre-
liminary analysis of the RRBS data obtained in 2013 
identifi ed differential methylation of genes such as 
BMP3 and GPR75. However, it was also observed that 
our mean base coverage (3.5×) was too low to confi -
dently identify most differentially methylated sites. 
Consequently, we generated additional sequences from 
eight AA and seven CA patients and increased the base 
coverage to 10×. Analysis of these data is  ongoing.
De Novo Assembly of Yeast and Rice 
Genomes Using Long Insert Libraries and 
the Paciﬁ c Biosciences RS II Instrument
P. Deshpande, S.M. Eskipehlivan, M. Kramer, S. Goodwin, 
E. Antoniou, W.R. McCombie [in collaboration with 
J. Gurtowski, H. Lee, M.C. Schatz, and J. Hicks, 
Cold Spring Harbor Laboratory; C. Heiner and G. Khitrov, 
Paciﬁ c Bioscience; S. McCouch, Cornell University]
Next-generation sequencing is an invaluable tool for 
the understanding of genetics across many organ-
isms. However, the relatively short reads generated by 
instruments such as the Illumina HiSeq pose a limi-
tation to the de novo assembly of large and complex 
genomes. The Pacifi c Biosciences instrument allows 
for the sequencing of fragments several tens of thou-
sands of base pairs in length. Such long reads provide 
superior structural information for de novo assembly, 
and they retain structural elements important to the 
understanding of genetic variation.
As a continuation of our yeast work from 2013, we 
used the Pacifi c Biosciences instrument to sequence 
three separate strains of yeast: W303 (as we have previ-
ously used), ethanol red, and a sake strain (kyokai #7). 
We compared the various purifi cation, library prep, 
and loading approaches to generate a quality  sequence. 
Overall, we generated more than 50× coverage of 
each strain with sequence read N50s in excess of 10 
kb. These strains will be assembled using HGAP and 
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the Celera Assembler. Once the genomes are assem-
bled, they will be probed for variations contributing to 
their industrial phenotypes, in particular their etha-
nol production capacity. These assemblies will also be 
compared to prior assemblies of these strains using a 
long read assembly to identify features not detected in 
the short read assembly approaches.
Building on our yeast work, we began sequenc-
ing a more complex genome, the IR64 strain of rice. 
The rice sequences were generated using the Pacifi c 
Biosciences RS II instrument with P5/C3 chemistry. 
We generated greater than 115× coverage across the 
genome with 48× coverage in reads longer than 10 kb. 
The longest read was 53,652 bp long. A de novo as-
sembly was built using HGAP and the Celera Assem-
bler. The N50 contig size is 4.02 Mbp, up from 20 kb 
in the previous Illumina-only assembly. The longest 
contig is 16 Mbp long, approaching the size of a com-
plete chromosome arm. The assembly has a high se-
quence identity (>99%) with known IR64 genes and 
produced complete gene models and promoter regions 
for nearly every gene. This dramatic increase in con-
tig length will likely have a signifi cant positive impact 
on our ability to annotate the features of these genes. 
Both the yeast and rice work are under preparation for 
publication of a manuscript.
Comparative Genomics of Three Rice 
Strains Using Whole-Genome Illumina 
Sequencing
E. Antoniou, M. Kramer, E. Ghiban, W.R. McCombie 
[in collaboration with M.C. Schatz, J.C. Stein, and 
D. Ware, Cold Spring Harbor Laboratory; L.G. Maron 
and S.R. McCouch, Cornell University]
In collaboration with the Ware lab at CSHL and the 
McCouch lab at Cornell University, we previously se-
quenced three strains of rice on Illumina HiSeq se-
quencers, representing the two major varietal groups 
and three of the fi ve major subgroups (indica [IR64], 
aus [DJ123], and temperate japonica [Nipponbare]). 
In 2014, we constructed de novo assemblies of the 
three genomes using the ALLPATHS-LG software 
with the recommended combination of a 180-bp 
overlap library with 2-kb and 5-kb jumping libraries. 
We then analyzed the genomes by comparing them 
to the published reference sequences for Nipponbare 
and Indica, as well as comparing the three genomes to 
one another. We published our fi ndings in the journal 
Genome Biology. We documented several megabases 
of each genome absent in the other two strains (4.8 
Mbp to 8.2 Mbp [423 kbp to 930 kbp exonic]) and 
analyzed the detailed genomic structures of several 
loci associated with important agricultural traits such 
as hybrid sterility, submergence tolerance, improved 
yield, and phosphorus defi ciency. These three genome 
assemblies will support future breeding and function-
al studies of this important food staple.
Technology Development and Assessment 
of Nanopore Sequencing
S. Goodwin, P. Deshpande, W.R. McCombie [in 
collaboration with J. Gurtowski, and M.C. Schatz, Cold 
Spring Harbor Laboratory]
The Oxford Nanopore device is a new instrument for 
next-generation sequencing that is currently undergo-
ing a beta testing phase. This instrument relies on the 
translocation of a long DNA molecule through a pro-
tein pore in order to perform sequencing. Unlike most 
sequencing-by-synthesis methods, this approach does 
not rely on an optical or fl uorescent signal. Rather, as 
the DNA is translocated through the pore, a charac-
teristic change in voltage is used to identify the com-
position of a 5-mer as it passes through the channel. 
This approach allows for the sequencing of very long 
contiguous molecules with minimal reagent costs.
The goal of this project is to evaluate the use of 
the Oxford Nanopore device for various sequencing 
routines. We began sequencing the yeast W303 strain 
in mid-2014. This strain was selected because we have 
previously worked with it for long read sequencing on 
the Pacifi c Biosciences instrument. Over the course of 
this project, we used 48 fl ow cells from three sepa-
rate versions of the chemistry: R6.0, R7.0, and R7.3. 
We also saw a large increase in the performance of 
the instrument. Early on, error rates were ~30% for 
the R6.0 chemistry. Those error rates have decreased 
to between 10% and 15% with the R7.3 fl ow cells, 
and we hope to see continued decreases. The typical 
N50 has also improved, ranging from ~5K for an R6.0 
fl ow cell to ~10K for an R7.3 fl ow cell (with a 10K 
input fragment size). We have generated contiguous 
sequences in excess of 150K bp. However, because of 
the high error rate and limited tools available for such 
long reads, we have been unable to align fragments 
longer than 60K. Finally, to overcome the high error 
rate present in the instrument, we have developed a 
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pipeline, called nanocorr, that can select the best se-
quences from our data set, correct them with MiSeq 
data, and assemble them with a greater than 99.8% 
accuracy. This work is currently under review.
In 2015, we will continue to evaluate the instru-
ment for hybrid and de novo assembly uses using the 
yeast model. We will also be evaluating the use of the 
instrument for full-length isoform sequencing from 
human and other cDNA samples.
Exome-Based Sequencing of Parent-
Offspring Trios with Schizophrenia
S. McCarthy, M. Kramer, J. Lihm, Y. Berstein, R. Solomon, 
E. Ghiban, E. Antoniou, W.R. McCombie [in collaboration 
with J. Gillis and S. Yoon, Cold Spring Harbor Laboratory; 
M. Mistry, and P. Pavlidis, The University of British 
Columbia; E. Kelleher, C. O’Brien, G. Donohoe, M. Gill, 
D.W. Morris, and A. Corvin, Trinity College Dublin]
In 2014, in collaboration with Trinity College Dublin, 
we published fi ndings from our study of de novo vari-
ants in 57 parent-offspring trios with schizophrenia (42 
trios with no family history of psychosis [sporadic] and 
15 trios with a family history of psychosis [familial]), 
in the journal Molecular Psychiatry. Despite a small 
sample, our work shed further light on the contribu-
tion of de novo variation to the genetic risk of schizo-
phrenia (fi rst found at CSHL) and also highlighted a 
common genetic pathology across neurodevelopmental 
disorders of possible therapeutic potential.
In summary, exome sequencing analysis of 57 trios 
with schizophrenia revealed a signifi cant increase in 
the rate of nonsense mutations in sporadic cases com-
pared to what was expected based on publicly available 
data of healthy unaffected trios (P = 0.01), suggesting 
that some of the de novo mutations identifi ed could be 
private, penetrant risk factors. Expanding our analy-
sis to include missense mutations (de novo mutations 
likely to disrupt or damage protein function that were 
enriched in genes less tolerant to new or rare muta-
tions) increased the strength of the result (P = 2 × 
10–5). Notably, many potentially functional de novo 
mutations were identifi ed in genes with prior genetic 
evidence for a role in autism and intellectual disability 
such as CHD8, MECP2, AUTS2, MLL2 (P = 0.02). 
Furthermore, de novo mutations signifi cantly over-
lapped chromatin modifi ers important for transcrip-
tion regulation, suggesting that perturbing the com-
ponents controlling the epigenetic regulation of gene 
expression could be a molecular pathogenetic mecha-
nism shared between schizophrenia and autism. Since 
we published our work, other available exome studies 
of neurodevelopmental disorders support our hypoth-
esis and open exciting avenues to explore novel mecha-
nisms for potential therapeutics for schizophrenia and 
autism.
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PLANT GENOME ORGANIZATION, EVOLUTION, AND FUNCTION
D. Ware K. Chougule Z. Lu M. Regulski W. Ware 
 Y. Jiao M.K. Monaco J. Stein S. Wei 
 V. Kumar J. Mulvaney J. Thomason L. Zhang
 S. Kumari M. Neves Dos Santos Leite P. Van Buren 
 Y.K. Lee C. Noutsos B. Wang 
 C. Liseron-Monﬁ ls A. Olson L. Wang 
Our lab has two primary goals: (1) research into plant 
genomics, with a focus on functional and comparative 
genomics of model plant systems and agriculturally 
important crop plants, and (2) development of tools, 
data sources, and resources for the genomics research 
community. We also contribute actively to three large-
scale, multi-institutional, cyber-infrastructure collab-
oratives designed to serve broad research and educa-
tional communities: Gramene, the National Science 
Foundation iPlant collaborative, and the Department 
of Energy (DOE) Systems Biology Knowledgebase 
(KBase).
Our lab is a dynamic research group, and its com-
position has changed during the past year. During this 
period, we have been joined by Vivek Kumar, Kapeel 
Chougule, Mike Regulski, and Joseph Mulvaney. 
 Andrea Eveland and Ken Youens-Clark have advanced 
their careers, taking positions as an assistant professor 
and a scientifi c developer, respectively. Visiting scien-
tists Zhiming Zhang and Fazhan Qiu have returned 
to China to lead their own research groups.
PLANT GENOME RESEARCH
In the last decade, the sequencing and annotation of 
complete plant genomes have helped us to understand 
plant function and evolution, as well as how to alter 
economically important traits. Efforts in many dis-
parate disciplines are required to generate reference 
genomes. The work starts with laboratory scientists, 
who generate the raw sequence data. Next, computa-
tional biologists and bioinformaticians, such as those 
in our lab, kick off a series of steps to interpret the raw 
data. The process of interpretation involves the assem-
bly of raw sequence reads into overlapping segments 
(“contigs”), which are used to create a scaffold. This 
scaffold, in turn, discerns the position, relative order, 
and orientation of contigs within the chromosomes. 
The next step is annotation, the discovery and de-
scription of genes and other functional elements, and 
homologies (evolutionary relationships) with other ge-
nomes. This information must be faithfully commu-
nicated and visualized in Web-based platforms, such 
as Gramene.
All of these activities are rapidly evolving with the 
advent of new sequencing technologies, algorithms, 
and data-handling requirements. For example, high-
depth and low-cost sequencing of RNA transcripts 
is providing a vast stream of new evidence that in-
forms genome annotation; this in turn has spurred 
the development of new software for modeling and 
performing genome annotation. Low-cost sequenc-
ing has also made it possible to ask whole new classes 
of questions, moving beyond the generation of single 
references for individual species and supporting the 
development of multispecies representation as “pan-
genome.” Ongoing projects within the maize, rice, 
and Arabidopsis research communities are now se-
quencing hundreds or thousands of genotypic back-
grounds, chosen from carefully  constructed popula-
tions, wild populations, and breeding germplasms 
in each species. Information about genetic variation 
is helping scientists to understand the genetic basis 
of phenotypic traits and the origins of domesticated 
crop species. New technologies are also driving re-
search in epigenetics, the study of heritable variation 
not caused by changes in the underlying genome se-
quence. Epigenetic mechanisms include modifi cation 
of DNA by methylation and various forms of histone 
modifi cation that can cause changes in gene expres-
sion and other phenotypes. Both types of modifi ca-
tions can be studied using new sequencing technolo-
gies and analytical methods.
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Updating the Maize B73 Reference Genome 
and Developing Pan-Genome Variation 
Pipelines
A. Olson, J. Stein, Y. Jiao, B. Wang, M. Regulski 
[in collaboration with The Maize Genome Sequencing 
Consortium; J. Glaubitz and E. Buckler, Cornell University; 
R. Fulton and R. Wilson, Washington University; K. Guill 
and M. McMullen, Missouri University, USDA ARS; D. 
Rank, P. Peluso, and T. Clark, Paciﬁ c Biosciences; M.Y. Law; 
and M. Yandell, University of Utah, Salt Lake City]
Work continues on refi ning the assembly and annota-
tion of the Maize B73 reference sequence. The third 
version (“RefGen_v3”) of the B73 assembly and its 
annotations are hosted on Gramene and have been 
deposited in GenBank along with contigs assembled 
from Roche/454 sequencing of a whole-genome shot-
gun library. RefGen_v3 incorporates some of these 
contigs in order to increase coverage of missing gene 
space. The contigs were selected based on alignment to 
FLcDNA sequences and then inserted into gaps in the 
RefGen_v2 assembly, guided by a genetic map as well 
as synteny with rice and sorghum. Approximately 500 
genes were added or improved using this method, and 
many unplaced physical map contigs could also be an-
chored based on these maps. The RefGen_v3 assembly 
was released following acceptance by GenBank.
Gene structural annotations were originally called 
using the Gramene/Ensembl Gene Builder, which 
takes into consideration ab initio gene predictions as 
well as aligned protein, cDNA, and EST evidence. To 
improve these gene models, MAKER-P software was 
run on RNA-Seq data from 96 public data sets, in col-
laboration with Mark Yandell (Law et al. 2014). Un-
translated regions of 1393 existing gene models were 
extended, and an additional 4466 protein-coding and 
2522 noncoding genes were predicted.
We also reviewed the current status of long-read 
sequencing from PacBio Systems to support improve-
ment of the B73 reference assembly. In 2014, these ef-
forts met with moderate success, as we combined the 
PacBio Systems technologies with short-read sequenc-
ing from the more established Illumina technology for 
the purposes of error correction. In both sequencing 
and assembly, the integration of multiple approaches 
improved the length and accuracy of the genome se-
quences we obtained, relative to what we could have 
achieved using either technology alone. For the maize 
reference B73 genome, we are using PacBio long reads 
to order contigs and fi ll in gaps. Based on the complex-
ity of the maize genome, our goal is to achieve 50× 
coverage; to date, we have generated 40 Gb of PacBio 
long reads data, representing 17.8× coverage. We have 
used these data to improve the order and orientation 
of sequences in the existing reference assembly and ex-
tend existing contigs; in the process, we have recovered 
160 Mb of missing sequences in the current maize B73 
genome. In addition to our work on genome assembly, 
we are using the same long-read sequencing technolo-
gy to generate full-length transcripts, characterization, 
and annotation of alternatively spliced transcripts.
In Zea mays, only ~50% of genomic content is shared 
between lines because of the tremendous haplotype di-
versity in this species. Therefore, a single reference as-
sembly for maize cannot serve as a suffi cient backbone 
for capturing and describing this variation, and this 
constraint poses an obstacle to our understanding of 
the genetic variation that controls interesting traits. To 
overcome this challenge, we need a suitably detailed and 
fl exible species-level representation (i.e., a maize “pan-
genome”). Our initial efforts are focused on develop-
ing a maize pan-genome comprising the B73 reference 
assembly and novel sequences from other inbred maize 
lines. There are three steps involved: (1) assembly of the 
additional accessions, (2) characterization of novel hap-
lotypes, and (3) genetic anchoring of the novel sequence. 
As proof of concept, we have generated 30×  Illumina 
reads of B97. At this depth, high-repeat content in maize 
challenges existing methods for de novo assembly; based 
on simulations of 30× reads sampled from the B73 ref-
erence, we expect to achieve ~80% coverage of anno-
tated genes. Because different assembly algorithms have 
different advantages, we have adopted a meta-assembly 
strategy. A meta-assembly of B97 was generated, and 
after performing an alignment to the bacterial artifi cial 
chromosome (BAC)-based B73 reference, we identifi ed 
~19.78 Mb of novel B97 sequences. We are now using 
population-based mapping approaches to support an-
choring of these scaffolds, relative to the reference B73 
physical map. This genetic mapping method was suf-
fi ciently accurate to place 77.6% of 1000 B73 gene se-
quences on the 10 maize chromosomes.
The Rice Pan-Genome
J. Stein [in collaboration with R. McCombie 
and M. Schatz, Cold Spring Harbor Laboratory; 
S. McCouch, Cornell University]
This year marks the 10th anniversary of the completion 
of the rice genome, Oryza sativa. The Nipponbare refer-
ence sequence stands out as the highest-quality assembly 
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available for any crop plant, and thus serves as a cor-
nerstone of functional genomics research. However, to 
fully probe the genetic diversity of rice, researchers need 
additional high-quality assemblies that are more repre-
sentative of the species as a whole. The complex history 
of rice domestication gave rise to fi ve subpopulations, 
each with specialized traits and cultivation geographies. 
Many large-scale structural differences among the dif-
ferent varieties have resulted in substantial variation in 
gene content. The full complement of genes that exist in 
diverse varieties is currently poorly understood in rice.
To begin to characterize the rice pan-genome, this 
NSF-funded research project produced new reference 
assemblies for two additional rice varieties belonging 
to the indica and aus subpopulations (Schatz et al. 
2014). Using Nipponbare (a japonica strain) as a posi-
tive control, we demonstrated that low-cost sequencing 
combined with advanced computational methods can 
yield gene-enriched de novo assemblies with high accu-
racy and completeness. Examination of several known 
quantitative trait loci (QTL) revealed differences in 
haplotype structure between the varieties. These dif-
ferences correlated with known phenotypic differences 
that infl uence traits such as crop yield, submergence 
tolerance, phosphorus uptake, and hybrid sterility. Re-
markably, each of the three varieties possesses several 
megabases of genomic sequence that are absent from 
the other two, and these unique sequences harbor hun-
dreds of genes. We do not yet know how much these 
differences in gene content contribute to adaptive traits 
(such as tolerance to abiotic stress) or agronomic fea-
tures (such as grain quality) that distinguish these rice 
varieties. Notably, however, an unusually large propor-
tion of strain-specifi c genes belong to the R-gene fam-
ily, which confers resistance to pathogenic microbes. 
Therefore, it is reasonable to speculate that differential 
expansion or contraction of the R-gene complement ac-
companied the geographical radiation of rice varieties, 
allowing them to develop resistance to disease-causing 
agents endemic to particular geographical regions.
Discovery and Application of Epigenetic 
Variation in Plant Genomes
Z. Lu, A. Olson, M. Regulski [in collaboration with 
R. Martienssen and R.  McCombie, Cold Spring Harbor 
Laboratory; R. Klein and P. Klein, USDA/Texas A&M 
University; and S. Brady, University of California, Davis]
DNA methylation plays important roles in regulating 
gene expression and controlling transposable elements 
(TEs). Patterns of DNA methylation, referred to as 
the “methylome,” must be faithfully propagated in 
order for plants and animals to undergo proper de-
velopment. To study methylation, genomic DNA is 
treated with sodium bisulfi te (Methyl-Seq), which 
converts unmethylated cytosine to thymine; methyla-
tion can then be detected at single-base resolution by 
sequencing the treated DNA and comparing the reads 
to the sequence of the unmodifi ed genome. In previ-
ous work, we achieved 20× – 30× coverage over the 
mappable portion of the maize genome and observed 
methylation patterns correlated with gene expression, 
small RNA genes, and alternative splicing. Cytosine 
methylation patterns were diverse in TEs, and espe-
cially in genes. These patterns were largely heritable 
in recombinant inbred lines (RILs); however, we ob-
served signifi cant deviations from heritability, many 
of which were conserved in different RILs. These 
fi ndings will help us to reveal the roles of DNA meth-
ylation in gene regulation and other biological func-
tions in the future.
In Sorghum, we are participating in a pilot project 
using laser capture microdissection (LCM) to extract 
specifi c tissues (rather than larger structures, which 
have more heterogeneous gene expression and meth-
ylation). In these tissue-specifi c RNA-Seq and Methyl-
Seq experiments, we will identify gene expression and 
DNA-methylation patterns associated with responses 
to abiotic stresses, such as drought and salinity, in the 
reference strain BTx623 and widely cultivated varieties.
Gramene: Comparative Genomic Resource 
for Plants
K. Chougule, Y. Jiao, V. Kumar, S. Kumari, M. Karey 
Monaco, J. Mulvaney, A. Olson, J. Stein, J. Thomason, 
S. Wei, K. Youens-Clark [in collaboration with P. Jaiswal, 
Oregon State University; P. Kersey and H. Parkinson, 
EMBL-European Bioinformatics Institute; L. Stein, Ontario 
Institute of Cancer Research; C. Taylor, American Society 
of Plant Biologists; and R. Wing, University of Arizona, 
Tucson]
The Gramene project provides online reference re-
sources for plant genomes and curated pathways to 
aid functional genomics research in crops and model 
plant species. Our website, www.gramene.org, facili-
tates studies of gene function by combining plant ge-
nome and pathway annotation with experimental data 
and cross-species comparisons. In other words, the 
data and tools in Gramene enable plant researchers 
to use knowledge about gene function in one species 
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to predict gene function in other species. This abil-
ity should advance our fundamental understanding of 
plant physiology, including economically important 
traits such as hybrid vigor, grain development, seed 
dormancy, drought tolerance, and resistance to dis-
eases. Last year, we signifi cantly expanded the Web-
site and streamlined the user interface and backend 
functions. The project accomplished several major 
milestones, culminating in our 43rd release (Decem-
ber 2014) since the inception of the project (Fig. 1). 
Highlights include the addition of 11 new species to 
our genome browsers: peach (Prunus persica), cocoa 
(Theobroma cacao), six rice-related species in the 
Oryza and Leersia genera, the multifaceted crop Bras-
sica oleracea, the primitive fl owering plant Amborella 
trichopoda, and the unicellular alga Ostreococcus luci-
marinus, which brought the total to 39 reference ge-
nomes. We also incorporated new genetic variation 
data (Fig. 2) for six crops including maize, sorghum, 
barley, tomato, and two species of rice, bringing the 
total to 10. Furthermore, we expanded our Plant Re-
actome database, which now includes 200 curated rice 
pathways and pathway projections in 17 species.
The Gramene team develops comparative genom-
ics databases in collaboration with the Ensembl Plants 
project at the European Bioinformatics Institute (EBI). 
Figure 1. Complete reference genomes in Gramene as of data 
release 44 (January 2015).
Figure 2. Single-nucleotide genetic diversity displayed in the context of functional protein domains.
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Perhaps the most signifi cant achievement from this 
collaboration was the addition of four Triticeae cere-
al genomes, including barley (Hordeum vulgare) and 
bread wheat (Triticum aestivum), whose whole-genome 
shotgun sequence assemblies had until recently been 
severely compromised due to their size and highly re-
petitive DNA composition. The barley genome is cur-
rently a “gene-ome” (i.e., mostly an assembly of gene 
regions anchored to a physical map).
The wheat genome is the largest (~17 Gbp) and 
most complex angiosperm genome ever sequenced, 
and it is more than fi ve times larger than the human 
genome. Its hexaploid genome (AABBDD) comprises 
three nearly identical ancestral subgenomes (AA, BB, 
and DD) and is estimated to contain about 124,000 
genes. The genomes of two of those diploid progeni-
tors, Triticum urartu (AA) and Aegilops tauschii (DD), 
were recently added to the Gramene/Ensembl Plants 
collection. Distinguishing among genes in the three 
subgenomes has been a challenge for plant geneti-
cists. Consequently, the fi rst wheat draft, although 
gene-rich, is still highly fragmented. Its assembly and 
gene annotation have been improved by integrating 
complementary and heterogeneous sequence-based 
genomic and genetic data sets; by performing align-
ments to ancestrally related DNA, RNA-Seq, ex-
pressed sequence tags (ESTs) and UniGene clusters; 
and by identifying homeologous genes across the sub-
genome components. The addition of the wheat ge-
nome to Gramene completed the triumvirate of major 
cereal grains (wheat, rice, and maize) in our collec-
tion. These three crops constitute 90% of worldwide 
grain production and are the keystones of future agri-
cultural sustainability.
Gramene continues to build a genus-level phyloge-
nomics resource for rice and related Oryza species. 
Rice emerged ~15 million years ago. Genus Oryza in-
cludes two cultivated species (Asian and African rice) 
and 21 wild species adapted to a broad range of tropi-
cal and subtropical habitats around the world. Ge-
nomics research aimed at exploiting such diversity for 
the purpose of crop improvement is also establishing 
Oryza as a model system for genus-level study of trait 
evolution, speciation, and domestication. Working 
with the NSF-funded Oryza Genome Evolution proj-
ect (Principal Investigator [PI]: Rod Wing, University 
of Arizona) and the international consortium known 
as I-OMAP, Gramene currently hosts high-quality ge-
nome assemblies for more than half of those species. 
Last year, Gramene added complete reference assem-
blies for six of these rice-related genomes, bringing the 
total to 12. One of the challenges of comparative ge-
nomics research is that different genome projects use 
different protocols to identify genes, leading to meth-
odological biases that confound comparative analysis. 
To remedy this, Gramene staff worked with the NSF 
Oryza Genome Evolution (OGE) project to develop a 
consistent annotation protocol (using the MAKER-P 
pipeline) that was applied to both the new genomes 
and the Oryza genomes previously sequenced and an-
notated by other projects. To compare both sets of an-
notations, the Gramene team created a new Website 
(oge.gramene.org) for visualization and analysis of 
I-OMAP genomes and phylogenetic trees.
PLANT SYSTEMS BIOLOGY
Exploring Arabidopsis Gene Regulatory 
Networks
L. Zhang, Y.K. Lee, C. Liseron-Monﬁ ls, C. Noutsos, 
B. Wang [in collaboration with S. Brady, University of 
California, Davis; DuPont-Pioneer, Inc.]
The goal of this work is to characterize gene regula-
tory networks associated with development and stress 
response. microRNA (miRNA) and transcription 
factors (TFs) have important roles in plant develop-
ment and responses to the environment. To under-
stand the important regulators of miRNA expression, 
we are using a gene-centered yeast one-hybrid (Y1H) 
experimental system to screen for TFs that bind to 
promoters of miRNA genes and their targets. Over 
the years, we have developed a library resource of 
950 Arabidopsis TFs, representing >95% of the TFs 
expressed in roots. Roots are important plant organs 
responsible for uptake of water and nutrients as well 
as the physical support of the plant. Understanding 
the genes responsible for root system architecture is 
critical to addressing key traits, including drought tol-
erance, cycling of nutrients such as phosphorus, and 
nitrogen uptake.
Expanding upon previous years’ work, the new 
interaction data enabled us to generate a gene regu-
latory network (GRN) comprising more than 5000 
protein–DNA interactions (PDIs) involving 645 TFs 
and 180 promoters. To this network, we have also 
incorporated known posttranscriptional regulatory 
pathways mediated by miRNAs upon their targets. 
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Although the network is enriched for genes expressed 
in root, it also serves as a model for other tissues in 
which those genes are expressed. Using comparative 
genomic projections, we are also beginning to model 
these networks in other species, including maize and 
sorghum. Ultimately, we plan to use these gene regu-
latory networks to generate testable hypotheses about 
cell-type-specifi c phenotypes.
To further validate the GRN and to dissect the 
phenotypic consequences of network perturbation, 
we are characterizing mutant TF lines. One T-DNA 
insertion mutant, hat22, exhibits a short root pheno-
type. Overexpression of AtHAT22, a homeobox do-
main transcription factor, results in longer primary 
roots, suggesting that this protein has a positive role 
in root development. Cellular-level investigations 
revealed that the short root length in the hat22 mu-
tant was the result of reduced cell number in meri-
stem zone. To obtain further insight into the role of 
AtHAT22 in the regulation of root development, we 
characterized the spatiotemporal expression pattern 
of AtHAT22. Specifi cally, we performed RNA-Seq 
and ChIP-Seq in order to directly investigate the 
genes regulated by AtHAT22: 3754 genes showed 
signifi cant (p  <  0.01) differential expression be-
tween the hat22 mutant and the wild type. Further-
more, most of the HAT22-binding peaks were close 
to TSSs (transcription start sites), and many pres-
ent in intergenic regions. We also found a consensus 
HAT22-binding motif using MEME. The Chip-
Seq data revealed that HAT22 bound the promoter 
region of HB21, a zinc fi nger homeobox  (ZF-HD) 
gene. Like the hat22 mutant, the hb21 mutant also 
exhibited a short root phenotype; moreover, the 
hat22/hb21 double mutant had much shorter roots 
than either single mutant, suggesting their genetic 
interaction within a common pathway. Further com-
parison of the transcriptome revealed a 30% overlap 
between the sets of genes differentially expressed in 
the hb21 and hat22 mutants.
GRNs are characterized by highly connected genes 
as “hubs” in the network. The ZF-HD TFs were iden-
tifi ed as hub genes within the miRNA network. An 
initial survey of six single loss-of-function mutants 
identifi ed from existing T-DNA collections revealed 
no observable root phenotypes, suggesting that the 
ZF-HD TFs are functionally redundant. To test this 
hypothesis, we generated multiple loss-of-function 
mutants using different approaches, including genetic 
crosses to a single loss-of-function mutant, genera-
tion of artifi cial miRNA, and independent repressor 
lines (Fig. 3). Combining multiple loss-of-function 
mutants within a single Arabidopsis line, we observed 
several phenotypes, including altered fl ower structures 
and an increased vegetative branching. In addition, we 
performed transcriptome profi ling of ZF-HD TF mu-
tants in order to characterize differentially expressed 
genes. The gene-expression profi les and phenotypic 
properties of the mutants suggested a role for ZF-HD 
TFs as regulators of developmental transitions. More-
over, the results of this work demonstrate that the 
miRNA GRN can be applied more generally, beyond 
the root system.
The basic leucine zipper (bZIP) TFs are another 
highly connected TF family. One member of the 
family, GBF2, binds many miRNA and miRNA tar-
get promoters. As with the ZF-HD TFs, single-gene 
loss-of-function mutants do not have clear pheno-
types. We are in the process of generating multiple 
Figure 3. Phenotype of the ZF-HD TF mutant. (Top) Branching 
phenotype of quadruple mutant, artiﬁ cial miRNA, and two in-
dependent repressor lines compared to wild-type plant Col-0. 
(Bottom) Lateral branching number of wild type and mutants.
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loss-of-function mutants by performing genetic cross-
es between the available single-gene mutant lines. Ini-
tial screens for homozygous mutants from multiple 
loci suggests that these mutants may be lethal or have 
large fi tness disadvantages.
In addition to our miRNA targeted GRN, as part 
of a collaboration with Siobhan Brady’s lab, the Y1H 
library has been used to mapped networks focused on 
the secondary cell wall (Taylor-Teeples et al. 2015) and 
nitrogen use effi ciency (NUE). The plant cell wall is 
an important factor for determining cell shape, func-
tion, and response to the environment. Secondary cell 
walls, such as those found in xylem, are composed of 
cellulose, hemicelluloses and lignin and account for 
the bulk of plant biomass. The coordination between 
transcriptional regulation of synthesis for each poly-
mer is complex and vital to cell function. The resulting 
GRN allows us to develop and validate new hypoth-
eses about secondary wall gene regulation under abi-
otic stress.
As sessile organisms, plants have limited means to 
explore and acquire nutrients from the environment, 
but they have evolved genetic mechanisms that con-
trol uptake and other responses to varying levels of 
mineral nutrients. Nitrogen is required by plants in 
greater amounts than any other mineral and is neces-
sary for basic cellular function. Higher plants most 
commonly take up nitrogen in the form of nitrate, 
but nitrate sources are often insuffi cient and heteroge-
neous in the soil. Nitrogen metabolism is regulated at 
the transcriptional, translational, and posttranslation-
al levels. We are mapping transcriptional control of 
genes involved in nitrogen uptake, assimilation, and 
downstream metabolism.
To support cross-species comparisons, in the last 
year, we obtained cloned sequences of 2017 unique 
maize TFs from the NSF-funded maize TFome proj-
ect awarded to Drs. Grotewold, Ohio State Univer-
sity, and Gray, University of Toledo (Burdo et al., 
Plant J 80 : 356 [2014]), and utilized them to develop 
a maize TF resource. The current collection consists 
of 1846 unique TFs, arranged in 96-well format. We 
have generated projections of the Arabidopsis network 
in maize and sorghum and are currently testing se-
lected specifi c hypotheses.
As part of this research, we are evaluating methods 
to combine expression data with gene network mod-
els. To support these activities, we have developed the 
NECorr tool. In contrast to other network inference 
tools that generate networks from expression data, 
NECorr analyzes an existing network in conjunction 
with expression data to defi ne the most important 
part of the network. To achieve this goal, NECorr 
uses a linear model to combine topological properties 
of the network with coexpression and differential ex-
pression data. To validate NECorr, we used a receiver 
operative characteristic (ROC) to determine the rela-
tionship between sensitivity and specifi city. Prelimi-
nary results indicate that NECorr identifi es candidate 
genes more accurately than methods relying on dif-
ferential  expression alone (AUCNECorr  =  0.75–0.9; 
AUCDiffer ential Expression  =  0.663). Using NECorr and 
our miRNA GRN, and making use of publicly avail-
able spatial-temporal expression data from Arabidopsis 
root, we determined that miR-398 mediates signifi -
cant cross-talk between stress responses and develop-
ment within transition zones of roots. These results 
were subsequently confi rmed by mutant analysis.
Developmental Networks Controlling 
Inﬂ orescence Architecture in Grasses
A.L. Eveland, S. Kumari, C. Liseron, Y. Jiao [in collaboration 
with D. Jackson, Cold Spring Harbor Laboratory; and Z. Xin 
and J. Burke, USDA ARS]
The goal of this work is to integrate genetics and ge-
nomics data sets to fi nd molecular networks that infl u-
ence the morphology (architecture) of grass infl ores-
cences (fl owers). Because infl orescences bear the fruits 
and grains that we eat, the genetic and regulatory fac-
tors that govern their formation are clearly relevant 
to important agronomic traits such as grain yield and 
harvesting ability. Our work in maize focuses on infl o-
rescence primordia sampled during key developmen-
tal transitions and in perturbed genetic backgrounds. 
The latter includes loss-of-function mutants in three 
important regulators of the RAMOSA (RA) pathway, 
which controls stem-cell fate decisions and ultimately 
the decision to branch. We established a robust sys-
tem for investigating the networks that modulate 
branching, including characterization of precise tim-
ing of developmental events and the associated spatio-
temporal changes in gene expression. We integrated 
genome-wide mRNA-Seq data to resolve coexpression 
networks during key stages of maize infl orescence de-
velopment, and we are currently working to expand 
these networks by incorporating additional data sets, 
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including genome-wide TF occupancy profi les and cis-
regulatory information. 
The following were the primary objectives for this 
project.
1. Establish a comprehensive pipeline for mRNA-Seq 
and ChIP-Seq data analysis in maize by evaluating 
and optimizing available software for mapping and 
quantitation. This also included testing various sta-
tistical methods to extract biological relevance.
2. Characterize genome-wide expression signatures 
specifi c to a given developmental event or branch-
ing phenotype. To this end, we made use of known 
developmental marker genes and their spatiotem-
poral transcriptional responses to genetic perturba-
tion in order to test our experimental system and 
establish a proxy for developmental staging.
3. Evaluate and implement clustering approaches to 
identify candidate genes that are coexpressed with 
key regulators and/or coincide with specifi c develop-
mental events. These efforts resulted in identifi cation 
of candidate genes, in particular developmentally 
regulated TFs and novel genes of unknown func-
tion that are potentially involved in stem-cell main-
tenance and determinacy. We continue to examine 
coexpression clusters for enrichment of functional 
processes and cis-regulatory motifs near the tran-
scriptional start sites (TSSs) of coexpressed genes.
4. Identify targets of the RA1 TF using ChIP-Seq and 
integrate the results with data from parallel mRNA-
Seq experiments. On the basis of this approach, we 
showed that one-third of genes with altered expres-
sion levels in the ra1 mutant are also bound by RA1 
(Eveland et al. 2014). As they become available, we 
are incorporating additional ChIP-Seq data sets to 
investigate combinatorial binding of TFs associated 
with the branching pathway. The ChIP-Seq data 
also provide in vivo confi rmation of binding sites 
of developmental regulators in maize, and the resul-
tant information is being used in efforts to resolve 
cis-regulatory modules across the maize genome.
In addition to maize, we have begun work on sor-
ghum, an important emergent bioenergy crop that 
is also used for human consumption in sub-Saharan 
Africa. In particular, we are using next-generation 
sequencing approaches to identify single-nucleotide 
mutations associated with an increase in seed number. 
Using this approach, we have identifi ed two genes that 
can change the structure of fl owers and generate more 
seeds. We intend to apply this strategy to a large-scale 
mutant study aimed at identifying candidate genes as-
sociated with developmental traits in the roots, shoots, 
and fl owers of sorghum.
In the next phase, we will prioritize candidates identi-
fi ed in this stage of the project by overlaying Arabidopsis 
regulatory network information (see previous section). 
The resulting hypotheses (e.g., those related to stress 
responses) can be tested in Arabidopsis and ultimately 
translated into agronomic systems. Candidate genes 
that are maize- and/or grass-specifi c are also of high pri-
ority, because they may contribute to the unique mor-
phology of maize infl orescences and/or features shared 
among other grasses. In addition, we will use compara-
tive genomics approaches, including both cross-species 
comparisons and integration of analogous RNA-Seq 
data sets from closely related grasses such as sorghum, 
to identify candidate genes that may contribute to grass-
specifi c aspects of infl orescence architecture.
CYBERINFRASTRUCTURE PROJECTS
The iPlant Collaborative
L. Wang, Z. Lu, C. Noutsos, K. Chougule, P. Van Buren, 
J. Stein
This project is a collaboration with Cold Spring Harbor 
Laboratory, employs more than 100 staff, and is head-
quartered at the University of Arizona (PIs: Stephen 
Goff, Doreen Ware, Nirav Merchant, Matthew Vaughn, 
and Eric Lyons). Dozens of collaborators are located at 
more than 20 institutions.
Our world is changing rapidly. The human popula-
tion is increasing while arable land and fi sheries are de-
creasing and food cultivation is being diverted for fuel 
production. Climate instability and energy sustainabil-
ity are impacting agricultural and ecological systems 
while concomitant changes in land-use patterns affect 
global biodiversity. To successfully address these issues, 
we need to understand how organisms’ appearance, 
physiology, and behavior are shaped by the interactions 
between their genetic makeup and the environment. 
Although these global challenges are sobering, the ef-
forts to respond productively will lead to exciting sci-
ence—provided that the computational infrastructure 
is in place to handle the necessary data sets, analyses, in-
terpretation of results, and dissemination of knowledge. 
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Advances in biological research technology have enabled 
scientists to amass unprecedented amounts of data, and 
many researchers fi nd themselves drowning in this sea 
of data. Foreseeing this major bottleneck in biological 
research, the NSF established the iPlant Collaborative 
(http://iplantcollaborative.org) in 2008 to develop cy-
berinfrastructure for life sciences research and democ-
ratize access to U.S. supercomputing capabilities.
Having completed its fi rst 5-year grant, the iPlant 
Collaborative has made extensive progress toward 
meeting these goals, and last year, it was renewed for 
another 5 years. Work in the last year culminated in 
the development of multiple platforms that are now 
being used by the research and educational commu-
nities. Staff at CSHL contributed directly to some 
of these cyberinfrastructure platforms or built upon 
existing platforms to provide scientists and educa-
tors with ready access to needed software and analysis 
tools. Within the Ware lab, these platforms include 
the iPlant Data Store, Discovery Environment (DE), 
and Atmosphere.
The iPlant Data Store was designed as a distrib-
uted storage system for hosting data on the Cloud, 
providing convenient access. The distributed system 
allows us to “bring the infrastructure to the data” to 
enable fast computing and, at the same time, to reduce 
the bandwidth required to transfer large amounts of 
next-generation sequencing data. Currently, the iPlant 
Data Store consists of two major storage systems with 
fast Internet connections, one at the University of 
Arizona (UA) and another one at the Texas Advanced 
Computing Center (TACC). CSHL itself has rela-
tively limited bandwidth relative to TACC and UA, 
making our institution an ideal case for validation of 
the iPlant model of bringing the infrastructure to the 
data. Because it makes more sense to utilize local com-
puting resources with iPlant pre-built analysis work-
fl ows via the iPlant AGAVE API than to copy the data 
to outside clusters (e.g., it takes >10 min to move 1 
GB data from CSHL to the TACC clusters), the Ware 
lab at CSHL decided to migrate the important iPlant 
platforms at CSHL. The fi rst target is the data store, 
and a local resource server (WildCat) has been suc-
cessfully added into the iPlant storage system, allow-
ing data transfer that is 80 times faster than with out-
side servers. For the next step, the Ware lab is going to 
synchronize the resource server with iPlant’s AGAVE 
servers at TACC, which will allow iPlant’s pre-built 
workfl ows to be run locally on CSHL computing 
servers. The migration of these important platforms 
will provide a proof-of-concept demonstration of the 
portability of iPlant Platforms for enrolling more in-
stitutes for effi cient data management and possibly 
utilization of national computing resources provided 
with good bandwidth.
The DE is the most visible portal for iPlant tools 
and services. This Web-based platform supports an 
“app store” model of user-extensible tools, automated 
workfl ows, and data storage. Users can take advantage 
of existing tools, integrated by iPlant staff and the user 
community, or add their own tools to use privately or 
share. Although users may not be aware of this, the 
underlying infrastructure provides access to iPlant’s 
massive data store at UA and TACC. Computation-
ally intensive tasks are handled by supercomputers lo-
cated at TACC and other centers within the Extreme 
Science and Engineering Discovery Environment 
(XSEDE). So far, more than 300 tools have been inte-
grated into the DE; these tools enable a broad range of 
research activities, including genome/transcriptome 
assembly, annotation, RNA-Seq quantitation, variant 
detection, GWAS (genome-wide association study), 
and phylogenetics. Members of the Ware lab have 
played important roles in contributing to workfl ow 
design, tool integration, validation, science tutorials, 
and documentation.
Atmosphere is iPlant’s confi gurable and Cloud-
enabled computational resource for the plant research 
community. From Atmosphere’s Web interface, users 
can launch a virtual machine (VM) with precon-
fi gured working environments and precustomized, 
ready-to-use software. Users can also create their own 
applications and environments as VMs and share 
them with others via Atmosphere. As with the DE, 
Atmosphere is a gateway to iPlant’s core infrastruc-
ture resources, including the high-performance grid 
computing environment and big-data storage system. 
Using the Atmosphere platform, we created a VM to 
be used for image analysis based on high-throughput 
phenotyping.
The success of genome research depends on our 
ability to accurately assemble, annotate, and derive 
meaning from sequence data; however, the extremes 
of genome size, polyploidy, diversity, and repeat con-
tent push the limits on the algorithms, expertise, and 
computational power currently available to research-
ers. In response, iPlant is fostering a community effort 
to identify best practices and state-of-the-art tools, 
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install them, optimize their performance on the na-
tion’s most powerful supercomputers, and make them 
available as free online resources. During the last 3 
years, the iPlant Discovery Environment has matured 
to provide a comprehensive set of tools and services 
for sequence handling, read alignments, RNA-Seq 
profi ling, and de novo genome and transcriptome as-
sembly (Fig. 4). To extend these capabilities, we have 
incorporated MAKER-P, a standardized, portable, 
and easy-to-use plant-genome annotation engine with 
built-in methods for quality control. As part of this 
effort, MAKER-P was specifi cally optimized to take 
advantage of the parallel computing environment of 
the TACC Lonestar cluster and is now a supported 
module. Performance testing showed that MAKER-P 
provides high-quality, full-fl edged annotation pipe-
lines on even the largest plant genomes in a matter of 
hours. MAKER-P is currently available for use as an 
Atmosphere image.
A major mission of iPlant is to promote adoption of 
the cyberinfrastructure through training workshops 
and outreach at academic institutions and scientifi c 
meetings. In 2014, members of our lab participated as 
instructors in several “Big Data” workshops focused 
on transcriptomics and population genomics using 
the DE and Atmosphere platforms.
KBase: The Department of Energy Systems 
Biology Knowledgebase
V. Kumar, S. Kumari, J. Thomason
This project is a collaboration with the DOE National 
laboratories and is led by PI Adam Arkin of Lawrence 
Berkeley National Laboratory (LBNL), with co-PIs 
Rick Stevens of Argonne National Laboratory (ANL), 
Robert Cottingham of Oak Ridge National Laboratory 
(ORNL), and Sergei Maslov of Brookhaven National 
Laboratory (BNL). I serve as the Plants Science Team 
Lead for KBase. Other PIs include Mike Schatz of Cold 
Spring Harbor Laboratory, Dave Weston of ORNL, and 
Pamela Ronald of the University of California, Davis.
The Systems Biology Knowledgebase (KBase, www
.kbase.us) has two primary goals. The scientifi c goal 
Figure 4. iPlant Workﬂ ow: Summary of iPlant apps and their relationships. The ﬂ owchart is divided into Assembly, An-
notation, Association, Visualization, and other components. A genome (or transcriptome) can be assembled by various 
assemblers and annotated with MAKER-P. The assembled genome will serve as reference genome for variant callers, 
and variant can be combined with trait data for association analysis. Annotation and association results can be visualized 
with various browsers and combined with pathway databases. All data can be accessed from the iPlant Data Commons.
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is to produce predictive models, reference data sets, 
and analytical tools and to demonstrate their utility in 
DOE biological research relating to bioenergy, carbon 
cycle, and the study of subsurface microbial commu-
nities. The operational goal is to create the integrated 
software and hardware infrastructure needed to sup-
port the creation, maintenance, and use of predictive 
models and methods for the study of microbes, micro-
bial communities, and plants.
KBase’s computational infrastructure is supported 
by a distributed, high-performance, cloud-based system 
that includes >3 petabytes of storage, more than 12,000 
cores for data processing, and 90 GBit/sec bandwidth 
over DOE’s Energy Sciences Network (ESnet). The 
KBase data model supports more than 900 data types, 
including sequence reads, assemblies, genomes, anno-
tations, expression data, quantitative phenotype data, 
and metagenomic profi les. The KBase data repository 
has integrated various data sets from public resources 
for thousands of microbes, hundreds of microbial com-
munities, and tens of plants. 
In addition, KBase supports more than 1000 anal-
ysis and access functions grouped into more than 30 
integrated service modules, including sequence assem-
bly, variation analysis, genome annotation, expression 
analysis, and various types of modeling (e.g., metabolic, 
regulatory, and fl ux balance analysis [FBA]). To cap-
ture complex, multistep analyses, users can build persis-
tent and provenance-based workfl ows that can capture 
complex, multistep analyses and mobilize rich annota-
tions, visualization widgets, reusable workfl ows, and 
custom scripts. This capability empowers users to create 
science that is transparent, reproducible, and reusable.
During 2014, the plants team implemented multi-
ple workfl ows, also known as narratives. These narra-
tives supported functionality such as (1) incorporating 
functional and network information (ontology, coex-
pression, protein–protein interaction, and pathway) 
in genome-wide association studies (GWAS) to iden-
tify genetic variants associated with traits of interest; 
(2) using RNA-Seq data to quantify expression and 
identify differentially expressed genes, constructing 
a coexpression network from gene expression data, 
and conducting an annotation enrichment analysis 
of densely interconnected clusters to identify func-
tional modules and draw biological inferences; (3) 
generating a genome from plant transcript sequences 
provided by the user, based on a set of gene mod-
els in a plant genome or an assembly of transcripts 
from next-generation sequencing (NGS) of a tran-
scriptome, and annotating the genome with meta-
bolic functions using PlantSEED Subsystems; and 
(4) generating a metabolic model using the annotated 
genome, followed by gap-fi lling and FBA (fl ux bal-
ance analysis) to simulate growth and identify the set 
of metabolic reactions that are active in plant biomass 
production.
Another focus within the project is the creation 
of a library of Web interface components (“wid-
gets”) for rapid development of reusable visualiza-
tions that can be dropped into disparate interfaces 
to present biological data with new insights. Such 
visualizations help scientists interpret complex data 
sets. Building upon standard Web libraries, such as 
jQuery, Bootstrap, and D3, has allowed the creation 
of a fl exible and very familiar widget standard. This 
standard provides dynamic visualizations that can 
immediately update as the underlying data changes, 
as well as interactive visualizations that allow graphs 
to operate as user interfaces such that image ma-
nipulations translate into actual data modifi cations 
in real time.
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Gurinder S. “Mickey” Atwal and colleagues are applying insights from the physical and com-
putational sciences to the study of population genetics, machine learning, and human disease. 
The Atwal lab has modeled the process by which genetic variants, or alleles, have evolved in the 
last 100,000 years of human history. This has recently led to surprising insights about the role 
of TP53, a master tumor suppressor gene, in female fertility and furthered our understanding of 
how complex gene networks evolve. The lab has analyzed the comparative genomics and physical 
organization of cancer-related genes and their role in mediating tumorigenesis across numerous 
tissue types. Recently, they have begun to focus efforts on understanding cancer genome evolution 
on shorter timescales by analyzing nucleotide sequences from single cells.
Ivan Iossifov focuses on the development of new methods and tools for genomic sequence analy-
sis and for building and using molecular networks, and he applies them to specifi c biomedical 
problems. He studies the genetics of common diseases in humans using two main tools: next-
generation sequencing and molecular networks representing functional relationships among ge-
netic loci. These approaches in combination enable the kind of large-scale studies necessary for 
furthering our understanding of the complex etiology of disorders such as autism, bipolar disorder, 
and cancer.
Alexander Krasnitz and colleagues use mathematical and statistical tools to discover key genetic 
elements involved in cancer and to understand how cancer cells evolve. Array-based comparative 
genome hybridization, a technique honed in the Wigler lab, and, more recently, sequencing ex-
periments have revealed subtle patterns of frequent and widespread aberration in cancer genomes. 
Krasnitz hypothesizes that recurrent, aberrant genomic loci observed in a range of cancer types are 
under selection and therefore are enriched in important cancer genes. He has developed a novel, 
comprehensive methodology to discover such “cores” and has used it to analyze multiple genome 
data sets in breast, liver, ovarian, and prostate cancer. The results have been shared with cancer 
biology labs across CSHL, and they have been a key enabling agent of functional studies using 
mouse models and RNA interference. Krasnitz has begun to apply these novel statistical tools to 
the latest generation of experimental data, which have characterized tumor samples down to the 
level of single cells. By interpreting single-cell genomes, he and colleagues seek to learn how spe-
cifi c tumors evolve and how cancer cells migrate to invade adjacent tissues and metastasize.
There is increasing evidence that rare and unique mutations have a signifi cant role in the etiology 
of many diseases such as autism, congenital heart disease, and cancer. Dan Levy’s group develops 
algorithms to identify these mutations from large, high-throughput data sets encompassing thou-
sands of nuclear families. After earlier working with high-resolution CGH arrays, Levy’s group 
now uses targeted sequence data. Levy has developed methods for identifying de novo mutations 
(i.e., those seen in a child but not in his or her parents) by simultaneously genotyping the entire 
family; the team is currently focused on building algorithms to detect copy-number variants and 
multiscale genomic rearrangements. Although their copy-number methods are based on “read” 
density, there are classes of mutations that require analysis at the level of the read. Thus, they 
are developing algorithms to identify insertions, deletions, inversions, transpositions, and other 
complex events. Other projects in the Levy lab include analysis of single-cell RNA, phylogenetic 
reconstruction from sparse data sets, and disentangling haplotypes from sperm and subgenomic 
sequence data.
Michael Schatz is a computational biologist and an expert at large-scale computational examina-
tion of DNA sequencing data, including the alignment, assembly, and analysis of next-generation 
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sequencing reads. These methods have been used to reconstruct the genomes of previously un-
sequenced organisms, probe sequence variations, and explore a host of biological features across 
the tree of life. Recent improvements in sequencing technologies are challenging our capacity to 
store and analyze the huge volume of DNA sequence data being generated. Consequently, Schatz 
is particularly interested in capitalizing on the latest advances in distributed and parallel comput-
ing, especially cloud computing technologies, to advance the state of the art in bioinformatics and 
genomics. In a recent breakthrough, Schatz was able to create a hybrid software-based solution 
to eliminate errors in so-called third-generation sequencing. This makes it remarkably easier to 
compile, align, and analyze full-genome sequences.
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G.S. Atwal R. Aboukhalil A. Gerwitz
Fueled by data generated from recent technological 
developments in DNA sequencing, our lab is primar-
ily focused on population genetics, cancer biology, 
and high-performance computing. We often tackle 
scientifi c questions analytically and computationally 
by invoking theoretical concepts from statistical phys-
ics and machine learning. A long-running thread in 
our work is the analysis of cancer genomes from an 
evolutionary perspective in order to determine how 
this informs on clinical outcome and therapy.
A major new research direction in our lab is the inves-
tigation of ectopic expression of the germline set of genes 
in various tumors. Previous work in our lab has estab-
lished the pleiotropic and ancient role of the TP53 path-
way in germline development. Preliminary results have 
also identifi ed ectopic expression of germline piwi genes 
in samples of glioblastoma multiforme extracted from 
the Cancer Genome Atlas. However, the landscape of 
ectopically expressed germline genes is unknown and 
their functional impact on cancer development remains 
elusive. We began an integrative study that sought to 
determine the ectopic expression of germline transcripts 
in glioblastoma multiforme and elucidate the predic-
tive value of germline molecular programs as diagnostic 
markers and immunogenic therapeutic targets.
Previous work in our lab, in collaboration with col-
leagues at the Cancer Institute of New Jersey and Weill 
Cornell Medical College, has established the association 
between single-nucleotide polymorphisms (SNPs) in 
the p53 tumor suppressor pathway and female infertility 
in mice and humans. This hypothesis was fi rst gener-
ated through computational investigations of haplotypic 
diversity and positive selection in genes in the TP53 
pathway, where we detected signatures of recent positive 
selection in SNPs present at high frequencies in various 
human populations. Selected alleles in SNPs in the LIF, 
Mdm2, Mdm4, and Hausp genes, each of which lies in 
the p53 molecular network, were found to be enriched 
in women undergoing in vitro fertilization (IVF) treat-
ment. Moreover, some of these SNPs have been demon-
strated to be associated with estrogen-driven cancer risk, 
highlighting the pleiotropic character of genetic variants 
in the p53 pathway. We have also sought association of 
SNPs in p63 and p73, and initial results are encouraging, 
although we await an increase in sample numbers before 
the results can be deemed to be statistically signifi cant.
Following up on these earlier investigations, we 
have begun exploring the contribution of multiple al-
leles from both a population genetics and a human 
disease perspective. In addition, we have begun refo-
cusing efforts applying the tools of population genet-
ics to understand single-cell evolution from tumors. 
In particular, we have been addressing the ubiquitous 
problem of how many cells and how much read cover-
age we will need before the inferred cell phylogeny ac-
curately refl ects the evolutionary history of the tumor. 
In addition, our lab has continued research in the use 
of information theory and other machine learning 
tools in addressing the tsunami of data generated by 
next-generation sequencing.
Bud Mishra, a faculty member of the Courant Insti-
tute, New York University, is an ongoing collaborator. 
Bud and I co-organized the RECOMB-Comparative 
Genomics conference, held for the fi rst time at Cold 
Spring Harbor Laboratory in October. Ricki Korff, an 
URP student during the summer of 2013, continues 
to intermittently work with us remotely on the project 
concerning the ectopic expression of germline genes in 
tumors. Aspects of this project were spearheaded by 
2014 URP student Ariel Gerwitz. Robert Aboukhalil, 
a graduate student from the Watson School, has con-
tinued to make progress developing software to analyze 
copy-number data obtained from single tumor cells. 
In addition, two fi rst-year students from the Watson 
School graduate program, Maria Nattestad and Daniel 
Kepple, joined the lab for rotation projects.
Responses to “Equitability, Mutual 
Information, and the Maximal 
Information Coefﬁ cient”
This work was done in collaboration with J. Kinney 
(Cold Spring Harbor Laboratory).
We received two published responses to our widely 
publicized manuscript on equitability, to which we 
Quantitative Biology  227
responded in return. The original paper dealt with 
the following question: How should one quantify 
the strength of association between two random 
variables without bias for relationships of a specifi c 
form? Despite its conceptual simplicity, this no-
tion of statistical “equitability” had yet to receive a 
defi nitive mathematical formalization. We argued 
that equitability is properly formalized by a self-
consistency condition closely related to Data Pro-
cessing Inequality. Mutual information, a funda-
mental quantity in information theory, was shown 
to satisfy this equitability criterion. These fi ndings 
were at odds with the recent work of Reshef et al.
(Science 334: 1518[2011]), which proposed an al-
ternative defi nition of equitability and introduced a 
new statistic, the “maximal information coeffi cient” 
(MIC), said to satisfy equitability in contradistinc-
tion to mutual information. These conclusions, 
however, were supported only with limited simula-
tion evidence, not with mathematical arguments. 
Upon revisiting these claims, we proved that the 
mathematical defi nition of equitability proposed by 
Reshef et al. cannot be satisfi ed by any (nontrivial) 
dependence measure. We also identifi ed artifacts in 
the reported simulation evidence. When these arti-
facts were removed, estimates of mutual informa-
tion were found to be more equitable than estimates 
of MIC. Mutual information was also observed to 
have consistently higher statistical power than MIC. 
We concluded that estimating mutual information 
provides a natural (and often practical) way to eq-
uitably quantify statistical associations in large data 
sets. The responses did not negate any of our origi-
nal results and conclusions.
Ectopic Germline Gene Expression 
in Cancer
This work was done in collaboration with R. Darnell 
(Rockefeller University) and A. Haase (Cold Spring 
Harbor Laboratory).
We initiated an integrative study that sought to deter-
mine the ectopic expression of germline transcripts in 
glioblastoma multiforme and elucidate the predictive 
value of germline molecular programs as diagnostic 
markers and therapeutic targets.
To determine the genome-wide landscape of re-
stricted germline expression, we developed an empiri-
cal Bayesian computational approach to analyze normal 
human soma and germline tissues represented across 
1236 heterogeneous expression data sets. Germline 
tissues were found to express a signifi cantly large, but 
tightly knit, network of genes (n = 1294, q-value = 10−2) 
that we inferred to be tissue-restricted; the functionality 
of these genes is enriched in molecular pathway process-
es such as piwi-interacting RNA (piRNA) metabolism 
(p = 10−6) and cell cycle processes (p = 10−36). By ana-
lyzing RNA-Seq data from the Cancer Genome Atlas, 
we identifi ed 385 high-confi dence germline genes ec-
topically expressed in glioblastoma multiforme samples, 
that have potential to serve as sources of neoantigens. 
Analyses of clinical survival data revealed a stratifi cation 
of patients with high and low number of germline gene 
transcripts, demonstrating that the germline genetic 
program can inform on clinical outcome.
To elucidate the role of the germline piRNA pro-
cessing pathway in cancer, our collaborators purifi ed 
ectopic piwi-complexes in cultured cancer cells and 
investigated the identity of associated nucleic acids. 
Next-generation sequencing revealed that the piwi 
proteins are not loaded with piRNAs, suggesting a 
piRNA-independent mechanism for their reactiva-
tion. Current experimental efforts are geared toward 
investigating piRNA pathways in patient samples.
Optimal Inference and Multistable 
Perception
The stochastic dynamics of multistable perception 
pose an enduring challenge to our understanding 
of neural signal processing in the brain. We formu-
lated a mathematical theory to show that the emer-
gence of perception switching and stability can be 
understood using principles of probabilistic Bayesian 
inference where the prior temporal expectations are 
matched to a scale-free power spectrum, characteris-
tic of fl uctuations in the natural environment. The 
optimal percept dynamics are inferred by an exact 
mapping of the statistical estimation problem to the 
motion of a dissipative quantum particle in a mul-
tiwell potential. In the bistable case, the problem is 
further mapped to a long-ranged Ising model. Op-
timal inference in the presence of a 1/f noise prior 
leads to critical dynamics, exhibiting a dynamical 
phase transition from unstable perception to stable 
perception, as demonstrated in recent experiments. 
The effect of stimulus fl uctuations and perception 
bias is currently being discussed.
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DE NOVO MUTATION IN AUTISM
I. Iossifov
I study the genetics of common diseases in humans, 
using two main tools: next-generation sequencing 
and molecular networks representing functional re-
lationship among genetic loci. These tools in com-
bination enable the large-scale studies necessary for 
furthering our understanding of the complex etiology 
of disorders such as autism, bipolar disorder, and can-
cer. I focus on both developing new methods (for se-
quence analysis and for building and using molecular 
networks) and applying them to specifi c biomedical 
problems.
Exome Sequencing Reveals De Novo 
Gene Disruptions in Children on the 
Autistic Spectrum
We found that children on the autistic spectrum 
(ASD) have increased incidence of de novo (DN) 
missense, “likely gene-disrupting” (LGD), and copy-
number variant (CNV) mutations compared to unaf-
fected siblings. We estimated that 70% of DN CNV, 
42% of DN LGD, and 13% of DN missense muta-
tions contributed to 6%, 9%, and 12% of diagno-
ses in simplex families, respectively. DN mutation in 
the coding sequence contributes to nearly 30% of all 
simplex diagnoses and 45% of female diagnoses; 27 
genes were recurrently hit by DN LGD mutations in 
affected children. CHD8 was hit by nine DN LGDs 
(in nine affected children), DYRK1A by four, and 
each of ANK2, GRIN2B, DSCAM, and CHD2 was 
hit by three DN LGDs. Males with DN LGDs or DN 
CNVs have lower IQ. The gene targets of DN LGDs 
in ASD males with lower IQ overlap with targets in 
ASD females and with individuals having intellectual 
disability or schizophrenia, but not signifi cantly with 
targets in ASD males having higher IQ. We estimate 
the number of vulnerable genes in which an LGD 
mutation can cause ASD in females or lower IQ ASD 
in males to be ~400, with a similar number of genes 
vulnerable to missense mutation. LGD targets are en-
riched for chromatin modifi ers and fragile X mental 
retardation protein (FMRP)-associated genes in both 
affected males of lower IQ and females. Embryoni-
cally expressed genes are signifi cantly enriched in DN 
targets, LGD, and missense only in affected females.
Ongoing Projects
Whole-genome sequencing of Simons Simplex Col-
lection. Whole-exome sequencing (WES) will not 
exhaust the information available in the Simons Sim-
plex Collection (SSC); more can be uncovered by 
whole-genome sequencing (WGS). As with WES, the 
main goal of WGS is gene target discovery in simplex 
families through the identifi cation of disruptive de 
novo events. Certainly, all the data that one can derive 
from exome capture can also be extracted from whole-
genome data, hopefully with more even coverage of 
the exons. By that alone, we anticipate extracting on 
the order of 30% more events. Additionally, we will 
observe de novo events in promoter regions, in evolu-
tionarily conserved regions near target genes, and in 
noncoding genes like microRNAs and long noncod-
ing RNAs. These genomic regions are not targeted 
by WES, yet they may add to the discovery of recur-
rent targets and to the list of causative mechanisms 
for genetic disruption. Although the interpretation of 
any individual event is likely to be diffi cult, we can 
nevertheless calculate a differential signal between af-
fected and unaffected siblings for various regions of 
suspected functionality. Finally, WGS will certainly 
facilitate the discovery of small copy-number changes 
and copy number–neutral rearrangements.
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IN SILICO CANCER GENOMICS
A. Krasnitz M. McGillivray G. Sun
Research in our group is focused on in silico cancer 
genomics. In the last 5 years, there has been explosive 
growth in the volume as well as quality and detail of 
cancer-related genomic data available for analysis. This 
development came about through rapid accumulation 
of public data sets generated by individual laboratories 
worldwide, through large-scale cancer genome proj-
ects such as TCGA (the Cancer Genome Atlas) and 
ICGC (International Cancer Genome Consortium), 
and with the advent of new experimental method-
ologies, especially next-generation sequencing and 
single-cell genomics. We see our goal as channeling 
this fl ood of data into a number of clinically relevant 
applications, including pinpointing and prioritizing 
targets for functional analysis; discovering genomic 
markers for clinical outcome and molecular classifi -
cation of cancer; and elucidating the clonal structure 
of tumors and its relation to progression, invasion, 
metastasis, and response to treatment. All our work is 
done in close coordination with experimental studies 
performed by the Wigler, Hicks, Powers, Lowe (pres-
ently at Memorial Sloan-Kettering Cancer Center), 
and Stillman laboratories here at CSHL.
Recurrence Analysis of Genomic Interval Data
Large collections of intervals commonly arise in high-
throughput genomics. For example, DNA copy-num-
ber analysis yields intervals of the genome correspond-
ing to gains or losses of DNA segments. Likewise, 
chromatin structure is often reported as intervals of 
the genome. In such cases, a common goal is infer-
ence of contiguous genomic target regions, which 
under certain model assumptions generates the ob-
served patterns in the data. We call such target regions 
“cores.” The typical evidence for cores is the presence 
of “recurrent” observations, suitably defi ned.
In cancer, genomes display complex patterns of 
DNA copy-number alteration, but recurrent aberra-
tions are observed within a given cancer type. Detec-
tion and quantitative characterization of the cores in 
a given malignancy are potentially benefi cial in two 
ways. First, it is plausible that at least some of the re-
currence owes to selective pressure on regions harbor-
ing cancer-related genes. Focusing on these regions 
may therefore facilitate cancer gene discovery. Second, 
once the cores are known, the genome of a tumor can 
be described in a drastically simplifi ed fashion by in-
dicating the presence or absence of copy-number al-
teration in any given core. This simplifi ed form of the 
data is better suited for further analysis, such as fi nd-
ing subtypes in a given type of cancer or discovering 
associations between genomic properties and clini-
cal parameters. Finally, differences in core patterns 
among individual tumor cells may be used to explore 
genomic heterogeneity of cancer and examine genea-
logical relationships among tumor cell populations.
We designed and implemented a method for iden-
tifying cores in large collections of genomic interval 
data. A descriptive name for the method is cores of 
recurrent events (CORE). Central to CORE is the 
notion of explanatory power. We say that a core ex-
plains an event and quantify the explanation provided 
as a number between 0 and 1. The explanation is a 
measure of how closely the event is matched by the 
core. We then seek a set of cores that jointly provide 
best possible explanation of the data, subject to addi-
tional criteria of statistical signifi cance. CORE is now 
available to the community via the Comprehensive R 
Archive Network (CRAN).
Tumor Cell Population Structure
Study of genomic and transcriptional properties of 
individual cells is now the focus of multiple research 
laboratories around the world. In application to can-
cer, this line of research has revealed the genomic 
complexity of the disease and the presence of multiple 
genealogically related cell populations in a tumor. De-
tailed knowledge of the clonal structure of a cancer 
potentially is of high clinical value: Multiplicity of 
clones or of lesions in most advanced clones is a pos-
sible measure of progression; spatial pattern of clone 
dispersal in a tumor may signal elevated propensity to 
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invade; lesions observed in individual clones but not in 
the bulk tissue may point to targets for therapy. DNA 
copy-number profi ling of cells from low-coverage se-
quencing is an accurate, economically feasible techno-
logical approach to the study of cancer subpopulation 
structure. Novel multiplex sequencing techniques, de-
veloped by the Wigler lab at CSHL, permit simulta-
neous sequencing of dozens of single-cell DNA speci-
mens and their subsequent copy-number profi ling at 
up to 50-kb resolution. Optimal use of these data for 
robust reconstruction of cancer cell phylogenies is a 
challenging computational problem calling for new 
and robust informatic and statistical tools.
In response, we used CORE to transform copy-
number profi les of single cells into a form suitable for 
phylogeny. As a result of this transformation, each 
profi le is characterized in terms of presence or absence 
in it of archetypal copy-number events recurrent in 
the single-cell populations. The entire set of copy-
number profi les of single cells sampled from a tumor 
is summarized as an incidence table, essentially a ma-
trix with cores as columns, single cells as rows and 
elements quantifying, on a scale between 0 and 1, 
how well a given core is matched by a copy-number 
event in a given cell. Distances among cells as rows 
of this matrix can be readily computed and used for 
distance-based phylogeny. This methodology has 
been used to reconstruct the cell population struc-
ture in a number of samples from prostate cancers. 
Importantly, this study shows that well-defi ned clones 
of tumor cells are likely to exist in prostates of patients 
with high, but not with low, Gleason scores. Further-
more, we see evidence that some of the clones spread 
to multiple anatomical sites within the affected pros-
tate, including sites with less malignant histopatho-
logical characteristics.
Prediction of Response to Anthracycline 
Therapy in Breast Cancer
Anthracyclines are a class of chemotherapeutic drugs 
that are effective and widely used in treatment of a 
number of cancers, in particular those of breast. Sen-
sitivity to these agents varies widely across the entire 
population of patients and likely depends on the pat-
tern of genomic alterations in the tumor. Anthracy-
cline administration also causes signifi cant side ef-
fects, most importantly cardiotoxicity, and should 
therefore be restricted to patient populations for which 
the expected benefi ts outweigh these risks. Yet despite 
more than 50 years of use, the anthracycline mecha-
nism of action is not fi rmly established, and there are 
as yet no reliable predictive markers. In response, we 
applied CORE to DNA copy-number profi les derived 
by the Hicks laboratory at CSHL from breast tumors 
of approximately 250 patients enrolled in the NEAT/
BR9601 clinical trial in Britain. The study was con-
ducted in collaboration with the Bartlett group at the 
Ontario Institute for Cancer Research. To discover 
markers of sensitivity to anthracyclines, we performed 
CORE analysis of the set of profi les and computed 
the incidence table. Next, we evaluated each core as 
a prospective marker of sensitivity and found dra-
matically higher benefi t from treatment in patients 
positive for a narrow amplifi ed region of chromo-
some 8. None of the marker-positive patients treated 
by anthracyclines have suffered a relapse in 5 years 
past treatment, whereas the marker-positive patients 
who were not treated displayed a markedly higher 
rate of relapse than the remainder of the cohort. 
Given these results, a validation study has been ini-
tiated, with the goal to similarly analyze hundreds 
of breast tumor samples from the MA.5 clinical trial 
in Canada.
Signiﬁ cantly Distinct Branches of 
Hierarchical Trees
Hierarchical clustering (HC) is widely used as a meth-
od of partitioning data and of identifying meaningful 
data subsets. Most commonly an application consists 
of visual examination of the dendrogram and intuitive 
identifi cation of subtrees that appear clearly distinct 
from the rest of the tree. Obviously, results of such 
qualitative analysis and conclusions from it may be 
observer-dependent. Quantifying the interpretation 
of hierarchical trees and introducing mathematically 
and statistically well-defi ned criteria for distinctness 
of subtrees would therefore be highly benefi cial.
We formulated and implemented a computational 
method termed tree branches evaluated statistically 
for tightness (TBEST) for identifying signifi cantly 
distinct tree branches in hierarchical clusters. For 
each branch of the tree, a measure of distinctness, or 
tightness, is defi ned as a rational function of heights, 
both of a given branch and of its parent. A statistical 
Quantitative Biology  233
procedure is then developed to determine the signifi -
cance of the observed values of tightness. We tested 
TBEST as a tool for tree-based data partitioning by 
applying it to four benchmark data sets. These rep-
resent four distinct types of biological data: mRNA 
expression, DNA copy-number variation, proteomics, 
and fl ow cytometry. In each of the four cases there is 
a well-defi ned and independently known partition of 
the data into classes. In all cases considered, TBEST 
reproduced these classes on par with or better than 
the existing techniques. The R language implementa-
tion of the method is now available, as an eponymous 
package, from the Comprehensive R Active Network 
(CRAN).
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COMPUTATIONAL GENETICS
D. Levy V. Kumar
The data-rich environment at CSHL generates a wealth 
of opportunities for the application of mathematics and 
computation to further our understanding of biology 
and genetics. The primary activities of our lab are al-
gorithm and protocol development, data analysis, and 
genetic theory, with a focus on sporadic human diseases 
such as autism, congenital heart disease, and cancer.
Autism Genetics, Mutation, and 
Computational Methods
Together with Michael Wigler, Michael Ronemus, 
and Ivan Iossifov here at CSHL, our efforts in autism 
attempt to bridge the gap between genetic theory and 
large-scale data analysis. Together with groups at the 
University of Washington and the University of San 
Francisco, we have completed the whole-exome analy-
sis on the entire Simons Simplex Collection (SSC), 
composed of 3000 families with exactly one child 
affected with autism. Analyzing more than 10,000 
exomes, we established a causal role for deleterious 
coding mutations in sensitive genes. The study uncov-
ered many candidate genes whose disruption is likely 
to result in an autism spectrum disorder, establishing 
a high-quality set of starting points for uncovering the 
functional relationships that underlie the disorder.
Although the study addressed the types of muta-
tions best observed by exome sequencing, namely, 
single-nucleotide mutations and small insertion and 
deletion events, we are building tools to extract other 
mutational modalities such as copy-number variations 
(CNVs) and genomic rearrangements.
Copy-Number Variation
The primary challenge in identifying CNVs from 
exome capture data is that the capture process distorts 
coverage in a manner that varies from sample to sample. 
Fortunately, the variability expressed in an individual 
sample is often recapitulated on a population level, and 
we can use our library of samples to identify the major 
elements of systemic noise. Our normalization proce-
dure is coupled to a hidden Markov model (HMM) 
that integrates over all the copy-number possibilities 
for a given sample and returns a probability for each 
copy state for each region of the genome. Joining our 
methods with a complementary approach developed by 
Chris Yoon, we have established a set of high-quality 
CNV calls from the noisy SSC exome data. Prelimi-
nary results support earlier microarray studies, estab-
lishing a similar rate for de novo CNVs and suggesting 
a role for rare transmitted variants that disrupt genes.
Genomic Rearrangements
Together with Peter Andrews here at CSHL, we have 
developed an algorithm for identifying large genomic 
rearrangements—deletions, insertions, transloca-
tions, and inversions—by cataloging discontinuities 
in the mapping of reads against the reference genome. 
Taking advantage of memory-intensive computational 
methods, we are able to rapidly identify all maximal 
exact matches (MEMs) between a read and a refer-
ence genome. This provides a scaffold for cataloging 
and indexing all of the sequence data such that we can 
quickly identify discontinuities: areas where placing 
the reads on the scaffold bends or breaks the reference 
genome. By looking across all samples, we can identify 
common events, spurious rearrangements, and global 
discrepancies within the reference. With all reads in-
dexed and anchored to the reference genome, we re-
assemble rare and de novo discontinuities within an 
individual or family. Analyzing large data sets requires 
an effi cient and robust data format and processing al-
gorithms, which we are currently deploying on both 
the 10,000 SSC exomes and a smaller whole-genome 
sequence data set.
Genetic Models of Autism
Autism is often described as the most highly heritable 
neurological disorder. Concordance for autism among 
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identical twins is as high as 90%. There are several 
other interesting statistics in the epidemiology of au-
tism that are less often noted. If a family has a single 
child with autism, the risk to the next born male child 
is about 20%. This elevated risk has led to an explana-
tion that autism is a multifactorial disorder and that 
several gene disruptions are needed to produce an au-
tism phenotype. That claim, however, is belied by an-
other statistic: given two children in the family with 
autism, the risk to a third-born male child is 50%.
One model that fi ts this data is to postulate two 
risk classes for autism—nearly all families have a very 
low risk of having a child with autism, whereas a small 
percentage of families have a very high risk. Together 
with Michael Wigler and Swagatam Mukhopadhyay 
here at CSHL, we have been exploring simple genetic 
models that recapitulate the observed risk statistics, 
both for boys and girls, as well as observations that 
stem from genetic analyses of autism spectrum disor-
der (ASD) families. Our model includes parameters 
such as de novo mutation rates, variability of pene-
trance, assortative mating, and the number and type 
of genetic targets.
Combinatorics allow for fast simulations of infi nite 
populations, providing a means for quickly exploring 
the space of possible models consistent with the ob-
servable measures. We fi nd that a simple model with 
two gene classes and different selection profi les for 
males and females is suffi cient to match observable 
risk and mutation rates. This model also makes pre-
dictions about gender ratios as a function of severity, 
the role of transmitted mutation, and the genetic load 
in the population.
Mutational Sequencing
Despite vast improvements in DNA sequencing, many 
problems of interpretation arise when trying to count 
or assemble molecules (templates) that are largely iden-
tical. In a recent paper, we show that by randomly mu-
tating DNA templates before amplifi cation, many of 
these problems are resolved. We can accurately count 
the number of templates by counting the number of 
unique patterns. By introducing distinctive patterns 
onto otherwise identical spans, we enhance our abil-
ity to correctly assemble sequences. This idea can be 
implemented with currently available mutagenesis 
protocols, and such techniques can have applications 
in RNA expression analysis, haplotype phasing, copy-
number determination, and genome assembly. Muta-
tional sequencing (muSeq) solves counting problems 
and effectively generates long reads from short-read 
sequence data.
We are developing new protocols to generate ran-
dom, uncorrelated mutations at a tunable rate. We are 
also developing algorithms for counting and assem-
bling mutational patterns in the noisy context of real 
sequence data. Having established working protocols 
and algorithms, we are now exploring applications 
ranging from the sensitive detection of rare mutation 
to single-cell isoform profi ling to de novo genome 
 assembly.
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COMPUTATIONAL SEQUENCE ANALYSIS
M. Schatz H. Fang S. Marcus F. Sedlazeck
 T. Garvin G. Narzisi R. Sherman
 J. Gurtowski M. Nattestad A.H. Wences
 H. Lee S. Ramakrishnan
Our lab develops novel computational analysis meth-
ods to study the structure and function of genomes, 
especially genomes with medical or agricultural sig-
nifi cance. These include methods for assembling 
sequence data into complete genomes, for aligning 
sequences to discover variations or measure transcrip-
tion levels, and for mining these data to discover rela-
tionships between an organism’s genome and its traits. 
We then apply these methods to study several biologi-
cal systems, for example, to discover mutations associ-
ated with human diseases such as cancer and autism 
or to reconstruct the genomes of important agricul-
tural crops and biofuels.
In the past year, our lab has grown by several new 
members. Han Fang is a new Ph.D. student in Ap-
plied Math at Stony Brook University who is jointly 
supervised by myself and Dr. Gholson Lyon. Han is 
particularly interested in transcriptional and trans-
lational regulation, using RNA-Seq and Ribo-Seq 
profi ling in yeast to study how genetic mutations can 
infl uence protein production. Maria Nattestad is a 
new student from the Watson School of Biological 
Sciences. Maria completed her undergraduate educa-
tion in Biology at the University of the Pacifi c and is 
currently researching the role of structural variations 
in cancer using single-molecule sequencing from Pa-
cifi c Biosciences (PacBio). Rachel Sherman joined us 
from Harvey Mudd College for the summer under-
graduate research program and developed a new algo-
rithm for multispecies comparative genomics. At the 
very end of the year, Fritz Sedlazeck joined us as a new 
postdoctoral researcher from Vienna, Austria, where he 
completed his Ph.D. in genomics and computer sci-
ence. He will be researching novel methods for DNA 
sequence assembly, using new long-read sequencing 
technology from PacBio, Oxford Nanopore, and the 
new 10X Genomics platform. We were also proud 
of Giuseppe Narzisi for his new position as Bioin-
formatics Scientist at the New York Genome Center 
and of Shoshana Marcus for her new role as Assistant 
Professor of Computer Science at the City University 
of New York at Kingsborough.
In the past year, our lab has made signifi cant con-
tributions to the study of the genetics of autism in col-
laboration with the Wigler, Iossifov, Levy, and Lyon 
labs here at CSHL. Most signifi cantly, we published 
our state-of-the-art algorithm Scalpel for fi nding in-
sertion and deletion mutations from short sequenc-
ing reads and applied it to identify several new au-
tism candidate genes. We also contributed to several 
genome-sequencing projects in collaboration with the 
McCombie and Ware labs, including publishing the 
rice, wheat, and the parrot genomes. We also devel-
oped new algorithmic advances toward the assem-
bly of genomes and the assembly of “pan-genomes.” 
 Finally, I am proud to say that I was awarded an NSF 
CAREER award to develop new algorithms for study-
ing genomes using new single-molecule sequencing 
technologies. This prestigious award recognizes the 
signifi cant research advances I have made since join-
ing the CSHL faculty in 2010 as well as my future 
research plans.
The Contribution of De Novo Coding 
Mutations to Autism Spectrum Disorder
Whole-exome sequencing has proven to be a power-
ful tool for understanding the genetic architecture of 
human disease. Here, we apply it to more than 2500 
simplex families, each having a child with an autistic 
spectrum disorder. By comparing affected to unaf-
fected siblings, we show that 13% of de novo missense 
mutations and 43% of de novo likely gene-disrupting 
(LGD) mutations contribute to 12% and 9% of di-
agnoses, respectively. Including copy-number vari-
ants, coding de novo mutations contribute to ~30% 
of all simplex and 45% of female diagnoses. Almost 
all LGD mutations occur opposite wild-type alleles. 
LGD targets in affected females signifi cantly overlap 
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the targets in males of lower intelligence quotient 
(IQ), but neither overlaps signifi cantly with targets 
in males of higher IQ. We estimate that LGD muta-
tion in ~400 genes can contribute to the joint class 
of affected females and males of lower IQ, with an 
overlapping and similar number of genes vulnerable 
to contributory missense mutation. LGD targets in 
the joint class overlap with published targets for intel-
lectual disability and schizophrenia and are enriched 
for chromatin modifi ers, FMRP-associated genes, and 
embryonically expressed genes. Most of the signifi -
cance for the latter comes from affected females.
Reducing INDEL Calling Errors in 
Whole-Genome and Exome 
Sequencing Data
Genome insertions and deletions (INDELs), espe-
cially those disrupting protein-coding regions of the 
genome, have been strongly associated with human 
diseases. However, there are still many errors with 
INDEL variant calling, driven by library prepara-
tion, sequencing biases, and algorithm artifacts. We 
characterized whole-genome sequencing (WGS), 
whole-exome sequencing (WES), and polymerase 
chain reaction (PCR)-free sequencing data from the 
same samples to investigate the sources of INDEL er-
rors. We also developed a classifi cation scheme based 
on the coverage and composition to rank high- and 
low-quality INDEL calls. We performed a large-scale 
validation experiment on 600 loci and found that 
high-quality INDELs have a substantially lower error 
rate than low-quality INDELs (7% vs. 51%). Simula-
tion and experimental data show that assembly-based 
callers are signifi cantly more sensitive and robust for 
detecting large INDELs (>5 bp) than alignment-
based callers, consistent with published data. The 
concordance of INDEL detection between WGS and 
WES is low (53%), and WGS data uniquely identi-
fi es 10.8-fold more high-quality INDELs. The vali-
dation rate for WGS-specifi c INDELs is also much 
higher than that for WES-specifi c INDELs (84% vs. 
57%), and WES misses many large INDELs. In addi-
tion, the concordance for INDEL detection between 
standard WGS and PCR-free sequencing is 71%, and 
standard WGS data uniquely identify 6.3-fold more 
low-quality INDELs. Furthermore, accurate detec-
tion with Scalpel of heterozygous INDELs requires 
1.2-fold higher coverage than that for homozygous 
INDELs. Finally, homopolymer A/T INDELs are a 
major source of low-quality INDEL calls, and they 
are highly enriched in the WES data. Overall, we 
show that accuracy of INDEL detection with WGS 
is much greater than that with WES even in the tar-
geted region. We calculated that 60× WGS depth of 
coverage from the Hi-Seq platform is needed to re-
cover 95% of INDELs detected by Scalpel. Although 
this is higher than the current sequencing practice, the 
deeper coverage may save total project costs because of 
the greater accuracy and sensitivity. We also investi-
gate sources of INDEL errors (e.g., capture defi ciency, 
PCR amplifi cation, and homopolymers) with various 
data that will serve as a guideline to effectively reduce 
INDEL errors in genome sequencing.
Accurate De Novo and Transmitted 
INDEL Detection in Exome-Capture 
Data Using Microassembly
We present here an open-source algorithm, Scalpel, 
that combines mapping and assembly for sensitive 
and specifi c discovery of insertions and deletions 
(INDELs) in exome-capture data. A detailed repeat 
analysis coupled with a self-tuning k-mer strategy 
allows Scalpel to outperform other state-of-the-art 
approaches for INDEL discovery, particularly in re-
gions containing near-perfect repeats. We analyzed 
593 families from the Simons Simplex Collection and 
demonstrated Scalpel’s power to detect long (≥30 bp) 
transmitted events and enrichment for de novo likely 
gene-disrupting INDELs in autistic children.
Whole-Genome De Novo Assemblies 
of Three Divergent Strains of Rice, 
Oryza sativa, Document Novel Gene 
Space of aus and indica
The use of high-throughput genome-sequencing 
technologies has uncovered a large extent of struc-
tural variation in eukaryotic genomes that makes 
important contributions to genomic diversity and 
phenotypic variation. When the genomes of differ-
ent strains of a given organism are compared, whole-
genome resequencing data are typically aligned to an 
established reference sequence. However, when the 
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reference differs in signifi cant structural ways from 
the individuals under study, the analysis is often in-
complete or inaccurate. Here, we use rice as a model 
to demonstrate how improvements in sequencing and 
assembly technology allow rapid and inexpensive de 
novo assembly of next-generation sequence data into 
high-quality assemblies that can be directly com-
pared using whole-genome alignment to provide an 
unbiased assessment. Using this approach, we are able 
to accurately assess the “pan-genome” of three diver-
gent rice varieties and document several megabases 
of each genome absent in the other two. Many of the 
genome-specifi c loci are annotated to contain genes, 
refl ecting the potential for new biological properties 
that would be missed by standard reference-mapping 
approaches. We further provide a detailed analysis of 
several loci associated with agriculturally important 
traits, including the S5 hybrid sterility locus, the Sub1 
submergence tolerance locus, the LRK gene cluster 
associated with improved yield, and the Pup1 clus-
ter associated with phosphorus defi ciency, illustrating 
the utility of our approach for biological discovery. 
All of the data and software are openly available to 
support further breeding and functional studies of 
rice and other species.
High-Coverage Sequencing and Annotated 
Assemblies of the Budgerigar Genome
Parrots belong to a group of behaviorally advanced 
vertebrates and have an advanced ability of vocal 
learning relative to other vocal-learning birds. They 
can imitate human speech, synchronize their body 
movements to a rhythmic beat, and understand 
complex concepts of referential meaning to sounds. 
However, little is known about the genetics of these 
traits. Elucidating the genetic bases would require 
whole-genome sequencing and a robust assembly of 
a parrot genome. We present a genomic resource for 
the budgerigar, an Australian Parakeet (Melopsittacus 
undulatus), the most widely studied parrot species in 
neuroscience and behavior. We present genomic se-
quence data that includes more than 300× raw read 
coverage from multiple sequencing technologies and 
chromosome optical maps from a single male animal. 
The reads and optical maps were used to create three 
hybrid assemblies representing some of the largest 
genomic scaffolds to date for a bird, two of which 
were annotated based on similarities to reference sets 
of nonredundant human, zebra fi nch, and chicken 
proteins and budgerigar transcriptome sequence as-
semblies. The sequence reads for this project were in 
part generated and used for both the Assemblathon 2 
competition and the fi rst de novo assembly of a giga-
scale vertebrate genome utilizing PacBio single-mole-
cule sequencing. Across several quality metrics, these 
budgerigar assemblies are comparable to or better 
than the chicken and zebra fi nch genome assemblies 
built from traditional Sanger sequencing reads, and 
they are suffi cient to analyze regions that are diffi -
cult to sequence and assemble, including those not 
yet assembled in prior bird genomes and promoter 
regions of genes differentially regulated in vocal-
learning brain regions. This work provides valuable 
data and material for genome technology develop-
ment and for investigating the genomics of complex 
behavioral traits.
Large-Scale Sequencing and Assembly of 
Cereal Genomes Using Blacklight
Wheat, corn, and rice provide 60% of the world’s 
food intake every day, and just 15 plant species make 
up 90% of the world’s food intake. As such, there is 
tremendous agricultural and scientifi c interest in se-
quencing and studying plant genomes, especially to 
develop a reference sequence to direct plant breeding 
or to identify functional elements. DNA sequencing 
technologies can now generate sequence data for large 
genomes at low cost; however, it remains a substan-
tial computational challenge to assemble the short se-
quencing reads into their complete genome sequences. 
Even one of the simpler ancestral species of wheat, 
 Aegilops tauschii, has a genome size of 4.36 gigabase-
pairs (Gbp), nearly 50% larger than the human ge-
nome. Assembling a genome this size requires com-
putational resources, especially RAM to store the 
large assembly graph, which is out of reach for most 
institutions. Here, we describe a collaborative effort 
between Cold Spring Harbor Laboratory and the 
Pittsburgh Supercomputing Center to assemble large, 
complex cereal genomes starting with Ae. tauschii, 
using the XSEDE shared memory supercomputer 
Blacklight. We expect these experiences using Black-
light to provide a case study and computational pro-
tocol for other genomics communities to leverage this 
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or similar resources for assembly of other signifi cant 
genomes of interest.
On Algorithmic Complexity of Biomolecular 
Sequence Assembly Problem
Because of its connection to the well-known NP- 
complete shortest superstring combinatorial optimiza-
tion problem, the sequence assembly problem (SAP) 
has been formulated in simple and sometimes unreal-
istic string-and-graph theoretic frameworks. We revisit 
this problem by reexamining the relationship between 
the most common formulations of the SAP and their 
computational tractability under different theoretical 
frameworks. For each formulation, we show examples 
of logically consistent candidate solutions that are nev-
ertheless unfeasible in the context of the underlying 
biological problem. We hope that this material will be 
valuable to theoreticians as they develop new formula-
tions of SAP as well as be of guidance to developers of 
new pipelines and algorithms for sequence assembly 
and variant detection.
SplitMEM: A Graphical Algorithm for 
Pan-Genome Analysis with Sufﬁ x Skips
Genomics is expanding from a single reference per spe-
cies paradigm into a more comprehensive pan-genome 
approach that analyzes multiple individuals together. 
A compressed de Bruijn graph is a sophisticated data 
structure for representing the genomes of entire popu-
lations. It robustly encodes shared segments, simple 
single-nucleotide polymorphisms, and complex struc-
tural variations far beyond what can be represented 
in a collection of linear sequences alone. We explore 
deep topological relationships between suffi x trees 
and compressed de Bruijn graphs and introduce an 
algorithm, SplitMEM, that directly constructs the 
compressed de Bruijn graph in time and space linear 
to the total number of genomes for a given maximum 
genome size. We introduce suffi x skips to traverse sev-
eral suffi x links simultaneously and use them to effi -
ciently decompose maximal exact matches into graph 
nodes. We demonstrate the utility of  SplitMEM by 
analyzing the nine-strain pan-genome of Bacillus an-
thracis and up to 62 strains of Escherichia coli, reveal-
ing their core-genome properties.
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QUANTITATIVE BIOLOGY FELLOW
Quantitative Biology Fellows are independent researchers who enter this position soon after re-
ceiving a Ph.D. They come from the fi elds of mathematics, physics, engineering, or computer 
science and spend 3–5 years at Cold Spring Harbor Laboratory applying techniques from these 
disciplines to important questions in biology.
Transcriptional Regulation, Biophysics, 
and Machine Learning
J. Kinney
My research combines theory, computation, and ex-
periment in an effort to better understand sequence-
function relationships in molecular biology.
My experimental work focuses primarily on the 
biophysics of transcriptional regulation in the bac-
terium Escherichia coli. In graduate school and as a 
postdoc, I developed an experimental method called 
“Sort-Seq” that allows the transcriptional activities of 
hundreds of thousands of different E. coli promoters to 
be measured in a single experiment. Sort-Seq data can 
be used to build quantitative biophysical models for 
how elementary protein–DNA and protein– protein 
interactions combine to regulate gene expression. I con-
tinue to use Sort-Seq to study transcriptional regula-
tion in E. coli, but I am also using similar techniques 
to study antibody–antigen interactions.
The analysis of Sort-Seq data also highlights in-
teresting problems in statistics and machine learn-
ing that have yet to be fully addressed. About half of 
my research effort is devoted to these theoretical and 
computational questions.
Parametric Inference in the Large Data Limit 
Using Maximally Informative Models
Kinney and Atwal (2014a) describe a basic problem in 
statistical inference. Our work was motivated by my 
analysis of Sort-Seq data, but it is also relevant to the 
measurement of receptive fi elds in sensory neuroscience.
Consider an experiment that produces an unlimit-
ed supply of data (e.g., activity measurements for many 
different variants of a bacterial promoter). Assume, 
however, that we do not know the precise quantita-
tive form of the experimental noise that contaminates 
these measurements. Such situations are common in 
Sort-Seq experiments and in other high-throughput 
biology assays. Nevertheless, not knowing how to 
model experimental noise causes problems for the sta-
tistical methods typically used to fi t models to such 
data. The reason is that standard statistics requires 
that one compute a quantity called “likelihood,” and 
computing this requires an explicit quantitative model 
for experimental noise.
Atwal and I show that using a quantity from infor-
mation theory called “mutual information” in place 
of likelihood circumvents the problem of not know-
ing the quantitative details of the experimental noise 
(Fig. 1). We also introduce the concept of “diffeo-
morphic modes”—directions in parameter space that 
mutual information cannot pin down. Importantly, 
this work shows that different model parameters can 
respond in qualitatively different ways to data. This 
is a general mathematical fi nding applicable to a wide 
range of statistical regression problems, including 
many “Big Data” problems in biology.
Equitability, Mutual Information, and the 
Maximal Information Coefﬁ cient
In Kinney and Atwal (2014b), we introduce a rigorous 
formulation of a statistical concept called “equitabili-
ty.” Equitability is a heuristic criterion, introduced and 
advocated by Reshef et al. (Science 334: 1518 [2011]), 
that general measures of statistical dependence should 
satisfy. We show that this criterion is naturally for-
malized as a weakened form of the “Data Processing 
Inequality,” a core concept in information theory. We 
also emphasize that this formal equitability criterion is 
satisfi ed by the well-known mutual information mea-
sure and that estimates of mutual information made 
on fi nite data can adhere well to this notion of equita-
bility in practice.
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Although the heuristic concept of equitability 
is valuable, we also fi nd that the primary claims of 
Reshef et al. regarding equitability were incorrect. 
In particular, we show that the “maximal informa-
tion coeffi cient” (MIC), a statistic that Reshef et al. 
introduced and that was said to satisfy equitability, 
does not actually have this mathematical property. 
This fi nding is important because the paper by Reshef 
et al. has become one of the most highly cited statistics 
papers of the last few years, and MIC appears to have 
gained widespread use. We hope that our paper will 
motivate scientists in need of an equitable measure of 
dependence to seriously consider using mutual infor-
mation instead of MIC.
Field Theoretic Methods for Estimating 
Low-Dimensional Probability Densities
As with many efforts to understand experimental 
data, analyzing Sort-Seq data requires the accurate 
estimation of continuous probability distributions 
(also known as probability densities). Despite the 
ubiquity and seeming simplicity of this problem, the 
best way to estimate a continuous probability distri-
bution from data—even in one dimension—remains 
unresolved. I believe, however, that fi eld theory meth-
ods from theoretical physics can ultimately provide a 
defi nitive practical solution to this important statisti-
cal problem.
Field theory methods for estimating probability 
densities date back to the mid 1990s. These meth-
ods are computationally intensive, however, and until 
Kinney (2014), no practical implementation of these 
methods was available. My work (Kinney 2014) shows 
that fi eld-theory-based density estimates can be com-
puted rapidly and deterministically using a homotopy 
algorithm. This paper also demonstrates, for the fi rst 
time, that such density estimation methods can per-
form excellently on simulated data.
In a more recent work, I show that the boundary 
conditions that were placed on estimated densities in 
previous fi eld-theoretic work are unnecessary. By re-
moving these boundary conditions, one recovers the 
well-known “maximum entropy” approach to density 
estimation in the infi nite smoothness limit. This uni-
fi cation of fi eld theory and maximum entropy meth-
ods for density estimation further suggests a novel 
way of testing the hypothesis that one’s data comes 
from a probability distribution having a specifi ed 
functional form.
By establishing the ability to rapidly compute 
fi eld theory density estimates and by showing how 
to remove prior assumptions about the boundary be-
havior of these densities, my work provides a solid 
foundation upon which to build a defi nitive practi-
cal solution to the density estimation problem in low 
dimensions. In the near future, I hope to show how 
such density estimation methods can be used to ac-
curately estimate mutual information and other im-
portant statistical quantities. I also hope to provide 
Figure 1.  Schematic illustration of constraints placed on dif-
feomorphic and nondiffeomorphic modes in parameter space 
by different objective functions. The ﬁ lled circle in each panel 
represents the correct model θ*; shades of gray represent the 
posterior distribution p(θ|data). (A,B) Likelihood places tight 
constraints along both diffeomorphic and nondiffeomorphic 
directions in parameter space. (A) θ* will typically lie within 
error bars if the correct noise function π* is used to compute 
likelihood L. (B) However, if an incorrect noise function π′ is 
used, θ* will generally violate inferred constraints along both 
diffeomorphic and nondiffeomorphic modes. (C) Alternatively, 
if uncertainties in the noise functions are explicitly accounted 
for in the computation of p(θ|data), one will ﬁ nd tight constraints 
on nondiffeomorphic modes but only weak constraints along 
diffeomorphic modes. (D) Mutual information places tight con-
straints on nondiffeomorphic modes but provides no constraints 
whatsoever on diffeomorphic modes. (Figure from Kinney and 
Atwal 2014a.)
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easy-to-use software that makes these statistical 
methods available for general use.
Ongoing Projects
A biophysical code for transcriptional regulation in 
E. coli. I have established a long-term collaboration 
with Rob Phillips (California Institute of Technol-
ogy), the goal of which is to build an accurate bio-
physical model of the transcriptional regulatory code 
of E. coli. We are focusing on this bacterium for two 
reasons. First, the underlying molecular biology of 
transcriptional regulation in E. coli is understood well 
at a qualitative level. This qualitative understanding 
is essential for the correct quantitative interpretation 
of Sort-Seq data. Second, transcription in E. coli is 
regulated in a hierarchical manner, with only a small 
number of proteins controlling a large number of 
regulatory sequences. Using in vitro single-molecule 
techniques together with in vivo Sort-Seq assays, we 
aim to systematically build a full sequence-dependent 
biophysical model for how regulatory proteins bind 
DNA, interact with one another, and modulate the 
rate of mRNA transcription.
Initial work on this project has been pursued by 
Daniel Jones, a graduate student who did his Ph.D. 
work with Rob Phillips followed by a short stint as a 
postdoc in my lab. We are currently wrapping up this 
phase of the project.
Sequence-function relationships in antibody–antigen 
recognition. Despite the central role that antibodies 
have in the adaptive immune system and in biotech-
nology, surprisingly little is known about how anti-
body–antigen affi nity depends on antibody sequence. 
For instance, how many possible antibodies can spe-
cifi cally bind an antigen of interest with 1-nm affi n-
ity, or with 1-pm affi nity? Does the sequence-affi nity 
landscape have a single optimum, or is it “glassy”? Do 
the sequence-affi nity landscapes for different anti-
body–antigen pairs exhibit any general features, for 
example, a universal “density of states”? In collabora-
tion with Aleksandra Walczak (ENS, Paris) and Thi-
erry Mora (ENS, Paris), I am pursuing a combination 
Figure 2. Field-theoretic estimation of two-dimensional probability densities. Shown is a simulated probability den-
sity Qtrue (composed of two Gaussian distributions), raw data sets R (of various size N) drawn from Qtrue, and density 
estimates computed from R using either kernel density estimation, Gaussian mixture modeling or the ﬁ eld theory 
method of Kinney (2014) with various values for the parameter α. (Figure from Kinney 2014.)
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of theory, computation, and experiment aimed at 
making progress on these important problems.
During the last 2 years, Rhys Adams, a postdoc 
working with Walczak, Mora, and myself, has been 
performing and analyzing Sort-Seq experiments de-
signed to address these questions. Using yeast display 
technology, he is able to measure the binding affi nities 
of thousands of variant antibodies to a specifi c antigen 
of interest. Our hope is that these data will allow us 
to build quantitative models of the sequence-affi nity 
landscape of this system, explore this landscape com-
putationally, and look for features that might general-
ize to other antibody–antigen pairs.
Formal diagrammatic methods for biochemical systems. 
My work on transcriptional regulation requires build-
ing quantitative biophysical models of molecular 
interactions. However, the only systematic way to 
currently represent models of such interactions is to 
explicitly list all the possible states of a system, a task 
that becomes exponentially more diffi cult as system 
size increases. For this reason, I am developing a formal 
diagrammatic method for concisely and rigorously 
defi ning thermodynamic models of biochemical 
systems. This method allows equilibrium partition 
functions to be calculated systematically and should 
eventually facilitate nonequilibrium calculations as 
well. This approach can be applied to a wide range 
of processes in systems biology. My hope is that such 
methods will serve a purpose much like Feynman 
diagrams do in physics, bridging the gap between 
one’s intuitive visual understanding of a system and 
rigorous quantitative models thereof.
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COLD SPRING HARBOR LABORATORY FELLOW
In 1986, Cold Spring Harbor Laboratory began a Fellows Program to encourage independent 
research by outstanding young scientists who, during their graduate studies, displayed exceptional 
promise of becoming leading scientists of the future. The purpose of this program is to provide 
an opportunity for these young scientists to work independently at the Laboratory for a period of 
3 years on projects of their own choosing. Fellows are provided with a salary, research support, and 
technical assistance so that they can accomplish their goals free of distraction. The interactions 
among research groups at the Laboratory and the program of courses and meetings on diverse top-
ics in biology contribute to a research environment that is ideal for innovative science by these Fel-
lows. The CSHL Fellows Program has been tremendously successful and has served as a paradigm 
for several analogous programs at other institutions, most recently a Fellows Program sponsored 
by the National Institutes of Health.
The success of the program is apparent from the list of distinguished alumni. Most notably, 
Carol Greider—recipient of the 2009 Nobel Prize in Physiology or Medicine for her work on 
telomerase and telomere function—joined the Fellows Program in 1998. After completing her 
fellowship, Carol was on the CSHL faculty for 9 years, and she is currently the Daniel Nathans 
Professor and Director of Molecular Biology and Genetics at Johns Hopkins University School of 
Medicine.
Previous CSHL Fellows Adrian Krainer (1986) and Marja Timmermans (1998) are now Pro-
fessors at the Laboratory, and Chris Vakoc (2008) and Florin Albeanu (2008) are currently hold-
ing Assistant Professor positions at CSHL. Scott Lowe (1995) is a Howard Hughes Medical In-
stitute (HHMI) Investigator. After nearly 15 years on the CSHL faculty, he recently took on a 
Professorship at Memorial Sloan-Kettering Cancer Center in New York City. Eric Richards (1989) 
currently is the Vice President of Research and Senior Scientist at the Boyce Thompson Institut 
for Plant Research at Cornell University; David Barford (1991) is a Fellow of the Royal Society 
and Professor of Molecular Biology at the Institute of Cancer Research in London; Ueli Gross-
niklaus (1994) is Professor at the Institute of Plant Biology, University of Zürich, Switzerland; and 
Térence Strick (2000) left at the end of his fellowship to become a Group Leader at the Institute 
Jacques Monod in Paris. Lee Henry (2000) joined HHMI’s Janelia Farm in Ashburn and joined a 
project headed by Thomas Südhof. Ira Hall (2004) is an Associate Professor and Associate Direc-
tor of the Genome Institute at Washington University. Patrick Paddison, who had joined the Fel-
lows Program in 2004, currently is an Associate Member at the Fred Hutchinson Cancer Research 
Center in Seattle, Washington.
Lingbo Zhang has been a Fellow at the Laboratory since 2013. He joined us from Harvey 
Lodish’s laboratory at the Whitehead Institute of the Massachusetts Institute of Technology, 
where he studied the regulation of erythroid progenitor cell self-renewal. As a CSHL Fellow, 
Lingbo is conducting genetic and small-molecule screens to discover novel regulators of normal 
and aberrant stem cell biology.
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UNDERSTANDING AND TARGETING SELF-RENEWAL OF NORMAL 
AND MALIGNANT ADULT STEM AND PROGENITOR CELLS
L. Zhang S. Chiappone G. Trivedi
Self-renewal is a unique property of stem and progeni-
tor cells, allowing them to undergo several cycles of cell 
division while maintaining an undifferentiated status. 
During normal development, self-renewal allows stem 
and progenitor cells in adult tissues and organs to ex-
pand, a phenomenon that leads to tissue regeneration 
and can serve as a key target for regenerative medi-
cine. However, compared to the well-known embry-
onic stem cell, our understanding of self- renewal in 
adult stem and progenitor cells is extremely limited, 
thus preventing us from therapeutically utilizing these 
cells. In addition to the crucial role of self-renewal in 
maintaining tissue homeostasis, malignant cells can 
hijack this property under pathological conditions to 
form cancer stem cells (or tumor-initiating cells) and 
contribute to carcinogenesis. Therefore, understand-
ing the molecular mechanisms underlying self-renew-
al of cancer stem cells is critical for the eradication of 
these cells and prevention of relapse. Furthermore, we 
are probing the mechanistic divergence of self-renewal 
in normal versus malignant stem and progenitor cells, 
a crucial strategy for the development of targeted 
therapy that selectively disrupts carcinogenesis but not 
normal tissue homeostasis.
The research in my laboratory focuses on the he-
matopoietic, or blood-forming, system, using this lin-
eage as a model system to uncover mysteries behind 
adult stem and progenitor self-renewal. Currently, we 
are mainly studying two important cell types, the early 
erythroid progenitor and the leukemia stem cell, in 
an effort to develop novel small chemical-compound-
based therapeutic strategies for a wide range of blood 
diseases, including severe anemias and leukemias that 
are resistant to existing treatments. To better recapitu-
late the genetic heterogeneity of these diseases, we are 
also using the CRISPR/Cas9 genome editing technol-
ogy to develop novel preclinical mouse models that 
possess combinatorial genetic lesions.
At the moment, bone marrow transplantation 
(BMT) is the only curative treatment for severe ane-
mias and leukemias. However, BMT is a diffi cult and 
risky procedure, and it is usually very hard or impossi-
ble to fi nd a suitable bone marrow donor. Therefore, the 
long-term goal of our research is to better understand 
the molecular mechanisms governing self-renewal of 
patients’ normal and malignant hematopoietic stem 
and progenitor cells in order to develop novel chemi-
cal approaches for these life-threatening blood diseases 
that bypass the standard complex BMT procedure.
Understanding and Targeting Early 
Erythroid Progenitor Self-Renewal 
as Novel Therapeutic Strategies for a 
Broad Spectrum of Resistant Anemias
Anemia is a global health problem, with more than 
1.6 billion people suffering from this disease. Ane-
mic patients have low numbers of red blood cells and 
hemoglobin, and severe life-threatening cases are as-
sociated with a wide variety of chronic diseases such 
as bone marrow failure disorders, myelodysplastic 
syndrome (MDS), many major types of cancer, and 
cancer chemotherapy/radiotherapy. A large portion 
of these severe anemias are resistant to existing hor-
mone therapies, highlighting the need for novel treat-
ment strategies. We therefore focus our research on 
the highly self-renewing early erythroid progenitor in 
order to harness its expansion and regeneration poten-
tial for the formation of thousands of erythrocytes in 
the treatment of resistant anemias.
To therapeutically use this cell type, we are current-
ly dissecting molecular pathways specifi cally required 
for self-renewal of the early erythroid progenitor, as 
well as identifying druggable proteins that can be ef-
fectively targeted. We have conducted a short hairpin 
RNA (shRNA)-based functional screening, focusing 
on genes that are enriched in early erythroid progeni-
tors. As a complementary approach, we have also per-
formed a small chemical compound-based forward 
genetics screening for chemical compounds that are 
able to boost early erythroid progenitor self-renewal.
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Strikingly, several proteins emerged as positive hits 
in both the shRNA and chemical compound screen-
ing. When these proteins are blocked by either shRNA 
or chemical compound approaches, expansion of pri-
mary early erythroid progenitors is triggered. Impor-
tantly, in a preclinical anemia mouse model, we have 
demonstrated that delivery of these small chemical 
compounds facilitates recovery from anemia by trig-
gering self-renewal of the early erythroid progenitor. 
This physiological effi cacy confi rms these proteins as 
potential bona fi de targets for anemia treatment.
Generation of Blood Disease Mouse Models 
with Combinatorial Genetic Lesions Using 
CRISPR/Cas9 Genome Editing Technology
Blood malignancies are genetically heterogeneous and 
complex diseases, and current mouse models do not 
faithfully recapitulate this heterogeneity and mul-
tiplicity. Therefore, through collaboration with the 
Gene Targeting Facility here at CSHL, we are using 
CRISPR/Cas9 genome editing technology to develop 
novel mouse models of blood diseases.
CRISPR/Cas9 technology allows us to concur-
rently modify multiple genomic loci by introducing 
point mutations and deletions with high effi ciency. 
We have designed single-guide RNA (sgRNA) and 
single-stranded DNA (ssDNA) corresponding to 
genes that are mutated in blood malignancies. To-
gether with the gene targeting facility, we are inject-
ing sgRNA and ssDNA along with Cas9 mRNA di-
rectly into fertilized zygotes. After transferring blas-
tocysts into the uteruses of pseudopregnant females, 
we will obtain and test newborn mice to determine 
whether they carry the targeted mutations. With 
these novel blood disease mouse models, we will be 
able to better evaluate the effi cacies of both existing 
therapies and novel therapies developed in our lab, as 
well as to predict their effi cacies for patients carry-
ing these different combinatorial genetic mutations. 
Additionally, these mouse models will help us better 
understand the pathophysiology of these genetically 
complex diseases.
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Perhaps the most signifi cant event for the Watson School of Biological Sciences (WSBS) in 2014 
was its successful completion of reaccreditation by the New York State Board of Regents and the 
New York State Education Department (NYSED). In consequence, the School is now accredited 
through September 16, 2021.
The reaccreditation process began in earnest in 2013 with the submission of a self-study by the 
school, followed by a site visit by state offi cials, scientists, and educators from institutions across 
New York State. The site visit was held from October 31 to November 1, 2013, after which the re-
view committee submitted a report on the School’s compliance with the Standards to NYSED and 
the Board of Regents. The School’s response, together with the original review committee report, 
was sent to the Board of Regents and Commissioner of Education for evaluation. On September 
16, 2014, the Board of Regents voted, as recommended by the Regents Advisory Council, and 
authorized renewal of the Laboratory’s accreditation for a period of 7 years.
Faculty Changes
Five new faculty members joined the Watson School in 2014: Douglas Fearon, Justin Kinney, 
Je Hyuk (Jay) Lee, Adam Siepel, and Jessica Tollkuhn. Professor Douglas Fearon studies how 
the immune system can be activated to fi ght cancer. His lab uses mouse models of pancreatic 
cancer to understand immune regulation in tumors and to develop therapies that use the im-
mune system to combat disease. He joins the Watson School from his previous position at Cancer 
Research UK and the University of Cambridge. Justin Kinney, an Assistant Professor and former 
Quantitative Biology Fellow, uses next-generation sequencing to understand protein–protein and 
protein–DNA interactions in a quantitative way. He takes a combination of theoretical, computa-
tional, and experimental approaches to dissect open problems in transcriptional regulation, DNA 
replication, and immunology. Assistant Professor Jay Lee develops sophisticated imaging and mo-
lecular sequencing techniques to understand how cancer cells arise and evolve. He is particularly 
interested in how cells interact with their local environment and how signals from the environ-
ment lead to changes in gene expression. Jay comes to the Watson School from his postdoctoral 
tenure in the lab of George Church at Harvard University. Professor Adam Siepel, the Chair of the 
Simons Center for Quantitative Biology, uses approaches from statistics, computer science, and 
evolutionary genetics to understand various complex problems in genetics. His lab is especially 
interested in how genomes change over time and uses this information to inform human health. 
Adam remains a professor of computational biology at Weill Cornell Medical College. Assistant 
Professor Jessica Tollkuhn investigates the regulation of sex-specifi c behaviors. Her group studies 
how transient hormone spikes during development lead to changes in gene expression and chro-
matin that, in turn, change the neural circuits that underlie male- or female-specifi c behaviors. 
Jessica comes to the Watson School from postdoctoral research in the lab of Nirao Shah at the 
University of California, San Francisco. These new faculty members have already participated in 
WSBS activities. Each of them has given a Research Topics talk to the fi rst-year students. They are 
also serving as members of thesis committees and expert qualifying examiners and have lectured 
in WSBS core courses. We look forward to their growing participation as members of the faculty.
Two faculty members also departed the School this year. Scott Lowe was one of the original 
instructors of the Scientifi c Reasoning and Logic Course. He also served on the Executive and 
Qualifying Exam Committees. He was on a number of thesis committees and was the thesis 
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research mentor to seven WSBS students. Scott Powers was also an instructor in the Scientifi c 
Reasoning and Logic Course and served as Chair on three thesis committees. We will miss them 
both and wish them every success in their future endeavors.
The 11th WSBS Graduation
On May 4, 2014, we celebrated the Watson School’s 11th graduation ceremony. Eleven students 
were awarded Ph.D. degrees: Marek Kudla, Hassana Oyibo, Michael Pautler, Yevgeniy Plavskin, 
and Joshua Sanders from the Entering Class of 2007; Philippe Batut, Dario Bressan, Melanie 
Eckersley-Maslin, Katie Liberatore, and Zinaida Perova from the Entering Class of 2008; and 
Kaja Wasik from the Entering Class of 2009. William Donovan from the Entering Class of 2012 
was awarded a master’s degree. An honorary degree was bestowed upon Dr. Richard Burgess, the 
James D. Watson Emeritus Professor of Oncology at the McArdle Laboratory for Cancer Re-
search, University of Wisconsin, Madison. Dick has published more than 250 papers in the fi elds 
of biochemistry and molecular biology and has made important scientifi c discoveries, including 
the identifi cation of the Escherichia coli RNA polymerase specifi city factor, sigma. From 1992 to 
2013, he taught the CSHL Protein Purifi cation Course, making him one of the longest serving 
course instructors in the Laboratory’s history. Additionally, he was part of the team that generated 
the 1996 CSHL Press manual based on the course, Strategies for Protein Purifi cation and Charac-
terization: A Laboratory Course Manual.
As with each graduation, we extended a special welcome to the family members and friends of 
our students who attended the ceremony.
2014 WSBS Graduates: (Left to right) WSBS Dean Alexander Gann, Chancellor Emeritus James Watson, Marek Kudla, Hassana Oyibo, 
CSHL Chairman Jamie Nicholls, CSHL President Bruce Stillman, Melanie Eckersley-Maslin, Dario Bressan, Kaja Wasik, Katie Liberatore, 
Michael Pautler, Philippe Batut, Yevgeniy Plavskin, Joshua Sanders
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Student
Thesis 
advisor
Academic 
mentor
Current 
position
Ozlem (Mert) 
Aksoy
Scott Lowe John Inglis Postdoctoral Fellow, University of California, 
San Francisco (Advisor: William Weiss)
Philippe Batut Thomas Gingeras Zachary Lippman Graduate Student Post, CSHL (Advisor: Thomas 
Gingeras)
Mitchell Bekritsky Michael Wigler W. Richard 
McCombie
Bioinformatic Scientist, Illumina, Inc., Cambridge, 
United Kingdom
Dario Bressan Gregory Hannon Z. Josh Huang Postdoctoral Fellow, University of California, 
San Francisco (Advisor: William Weiss)
Stephane Castel Robert Martienssen Lloyd Trotman Postdoctoral Fellow, New York Genome Center 
(Advisor: Tuuli Lappalainen)
Kristen Delevich Bo Li Stephen Shea Postdoctoral Fellow, Stanford University 
(Advisor: Linda Wilbrecht)
Melanie Eckersley-
Maslin
David Spector Gregory Hannon Postdoctoral Fellow, Cambridge University 
(Advisor: Wolf Reik)
Sang-Geol Koh Anthony Zador Glenn Turner Scientist, Start-up Company, Korea
Katie Liberatore Zachary Lippman Adrian Krainer Postdoctoral Fellow, U.S. Department of 
Agriculture, University of Minnesota (Advisor: 
Shahryar Kianian)
Ian Peikon Anthony Zador Mickey Atwal Scientist, Google X, California
Zinaida Perova Bo Li Linda Van Aelst Postdoctoral Fellow, Cambridge University 
(Advisor: Tiago Branco)
Nilgun Tasdemir Scott Lowe Josh Dubnau Postdoctoral Fellow, University of Pittsburgh 
(Advisor: Nancy Davidson)
Elvin Wagenblast Gregory Hannon Jan Witkowski Graduate Student Post, CSHL (Advisor: Gregory 
Hannon)
Kaja Wasik Gregory Hannon Jan Witkowski Graduate Student Post, CSHL (Advisor: Gregory 
Hannon)
Susann Weissmueller Scott Lowe Raffaella Sordella Equity Research Associate, MLV & Co., Connecticut
Cinthya Zepeda 
Mendoza
David Spector Thomas Gingeras Postdoctoral Fellow, Brigham and Women’s Hospital, 
Harvard Medical School (Advisor: Cynthia 
Morton)
2014 THESIS DISSERTATION DEFENSES
ENTERING CLASS OF 2008
Ozlem (Mert) Aksoy, May 7, 2014
The role of E2F7 in senescence and development.
Thesis Examining Committee
Chair: Lloyd Trotman
Research Mentor: Scott Lowe
Academic Mentor: John Inglis
Committee Member: David Spector
(continued )
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2014 THESIS DISSERTATION DEFENSES (continued)
Committee Member:  Emily Bernstein, Mount Sinai 
 School of Medicine
External Examiner:  Eva Hernando-Monge, 
 New York University
Philippe Batut, January 13, 2014
Promoter evolution in Drosophila: Noncoding transcription 
and transposon-driven innovation.
Thesis Examining Committee
Chair: Gregory Hannon
Research Mentor: Thomas Gingeras
Academic Mentor: Zachary Lippman
Committee Member: Adrian Kraine
Committee Member: Josh Dubnau
External Examiner:  Brenton Gravely, University of 
 Connecticut
Mitchell Bekritsky, June 25, 2014
Detecting de novo microsatellite mutations in a population of 
families with sporadic autism.
Thesis Examining Committee
Chair: Mickey Atwal
Research Mentor: Michael Wigler
Academic Mentor: W. Richard McCombie
Committee Member: Raffaella Sordella
Committee Member: Michael Schatz
External Examiner: Bud Mishra, New York University
Dario Bressan, January 27, 2014
A novel technology for the space-specifi c recovery of biological 
molecules.
Thesis Examining Committee
Chair: Linda Van Aelst
Research Mentor: Gregory Hannon
Academic Mentor: Z. Josh Huang
Committee Member: Anthony Zador
Committee Member: Josh Dubnau
External Examiner:  Robert Darnell, The Rockefeller 
 University
Sang-Geol Koh, June 26, 2014
The role of callosal projections in auditory coding.
Thesis Examining Committee
Chair: Pavel Osten
Research Mentor: Anthony Zador
Academic Mentor: Glenn Turner
Committee Member: Adam Kepecs
Committee Member: Alexei Koulakov
External Examiner:  Richard Mooney, Duke 
 University School of Medicine
Nilgun Tasdemir, May 21, 2014
Investigating the role of Brd4 in cellular senescence and 
normal tissue homeostasis.
Thesis Examining Committee
Chair: Linda Van Aelst
Research Mentor: Scott Lowe
Academic Mentor: Josh Dubnau
Committee Member: Alea Mills
Committee Member: Raffaella Sordella
External Examiner:  Johanna Joyce, Memorial 
 Sloan-Kettering Cancer Center
Elvin Wagenblast, July 23, 2014
A molecular characterization of breast cancer progression, 
including onset, tumor growth, and metastasis.
Thesis Examining Committee
Chair: Marja Timmermans
Research Mentor: Gregory Hannon
Academic Mentor: Jan Witkowski
Committee Member: Mikala Egeblad
External Examiner:  Charles Sawyers, Memorial 
 Sloan-Kettering Cancer Center
Susann Weissmueller, May 5, 2014
Molecular mechanisms and therapeutic implications of 
chromosome 17p alterations.
Thesis Examining Committee
Chair: David Tuveson
Research Mentor: Scott Lowe
Academic Mentor: Gregory Hannon
Committee Member: Linda Van Aelst
Committee Member: Christopher Vakoc
External Examiner:  Carol Prives, Columbia 
 University
ENTERING CLASS OF 2009
Stephane Castel, June 19, 2014
Transcriptional regulation in the context of DNA replication 
by RNA interference in fi ssion yeast.
Thesis Examining Committee
Chair: James Hicks
Research Mentor: Robert Martienssen
Academic Mentor: Lloyd Trotman
Committee Member:  Matthew O’Connell, Mount 
 Sinai School of Medicine
External Examiner:  Benoit Arcangioli, Institut 
 Pasteur
Kristen Delevich, July 29, 2014
Synaptic effects of Disrupted-in-Schizophrenia 1 loss-of-
function in the medial prefrontal cortex and thalamofrontal 
feedforward inhibitory circuit.
Thesis Examining Committee
Chair: Z. Josh Huang
Research Mentor: Bo Li
(continued )
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Academic Mentor: Stephen Shea
Committee Member: Anthony Zador
External Examiner: Barry Connors, Brown University
Wee Siong Goh, August 29, 2014
Biogenesis and Function of piRNAs.
Thesis Examining Committee
Chair: Marja Timmermans
Research Mentor: Gregory Hannon
Academic Mentor: Hiro Furukawa
Committee Member: Christopher Hammell
Committee Member: Adrian Krainer
External Examiner:  Victor Ambros, University of 
  Massachusetts Medical School
Ian Peikon, September 26, 2014
Encoding of neural circuit information into DNA.
Thesis Examining Committee
Chair: Josh Dubnau
Research Mentor: Anthony Zador
Academic Mentor: Mickey Atwal
Committee Member: Bruce Stillman
External Examiner:  Cori Bargmann, The Rockefeller 
 University
Kaja Wasik, March 21, 2014
Unusual aspects of piRNA pathways in mice and 
fl atworms.
Thesis Examining Committee
Chair: Zachary Lippman
Research Mentor: Gregory Hannon
Academic Mentor: Jan Witkowski
Committee Member: Christopher Hammell
External Examiner:  Ruth Lehmann, New York 
 University
Cinthya Zepeda Mendoza, September 24, 2014
Impact of copy-number variation on chromatin interactions 
at the mouse 4E2 chromosome region.
Thesis Examining Committee
Chair: Robert Martienssen
Research Mentor: David Spector
Academic Mentor: Thomas Gingeras
Committee Member: Alea Mills
Committee Member:  Thomas Reid, National 
 Institutes of Health
External Examiner:  James Lupski, Baylor College of 
 Medicine
Teaching Award
At the graduation ceremony this year, WSBS Associate 
Professor Zachary Lippman was presented with the 
ninth annual Winship Herr Faculty Teaching Award, 
named in honor of the School’s founding Dean. Zach 
is the instructor of the Specialized Disciplines Course in 
Genetics and Genomics and was chosen by the students 
for this award, based on his enthusiasm and creativity 
in teaching. In addition to receiving this honor, Zach, 
who earned his Ph.D. degree from the Watson School in 
2005, graduated his fi rst student during this ceremony—
that is, the School’s fi rst second-generation student. Here 
is some of what the students said about Zach’s teaching 
in their nominations:
“Zach was one of the instructors who really managed to 
infect everyone with his enthusiasm about the subject. His 
preparation for the lectures was excellent—minimizing confusion and being able to explain im-
portant and complex concepts in an understandable manner. Moreover, he was  dedicated to the 
course, available for feedback and questions at any time, and succeeded in understanding every-
one’s needs and adapting his teaching to them.”
 “The critical and analytical thinking skills I learned from Zach will carry over into any area of 
research in which I fi nd myself in the future.”
Zachary Lippman
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DOCTORAL THESIS RESEARCH
Student Academic mentor Research mentor Thesis research
ENTERING CLASS OF 2009
Silvia Fenoglio
Elisabeth Sloan Livingston Fellow 
Linda Van Aelst Gregory Hannon RNAi screening to identify putative therapeutic 
targets for the treatment of pancreatic cancer.
ENTERING CLASS OF 2010
Arkarup Bandyopadhyay
Goldberg Lindsay Fellow
Zachary Lippman Florin Albeanu Identity and intensity encoding of odors in 
rodents.
Colleen Carlston
John and Amy Phelan Student
National Science Foundation Fellow 
Hiro Furukawa Christopher 
Hammell
Identifi cation and characterization of noise-
suppressor genes that act via microRNAs in 
Caenorhabditis elegans larval development.
Matthew Koh
George A and Marjorie Anderson 
Fellow
Bo Li Florin Albeanu Roles of olfactory bulb inhibitory microcircuits in 
shaping the temporal response properties of mitral 
cells.
Lisa Krug
NIH Predoctoral Trainee 
Stephen Shea Josh Dubnau Mechanisms of transposon regulation in the 
central nervous system.
Jack Walleshauser
Barbara McClintock/NIH 
Predoctoral Trainee
Christopher 
Hammell
Leemor Joshua-Tor Structural basis for TUT4 uridylation of 
pre-let-7/lin28 complex.
ENTERING CLASS OF 2011
Robert Aboukhalil
NIH Predoctoral Trainee
Starr Centennial Scholar
Josh Dubnau Mickey Atwal
Michael Wigler
Using single-cell RNA-Seq to investigate tumor 
heterogeneity and evolution.
Brittany Cazakoff
Edward and Martha Gerry Fellow
NSERC Scholar
Christopher 
Hammell
Stephen Shea Dynamic granule cell processing of odor 
information.
Joaquina Delas Vives
La Caixa Fellow
Boehringer Ingelheim Fonds Fellow
Nicholas Tonks Gregory Hannon Functional role of long non-coding RNAs in 
hematopoiesis.
Anja Hohmann
David H. Koch Fellow
Boehringer Ingelheim Fonds Fellow
John Inglis Christopher Vakoc Exploring the role of bromodomain-containing 
protein 9 (Brd9) in the maintenance of acute 
myeloid leukemia.
Justus Kebschull
David and Fanny Luke Fellow
Genentech Foundation Fellow
Boehringer Ingelheim Fonds Fellow
Marja Timmermans Anthony Zador Grasping the brain.
Fred Marbach
Farish-Gerry Fellow
Josh Dubnau Anthony Zador A study of auditory corticostriatal cells in the 
behaving mouse.
Onyekachi Odoemene
NIH Individual Fellowship
William Randolph Hearst Scholar 
Stephen Shea Anne Churchland The role of neural inhibition in perceptual 
decision-making.
Sophie Thomain
George A. and Marjorie H. Anderson 
Fellow
Josh Dubnau Zachary Lippman Characterization of a new meristem maintenance 
pathway in tomato and Arabidopsis thaliana and its 
relation to pollen tube growth.
Charles Underwood
William R. Miller Fellow 
Michael Schatz Robert 
Martienssen
Epigenetic inheritance through mitosis and meiosis 
in Arabidopsis thaliana.
ENTERING CLASS OF 2012
Talitha Forcier
NIH Predoctoral Trainee
William Randolph Hearst Scholar
Nicholas Tonks Michael Wigler Determining the change of transcriptional events 
from single-cell RNA analysis.
Tyler Garvin
NIH Predoctoral Trainee
Zachary Lippman Michael Schatz Structural variants and gene networks underlying 
complex human disease.
(continued )
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DOCTORAL THESIS RESEARCH (continued)
Student Academic mentor Research mentor Thesis research
Yu-Jui (Ray) Ho
David and Fanny Luke Fellow
Michael Schatz Molly Hammell Methods development for low-input RNA-
Seq analysis and application to breast cancer 
heterogeneity.
Paul Masset
Florence Gould Fellow
Jan A. Witkowski Adam Kepecs Representations of decision confi dence in the 
brain: From Bayes’ rule to channelrhodospin.
Annabel Romero Hernandez
Genentech Foundation Fellow
Adrian R. Krainer Hiro Furukawa Molecular mechanisms of inhibition in NMDA 
receptors.
Abram Santana
Robert and Theresa Lindsay Fellow
William Randolph Hearst Scholar
Lloyd Trotman David Tuveson Pancreatic tumor biology and therapy.
ENTERING CLASS OF 2013
Giorgia Battistoni
Starr Centennial Scholar
Christopher 
Hammell
Gregory Hannon One-carbon metabolism and DNA methylome 
dynamics in pancreatic cancer.
Lital Charatifsky
Israeli WSBS Fellow
John Inglis Anne Churchland Neural circuits for multisensory integration in 
normal and disease states.
Sanchari Ghosh
Charles A. Dana Fellow
Josh Dubnau Anthony Zador Role of corticostriatal plasticity in learning an 
auditory discrimination task.
Michael Gutbrod
Bristol-Myers Squibb Fellow
Zachary Lippman Robert 
Martienssen
Small RNA and the RNAi pathway in transposable 
element regulation and differentiation in the 
preimplantation embryo.
Daniel Kepple
Crick-Clay Fellow
NIH Predoctoral Trainee
David Stewart Alexei Koulakov The human olfactory space.
Laura Maiorino
George A and Marjorie Anderson 
Fellow 
Nicholas Tonks Mikala Egeblad Understanding the role of the epithelial–
mesenchymal plasticity in pancreatic cancer 
metastasis.
Maria Nattestad
John and Amy Phelan Student 
Linda Van Aelst Michael Schatz Algorithms for analyzing and assembling complex 
genomes.
Georgi Yordanov
Leslie C. Quick, Jr. Fellow
Leemor Joshua-Tor David Tuveson Role of c-Myc in pancreatic cancer.
Admissions 2014
The Watson School received 276 applications for the Entering Class of 2014 and is indebted to 
its  Admissions Committee, which reviewed, interviewed, and selected candidates for our doctoral 
 program. The Admissions Committee for the 2014 entering class comprised Adrian Krainer (chair), 
Mickey Atwal, Anne Churchland, Zachary Lippman, W. Richard McCombie, Stephen Shea, Nicho-
las Tonks, Christopher Vakoc, Linda Van Aelst, and myself.
Entering Class of 2014
On August 18, 2014, the WSBS welcomed the 16th incoming class. The eight students—Emilis Bruzas, 
Hamza Giaffar, Jacqueline Giovanniello, Devinn Lambert, Sashank Pisupati, Colin Stoneking, Jue 
Xiang Wang, and Anqi Zhang—hail from the United States, Canada, Germany, India, Lithuania, and 
the United Kingdom.
Academic Mentoring
The Watson School takes great pride in the level of mentoring that it offers its students. 
One example is our two-tiered mentoring approach, whereby each student chooses both an 
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ENTERING CLASS OF 2014
Emilis Bruzas, University of Cambridge: B.A. in Biochemistry 
(2014); Natural Sciences Tripos Pt IB College Scholarship 
(Thomas Hobbes 1631) (2012, 2013); Hardy Award for 
Biological Science (2013)
Academic Mentor: Alea Mills
Hamza Giaffar, Imperial College London: M.Sci. in Chemistry 
(2012), Associate of the Royal College of Science (ARCS)
Academic Mentor: Jan Witkowski
Jacqueline Giovanniello, Brown University: B.S. in Human Biology 
(2012); Distinction of Honors in the Department of Biology 
(2012); Dean’s Discretionary Grant for Undergraduate Research 
(2010–2012); Cardiovascular Research Center Grant (2010–2012)
Academic Mentor: Bruce Stillman
Elizabeth Hutton, Princeton University: B.S. in Molecular Biology 
(2014); Quantitative and Computational Biology Certifi cate 
(2014); Offi ce of the Dean, College Senior Thesis Funding 
Award (2013); Princeton University German Summer Work 
Program Award (2012)
Academic Mentor: Molly Hammell
Devinn Lambert, Rutgers University: B.S. in Biotechnology (2013); 
M.Phil. Plant Sciences, University of Cambridge (2014); Gates 
Foundation Fellowship (2014); National Science Foundation 
Graduate Research Fellowship Program (2013); Marshall Finalist 
(2012); Goldwater Scholar (2012); Singapore International 
PreGraduate Award (2011); National Science Foundation 
Biotechnology Scholar (2009–2013); Cap & Skull Senior Honors 
Society (2012); Dunbar Fund for Excellence Grant (2011); 
Award for Academic Excellence, Rutgers VP of Undergraduate 
Education (2011); Rutgers Aresty Research Fellow (2010)
Academic Mentor: David Stewart
Sashank Pisupati, Indian Institute of Technology, Kanpur: B.Tech. 
in Biological Sciences and Bioengineering (2014); Baljit and 
Nirmal Dhindsa UG Scholarship (Fall 2010, 2011); KVPY 
Fellowship (2009); Runner up in “Mimamsa 2012,” a national 
intercollegiate science challenge (2012); Second in Robocamp, 
a Robotics Workshop held by IIIT Hyderabad (2011)
Academic Mentor: Stephen Shea
Colin Stoneking, University of Cambridge: B.A. in Neuroscience 
(2012); M.S. in Statistics, ETH Zurich (2014); The 
Undergraduate Prize for Physiology, The Physiological Society 
(2012); Robert Dobson Memorial Prize, Emmanuel College, 
Cambridge (2010)
Academic Mentor: Zachary Lippman
Jue Xiang Wang, University of Cambridge: B.A./M.Sci. in Natural 
Sciences/Biochemistry (2013); First Class Grade (2013)
Academic Mentor: Mikala Egeblad
Anqi Zhang, McGill University: B.Sci. in Neuroscience, with a 
minor in Mathematics (2014); NSERC Undergraduate Student 
Research Award, University of Waterloo (Summer 2013); 
McGill RE Powell Scholarship (2010–2013); Dean’s Honour 
List (2011)
Academic Mentor: Michael Schatz
2014 WSBS Entering Class: (Left to right) Sashank Pisupati, Anqi Zhang, Elizabeth Hutton, Emilis Bruzas, Jue Xiang Wang, Hamza Giaffar, 
Devinn Lambert, Jacqueline Giovanniello, Colin Stoneking
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academic and a research mentor. The academic mentor is critical for monitoring students—
and offering advice—during the intensive coursework of the fi rst term, during their rotations, 
and when identifying a suitable research mentor. Furthermore, the academic mentor contin-
ues to follow them throughout their doctoral experience, often serving as important advocates 
for the students. Entering students select, by mutual agreement, a member of the research or 
nonresearch faculty to serve as an academic mentor. This program continues to receive much 
support from the faculty who volunteer to be academic mentors, and it has rightfully become 
a vital ingredient in our success. The following are the Academic Mentors for the Entering 
Class of 2014.
STUDENT MENTOR STUDENT MENTOR
Emilis Bruzas Alea Mills Sashank Pisupati Stephen Shea
Hamza Giaffar Jan Witkowski Colin Stoneking Zachary Lippman
Jacqueline Giovanniello Bruce Stillman Jue Xiang Wang Mikala Egeblad
Elizabeth Hutton Molly Hammell Anqi Zhang Michael Schatz
Devinn Lambert David Stewart Emilis Bruzas Alea Mills
The Fall Term Curriculum
Our faculty continues to do an outstanding job developing and delivering the curriculum, and 
we are extremely grateful for the time and effort they spend on maintaining the high quality of 
the courses. The Curriculum Development and Integration Committee (CDIC)—Carrie Cowan 
(chair), David Jackson, Michael Schatz, Nicholas Tonks, and Glenn Turner—oversees develop-
ment of the curriculum. In addition to the course instructors and guest lecturers from within the 
Laboratory, our courses attract an impressive array of guest lecturers from other institutions.
Recruiting Efforts
This year, we once again focused primarily on targeted visits to graduate fairs and minority con-
ferences to identify prospective students for the Watson School. In addition to these visits, the 
WSBS generated new mailing lists for the distribution of information to top undergraduate sci-
ence departments around the world. A multiprogram booklet was designed for this recruitment 
season. Additionally, emails were sent to personalized contacts and an electronic mailing list of 
more than 50,000 individuals who receive information from the Cold Spring Harbor Labora-
tory Press or have attended CSHL Meetings and Courses or Banbury meetings. We are grateful 
to these departments for sharing this contact list. The targeting efforts appear to be successful 
in that the number of applications received—310—for the Entering Class of 2015 is the largest 
number to date.
WATSON SCHOOL OF BIOLOGICAL SCIENCES 2014 RECRUITMENT SCHEDULE
Event Location Date
Rutgers University STEPed UP for Success Program, Visit and Information Session Cold Spring Harbor Laboratory April 4
American Association of Cancer Research, Annual Meeting San Diego, California April 5–9
Molloy College, Visit and Information Session Cold Spring Harbor Laboratory April 25
Vassar College, Visit and Information Session Cold Spring Harbor Laboratory May 2
UMDNJ–NJ Medical School, PHRI, Visit and Information Session Cold Spring Harbor Laboratory August 1
Brookhaven National Laboratory, Graduate School Fair and Undergraduate 
Research Program Symposium
Brookhaven, New York August 6
(continued )
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WATSON SCHOOL OF BIOLOGICAL SCIENCES 2014 RECRUITMENT SCHEDULE (continued)
Event Location Date
Big 10+ Graduate School Expo (Purdue University), Graduate School Fair West Lafayette, Indiana September 21–22
University of Maryland, Baltimore County, Meyerhoff Scholars Program, 
Information Session
Baltimore, Maryland October 1
Johns Hopkins University Information Session Baltimore, Maryland October 1
Hunter College MARC and RISE/MBRS, Information Session New York, New York October 7
University of Cambridge, Information Session Cambridge, England October 16
University of Southern California, Information Session Los Angeles, California October 16
Society for Advancement of Chicanos and Native Americans in Science 
(SACNAS), National Conference
Los Angeles, California October 16–18
American Society for Human Genetics, Annual Meeting San Diego, California October 18–22
Columbia University, Information Session New York, New York October 20
Stanford University, Graduate School Fair Stanford, California October 21
University of California, Berkeley, Information Session Berkeley, California October 22
Harvard University, Information Sessions Cambridge, Massachusetts November 6
California Forum for Diversity in Graduate Education, Graduate School Fair San Diego, California November 8
Annual Biomedical Research Conference for Minority Students (ABRCMS), 
National Conference
San Antonio, Texas November 12–15
Society for Neuroscience Annual Meeting, Graduate School Fair Washington, D.C. November 15–19
American Society for Cell Biology, Annual Meeting Philadelphia, Pennsylvania December 6–10
Interinstitutional Academic Interactions
WSBS students account for approximately half of the total graduate student population here at 
CSHL. The other half comprise visiting graduate students from other universities who have decid-
ed to conduct some or all of their thesis research in CSHL faculty members’ laboratories. A large 
fraction of students are from Stony Brook University (SBU), via a program established between 
CSHL and SBU more than 30 years ago. Over the years, we have established relationships with 
other institutions around the world, enabling their students to conduct research here at CSHL. 
Currently, we have visiting students from institutions in France, India, Portugal, and the United 
States. The Watson School provides a contact person for the students and maintains relationships 
with the administrators from their home institutions. These students are fully integrated into the 
CSHL community and receive all the necessary assistance as they navigate the complexities of 
performing doctoral research away from their home institutions. The following students joined us 
from SBU this year.
STUDENT CSHL RESEARCH MENTOR STONY BROOK UNIVERSITY PROGRAM
Derek Cheng David Tuveson Molecular Genetics and Microbiology
Hsiang-Chen Chou Bruce Stillman Molecular and Cellular Biology
Han Fang Michael Schatz Applied Mathematics and Statistics
Shanshan Li James Hicks Applied Mathematics and Statistics
Jason O’Rawe Gholson Lyon Molecular Genetics and Microbiology
Dongyan Song Nicholas Tonks Molecular and Cellular Biology
Allen Yu David Spector Molecular Genetics and Microbiology
Graduate Student Symposium
Each year, the students participate in two Graduate Student Symposia held at the Laboratory’s 
Genome Research Center in Woodbury: one in May, the other in October. Each Symposium 
Dean’s Report  263
consists of senior students giving short talks. Coffee breaks and lunch provide opportunities for 
more informal interactions. The prize for best talk for the May session was awarded to WSBS stu-
dent Brittany Cazakoff (Shea lab), and for the October session, it was shared by Annabel Romero 
Hernandez (WSBS, Furukawa lab) and Bobby Wysocki (SBU, Egeblad lab). We are grateful to 
the two student chairs, Debjani Pal (SBU) and Arkarup Bandyopadhyay (WSBS), for their hard 
work and to WSBS’s Kim Geer for helping make the Symposium a great success.
Graduate Student and Postdoctoral Fellow Departures
With each year come not only new arrivals, but also departures. The following graduate students 
and postdoctoral fellows left the Laboratory during 2014:
Postdoctoral Fellows
Christine Ardito Balazs Hangya Haohong Li Roberto Perales
Huyen Bui Miao He Jinyu Li Lisa Prazak
Alexander Campbell Michael Huebner Li Li Jonathan Preall
Marcela Dotto Ke Jiang Cora MacAlister Andrea Schorn
Cheryl Eifert Shimpei Kawaoka Shoshana Marcus Naoki Takada
Andrea Eveland Sukant Khurana Adaobi Mofunanya Yi Wei
Pascal Grange Claus-Dieter Kuhn Amit Mukherjee Huiqing Zhan
Baofeng Guo Duda Kvitsiani June Hee Park Ling Zhang
Graduate Students
Ozlem (Mert) Aksoy Stephane Castel Katie Liberatore John Sheppard
Deanna Bahel Hyejin Cho Felix Muerdter Guoli Sun
Taimour Balan Shipra Das Hassana Oyibo Nilgun Tasdemir
Mitchell Bekritsky William Donovan Zinaida Perova Assaf Vestin
Fatma Bezirci Melanie Eckersley-Maslin Yevgeniy Plavskin Susann Weissmueller
Megan Bodnar Paloma Guzzardo Huan Qi Chunsu Xu
Dario Bressan Nihan Kara Joshua Sanders
Executive Committee
The School’s Executive Committee, in its monthly meetings, provides year-round direction for the 
School and its students through its invaluable policy recommendations. I wish to thank faculty 
members Mickey Atwal, Mikala Egeblad, Adrian Krainer, Bo Li, David Spector, David Stewart, 
and Linda Van Aelst. I would also like to thank the student representatives Debjani Pal (SBU) and 
Brittany Cazakoff (WSBS), who contributed to discussions and provided useful suggestions and 
feedback from their colleagues.
The Watson School Continues to Beneﬁ t from Generous Benefactors
We are extremely grateful for the generous donors whose one-time gifts or continued support 
made our 2014 programs possible, including the Annenberg Foundation, Lita Annenberg Hazen 
Foundation, Bristol-Myers Squibb Company, Mr. and Mrs. Landon Clay, Lester Crown, the 
Dana Foundation, Henriette and Norris Darrell, the Samuel Freeman Charitable Trust, the Wil-
liam Stamps Farish Fund, the Genentech Foundation, Mr. and Mrs. Alan Goldberg, Florence 
Gould Foundation, Gonzalo Río Arronte Foundation, William Randolph Hearst Foundation, 
Dr. and Mrs. Mark Hoffman, Annette Kade Charitable Trust, Mr. David H. Koch, Mr. and 
Mrs. Robert D. Lindsay and Family, Mr. and Mrs. David Luke III, Marjorie A. Matheson, Mr. 
and Mrs. William R. Miller, OSI Pharmaceuticals Foundation, Estate of Edward L. Palmer, 
Mr. and Mrs. John C. Phelan, the Quick Family, Estate of Elisabeth Sloan Livingston, the Starr 
Foundation, the Roy J. Zuckerberg Family Foundation, and anonymous donors.
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We are also continuously grateful for our endowed lectureships: the John P. and Rita M. Cleary 
Visiting Lectureship, the George W. Cutting Lectureship, the William Stamps Farish Lecture-
ship, the Martha F. Gerry Visiting Lectureship, the Edward H. Gerry Visiting Lectureship, the 
Edward H. and Martha F. Gerry Lectureship, the Susan T. and Charles E. Harris Visiting Lec-
tureship, the Klingenstein Lectureship, the Mary D. Lindsay Lectureship, the Pfi zer Lectureship, 
the George B. Rathmann Lectureship, the Seraph Foundation Visiting Lectureship, and the Sigi 
Ziering Lectureship.
We are also very fortunate to hold a prestigious National Research Service Award Predoctoral 
Training Grant from the National Institutes of Health, National Institute of General Medical 
Sciences.
Student and Alumni Achievements
To date, 81 students have received their Ph.D. degrees from the WSBS. Nineteen graduates 
currently hold tenure-track faculty positions. In 2014, Monica Dus took an assistant professor 
position at the University of Michigan, Yaniv Erlich joined the New York Genome Center and 
Columbia University as an assistant professor, and Ira Hall moved to Washington University, 
St. Louis, as an associate professor. Our graduates have also moved into infl uential positions 
in administration, publishing, consulting, and industry. In 2014, Mitchell Bekritsky joined 
Illumina as a Bioinformatic Scientist, Rebecca Bish joined D.E. Shaw Research as a Senior Sci-
entifi c Editor, Paloma Guzzardo took a scientist position at Haplogen, Fred Rollins joined LEK 
Consulting as a consultant, and Susann Weissmueller became an Equity Research Associate at 
MLV & Co.
The WSBS students continue to impress us with their accomplishments. They publish their re-
search fi ndings in prestigious international journals—more than 300 papers to date—and obtain 
fellowships to pursue their research interests.
In 2014, our current students and alumni were successful in receiving the following prestigious 
awards and fellowships:
• WSBS student Yu-Jui (Ray) Ho was awarded a Cutting-Edge Talent and Training Scholarship 
from the Ministry of Education of Taiwan.
• WSBS student Onyekachi Odoemene was awarded a Ruth L. Kirschstein National Research 
Service Award Individual Fellowship.
• WSBS graduate Shraddha Pai received a Canadian Institutes of Health Research Postdoctoral 
Fellowship.
• WSBS graduate Niraj Tolia received a Burroughs Wellcome Fund Investigators in the Patho-
genesis of Infectious Disease Award.
• WSBS graduate Michelle Cilia received a Herbert L. Rothbart Outstanding Early Career 
Research Scientist Award.
• WSBS graduate Ira Hall was promoted to Associate Professor.
Prizes for the best posters by a postdoctoral fellow and by a graduate student were awarded at 
the Laboratory’s annual In-House Symposium held in November 2014. The poster session pro-
vides a forum for the postdoctoral fellows and students to show off their research and gives the 
entire scientifi c community a chance to come together and share ideas beyond the walls of their 
individual laboratories. This year, Jack Walleshauser, a Watson School student from Leemor Josh-
ua-Tor’s laboratory, won the graduate student prize. The postdoctoral prize was shared between 
Keerthi Krishnan from Josh Huang’s laboratory and Billy Lau from Stephen Shea’s laboratory, for 
their collaborative project.
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2014 WSBS STUDENT (CURRENT OR PREVIOUS) PUBLICATIONS
Bolden JE, Tasdemir N, Dow LE, van Es JH, Wilkinson JE, Zhao Z, Clevers H, Lowe SW. 2014. Inducible in vivo 
silencing of Brd4 identifi es potential toxicities of sustained BET protein inhibition. Cell Rep 8: 1919–1929.
Bots M, Verbrugge I, Martin BP, Salmon JM, Ghisi M, Baker A, Stanley K, Shortt J, Ossenkoppele GJ, Zuber J, 
Rappaport AR, Atadja P, Lowe, SW, Johnstone RW. 2014. Differentiation therapy for the treatment of t(8;21) acute 
myeloid leukemia using histone deacetylase inhibitors. Blood 123: 1341–1352.
Castel SE, Ren J, Bhattacharjee S, Chang AY, Sánchez M, Valbuena A, Antequera F, Martienssen RA. 2014. Dicer 
promotes transcription termination at sites of replication stress to maintain genome stability. Cell 159: 572–583.
Chen C, Liu Y, Rappaport AR, Kitzing T, Schultz N, Zhao Z, Shroff AS, Dickins RA, Vakoc CR, Bradner JE, Stock 
W, Lebeau MM, Shannon KM, Kogan S, Zuber J, Lowe SW. 2014. MLL3 is a haploinsuffi cient 7q tumor suppressor 
in acute myeloid leukemia. Cancer Cell 25: 652–665.
Cazakoff BN, Lau BYB, Crump KL, Demmer HS, Shea SD. 2014. Broadly tuned and respiration-independent 
inhibition in the olfactory bulb of awake mice. Nat Neurosci 17: 569–576.
Cressy M, Valente D, Altick A, Kockenmesiter E, Honegger K, Qin H, Mitra PP, Dubnau J. 2014. Laboratory evolution 
of adenylyl cyclase independent learning in Drosophila and missing heritability. Genes Brain Behav 13: 565–577.
Dow LE, Nasr Z, Saborowski M, Ebbesen SH, Manchado E, Tasdemir N, Lee T, Pelletier J, Lowe SW. 2014. 
Conditional reverse Tet-transactivator mouse strains for the effi cient induction of TRE-regulated transgenes in mice. 
PLoS ONE 9: e95236.
Eckersley-Maslin MA, Thybert D, Bergmann JH, Marioni JC, Flicek,P, Spector DL. 2014. Random monoallelic gene 
expression increases upon embryonic stem cell differentiation. Dev Cell 4: 351–365.
Eckersley-Maslin MA, Spector DL. 2014. Random monoallelic expression: Regulating gene expression one allele at a 
time. Trends Genet 30: 237–244. Review
Faehnle CR*, Walleshauser J*, Joshua-Tor L. 2014. Mechanism of Dis3l2 substrate recognition in the Lin28-let-7 
pathway. Nature 514: 252–256.
Goh WS, Seah JW, Harrison EJ, Chen C, Hammell CM, Hannon GJ. 2014. A genome-wide RNAi screen identifi es 
factors required for distinct stages of C. elegans piRNA biogenesis. Genes Dev 28: 797–807.
Ganapathy G, Howard JT, Ward JM, Li J, Li B, Li Y, Xiong Y, Zhang Y, Zhou S, Schwartz DC, Schatz M, Aboukhalil 
R, Fedrigo O, Bukovnik L, Wang T, Wray G, Rasolonjatovo I, Winer R, Knight JR, Koren S, Warren WC, Zhang 
G, Phillippy AM, Jarvis ED. 2014. High-coverage sequencing and annotated assemblies of the budgerigar genome. 
Gigascience 3: 11.
Gerstein MB, Rozowsky J, Yan KK, Wang D, Cheng C, Brown JB, Davis CA, Hillier L, Sisu C, Li JJ, . . ., Schlesinger 
F, et al. 2014. Comparative analysis of the transcriptome across distant species. Nature 512: 445 –448.
Hohmann AF, Vakoc CR 2014. A rationale to target the SWI/SNF complex for cancer therapy. Trends Genet 30: 
356–363. Review.
Jacob Y, Bergamin E, Donoghue MT, Mongeon V, LeBlanc C, Voigt P, Underwood CJ, Brunzelle JS, Michaels 
SD, Reinberg D, Couture J-F, Martienssen RA. 2014. Selective methylation of histone H3 variant H3.1 regulates 
heterochromatin replication. Science 343: 1249–1253.
Knott SR, Maceli AR, Erard N, Chang K, Marran K, Zhou X, Gordon A, El Demerdash O, Wagenblast E, Kim S, 
Fellmann C, Hannon GJ. 2014. A computational algorithm to predict shRNA potency. Mol Cell 56: 796–807.
Meikar O, Vagin VV, Chalmel F, Sõstar K, Lardenois A, Hammell M, Jin Y, Da Ros M, Wasik KA, Toppari J, . . ., 
Scuoppo C, et al. 2014. PTEN action in leukaemia dictated by the tissue microenvironment. Nature 509: 402–406.
Odoemene O, Churchland AK. 2014. Listening for the right sounds. Neuron 82: 944–945. Review.
Oyibo HK, Znamenskiy P, Oviedo HV, Enquist LW, Zador AM. 2014. Long-term cre-mediated retrograde ragging of 
neurons using a novel recombinant pseudorabies virus. Front Neuroanat 8: 86.
Peikon ID, Gizatullina DI, Zador AM. 2014. In vivo generation of DNA sequence diversity for cellular barcoding. 
Nucleic Acids Res 42: e127.
Rudalska R, Dauch D, Longerich T, McJunkin K, Wuestefeld T, Kang TW, Hohmeyer Rechavi O, Houri-Ze’evi L, Anava 
S, Goh WS, et al. 2014. Starvation-induced transgenerational inheritance of small RNAs in C. elegans. Cell 158: 277–287.
Sanders JI, Kepecs A. 2014. A low-cost programmable pulse generator for physiology and behavior. Front Neuroeng 7: 43.
Sun J, Ramos A, Chapman B, Johnnidis JB, Le L, Ho YJ, Klein A, Hofmann O, Camargo FD. 2014. Clonal dynamics 
of native haematopoiesis. Nature 514: 322–327.
Tschaharganeh DF, Xue W, Calvisi DF, Evert M, Michurina TV, Dow LE, Banito A, Katz SF, Kastenhuber ER, 
Weissmueller S, et al. 2014. p53-Dependent nestin regulation links tumor suppression to cellular plasticity in liver 
cancer. Cell 158: 579–592.
Wang M, Perova Z, Arenkiel BR, Li B. 2014. Synaptic modifi cations in the medial prefrontal cortex in susceptibility 
and resilience to stress. J Neurosci 34: 7485–7492.
Weissmueller S*, Manchado E*, Saborowski M, Morris JP 4th, Wagenblast E, Davis CA, Moon SH, Pfi ster NT, 
Tschaharganeh DF, Kitzing T, et al. 2014. Mutant p53 drives pancreatic cancer metastasis through cell-autonomous 
PDGF receptor β signaling. Cell 157: 382–394.
* Authors contributed equally to the work.
Watson School student is designated in boldface.
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WSBS GRADUATES IN FACULTY AND SENIOR POSITIONS
Name Current position
Rebecca Bish Senior Scientifi c Editor, D.E. Shaw Research
François Bolduc Assistant Professor, University of Alberta, Canada
Darren Burgess Associate Editor, Nature Reviews Cancer and Nature Reviews Genetics, United Kingdom
Amy Caudy Assistant Professor, University of Toronto, Canada
Daniel Chitwood Assistant Professor, Donald Danforth Plant Science Center, St. Louis
Michelle Cilia Research Molecular Biologist, U.S. Department of Agriculture, The Boyce Thompson 
Institute; Adjunct Assistant Professor, Cornell University
Catherine (Cormier) Seiler Scientifi c Liaison, Arizona State University
Monica Dus Assistant Professor, University of Michigan
Yaniv Erlich Assistant Professor, N.Y. Genome Center, Columbia University
Rebecca Ewald Manager, Business Development, Ventana Medical Systems
Elena Ezhkova Assistant Professor, Mount Sinai School of Medicine
Patrick Finigan Associate II, Regulatory Affairs CMC, Genzyme
Ira Hall Associate Professor, Washington University School of Medicine, St. Louis
Christopher Harvey Assistant Professor, Harvard University
Tomáš Hromádka Assistant Professor, Slovak Academy of Sciences
Keisha John Director of Diversity Programs, Offi ce of Graduate and Postdoctoral Affairs at University 
of Virginia
Zachary Lippman Associate Professor, Cold Spring Harbor Laboratory
Marco Mangone Assistant Professor, Arizona State University
Masafumi Muratani Associate Professor, University of Tsukuba, Japan
Elizabeth Murchison Reader, Cambridge University; Fellow, Kings College, United Kingdom
Patrick Paddison Assistant Member, Fred Hutchinson Cancer Research Center
Emiliano Rial-Verde Associate Principal, McKinsey & Co., Inc., Geneva, Switzerland
Frederick Rollins Consultant, LEK Consulting, Boston, Massachusetts
Ji-Joon Song Associate Professor, Korea Advanced Institute of Science and Technology (KAIST), South 
Korea
Niraj Tolia Assistant Professor, School of Medicine, Washington University, St. Louis
Wei Wei Assistant Professor, University of Chicago
Susann Weissmueller Equity Research Associate, MLV & Co., Connecticut
Jeremy Wilusz Assistant Professor, University of Pennsylvania
Alexander Gann
WSBS Professor and Dean
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SPRING CURRICULUM
Topics in Biology
ARRANGED BY Alyson Kass-Eisler and Jan A. Witkowski
Each year, invited instructors offer 7-day courses at the Banbury Conference Center to explore 
specialized topics outside the expertise of the Cold Spring Harbor Laboratory faculty. These 
courses include morning and evening lectures, as well as afternoon sessions during which students 
read assigned papers or work on problem sets and presentations. In Spring 2014 there were two 
such courses: Immunology and Microbial Pathogenesis.
Immunology
April 27–May 3 Attended by the entering classes of 2011 and 2012
INSTRUCTOR Hidde Ploegh, Whitehead Institute
VISITING LECTURERS Yasmine Belkaid, National Institutes of Health
TEACHING FELLOWS Vinidhra Mani, Harvard University
 Marisella Panduro Sicheva, Harvard University
 Matthew Woodruff, Harvard University
(Left to right; seated) Kachi Odoemene, Hidde Ploegh. (Left to right; standing) Tyler Garvin, Abram Santana, Giorgia 
Battistoni, Fred Marbach, Charles Underwood, Robert Wysocki, Paul Masset, Justus Kebschull, Yasmine Belkaid, Robert 
Aboukhalil, Vinidhra Mani, Annabel Romero Hernandez, Brittany Cazakoff, Anja Hohman, Matt Woodruff, Talitha Forcier, 
Marisella Panduro Sicheva, Joaquina Delas Vives
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Immunology focuses on understanding the mechanisms by which multicellular organisms defend 
themselves against external threats of microbial aggression and internal threats associated with 
genetic instability and cellular transformation. The course focused on the innate immune system 
and the adaptive immune system. Innate immunity defends against microbes by recognizing evo-
lutionarily conserved molecular patterns; the adaptive immune system has enormous fl exibility in 
molecular recognition, but it can also target self to cause autoimmune diseases.
Microbial Pathogenesis
May 4–10 Attended by the entering classes of 2010 and 2013
INSTRUCTORS Stanley Maloy, Center for Microbial Sciences, San Diego
 Ronald K. Taylor, Dartmouth Medical School
VISITING LECTURERS Nancy Freitag, University of Illinois, Chicago
 Karla Satchell, Northwestern University Medical School
 Michele Swanson, University of Michigan Medical School
This course focused on the mechanisms of microbial pathogenesis and the host response and the 
scientifi c approaches that are used to investigate these mechanisms. How do microbes adhere 
to host cells? How do environmental cues direct the response of microbial pathogens? How do 
microbial pathogens modulate host cells to expedite virulence? How do host cells respond to 
microbial pathogens? How does the host immune system react to microbial pathogens? What 
does genomics tell us about how microbial pathogens evolve? How do emerging pathogens take 
advantage of new ecological niches? Although there are numerous microbial pathogens, many use 
similar approaches to solve these common problems.
(Left to right) Ronald Taylor, Jack Walleshauser, Anja Hohmann, Stanley Maloy, Arkarup Bandyopadhyay, Giorgia Battistoni, 
Sanchari Ghosh, Michael Giangrasso, Maria Nattestad, Lital Chartarifsky, Georgi Yordanov, Daniel Kepple, Laura Maiorino, 
Matt Koh, Colleen Carlston, Lisa Krug, Michael Gutbrod
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Teaching Experience at the Dolan DNA Learning Center
DIRECTOR David A. Micklos
INSTRUCTORS Amanda McBrien (Lead)
 Jennifer Galasso
 Elna Gottlieb
 Erin McKechnie
 Bruce Nash
 Brooke Roeper
 Jermel Watkins
Science has an increasing role in society, and there is an increasing need for biologists to edu-
cate nonscientists of all ages about biology. The Watson School of Biological Sciences doctoral 
program offers its students the opportunity to teach in the Laboratory’s Dolan DNA Learning 
Center, where laboratory courses are taught to high school and middle school students. In so 
doing, they learn how to communicate with nonbiologists and to inspire and educate creative 
young minds. The teaching module entailed pairs of students teaching one morning or afternoon 
a week for 12 weeks. In the initial weeks, the Dolan DNA Learning Center instructors taught 
the Watson School students the didactic process; it was not until the fi fth week that the graduate 
students taught on their own. At the end of the 12 weeks, the students were very excited about 
their teaching experience.
Laboratory Rotations
The most important element of a doctoral education is learning to perform independent research. 
After the fall term courses, students participate in laboratory rotations. These rotations provide 
students and faculty the opportunity to get to know each other and to explore possibilities for doc-
toral thesis research. At the end of each rotation, students make short presentations of their studies 
to the other students and their rotation advisors. These talks give students an opportunity to share 
their laboratory experiences and to practice giving scientifi c presentations. This year, 20 WSBS 
faculty members served as rotation mentors, some mentoring more than one student.
ROTATION MENTORS Mickey Atwal Adam Kepecs Glenn Turner 
 Anne Churchland Alexei Koulakov David Tuveson 
 Mikala Egeblad Bo Li Christopher Vakoc 
 Hiro Furukawa Robert Martienssen Linda Van Aelst 
 Jesse Gillis Michael Schatz Michael Wigler 
 Thomas Gingeras Stephen Shea Anthony Zador 
 Christopher Hammell David Spector  
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The students began the semester by attending boot camps in Molecular, Cellular, and Quan-
titative Biology. These boot camps introduced the students to the techniques and terminology 
that they will encounter in subsequent courses. The Molecular and Cellular Biology boot camp 
featured seven lectures from faculty members Hiro Furukawa, Dick McCombie, Darryl Pappin, 
David Spector, Lloyd Trotman, Christopher Vakoc, and Linda Van Aelst. The Quantitative Biol-
ogy boot camp lectures were given by Mickey Atwal, Justin Kinney, and Michael Schatz.
CORE COURSES
The Leslie C. Quick, Jr. Core Course on Scientiﬁ c 
Reasoning and Logic
INSTRUCTORS Linda Van Aelst (Lead) Alexander Gann
 Christopher Hammell Bo Li
 Leemor Joshua-Tor David Tuveson
GUEST LECTURERS Douglas Fearon
 Hiro Furukawa
 Justin Kinney
 Adrian Krainer
 Robert Martienssen
This core course forms the heart of the curriculum, at which students (1) acquire a broad base 
of knowledge about the biological sciences, (2) learn the scientifi c method, and (3) learn how to 
think critically. The initial four to fi ve modules are on a different general theme. For each module, 
students read an assigned set of research articles, and at the end of the module, they provide writ-
ten answers to a problem set that guides them through several of the articles.
Twice weekly, students attend lectures related to the module’s topic that include concepts and 
fundamental information as well as experimental methods. The students meet among themselves 
to discuss the assigned papers not covered by the problem set. Each week, students spend an 
evening discussing the assigned articles with faculty. In the fi nal module of the course, students 
participate in a mock study-section in which real National Institutes of Health R01 grants are re-
viewed and critiqued. This allows students to evaluate the questions before the answers are known, 
assess routes toward discovery before knowing where they will end, and make critical judgments 
about how to proceed in the face of an uncertain outcome.
The following were the module topics for this course.
Topic Instructor(s)
Mechanism and Structure of Gene Regulation Alex Gann 
Leemor Joshua-Tor
Gene Regulatory Logic and the Construction of Multicellular 
Organisms: Insights from Flies, Plants, and Worms
Christopher Hammell
The Brain: Wiring, Plasticity, and Maladaptation Bo Li
Cancer David Tuveson
Study Section Linda Van Aelst
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The Darrell Core Course on Scientiﬁ c Exposition and Ethics
INSTRUCTORS David J. Stewart (Lead)
 Mikala Egeblad
 Arne Stenlund
GUEST LECTURERS Lisa Bianco
 Carrie Cowan
 Diane Esposito
 Alyson Kass-Eisler
VISITING LECTURERS Olga Akselrod, The Innocence Project
 Michael Bielski, The Center for Biotechnology
 Keith Baggerly, M.D. Anderson Cancer Center
 Robert Charrow, Greenberg Traurig, LLC
 Stephen Hall, New York University
 Avner Hershlag, North Shore University Hospital
 Dennis Meredith, Research Communication Consultant
 Elizabeth Phimister, New England Journal of Medicine
 Yvette Seger, FASEB
 Tung-Tien Sun, New York University
The 2014 Scientifi c Exposition and Ethics (SEE) core course was led by David Stewart, Arne 
Stenlund, and Mikala Egeblad. The course hosted expert guest lecturers who covered topics in-
cluding scientifi c presentations, the editorial review process, the ethical and legal responsibilities 
of scientists, DNA profi ling and postconviction appeals, and reproductive genetics.
This core course offered instruction in the fundamental elements of scientifi c exposition—
writing skills and public speaking—and ethics. The ability to communicate effectively and to 
appreciate the intricacies of ethical issues are essential skills for biologists; both subjects were 
taught in a series of example-based lectures and discussion groups. Writing skills included the fun-
damentals of modern scientifi c English and the organization and preparation of papers, research 
abstracts, and grant applications. Oral presentation skills were taught by instructors with different 
modes of presentation. Together with instructors, students critiqued formal seminar presentations 
at the Laboratory. Instruction and discussions about ethics included the ethical implications of 
biological discovery on society as well as the nature and boundaries of ethical behavior of scientists 
and their rights and responsibilities. A primary objective of the course was that students consider 
exposition and ethics integral aspects of scientifi c research.
Research Topics
ORGANIZERS Kimberley Geer
 Alyson Kass-Eisler
This core course provided students with an in-depth introduction to the fi elds of research that the 
Laboratory scientists investigate. Students and faculty attended a weekly Research Topics seminar, 
at which faculty members and CSHL fellows presented their current research topics and methods 
of investigation each Wednesday evening over dinner. The students learned how to approach im-
portant problems in biology. These seminars, together with the annual fall Laboratory In-House 
Symposium, provided students with a basis for selecting laboratories in which to do rotations.
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Specialized Disciplines Courses
The students in the Entering Class of 2014 took a total of four Specialized Disciplines courses this 
fall: Genetics and Genomics, Cellular Structure and Function, Systems Neuroscience, and Quantitative 
Biology.
Genetics and Genomics
INSTRUCTORS Zachary Lippman (Lead)
 Michael Schatz
CSHL GUEST LECTURERS Jesse Gillis
 David Jackson
 Gholson Lyon
EXTERNAL GUEST LECTURER Kirsten Bomblies, Harvard University
This course placed modern genetics and genomics into the context of classical genetics. History, 
technique, and perspective of genetic inference were described around four levels of analysis: for-
ward genetics, natural genetic variants, gene interaction, and genomics. Emphasis was on inte-
grating classical with modern questions of genetic analysis: How are genes mapped and “cloned”? 
How do gene mutations help to defi ne biological processes? How are more complex traits geneti-
cally dissected into simpler (underlying) components? What concepts and techniques are used to 
organize genes into pathways and networks? What defi nes a gene and what gene variation exists 
in natural populations? What are the functional consequences of gene variation, and how is it 
detected? How are genomes organized and coordinately regulated? How can genomic informa-
tion be catalogued, organized, and mined? These questions and concepts were fl eshed out using 
examples from the literature.
Cellular Structure and Function
INSTRUCTORS Carrie Cowan
 Linda Van Aelst
CSHL GUEST LECTURERS Raffaella Sordella
 David Spector
 Bruce Stillman
EXTERNAL GUEST LECTURERS Francesca Bartolini, Columbia University
 Aron Jaffe, Novartis
 Alexey Khodjakov, Wadsworth Laboratory
 Sandy Simon, The Rockefeller University
 Orion Weiner, University of California, San Francisco
With the complete genome sequence available for many organisms, it becomes imperative to un-
derstand the function of the gene products. This understanding requires an increasing apprecia-
tion of the structure and function of the cell, as well as dynamic associations within the cell. This 
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course provided a basic overview of the structural and functional organization of cells with par-
ticular emphasis on cellular compartmentalization and communication. Topics of focus included 
the cytoskeleton, cell adhesion and signaling, membrane transport, gene expression, and nuclear 
organization. In addition, the course provided insight into the basic toolbox of the cell biologist 
of the 21st century.
Systems Neuroscience
INSTRUCTORS Adam Kepecs (Lead)
 Glenn Turner
GUEST INSTRUCTORS Anne Churchland
 Alexei Koulakov
 Stephen Shea
 Anthony Zador
This course introduced students to neuroscience, with a focus on learning and plasticity from its 
cellular basis through development to systems and behavior. Both experimental and theoretical 
viewpoints were explored. The course started with the basics of electrical signaling in neurons: 
ion channels, action potentials, and synaptic transmission. The cellular basis of learning, includ-
ing Hebb’s postulates, and LTP (long-term synaptic potentiation), were discussed. The course 
explored the consequences of synaptic learning rules by examining how experience shapes the wir-
ing of the nervous system during development and investigated how such building blocks translate 
into whole-organism behavior. The course then examined classical conditioning and asked how 
changes in synaptic transmission could underlie such behavior. Computational associative learn-
ing models of the learning process were also discussed.
From behaviors that focus on simple memories, the course turned to behaviors that require 
making perceptual decisions. This was accomplished by covering some basic concepts of percep-
tual neuroscience, such as neuronal “receptive fi elds,” and using these to discuss current results 
and models of perceptual decision making. Finally, the course turned to the learning of behaviors 
through reward and punishment, what is known as reinforcement learning. The course concluded 
with a discussion of the role of dopamine in reward and learning, the theory of reinforcement 
learning, and pathologies of reward-seeking behavior.
Quantitative Biology
INSTRUCTORS Mickey Atwal (Lead)
 Michael Schatz
GUEST LECTURERS Justin Kinney
 Alexander Krasnitz
With the advent of high-throughput technologies in biology, it has become necessary for biologi-
cal researchers to be able to analyze and interpret high-dimensional data and frame hypotheses 
mathematically. To this end, this course aimed to equip students with a basic training in modern 
statistical methods. By the end of the course, students not only were able to answer many of the 
simple statistical questions that arise in data analyses, but also became familiar with the more 
274  Watson School of Biological Sciences
complex techniques used by computational biologists. Topics covered included error fl uctuations, 
calculating the signifi cance of an experimental result, Bayesian inference, information theory, 
power calculations, dimensional reduction, and DNA sequence analyses. In addition, this course 
introduced mathematical modeling, motivated by classic examples in quantitative biology such as 
the Delbrück–Luria experiment, Hopfi eld’s kinetic proofreading, and Kimura’s neutral theory of 
population genetics.
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POSTDOCTORAL PROGRAM
PROGRAM DIRECTOR Nicholas Tonks
PROGRAM ADMINISTRATOR Alyson Kass-Eisler
Cold Spring Harbor Laboratory (CSHL) is proud of its rich tradition in postdoctoral educa-
tion and has a deep commitment to the postdoctoral experience. CSHL has long been recog-
nized as a place for nurturing young scientists, with postdoctoral researchers being an integral 
part of the discovery process. Current fi elds of research expertise include genetics; molecular, 
cellular, and structural biology; neuroscience; cancer; plant biology; genomics; and quantita-
tive biology. The postdoctoral community at CSHL is diverse and international, arriving at the 
Laboratory with many different backgrounds and with needs that change during the course 
of the postdoctoral years. The Postdoctoral Program Offi ce works closely with the fellows and 
the Laboratory’s administration to coordinate and organize educational and career develop-
ment activities. Alyson Kass-Eisler, the Postdoctoral Program Offi cer, and Nicholas Tonks, 
the Scientifi c Director of the Postdoctoral Program, provide the day-to-day support for the 
postdoctoral program, which is overseen by the Dean of the Watson School of Biological Sci-
ences (WSBS), Alexander Gann.
The Postdoctoral Liaison Committee (PDLC)—an elected group of postdocs who help share 
information and ideas between the administration and the postdoctoral community—continues 
to enhance the postdoctoral experience at CSHL. The PDLC is the voice of the community and 
has regular meetings with CSHL President Bruce Stillman. In 2014, new members Sara Ballouz, 
Daniel Ferrante, and Serif Senturk joined returning members Jonathan Ipsaro, Saikat Nandi, and 
Benjamin Roche. The PDLC organized two successful retreats this year aimed at fostering net-
working and collaboration. The day-long retreats took place at the Banbury Conference Center 
and included research talks, chalk talks, and discussions sessions. The PDLC also oversees and 
distributes funds to two career development groups as described below. These groups are primar-
ily composed of postdoctoral fellows but also include graduate students. Today’s postdocs face a 
number of challenges, including a very diffi cult job market. CSHL works hard to give its postdocs 
the upper hand when it comes to competing for the scarce jobs that are available. More and more, 
it has become our responsibility to introduce a diversity of career opportunities that are available 
and to provide the tools to our postdocs to prepare for these positions. Thanks to the assistance 
from PDLC and these career development groups, a number of fantastic events took place.
The Career Development Program (CDP) provides programming geared toward careers in 
academia. In the “Conversations with Faculty” series, the postdocs were given career insights in 
an informal and interpersonal format. Sessions included Gaining Teaching Experience with guest 
panelists Cristina Fernandez Marco, Jaclyn Novatt, and Lisa Prazak; Securing a Faculty Position 
at a Teaching-Centered Institution with Allison Abbott (Associate Professor, Marquette Univer-
sity); and The Two-Body Problem: The Diffi culty Academic Couples Find Obtaining Jobs at the 
Same University or within a Reasonable Commuting Distance from Each Other with Jennifer 
Morgan (Associate Scientist, Eugene Bell Center for Regenerative Biology and Tissue Engineering 
at the Marine Biological Laboratory).
The CDP also hosted a special discussion with Dr. Richard Nakamura, Director of the Na-
tional Institutes of Health’s (NIH) Center for Scientifi c Review. Dr. Nakamura talked about his 
career trajectory, his experiences within and outside of the NIH, and his opinions on the future of 
academic scientifi c research.
276  Watson School of Biological Sciences
We have also been working on building connections with local colleges and universities to pro-
vide teaching experience opportunities for interested postdocs. Informal partnerships are now in 
place with Molloy College and Long Island University. In addition, selected postdoctoral fellows 
continue to participate in the Watson School as tutors—either one-on-one or in the classroom 
 setting—thus providing the postdocs with valuable experience in teaching and mentoring.
The Bioscience Enterprise Club (BEC) provides information for nonacademic careers and has 
also been organizing a series of seminars and workshops. The areas of interest include biotech-
nology, intellectual property, law, regulatory affairs, and venture capitalism. This year’s guests 
included Victoria Aranda, Senior Editor, Nature Medicine; Jim Hayward, CEO, Applied DNA; 
Yvette Seger, Director of Science Policy, Federation of American Societies for Experimental Biol-
ogy; and Rebecca Bish, Senior Scientifi c Editor at D.E. Shaw Research.
A discussion of Careers in Medical Genetics was paneled by Dr. David Tegay (New York In-
stitute of Technology), Dr. Bhuma Krishnamachari (New York Institute of Technology), and Dr. 
Ann-Leslie Zaslav (Stony Brook University), and Jeff Nagel hosted a workshop on management 
and leadership skills needed to run a lab. BEC also organized a trip to the local biopharmaceutical 
company Regeneron. In collaboration with the CSHL iPlant initiative and the Software Carpen-
try, they organized a 2-day bioinformatics boot camp for postdocs at CSHL. BEC and CDP also 
co-hosted a visit from Dr. Latasha Wright, Staff Scientist and Director of Development at BioBus, 
a “high-tech laboratory on wheels.”
To celebrate National Postdoc Appreciation week, an ice cream social was held on the Delbrück 
patio. It was a great opportunity for the community to get together for some fun, as well as to net-
work and fi nd out about the ongoing programs we have been conducting. The PDLC also orga-
nized an inaugural CSHL Music Festival, featuring some of our very musically talented postdocs.
Through the CSHL Human Resources department, the postdocs have had access to free job-
seeker webinars hosted by the Higher Education Research Consortium. The 2014 webinars in-
cluded “Making Your Case: Writing Cover Letters for Non-Academic Jobs” and “Jobs in the 
Federal Government.”
“Demystifying Science,” which began in 2011, enlists postdoctoral fellows to bring their exper-
tise and teaching interests to the educationally diverse staff of the Laboratory. In the 2014 sessions, 
geared toward a general audience, postdocs have talked about Fighting Cancer with our Own 
Army, Decoding the Noncoding Genome, and Ebola: Fact and Fiction.
On September 18, 2014, the Rally for Medical Research, a broad coalition of groups from 
the medical research advocacy community, met with House and Senate offi ces in Washington, 
D.C., to urge Congress to make funding for the NIH a national priority. Cristina Aguirre-Chen, 
a postdoc in Christopher Hammell’s lab, represented the CSHL postdoctoral community at this 
important event.
Since 2003, all postdoctoral fellows and graduate students at the Laboratory have been enrolled 
in a special initiative of the New York Academy of Science (NYAS), the Science Alliance. The 
Science Alliance for graduate students and postdoctoral fellows is a consortium of universities, 
teaching hospitals, and independent research facilities in the New York City metro area that have 
formed a partnership with NYAS. The aim of the Alliance is to provide career and professional 
development monitoring for postdoctoral fellows and graduate students in science and engineer-
ing, through a series of live events and a dedicated web portal. In addition, the Science Alliance 
gives graduate students and postdoctoral fellows the opportunity to network with their peers 
across institutions and with key leaders in academia and industry. This year, the Science Alliance 
meetings and workshops included Perspectives in STEM, an Evening with Dr. Laurie Leshin; 
Making the Leap: A Non-Academic Career Planning and Job Search Boot Camp; Supporting 
Dynamic STEM Careers for Underrepresented Minorities; Building a Collaborative International 
Network; Scientists Teaching Science; Graduate Student and Postdoc Career Symposium at the 
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NewYorkBio Annual Conference; Survival Skills for Young Investigators; Journey Through Sci-
ence Day; Networking and IDPs Workshop; Risky Business: A Pharmaceutical Industry Strategy 
Workshop; How to Turn Your Science Project into a Product: A Creative Thinking Workshop by 
The Solution Lab; From Scientist to CSO: Experiencing the Scientifi c Method as Your Guide to 
Career Success; Grantsmanship for Graduate Students and Postdocs; But I Have No Skills: De-
bunking Myths and Exploring Career Options for Ph.D.s; The Craft of Scientifi c Presentations; 
The Non-Academic Job Search: Target the Job, Tailor the Approach; Interpersonal Skills: The 
Keys to Effective Communication and Managing Diffi cult Conversations; Management Consult-
ing: Using Your Scientifi c Mind to Solve Business Problems; and An Introduction to Teaching 
Science Online.
Additionally, Dr. Thomas Magaldi, then the Director of Science Alliance at the NYAS, visited 
CSHL to give a talk on Preparing for Careers in Science Policy. During the talk, he discussed a 
variety of science policy careers, what types of fellowships help in exploring those careers, and 
what can be done during graduate school and/or postdoc to increase the chances of transitioning 
into the world of policy.
On November 6, the Offi ce of Sponsored Programs, the Development Department and the 
Postdoc Program Offi ce held a very popular course on grant writing. The sessions included In-
troduction to Grants and External Funding; The Grant Application; The Grant Abstract/Public 
Summary; Peer Review Panel Discussion; Research Compliance; Fellowships, Career Develop-
ment Awards and Resources for Postdocs; and Effective Writing Skills.
Finally, an important measure of our postdoctoral program’s success is the ability of 
postdoctoral fellows to secure positions at the end of their training. In 2014, our fellows took 
positions at Aarhus University, Adelphi University, Donald Danforth Plant Science Center, Dow 
AgroSciences, Farmingdale State College, Pfi zer, Roche, the University of Basel, the University of 
Bayreuth, and the University of Michigan.
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UNDERGRADUATE RESEARCH PROGRAM
PROGRAM DIRECTORS Anne Churchland
 Michael Schatz
PROGRAM ADMINISTRATOR Kimberly Creteur
Established more than 50 years ago, the CSHL Undergraduate Research Program (URP) plays a 
major role in providing and setting the standard for meaningful hands-on undergraduate research 
training in biology. The 10-week program begins the fi rst week of June. During the fi rst week, the 
students attend various orientations and receive a guided historical tour of campus and all the fa-
cilities and resources available to them. This ensures a smooth transition into the Laboratory com-
munity and research. The URPs work, live, eat, and play among CSHL scientists, and they have 
a very busy academic and social calendar throughout the remaining nine weeks of the summer. 
The students receive training in scientifi c research, science communication, career preparation, 
and bioinformatics and computational biology, all while interacting socially with fellow program 
participants and members of the CSHL community in formal and informal activities. Some of 
the 2014 activities included a pizza party with Dr. and Mrs. Watson, dinner with Dr. and Mrs. 
Stillman, volleyball games, designing the URP T-shirt, competing in the annual Scavenger Hunt, 
and the ever-famous URP versus PI volleyball match.
The students’ scientifi c development is the most important component of the program. There-
fore, in the beginning of the summer, the URPs write an abstract and present a talk on their 
proposed research. The URP participants work alongside scientists and become increasingly inde-
pendent throughout the summer. Concluding the program in August, the URP students prepare 
a fi nal report and present their results in a 15-minute talk at the URP Symposium. As in previous 
years, the program directors and faculty mentors were highly impressed with the accomplishments 
of the URP students.
2014 Undergraduate Research Program Participants
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The following 27 students, selected from 819 applicants, took part in the 2014 program:
Henry Ashworth, Eckerd College
Advisor: Mikala Egeblad
Funding: Robert H.P. Olney Fellowship
The mystery of lysyl oxidase in pancreatic cancer.
Patricia Aubel, San Jose State University
Advisor: W. Richard McCombie
Funding: National Science Foundation
Variant detection with PacBio SMRT sequencing system.
Syndi Barish, The College of New Jersey
Advisor: Gholson Lyon
Funding: National Science Foundation
Creation and characterization of an isogenic knockout 
in Naa50, a catalytic component of amino-terminal 
acetyltransferase (NAT) A and E in Saccharomyces cerevisiae.
Nikaela Bryan, University of Maryland, Baltimore County
Advisor: Anne Churchland
Funding: HHMIEXROP
Optogenetic interrogation of mouse posterior parietal cortex 
during perceptual decision-making.
Cassandra Burdziak, Rutgers University, New Brunswick
Advisor: Thomas Gingeras
Funding: National Science Foundation
Characterization of cell-specifi c fragmenting patterns among 
exosomal small RNAs.
Daniel Burkhardt, University of Massachusetts, Amherst
Advisor: Doreen Ware
Funding: National Science Foundation
Searching for SNPs in stay-green sorghum.
John Cannon, Carleton College
Advisor: Anne Churchland
Funding: Burroughs Wellcome Fellowship
Optogenetic approaches to studying perceptual decision-
making in the posterior parietal cortex.
John Simon Chow, Georgia Institute of Technology
Advisor: Alexander Krasnitz
Funding: National Science Foundation
Convex optimization algorithms for population structure 
analysis in tumors.
Michael Dinh, University of Notre Dame
Advisor: Stephen Shea
Funding: University of Notre Dame URP Scholarship
Olfactory modulation of the auditory cortex by medial amygdala.
Luz Brielle Dojer, Boston University
Advisor: Alea Mills
Funding: National Science Foundation
The role of chromodomain helicase DNA-binding protein 
5 in neural stem cells.
Leila Elabbady, Wellesley College
Advisor: Josh Dubnau
Funding: Alfred L. Goldberg Fellowship
The transposon storm hypothesis of neurodegeneration.
Carolina Falcon-Campos, National Polytechnic 
Institute, Mexico
Advisor: David Jackson
Funding: Von Stade Fellowship
Identifi cation of novel regulators of cell-to-cell traffi cking via 
plasmodesmata in Arabidopsis thaliana.
Ariel Gewirtz, Swarthmore College
Advisor: Mickey Atwal
Funding: H. Bentley Glass Fellowship
Ectopic germline gene expression in glioblastoma multiforme 
and breast cancer.
Michael Gross, Cornell University
Advisor: Florin Albeanu
Funding: William Shakespeare Fellowship
Behavioral effects of corticobulbar feedback manipulation 
in mice.
Melina-Theoni Gyparaki, The University of Edinburgh
Advisor: Marja Timmermans
Funding: William Townsend Porter Foundation Scholarship
Functional analysis of small RNA–ARGONAUTE 
associations and their roles in plant development.
Margaret Henderson, Cornell University
Advisor: Partha Mitra
Funding: Joan Redmond Read Fellowship
Improving the precision of stereotactic injections for mapping 
the mouse brain.
Samuel Johnson, Brown University
Advisor: Alexei Koulakov
Funding: Emanuel Ax Fellowship
PCR primer design for mouse olfactory receptors.
Danxun Li, University of California, Berkeley
Advisor: Bo Li
Funding: 30th Anniversary URP Scholarship
Decoding reward learning and valuation behavior in cell 
populations in the globus pallidus.
Vicki Mercado, Whittier College
Advisor: David Tuveson
Funding: Garfi eld Fellowship
Determining the sensitivity of pancreatic cancer cells to 
endoplasmic reticulum stress.
Beverly Mok, University of Cambridge
Advisor: Christopher Vakoc
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Funding: James D. Watson Undergraduate Scholarship
Role of mediator complex in AML maintenance.
Mira Nencheva, Stanford University
Advisor: Adam Kepecs
Funding: Dorcas Cummings Scholarship
Optogenetic manipulation of orbitofrontal-ventrostriatal 
pathway during decision making in rats.
Lucy Rummler, Clemson University
Advisor: Zachary Lippman
Funding: National Science Foundation
Meristem regulation and the fi n and fan mutants in tomato.
Michael Sayegh, Harvard College
Advisor: Bruce Stillman
Funding: Former URP Fund Scholarship
Gene regulation via RB and ORC1 interaction.
Selin Schamiloglu, Columbia University
Advisor: Z. Josh Huang
Funding: James D. Watson Fellowship
Investigating the role of chandelier cells in fear circuitry.
Rachel Sherman, Harvey Mudd College
Advisor: Michael Schatz
Funding: National Science Foundation
Whole-genome assembly and alignment pipeline for unique 
gene discovery
Toby Turney,
University of Notre Dame
Advisor: Darryl Pappin
Funding: Howard Hughes Medical Institute Scholarship
Improving the yield and purity in a large-scale expression and 
purifi cation of velocin-N.
Victoria Wang, University of Cambridge
Advisor: Lloyd Trotman
Funding: Libby Fellowship
CRISPR/Cas9 as a genome-editing tool to investigate 
metastatic prostate cancer.
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PARTNERS FOR THE FUTURE
PROGRAM DIRECTOR David Jackson
PROGRAM ADMINISTRATOR Michelle Krull
The Partners for the Future Program, established by Dr. James Watson in 1990, provides an oppor-
tunity for talented Long Island high school students to have hands-on experience in biomedical re-
search at Cold Spring Harbor Laboratory. This highly competitive program is open to Long Island 
high school students in their junior year. Each high school science chairperson may nominate up 
to three students. The top candidates are interviewed by CSHL scientists. Students selected for the 
program are paired with a scientist mentor and spend a minimum of 10 hours per week, September 
through March of their senior year, conducting original research. At the conclusion, the students 
present their projects to an enthusiastic audience of the students, scientifi c mentors and colleagues, 
CSHL administrators, parents, and teachers. Although the students learn a great deal about mod-
ern biology and state-of-the-art research techniques, the main advantage of the program is that they 
are exposed to day-to-day life in a lab. Interacting with scientists and support staff, the students 
learn to defi ne and pursue a research goal while solving problems that may occur along the way.
The 2014–2015 Partners for the Future were chosen from among 54 nominations. They are:
Partner High School Laboratory CSHL Mentor
Luke Antolin Cold Spring Harbor High School Adam Kepecs Hyun Jae Pi
Michael Callahan Farmingdale High School Robert Martienssen Rowan Herridge
Henry Cheung Seaford High School Mikala Egeblad Mario Shields
Melissa Cipolla Friends Academy Molly Hammell Oliver Tam
Noah Davis Earl L. Vandermeulen High School Gholson Lyon Gholson Lyon
Harshil Garg Bethpage High School Michael Wigler Swagatam Mukhopadhyay
Chi Ying “Jillian” Ho The Stony Brook School Gholson Lyon Gholson Lyon
Hannah Johnston Harborfi elds High School Adam Kepecs Sachin Ranade
Annet Kuruvilla East Meadow High School Adrian Krainer Tomoki Nomakuchi
Shreeya Panigrahi Sayville High School Stephen Shea Brittany Cazakoff and Dennis Eckmeier
Michelle Shen Syosset High School David Jackson Huyen Bui
Rachel Wesley Oyster Bay High School Doreen Ware Lifang Zhang
Seungmin Yi The Wheatley School Mikala Egeblad Ana Margarida Santos De Almeida
Partners for the Future participants

MEETINGS & COURSES
PROGRAM

285
ACADEMIC AFFAIRS
The Cold Spring Harbor Laboratory meetings and courses program attracts scientists from all 
over the world to communicate, learn, and critique the latest ideas and approaches in the biological 
sciences. The program consists of advanced laboratory and lecture courses, as well as large meet-
ings and biotechnology conferences that are held almost year-round. The meetings and courses 
program at the Laboratory attracted strong attendance with almost 7100 meeting participants 
and almost 1400 course participants (trainees, teaching, and support faculty). The Cold Spring 
Harbor Asia program including 21 conferences and one summer school has to date attracted more 
than 3500 participants, bringing the anticipated year-end total for both the United States- and 
China-based programs to more than 12,000.
The Laboratory held 27 academic meetings this year, which brought together scientists from 
around the world to discuss their latest research. The spring meeting season culminated in the 
annual Cold Spring Harbor Symposium, which focused on cognition. The timing of this topic 
coincided with President Obama’s BRAIN initiative to map the workings of the human brain. 
The Symposium spanned a broad range of approaches toward increased understanding of cogni-
tion in humans and other animals including molecular, physiological imaging, and behavioral ap-
proaches. Fundamental biological discoveries were balanced with applications relevant to societal 
well-being including exploration of brain disorders. The 79th Symposium in this historic series 
attracted around 300 participants, including many notable neuroscientists such as David Ander-
son, Richard Axel, Cori Bargmann (organizer), Daphne Bavelier (organizer), Patricia Church-
land, Karl Deisseroth, Robert Desimone, Allison Doupe, Ann Graybiel, Thomas Jessell, Nancy 
Kanwisher, David Kleinfeld, Patricia Kuhl, Joseph LeDoux, Eve Marder, Markus Meister, J. 
Anthony Movshon, Eric Nestler, John Reynolds, Terry Sejnowski (organizer), Michael Stryker, 
 Susumu Tonegawa, and Daniel Wolpert. Dissemination includes the proceedings of the Symposium 
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published each year by the CSHL Press, and videotaped interviews with leading speakers by edi-
tors and journalists attending the Symposium, now available on our Leading Strand YouTube. 
The Symposium therefore reaches a much wider audience nationally and internationally than can 
possibly attend.
Cold Spring Harbor Laboratory meetings are unique in assembling a program with very few 
invited speakers. Instead, meeting organizers are encouraged to select talks from abstracts that are 
submitted on the basis of scientifi c merit, ensuring that the latest fi ndings will be presented and 
that young scientists will have the chance to describe their work. 2014 saw the introduction of 
several successful new meetings on Avian Model Systems, The PARP Family, and Biological Data 
Science. The annual meeting on The Biology of Genomes was oversubscribed as usual, attracting 
almost 100 online subscriptions and more than on Twitter, and many others attracted strong at-
tendance despite the funding climate. Many of these meetings have become essential for those in 
the fi eld and are held on a biannual basis. Two special meetings convened under the auspices of 
the CSHL Genentech Center. Conferences on the History of Molecular Biology and Biotechnol-
ogy addressed the history of messenger RNA and plasmids, respectively, and each attracted rather 
different audiences than our regular meetings. Partial support for individual meetings is provided 
by grants from the National Institutes of Health, National Science Foundation, foundations, and 
companies. Core support for the meetings program is provided by the Laboratory’s Corporate 
Sponsor Program.
The Courses program covers a diverse array of topics in molecular biology, neurobiology, struc-
tural studies, and bioinformatics. Instructors update their course curricula annually, invite new 
speakers who bring a fresh perspective, and introduce new techniques and experimental approach-
es based on student feedback and progress in the fi eld. Recently introduced courses on Single-Cell 
Analysis and Synthetic Biology run in parallel with well-established courses in genetics, neurosci-
ence, plant biology, and bioinformatics. New techniques, for example, genome editing using tools 
such as CRISPR, are introduced as methodologies develop and evolve. We strongly encourage 
each course to include the latest technical and conceptual developments in their respective fi elds.
Instructors, lecturers, and assistants come from universities, medical schools, research insti-
tutes, and companies around the world to teach at Cold Spring Harbor. Students include ad-
vanced graduate students, postdoctoral trainees, principal investigators, and senior scientists from 
around the world.
A new 1-week lecture course on Genetics and Neurobiology of Language addressed core ques-
tions about the bases and origins of speech and language, through talks, interactive sessions, 
keynotes, and debates, involving leading experts from a range of disciplines. The course integrated 
the state-of-the-art from complementary perspectives, including development, cognitive models, 
neural basis, gene identifi cation, functional genomics, model systems, and comparative/evolution-
ary studies.
Instructors, course assistants, and course lecturers come from universities, medical schools, 
research institutes, and companies around the world to teach at Cold Spring Harbor. Their excel-
lence and dedication make the course program work so well. We would especially like to thank 
Drs. Randy Johnson, Gregory Macleod, Cynthia McMurray, Kate O’Connor-Giles, Adrian 
Rothenfl uh, Amy Sater, Xin Sun, Gerald Thomsen, and Stephan Treue, who all retired after many 
years of service. The sad news that Carlos Barbas, distinguished instructor in the Phage Display 
course for more than two decades, passed away in early summer was a shock to all of us who knew 
and respected him and so enjoyed his excellent teaching and wry humor.
Grants from a variety of sources support the courses. The core support provided through the 
recently renewed grant from the Howard Hughes Medical Institute remains critical to our course 
program. The courses are further supported by multiple awards from the National Institutes of 
Health and the National Science Foundation, and additional support for individual courses is 
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provided from various foundations and other sources. The courses also depend on equipment and 
reagents that are loaned or donated by a large number of companies, partnerships that are invalu-
able in ensuring that the courses offer training in the latest technologies.
Now in its fi fth year of operation, the Cold Spring Harbor Asia (CSHA) program, under the 
direction of Dr. Maoyen Chi, is headquartered at the Suzhou Dushu Lake Conference Center, a 
purpose-built academic conference center on the outskirts of old Suzhou, within a high-technology 
suburb (SIP). CSHA’s scientifi c program includes large symposia and meetings, training work-
shops, and Banbury-style discussion meetings. CSHA is a wholly owned subsidiary of CSHL and 
is not beholden to outside partners in terms of our scientifi c programming. In 2014, 21 scientifi c 
conferences, one summer school, and two special CSHA sessions at Japanese meetings were held, 
predominantly attracting scientists from the Asia/Pacifi c region. The program is now making 
headway in attracting junior Asian scientists and the >15% growth in attendance between 2013 
and 2014 bodes well for the future. This program is described in more detail in a separate Annual 
Report.
Alumni Notes: Winners of the 2014 Nobel Prize in Physiology or Medicine, Edvard and May-
Britt Moser, have presented at many CSHL neuroscience meetings (the latter gave the keynote at 
the 2014 axon guidance meeting only weeks before the prize) and both spoke at the inaugural 
Crick Symposium in Suzhou in 2010. John O’Keefe gave the keynote at a CSHL/Wellcome Trust 
neuroscience conference in 2009. Winners of the 2014 Nobel Prize in Chemistry, Eric Betzig and 
Stefan Hell, have both participated in imaging-related meetings and courses at CSHL over the 
past decade, and the third laureate in chemistry, William Moerner, presented at the CSHA imag-
ing meeting in Suzhou in 2013. We now count nine Nobel laureates among the student alumni 
of the course program.
The meetings and courses program staff is composed of a lean team of talented professionals 
who handle the complexities of database design, programming, Web and multimedia design, edu-
cational grants management, marketing and recruitment, conference and course administration, 
audiovisual services, and other activities. We wish Andrea Stephenson, who ably served as Course 
Registrar and Offi ce and Operations Manager to the program for many years, the best of luck as 
she transitions into her new life in North Carolina.
Terri Grodzicker
Dean of Academic Affairs
David Stewart
Executive Director, 
Meetings & Courses Program/ 
President, Cold Spring Harbor Asia
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79TH COLD SPRING HARBOR LABORATORY 
SYMPOSIUM ON QUANTITATIVE BIOLOGY
Cognition
May 28–June 2 290 participants
ARRANGED BY Cori Bargmann, The Rockefeller University
 Daphne Bavelier, University of Geneva and University of Rochester
 Terrence Sejnowski, The Salk Institute for Biological Studies
 David Stewart, Cold Spring Harbor Laboratory
 Bruce Stillman, Cold Spring Harbor Laboratory
The Laboratory selected the theme of Cognition for the 79th Symposium in this historic se-
ries largely because of the tremendous advances being made by neuroscientists and psycholo-
gists working on cognitive processes at scales varying from the molecular to whole-brain and 
theoretical studies. Previous Symposia that addressed the brain included the fourth Symposium 
on Excitation Phenomena (1936), The Neuron (1952), Sensory Receptors (1965), The Synapse 
(1975), Molecular Neurobiology (1983), The Brain (1990), and Function and Dysfunction in the 
Nervous System (1996), and thus a return to the general theme of neuroscience was long overdue. 
Furthermore, a number of national projects into brain function have been initiated during the past 
few years, including President Barack Obama’s announcement of the BRAIN (Brain Research 
through Advancing Innovative Neurotechnologies) Initiative in April 2013, a collaborative re-
search project akin to the Human Genome Project, with the ultimate goal of mapping the activity 
of every neuron in the brain by 2025. These projects and initiatives refl ect the fact that many neu-
roscientists are increasingly optimistic that major obstacles in understanding brain function may 
be overcome through the use of new technologies and approaches and that these advances may 
shed light on novel approaches to treat psychiatric, neurological, and neurodegenerative diseases.
The 2014 Symposium was designed to span a broad range of approaches toward increased under-
standing of cognitive processes in the brain including cell/molecular biology; developmental neuro-
biology; genetics and genomics; electrophysiological approaches; functional neuroimaging at cellular 
and whole-brain resolutions; computational neuroscience; behavioral, ethological, and psychophysical 
G. Buzsak, J. Kubie, S. Tonegawa A. Pouget, D. Bavelier, P. Churchland, J. DiCarlo
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studies; and evolutionary/comparative neuroscience. The program of 
invited speakers was arranged to ensure that fundamental discoveries 
were balanced with approaches relevant to societal well-being, includ-
ing a variety of stratagems for harnessing our increased understanding 
of brain function to improve treatment of mental illness and brain 
disorders. Speakers responded to the challenge of putting their own 
research, whether based on single-neuron studies, circuits, or whole-
brain studies, into a broader context, allowing for a tremendous 
amount of cross-talk across disciplines with much insight gained from 
this unusually broad meeting. This is one of the strengths of the Sym-
posium, and the 2014 meeting was particularly successful in high-
lighting emerging connections between molecular/cellular networks 
and higher brain functions such as language and decision-making.
Opening night speakers included Richard Axel (Columbia Univer-
sity) on innate and learned responses to odors, Allison Doupe (Univer-
sity of California, San Francisco) on vocal motor plasticity, Matthew 
Rushworth (University of Oxford) on decision-making, and Patricia 
Kuhl (University of Washington), who addressed language acquisition. 
One of the three Churchland neuroscientists who spoke at the Sympo-
sium, Patricia Churchland (University California, San Diego) addressed “The brains behind morality” 
in an excellent Dorcas Cummings Lecture for Laboratory friends, neighbors, and Symposium partici-
pants in advance of the annual dinner parties. Terry Sejnowski delivered a compelling and illuminating 
summary at the conclusion of the symposium.
This Symposium was attended by almost 300 scientists from universities around the country 
and internationally, and the program included 60 invited presentations, six short talks selected from 
the openly submitted abstracts on the basis of scientifi c merit, and 130 poster presentations. To dis-
seminate the latest results and discussion of the Symposium to a wider audience, attendees were able 
to share many of the Symposium talks with their colleagues who were unable to attend using the 
Leading Strand video archive. A collection of interviews by Karen Carniol (Cell), Ann Goldstein 
(Neuron), Charvy Narain (Nature Neuroscience), Gary Stix (Scientifi c American), and Jan Witkowski 
(CSHL Banbury Center), with leading experts in the fi eld, were arranged during the Symposium 
and distributed as free video from the Cold Spring Harbor Symposium interviews Web site.
This meeting was funded in part by Forest Laboratories and the Swartz Foundation. Con-
tributions from the following companies and foundations provided support for the Symposium: 
Agilent Technologies, Bristol-Myers Squibb Company, DuPont/Pioneer Hi-Bred International, 
 Genentech, Hudson-Alpha Institute for Biotechnology, Life Technologies (part of Thermo Fisher 
Scientifi c), Monsanto Company, and New England BioLabs. Financial support from the corporate 
sponsors of our meetings program is essential for these 
Symposia to remain a success, and we are most grateful 
for their continued support.
PROGRAM
Introduction
B. Stillman, Cold Spring Harbor Laboratory
Multisensory Integration and Behavioral Outcomes
Chairperson: K. Svoboda, HHMI/Janelia Farm Research 
Campus, Ashburn, Virginia
Physiology of Cognition
Chairperson: D. Angelaki, Baylor College of Medicine, 
Houston, Texas
J. Watson, H. Hoekstra, A. Gann
A.F. Ebihara, O.A. Gonzalo
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Object Recognition
Chairperson: D. Angelaki, Baylor College of Medicine, 
Houston, Texas
Communication, Language, and Higher Cognition
Chairperson: A. Doupe, University of California, 
San Francisco
Neural Substrates of Memory
Chairperson: A. Doupe, University of California, 
San Francisco
Movement and Motor Control
Chairperson: R. Desimone, MIT McGovern Institute for 
Brain Research, Cambridge, Massachusetts
Genes and Circuits
Chairperson: C. Dulac, HHMI/Harvard University, 
Cambridge, Massachusetts
Cognitive Disorders and Enhancement I
Chairperson: C. Dulac, HHMI/Harvard University, 
Cambridge, Massachusetts
Attention and Value
Chairperson: D. Wolpert, University of Cambridge, 
United Kingdom
Dorcas Cummings Lecture: The Brains Behind 
Morality
P. Smith Churchland, University of California, San Diego
Visual Perception and Neural Computation
Chairperson: A. Graybiel, Massachusetts Institute of 
Technology, Cambridge
Short Talks from Abstracts
Chairperson: T. Zador, Cold Spring Harbor Laboratory
Cognitive Disorders and Enhancement II
Chairperson: E. Nestler, Mount Sinai University, New York
Perceptual Judgment and Decision-Making
Chairperson: M. Carrasco, New York University, New York
Social Cognition and Complex Behavior
Chairperson: D. Anderson, HHMI/California Institute of 
Technology, Pasadena
Summary
T. Sejnowski, The Salk Institute for Biological Studies
D. Gardner, D. Kleinfeld, R. Axel
C. Duan, A. Akrami
K. Svoboda, B. Stillman B. Marlin Y. Dan, J.A. Movshon
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MEETINGS
Avian Model Systems
March 5–8 109 participants
ARRANGED BY David Clayton, Queen Mary University of London, United Kingdom
 Rusty Lansford, Children’s Hospital Los Angeles/University of Southern California
 Andrea Streit, Kings College London, United Kingdom
This meeting brought together internationally leading scientists who refl ect the multidisciplinary 
approaches of the avian fi eld. The avian research community primarily uses chicken, quail, and zebra 
fi nch to investigate seminal issues in embryology, behavior, neurobiology, immunology, stem cell 
biology, and endocrinology to name a few. During the past decade, this has become the key meet-
ing for the research community who use avian model systems to exchange ideas, techniques, and 
reagents and to form new collaborations. Importantly, it provides a platform for junior scientists to 
present their research and to interact with scientists working at the frontiers of their respective fi elds.
The meeting began with a keynote presentation by Dave Burt detailing the evolution and cur-
rent state of avian genomics, celebrating a decade since the chicken genome sequence was pub-
lished. There were approximately 50 poster presentations that mixed well with the wine and cheese.
A wrap-up session included a lively discussion about how large and diverse the avian commu-
nity has become, integrated with explorations of how best to unite the avian community. Agreed 
upon Websites were being designed and installed prior to our fi nal CSHL lunch. Plans were made 
to hold a meeting every 2 years alternating among Asia (Taiwan 2016), Europe (France 2018), 
and the United States (TBD 2020) to allow more people to attend this meeting and build a strong 
“avian community.”
Our Avian Model Systems meeting was preceded by a successful “hands-on” Avian Genom-
ics Workshop (March 4–5, 2014) run in collaboration with Ensembl/European Bioinformatics 
Institute and Wellcome Trust Sanger Institute. The workshop combined lecture and hands-on 
problems that were worked through by the students to better understand how to generate and use 
genomics, transcriptomics, and CHiP epigenomics information and analysis for their own studies.
This meeting was funded in part by the University of Arizona; Developmental Dynamics, 
Elsevier/Mechanisms of Development and International Society of Developmental Biologists; 
and the Society for Developmental Biology.
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PROGRAM
Keynote Address: Avian Genomics a Decade after the 
Publication of the Chicken Genome Sequence
D.W. Burt, University of Edinburgh, United Kingdom
Avians as Models for Disease
Chairpersons: A. Nieto, Universidad Miguel Hernandez-
CSIC, Alicante, Spain; S. White, University of California, 
Los Angeles
The Shape of Things to Come
Chairpersons: C.M. Chuong, University of Southern 
California, Los Angeles; P. Kulesa, Stowers Institute for 
Medical Research, Kansas City, Missouri
Evolution: A Bird’s Eye View
Chairpersons: R. Schneider, University of California, 
San Francisco; J. Gros, Institut Pasteur, Paris, 
France
Bird Brains and Behavior
Chairpersons: C. Scharff, Freie Universitat Berlin, Germany; 
S. London, University of Chicago, Illinois
Where Is the Value in Genomics?
Chairpersons: W. Warren, Washington University School of 
Medicine, St. Louis, Missouri; B. Faircloth, University of 
California, Los Angeles
Birds for the Future: Models for Development
Chairpersons: T. Sauka-Spengler, University of Oxford, 
United Kingdom; C. Stern, University College London, 
United Kingdom
Stem Cells from an Avian Perspective
Chairpersons: M. McGrew, The Roslin Institute, 
Edinburgh, United Kingdom; B. Pain, INSERM U846, 
Bron, France
H.C. Cheng, R. Lansford K. Wada, D. Clayton
M. Skinner, J. George N. Day
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Panel discussion
Systems Biology: Global Regulation of Gene Expression
March 18–22 229 participants
ARRANGED BY Timothy Hughes, University of Toronto, Canada
 John Stamatoyannopoulos, University of Washington
 Sarah Teichmann, European Bioinformatics Institute, United Kingdom
Systems Biology aims to understand the emergent properties of molecular networks in cells by 
using systematic and global approaches. One of the most actively researched areas of systems 
biology in recent years has been global regulation of gene expression, which coordinates complex 
metabolic and developmental programs in organisms. This ninth conference, like those in previ-
ous years, captured the continuing rapid progress and many new discoveries in this young and 
exciting fi eld. The 4-day meeting featured 48 talks and 128 poster presentations covering a broad 
range of topics. The speakers, poster presenters, and other conference attendees were composed 
of a mix of students, postdocs, and principal investigators at all levels. Exciting highlights of the 
meeting were two keynote speeches: Dr. Naama Barkai, who has been a leader in the area of 
systems biology of gene expression for many years, described the fi rst quantitative dissection of 
the contributions of initiation and elongation of transcription versus translation to yeast fi tness 
under various growth conditions (phosphate starvation, nitrogen starvation, etc.). Dr. Orkin 
presented his work on understanding hematopoiesis and unraveling the correct lineage tree, as 
well as a careful dissection of the switch in expression from fetal to adult globin chains, with 
relevance to sickle cell anemia.
Many new techniques were featured this year that used next-generation sequencing, argu-
ably the largest advance being in single-cell genomics technologies. This exciting new area 
takes the regulation of gene expression from averages of hundreds or millions of cells right 
down to the resolution of a single cell. Many of the presentations also described new ap-
proaches to the analysis of data, and these computational advances are driving the fi eld for-
ward at a tremendous pace. One example is the new chromatin immunoprecipitation high-
throughput sequencing (ChIP-Seq) normalization technique that allows diverse data sets to 
be compared collectively (presented by the Ideker lab). Further advances relative to previous 
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years are the ubiquitous inclusion of the genome-wide association study (GWAS) of disease-
related mutations, so that many studies of gene expression are now directly linked to human 
phenotypes.
The integration of genome biology with bioinformatics, genetics, and single-cell approaches 
at this conference is testament to this very exciting era in research on gene expression regulation.
This meeting was funded in part by the National Cancer Institute, a branch of the National 
Institutes of Health.
PROGRAM
Keynote Address
N. Barkai, Weizmann Institute of Science, Rehovot, 
Israel
Transcriptional Regulatory Networks
Chairperson: E. Rothenberg, California Institute of 
Technology, Pasadena
Chromatin/Epigenomics
Chairperson: H. Chang, HHMI/Stanford University School of 
Medicine, California
Analysis of Rare and Single Cells
Chairperson: E. Segal, Weizmann Institute of Science, Rehovot, 
Israel
Posttranscriptional Regulation/Technology
Chairperson: K. Neugebauer, Yale University, New Haven, 
Connecticut
Keynote Address: Blood as a Platform for Systems 
 Biology
S. Orkin, Dana-Farber Cancer Institute, Boston, 
Massachusetts
Nuclear Architecture
Chairperson: J. Lieb, Princeton University, Princeton, 
New Jersey
Transcription Factors
Chairperson: T. Hughes, University of Toronto, Canada
cis-Regulatory Logic
Chairperson: M. Bulyk, Brigham and Women’s Hospital, 
Harvard Medical School, Boston, Massachusetts
Cell and Tissue Regulation
Chairperson: J. Stamatoyannopoulos, University of 
Washington, Seattle
T. Hughes, S. Teichmann, J. Stamatoyannopoulos S. Churchman, A. Sidow
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PTEN Pathways and Targets
March 25–28 93 participants
ARRANGED BY Suzanne Baker, St. Jude Children’s Research Hospital
 Anne Brunet, Stanford University
 Lewis Cantley, Weill Cornell Medical College
 Pier Paolo Pandolfi , Beth Israel Deaconess Medical Center and Harvard Medical School of Medicine
This fi fth CSHL conference was a dynamic discussion forum, bringing together top scientists 
studying the PTEN/PI-3 kinase pathway using biochemical and molecular approaches and in 
vivo model systems. Attending this 2014 meeting was a diverse group of scientists who study 
various molecular, genetic, and biochemical approaches to the analysis of the PTEN pathway 
at the cellular level and in development and diseases in-
cluding cancer, diabetes, and neurological disorders such 
as autism. Junior and senior researchers discussed their lat-
est research fi ndings and technical approaches toward the 
analysis of the PTEN pathway. Particular emphasis was 
given to model systems, disease pathogenesis and therapy.
A total of 46 investigators presented in the seven sci-
entifi c sessions, with 46 platform and 19 poster presenta-
tions and 93 registered attendees. The six platforms and 
one poster session were marked by cutting-edge dynamic 
presentations and enthusiastic exchanges of unpublished 
new results. During the scientifi c sessions, participants 
engaged in a vibrant discussion in the question and an-
swer sessions. All of the poster sessions were also very well 
attended.
Essential funding for the meeting was provided by the National Cancer Institute and the 
 National Institute on Aging, branches of the National Institutes of Health, and by Novartis.
P. Paolo Pandolﬁ , L. Cantley, A. Brunet, S. Baker
S. Morrison, M. Hansen D. Sabatini, A. Brunet
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PROGRAM
Upstream Signaling in the PTEN Pathways
Chairperson: D. Alessi, University of Dundee, United Kingdom
Keynote Address
R. Parsons, Icahn School of Medicine at Mount Sinai, 
New York
Downstream Signaling in the PTEN Pathway
Chairperson: D. Sabatini, Massachusetts Institute of 
Technology, Cambridge
PTEN in Stem Cell Function, Development, and Disease
Chairperson: S. Morrison, University of Texas Southwestern 
Medical Center, Dallas
Cancer and PTEN Signaling
Chairperson: P.P. Pandolfi , Beth Israel Deaconess 
Medical Center, Harvard Medical School, Boston, 
Massachusetts
Metabolism and Aging
Chairperson: A. Brunet, Stanford University, California
Complex Regulation of PTEN Signaling
Chairperson: L. Trotman, Cold Spring Harbor Laboratory
G. De Sabbata, A. Ortega E. Collmann, N. Rosen
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Neuronal Circuits
April 2–5 167 participants
ARRANGED BY Dmitri Chklovskii, Janelia Farm Research Campus
 Carl Petersen, Ecole Polytechnique Federale de Lausanne
 Kristin Scott, University of California, Berkeley
The anatomical and functional connectivity of neurons un-
derlies the simplest of behavioral decisions to the most com-
plex cognitive tasks. Unprecedented advances in the ability 
to monitor the activity of large neural populations, to rapidly 
and precisely manipulate the activity of neurons with opto-
genetic approaches, and to trace connectivity with synaptic 
resolution are providing a new systems-level view of neural 
circuit processing. Coupling recent technological advances 
with computational modeling and quantitative behavioral 
approaches has the potential to reveal how the dynamic 
computations of the brain underlie thought and behavior. 
This meeting highlights recent progress in elucidating neural 
circuit function across nervous systems.
In keeping with the original goals of this meeting, re-
searchers working in a variety of different organisms and systems were brought together to share 
their scientifi c and technological advances, focusing on recent advances in neuronal circuit pro-
cessing. This meeting included six slide sessions, covering a range of topics in the visual system, 
chemosensory systems, behavior, cortical processing, methods, and plasticity, and a very interac-
tive poster session.
For the fourth meeting of this kind, the response of the fi eld was very enthusiastic. The meeting 
brought together 167 participants from all over the world, most of whom made either oral or poster 
presentations. Particularly impressive were the large numbers of students (30%) and postdoctoral fel-
lows (36%) participating in the meeting. Invited talks were given by Ed Boyden, MIT; Marla Feller, 
University of California, Berkeley; Michael Hausser, University College London; Fritjof Helmchen, 
University of Zurich; Elly Nedivi, MIT; Michael Reiser, HHMI/Janelia Farm Research Campus; 
Bernardo Sabatini, HHMI/Harvard Medical School; Scott Sternson, HHMI/Janelia Farm Research 
D. Chklovskii, C. Petersen, K. Scott
D. Van Essen, J. Vogelstein E. Aksay, K. Svoboda, F. Helmchen
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Campus; Karl Svoboda, HHMI/Janelia Farm Research Campus; David Van Essen, Washington 
University; Leslie Vosshall, HHMI/Rockefeller University; and Tony Zador, Cold Spring Harbor 
Laboratory. The meeting provided an important forum for the exchange of ideas and approaches 
and helped scientists in the fi eld get the most up-to-date information, as well as enabling them to 
meet, to network, and to establish collaborations. Based on the uniformly enthusiastic comments 
of the participants, the intensity of the oral and poster sessions, the productive question and answer 
sessions, and the large crowds that stayed up late to discuss science, the meeting was a great success.
A highlight of the meeting program was the Larry Katz Memorial Lecture, thanks to the gener-
ous donation of many colleagues in the fi eld, which recognizes an outstanding research contribu-
tion by a graduate student. Although the number of nominations was smaller than in previous 
years, the overall quality of the 11 nominees was truly spectacular, representing an international 
cohort of exceptional graduate students. The selection committee was composed of the three cur-
rent organizers and three past organizers, Cori Bargmann, HHMI/Rockefeller University; Liqun 
Luo, HHMI/Stanford; and Ed Calloway, Salk Institute. The committee unanimously selected 
Hidehiko Inagaki, California Institute of Technology, as the 2014 Lecturer. He gave a wonderful 
presentation about his graduate research. There was a consensus among the organizers and the 
committee that a history of the Larry Katz prize should be included in the program booklet.
This meeting was funded in part by the National Institute of Neurological Disorders and 
Stroke, a branch of the National Institutes of Health.
PROGRAM
Technology
Chairperson: E. Nedivi, Massachusetts Institute of Technology, 
Cambridge
Vision
Chairperson: M. Hausser, University College, London
Dendrites and Plasticity
Chairperson: M. Reiser, HHMI/Janelia Farm Research 
Campus, Ashburn, Virginia
Neocortex
Chairperson: C. Petersen, EPF Lausanne, Switzerland
Behavior
Chairperson: K. Scott, University of California, Berkeley
Neuromodulation
Chairperson: M. Chklovskii, HHMI/Janelia Farm Research 
Institute, Ashburn, Virginia
Larry Katz Lecture: Neuronal Mechanism of State Control 
in Drosophila melanogaster
H. Inagaki, HHMI/Janelia Farm Research Campus, Ashburn, 
Virginia
K. Podgorski, M. Stephenson Jones A. Hussain, L. Vosshall
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The PARP Family and Friends: Gene Regulation and Beyond
April 9–12 100 participants
ARRANGED BY W. Lee Kraus, University of Texas Southwestern Medical Center
 Michael Hottiger, University of Zurich, Switzerland
 Karolin Luger, Colorado State University
This fi rst CSHL meeting on the poly(ADP-ribose) poly-
merase (PARP) family members and associated proteins 
marked 50 years since the discovery of poly(ADP-ribose) 
(PAR) by Chambon and Mandel in 1963. This was an his-
toric meeting for the PARP fi eld. Although there have been 
20 previous meetings during the past four decades, this was 
the fi rst time that a major scientifi c conference organization 
like CSHL sponsored the meeting. As this meeting clearly 
demonstrated, the fi eld has matured and come into focus. 
Although the fi eld has historically focused on the roles of 
PARP proteins in DNA-damage response, studies over the 
past decade have linked PARP-1 and other family members 
to the regulation of chromatin structure and transcription. 
This meeting integrated these two areas of research, high-
lighting key areas of overlap as well as distinct areas of difference. Other areas of focus at the 
meeting included gene regulation and chromatin, signaling and cancer, PARPs and RNA, and the 
biology of ADP-ribosylation (targets, binding proteins, and metabolism). Although the meeting 
had a decided mechanistic and molecular focus, emerging information about the physiological 
and pathophysiological roles of PARPs was also covered in detail, including the clinical applica-
tions of PARP inhibitors. All of these areas were covered in the poster session as well, providing a 
forum for continued discussion. Finally, the meeting 
highlighted new approaches for studying PARP func-
tion, including genomics and proteomics.
A goal of this meeting was to bring together re-
searchers who have traditionally been part of the PARP 
fi eld with those who are new to the fi eld. The meeting 
W.L. Kraus, K. Luger, M.O. Hottiger
H. Schuler, S. Krauss, N.W. Chi A. Ladurner, R. Santoro
300  Meetings
was a great success in this regard. In addition to the scientifi c program, the meeting included a fac-
ulty forum over lunch to discuss the state of the fi eld and where it is headed, as well as to plan future 
activities and initiatives to strengthen and broaden the fi eld. There was a unanimous view and strong 
support for future CSHL meetings on the PARP family.
This meeting was funded in part by the National Institute of Allergy and Infectious Diseases, 
a branch of the National Institutes of Health.
PROGRAM
Molecular Functions and Mechanisms
Chairperson: W.L. Kraus, University of Texas Southwestern 
Medical Center, Dallas
Keynote Address: Local and Genome-Wide Dissection 
of the Mechanisms of Regulated Transcription and the 
 Accompanying Interplay with Chromatin
J.T. Lis, Cornell University, Ithaca, New York
DNA Repair, Gene Regulation, and Chromatin
Chairperson: P. Chang, Massachusetts Institute of Technology, 
Cambridge
Signaling and Cancer
Chairperson: S. Smith, New York University School of 
Medicine, New York
Physiology and Pathophysiology
Chairperson: A. Ladurner, University of Munich, Germany
The Biology of ADP-Ribosylation: Targets, Binding 
 Proteins, and Metabolism
Chairperson: K. Luger, HHMI/Colorado State University, 
Fort Collins
Signaling, Chromatin, and RNA Biology
Chairperson: M.O. Hottiger, University of Zurich, Switzerland
J. Pascal, J. Lis R. Conaway, J. Conaway, J. Pascal
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Gene Expression and Signaling in the Immune System
April 22–26 276 participants
ARRANGED BY Sankar Ghosh, Columbia University College of Physicians & Surgeons
 Dan Littman, HHMI/New York University School of Medicine
 Diane Mathis, Harvard Medical School
 Stephen Nutt, The Walter & Eliza Hall Institute, Australia
This meeting was held for the seventh time in 2014, 
in unseasonable rain and cold temperatures for spring-
time in New York. More than 275 registrants, including 
~30% from outside the United States and many fi rst-
time attendees, participated in a highly engaging and 
interactive 4-day meeting. Although there are many 
immunology meetings, the unique aspect of this CSHL 
meeting is its focus on molecular and biochemical as-
pects of the development and function of the immune 
system. In addition, this meeting attracts a broad range 
of scientists who use the immune system as a model to 
study basic principles of biological regulation.
Talks were presented by a mix of invited speakers and 
investigators selected from a group of more than 200 
submitted abstracts. A signifi cant number of junior in-
vestigators were asked to give talks. Most speakers focused almost exclusively on their unpublished 
work. There were a number of exciting talks; for example, Amy Wagers (Harvard) presented 
exciting data on a blood-borne mediator that “rejuvenates” the muscle stem cells of old mice and 
discussed the cross-talk between these cells and lymphocytes. Ido Amit (Weissman Institute) 
developed and exploited novel, very sensitive ChIP-Seq (chromatin immunoprecipitation– 
high-throughput sequencing) technology to test, and ultimately challenge, the classical Wad-
dington model of lineage differentiation. Steve Smale (University of California, Los Angeles) 
presented exciting studies which showed that by using the technology of RNA-Seq, the composi-
tion of the infl ammatory gene expression program in macrophages can be determined not just by 
D. Mathis, S. Ghosh, S. Nutt, D. Littman
R. Reiner, M. Busslinger L. CorCovan, G. Belz
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transcription, but by the process of splicing of transcripts and their export to the cytosol. Such 
talks highlighted the relevance of the data discussed at this meeting not only to immunology, 
but also to the broader scientifi c community. Oral presentations were supplemented by afternoon 
poster sessions that were extremely well attended and provided a forum for all meeting partici-
pants (including many graduate students and postdocs) to share their most recent data. In addi-
tion, attendees took advantage of an engaging piano recital and an evening performance by the 
ever-evolving Yale-based music group “The Cellmates” led by Richard Flavell.
This meeting was funded in part by the National Institute of Allergy and Infectious Diseases, 
a branch of the National Institutes of Health.
PROGRAM
Stem Cells and Developmental Decisions
Chairperson: I. Weissman, Stanford University School of 
Medicine, California
Innate Immune Cell Development
Chairperson: S. Nutt, The Walter and Eliza Hall Institute, 
Parkville, Australia
Adaptive (Lymphoid) Cell Development
Chairperson: M. Busslinger, Research Institute of Molecular 
Pathology, Vienna, Austria
Chromatin Structure and Epigenetic Regulation
Chairperson: R. Flavell, Yale University School of Medicine, 
New Haven, Connecticut
Antigen Receptor Gene Assembly and Modifi cation
Chairperson: D. Schatz, HHMI/Yale University Medical 
School, New Haven, Connecticut
Signaling
Chairperson: D. Littman, HHMI/New York University School 
of Medicine, New York
Regulation of Immune Cell Function
Chairperson: D. Mathis, Harvard Medical School, Boston, 
Massachusetts
Regulation of Innate Cell Function
Chairperson: S. Ghosh, Columbia University, New York
L. Thompson, H. Roy C. Luo
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Molecular Chaperones and Stress Responses
April 29–May 3 168 participants
ARRANGED BY Andrew Dillin, HHMI/University of California, Berkeley
 Judith Frydman, Stanford University
 F. Ulrich Hartl, Max-Planck Institute for Biochemistry, Germany
This meeting continues the rich tradition of a forum where cutting-edge analyses of molecular 
mechanisms of protein folding are presented in the context of its biological importance and health 
relevance. The high attendance, large number of posters, and lively audience participation in the 
sessions and in the informal activities that followed are testament to the success of the meeting 
and to the successful balance of the sessions. The fi eld of chaperone research is evolving and this 
CSHL meeting is evolving with it and is proving to be the cornerstone meeting for this rich and 
exciting fi eld. The meeting refl ected the many branches of biology and medicine that are now 
understood to be regulated by molecular chaperones. In addition to well-established biochemical 
and biophysical methods for studying chaperone function, this meeting featured presentations 
using single-molecule methods and advanced computational approaches to the study of signaling 
networks involved in control of chaperone gene expression.
This year’s meeting featured three new sessions: one on Spatial Quality Control chaired by 
Dr. Thomas Nystrom and the other on Misfolding Diseases chaired by Nobel laureate Dr. Stan 
Prusiner. The former highlights the emerging understanding that recognition and targeting of 
misfolded proteins to degradation is spatially regulated within the cell and the latter highlighted 
the close links between protein misfolding and neurodegenerative diseases and cancer. An entire 
section was devoted to Proteostasis, highlighting the connections between ribosomes and chaper-
ones and novel signaling pathways involved in protein folding homeostasis. Among the cutting-
edge themes explored were presentations on systems-level studies focused on understanding the 
circuitry that maintains protein homeostasis. Talks on the effect of disruption of these networks 
by cancer or aging emphasized the delicate balance between folding and misfolding required to 
maintain a healthy proteome.
This meeting was funded in part by the National Institute on Aging, a branch of the National 
Institutes of Health.
R. Morimoto, P. Genevaux S. Prusiner M. Ladjimi, W. Houry
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PROGRAM
Proteostasis
Chairpersons: H. Kampinga, University Medical Center 
Groningen, University of Groningen, The Netherlands; 
R. Morimoto, Northwestern University, Evanston, Illinois
Spatial Quality Control
Chairpersons: T. Nystrom, Goteborg University, Sweden; 
U. Jakob, University of Michigan, Ann Arbor
Diseases
Chairpersons: S. Prusiner, University of California, San 
Francisco; S. Lindquist, Whitehead Institute for Biomedical 
Resarch, Cambridge, Massachusetts
Machines and Mechanisms
Chairpersons: R. Klevit, University of Washington, Seattle; 
M. Hayer-Hartl, Max-Planck Institute of Biochemistry, 
Martinsried, Germany
Systems and Networks
Chairpersons: A. Amon, Massachusetts Institute of Technology, 
Cambridge; J.S. Weissman, HHMI/University of California, 
San Francisco
Degradation
Chairpersons: R. Hampton, University of California, San 
Diego; B.A. Schulman, HHMI/St. Jude Children’s Research 
Hospital, Memphis, Tennessee
ER
Chairpersons: T. Sommer, Max-Delbruck Center for 
Molecular Medicine, Berlin, Germany; L. Hendershot, 
St. Jude Children’s Research Hospital, Memphis, Tennessee
D. Wolf, C. Enenkel B. Schulman, S. Misra M. Kampmann, A. Bertolotti
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The Biology of Genomes
May 6–10 562 participants
ARRANGED BY Carlos Bustamante, Stanford University
 Michel Georges, University of Liege, Belgium
 Elaine Mardis, Washington University School of Medicine
 Molly Przeworski, Columbia University
This meeting marked the 27th annual gathering of genome scientists at CSHL. Scientists from 
around the world attended the meeting, with more than 381 abstracts describing a broad array of 
topics relating to the production, analysis, and interpretation of genomes from diverse organisms. 
The meeting built upon the remarkable progress in the sequencing, functional annotation, and 
analysis of genomes from many human individuals, “model organisms,” other animals including 
new genomic studies of rabbit, cichlid fi sh, and an exploration of differential exon usage in primate 
species. A new session topic focused on translational genomics and genetics, featuring lectures on 
undiagnosed pediatric disease, sequencing the Utah population, and sequencing of Parkinsons’ 
disease patients, among others. Because “translation” also applies to agriculture, a lecture about 
how maize diversity can be used for accelerated breeding was included in this session. The predomi-
nance of computational efforts in genomics was outlined by speakers covering a broad range of 
topics from oncogene discovery, posttranscriptional gene regulation from integrated data analysis, 
heritability of regulatory variants compared to coding variants in common disease, and single-cell 
RNA-sequencing studies that examine cell cycle variation. Next-generation sequencing continues 
to translate into the clinic as outlined by several speakers who described the role of genomics in 
identifying new cancer drivers, functional screening by CRISPR-Cas9, acquisition of chemoresis-
tance in ovarian cancers, and an overview of mutational processes that play a role in human cancer.
All sessions were well attended, stretching the capacity of the CSHL facilities. Peter Donnelly 
and Nancy Moran gave the keynote presentations. Lawrence Brody moderated The ELSI (Ethi-
cal, Legal, and Social Implications) panel and the panelists included Arti Rai, Claire Laporte, and 
Richard Gold.
This meeting was funded in part by the National Human Genome Research Institute, a branch 
of the National Institutes of Health; Fluidigm; Illumina; and Ingenuity Systems.
Z. Chen, S. Shenoy, D. Chang, E. Roberts, M. Ilan X. Estivill, S. Ossowsk
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Functional Genomics
Chairpersons: Y. Gilad, University of Chicago, Illinois; 
J. Rinn, Harvard University, Cambridge, Massachusetts
Genetics of Complex Traits
Chairpersons: M. Ritchie, Pennsylvania State University, 
University Park; N. Wray, University of Queensland, 
Brisbane, Australia
Cancer and Medical Genomics
Chairpersons: R. Karchin, Johns Hopkins University, 
Baltimore, Maryland; M. Stratton, Wellcome Trust Sanger 
Institute, Hinxton, United Kingdom
Population Genomics
Chairpersons: P. Andolfatto, Princeton University, New Jersey; 
E. Kenny, Icahn School of Medicine at Mount Sinai, New York
ELSI Panel and Discussion: The Court Has Spoken—
What Did It Say? Implications of Recent U.S. Supreme 
Court Decisions on Diagnostic Testing and Gene Patenting
Moderator: L. Brody, National Human Genome Research 
Institute, National Institutes of Health
Panelists: A. Rai, Duke University; C. Laporte, Foley Hoag, 
LLP; R. Gold, McGill University
Computational Genomics
Chairpersons: D. Pe’er, Columbia University, New York; 
M. Stephens, University of Chicago, Illinois
Evolutionary and Nonhuman Genomics
Chairpersons: L. Andersson, Uppsala University, Sweden; 
J. Tung, Duke University, Durham, North Carolina
Guest Speakers
P. Donnelly, Wellcome Trust Centre for Human Genetics; 
N. Moran, University of Texas, Austin
Translational Genomics and Genetics
Chairpersons: E. Buckler, Cornell University and USDA-
ARS, Ithaca, New York; A. Butte, Stanford University, 
California
M. Michalovova, C. Miller O. Bahcall, B. Stranger A.A. Buil, D. Parts
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The Cell Cycle
May 13–17 212 participants
ARRANGED BY Sue Biggins, Fred Hutchinson Cancer Research Center
 Jacqueline Lees, MIT Center for Cancer Research
 David Toczyski, University of California, San Francisco
This 12th biannual meeting was held this year at Cold 
Spring Harbor. This conference is internationally recog-
nized for its ability to bring together scientists who study 
cell cycle regulation in eukaryotes ranging from yeast to 
humans. As usual, the meeting began with a keynote talk 
from a leader in the fi eld. We were fortunate to have An-
gelika Amon, the Kathleen and Curtis Marble Professor of 
Cancer Biology at MIT and professor of the HHMI, tell us 
about how aneuploidy causes the accumulation of unfolded 
proteins, leading to lysosomal degradation defects. After 
the keynote talk, the evening session continued with six 
talks focused on cytokinesis and chromosome dynamics. 
The remainder of the meeting was organized around seven 
lecture sessions and two poster sessions, which focused on 
the major stages of the cell division cycle, with an emphasis in each session on the molecular 
mechanisms that govern cell cycle progression. Many of these sessions emphasized the long-standing 
problems in cell cycle control, including the transcriptional mechanisms controlling entry in the 
cell cycle, the mechanisms that initiate and control chromosome duplication, the events that trig-
ger the complex events of chromosome segregation in mitosis, and the numerous checkpoint sys-
tems that ensure that cell cycle events occur in the correct order. The meeting represented many 
approaches, including chemical genetics, kinetics, single-cell assays, biochemistry, microscopy, 
and computational approaches. There were also a number of talks and posters about development 
and other specialized aspects of the cell cycle. The meeting connected cell cycle regulation with 
cancer biology with reports about the functions of oncogenes and tumor suppressors in cell 
J. Lees, D. Toczyski, S. Biggins
C. Pantelidou P. Sandra, C. Schwennicke, G. Müller, K. Engeland, L. Binder, D. Varma C. Wurzenberger, G. Kops
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cycle control. As always, major model systems for cell cycle analysis were represented, and the 
striking phylogenetic conservation of cell cycle regulatory mechanisms was readily evident. It was 
another landmark meeting for the cell cycle fi eld, and the participants continue to look forward to 
equally exciting meetings in future years.
Cold Spring Harbor Laboratory would like to thank Bethyl Laboratories for their generous 
support of this meeting.
PROGRAM
Keynote Address: Effects of Chromosome Segregation 
 Errors on Cell Physiology
A. Amon, Massachusetts Institute of Technology
Cytokinesis and Chromosome Dynamics
Chairperson: D. Pellman, Dana-Farber Cancer Institute, 
Boston, Massachusetts
S Phase
Chairpersons: J. Cook, University of North Carolina, 
Chapel Hill; A. Dutta, University of Virginia, Charlottesville
Checkpoints
Chairpersons: L. Zou, Massachusetts General Hospital, 
Harvard Medical School, Boston; A. Musacchio, Max-
Planck Institute for Molecular Physiology, Dortmund, 
Germany
G0-G1 Control
Chairpersons: P. Sicinski, Dana-Farber Cancer Institute, 
Harvard Medical School, Boston, Massachusetts; N. Dyson, 
Massachusetts General Hospital, Boston
Mitosis
Chairpersons: I. Cheeseman, Whitehead Institute, Cambridge, 
Massachusetts; J. DeLuca, Colorado State University, 
Fort Collins
Cell Cycle Decisions
Chairpersons: O. Cohen-Fix, NIDDK, National Institutes of 
Health, Bethesda, Maryland; J. Campisi, Buck Institute for 
Research on Aging, Novato, California
Metaphase to Anaphase
Chairpersons: M. Rape, University of California, 
Berkeley; J. Ferrell, Stanford University, California
Regulation of CDK
Chairpersons: K. Oegema, Ludwig Institute for Cancer 
Research, La Jolla, California; D. Morgan, University of 
California, San Francisco
S. Biggins, A. Musacchio B. Mierzwa J. DeLuca, A. Amon
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Retroviruses
May 19–24 409 participants
ARRANGED BY John Guatelli, University of California, San Diego
 Welkin Johnson, Boston College
Organizers Drs. John Guatelli and Welkin Johnson are regular 
attendees who like many of the participants have “grown up” 
at this meeting and within its distinct community of scientists. 
Indeed, a characteristic feature of this meeting remains the high 
number of repeat attendees who come each year, where friend-
ships and collaborations are both initiated and maintained. In 
keeping with this theme, the organizers chose to recognize with 
a keynote talk the contributions of one of the strongest sup-
porters of the meeting, Dr. Paul Bieniasz. Paul presented an 
overview of his many contributions to basic retrovirology with 
a remarkable blend of the personal and scientifi c. His talk was 
very well received by the attendees, many of whom found it 
inspirational.
The other keynote speaker was Dr. Mary Carrington, who also presented a very well-received 
and humorous talk that highlighted her work on how immunogenetic variation affects the out-
come of disease caused by HIV. This talk, like that of Dr. Bieniasz, fi t a continuing trend in the 
meeting toward an emphasis on the host–pathogen relationship during retroviral infections.
Three annual prizes, originally instituted and endowed by the community of regular attend-
ees with assistance from the CSHL Meetings staff, were also awarded. These prizes memorialize 
three of our former colleagues who passed away unexpectedly in recent years (The Daniel Wolf 
Prize, The Ute von Schwedler Prize, and the Andy Kaplan Prize) and serve to encourage up-and-
coming scientists at the grad and postdoc/junior levels. The prizes are also a testament to the 
community nature of the CSH Retroviruses meeting and the continuity of the attendees over 
the years.
As previously, the meeting was organized into 13 sessions (10 oral and three posters); the pre-
sentations featured unpublished, primarily basic, research. The sessions focused on traditional 
W. Johnson, J. Guatelli
Z. Williams, I. Muñoz-Arias H. Levin, S. Hughes
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areas, such as specifi c aspects of the retroviral life cycle, as well as on classes of host defenses, 
especially specifi c restriction factors and the viral proteins that counteract them. A general session 
on evolution and endogenous retroviruses opened the meeting, and a general session on innate 
and intrinsic immunity to retroviruses closed the meeting. The organizers attempted to distribute 
talks that could fi t in alternative sessions in a manner that led to each session having “something 
for everyone.” Scientifi c highlights of the meeting included new insights into the mechanism of 
action of previously known restriction factors and the viral proteins that counteract them, such as 
the structure of the ternary complex the restriction factor SAMHD1, the lentiviral protein Vpx, 
and the cellular factor DCAF; and various aspects of newly recognized antiretroviral host pro-
teins such as the interferon-induced protein Mx2 and the IFITMs. A range of basic information 
regarding the retroviral life cycle, such as the role of nuclear import in integration site selection 
and the role of the integrase protein in virion maturation, was also presented. As previously, the 
meeting also exemplifi ed new techniques of scientifi c investigation that could be applied both to 
the discipline of retrovirology and to other work.
This meeting was funded in part by the National Institute of Allergy and Infectious Diseases, 
a branch of the National Institutes of Health; and Gilead Sciences, Inc.
PROGRAM
Evolution and Endogenous Retroviruses
Chairpersons: S. Goff, Columbia University, New York;
H. Levin, NICHD, National Institutes of Health, Bethesda, 
Maryland
Third Annual Ute von Schwedler Prize for Retrovirology
Awarded to: S.J. Rinh, The Rockefeller University
Entry
Chairpersons: R. Swanstrom, University of North Carolina, 
Chapel Hill; G. Melikian, Emory University, Atlanta, 
Georgia
Postentry I
Chairpersons: Z. Ambrose, University of Pittsburgh 
School of Medicine, Pennsylvania; S. Ross, University of 
Pennsylvania, Philadelphia
Keynote Address: The Infl uence of Immunogenetic 
 Variation on HIV Disease
M. Carrington, National Cancer Institute-Frederick
APOBEC, VIF, Mutagenesis
Chairpersons: V. Simon, Icahn School of Medicine, 
New York; L. Mansky, University of Minnesota, 
Minneapolis
PostEntry II
Chairpersons: E. Campbell, Loyola University-Chicago, 
Maywood, Illinois; S. Wilson, University of Glasgow, 
United Kingdom
Eighth Annual Andy Kaplan Prize
Awarded to: C. Goujon, King’s College London
E. Olson, I. Rouzina C. Mu˜nk, K. Sato R. Sutton, W. Walker
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VPX, SAMHD1, and VPR
Chairpersons: R. Gummuluru, Boston University School of 
Medicine, Massachusetts; F. Diaz-Griffero, Albert Einstein 
College of Medicine, Bronx, New York
Integration and Integrase
Chairpersons: M. Kvaratskhelia, The Ohio State University, 
Columbus; A. Engelman, Dana-Farber Cancer Institute, 
Boston, Massachusetts
Keynote Address
P. Bieniasz, Aaron Diamond AIDS Research Center, 
New York
Assembly
Chairpersons: K. Bishop, MRC National Institute for 
Medical Research, London, United Kingdom; J. Lingappa, 
University of Washington, Seattle
Late Replication, VPU, BST2/Tetherin
Chairpersons: S. Neil, King’s College London, United 
Kingdom; E. Cohen, Institut de Recherches Cliniques de 
Montréal, Canada
Innate/Intrinsic Immunity
Chairpersons: D. Evans, University of Wisconsin, Madison; 
M. Li, University of California, San Diego
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Glia in Health and Disease
July 17–21 247 participants
ARRANGED BY Dwight Bergles, Johns Hopkins University
 Marc Freeman, University of Massachusetts
Glial cells are as abundant as neurons in the nervous sys-
tem, but the diverse roles played by these cells under physi-
ological and pathological conditions are not well under-
stood. In this fi fth summer meeting, students and scientists 
from across the world gathered to discuss recent progress 
in this rapidly expanding fi eld. Speakers presented excit-
ing new data on a variety of important topics, such as the 
benefi cial and detrimental roles of microglia, glial control 
of brain metabolism, development and plasticity of myelin, 
and regulation of the blood brain barrier. The atmosphere 
was supportive, and there were lively discussions in oral ses-
sions, the poster sessions, and in informal gatherings. Re-
search involving vertebrate and invertebrate model systems 
was presented along with new developments in state-of-the-
art methodologies that are providing new insight into glial cell functions. One of the highlights of 
the meeting was the keynote address from Dr. Loren Looger, who described new molecular tools 
that he has developed to monitor and manipulate the behavior of glia in vivo. By the conclusion 
of the meeting, it was clear that information about properties and functions of glia is increasing 
exponentially, enabled by technological advances in the areas of imaging and molecular genetics. 
These studies are beginning to yield new insight into the roles of distinct groups of glia in central 
nervous system (CNS) development, information processing in neural circuits, disease progres-
sion, and CNS repair.
This meeting was funded in part by the National Institute of Neurological Disorders and 
Stroke, a branch of the National Institutes of Health.
M. Freeman, D. Bergles
P. Honsa, S. Kang N. Gunhanlar, E. Romanelli
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PROGRAM
Benefi cial and Detrimental Roles of Microglia
Chairpersons: R.M. Ransohoff, Massachusetts General 
Hospital, Boston; W. Gan, New York University, New York
Neuronal Structural Plasticity and Synaptic Pruning
Chairpersons: B. Stevens, Children’s Hospital Boston, 
Massachusetts; B. Barres, Stanford University, California
Glial Control of Brain Metabolism
Chairpersons: D. Attwell, University College London, 
United Kingdom; J. Rothstein, Johns Hopkins University, 
Baltimore, Maryland
Cell-Fate Specifi cation
Chairpersons: R. Rowitch, University of California, 
San Francisco; M. Götz, Lugwig Maximilians University, 
Munich, Germany
Roles of Astroglial Ca2+ Signaling
Chairpersons: B. Khakh, University of California, 
Los Angeles; D. Bergles, Johns Hopkins University, Baltimore, 
Maryland
Keynote Address
L. Looger, HHMI/Janelia Farm Research Campus
Development and Plasticity of Myelin
Chairpersons: W. Macklin, University of Colorado, Denver; 
J. Chan, University of California, San Francisco
Blood-Brain Barrier Regulation
Chairpersons: R. Daneman, University of California, 
San Francisco; J. Filosa, Georgia Health Sciences University, 
Augusta
Reactive Gliosis and Glial Scars
Chairpersons: L. Dimou, Ludwig Maximilians University, 
Munich, Germany; R. Giger, University of Michigan, 
Ann Arbor
B. Stevens
M. Iruarrizaga, N. Wu R. Garcia, B. Khakh, J. Petravicz, D. Bergles
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Messenger RNA: From Discovery to Synthesis and Regulation 
in Bacteria and Eukaryotes
August 9–11 128 participants
ARRANGED BY James Darnell, The Rockefeller University
 Adrian Krainer, Cold Spring Harbor Laboratory
 Mila Pollock, Cold Spring Harbor Laboratory
The appoximately 140 attendees at this conference included 40–45 graduate students and post-
doctoral fellows, satisfying one important aim of the meeting: to give younger scientists the fl avor 
of important research from the late 1950s onward. In organizing the meeting, Jim Darnell and 
Adrian Krainer, both scientists who have worked in the fi eld for decades, and Mila Pollock, Execu-
tive Director of the Cold Spring Harbor Laboratory Library and Archives, who is dedicated to pre-
serving the history of molecular biology, encouraged all speakers to address how they fi rst arrived 
at studying an aspect of mRNA formation and function. The talks began with the 1958–1960 
history leading to the idea of “messenger RNA” and its discovery as a newly identifi ed molecule 
in bacteria. Immediately following came the history of the confi rmation that the mRNA concept 
carried over to mammalian cells and the beginnings of establishing the biochemical requirements 
in eukaryotes.
The fi rst discussions about bacterial mRNA were presented by original participants in the 
revolution: Jim Watson, Sydney Brenner, Art Pardee, and Matt Meselson. Central to this progress 
was bacterial genetics, especially that which involved inducible enzymes, notably β-galactosidase, 
of course, and also T-even bacteriophage molecular biology.
Bacteria, lacking nuclei, offer their mRNA to ribosomes for immediate use, whereas eukaryotic 
cells have their DNA sequestered in a nucleus, and were soon found to exhibit unanticipated com-
plications to mRNA formation. The fi rst extractions of total mammalian cell RNA revealed previ-
ously undiscovered RNA processing. First, giant nucleolar RNA molecules (primary transcripts) 
L. Maquat, A. Krainer, M. Pollock, R. Roeder, J. Warner, M. Meselson, J. Darnell, W. Gilbert, B. Stillman
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were found to be precursors to shorter cytoplasmic ribosomal RNAs. Large nuclear DNA-like 
RNAs not related to ribosomes were also identifi ed. Cytoplasmic polyribosomes were found and 
they contained shorter DNA-like mRNA. Both the large DNA-like RNA and the mRNA had 
5′ caps as well as 3′ poly(A) addition, so RNA processing seemed likely in mRNA formation also. 
These experiments formed the history of eukaryotic mRNA from ~1963 to 1974.
In 1977, RNA splicing, which uses only disparate parts (exons) of large primary transcripts, 
while destroying the unused intervening parts (introns), was discovered. This discovery came 
through studies with adenovirus, a DNA virus that uses the host’s nuclear machinery to produce 
its mRNAs.
This exciting discovery was described for the fi rst time at the 1977 CSHL symposium in June 
by two research groups. Richard Roberts and Louise Chow, former CSHL workers, and Arnold 
Berk, representing the MIT lab of Phil Sharp, described the experiments showing that late in 
adenovirus infection, multiple different segments of a long primary transcript somehow were 
“spliced” together to make the various mRNAs, exhibiting at once basic splicing and also demon-
strating alternative splicing.
Several successive sessions provided details of how these processes—enzymatic synthesis of 
mRNA precursors, enzymatic 5′ and 3′ modifi cations of the transcripts, and the newly recognized 
RNA chemistry of splicing—were found to be carried out by large protein complexes or ribonu-
cleoprotein plus protein components of the spliceosome.
The complex fates of mRNA in the eukaryotic cytoplasm were the topic in several consecutive 
sessions. In some cases, there is directed movement of particular mRNAs to specifi c cellular lo-
cales and, most important, the fi nal concentration of eukaryotic mRNA depends not only on the 
rate of synthesis, but also on the regulated relative stability of different mRNA molecules. Finally, 
the translation into protein of different mRNAs requires a host of translation factors. The major 
insights that have been obtained into the mechanisms and regulation of all these events were dis-
cussed in the concluding sessions of the meeting.
As noted above, a major purpose of the meeting was to provide for beginning scientists (as well 
as those currently in mid-career) some fi rst-hand insights into very important discoveries that now 
range from 30 to 55 years old. From the many positive comments from attendees, it seems that the 
mission was at least partly accomplished.
We would like to gratefully acknowledge support from the following organizations, which 
made this conference possible: New England Biolabs, Looger, Rockefeller University, and Cold 
Spring Harbor Laboratory. Additional support was provided by Lexogen and Life Sciences 
Foundation.
A. Krainer, R. Roberts, O. Anezakow, R. Karni, M. Gierszewska R. Singer, J. Manley, C. Manley, D. Labbe, N. Sonnenberg
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PROGRAM
Bacterial mRNA, The Idea and Regulation
Chairperson: Tom Maniatis, Columbia University Medical 
Center, New York
The Successful Hunt for Eukaryotic mRNA and 
End Decorations
Chairperson: James Darnell, The Rockefeller University, 
New York
Origin of mRNA, Adenovirus to the Rescue
Chairperson: Joan Steitz, Yale University/HHMI, 
New Haven, Connecticut
Enzymes and Eukaryotic mRNA
Chairperson: Nahum Sonenberg, McGill University, 
Montreal, Quebec, Canada
Mechanisms of Splicing
Chairperson: Richard Roberts, New England BioLabs, 
Ipswich, Massachusetts
Nascent RNA: Associated Proteins and Early Events
Chairperson: Robert Roeder, The Rockefeller University, 
New York
Transport, Turnover, and Translation of Eukaryotic 
mRNA
Chairperson: Walter Gilbert, Harvard University, Cambridge, 
Massachusetts
L. Maquat, R. Overell A. Pardee, J. Watson M. Meselson, G. Enikolopov
J. Watson, J. Stietz, W. Gilbert, J. Witkowski, S. Brenner, J. Darnell, K. Maxson, M. Pollack, A. Gann
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Mechanisms and Models of Cancer
August 12–16 409 participants
ARRANGED BY Benjamin Neel, Princess Margaret Cancer Center, Canada
 Karen Vousden, Cancer Research United Kingdom Beatson Institute
 William Weiss, University of California, San Francisco
 Eileen White, The Rutgers Cancer Institute of New Jersey
Mechanisms that drive human cancers, along with cell- 
and animal-based models to test these mechanisms, remain 
central to our understanding of human malignancies. The 
current explosion in molecular cataloging of mutation, ex-
pression analyses, and epigenetic regulation that illuminate 
distinct human cancer types has carried with it an improved 
understanding of cancer metabolism and epigenetics, of-
fering new therapeutic opportunities. Our ability to un-
derstand cross-talk between cancer cells and stromal cells 
continues to improve, leading to immunotherapies that 
promise cures for diseases that had been rapidly fatal. This 
fi fth meeting held at the Laboratory again convened an 
international group of investigators whose collective work 
focused on these themes. Oral and poster presentations pro-
vided beautiful examples of how new insights have been gained from application of interdisciplin-
ary approaches that utilize genetics, developmental biology, genomics and proteomics, and model 
organisms (principally sophisticated mouse models, with signifi cant advances in methods for rapid 
genomic editing of normal and cancer genomes since our 2012 meeting) to advance the develop-
ment of rational therapeutics. A keynote address by Gerard Evan clarifi ed roles for MYC not just 
as a driver for cancer, but also as a cancer engine, as blockade of MYC showed effi cacy even in 
tumors that did not amplify or overexpress this oncoprotein. A keynote by Arnold Levine provided 
an introduction to p53 signaling, which illuminated new roles for this important tumor suppressor.
This meeting was funded in part by the National Cancer Institute, a branch of the National 
Institutes of Health.
K. Vousden, E. White, W. Weiss, B. Neel
L. Trotman, P.P. Scaglioni M. Wilhelm, G. Selivanova, A. Henriksson
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PROGRAM
Keynote Address: Targeting Cancer’s Engines, Not Its 
Drivers
G.I. Evan, University of Cambridge, United Kingdom
Experimental Therapeutics
Chairpersons: T. Letai, Dana-Farber Cancer Institute, 
Boston, Massachusetts; D. Tuveson, Cold Spring Harbor 
Laboratory
Mouse Models and Stem Cells
Chairpersons: C. Abate-Shen, Columbia University, 
New York; L. Parada, University of Texas Southwestern 
Medical Center, Dallas
Genomics and Epigenomics
Chairpersons: N. Jabado, McGill University Health Center, 
Montreal, Canada; J. Bradner, Dana-Farber Cancer 
Institute, Boston, Massachusetts
Keynote Address: The Evolution of Thymic Lymphomas 
in p53 Knock-Out Mice
A.J. Levine, Institute for Advanced Studies and Rutgers Cancer 
Institute of New Jersey
Cancer Drivers and Metabolism
Chairpersons: C. Prives, Columbia University, New York; 
L. Cantley, Weill Cornell Medical College, New York
Keynote Address: Oncogenic Ras Signaling: From Biology 
to Therapeutics
D. Bar-Sagi, New York University Langone Medical Center
RAS
Chairpersons: K. Cichowski, Brigham and Women’s Hospital, 
Boston, Massachusetts; M. McMahon, University of 
California, San Francisco
Signaling and Metastases
Chairpersons: G. Lozano, University of Texas MD Anderson 
Cancer Center, Houston; Y. Kang, Princeton University, 
New Jersey
Cancer Targets and Therapeutics
Chairpersons: M. Park, McGill University, Montreal, 
Canada; R. Levine, Memorial Sloan-Kettering Cancer 
Center, New York
Metabolism and Transformation
Chairpersons: W. Kaelin, HHMI/Dana Farber Cancer 
Institute, Boston, Massachusetts; E. Gottlieb, Cancer 
Research UK, Glasgow, United Kingdom
S. Lowe, R. Sordella
R. Ferretti, J. Lees, K. Masoumi M. Hemann, J. Zuber
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Nuclear Organization and Function
August 19–23 216 participants
ARRANGED BY Edith Heard, Curie Institute, France
 Martin Hetzer, Salk Institute for Biological Studies
 David L. Spector, Cold Spring Harbor Laboratory
The opening session on Tuesday evening highlighted 
 current studies of cell cycle and DNA repair, with Kim 
Naysmyth giving a stimulating discussion of the role of 
cohesin in DNA entrapment in yeast and gene regulation 
in fl ies. Jacqueline Barlow (Nussenzweig lab) showed that 
heavily transcribed and early replicated regions form fragile 
sites, presumably due to collisions between the transcrip-
tional and replication machineries, and that these sites can 
be a source of aberrant DNA rearrangement in B-cell lym-
phomas. Vishnu Dileep (Gilbert lab) presented work on the 
reorganization of chromatin during early G1 that refl ects 
the temporal and developmental control of DNA replica-
tion. Xiang Deng (Belmont lab) presented insights into the 
large-scale plasticity of chromatin fi bers during DNA repli-
cation, using live cell and super-resolution imaging.
In the session on the Nuclear Membrane and Nuclear Lamina, U. Kutay discussed the target-
ing of membrane proteins to the inner nuclear membrane and the role that nuclear localization sig-
nal sequences may have in targeting a protein back to the chromatin compartment. Megan King 
showed that the physical association of chromatin with the inner nuclear membrane provides stiff-
ness necessary to buffer cytoskeletal forces in interphase. Roland Foisner showed that chromatin 
association sites of A-type lamins and LAP2α cover long-range genomic regions that unexpectedly 
are located outside lamin-associated domains (LADs). Using structured illumination microscopy, 
Takeshi Shimi (Goldman lab) showed that individual lamin fi laments have a diameter of 10 nm.
D. Spector, E. Heard, M. Hetzer
Wine and Cheese Party
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Robert Singer led off the session on Biology of Nuclear RNA describing a single-molecule ap-
proach to track individual mRNA molecules in living cells. Andy Belmont focused on an innova-
tive technique to show that speckle-proximal domains correlate with gene-rich chromosome “R” 
bands, and speckle-distal domains correspond to LADs. Gayatri Arun (Spector lab) presented ex-
citing new insights into the role of the Malat1 lncRNA in breast cancer progression. Several other 
noncoding RNAs were also discussed, including the X-chromosomal FIRRE RNA proposed to be 
involved in enabling long-range chromosomal interactions, nucleolar Alu-containing RNAs, and 
centromeric RNAs with a role in telomerase.
In the Chromosome Conformation and Epigenetics session, Genevieve Almouzni described 
recent work exploring how CenH3/CENP-A in human cells depends on the chaperone DAXX. 
Elena Ezhkova discussed the impact of polycomb repressive complex 2 (PRC2) proteins in skin 
stem-cell differentiation control. Filipe Jacinto (Hetzer lab) presented exciting work on the role of 
Nup153 in the recruitment of the PRC1 complex to developmental genes in embryonic stem cells 
(ESCs). New insights into the relationship between nuclear position, chromatin state, transcrip-
tion, and replication timing were presented by Wendy Bickmore. Kyle Eagan (Kornberg lab) and 
Kerstine Wendt discussed the structure and function of topologically associated domains (TADs).
In the Transcription session, Victor Corces discussed the role of architectural proteins in the 
three-dimensional organization of the genome and their impact on modulating TAD organiza-
tion and gene expression during heat shock. Several talks discussed the roles of transcription fac-
tor binding in enabling 3D organization and variability in gene expression. Several single-cell or 
single-molecule studies were presented, for example, by Bas van Steensel, in the context of LADs. 
A talk from Gerd Blobel’s lab discussed the role of chromosome structure in the mitotic memory 
of gene expression states.
Jason Brickner led off the session on Chromosome Structure and showed that gene localization 
and clustering within the yeast nucleus are regulated by transcription factor activation, abun-
dance, and steric interference by transcription repression and modifi cation of chromatin structure 
at the nuclear pore complex (NPC). Hanhui Ma (Pederson lab) used the CRISPR/Cas9 method 
to visualize DNA sequences in chromosomes in live cells. Susan Gasser discussed the role of het-
erochromatin and nuclear organization in Caenorhabdidtis elegans development.
In the session on Nucleocytoplasmic Transport, Broder Schmid (Gorlich lab) showed that 
Nup98 FG domains spontaneously phase separate into particles with exquisite NPC-like perme-
ability. Christopher Lord (Wente lab) made the interesting observation that yeast mutants lacking 
GLFG domains of Nup116 display decreased replicative life span and linked nuclear transport to 
B. van Steensel, K. Nasmyth C. Sjögren, S. Buonomo R. Goldman, R. Singer
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mitochondrial function. Greg Matera gave an exciting talk about the engineering of histone genes 
using bacterial artifi cial chromosome (BAC)-based transgenic arrays in Drosophila.
In the fi nal session on Nuclear Function in Development and Disease, Megan Bodnar-Hogan 
(Spector lab) showed that the alleles of the Oct4 gene transiently pair during ESC differentiation, 
which might be critical for proper gene regulation. Aaron Straight showed that distinct domains 
of CENP-A act cooperatively to direct CENP-A assembly. Ronan Chaligne (Heard lab) showed 
that the aberrant expression of genes from the inactive X chromosome in breast cancer is associat-
ed with genome-wide depletion of H3K27me3 and enrichment of H4Ac and thus can be used as a 
prognostic or diagnostic tool in the clinic. Barbara Meyer discussed condensin-driven remodeling 
of X-chromosome topology during dosage compensation, which involves higher-order chromatin 
structure and association with NPCs.
PROGRAM
Cell Cycle and DNA Repair
Chairpersons: D. Gilbert, Florida State University, 
Tallahassee; K. Nasmyth, University of Oxford, 
United Kingdom
The Nuclear Membrane and Nuclear Lamina
Chairpersons: R. Foisner, Medical University Vienna, Austria; 
U. Kutay, ETH Zurich, Switzerland
Biology of Nuclear RNAs
Chairpersons: A. Belmont, University of Illinois, Urbana; 
R. Singer, Albert Einstein College of Medicine, Bronx, New York
Chromosome Conformation and Epigenetics
Chairpersons: G. Almouzni, Institut Curie, Paris, France;
W. Bickmore, University of Edinburgh, United Kingdom
Transcription
Chairpersons: V. Corces, Emory University, Atlanta, Georgia;
B. Van Steensel, Netherlands Cancer Institute, Amsterdam
Chromatin Organization
Chairpersons: J. Brickner, Northwestern University, Evanston, 
Illinois; S. Gasser, Friedrich Miescher Institute for Biomedical 
Research, Basel, Switzerland
Nucleocytoplasmic Transport
Chairperson: M. Hetzer, Salk Institute for Biological Studies, 
La Jolla, California
Nuclear Function in Development and Disease
Chairpersons: B. Meyer, University of California, Berkeley;
A. Straight, Stanford University, California
D. Gilbert, S. Buonomo
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Regulatory and Noncoding RNAs
August 26–30 286 participants
ARRANGED BY Gregory Hannon, Cold Spring Harbor Laboratory
 Elisa Izaurralde, Max-Planck Institute for Developmental Biology, Germany
 Michael Terns, University of Georgia
In the 50 years since RNA was identifi ed as a central com-
ponent in the fl ow of genetic information, it has become 
increasingly clear that RNA is more than a mere messen-
ger and has central roles across numerous biological pro-
cesses required for cell viability and function. In addition 
to the well-characterized prokaryotic and eukaryotic small 
RNAs such as CRISPRs, microRNAs, and Piwi-activat-
ing RNAs (piRNAs), eukaryotic genomes are pervasive-
ly transcribed to generate thousands of long noncoding 
RNAs (lncRNAs), which are emerging as key regulators 
of diverse cellular processes, but their precise physiological 
function is just beginning to be elucidated. Students and 
scientists engaged in multidisciplinary discussions regard-
ing the diverse and multifaceted roles of noncoding RNA 
across species and in a broad range of cellular processes. Sessions focused on recent, unpublished 
discoveries in the fi elds of prokaryotic and eukaryotic long and short noncoding RNAs. There 
were ample opportunities for discussions in the oral sessions, the poster sessions, and in informal 
settings. There was a strong sense of community, and the conviction that this meeting provides 
an excellent framework to bolstering discussions of the roles of noncoding RNAs, enhancing our 
understanding of gene regulation and function.
E. Izaurralde, M. Terns, G. Hannon
V. Ambros, N. Kim H. Persson, R. Søkilde, I. Newie N. Proudfoot, A. Molla
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PROGRAM
Keynote Address
D. Bartel, HHMI/Whitehead Institute/Massachusetts Institute 
of Technology
Keynote Address
J. Rinn, Harvard University
Noncoding RNAs in Prokaryotes
Chairpersons: J. Doudna, University of California, Berkeley;
J. Vogel, University of Würzburg, Germany
Transcription and Gene Silencing
Chairpersons: M. Buehler, Friedrich Miescher Institute, 
Basel, Switzerland; N. Proudfoot, University of Oxford, 
United Kingdom
CircRNA and piRNA Biogenesis
Chairpersons: A. Aravin, California Institute of Technology, 
Pasadena; M. Siomi, University of Tokyo, Japan
Biological Function of piRNAs
Chairpersons: R. Ketting, Hubrecht Institute, Utrecht, 
The Netherlands; D. O’Carroll, EMBL, Monterotondo, 
Italy
miRNAs: Biogenesis and Mechanisms
Chairperson: N. Kim, Seoul National University, Korea
Silencing Pathways in Plants and Other Species
Chairpersons: X. Chen, HHMI/University of California, 
Riverside; S. Jacobsen, HHMI/University of California, 
Los Angeles
Long Noncoding RNAs and Editing
Chairperson: A. Lambowitz, University of Texas, Austin
324
Translational Control
September 2–6 355 participants
ARRANGED BY Thomas Dever, National Institutes of Health
 Rachel Green, Johns Hopkins University
 Robert Schneider, New York University School of Medicine
This meeting attracted participants from around the world 
and included Ruth Lehmann, Jon R. Lorsch, and Robert 
H. Singer as keynote speakers, eight platform sessions, and 
three poster sessions that covered 279 abstracts.
Having celebrated more than a quarter century of Trans-
lational Control meetings at CSHL, this meeting demon-
strated the continued interest and importance of research on 
protein synthesis and its control in guiding gene expression 
in both healthy and diseased cells. Research in protein syn-
thesis ranges from studies examining the molecular intricacies 
of the ribosome to profi ling the genome-wide changes in the 
distribution of translated mRNAs in different tissues. This 
research also now includes its many manifestations in human 
disease, ranging from viral infection to cancer to neurological diseases when regulation goes awry. 
By bringing together a wide variety of researchers with different areas of expertise, this meeting 
serves a foundational role for a growing community of established and young investigators.
This year, the program was organized into seven main topics. The fi rst session on Initiation 
opened on Tuesday. A highlight was the keynote address by Jon Lorsch, an established member 
of the fi eld and the new director of the National Institute of General Medical Sciences at the 
National Institutes of Health. In his talk, Jon described proposals to investigate alternate  funding 
programs for researchers, as well as studies from his and collaborator laboratories revealing a high-
resolution structure of the ribosome in the act of selecting the start codon for translation. The 
following sessions included two additional keynote addresses by Rob Singer and Ruth Lehmann, 
as well as 82 short talks selected from among the submitted abstracts. In addition, 194 abstracts 
presented as posters in three sessions were well attended in both Bush Hall and the Hershey 
Building and prompted many discussions and exchange of ideas.
R. Schneider, R. Green, T. Dever
R. Schneider, I. Mohr W. Gilbert, A. Jacobson
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New technologies had a prominent role in the meeting. Cryo-electron microscopy (EM) struc-
tures of initiating and elongating ribosome complexes were presented at near-atomic resolution, re-
fl ecting the recent advances in direct detection technologies that have revolutionized the EM fi eld. 
Ribosomal profi ling studies examining the genome-wide distribution of ribosomes on mRNAs 
in a cell provided new insights into translational control, mRNA turnover, ribosome recycling 
following termination, and the impact of differentiation or activating signals on the repertoire of 
translated mRNAs. Intriguingly, two talks revealed linkages between promoter usage for mRNA 
transcription, localization of the mRNA in a cell, and mRNA translation.
Additional highlights of the meeting included new insights into the mechanism and physiological 
importance of translational control and an emerging role of translational regulation in disease in-
cluding viral infection, neurological diseases such as fragile-X syndrome, and many forms of human 
cancer. Interestingly, translation factors were identifi ed as nexus points for anticancer therapy and 
novel drug development. Unanticipated functions were reported for components of the translational 
machinery including a role for ribosomal proteins in directing the translation of key developmental 
control mRNAs. In a twist of function, microRNAs were shown to activate translation of select 
mRNAs, and translational changes at egg activation and during development were linked to control 
of mRNA polyadenylation and to inactivation of translational repressors, respectively. Molecular 
and biophysical studies provided new insights into ribosomal frameshifting including an intrigu-
ing link to microRNAs and to mRNA turnover; and fi nally, ribosome ubiquitylation was linked to 
protein quality control, and mRNA decay was reported to have important roles in autoregulatory 
pathways, selenium bioavailability, stem-cell fate, and T-cell activation.
In summary, the 2014 meeting continues the key role of the Translational Control meeting as 
the major focal point for the ongoing excitement and growth of this fi eld of research.
PROGRAM
Initiation
Chairperson: G. Pavitt, University of Manchester, United 
Kingdom
Turnover
Chairperson: T. Inada, Tohoku University, Sendai, Japan
Ribosomes
Chairperson: D. Wilson, University of Munich, Germany
Elongation and Termination
Chairperson: S. Blanchard, Weill Cornell Medical School, 
New York
Development
Chairperson: E. Gavis, Princeton University, New Jersey
Disease
Chairperson: P. Todd, University of Michigan, Ann Arbor
Regulation I
Chairperson: C. Calkhoven, University Medical Center 
Groningen, The Netherlands
Regulation II
Chairperson: N. Ingolia, University of California, 
Berkeley
S. Blanchard, A. Ferguson B. Bukau R. Luna, A. Marintchev
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Epigenetics and Chromatin
September 9–13 366 participants
ARRANGED BY Shelley Berger, University of Pennsylvania
 Robert Kingston, Massachusetts General Hospital and Harvard Medical School
 Juerg Mueller, Max-Planck Institute of Biochemistry, Germany
This second meeting following the successful start of this conference in 2012 
brought together researchers working on different aspects of chromatin biology 
and epigenetics. The focus was on molecular mechanisms by which chromatin 
and chromatin-modifying protein complexes regulate gene transcription. The 
spectrum of the oral and poster presentations illustrated that the fi eld has been 
making progress through studies that range from atomic resolution structure 
determination of chromatin proteins to the functional analyses of regulatory 
networks at the organism level.
The high attendance, large numbers of posters, and the sustained involve-
ment of the participants throughout the meeting were testament to its success. 
Scientists from 31 countries attended, and for many of these, it was their fi rst 
visit to Cold Spring Harbor. Several of the oral presentations selected from ab-
stracts and given by junior principal investigators, postdocs, or students turned 
out to be scientifi c highlights, showing the success of this meeting format as a 
presentation platform for junior researchers. The emergence of novel mechanistic themes in the 
fi eld, the progress in methodologies, and the presentations by junior scientists allowed for sus-
tained interest by the large and diverse audience throughout the different sessions.
These sessions covered the function and mechanisms of chromatin-modifying enzymes and the 
role of chromatin modifi cations in gene activation and repression (three sessions). The functions 
of chromatin proteins and noncoding RNAs in genome- and chromosome-wide regulation of 
gene expression were discussed in two different sessions and the processes that mediate long-range 
interactions and three-dimensional genome organization were discussed in a further session. The 
remaining two sessions focused on chromatin dynamics and remodeling and on the role of chro-
matin in controlling developmental processes at the organism level.
R. Kingston
C. Muchardt, S. Oberdoerffer, P. Hosseini B. Lesch, J. Cocquet R. Young
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Among the highlights of the meeting were presentations of the fi rst crystal structure of a his-
tone-modifying enzyme bound to a nucleosome, of novel approaches to investigate the dynamics 
of the genesis of chromatin states following DNA replication, about the function of DNA-binding 
proteins with “boundary” function in delimiting chromatin domains, or about the role of chro-
matin-modifying proteins in aging. These talks, together with presentations reporting unexpected 
fi ndings about the function of particular histone modifi cations, or snapshots providing insight 
into the three-dimensional organization of chromosomes, illustrated that chromatin still offers 
vast uncharted territory that waits to be explored.
PROGRAM
ncRNA
Chairperson: S. Grewal, NCI, National Institutes of Health, 
Bethesda, Maryland
Keynote Address: X-Chromosome Inactivation in Develop-
ment and Cancer
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Chairpersons: A. Akhtar, Max-Planck Institute of Immunology 
and Epigenetics, Freiburg, Germany; C. Peterson, University 
of Massachusetts Medical Center, Worcester
Keynote Address: Analysis of the Role of Spt6 in Controlling 
Transcriptional Accuracy in Yeast
F. Winston, Harvard Medical School, Boston, Massachusetts
Chromatin Genome-Wide
Chairpersons: R. Young, Whitehead Institute/Massachusetts 
Institute of Technology, Cambridge; L. Boyer, Massachusetts 
Institute of Technology, Cambridge
Covalent Modifi cation/Activation
Chairpersons: F. Winston, Harvard Medical School, Boston, 
Massachusetts; J. Tyler, University of Texas MD Anderson 
Cancer Center, Houston
Long-Range Interactions
Chairperson: E. Heard, Curie Institute, Paris, France
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Chairpersons: K. Helin, Biotech Research & Innovation Centre 
(BRIC), Copenhagen, Denmark; K. Zaret, University of 
Pennsylvania, Perelman School of Medicine, Philadelphia
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Chairpersons: A. Shilatifard, Stowers Institute for Medical 
Research, Kansas City, Missouri; G. Narlikar, University of 
California, San Francisco
Development and Inheritance
Chairpersons: W. Bickmore, MRC Human Genetics Unit, 
Edinburgh, United Kingdom; B. Cairns, University of Utah 
Huntsman Cancer Institute, Salt Lake City
N. Blackledge I. Gonzalez, C. Alabert M. Timmers, R. Baas
328
Axon Guidance, Synapse Formation, and Regeneration
September 16–20 285 participants
ARRANGED BY Greg Bashaw, University of Pennsylvania
 Alain Chedotal, Vision Institute, INSERM, Paris
 Yishi Jin, University of California, San Diego
The human brain has billions of nerve cells (neurons), and each neuron is typically connected 
to hundreds of other neurons via synapses in a highly precise fashion. This complex neural wir-
ing underlies the ability of humans, and other animals, to 
interact with the outside world, to learn, and to perform 
complex behaviors. Defects in the development of neural 
connections are being increasingly linked to the cause of 
neurological disease. One of the major challenges for the 
fi eld of neuroscience is to understand how nerve connec-
tions are made accurately and reliably. In the past decade, 
our understanding of the mechanisms that control axon 
growth and guidance, synaptogenesis, and the remodel-
ing of neural circuits during development has progressed 
rapidly from phenomenology to the identifi cation of spe-
cifi c molecular control mechanisms.
This ninth meeting in the series focused on key issues in 
axon guidance, circuit formation, synaptogenesis and axon 
regeneration, and included sessions devoted to particular problems in the assembly, plasticity, 
and repair of the nervous system, with speakers chosen from among the participants submitting 
abstracts by session chairs who are leaders in the fi eld. The response of the fi eld to this conference 
was one of overwhelming enthusiasm with more than 285 participants—240 of whom submit-
ted abstracts despite several Gordon Conferences held late in the summer on similar topics and 
the concurrent CSHL–Asia Neurobiology meeting. Forty-nine abstracts were selected for talks, 
in seven sessions, the remaining abstracts being presented as posters. Advanced and starting as-
sistant professors, postdoctoral fellows, and graduate students were well represented as speakers 
and participants. Session chairs at the meeting were well balanced between men and women, 
and the meeting had a clear international presence with participants from Europe, Australia, and 
Asia. Many of the outstanding talks this year were by graduate students. All of the major areas 
of research in the fi eld were covered, as were all of the major approaches (cellular, physiological, 
anatomical, molecular, dynamic imaging, biochemical, and genetic). In addition, there were three 
keynote addresses. The fi rst was given by Professor Cori Bargmann, a prominent fi gure in the fi eld 
of neuronal development, as well as in circuit contribution to complex behaviors in Caenorhabditis 
elegans. She reviewed her work on peptide modulation of behavior and also described her work as 
co-chair of the President’s Brain Initiative Committee.
The second and third keynote lectures were a pairing of speakers who have made profound 
and transformative contributions to dissecting neural circuits underlying complex behaviors. Karl 
Deisseroth focused on recent advances in optical techniques to dissect circuit function (optogenet-
ics, a fi eld that he founded), as well as the application of “Clarity” to the anatomical analysis and 
three-dimensional reconstruction of complex tissues. May-Britt Moser spoke on her transforma-
tive work on “grid cells,” special cells in the entorhinal cortex that endow mammalian species with 
a sense of place.
G. Bashaw, Y. Jin, A. Chedotal
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Also for the second time, this meeting held an informal event on professional development. 
Topics included how to search for mentors (postdoc or faculty), how to prepare for job interviews 
(academic or industry), how to write grants, managing teaching and research, how to balance life 
and work, and how to handle paper reviews. Two special discussion sessions were dedicated to 
publishing by the attending journal editors and to careers as a physician-scientist by investigators 
with an M.D. or M.D.-Ph.D. degree and clinical experience. About half of the senior investigators 
participated in the event. The students and postdocs expressed high appreciation for the close 
interaction and valuable advice they gained through this event. The business meeting was con-
ducted with open discussion.
Overall, this meeting provided an important forum for ideas and approaches and helped scien-
tists in the fi eld get the most up-to-date information, as well as enabling them to meet, to network, 
and to establish collaborations. As at the previous meeting, a need was identifi ed for an additional 
poster session because the number and quality of abstracts submitted for posters was so high. The 
three poster sessions were extremely well attended. In addition, fewer talks were scheduled in the 
evening, and a talk session after the evening keynote was eliminated to allow time for discussion 
and attendee interactions. Based on the enthusiastic comments of the participants, the intensity 
of the oral and poster sessions, and the large crowds that stayed up late every night at the bar to 
discuss science, the meeting was a great success.
This meeting was funded in part by National Institute for Neurological Disorders and Stroke, 
a branch of the National Institutes of Health.
PROGRAM
Axon to Synapse I
Chairpersons: W. Grueber, Columbia University, New York; 
A. Sagasti, University of California, Los Angeles
Synapse to Circuit I
Chairpersons: E. Nedivi, Massachusetts Institute of Technology, 
Cambridge; P. Scheiffele, University of Basel, Switzerland
Special Lecture
C. Bargmann, The Rockefeller University
Regeneration and Disease I
Chairpersons: A. DiAntonio, Washington University School 
of Medicine, St. Louis, Missouri; L.-H. Tsai, HHMI/
Massachusetts Institute of Technology, Cambridge
Axon to Synapse II
Chairpersons: F. Charron, IRCM/McGill University, 
Montréal, Canada; G. Lopez-Bendito, UMH-CSIC, 
Alicante, Spain
E. Stoeckli, Y. Zou, A. Sitko, T. Sakural, J. Frei B. Grill, A. Sagasti
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Synapse to Circuit II
Chairpersons: D. Colon-Ramos, Yale University, 
New Haven, Connecticut; K. McAllister, University of 
California, Davis
Regeneration and Disease II
Chairpersons: C. Bagni, Catholic University of Leuven, Belgium; 
Z. He, Children’s Hospital, Boston, Massachusetts
Special Lectures
K. Deisseroth, Stanford University, Stanford, California; 
M.-B. Moser, Kavli Institute for Systems Neuroscience, 
Norway
Axon to Synapse III
Chairpersons: S. Guthrie, King’s College London, United 
Kingdom; L. Richards, University of Queensland, St. Lucia, 
Australia
L. Boubakar L. Richards, K. Brose
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The History of Plasmids
September 21–23 128 participants
ARRANGED BY Stanley N. Cohen, Stanford University School of Medicine
 Stanley Falkow, Stanford University School of Medicine
 Richard Novick, New York University
 Dhruba Chattoraj, National Cancer Institute
 Chris Thomas, University of Birmingham, United Kingdom
 Jan Witkowski, Cold Spring Harbor Laboratory
This meeting was the third meeting held under the auspices of the Genentech Center for the 
History of Molecular Biology and Biotechnology at Cold Spring Harbor Laboratory. It was at-
tended by scientists and historians of science drawn from the United States and abroad. Keynote 
presentations were given on the opening evening by Stanley N. Cohen, Stanley Falkow, and Rich-
ard Novick, covering the basic biology of plasmids and their importance in public health and in 
biotechnology. These broad categories were covered in more detail during the rest of the meeting. 
Among the many notable participants were three whose work contributed to the biotechnology in-
dustry: Stanley Cohen, who, with Herb Boyer, developed plasmids as vectors for cloning; Ananda 
Chakrabarty, whose Supreme Court case opened the door to the patenting of life forms; and Marc 
van Montague, who, with Jeff Schell, developed cloning techniques for plants. A highlight of the 
meeting was a roundtable discussion of the historians’ and scientists’ views on the history of plas-
mids and history of science in general.
The meeting was made possible by generous support from the Society for Microbiology, Life 
Sciences Foundation, MedImmune Inc., Monsanto, and anonymous donors.
PROGRAM
Antibiotic Resistance
Chairperson: C. Thomas, University of Birmingham, 
United Kingdom
Bacterial Toxins and Microcins: Plasmids and 
Pathogenicity
Chairperson: G. Jacoby, Lahey Clinic, Burlington, 
Massachusetts
Plasmid Host Range and Evolution
Chairperson: R. Curtiss III, Arizona State University, Tempe
The Nature of Plasmids
Chairperson: B. Funnell, University of Toronto, Ontario, Canada
Transposition and Genetic Recombination
Chairperson: J. Mekalanos, Harvard Medical School, Boston, 
Massachusetts
Plasmid-Borne Genes and Metabolic Functions
Chairperson: G. Wagner, Uppsala University, Sweden
Roundtable: Historians’ and Scientists’ Views and 
General Discussion on the Role of Plasmids in the 
Overall History of the Biological Sciences
Chairperson: J. Witkowski, Banbury Center, Cold Spring 
Harbor Laboratory
Plasmids and Plants
Chairperson: J. Davies, University of British Columbia, 
Vancouver, Canada
Plasmid DNA Replication
Chairperson: S. Brom, Universidad Nacional Autonóma de 
México, Cuernavaca, Morelos Mexico
Interbacterial Transferability
Chairperson: D. Chattoraj, National Cancer Institute, 
Bethesda, Maryland
Stability, Partitioning, and Post-Segregation Lethality
Chairperson: D. Sherratt, University of Oxford, 
United Kingdom
Plasmids as Whole Systems
Chairperson: E. Top, University of Idaho, Moscow
Session 13: Future Directions in Plasmid Biology
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Molecular Genetics of Aging
September 29–October 3 277 participants
ARRANGED BY Vera Gorbunova, University of Rochester
 Malene Hansen, Sanford-Burnham Medical Research Institute, La Jolla
 David Sinclair, Harvard Medical School
Aging is the most prominent risk factor for developing a 
number of serious diseases, ranging from neurodegenera-
tion to cancer. Research from a number of laboratories has 
shown that the genetic makeup, along with the environ-
ment, plays a prominent role in the aging process. Among 
many signifi cant fi ndings is the identifi cation and charac-
terization of several molecular pathways that infl uence the 
rate of aging and susceptibility to age-related disorders in 
diverse species, from yeast to humans.
This conference provided a stimulating and informa-
tive forum for the latest results and emerging ideas in 
aging research at the molecular, cellular, and organismal 
levels. A session on longevity genes and human biology 
provided an update on the latest results on specifi c gene 
loci and their age-related effects. Dr. Cynthia Kenyon, who spoke about the new aging-focused 
company Calico, closed the session. Another session focused on DNA repair and senescence 
and highlighted new mechanisms that drive cells to stop proliferating with time. A new initia-
tive, the next session centered on comparative biology of aging and nonstandard animal models. 
This was an interesting session highlighting research using a variety of species, including kil-
lifi sh and naked mole rats. Following the fi rst poster session (featuring more than 100 posters), 
the next oral session was devoted to how cells maintain homeostasis, for example, by ensuring 
functional mitochondria. The conference subsequently featured a session on epigenetics, dis-
cussing age-related changes in DNA/chromatin organization. An emerging theme that came 
up in several talks of this session was activation of retrotransposons with age. Two subsequent 
sessions were devoted to the popular topic of metabolism, and how metabolic alterations have 
V. Gorbunova, M. Hansen
L. Guarente, D. Lombard H. Aquilaniu, R. SchmooklerJ. Weise, H. Feldser
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strong effects on aging. These sessions were split between a second poster session and a session 
on immunity and stem cells, emphasizing the importance of these cellular defense mechanisms 
and compartments for the aging process. The fi nal session focused on discussing nutrient sens-
ing and interventions and highlighted the latest fi ndings on noninvasive approaches to interfer-
ing with the aging process.
The conference was attended by researchers from many different fi elds who collectively con-
tributed to a very vibrant and exciting discussion forum focused on obtaining a better understand-
ing of the molecular mechanisms of aging so that better treatments can be developed against 
age-related diseases.
This meeting was funded in part by the National Institute on Aging, a branch of the National 
Institutes of Health; the Glenn Foundation for Medical Research; and Calico.
PROGRAM
Longevity Genes/Human Biology
Chairpersons: D. Chen, University of California, Berkeley; 
R. Shmookler-Reis, University of Arkansas for Medical 
Sciences, Little Rock
DNA Repair/Senescence
Chairpersons: L. Niedernhofer, Scripps Florida, Jupiter; 
S. Ahmed, University of North Carolina, Chapel Hill
Comparative Biology/Nonstandard Models
Chairpersons: A. Seluanov, University of Rochester, New York;
V. Gladyshev, Brigham and Women’s Hospital, Harvard 
Medical School, Boston, Massachusetts
Homeostasis
Chairpersons: T. Finkel, NHLBI, National Institutes of 
Health, Bethesda, Maryland; A. Dillin, HHMI/University of 
California, Berkeley
Epigenetics
Chairpersons: J. Sedivy, Brown University, Providence, Rhode 
Island; V. Lunyak, Buck Institute for Research on Aging, 
Novato, California
Metabolism I
Chairpersons: D. Cai, Albert Einstein College of Medicine, 
Bronx, New York; J. Auwerx, Ecole Polytechnique Fédérale 
de Lausanne, Switzerland
Immunity/Stem Cells
Chairpersons: A. Wagers, Harvard University, Cambridge, 
Massachusetts; S. Morrison, HHMI/University of Texas 
Southwestern Medical Center, Dallas
Metabolism II
Chairpersons: L. Guarente, Massachusetts Institute of 
Technology, Cambridge; M. Donath, University Hospital 
Basel, Switzerland
Nutrient Sensing and Interventions
Chairpersons: J. Mitchell, Harvard School of Public Health, 
Boston, Massachusetts; S. Simpson, University of Sydney, 
Australia
M. Gill, T. Hoppe S. Libert, V. Gladyshev
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Germ Cells
October 7–11 198 participants
ARRANGED BY Stephen DiNardo, Perelman School of Medicine at the University of Pennsylvania
 Mary Ann Handel, The Jackson Laboratory
 E. Jane Hubbard, New York University School of Medicine
Sessions and Science: The signifi cance of this meeting de-
rives from its emphasis on high-resolution analysis from in 
vivo studies using cellular, molecular, and/or genomic ap-
proaches. Importantly, this is coupled to an examination 
of germ cell biology comparatively among diverse organ-
isms. The meeting met these historically high standards. 
Attendance was high, which hit the average of the last six 
meetings. Such participation in the currently dismal fund-
ing climate demonstrates how strongly the community sup-
ports this valued meeting and its format.
The co-organizers fashioned several new session themes. 
For example, exciting progress unifying diverse biological 
systems led to a novel session on “Evolution and Conserva-
tion,” bookended by outstanding invited speaker talks on 
evolutionary origins of meiosis and germ cell specifi cation (Logsdon, Extavour). Another new ses-
sion focused on “Energetics and External Infl uences on the Germ Line,” which featured surprising 
roles of mitochondria and hypoxia (Capel, Hurd/Lehmann, Oatley), along with additional meta-
bolic infl uences on germ cells (Arkov, Drummond-Barbosa). These new sessions were comple-
mented by outstanding work across traditionally strong areas including progress on fertilization 
and sperm receptor candidates (Dean); surprising parallels between vertebrate and invertebrate 
oogenesis (Greenstein, Lei/Spradling), as well as the nature of conserved germ granules (Sey-
doux); the plasticity of sexual fate (Matunis, Van Doren); meiotic crossover selection and licens-
ing (Hawley, Campos-Ortera, Yanowitz); and syndromes associated with assisted reproduction 
(Bartolomei). Of special note was a talk involving high school science outreach with implications 
for public policy on dietary supplements (O’Reilly).
M.A. Handel, S. DiNardo, E.J. Hubbard
M. Amoyel, L. Wingert G. Fanourgakis, M. Stanzione
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Diversity: The meeting was balanced for experimental systems with 22 talks on mouse 
or human systems, 13 on Caenorhabditis elegans, 15 on the fruit fl y, and six on other mod-
els. This allowed participants to appreciate deeply conserved mechanisms and underscored 
a great strength of the meeting: signifi cant inclusion of nonmammalian systems and a clear 
focus on basic biology. Additionally, the meeting provided ample opportunity for early-career 
scientists: The 56 talks included 10 student, 15 postdoctoral, eight junior, and fi ve mid-
career faculty (gender balance, 31 male, 25 female), with nine international speakers. New 
perspectives were also fostered, as seven of the invited slots had not given invited speaker talks 
previously.
Finally, two successful changes in format were implemented to encourage discussion. First, 
the average length of speaking time for each session was reduced, increasing time for questions 
and discussion. Second, organizers gave CSHL T-shirts to the fi rst two students posing ques-
tions at each session in order to encourage questions from this underrepresented group. As a 
consequence, talks averaged 10–12 questions, with signifi cant time for discussion from various 
perspectives.
This meeting thus continues to be a great success as judged by the criteria of exemplary sci-
ence, the breadth and depth of its discussion, and attendance. The co-organizers have always been 
drawn from the broader germline community, each with keen appreciation of the strengths of this 
meeting. Thus, the co-organizers selected Bob Braun, who eminently meets these criteria, as one 
of the 2016 co-organizers. While in the past the current co-organizers would select the three future 
co-organizers, this year’s mandate was to select only one. We are confi dent that Bob will fi ll out 
the co-organizer slate with colleagues who appreciate the necessity of maintaining organism and 
system diversity.
This meeting was funded in part by National Institute of Child Health and Human Devel-
opment, a branch of the National Institutes of Health; the Lalor Foundation; and the March of 
Dimes Birth Defects Foundation.
PROGRAM
Germ Cell Specifi cation and Identity
Chairpersons: B. Capel, Duke University Medical Center, 
Durham, North Carolina; C. Extavour, Harvard University, 
Cambridge, Massachusetts
Gametes, Fertilization and Egg Embryo Transition
Chairpersons: M. Van Doren, Johns Hopkins University, 
Baltimore, Maryland; J. Yanowitz, Magee-Women’s Research 
Institute, Pittsburgh, Pennsylvania
R.S. Hawley, A. Spradling Q. En, Y.J. Wu
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Protecting the Germ Line and Offspring
Chairpersons: S. Arur, MD Anderson Cancer Center, Houston, 
Texas; X. Chen, Johns Hopkins University, Baltimore, 
Maryland
Germ Granules and Posttranscriptional Regulation
Chairpersons: D. Katz, Emory University, Atlanta, Georgia; 
M. Wilkinson, University of California, San Diego
Energetics and External Infl uences on Germ Cells
Chairpersons: J. Dean, National Institutes of Health, Bethesda, 
Maryland; M. Colaiacovo, Harvard Medical School, Boston, 
Massachusetts
Germline Stem Cells and Niches
Chairpersons: E. Matunis, Johns Hopkins University School 
of Medicine, Baltimore, Maryland; P. Cohen, Cornell 
University, Ithaca, New York
Meiotic Initiation and Meiosis
Chairpersons: J. Logsdon, University of Iowa, Iowa City;
M. Lilly, NICHD, National Institutes of Health, Bethesda, 
Maryland
Evolution and Conservation
Chairpersons: M.L. King, University of Miami School of 
Medicine, Florida; D. Greenstein, University of Minnesota, 
Minneapolis
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Nuclear Receptors and Disease
October 28–November 1 141 participants
ARRANGED BY Ron Evans, HHMI/Salk Institute for Biological Studies
 Karen Knudsen, Thomas Jefferson University
 Anastasia Kralli, The Scripps Research Institute
 Susanne Mandrup, University of Southern Denmark
This fi fth meeting has been held biennially since 2006. 
Nuclear receptors are ligand-regulated transcription fac-
tors that have key roles in cell growth and differentiation, 
development, and physiology. Their deregulated activity is 
implicated in the development or progression of different 
types of cancer, developmental disorders, and metabolic dis-
eases. Accordingly, nuclear receptors can also serve as targets 
for therapeutic intervention in many of these diseases. The 
meeting provided a unique forum for basic and clinical re-
searchers in the fi eld to discuss new developments in areas 
ranging from basic molecular mechanisms and cellular func-
tions to physiological functions, pathological roles in cancer 
and metabolic disease, and potential as therapeutic targets.
The meeting started with two outstanding keynote talks 
that highlighted the molecular mechanisms versus clinical implications overarching theme. Peter 
Fraser presented new approaches that reveal large-scale chromosome structure, map long-range chro-
matin interactions, and link three-dimensional organization to control of gene expression. Peter Nel-
son discussed how changes in androgen receptor signaling can enable prostate cancer to progress to 
recurrent “castration-resistant” disease. The opening session was followed by eight oral sessions and 
two poster sessions that continued on the interplay of basic science with roles of nuclear receptors in 
diseases. Sessions 2 and 4 focused on epigenetic regulation and the roles of chromatin, cofactors, and 
posttranslational modifi cations in determining nuclear receptor activity at different cellular, physi-
ological, and disease models. Session 8 furthered the basic mechanism side by reports on genomic 
binding of receptors and structural insights of receptors and receptor cofactors. Session 7 focused on 
R. Evans, S. Mandrup
C. Helsen, D. Boyanova C. Wall, H. Uhlenhaut
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cancer, and Sessions 5 and 9 displayed the latest developments in the fi eld of metabolism. Session 
10 on the fi nal day closed with talks on infl ammation and age-related diseases. Overall, there were 
47 talks: 28 long talks from invited speakers and the four organizers and 19 short talks chosen from 
abstracts and aiming at enhancing exposure of younger investigators. The two poster sessions (73 
posters presented in Sessions 3 and 6) further enhanced the program by highlighting research in all 
areas and creating an active setting for interactions and further discussions.
All sessions were characterized by the presentation of unpublished research and open and lively 
discussions. The format of this meeting, centered on a class of molecules that function in diverse 
pathways and are implicated in a wide range of diseases, enabled the cross-fertilization of ideas 
developed in one biological system but widely applicable to others, the emergence of common 
themes and concepts across diseases, and a cross-education of experts in cancer, metabolic disease, 
and age-related diseases that is essential in our efforts to harness the regulatory capacities of these 
receptors in therapeutic approaches.
This meeting was funded in part by the National Institute of Diabetes and Digestive and Kid-
ney Diseases, a branch of the National Institutes of Health.
PROGRAM
Keynote Address: Splicing, Repression, and Co-Option: 
How the AR Retains Command of Prostate Cancer 
Mutiny After Mutiny
P. Nelson, University of Washington School of Medicine, 
Seattle
Keynote Address: Long-Range Interactions, Chromosome 
Structure, and Genome Organization Links to Gene 
Expression Control
P. Fraser, Babraham Institute, Cambridge, United Kingdom
Chromatin and Transcriptional Networks
Chairperson: R. Evans, The Salk Institute for Biological 
Studies, La Jolla, California
Cofactors and Mechanisms
Chairperson: D. McDonnell, Duke University, Durham, 
North Carolina
Metabolism
Chairperson: A. Kralli, The Scripps Research Institute, 
La Jolla, California
Cancer
Chairperson: K. Yamamoto, University of California, 
San Francisco
Structure and Ligands
Chairperson: C. Rochette-Egly, IGBMC/INSERM, 
Illkirch, France
Metabolic Disorders
Chairperson: M. Lazar, University of Pennsylvania, 
Philadelphia
Infl ammation and Aging
Chairperson: B. Desvergne, University of Lausanne, 
Switzerland
J. Francois, A.E. Swinstead I. Rogatsky, M. Lazar
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Biological Data Science
November 5–8 200 participants
ARRANGED BY Anne Carpenter, Broad Institute of Harvard/Massaschusetts Institute of Technology
 Michael Schatz, Simons Center for Quantitative Biology, Cold Spring Harbor
 Matt Wood, Amazon Web Services
This inaugural conference was the fi rst in a new biennial series focusing on the infrastructure, 
software, and algorithms needed to analyze large data sets in biological research. It brought to-
gether researchers from diverse areas of biology and diverse computational domains, with interest 
in large-scale data analysis in common. The goal of the meeting was for attendees to step a bit 
outside their usual domain and glean lessons from other areas of research. In this, it was a success. 
With a heavy emphasis on genome sequence and transcriptional expression data, attendees none-
theless spanned numerous data-intensive fi elds such as imaging, proteomics, and text mining. The 
talks and poster presentations were similarly diverse.
Two hundred researchers participated in the inaugural meeting, with 107 abstracts submitted 
from academic, government, and industry laboratories by researchers who regularly mine large 
data sets for genomics, imaging, translational, and clinical projects. There were 10 invited talks 
and two keynote lectures, as well as 33 additional talks selected from submitted abstracts and 74 
poster presentations. The fi rst keynote lecture was given by David Haussler, who described the 
timeliness, need for, and overall design of the Global Alliance for Genomics and Health. The sec-
ond keynote was a master lecture given by Kristin Lauter, who described new methods for securely 
but privately sharing data sets. The meeting participants had a strong presence on Twitter, with all 
of the talks opting to be discussed on Twitter and live-tweeted by a number of audience members 
(hashtag #biodata14).
J. Williams, D. Haussler, A. Carpenter, M. Schatz, D. Church
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PROGRAM
Keynote Address: Global Exchange of Human Genetic 
Data for Medicine and Research
D.H. Haussler, HHMI/University of California, Santa Cruz
Data and Data Mining I
Chairpersons: D. Church, Personalis, Inc. Menlo Park, 
California; M. Massie, University of California, Berkeley
Data and Data Mining II
Chairperson: O. Troyanskaya, Princeton University, New Jersey
Compute Infrastructure
Chairpersons: R. Stevens, Argonne National Lab/University 
of Chicago, Illinois; J. Taylor, Johns Hopkins University, 
Baltimore, Maryland
Algorithmics
Chairpersons: B. Langmead, Johns Hopkins University, 
Baltimore, Maryland; M. Carneiro, Broad Institute, 
Cambridge, Massachusetts
Biological Software
Chairpersons: J. Williams, Cold Spring Harbor Laboratory; 
R. Margolis, NIDDK, National Institutes of Health, 
Bethesda, Maryland
Master Lecture: Homomorphic Encryption as a Tool to 
Preserve Privacy in Genomic Computation
K.E. Lauter, Microsoft Research, Redmond, Washington
Human Biology
Chairpersons: E. Perakslis, Harvard Medical School, Boston, 
Massachusetts; M. Gerstein, Yale University, New Haven, 
Connecticut
S. Payne, S. Tsuji H. Sussman, A. Mortazavi A. Cox, Y. Huang
M. Burnett, S. Sadedin H.T. Wu, D. Ray
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Personal Genomes: Discovery, Treatment, and Outcomes
November 12–15 156 participants
ARRANGED BY Ann Daly, Newcastle University, United Kingdom
 Nicholas Katsanis, Duke University
 Deanna Kroetz, University of California, San Francisco
 James R. Lupski, Baylor College of Medicine
This seventh meeting again combined both the content of 
the Personal Genomes Meeting and that of the Pharma-
cogenomics Meeting to bring together scientifi c commu-
nities interested in gleaning medically actionable informa-
tion from individual personal genomes. The meeting was 
entitled “Personal Genomes: Discovery, Treatment, and 
Outcomes” and was a further step toward Precision Medi-
cine that utilizes genomic information for guiding differ-
ential diagnoses and potentially optimizing and directing 
therapeutic interventions based on individual genetic/ge-
nomic variation. Keynote speaker Richard Lifton described 
a series of clinical examples showing the value of exome 
sequencing in diagnosis and treatment of rare diseases. He 
provided a range of fascinating examples and showed clear-
ly that exome sequencing gives valuable insights into clinical issues. For example, sequencing of 
pseudohyperaldosteronism type II cases revealed that this phenotype is associated with dominant 
mutations in one of four different genes. Further study of these mutations has led to identifi ca-
tion of a novel pathway involved in angiotensin II signaling, and improved understanding of this 
pathway explains why high dietary potassium lowers blood pressure. Rick showed data that gave 
insights into how human genetic approaches and the discovery of loss-of-function “protective vari-
ants” could provide the gene entry into therapeutic targets. The keynote was followed by two fur-
ther talks. Misha  Angrist provided a personal, thought- provoking 
and mainly positive perspective on the Personal Genomes project, 
which he described as “mostly probabalistic but occasionally de-
terministic.” We then switched to pharmacogenomics with Alan 
Shuldiner, who described the importance of the CYP2C19 geno-
type to the outcome of clopidogrel treatment and the ongoing 
challenges for clinical implementation. This varied opening ses-
sion encompassing the two main strands of the meeting was a 
great start.
On the second day, we covered clinical sequencing and the in-
terpretation of genome variation, with emphasis on moving from 
populations to individuals, followed by a session on somatic cell 
genomics with emphasis on cancer. In both of these sessions, the 
challenges of data interpretation and clinical translation were dis-
cussed. In the morning session, one highlight included a study 
showing how the combination of rare null variants and a common 
risk allele at a locus could result in the common complex trait of 
scoliosis. A poster session with 41 posters also took place in the 
early evening. We then moved to population sequencing, which 
J. Lupski, D. Kroetz, A. Daly
G. Oliver, R. Weinshilboum, L. Wang
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emphasized multiethnic groups and minority populations, and to pharmacogenomics on day 3. 
The utility of exome sequencing in pharmacogenomics in addition to Mendelian diseases was dem-
onstrated by studies on warfarin dosing and adverse drug reactions that detected several novel 
genetic risk factors. The ethics panel session, which is always a feature of the meeting, involved an 
Oxford-style debate with the motion “Implementation of DNA sequencing in clinical medicine: 
The bar has been set too high,” with Munir Pirmohamed in favor and Bob Nussbaum against. At 
the start of the debate, the audience voted in favor of the motion, but by the end of session, they had 
been persuaded by Bob to reject it. Both Munir and Bob did a terrifi c job arguing their position!
On the fi nal day, a second keynote lecture was given by Nancy Cox, who spoke on moving 
beyond coding sequences to investigate regulatory variants using “multiomics” approaches. Most 
of the examples she showed were concerned with complex diseases, but these new approaches can 
also be applied to pharmacogenomics and Mendelian disorders. Further talks on moving beyond 
coding sequences were also included in this exciting fi nal session.
Once again, the meeting was a celebration of the advances in genomic technologies, their 
application to personal genomes, and how the variation discovered can transition to clinical ap-
plication. It is clear that excellent progress is being made on many different fronts using genome 
sequencing, but considerable challenges in both moving into noncoding regions and clinical im-
plementation remain.
This meeting was funded in part by Regeneron Pharmaceuticals, Inc., and Quest Diagnostics/
Athena Diagnostics.
PROGRAM
Patient Genomes: Discovery and Personal Perspectives
Chairperson: J. Lupski, Baylor College of Medicine, Houston, 
Texas
Keynote Address: Genes, Genomes, and the Future of 
Medicine
R. Lifton, Yale University School of Medicine
Clinical Sequencing
Chairperson: N. Katsanis, Duke University, Durham, 
North Carolina
Interpreting Genome Variation I: From Populations to 
Individuals
Chairperson: S. Leal, Baylor College of Medicine, Houston, Texas
Somatic Cell Genomics
Chairperson: D. Kroetz, University of California, 
San Francisco
Population-Based Sequencing
Chairperson: A. Shuldiner, University of Maryland School of 
Medicine, Baltimore
Pharmacogenetics
Chairperson: A. Daly, Newcastle University Medical School, 
United Kingdom
Ethics Panel
Chairperson: N. Katsanis, Duke University, Durham, 
North Carolina
B. Ozenberger, J. Hu D. Deacon, S. Waszak, W. Mueller
344  Meetings
Interpreting Genomic Variation II: Beyond Coding 
Sequence
Chairperson: N. Cox, University of Chicago, Illinois
Keynote Address: New Ways of Integrating Genome Varia-
tion and Genome Function to Inform Pharmacogenomics 
Discovery and Translation
J. Cox, University of Chicago, Illinois
E. Woodahl, M. Angrist F. Ouellette, M. Cherry
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Neurodegenerative Diseases, Biology, and Therapeutics
December 3–6 179 participants
ARRANGED BY Karen Duff, Columbia University Medical Center
 Jeffrey Rothstein, Johns Hopkins University School of Medicine
 John Trojanowski, University of Pennsylvania School of Medicine
Up to one-half of those aged 85 years or older will develop one 
or multiple debilitating neurodegenerative diseases (NDDs) 
of the central nervous system. These diverse NDDs include 
Alzheimer’s disease (AD), Parkinson’s disease (PD), fronto-
temporal lobe degeneration (FTLD), Huntington’s disease 
(HD), and amyotrophic lateral sclerosis (ALS). To refl ect 
some of the newest and most relevant research while pro-
viding a diverse base of current advances in understanding 
these neurodegenerative diseases, the topics in this meeting 
included prion-like spread of diseases including AD, PD, 
and tauopathies, new biology of the ALS/FTLD C9ORF72 
mutation, new thoughts about biomarkers and comorbidi-
ties, the role of RNA in the pathogenesis of neurodegenera-
tive diseases, the role of glia (especially their potential as tar-
gets for therapy), and a number of therapeutic targets and approaches including immune therapy, 
small-molecule drugs, and gene inactivation strategies.
Although most forms of neurodegenerative disease occur in the absence of obvious heritability 
or identifi able genetic mutations, it has been possible during the past 25 years to discover un-
common genetic mutations as well as risk-modifying DNA changes in some neurodegenerative 
diseases, and predictable causative changes in others. For some of the neurodegenerative diseases, 
common genetic abnormalities lead to a spectrum of disease phenotypes, which is clearly seen 
for FTLD and ALS. New insight into disease mechanisms and possible overlapping therapeutic 
approaches are implicated. From these fi ndings, transgenic technology has rapidly led to the de-
velopment of mouse, fruit fl y, and nematode model systems that partly recapitulate the clinical 
J. Rothstein, K. Duff, J. Trojanowski
K. Spiller, S. Porta, K. Ring J. Buxbaum, M. Hoffman
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abnormalities of the human diseases as well as some of the hallmark molecular and morphologi-
cal pathology of the conditions. Of particular relevance in this respect is the emergence of new 
ideas about the spread of disease entities within the brain and from the periphery, similar to that 
seen in the prion diseases, which has become a dominant topic in AD, FTLD, and PD research. 
New tools using human-induced pluripotent cells derived from these degenerative diseases were 
also discussed. This new and exciting fi eld of research was well represented.
This biannual meeting series started in 2000, and as in previous years, the explicit goal of 
the meeting focuses on identifying disease pathways and facilitating the translation of “break-
through” science into effective medicines. At this year’s meeting, numerous academic labs and 
commercial drug discovery organizations presented data on novel compounds, clinical trial re-
sults, or new druggable pathways for AD, PD, FTLD, HD, ALS, spinal muscular atrophy, spino-
cerebellar ataxia, and prion diseases. Indeed, of the 179 participants, 19 came from industry. In 
recent years, various molecular, biochemical, and cell-based screens have led to the development 
of small-molecule, peptide, and oligonucleotide compounds that show promise in neurodegenera-
tive disease models. Importantly, the emergence of gene inactivation strategies using stabilized 
antisense oligonucleotides has shown particular promise both as a tool for studying pathogenesis 
and, more importantly, as a clinically relevant therapeutic agent that could be used to knock down 
pathological proteins or pathways affected in several diseases.
For this meeting, platform sessions were organized around common technological themes. 
Chairpersons, invited speakers, and speakers selected from submitted abstracts were drawn from 
the academic and pharma sectors, representing 19 countries. The discussion of new unpublished 
data was emphasized and adequate time was left for discussion of each presentation. Poster pre-
sentations also covered a wide range of neurodegenerative disease pathways, new animal and 
insect models, and novel therapeutic insights. Posters were displayed for an extended period 
during the meeting, and poster viewing was especially encouraged during the cocktail hours 
before the evening meals. In general, the meeting was most notable for its breadth of coverage 
of different neurodegenerative diseases, insightful and novel presentations, as well as in-depth 
discussions of each presentation—and the insights gleaned from lively interaction among the 
diverse participants.
This meeting was funded in part by National Institute of Neurological Disorders and Stroke, a 
branch of the National Institutes of Health; and Merck Research Laboratories.
I. Ahmed, Y. Wairkar J. Jankowsky, T. Maniatis
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PROGRAM
Prion-Like Neurodegeneration
Chairperson: V. Lee, University of Pennsylvania School of 
Medicine, Philadelphia
AD/PD Pathology
Chairperson: K. Duff, Columbia University, New York
TDP43/C9orf72: RNA Metabolism in Neurodegenerative 
Disease
Chairperson: J. Rothstein, Johns Hopkins University School of 
Medicine, Baltimore, Maryland
Submitted Abstracts
Chairperson: J. Trojanowski, University of Pennsylvania 
School of Medicine, Philadelphia
Neurons and Glia: Therapeutic Opportunities
Chairperson: S. Przedborski, Columbia University, 
New York
Neurons and Glia: Models
Chairperson: R. Ransohoff, Cleveland Clinic, Ohio
Submitted Abstracts
Chairperson: J. Trojanowski, University of Pennsylvania 
School of Medicine, Philadelphia
Gene Inactivation and Protein-Lowering Strategies
Chairperson: T. Miller, Washington University, St. Louis, 
Missouri
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Blood Brain Barrier
December 10–13 130 participants
ARRANGED BY Britta Engelhardt, University of Bern, Switzerland
 Stefan Liebner, Goethe University Clinic, Germany
 Ryan Watts, Genentech, Inc.
Highlighted at this meeting were advances in the cellular 
and molecular aspects of blood brain barrier (BBB) devel-
opment, function, and disease. The conference was well at-
tended, particularly by young scientists (graduate students 
and postdoctoral fellows), who also had a prominent role in 
giving oral presentations. This made for a lively discussion 
of unpublished data, giving foresight into the future of BBB 
research.
As in years past, the conference had a substantial rep-
resentation of genetic model organisms, imaging, in vitro 
models, and powerful molecular genetics that highlighted 
invertebrate and vertebrate BBB physiology and develop-
ment. A major focus of the conference was the emerging 
fi eld of BBB maintenance, with a focus on molecular mech-
anisms of BBB modulation for drug transport, and a growing focus on the BBB in disease.
Two keynote addresses were given by Richard Daneman on BBB development and function 
and Maiken Nedergaard on the newly described glymphatic system in regulation of fl uid fl ow 
in the central nervous system. As is traditional at CSHL meetings, selection of material for oral 
and poster presentation was made by the organizers and individual session chairs on the basis of 
scientifi c merit.
This meeting was funded in part by National Institute of Neurological Disorders and Stroke, 
a branch of the National Institutes of Health; and Forest Laboratories, Inc.
S. Liebner, R. Watts, B. Engelhardt
R. Dieguez, H.A. Andrews J. Smith, J. Abbot
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PROGRAM
BBB Development
Chairpersons: J. Nathans, Johns Hopkins School of Medicine, 
Baltimore, Maryland; B. Vanhollebeke, Université Libre de 
Bruxelles, Gosselies, Belgium
The Functional BBB
Chairpersons: D. Agalliu, University of California, Irvine; 
C. Gu, Harvard Medical School, Boston, Massachusetts
Keynote Address
R. Daneman, University of California, San Francisco
BBB in a Dish
Chairpersons: E. Shusta, University of Wisconsin, Madison; 
J. Wong, Houston Methodist Research Institute, Texas
Molecular BBB Transport
Chairpersons: P.-O. Freskgard, F. Hoffmann-La Roche 
AG, Basel, Switzerland; J. Yu Zuchero, Genentech, South 
San Francisco, California
The Diseased BBB
Chairpersons: R. Klein, Washington University School 
of Medicine, St. Louis, Missouri; R. Bell, Pfi zer, Inc., 
Cambridge, Massachusetts
Keynote Address
M. Nedergaard, University of Rochester Medical Center
Pericytes, Astrocytes, and the BBB
Chairpersons: J. Abbott, King’s College London, United 
Kingdom; B. Appel, University of Colorado School of 
Medicine, Aurora
M. Allingham, N. Acharya F. Elwood, M. Allingham
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POSTGRADUATE COURSES
Workshop on Leadership in Bioscience
March 14–16
INSTRUCTORS C. Cohen, Science Management Associates, Newton, Massachusetts
 D. Kennedy, Workshop Co-Facilitator, Cambridge, Massachusetts
This highly interactive 3.5-day workshop develops the skills students need to lead and interact ef-
fectively with others, in both one-on-one and group settings. It focused on techniques, situations, 
and challenges that relate specifi cally to leading and managing in the scientifi c workplace. It also 
emphasized learning by doing and involved role-playing, giving and receiving feedback, and group 
problem solving. Much of the learning was peer-to-peer. Participants were expected to discuss 
their own experiences and listen to others as they discuss theirs.
The workshop helped participants identify areas where they needed guidance and growth, 
as well as how to capitalize on areas of strength. Participants had the opportunity to share their 
experiences and challenges with others and to receive feedback and guidance from others with 
experience in leading scientists in a variety of settings. At the end of the course, participants were 
linked through a unique on-line community in which they could continue learning from one 
another and from the course instructors.
This workshop was supported with funds provided by American Express Philanthropy.
Workshop on Leadership in Bioscience  351
PARTICIPANTS
Anczukow-Camarda, O., Ph.D., Cold Spring Harbor 
Laboratory
Balu, D., Ph.D., McLean Hospital, Belmont, Massachusetts
Cash, K., Ph.D., Northeastern University, Boston, 
Massachusetts
Crenshaw, S., Ph.D., University of North Carolina, Chapel 
Hill
De Las Penas, A., Ph.D., IPICYT, Mexico
De Marco Garcia, N., Ph.D., Weill Cornell Medical College, 
New York
Dixon, S., Ph.D., Stanford University, California
Dumond, J., Pharm., University of North Carolina Eshelman 
School of Pharmacy, Chapel Hill
Dunn, F., Ph.D., University of Washington, Seattle
Eisenhoffer, G., Ph.D., University of Utah, Salt Lake City
Fredriksson, L., Ph.D., Karolinska Institutet, Sweden
Hon, G., Ph.D., Ludwig Institute for Cancer Research, 
San Diego, California
Knodler, L.L., Ph.D., Washington State University, 
Pullman
Koles, K., Ph.D., Brandeis University, Waltham, Massachusetts
Limonta, D., Ph.D., Pedro Kouri Institute of Tropical 
Medicine, Cuba
Malone, J., Ph.D., University of Connecticut, Storrs
Payen, C., Ph.D., University of Washington, Seattle
Pi, H.J., Ph.D., Cold Spring Harbor Laboratory
Sansom, S., Ph.D., University of Oxford, United Kingdom
Short, S., Ph.D., University of North Carolina, Chapel Hill
Valdes-Ferrer, S., Ph.D., Feinstein Institute for Medical 
Research, Manhasset, New York
Vogel, C., Ph.D., New York University, New York
Weidner, J., Ph.D., Karolinska Institutet, Sweden
Will, B., Ph.D., Albert Einstein College of Medicine, Bronx, 
New York
Wong, A., Ph.D., Janelia Farm, Ashburn, Virginia
Zheng, X., Ph.D., University of North Carolina, Chapel Hill
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Protein Puriﬁ cation and Characterization
April 1–15
INSTRUCTORS A. Courey, University of California, Los Angeles
 S.-H. Lin, MD Anderson Cancer Center/University of Texas, Houston
 M. Marr, Brandeis University, Waltham, Massachusetts
 S. Nechaev, University of North Dakota School of Medicine, Grand Forks
ASSISTANTS A. Abbas, University of North Dakota School of Medicine, Grand Forks
 J. Cao, University of California, Los Angeles
 M. Chambers, University of California, Los Angeles
 M. Donovan, Brandeis University, Waltham, Massachusetts
 Y.-C. Lee, MD Anderson Cancer Center, Houston, Texas
 H.-C. Liu, MD Anderson Cancer Center, Houston, Texas
 A. Samarakkody, University of North Dakota School of Medicine, Grand Forks
 M. Spellberg, Brandeis University, Waltham, Massachusetts
This course was for scientists who were not familiar with techniques of protein isolation and char-
acterization. The course was extremely rigorous and included laboratory work during the day, as 
well as lectures with discussions and student talks in the evenings. Students are typically graduate 
students, postdoctoral scholars, staff scientists, and professors with specialized scientifi c expertise 
who now need to learn about protein purifi cation and characterization. The course emphasized 
laboratory strategies and current best practices in the fi eld.
Each student became familiar with major techniques in protein purifi cation by performing four 
separate isolations: (1) a regulatory protein (calmodulin) from mammalian tissue (cow brain); 
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(2) a sequence-specifi c DNA-binding protein (transcription factor AP1) from HeLa cell nuclei; (3) 
a recombinant protein overexpressed as inclusion bodies in Escherichia coli; and (4) a membrane-
bound protein (insulin receptor) from rat liver.
Students were divided into four groups of four and spent 3 days in each of the above four mod-
ules. In addition to the primary purifi cation in a given module, a number of relevant characteriza-
tions were performed on each protein, giving students experience with immunological and bio-
chemical assays, peptide mapping, protein sequencing, and mass spectrometry. Students learned 
bulk fractionation and electrophoretic and chromatographic techniques, including precipitation 
by salts, pH, and ionic polymers; ion exchange, gel fi ltration, hydrophobic interaction, and reverse 
phase chromatography; lectin affi nity, ligand affi nity, oligonucleotide affi nity, and immunoaffi ni-
ty chromatography; polyacrylamide gel electrophoresis and electroblotting; and high-performance 
liquid chromatography. Students also learned procedures for solubilizing proteins from inclusion 
bodies and refolding them into active monomeric forms and for solubilizing membrane proteins 
by detergent screens. Evenings in the course involved lectures about topics that complement the 
laboratory curriculum: protein structure; modifi cation of proteins; methodologies for protein pu-
rifi cation, stabilization, and characterization; high-throughput protein purifi cation; and applica-
tions of protein biochemistry to molecular cell biology and cancer research.
This course was supported with funds provided by the National Cancer Institute.
PARTICIPANTS
Bakman, I., B.Sc., Brooklyn College, The City University of 
New York, Brooklyn
Blaby, C., Ph.D., University of California, Los Angeles
Bowling, J., B.A., St. Jude Children’s Research Hospital, 
Memphis, Tennessee
Cirak, S., Ph.D., Children’s National Medical Centre, 
Washington D.C.
Criado-Marrero, M., B.S., Ponce School of Medicine, Ponce, 
Puerto Rico
Dahmen, J., Ph.D., Matrix Genetics, Seattle, Washington
Doerfel, M., Ph.D., Cold Spring Harbor Laboratory
Jones, J., B.S., Idaho State University Meridian Health 
Science Center, Meridian
Lansky, S., B.S., The Hebrew University of Jerusalem, Israel
Masocha, W., Ph.D., Kuwait University, Safat
Nielsen, N., M.S., University of Oslo, Norway
Rafi que, S., Ph.D., Centre for Applied Molecular Biology, 
Thokar niaz baig, Lahore, Pakistan
Roda, R., Ph.D., New York University, New York
Turner, B., M.S., University of Kansas, Lawrence
Uddin, Y., B.S., Georgia Institute of Technology, Atlanta
Wu, Q., Ph.D., Cold Spring Harbor Laboratory
SEMINARS
Courey, A., University of California, Los Angeles: Welcome 
and Introduction to Course. System-wide analyses of 
Groucho and SUMO in Drosophila.
Pappin, D., Cold Spring Harbor Laboratory: Introduction to 
mass spectrometry of proteins. Quantitative approaches to 
mass spectrometry of proteins.
Love, J., Albert Einstein School of Medicine, New York: 
High-throughput production of eukaryotic soluble and 
membrane proteins.
Marr, M., Brandeis University, Boston, Massachusetts: 
Introduction to protein purifi cation. Multilevel control of 
gene expression response to cellular stress.
Nechaev, S., University of North Dakota, Grand Forks: 
Analysis of EMT genes reveals a role of polII pausing in 
gene activation.
Lin, S.-H., MD Anderson Cancer Center, Houston, Texas: 
Secretome analysis of prostate cancer bone metastasis.
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Quantitative Imaging: Cells to Molecules
April 2–15
INSTRUCTORS H. Elliott, Harvard Medical School, Cambridge, Massachusetts
 M. Krummel, University of California, San Francisco
 H. Shroff, National Institutes of Health, Bethesda, Maryland
 J. Waters, Harvard Medical School, Boston, Massachusetts
ASSISTANTS K. Corbin, University of California, San Francisco
 A. Ettinger, University of California, San Francisco
 A. Kumar, National Institutes of Health, Bethesda, Maryland
 T. Lambert, Harvard Medical School, Boston, Massachusetts
 H. Pinkard, University of California, San Francisco
This course focused on advanced quantitative fl uorescence microscopy techniques used for imag-
ing a range of biological specimens, from cells to single molecules. The course was designed for 
cell and molecular biologists with little or no microscopy experience who wish to begin using 
microscopy in their own research. Students gained a theoretical understanding of, and hands-on 
experience with, state-of-the-art equipment used in quantitative fl uorescence microscopy, includ-
ing laser-scanning and spinning-disk confocal microscopy, deconvolution methods, total internal 
fl uorescence microscopy (TIRF), superresolution methods (structured illumination, STORM, 
and PALM), multiphoton microscopy, light sheet microscopy, and digital image processing and 
analysis. Students learned how to design and implement a wide range of imaging experiments 
using these techniques. They also used the techniques to address specifi c quantitative questions 
and then discussed the results daily as a group, learning to troubleshoot the common problems 
that occur in the course of a quantitative imaging experiment. Among the lectures presented 
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were microscopy basics, image analysis basics, CCD and sCMOS, cameras, confocal microscopy, 
 multiphoton microscopy, deconvolution, TIRF, single-molecule imaging, imaging ratiometric 
“biosensors” (including FRET), light sheet microscopy, and superresolution techniques. Students 
also learned guidelines for choosing fl uorescent proteins and worked with live samples requir-
ing environmental control. Additional lecturers for 2014 included George Patterson (National 
 Institutes of Health), Paul Goodwin (GE Healthcare), and Adam Cohen (Harvard University).
This course was supported with funds provided by the National Cancer Institute.
PARTICIPANTS
Banala, S., Ph.D., Janelia Farm Research Campus, Ashburn, 
Virginia
Duquette, P., B.Sc., McGill University, Montreal, Canada
Eun, Y., Ph.D., Harvard University, Cambridge, 
Massachusetts
Finn, C., Ph.D., Rocky Mountain Laboratories, Hamilton, 
Montana
Heinritz, J., B.S., Yale University/HHMI, New Haven, 
Connecticut
Hempel, A., Ph.D., University of California, San Diego
Johnson, R., B.S., SUNY Albany and Wadsworth Center 
NYSDOH, Albany, New York
Jordi, J., Ph.D., University of Zurich, Switzerland
Komorowski, M., Ph.D., Polish Academy of Sciences, 
Warszawa, Poland
Law, K., B.S., Icahn School of Medicine at Mount Sinai, 
New York
Nelson, S., B.S., University of Colorado School of Medicine, 
Aurora
Ondracka, A., Diplomat., The Rockefeller University, New 
York
Renvoise, B., Ph.D., NINDS, National Institutes of Health, 
Bethesda, Maryland
Ross, K., Ph.D., University of Strathclyde, Glasgow, United 
Kingdom
Ruckh, T., Ph.D., Northeastern University, Boston, 
Massachusetts
Slaidina, M., Ph.D., New York University School of 
Medicine, New York
SEMINARS
Cohen, A., Harvard University, Cambridge, Massachusetts: 
Bringing bioelectric phenomena to light.
Patterson, G., National Institutes of Health, Bethesda, 
Maryland: Fluorescent proteins.
Shroff, H., National Institutes of Health, Bethesda, Maryland: 
Superresolution imaging. Light sheet microscopy. Faster and 
sharper: New technologies for 4D imaging.
Elliott, H., Harvard Medical School, Cambridge, 
Massachusetts: Image segmentation. Ratio imaging and 
FRET. Image analysis.
Waters, J., Harvard Medical School, Boston, Massachusetts: 
Quantitative microscopy basics. Objective lenses. 
Transmitted light microscopy. Fluorescence microscopy. 
Quantitative digital imaging. Live-cell imaging.
Krummel, M., University of California, San Francisco: 
Confocal microscopy. Live confocal microscopy, FRAP, 
and photoactivation. TIRF. The immune response in four 
dimensions. Multiphoton.
Goodwin, P., Applied Precision, Inc., Issaquah, Washington: 
Deconvolution.
Lambert, T., Harvard Medical School, Boston, 
Massachusetts: Digital Cameras.
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Cell and Developmental Biology of Xenopus
April 4–15
INSTRUCTORS K. Liu, Kings College, London, United Kingdom
 A. Sater, University of Houston, Texas
 G. Thomsen, Stony Brook University, Stony Brook, New York
ASSISTANTS R. Miller, The University of Texas Medical School, Houston
 J. Oomen-Hajagos, Stony Brook University, Stony Brook, New York
 B. Steventon, Institut Pasteur, Paris, France
 T. Nakayama, University of Virginia, Charlottesville
Xenopus is the leading vertebrate model for the analysis of gene function in development. The 
combination of lineage analysis, gene-knockout strategies, experimental manipulation of the em-
bryo, and genomic/bioinformatic techniques makes it ideal for studies on the molecular control of 
embryo patterning, morphogenesis, and organogenesis. Moreover, recent advances in Xenopus ge-
nomics offer new opportunities to integrate computational strategies with experimental approach-
es, including genome editing-based strategies for gene knockout. The course combined intensive 
laboratory training with daily lectures from recognized experts in the fi eld. Students learned both 
emerging technologies and classical techniques to study gene function in Xenopus development. 
An important element was the informal interaction between students and course faculty.
Technologies covered included oocyte and embryo culture, lineage analysis and experimental 
manipulation of embryos, time-lapse imaging of morphogenesis, gain- and loss-of-function analy-
sis using mRNAs, antisense oligonucleotides, and the CRISPR/Cas9 system, whole-mount in situ 
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hybridization, immunocytochemistry, genomics and bioinformatics, chromatin immunoprecipi-
tation, preparation of transgenic embryos, and use of Xenopus tropicalis for genetic analyses. This 
course was designed for those new to the Xenopus fi eld, as well as for those wanting a refresher 
course in the emerging technologies. The course was open to investigators from all countries.
This course was supported with funds provided by the National Institute of Child Health and 
Human Development.
PARTICIPANTS
Benlamara, S., B.S., Institute of Systems and Synthetic 
Biology, Evry, France
Buescher, J., Ph.D., Nationwide Children’s Hospital–
Research Institute, Columbus, Ohio
Chang, L.-S., M.S., German Cancer Research Center, 
Heidelberg, Germany
Easterling, M., B.S., Washington State University, Pullman
Guay, J., B.S., Tufts University, Medford, Massachusetts
Hayes, M., B.S., University of Iowa, Iowa City
Kudra, R., B.A., University of Connecticut, Storrs
Mazzeo, I., M.S., Universita di Trento, Trento, Italy
Michal, J., M.S., Washington State University, Pullman
Pasternak, M., M.S., MRC Laboratory of Molecular Biology, 
Cambridge, United Kingdom
Talhouarne, G., B.S., Carnegie Institution for Science, 
Baltimore, Maryland
Van Itallie, E., B.A., Harvard Medical School, Boston, 
Massachusetts
Warren, C., B.A., Albert Einstein College of Medicine, 
Bronx, New York
Yaklichkin, S., Ph.D., Baylor College of Medicine, Houston, 
Texas
SEMINARS
Sater, A., University of Houston, Texas: microRNAs and the 
specifi cation of the Xenopus eye fi eld. Xenopus: History and 
prospects.
El-Hodiri, H., Ohio State University, Columbus: The retinal 
homeobox (Rx) gene plays essential roles in the regenerating 
retina.
Cousin, H., University of Massachusetts, Amherst: The 
Xenopus cranial neural crest: The perfect model system to 
study collective cell migration and craniofacial evo-devo.
Thomsen, J., Stony Brook University, Stony Brook, New 
York: The organizer.
Wallingford, J., University of Texas, Austin: The awesome 
power of living imaging in Xenopus.
Liu, K., Kings College, London, United Kingdom: 
Craniofacial anomalies: Modeling gene function in the 
neural crest.
Gilchrist, M., National Institute for Medical Research, London, 
United Kingdom: Using high-resolution RNA-Seq data to 
untangle mechanisms of gene activation in early development.
Khokha, M., Yale University, New Haven, Connecticut: 
Gene discovery in humans with birth defects, functional 
analysis in Xenopus: A powerful combination.
Klein, P., University of Pennsylvania School of Medicine, 
Philadelphia: Mechanisms of Wnt signaling in early 
development.
Miller, R., The University of Texas Medical School, 
Houston: Shaping kidney tubules through Wnt signaling 
and cilia.
Keller, R., University of Virginia, Charlottesville: 
Cell motility and mechanobiology of early Xenopus 
morphogenesis.
Grainger, R., University of Virginia, Charlottesville: Analysis 
of eye formation in Xenopus: Model system for genetic 
and genomic studies of determination, induction, and 
organogenesis.
Blythe, S., Princeton University, New Jersey: Imminent 
catastrophe: Coordination of DNA replication and zygotic 
genome activation.
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Workshop on Schizophrenia
June 4–10
INSTRUCTORS A. Abi-Dargham, Columbus University College of Physicians & Surgeons, New York
 J. Hall, Cardiff University School of Medicine, Cathays, United Kingdom
 A. Sawa, Johns Hopkins University, Baltimore, Maryland
ASSISTANTS K. Delevich, Cold Spring Harbor Laboratory
 T. Lancaster, Cardiff University, United Kingdom
This workshop provided students with the most current understanding of the molecular, cellular, 
and neural systems underlying the disturbances in brain function in these devastating illnesses. 
During the 7-day workshop, students learned about the clinical aspects of schizophrenia, schizoaf-
fective disorder, and bipolar disorder. They also explored in detail the genetic and neurobiological 
underpinnings of these complex psychiatric disorders. The Workshop included sessions focused 
on the clinical syndrome, basic neurobiology, cognitive neuroscience, neuroimaging, genetics and 
genomics, endophenotypes, and gene expression and gene modulation. In addition to hearing 
about the most recent research in these areas, controversial topics and challenges to basic assump-
tions in the fi eld were explored and discussed. A diverse faculty brought the most up-to-date re-
sults and theories to the students, making this Workshop a valuable resource for young researchers 
starting out in this fast-moving and expansive fi eld. Not only did it help them build the founda-
tion for their future research, it also introduced them to many potential collaborators working 
to understand schizophrenia and similar disorders from different perspectives. Although these 
7 days featured intense lecture sessions throughout, students had free time for reading, informal 
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discussions, and recreation on the beautiful campus of the Banbury Center, which includes a 
beach, a pool, and a tennis court.
This Workshop was supported with funds provided by Cold Spring Harbor Laboratory and 
the Stanley Foundation.
PARTICIPANTS
Andrade, G., Ph.D., Albert Einstein College of Medicine, 
Bronx, New York
Argyelan, M., Ph.D., The Zucker Hillside Hospital, Glen 
Oaks, New York
Birknow, M., M.S., University of Copenhagen, Denmark, 
Valby, Denmark
Bohlken, M., Ph.D., University Medical Center, Utrecht, 
The Netherlands
Boyd, F., B.S., University of Arizona, Phoenix
Choueiry, J., Ph.D., University of Ottawa, Canada
Clifton, N., Ph.D., Cardiff University, United Kingdom
Deakin, J., M.B.Phil., University of Cambridge, United 
Kingdom
Ferraro, L., M.S., Section of Psychiatry, Palermo, Italy
Gibson, L., Ph.D., Temple University, Philadelphia, 
Pennsylvania
Lam, M., Ph.D., Institute of Mental Health, Singapore
Mihaljevic, M., M.D., Clinic of Psychiatry, Clinical Centre 
of Serbia, Belgrade, Serbia
Ordonez, A., M.D., NIMH, National Institutes of Health, 
Bethesda, Maryland
Parker, K., Ph.D, University of Iowa, Iowa City
Passeri, E., Ph.D., Johns Hopkins, Baltimore, Maryland
Primerano, A., M.D., Medical Genetics University Hospital 
Mater Domini, Catanzaro, Italy
Sarpal, D., M.D., Hofstra North Shore–LIJ School of 
Medicine, Glen Oaks, New York
Scharf, S., F. Hoffmann-La Roche Ltd., Basel, Switzerland
Schnakenberg, A., Ph.D., Indiana University, Bloomington
Solis, M., Ph.D., Schizophrenia Research Forum, Seattle, 
Washington
Sykes, L., Ph.D., Cardiff University, United Kingdom
SEMINARS
Hall, J., Cardiff University School of Medicine, Cathays, 
United Kingdom: Course overview.
Murray, R., Kings College, London, United Kingdom: 
Clinical syndrome and risk factors.
Yolken, B., Johns Hopkins Children’s Center, Baltimore, 
Maryland: Epidemiology of schizophrenia and psychiatric 
disorders.
Cannon, T., Yale University, New Haven, Connecticut: 
Biomarkers of vulnerability and progression in the psychosis 
prodrome.
Seidman, L., Massachusetts General Hospital, Boston: 
Lifespan developmental evolution of neurocognition in 
schizophrenia.
Fletcher, P., University of Cambridge, United Kingdom: A 
cognitive understanding of psychosis.
Weinberger, D., Lieber Institute for Brain Development, 
Baltimore, Maryland: Epistasis in schizophrenia genetics: 
What’s missing is not heritability.
Corvin, A., Trinity College Dublin, Dublin, Ireland.
Malhotra, A., The Zucker Hillside Hospital, Glen Oaks, 
New York: Pharmacognetic approaches to schizophrenia.
Law, A., University of Colorado, Denver, Aurora: 
Neuregulin/ErbB signaling in neurodevelopment, 
cognition, and schizophrenia: From human to rodent.
Lewis, D., University of Pittsburgh, Pennsylvania.
Akbarian, S., Icahn School of Medicine at Mount Sinai, 
New York: Epigenetic dysregulation in schizophrenia.
Sawa, A., Johns Hopkins University School of Medicine, 
Baltimore, Maryland.
Brennand, K., Mount Sinai School of Medicine, New 
York: Using induced pluripotent stem cells to study 
schizophrenia.
Moore, H., Columbia University, New York.
Meyer-Lindenberg, A., University of Heidelberg, Germany.
Abi-Dargham, A., Columbia University, New York: Imaging 
dopamine transmission in schizophrenia with PET. Careers 
in Academia: Highlights and challenges.
Desmond, N., National Institutes of Health, Bethesda, 
Maryland.
O’Donnell, P., Pfi zer, Cambridge, Massachusetts: Careers in 
the pharmaceutical industry.
360
Advanced Bacterial Genetics
June 4–24
INSTRUCTORS D. Hughes, Uppsala University, Sweden
 B. Lazazzera, University of California, Los Angeles
 F. Yildiz, University of California, Santa Cruz
ASSISTANTS S. Elgamal, The Ohio State University, Columbus
 E. Garmendia, Uppsala University, Sweden
 D. Zamorano Sanchez, University of California, Santa Cruz
This course presented logic and methods used in the genetic dissection of complex biological pro-
cesses in diverse bacteria. Laboratory methods included classical mutagenesis using transposons, 
mutator strains, and chemical mutagens; recombineering with single- and double-stranded DNA; 
detection of gene expression changes using various reporter genes; the mapping of mutations using 
genetic and physical techniques; modern approaches to the generation and analysis of targeted 
gene disruptions and fusions using polymerase chain reaction (PCR) and cloning methods; epi-
tope insertion mutagenesis; site-directed mutagenesis; and fl uorescence microscopy. Key compo-
nents of the course used sophisticated genetic methods in the analysis of model bacteria (including 
Escherichia coli, Salmonella, Bacillus subtilis, and Vibrio cholerae), and the use of the wealth of new 
genomic sequence information to motivate these methods. Invited lecturers presented various 
genetic approaches to study bacterial mechanisms of metabolism, development, and pathogenesis.
The course admitted 16 students, both foreign and United States residents, from diverse back-
grounds and career levels for intensive (but fun) instruction in microbial genetics.
This course was supported with funds provided by the National Science Foundation.
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PARTICIPANTS
Acar, H., B.S., Institute of Science and Technology, 
Klosterneuburg, Austria
Aubee, J., B.S., Howard University College of Medicine, 
Washington, D.C.
Coates, J., B.S., Emory University, Atlanta, Georgia
de Gier, J.-W., Ph.D., Stockholm University, Sweden
Harty, C., B.S., Geisel School of Medicine at Dartmouth, 
Hanover, New Hampshire
Jensen, L., B.Sc., Technical University of Denmark, Denmark
Kingsbury, D., DACVII, University of California, Davis
Kumar, V., Ph.D., Stony Brook University, Stony Brook, 
New York
Teschler, J., B.S., University of California, Santa Cruz
Turnbull, K., B.Sc., Newcastle University, Newcastle upon 
Tyne, United Kingdom
van Vliet, S., M.Sc., Eawag, Dubendorf, Switzerland
Wei, Z., B.S., Harvard University, Cambridge, 
Massachusetts
Williams, T., B.S., University of North Carolina, Charlotte
Wolff, K., Ph.D., Merck Research Laboratories, Kenilworth, 
New Jersey
Zemke, A., Ph.D., University of Pittsburgh, Pennsylvania
Zhou, J., Ph.D., Dartmouth College, West Lebanon, 
New Hampshire
SEMINARS
Camilli, A., Tufts University, Boston, Massachusetts: Genetic 
analysis of the Vibrio cholera life cycle.
Gross, C., University of California, San Francisco: Reaching 
for functional genomics in bacterias.
Kearns, D., Indiana University, Bloomington: A bifunctional 
fl agellar clutch disables motility in Bacillus subtilis biofi lm.
Zhu, J., University of Pennsylvania, Philadelphia: Genetic 
tools to study gene expression during bacterial pathogen 
infection.
Blokesch, M., Swiss Federal Institute of Technology, 
Lausanne, Switzerland: Visualizing the DNA uptake 
process in naturally competent Vibrio cholera.
Laub, M., Massachusetts Institute of Technology, 
Cambridge: Mapping, rewiring, and evolving protein–
protein interfaces in bacteria.
Gitai, Z., Princeton University, New Jersey: Mechano-
microbiology: How mechanical forces shape bacterial cells 
and communities.
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Mouse Development, Stem Cells, and Cancer
June 4–24
INSTRUCTORS X. Sun, University of Wisconsin, Madison
 R. Johnson, MD Anderson Cancer Center, Houston, Texas
CO-INSTRUCTORS D. Wellik, University of Michigan Medical Center, Ann Arbor
 M. Lewandoski, National Cancer Institute, Frederick, Maryland
ASSISTANTS H. Adams, MD Anderson Cancer Center, Houston, Texas
 Y. Furuta, RIKEN, Center for Development Biology, Kobe, Japan
 R. Kadzik, University of Pennsylvania, Perleman School of Medicine, Philadelphia
 B. Larsen, University of Michigan, Ann Arbor
 D. Rux, University of Michigan, Ann Arbor
 Y. (Tina) Zhang, University of Wisconsin, Madison
This intensive lecture and laboratory course was designed for biologists interested in using mouse 
models to study mammalian development, stem cells, and cancer. The lecture portion of the 
course, taught by leaders in the fi eld, provided the conceptual basis for contemporary research in 
embryogenesis, organogenesis, embryonic, adult, and induced pluripotent stem cells, and cancer 
biology. The laboratory portion of the course provided an extensive hands-on introduction to 
engineering of mouse models, stem cell technologies, and molecular analysis of mouse embryos 
and tissues.
The experimental techniques included pronuclear microinjection, isolation, culture, and ma-
nipulation of pre- and postimplantation embryos; embryo transfer; embryo electroporation and 
roller culture; embryo and sperm freezing; genetic manipulation of embryonic stem cells includ-
ing genome by CRISPR/Cas9, production of chimeras, the generation and differentiation of 
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embryonic stem cells as well as induced pluripotent stem cells; isolation of mouse embryonic 
fi broblasts; teratoma formation assay; vibratome and cryosectioning; in situ hybridization; immu-
nostaining; vascular injections; skeletal preparation; organ explant culture; confocal imaging; and 
live time-lapse microscopy of early embryos, explanted tissues, and tumors in vivo.
This course was supported with funds provided by the National Cancer Institute.
PARTICIPANTS
Balmer, S., Ph.D., Icahn School of Medicine, Mount Sinai, 
New York
Bishop, K., Ph.D., Maine Medical Center, Scarborough
Carmona-Fontaine, C., Ph.D., Memorial Sloan-Kettering 
Cancer Center, New York
Cheng, L., M.S., Mayo Clinic, Rochester, North Carolina
Chung, Y.R., M.S., Memorial Sloan-Kettering Cancer 
Center, New York
Dingwall, H., B.S., Harvard University, Cambridge, 
Massachusetts
Gordon, P., B.BM.E., University of Utah, Salt Lake City
He, M., Ph.D., Cold Spring Harbor Laboratory
Korde, A., M.S., Ph.D., Louisiana State University, 
Baton Rouge
Lim, X., Ph.D., Institute of Medical Biology, Singapore
Osorio Da Silva, L., Ph.D., The University of Hong Kong, 
Hong Kong
Plaza Reyes, A., M.S., Karolinska Institutet, Stockholm, 
Sweden
Prunskaite-Hyyrylainen, R., M.Sc., Ph.D., University of 
Oulu, Finland
Ramjee, V., M.D., University of Pennsylvania, Philadelphia
SEMINARS
Ralston, A., University of California, Santa Cruz; Early 
mouse embryo-derived stem cells and chimeras.
Tabin, C., Harvard Medical School, Boston, Massachusetts: 
Using mouse genetics to explore the development and 
evolution of vertebrate morphology.
Largaespada, D., University of Wisconsin, Madison: Sleeping 
Beauty and cancer.
Threadgill, D., North Carolina State University, Raleigh: 
Quantitative trait analysis in mice.
Solter, D., Institute of Molecular Biology, Singapore: Historical 
overview of mouse as a model system. Mouse preimplantation.
Wellik, D., University of Michigan Medical Center, Ann 
Arbor: Hox genes: Muscloskeletal development and repair.
Yancopoulos, G., Regeneron Pharmaceuticals, Inc., 
Tarrytown, New York: Growth factors and cancer.
Hang, H., The Jackson Laboratory, Bar Harbor, Maine: 
CRISPR/Cas9 and pluripotency.
Maillard, I., University of Michigan, Ann Arbor: Mouse 
hematopoiesis.
Rivera, J., University of Massachusetts Medical School, 
Worcester: Postimplantation mouse development.
Huang, J., Cold Spring Harbor Laboratory: Mapping neural 
circuits.
Sanes, J., Harvard University, Cambridge, Massachusetts: 
Neural genetics.
Capecchi, M., University of Utah School of Medicine, Salt 
Lake City: Homologous recombination and knockout mice.
Lewandoski, M., NCI, National Institutes of Health, 
Frederick, Maryland: Mouse genetics Technologies I. 
Somitogenesis.
Egeblad, M., Cold Spring Harbor Laboratory: Cancer 
imaging in mice.
Klein, O., University of California, San Francisco: Dental 
and intestinal stem cells.
Tam, P., Children’s Medical Research Institute, Australia: 
Mouse gastrulation.
Trainor, P., Stowers Institute for Medical Research, Kansas 
City, Missouri: Mouse craniofacial development and disease.
Soriano, P., Mt. Sinai School of Medicine, New York: 
Signaling. Mouse genetics Technologies II.
Johnson, R., MD Anderson Cancer Center, Houston, Texas: 
Liver cancer.
Lovell-Badge, R., MRC National Institute for Medical 
Research, United Kingdom: Mouse sex determination.
Lowe, S., Memorial Sloan-Kettering Cancer Center, New 
York: Probing cancer drivers and dependencies using mouse 
models and RNAi.
Huppert, S., Cincinnati Children’s Hospital Medical Center, 
Ohio: Liver development.
Sun, X., University of Wisconsin, Madison: Lung.
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Ion Channels and Synaptic Transmission
June 4–24
INSTRUCTORS S. Brenowitz, Janelia Farm Research Campus/HHMI, Auburn, Virginia
 I. Duguid, University of Edinburgh, United Kingdom
 P. Kammermeier, University of Rochester Medical Center, New York
CO-INSTRUCTOR T. Branco, University College London, United Kingdom
ASSISTANTS A. Che, University of Connecticut, Storrs
 K. Kuchibhotla, New York University School of Medicine, New York
 J. Lueck, University of Iowa Carver College of Medicine, Iowa City
 J. Schiemann, University of Edinburgh, United Kingdom
 V. Stempel, Charite Berlin, Germany
 N. Wanaverbecq, Air-Marseille University, Marseille, France
The primary goal of this course was to investigate, through lectures and laboratory work, the 
properties of ion channels that allow neurons to carry out their unique physiological functions in 
a variety of neural systems. Areas of particular interest included channels that (1) are activated by 
the neurotransmitter at central and peripheral synapses, (2) are activated by voltage changes in 
axons and dendrites, (3) respond to neuromodulators with changes in functional properties, (4) 
are developmentally required and regulated, or (5) are light-gated and engineered to express in 
specifi c neural subtypes. The research interests of guest lecturers refl ect these areas of emphasis.
The laboratory component of the course introduced students to state-of-the-art electrophysi-
ological approaches for the study of ion channels in their native environments. Hands-on exercises 
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included patch-clamp recording of ion channel activity in acutely isolated or cultured cells or 
neurons in brain slice preparations. Different recording confi gurations were used (e.g., whole-cell, 
cell-attached, and dendritic patches, and using voltage- and current-clamp confi gurations) to ex-
amine macroscopic or single-channel activity. Similarly, various methods of ligand and drug ap-
plication were demonstrated. The advantages and disadvantages of each method, preparation, and 
recording technique were considered with respect to the specifi c scientifi c questions being asked. 
Admissions priority is given to students and postdocs with a demonstrated interest, specifi c plans, 
and a supportive environment to apply these techniques to a defi ned problem.
This course was supported by the Howard Hughes Medical Institute.
PARTICIPANTS
Anatharam, A., Ph.D., Wayne State University, Detroit, 
Michigan
Bishop, H., B.S., University of California, Davis
Costa, K., M.S., Goethe University Frankfurt, Frankfurt am 
Main, Germany
Daie, K., Ph.D., Weill Cornell Medical College, New York
Evans, D., B.Sc., MRC Laboratory of Molecular Biology, 
Cambridge, United Kingdom
Fok, A., Ph.D., New York University School of Medicine, 
New York
Mersch, D., Ph.D., University of Lausanne, Switzerland
Mironova, Y., B.S., University of Michigan, Ann Arbor
Morrie, R., B.S., University of California, Berkeley
Wang, L., B.S., University of Michigan, Ann Arbor
Wulf, M.-A., M.Med., University Hospital Zurich, 
Switzerland
Yan, L., B.S., The Scripps Research Institute, San Diego, 
California
SEMINARS
Lee, A., Janelia Research Campus, Ashburn, Virginia: 
Whole-cell recordings in freely moving rodents.
Lee, A., University of Iowa, Iowa City: Cav1 Ca2+ channel at 
ribbons synapses.
Plested, A., Leibnitz Institute for Molecular Pharmacology, 
Berlin, Germany: Superactivation of AMPA receptors by 
auxiliary proteins.
Montell, C., University of California, Santa Barbara: Control 
of animal behavior and decision making with TRP channels.
Nimigean, C., Weill Cornell Medical College, New 
York: Insights into gating and selectivity mechanisms in 
potassium channels from prokaryotic channels.
Shepherd, G., Northwestern University, Chicago, Illinois: 
Synaptic circuit organization of mouse motor cortex.
Colecraft, H., Columbia University, New York: Ion channel 
modulation. Calcium channel engineering.
Sjostrom, J., McGill University, Montreal, Quebec, Canada: 
Spike-timing-dependent plasticity in neocortex.
Trussell, L., Oregon Health and Science University, Portland: 
Electrical synaptic transmission redefi nes the principal 
cell–interneuron relationship in an auditory microcircuit.
Isom, L., University of Michigan, Ann Arbor: Role of sodium 
channel SCN1A and CN1B in inherited epilepsy.
Shah, M., University College London, United Kingdom: 
Presynaptic HCN channels in the entorhinal cortex: 
Function, plasticity, and traffi cking.
Xu-Friedman, M., University of Buffalo, SUNY, New York: 
Regulation of release probability at an auditory synapse.
Hausser, M., University College London, United Kingdom: 
Single-neuron computation.
Kammermeier, P., University of Rochester Medical Center, 
Rochester, New York: Intro/testing potential.
Duguid, I., University of Edinburgh, Germany: Intro/resting 
potential.
Nicoll, R., University of California, San Francisco: Long-
term potentiation: 40 years on.
Brenowitz, S., Janelia Farm Research Campus/HHMI, 
Auburn, Virginia: V-clamp-Rs/analysis-Igor.
Oertner, T., Center for Molecular Neurobiology Hamburg 
(ZMNH), Germany: Synapses: Killed by their lazy 
lifestyle?
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Genetics of Complex Human Diseases
June 12–18
INSTRUCTORS A. Al-Chalabi, Kings College, London, United Kingdom
 L. Almasy, Texas Biomedical Research Institute, San Antonio
Complex diseases are conditions that are infl uenced by the actions of multiple genes and their interac-
tions with each other and with the environment. This lecture course considered the major strategies 
for studying the genetic basis of complex disorders such as diabetes, cardiovascular disease, cancer, 
Alzheimer’s disease, schizophrenia, and epilepsy. We discussed genetic-epidemiologic study designs 
and methods for quantifying the strength of genetic infl uences on a disease. A major focus was the 
analysis of the exome chip, exome sequencing data, and whole-genome sequencing data. We also 
discussed the effi ciency and robustness of different designs for such analysis and how evidence from 
epidemiologic studies informs both the design and interpretation of molecular genetic studies. Study 
design and methods for analysis of quantitative risk factors related to complex diseases were covered 
as well as haplotype mapping, analysis of structural variation, meta-analysis, and gene–environment 
interaction. An overview of high-throughput laboratory methods was given to provide participants 
with insight into the applications of these techniques. Illustrations were provided through discussion 
of results from ongoing studies of a variety of complex diseases and related risk factors.
PARTICIPANTS
Alghamdi, J., Ph.D., Institute of Cardiovascular and Medical 
Sciences, Glasgow, United Kingdom
Cardenas, P., B.S., Self-employed, Allen, Texas
Ghosh, R., Ph.D., Princeton University, New Jersey
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Grigorev, K., Bioinformatics Institute of Saint Petersburg, Russia
Jarvis, J., Ph.D., Coriell Institute for Medical Research, 
Camden, New Jersey
Lezhnina, K., M.S., M.V. Lomonosov Moscow State 
University, Russia
Makeeva, O., Ph.D., Head of Research Planning Group, 
Tomsk, Russia
McEachin, Z., Ph.D., Emory University/Georgia Institute of 
Technology, Atlanta
Miranda-Angulo, A., Ph.D., University of Antioquia, 
Medellin, Colombia
Rotunno, M., Ph.D., National Institutes of Health, Bethesda, 
Maryland
Saha Mandal, A., Ph.D., University of Calgary, Calgary, 
Canada
Terry-Lorenzo, R., Ph.D., Sunovion Pharmaceuticals, 
Marlborough, Massachusetts
Torres, J., Ph.D., University of Chicago, Illinois
Umoh, M., B.A.S., Emory University, Atlanta, Georgia
Verbel, D., M.P.H, Eisai Inc., Woodcliff Lake, New Jersey
Wang, W., Ph.D., University of Minnesota, Twin Cities, 
Minneapolis 
Xu, K., Ph.D., Bristol Myers-Squibb Company, Pennington, 
New Jersey
SEMINARS
Sinsheimer, J., David Geffen School of Medicine at the 
University of California, Los Angeles: Statistics 101.
Borecki, I., Washington University School of Medicine, 
St. Louis, Missouri: Introduction to genetic epidemiology.
Loos, R., Mount Sinai School of Medicine, New York: 
Gene–environment interaction and common disease.
Breen, G., Kings College London, United Kingdom: miRNA 
and microsatellites.
Al-Chalabi, A., Kings College, and Laura Almasy, Texas 
Biomedical Research Institute: Informal session. Basic 
association strategies. Any additional topics.
Neale, B., Massachusetts General Hospital, Boston: Exome 
arrays and imputation.
McCombie, W., Cold Spring Harbor Laboratory: Next-
generation sequencing.
Bestor, T., Columbia University, New York: Epigenetic basis 
of genotype-independent phenotypic variation.
Fromer, M., Icahn School of Medicine at Mount Sinai, New 
York: Fully leveraging exome sequencing data for disease 
association.
Sham, P., The University of Hong Kong, Hong Kong, China: 
Power considerations.
Knight, J., Centre of Addiction and Mental Health, Toronto, 
Canada: Complex association strategies: Using additional 
data.
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Statistical Methods for Functional Genomics
June 18–July 1
INSTRUCTORS H. Bussemaker, Columbia University, New York
 S. Davis, National Institutes of Health, Bethesda, Maryland
 O. Elemento, Weill Cornell Medical College, New York
ASSISTANTS V. FitzPatrick, Columbia University, New York
 E. Giannopoulou, Weill Cornell Medical College, New York
 C. Rastogi, Columbia University, New York
During the past decade, high-throughput assays have become pervasive in biological research 
because of both rapid technological advances and decreases in overall cost. To properly analyze 
the large data sets generated by such assays and thus make meaningful biological inferences, both 
experimental and computational biologists understood the fundamental statistical principles un-
derlying analysis methods. This course was designed to build competence in statistical methods 
for analyzing high-throughput data in genomics and molecular biology.
Detailed lectures and presentations by instructors and guest speakers were combined with 
hands-on computer tutorials. The methods covered in the lectures were applied to example high-
throughput data sets.
This course was supported with funds provided by the National Institute of General Medical Sciences.
PARTICIPANTS
Alexander Rascon, C., M.Phil., The Rockefeller University, 
New York
Almada, A., Ph.D., Harvard University, Cambridge, 
Massachusetts
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Blythe, S., Ph.D., Princeton University, New Jersey
Cedernaes, J., M.D., Uppsala University, Sweden
De Kumar, B., Ph.D., Stowers Institute for Medical Research, 
Kansas City, Missouri
Deshotel, M., B.S., University of Utah, Salt Lake City
Fitzgerald, D., B.A., SUNY at Albany, New York
Hassan, S., Ph.D., Oregon Health and Science University, 
Portland
Hu, Y., Ph.D., Bristol-Myers Squibb, Pennington, New Jersey
Huisman, S., B.S., Delft University of Technology, The 
Netherlands
Jacob, L., Ph.D., Memorial Sloan-Kettering Cancer Center, 
New York
James, T., M.Sc., Karolinska University Hospital, Stockholm, 
Sweden
Konopacki, C., B.S., Gerstner Sloan-Kettering Graduate 
School, New York
McGeachy, A., B.A., Berkeley University, California
Medway, C., Ph.D., Mayo Clinic, Jacksonville, Florida
Murtha, M., Ph.D., New York University School of 
Medicine, New York
Nettles, K., Ph.D., The Scripps Research Institute, Jupiter, 
Florida
Nurmi, E., Ph.D., University of California, Los Angeles
Pashos, E., Ph.D., University of Pennsylvania, Philadelphia
Schmidt, J., M.Sc., Friedrich Miescher Institute for 
Biomedical Research, Basel, Switzerland
Storvall, H., M.S., Karolinska Institutet, Stockholm, Sweden
Walrad, P., Ph.D., University of York, Heslington, United 
Kingdom
Wells, C., Ph.D., Clemson University, Clemson, South 
Carolina
Will, B., Ph.D., Albert Einstein College of Medicine, Bronx, 
New York
SEMINARS
Culhane, A., Harvard University School of Public Health, 
Boston, Massachusetts: Exploratory data analysis.
Kundaje, A., Stanford University, California: Lecture and Lab: 
Working with ENCODE and Roadmap epigenomics data.
Leslie, C., Memorial Sloan-Kettering Cancer Center, New 
York: Posttranscriptional regulation.
Hodges, E., Cold Spring Harbor Laboratory: DNA 
methylation, noncoding transcription, and a basis for 
identifying active enhancers.
Stamatoyannopoulos, J., University of Washington School 
of Medicine, Seattle: Decoding the human genome—
Part 1: Mapping and analysis of regulatory DNA. 
Decoding the human genome—Part II: Encoding 
complex regulatory programs.
Pickrell, J., New York Genome Center, New York: Joint 
analysis of functional genomic data and genome-wide 
association studies of 18 human traits.
Kinney, J., Cold Spring Harbor Laboratory: Using deep 
sequencing to characterize the biophysical mechanisms of a 
transcriptional regulatory sequence.
Carlson, M., Fred Hutchinson Cancer Research Center, 
Seattle, Washington: Bioconductor annotation and data 
resources.
Reimers, M., Virginia Commonwealth University, 
Richmond: Epigenomics. Integrative analysis.
Irizarry, R., Johns Hopkins Bloomberg School of Public 
Health, Baltimore, Maryland: Batch effects, experimental 
design, and methylation data analysis.
Lappalainen, T., New York Genome Center/Columbia 
University, New York: Understanding functional variation 
in the human genome with transcriptome sequencing.
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Frontiers of Techniques in Plant Science
June 27–July 17
INSTRUCTORS M. Johnson, Brown University, Providence, Rhode Island
 S.-H. Shiu, Michigan State University, E. Lansing
 M. Timmermans, Cold Spring Harbor Laboratory
ASSISTANTS P. Atkins, University of Minnesota, St. Paul
 Y. Chen, Michigan State University, E. Lansing
 V. Jawahir, University of Missouri, St. Louis
 N. Panchy, Michigan State University, E. Lansing
This course provided an intensive overview of topics in plant genetics, physiology, biochemistry, 
development, and evolution as well as hands-on experiences in molecular, analytical, computa-
tional, and high-throughput approaches to understanding plant biology. It emphasized recent 
results from model organisms including Arabidopsis, maize, tomato, and a variety of other plants 
and provided an introduction to current methods used in basic and applied plant biology. The 
course was designed for scientists with some experience in molecular techniques or in plant bi-
ology who wished to work with plants using the latest technologies. The course consisted of a 
vigorous lecture series, hands-on laboratories, informal discussions, and social activities designed 
to foster an intense but enjoyable learning environment. The instructors and a stellar group of 
speakers who are acknowledged leaders in their fi elds presented up-to-the-moment research and 
led laboratory sessions on a wide range of topics in plant research.
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The seminar series included plant morphology and anatomy, development, evolution, light and 
circadian biology, hormones, small RNAs and epigenetic inheritance, biotic and abiotic inter-
actions, plant biochemistry, crop domestication, and applications addressing current agronomic 
problems. Speakers provided expert overviews of their fi elds, followed by in-depth discussions 
of their own work. The laboratory sessions provided exposure to cutting-edge experimental and 
computational techniques currently used in plant research. These included approaches for study-
ing plant development, transient gene expression, applications of fl uorescent proteins, genome 
editing, and chromatin immunoprecipitation. Students gained hands-on experience on computa-
tional tools and environments for genome assembly, transcriptomics, construction of gene regula-
tory networks, identifi cation of quantitative trait loci, mapping by sequencing, and mathematical 
modeling of development and hormone action. The course included several short workshops on 
important themes in plant research. Throughout the course, students interacted individually and 
informally with the speakers to further enrich the learning experience.
This course was supported with funds provided by the National Science Foundation.
PARTICIPANTS
Akoz, G., M.Sc., University of Veterinary Medicine and 
GMI, Vienna, Austria
Campbell, J., B.A., University of Minnesota, St. Paul
Castro Guerrero, N., Ph.D., University of Missouri, 
Columbia
Choudury, S., B.S., The Ohio State University, Columbus
Conrad, J., B.A., Dartmouth College, Hanover, 
New Hampshire
Duarte, G., Ph.D., State University of Campinas (Unicamp), 
Campinas, Brazil
Gray, S., Ph.D., University of California, Davis
Keshishian, E., Ph.D., Auburn University, Auburn, 
Alabama
Lee, S., B.S., Rutgers, The University of New Jersey, 
New Brunswick
Lee, U.-S., M.S., University of Pennsylvania, Philadelphia
Luginbuehi, L., M.S., John Innes Centre, Norwich, United 
Kingdom
Monroe, J., B.S., Colorado State University, Fort Collins
Rains, M., B.Sc., Algoma University and Queen’s University, 
Sault Ste. Marie, Canada
Swift, J., M.S., New York University, New York
Volkova, P., M.A., Russian Institute of Agricultural 
Radiology and Agroecology, Obninsk, Russia
Warczak, T., Ph.D., Dartmouth College, Hanover, 
New Hampshire.
SEMINARS
Kramer, E., Harvard University, Cambridge, Massachusetts: 
How-to-EvoDevo: Pitfalls and considerations in comparative 
development. Aquilegia as a test case for developing new 
model systems.
Grotewold, E., Ohio State University, Columbus: Control of 
plant gene expression: From the parts to the network.
Howe, G., Michigan State University, E. Lansing: Plant–
insect interactions.
Doebley, J., University of Wisconsin, Madison: Evolutionary 
genetics of maize.
Maloof, J., University of California, Davis: Light signaling.
Sinha, N., University of California, Davis: Introduction to 
plant biology. Using gene coexpression networks to identify 
developmental regulators.
Peck, S., University of Missouri, Columbia: New insights 
into non-self recognition between hosts and pathogens.
Brady, S., University of California, Davis: Regulation of root 
development in tomato.
Harmer, S., University of California, Davis: Circadian 
rhythms.
Brutnell, T., Donald Danforth Plant Science Center, 
St. Louis, Missouri: A systems approach to understanding 
and engineering C4 photosynthesis.
Grossniklaus, U., University of Zurich, Switzerland: Plant 
reproduction from a female gametophyte’s perspective.
372
Drosophila Neurobiology: Genes, Circuits, and Behavior
June 29–July 17
INSTRUCTORS K. Kaun, Brown University, Providence, Rhode Island
 G. Macleod, Florida Atlantic University, Jupiter
 K. O’Connor-Giles, University of Wisconsin, Madison
 A. Rothenfl uh, University of Texas Southwestern Medical Center, Dallas
ASSISTANTS J. Bruckner, University of Wisconsin, Madison
 E. Imler, University of Arizona, Tucson
 S. Gratz, University of Wisconsin, Madison
 A. Narayanan, University of Texas Southwestern Medical Center, Dallas
This laboratory/lecture course was intended for researchers at all levels from beginning graduate 
students through established primary investigators who want to use Drosophila as an experimental 
system for nervous system investigation. The two and a half-week course was designed to intro-
duce students to a wide variety of topics and techniques, including the latest approaches to study 
nervous system development, activity, and connectivity, as well as complex behaviors and disease 
models. Daily research seminars presented comprehensive overviews of specifi c subfi elds of ner-
vous system function or focus on specifi c techniques and approaches to study fl y neurobiology. 
Expert guest lecturers discussed their fi ndings and approaches and brought along their own assays 
and techniques for students to learn in the laboratory part of the course. The hands-on portion of 
the course was centered around student-led projects, where gene mutants are discovered and ana-
lyzed throughout the course utilizing the different morphological and physiological measurements 
and behavioral paradigms at hand. This included electrophysiological and in vivo calcium record-
ings, anatomical examination, and circuit mapping, as well as numerous quantitative behavioral 
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measures. Collectively, the course provided a comprehensive and practical introduction to modern 
experimental methods for studying the Drosophila nervous system.
The course was supported by funds provided by the National Institute on Drug Abuse and the 
Howard Hughes Medical Institute.
PARTICIPANTS
Arzan Zarin, A., Ph.D., University of Oregon/HHMI, 
Eugene
Braco, J., B.S., Wake Forest University, Winston-Salem, 
North Carolina
Chin, J., B.Sc., Temasek Life Sciences Laboratory, 
Singapore
Davis, S., B.A., Baylor College of Medicine, Houston, Texas
Fischer, C., B.S., Yale University, New Haven, Connecticut
Giachello, C., Ph.D., University of Manchester, United 
Kingdom
Gonzalez, A., B.S., Universidad Central del Caribe, 
Bayamon, Puerto Rico
Louis, T., Ph.D., The Scripps Research Institute, Jupiter, 
Florida
Privman, E., B.S., University of Virginia, Charlottesville
Soto Padilla, A., M.Sc., University of Groningen, The 
Netherlands
Vaccaro, A., B.S., ESPCI Paris Tech, Paris, France
Wan, Y., B.S., Janelia Farm Research Campus/HHMI, 
Ashburn, Virginia
SEMINARS
Rothenfl uh, A., University of Texas Southwestern, Dallas: 
Using genetics to study behavior in Drosophila: Alcohol as 
a case study.
Keene, A., University of Reno, Nevada: Circadian rhythms 
and sleep in Drosophila.
Collins, C., University of Michigan, Ann Arbor: Axon injury 
and repair.
Lee, C.-h., NICHD, National Institutes of Health, Bethesda, 
Maryland: Visual system development.
McKellar, C., and Albin, S., Janelia Farm Research Campus, 
Ashburn, Virginia: Brain anatomy and genetic tools for 
mapping circuits underlying behavior.
Kravitz, E., Harvard University, Cambridge, Massachusetts: 
Aggression in Drosophila.
Levitan, E., University of Pittsburgh, Pennsylvania: Imaging 
dense core vesicles and neurosecretion.
Turner, G., Cold Spring Harbor Laboratory: Studying neural 
activity in the central nervous system.
Macleod, G., Florida Atlantic University, Jupiter: Calcium 
and pHlourin imaging to measure neuronal activity.
Darnell, B., The Rockefeller University, New York: Applying 
advanced techniques in molecular neurosciences to the 
human brain.
Dubnau, J., Cold Spring Harbor Laboratory: Drosophila 
learning and memory.
O’Connor-Giles, K., University of Wisconsin, Madison: 
Genetic approaches to understanding synaptogenesis.
Rolls, M., Penn State University, University Park, 
Pennsylvania: Neuronal polarity.
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Advanced Techniques in Molecular Neuroscience
July 1–17
INSTRUCTORS C. Lai, Indiana University, Bloomington
 J. Loturco, University of Connecticut, Storrs
ASSISTANTS S. Cerceo-Page, Lieber Institute at Johns Hopkins, Baltimore, Maryland
 F. Chen, University of Connecticut, Storrs
 C. Fricano, Dartmouth College, Lebanon, New Hampshire
 M. Girgenti, University of Connecticut, Storrs
 K. Griffi n, Indiana University, Indianapolis
 J. Lubner, University of Connecticut, Storrs
 S. Maloney, Washington University School of Medicine, St. Louis, Missouri
 A. Mitchell, Icahn School of Medicine at Mount Sinai, New York
 M. Rannals, Lieber Institute for Brain Development, Baltimore, Maryland
 D. Roosien, University of Michigan, Ann Arbor
 M. Sakai, Indiana University, Bloomington
 K. Sakers, Washington University School of Medicine, St. Louis, Missouri
 T. Tekieli, University of Michigan, Ann Arbor
 M. Williams, Dartmouth College, Lebanon, New Hampshire
 A. Zybura, Indiana University, Bloomington
This laboratory and lecture course was designed to provide neuroscientists at all levels with a 
conceptual and practical understanding of several of the most advanced techniques in molecular 
neuroscience. The course curriculum was divided into three sections: an extensive and up-to-
date set of laboratory exercises, daily lectures covering the theoretical and practical aspects of the 
various methods used in the laboratory, and a series of evening research seminars. The informal 
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and interactive evening lectures were given by leading molecular neuroscientists and served to 
illustrate the ways in which the various experimental approaches have been used to advance 
specifi c areas of neurobiology. In this year’s course, the laboratory portion included topics such 
as an introduction to the design and use of animal virus vectors in neurobiology; the use of 
CRISPR genome editing and RNA interference (RNAi) approaches for regulating the expression 
of specifi c genes in neurons; practical exercises in gene delivery systems including mammalian 
cell infection and transfection and electroporation techniques for targeted gene transfer in vivo; 
an introduction to overall strategies, use, and design of bacterial artifi cial chromosome (BAC) 
transgenic vectors; real-time reverse transcription–polymerase chain reaction (RT-PCR) analy-
ses; assays of chromatin and chromatin structure in neurons; and mRNA isolation from specifi ed 
neural subtypes by TRAP.
This course was supported with funding from the Howard Hughes Medical Institute.
PARTICIPANTS
Asiminas, A., B.Sc., The University of Edinburgh, United 
Kingdom
Behm, M., M.S., Stockholm University, Sweden
Cancer, M., M.Sc., Uppsala University, Sweden
Carter, C., Ph.D., University of Iowa/HHMI, Iowa City
de Lartigue, G., Ph.D., University of California, Davis
Harkness, J., B.A., Oregon Health & Science University, 
Portland
Jurkin, J., Ph.D., Institute of Molecular Biotechnology, 
Vienna, Austria
Kim, C., Ph.D., Janelia Farm Research Institute/HHMI, 
Ashburn, Virginia
Lin, T., B.S., Georgia Regents University, Augusta
McMichael, G., M.Phil., The University of Adelaide, North 
Adelaide, Australia
Nie, E., B.S., University of California, Los Angeles
Osorio, J., M.D., University of Rochester Medical Center, 
New York
Punal, V., Ph.D., Duke University, Durham, North Carolina
Thomas, E., B.S., Yale University, New Haven, Connecticut
Vayndorf, E., Ph.D., University of Alaska, Fairbanks
Yu, X.-W., Ph.D., National Institutes of Health, Bethesda, 
Maryland
SEMINARS
Shaeffer, A., Icahn School of Medicine at Mount Sinai, 
New York: Epigenetic control of neuronal functional 
diversity.
Barres, B., Stanford University School of Medicine, 
California: What do astrocytes do?
Stevens, B., Children’s Hospital Boston, Harvard Medical 
School, Boston, Massachusetts: Wiring and unwiring the 
brain: Role of glia and the classical complement cascade.
Mayford, M., The Scripps Research Institute, La Jolla, 
California: Genetic control of memory representation.
Darnell, R., The Rockefeller University/HHMI, New York: 
Applying advanced techniques in molecular neuroscience to 
the human brain.
Akbarian, S., Icahn School of Medicine at Mount Sinai, New 
York: Exploring higher-order chromatin and regulatory 
noncoding DNA in the brain.
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Single-Cell Analysis
July 2–15
INSTRUCTORS J. Eberwine, University of Pennsylvania Perelman School of Medicine, Philadelphia
 C. McMurray, University of California, Berkeley
ASSISTANTS P. Buckley, Janssen Research & Development, LLC, Spring House, Pennsylvania
 J. Hyman, Lawrence Berkeley National Laboratory, Berkeley, California
 K. Frankel, Lawrence Berkeley Laboratory, Berkeley, California
 D.-Y. Lee, Lawrence Berkeley Laboratory, Berkeley, California
 J. Morris, University of Pennsylvania, Philadelphia
 A. Polyzos, Lawrence Berkeley National Laboratory, Berkeley, California
The goal of this 2-week course was to familiarize students with the most recent cutting-edge 
technologies for characterization of single cells. Important in this process was highlighting the 
advantages of analyzing single cells in isolation and in their natural microenvironment. Sections 
of the course were taught by scientists who are experts in particular areas of single-cell analysis. 
Topics covered included quantitative single-cell analysis by RNA-Seq, genomic DNA analysis, 
epigenetics, RNA localization analysis, proteomics, protein translation, and metabolomics. The 
techniques taught included real-time live-cell quantifi cation where appropriate. In addition, mul-
tiple techniques to isolate specifi c cell populations and individual cells were taught. The course 
included the use of model systems such as mouse, Drosophila, Caenorhabditis elegans, Aplysia, and 
Planaria.
This course was supported with funding from the Howard Hughes Medical Institute.
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PARTICIPANTS
Chatzi, A., Ph.D., Weill Cornell Medical College, New York
Dergalev, A., Sp.S., A.N. Bach Institute of Biochemistry, 
Moscow, Russia
Grabocka, E., Ph.D., New York University Langone Medical 
Center, New York
Hard, J., B.S., Karolinska Institute, Solina, Sweden
Kaminskaya, A., Ph.D., Federal Medical Biological Agency, 
Saint Petersburg, Russia
Lobanova, E., Ph.D., Albert Eye Research Institute, Durham, 
North Carolina
Ma, K., B.S., The University of Texas, Austin
Naguro, I., Ph.D., The University of Tokyo, Japan
Peschansky, V., Ph.D., University of Miami, Miller School of 
Medicine, Florida
Salmen, F., M.S., Royal Institute of Technology, Solna, Sweden
Scurry, A., B.S., University of Nevada School of Medicine, 
Reno
Shoykhet, M., Ph.D., Washington University School of 
Medicine, St. Louis, Missouri
Soderberg, L., M.S., Royal Institute of Technology, Solna, 
Sweden
Teng, M., B.S., Sanger Institute, Cambridge, United 
Kingdom
Vanaerschot, M., M.S., Institute of Tropical Medicine, 
Antwerp, Belgium
Yamauchi, K., B.S., University of California, Berkeley
Zheng, F., B.A., Purdue University, West Lafayette, 
Indiana
Zigoneanu, I., Ph.D., University of North Carolina, 
Chapel Hill
SEMINARS
Larabell, C., Lawrence Berkeley Laboratory, Berkeley, 
California: X-ray high-resolution imaging.
McMurray, C., Lawrence Berkeley Laboratory, Berkeley, 
California: Metabolomics.
Eberwine, J., University of Pennsylvania, Philadelphia: 
Transcriptomics.
Sweedler, J., University of Illinois, Chicago: Proteomics.
Kim, J., University of Pennsylvania, Philadelphia: 
Biocomputation.
McConnell, M., University of Virginia, Charlottesville: 
Genomics.
Albritton, N., University of North Carolina, Chapel Hill: 
Cell manipulation.
Sims, P., Columbia University, New York: MicroFluidics.
Finkbeiner, S., University of California, San Francisco: Cell 
dynamics.
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Computational Neuroscience: Vision
July 11–24
INSTRUCTORS G. Boynton, University of Washington, Seattle
 G. Horwitz, University of Washington, Seattle
 J. Pillow, The University of Texas, Austin
 S. Treue, German Primate Center, Goettingen, Germany
Computational approaches to neuroscience will produce important advances in our understand-
ing of neural processing. Prominent success will come in areas where strong inputs from neuro-
biological, behavioral, and computational investigation can interact. The theme of the course 
was that an understanding of the computational problems, the constraints on solutions to these 
problems, and the range of possible solutions can help guide research in neuroscience. Through a 
combination of lectures and hands-on experience with MATLAB-based computer tutorials and 
projects, this intensive course examined visual information processing from the retina to higher 
cortical areas, spatial pattern analysis, motion analysis, neuronal coding and decoding, attention, 
and decision-making.
This course was supported with funding from the Howard Hughes Medical Institute.
PARTICIPANTS
Bakst, L., Ph.D., University of Washington, Seattle
Bondy, A., Ph.D., NEI, National Institutes of Health, 
Bethesda, Maryland
Hüer, J., M.S., German Primate Center, Goettingen, 
Germany
Itthipuripat, S., Ph.D., University of California, San Diego
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Kar, K., Ph.D., Rutgers University, Newark, New Jersey
Katz, L., Ph.D., University of Texas, Austin
Kim, M., Ph.D., New York University, New York
Morimoto, M., M.S., Janelia Farm/HHMI, Ashburn, 
Virginia
Nitzany, E., M.S., Weill Cornell Medical College/Cornell 
University, Ithaca, New York
Olsson, C., Ph.D., New York University, New York
Ponce, C., Ph.D., Harvard Medical School, Boston, 
Massachusetts
Popovkina, D., Ph.D., University of Washington, Seattle
Ravi, S., Ph.D., University of Southern California, 
Los Angeles
Roth, N., B.A., University of Pennsylvania, Philadelphia
Sabastian, S., B.S., University of Texas, Austin
Sedigh-Sarvestani, M., Ph.D., University of Pennsylvania, 
Philadelphia
Snow, M., M.D./Ph.D., Albert Einstein College of Medicine, 
Bronx, New York
Tikidji-Hamburyan, A., Ph.D., Stanford University, 
California
Trott, A., Ph.D., Harvard Medical School, Boston, 
Massachusetts
Vincent, J., Ph.D., University of Washington, Seattle
Vincent, J., Ph.D., Harvard Medical School, Boston, 
Massachusetts
Wei, X.-X., Ph.D., University of Pennsylvania, Philadelphia
Yao, X., Ph.D., University of Southern California, Monterey 
Park
Yates, J., Ph.D., The University of Texas, Austin
SEMINARS
Movshon, J.A., New York University, New York: The 
elements of early vision.
Pillow, J., The University of Texas, Austin: Intro to neural 
encoding models and generalized linear models (GLMs).
Chichilnisky, E.J., The Salk Institute, La Jolla, California: 
Retina.
Simoncelli, E., New York University, New York: Encoding/
decoding of visual information.
Horwitz, G., University of Washington, Seattle: White noise 
analysis of V1 neurons.
Boynton, G., University of Washington, Seattle: fMRI in the 
LGN and V1. Psychophysics/signal detection theory.
Palmer, S., University of Chicago, Hyde Park, Illinois: 
Information in the early visual system.
Heeger, D., New York University, New York: Normalization 
as a canonical neural computation.
Cohen, M., University of Pittsburgh, Pennsylvania.
Li, Z., Cornell University, Ithaca, New York.
Priebe, P., Northwestern University, Chicago, Illinois: Spike 
threshold, inhibition, and stimulus selectivity in primary 
visual cortex.
Brainard, D., University of Pennsylvania, Philadelphia: 
Computational color vision.
Fairhall, A., University of Washington, Seattle.
Olshausen, B., University of California, Berkeley: 
Computational models of perception and scene analysis.
Rust, N., University of Pennsylvania, Philadelphia: The 
neural mechanisms responsible for identifying and fi nding 
objects.
DeAngelis, G., University of Rochester, New York: Linking 
neurons to behavior: Motion and depth.
Treue, S., German Primate Center, Goettingen, Germany
Serences, J., University of California, San Diego: Attentional 
modulations in human cortex.
Ma, W.J., New York University, New York: Psychophysics 
and Bayesian modeling.
Churchland, A., Cold Spring Harbor Laboratory: Integrating 
vision with other modalities: Insights into optimal behavior 
and the structure of neural populations.
Kiani, R., New York University, New York.
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Proteomics
July 15–28
INSTRUCTORS M. Bereman, North Carolina State University, Raleigh
 M. Cilia, Cornell University, Ithaca, New York
 I. Cristea, Princeton University, New Jersey
 D. Pappin, Cold Spring Harbor Laboratory
ASSISTANTS M. Alexander, Cornell University, Ithaca, New York
 H. Budayeva, Princeton University, New Jersey
 B. Diner, Princeton University, New Jersey
 T. Greco, Princeton University, New Jersey
 T. Hassan, Cold Spring Harbor Laboratory
 P. Pinheiro, Cornell University, Ithaca, New York
 K. Rivera, Cold Spring Harbor Laboratory
 J. Wilson, Cold Spring Harbor Laboratory
This intensive laboratory and lecture course focused on cutting-edge proteomic approaches and 
technologies. Students gained practical experience purifying and identifying protein complexes 
and posttranslational modifi cations. In a section focused on quantitative whole-proteome anal-
yses or top-down proteomics, students gained hands-on experience using two-dimensional gel 
electrophoresis and mass spectrometry analysis. Students used differential in-gel electrophoresis 
(DIGE) for gel-based protein quantifi cation. Differentially expressed proteins were recognized 
by statistical methods using advanced gel analysis software and identifi ed using MALDI mass 
spectrometry. For shotgun proteomic analysis sections or bottom-up proteomics, students used 
label-free and covalent isotopic-labeling quantitative approaches to differentially profi le changes in 
protein complexes and whole proteomes. Students were trained in high-sensitivity microcapillary 
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liquid chromatography coupled with nanospray-ESI and tandem mass spectrometry analysis and 
learned both single-dimension and multidimensional separation methods. In a section focused on 
targeted proteomics, they learned to analyze and process shotgun proteomic data for the devel-
opment of SRM/MRM assays that accurately identify and quantify targeted proteins. Students 
designed transitions for selected peptides and performed SRM/MRM mass spectrometry assays. 
They learned to process and interpret the acquired data to measure changing quantities of targeted 
proteins in a variety of biological samples. For all sections of the course, a strong emphasis was 
placed on data analysis. A series of outside lecturers discussed various proteomics topics including 
imaging by mass spectrometry, de novo sequence analysis, advanced mass spectrometry methods, 
protein arrays, and functional proteomics. The aim of the course was to provide each student with 
the fundamental knowledge and hands-on experience necessary for performing and analyzing 
proteomic experiments. The overall goal was to train students to identify new opportunities and 
applications for proteomic approaches in their biological research.
This course was supported with funds provided by the National Institute of Child Health and 
Human Development.
PARTICIPANTS
Cendrowski, S., Ph.D., National Biodefense Analysis and 
Countermeasures Center, Frederick, Maryland
Chamoun, R., Ph.D., McGill University, Ste. Anne de 
Bellevue, Canada
Cheng, Z., B.S., New York University, New York
Engle, D., Ph.D., Cold Spring Harbor Laboratory
Garrett, A., Ph.D., Center of Disease Control and 
Prevention, Atlanta, Georgia
Harold, A., B.S., Duke University, Durham, North Carolina
Hong, M., M.S., Icahn School of Medicine at Mount Sinai, 
New York
Lee, E.B., Ph.D., Seoul National University College of 
Medicine, South Korea
McDonald, C., D.V.M., Cornell University, Ithaca, 
New York
Medzihradszky, M., Ph.D., University of Heidelberg, 
Heidelberg, Germany
Reynolds, N., Ph.D., Yale University, New Haven, 
Connecticut
Shi, Z., B.S., Stanford University, California
Simsek, D., Ph.D., Stanford University, California
Suryawanshi, A., Ph.D, Institute of Life Sciences, 
Bhubaneswar, India
Tomlinson, R., M.S., AstraZeneca, Waltham, Massachusetts
Uehling, J., M.S., Duke University, Durham, 
North Carolina
SEMINARS
Nesvizhskii, A., University of Michigan, Ann Arbor: 
Analysis of affi nity purifi cation mass spectrometry data for 
reconstruction of protein–protein interactions.
Pappin, D., Cold Spring Harbor Laboratory: Identifi cation of 
proteins using tandem mass spectrometry.
Muddiman, D., North Carolina State University, Raleigh: 
Thing 1 and Thing 2 (and Thing 3): ESI, MALDI, and 
hybrids of the two. Controlling chaos: Adventures in 
absolute protein quantifi cation.
Conlon, F., University of North Carolina, Chapel Hill: 
Functional investigation of the cardiac interactomes.
Clauser, K., Broad Institute of MIT and Harvard, 
Cambridge, Massachusetts: De novo interpretation of 
tandem mass spectra.
Medzihradszky, K., University of San Francisco, California: 
How to interpret/evaluate MS/MS spectra: Focus on PTM 
assignments.
Bereman, M., North Carolina State University, Raleigh: 
Introduction to mass spectrometry. Systems suitability for 
LC-MS/MS.
MacCoss, M., University of Washington, Seattle: 
Introduction to peptide quantifi cation and targeted 
proteomics. Beyond data-dependent acquisition: Sometimes 
we need to go backward before we can go forward.
382
Eukaryotic Gene Expression
July 22–August 11
INSTRUCTORS K. Adelman, NIH/NIEHS, Research Triangle Park, North Carolina
 G. Narlikar, University of California, San Francisco
 A. Shilatifard, Stowers Institute for Medical Research, Kansas City, Missouri
 D. Taatjes, University of Colorado, Boulder
ASSISTANTS B. Allen, University of Colorado, Boulder
 E. Bowman, NIH/NIEHS, Durham, North Carolina
 D. Gilchrist, NIEHS, Research Triangle Park, North Carolina
 R. Rickels, Stowers Institute for Medical Research, Kansas City, Missouri
 C. Zhou, University of California, San Francisco
This course was designed for students, postdocs, and principal investigators who had recently 
ventured into the exciting area of gene regulation. The course focused on state-of-the-art strategies 
and techniques used in the fi eld. Emphasis was placed both on in vitro and in vivo protein–DNA 
interactions and on novel methodologies to study gene regulation. Students made nuclear extracts, 
performed in vitro transcription reactions, and measured RNA levels using primer extension. 
Students isolated transcription factor complexes and assessed their activity in functional assays. In 
addition, students learned techniques for the assembly and analysis of chromatin in vitro. These 
included transcription assays, chromatin footprinting, and chromatin remodeling assays.
During the past few years, the gene regulation fi eld has developed in vivo approaches to study 
gene regulation. Students learned widely used techniques such as quantitative reverse transcrip-
tion–polymerase chain reaction (qRT-PCR) and chromatin immunoprecipitation (ChIP). They 
also used RNA interference (RNAi) for specifi c knockdown experiments. Determining cellular 
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gene expression profi les has been accelerated tremendously by microarray and sequencing technol-
ogy. Students received hands-on training in performing and interpreting results from microarrays, 
ChIP-Seq, and RNA-Seq data sets.
This course was supported with funds provided by the National Cancer Institute.
PARTICIPANTS
Benegiamo, G., M.Sc., Salk Institute for Biological Studies, 
La Jolla, California
Bockstaller, M., M.Sc., Ludwig-Maximilians-Universitaet 
Muenchen, Munich, Germany
Chen, H., Ph.D., National Institutes of Health, Bethesda, 
Maryland
Coulon, A., Ph.D., National Institutes of Health, Bethesda, 
Maryland
Ganguly, S., Ph.D., National Cancer Institute, Bethesda, 
Maryland
Handley, A., B.Sc., Ludwig-Maximilians-Universitaet 
Muenchen, Munich, Germany
Guss, K., Ph.D., Dickinson College, Carlsle, Pennsylvania
Labbe, D., Ph.D., Harvard Medical School/DFCI, Boston, 
Massachusetts
Lauridsen, F., B.A., University of Copenhagen, Denmark
Muthurajan, U., Ph.D., Colorado State University, Fort Collins
Novatt, J., Ph.D., Cold Spring Harbor Laboratory
Palchaudhuri, R., Ph.D., Harvard University, Cambridge, 
Massachusetts
Park, J., Ph.D., Harvard Medical School, Boston, 
Massachusetts
Pera-Gresely, B., Ph.D., Weill Cornell Medical College, 
New York
Wolter, J., B.S., Arizona State University, Tempe
Yu, S., B.S., Stockholm University, Sweden
SEMINARS
Meyer, B., University of California/HHMI, Berkeley: Dosage 
compensation in Caenorhabditis elegans.
Wu, C., Janelia Farm Research Campus/HHMI, Ashburn, 
Virginia: Interplay between chromatin structure and 
transcription.
Burge, C., Massachusetts Institute of Technology, 
Cambridge: Genomic analysis of splicing patterns using 
RNA-Seq reveals interesting evolutionary and regulatory 
strategies.
Bentley, D., University of Colorado School of Medicine, 
Aurora: Cotranscriptional mRNA proessing.
Furlong, E., European Molecular Biology Laboratory, 
Heidelberg, Germany: Development and activity of 
enhancers in Drosophila.
Kugel, J., University of Colorado, Boulder: Fundamental 
gene regulatory strategies and their regulation by noncoding 
RNAs.
Tyler, J., University of Texas, MD Anderson Cancer Center, 
Houston: Regulation of chromatin assembly during DNA 
replication and transcription.
Kadonaga, J., University of California, San Diego: Novel 
core promoter motifs work within specialized transcription 
systems.
Lis, J., Cornell University, Ithaca, New York: Pausing of 
RNA polymerase II.
Whetstine, J., Massachusetts General Hospital and Harvard 
Medical School, Charlestown: Histone demethylases in 
health disease.
Neugebauer, K., Yale University, New Haven, Connecticut: 
Functional coupling between transcription and splicing.
Di Croce, L., Center for Genomic Regulation, Barcelona, Spain: 
Development control of chromatin modifying enzymes.
Shiekhattar, R., University of Miami, Coral Gables, 
Florida: Integrator complex as a general regulator of polII 
transcription.
Kingston, R., Massachusetts General Hospital and Harvard 
Medical School, Boston: Noncoding RNAs and Polycomb.
Berger, S., University of Pennsylvania, Philadelphia: Changes 
in chromatin architecture and transcription that occur 
during aging.
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Yeast Genetics and Genomics
July 22–August 11
INSTRUCTORS G. Brown, University of Toronto, Ontario, Canada
 M. Dunham, University of Washington, Seattle
 M. Gartenberg, Robert Wood Johnson Medical School, Piscataway, New Jersey
ASSISTANTS M. Borrie, Robert Wood Johnson Medical School, Piscataway, New Jersey
 M. Sanchez, University of Washington, Seattle
 T. Sing, University of Toronto, Ontario, Canada
This course is a modern, state-of-the-art laboratory course designed to teach students the full 
repertoire of genetic approaches needed to dissect complex problems in the yeast Saccharomyces 
cerevisiae. Combinations of classical and modern genetic approaches were emphasized, includ-
ing the isolation and characterization of mutants, tetrad analysis, complementation, and mitotic 
recombination. Students learned array-based methods, next-generation sequencing, and genome-
based methods of analysis facilitated by the yeast genome sequence, the deletion collection, and 
other genomic resources available to the community. Molecular genetic techniques, including 
yeast transformation, gene replacement by polymerase chain reaction (PCR), construction and 
analysis of gene fusions, and generation of mutations, were also emphasized.
Students used classical approaches and modern whole-genome sequencing to gain experience 
in identifying and interpreting various kinds of genetic interactions including suppression and 
synthetic lethality (including SGA). Students immersed in yeast genomics and performed and 
interpreted experiments using DNA arrays, whole-genome sequencing, and multiplexed DNA 
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barcode sequencing. Students gained fi rst-hand experience in modern cytological approaches such 
as epitope tagging and imaging yeast cells using indirect immunofl uorescence, green fl uorescent 
protein (GFP) fusions, and a variety of fl uorescent indicators for different subcellular organelles. 
Lectures on fundamental aspects of yeast genetics were presented along with seminars given by 
prominent experts in the fi eld on topics of current interest.
This course was supported with funds provided by National Science Foundation and the 
Howard Hughes Medical Institute.
PARTICIPANTS
Barber, J., Ph.D., RIKEN Institute, Wako, Japan
Ewald, F., M.S., University of Gothenburg, Sweden
Fine, R., B.S., University of Virginia, Charlottesville
Hanson, S., Ph.D., University College Dublin, Ireland
Jayashankar, V., M.S., University of California, Irvine
Kumar, A., Ph.D., University of Miami, Florida
Ledbetter, R., M.S., Utah State University, Logan
Lothrop, A., Ph.D., Tufts University, Medford, 
Massachusetts
McMillen, D., Ph.D., University of Toronto Mississauga, 
Canada
Kyle Mohler, K., B.S., The Ohio State University, Columbus
Sampaio, N.M., B.S., Colorado State University, Ft. Collins
Shen, D., B.S., Lehigh University, Bethlehem, Pennsylvania
Silva, G., Ph.D., New York University, New York
Stenberg, S., B.Sc., Norwegian University of Life Sciences, 
As, Norway
Thomas, V., Northwestern University, Evanston, Illinois
Wu, Y., M.S., University of Toronto, Canada
SEMINARS
Gladfelter, A., Dartmouth College, Hanover, New 
Hampshire: Protein aggregation organizes cytosol for the 
cell cycle and symmetry breaking.
Stillman, B., Cold Spring Harbor Laboratory: Biochemistry 
and genetics of DNA replication in Saccharomyces cerevisiae.
Myers, C., University of Minnesota, Minneapolis: Lessons 
from large-scale analysis of genetic interactions in yeast.
Drubin, D., University of California, Berkeley: Harnessing 
actin dynamics for traffi cking events in budding yeast.
Zakian, G., Princeton University, Princeton, New Jersey: 
Getting from there to here, the history of a scientifi c 
project.
Keasling, J., University of Berkeley, Lawrence Berkeley 
National Laboratory, and Joint BioEnergy Institute, 
Emeryville, California: Metabolic engineering of yeast for 
production of fuels and chemicals.
McCusker, J., Duke University Medical Center, Durham, 
North Carolina: The 100-genomes strains population 
genomics, genotypic/phenotypic variation, and emergence 
of an opportunistic pathogen.
Costanzo, M., Stanford University School of Medicine, 
California: Harnessing the awesome power of yeast with the 
Saccharomyces Genome Database.
Rando, O., University of Massachusetts Medical School, 
Worcester: Structural biology of the yeast genome.
Philippsen, P., University of Basel, Switzerland: Cell growth 
but no divisions: The lifestyle of a group of multinucleated 
fi lamentous fungi controlled by a budding-yeast-like 
genome.
Rothstein, R., Columbia University Medical Center, New 
York: Transformation, recombination, and choreography of 
the DNA damage response.
Emr, S., Cornell University/Weill Institute, Ithaca, New 
York: Sorting out protein traffi c: A geneticist’s journey from 
genes to proteins to functions.
Haase, S., Duke University, Durham, North Carolina: 
Network control of cell-cycle transcription program.
Jaspersen, S., Stowers Institute for Medical Research, Kansas 
City, Missouri: Divide and conquer: The nuclear envelope 
and mitosis.
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Imaging Structure and Function in the Nervous System
July 23–August 11
INSTRUCTORS J. Waters, Allen Institute for Brain Science, Seattle, Washington
 K. Zito, University of California, Davis
 F. Albeanu, Cold Spring Harbor Laboratory
 P. Tsai, University of California, San Diego, La Jolla
ASSISTANTS C. Johnson, University of California, Berkeley
 J. Lambert, University of California, Davis
 R. Larsen, Allen Institute for Brain Science, Seattle, Washington
 F. Munoz-Cuevas, University of Maryland, Baltimore
 J. Zhuang, Allen Institute for Brain Science, Seattle, Washington
Advances in light microscopy and digital image processing and the development of a variety of 
powerful fl uorescent probes present expanding opportunities for investigating the nervous sys-
tem, from synaptic spines to networks in the brain. This intensive laboratory and lecture course 
provided participants with the theoretical and practical knowledge to use emerging imaging 
technologies. The primary emphasis of the course was on vital light microscopy. Students learned 
the principles of light microscopy, as well as use of different types of cameras, laser-scanning 
systems, functional fl uorophores, delivery techniques, and digital image-processing software. In 
addition to transmitted light microscopy for viewing cellular structure, the course examined a 
variety of molecular probes of cell function, including calcium-sensitive dyes and optogenet-
ic and photoactivatable molecules. Particular weight was given to multiphoton laser-scanning 
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microscopy and to biological fl uorophores, especially green fl uorescent protein (GFP) and its 
variants. We used a spectrum of neural and cell biological systems, including living animals, 
brain slices, and cultured cells.
Applicants had a strong background in the neurosciences or in cell biology. In their personal 
statements, applicants specifi ed (1) their experience with optical techniques, (2) how they would 
apply optical methods in their current projects, (3) the microscope systems available to them, and 
(4) their long-term goals in learning more about optical methods.
This course was supported in part by the Howard Hughes Medical Institute and the Burroughs 
Wellcome Fund.
PARTICIPANTS
Bicker, S., Ph.D., University of Marburg, Marburg an der 
Lahn, Germany
Bouvier, G., M.S., Institut de Biologie de l’Ecole Normale 
Superieure, Paris, France
Crisp, S., Ph.D., University College London, United 
Kingdom
Deutsch, D., Ph.D., Princeton University, New Jersey
Dosumu-Johnson, R., B.S., Harvard Medical School, Boston, 
Massachusetts
Gabitto, M., B.S., Columbia University, New York
Issa, E., Ph.D., Massachusetts Institute of Technology, 
Cambridge
Moore, A., B.S., Brandeis University, Waltham, Massachusetts
Nelson, A., B.A., Duke University Medical Center, Durham, 
North Carolina
O’Farrell, F., B.Sc., University College London, United 
Kingdom
Ohayon, S., Ph.D., Massachusetts Institute of Technology, 
Cambridge
Sato, T., M.D., University College London, United Kingdom
Schroeder, S., Ph.D., University College London, United 
Kingdom
Wijetunge, L., Ph.D., University of Edinburgh, United 
Kingdom
SEMINARS
Dombeck, D., Northwestern University, Evanston, Illinois: 
Awake imaging in the hippocampus.
O’Connor, D., Johns Hopkins University School of 
Medicine, Baltimore, Maryland: Extended Ca imaging: 
Kinetics and spike detection.
Engert, F., Harvard University, Cambridge, Massachusetts: 
2P microscopy; lasers.
Albeanu, F., Cold Spring Harbor Laboratory: Intrinsic imaging.
Lanni, F., Carnegie-Mellon University, Pittsburgh, 
Pennsylvania: Nature of light, coherence, wave description, 
polarization. Incoherent emission pt source, PSF/Airy 
pattern, Fourier/OTF, aberrations.
Waters, J., Northwestern University, Chicago, Illinois: Noise 
and detectors.
Lichtman, J., Harvard University, Cambridge, Massachusetts: 
Confocal microscopy.
Waters, J., Harvard Medical School, Boston, Massachusetts: 
Cameras and PMTs; noise (sources and troubleshooting) 
and saturation.
Mertz, J., Boston University, Massachusetts: Contrast: Phase, 
DIC, De Senarmont DIC, Dodt tube.
Biteen, J., University of Michigan, Ann Arbor: STORM/
PALM, STED, structured illumination.
Zito, K., University of California, Davis: Photolysis.
Deisseroth, K., Stanford University, California: 
Optogenetics: Recent advances/CLARITY.
Loew, L., University of Connecticut Health Center, 
Farmington: Imaging voltage.
Ji, N., Janelia Farm Research Campus/HHMI, Ashburn, 
Virginia: Deep imaging/adaptive optics.
Griesbeck, O., Max-Planck Institute of Neurobiology, 
Martinsried, Germany: XFP calcium indicators.
Tsai, P., University of California, San Diego, La Jolla: Ray 
tracing, refraction, lenses. Fluorescence/Fred’s rocks, 
Jablonski diagrams, fi lters.
Yasuda, R., Max-Planck Florida Institute for Neuroscience, 
Jupiter: FRET and FLIM.
Kuhlman, S., Carnegie Mellon University, Pittsburgh, 
Pennsylvania: In vivo 2p guided patch.
Emiliani, V., CNRS, INSERM, University Paris Descartes 
Paris, France: SLM.
Murthy, V., Harvard University, Cambridge, Massachusetts: 
Holographic photoactivation.
Denk, W., Max-Planck Institute for Medical Research, 
Heidelberg, Germany: Block-face EM/connectome.
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Synthetic Biology
July 21–August 11
INSTRUCTORS K. Haynes, Arizona State University, Tempe
 J. Lucks, Cornell University, Ithaca, New York
 P. Peralta-Yahya, Georgia Institute of Technology, Atlanta
 D. Savage, University of California, Berkeley
 J. Tabor, Rice University, Houston, Texas
ASSISTANTS R. Davis, Arizona State University, Tempe
 E. Olson, Rice University, Houston,Texas
 V. Peterson, Georgia Institute of Technology, Atlanta
 M. Takahashi, Cornell University, Ithaca, New York
 R. Yokoo, University of California, Berkeley
Synthetic biology is a discipline wherein living organisms are genetically programmed to carry 
out desired functions in a reliable manner. This fi eld takes inspiration from our ever-expanding 
ability to measure and manipulate biological systems, as well as the philosophical refl ections of 
Schrödinger and Feynman that physical laws can be used to describe and rationally engineer biol-
ogy to accomplish useful goals. After all, cells are the world’s most sophisticated chemists, and 
their ability to learn to adapt to changing environments offers enormous potential to solving mod-
ern engineering challenges. Nonetheless, biological systems are noisy, massively interconnected, 
and nonlinear, and they have not evolved to be easily engineered. The grand challenge of synthetic 
biology is to reconcile the desire for a predictable, formalized biological design process with the 
inherent “squishiness” of biology.
This course was supported by the Howard Hughes Medical Institute and the U.S. Offi ce of 
Naval Research.
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PARTICIPANTS
Bhatnagar, P., Ph.D., Baylor College of Medicine, Houston, 
Texas
Brechun, K., B.S., University of Toronto, Canada
Canady, T., B.A., Carnegie Mellon University, Pittsburgh, 
Pennsylvania
Cavaleiro, A., M.S., Novo Nordisk Foundation Centre for 
Biosustainability, Horsholm, Denmark
Chessher, A., Ph.D., Manchester Institute of Biotechnology, 
Manchester, United Kingdom
Coffman, C., Ph.D., University of Missouri, Columbia
Ghosh, S., M.S., CSIR-Indian Institute of Chemical Biology, 
Kolkata, India
Hecht, A., Ph.D., National Institute of Standards and 
Technology, Stanford, California
Inda, M., Ph.D., IBR, Rosario, Argentina
Kennedy, L., Ph.D., United States Naval Academy, 
Annapolis, Maryland
Kumaran, R.I., Ph.D., Cold Spring Harbor Laboratory
Lopatkin, A., B.S., Duke University, Durham, North 
Carolina
Munson, M., Ph.D., National Institute of Standards and 
Technology, Stanford, California
Raghavan, S., Ph.D., Biomedical Sciences Institute, 
Singapore
Rasaputra, K., Ph.D., University of Houston, Texas
Woodsworth, D., B.Sc., British Columbia Cancer Research 
Center, Vancouver, Canada
SEMINARS
Ellington, A., University of Texas, Austin: Directed evolution 
as synthetic biology.
Klavins, E., University of Washington, Seattle: Computation 
with multicellular systems.
Wang, H., Columbia University, New York: Multiplex 
genome engineering in cells and communities.
Keasling, J., University of California, Berkeley/Lawrence 
Berkeley National Laboratory, Emeryville: Synthetic (yeast) 
biology for synthetic chemistry.
Hoff, K., Genomatica, Inc., San Diego, California: An 
industrial synthetic biology.
Dunlop, M., University of Vermont, Burlington: Engineering 
feedback control systems in microbes.
Palmer, M., Stanford University, California: Responsible 
innovation.
Jewett, M., Northwestern University, Evanston, Illinois: 
Engineering biology by design thinking outside the cell.
Gonzalez, R., Rice University, Houston, Texas: Engineering 
biology for fuel and chemical production.
Murray, R., California Institute of Technology, Pasadena: 
Rapid prototyping and debugging of biomolecular circuits 
using cell-free breadboards.
Weiss, R., Massachusetts Institute of Technology, 
Cambridge: Mammalian cell engineering.
Qi, S., University of California, San Francisco: Editing and 
regulation of the mammalian genome using CRISPR.
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Genetics and Neurobiology of Language
July 28–August 3
INSTRUCTORS S. Fisher, Max-Planck Institute for Psycholinguistics, Nijmegen, The Netherlands
 D. Poeppel, University Maryland College Park, College Park
 K. Watkins, Oxford University, United Kingdom
Why are children able to acquire highly sophisticated language abilities without needing to be 
taught? What are the neurobiological and neurophysiological processes that underpin human 
speech and language and how do they go awry in developmental and acquired disorders? Which 
genetic factors contribute to this remarkable suite of human skills and are there evolutionary 
precursors that we can study in other species? This unique new CSHL course addressed core ques-
tions about the bases and origins of speech and language through talks, interactive sessions, key-
notes, and debates involving leading experts from a range of disciplines. It integrated the state-of-
the-art from complementary perspectives, including development, cognitive models, neural basis, 
gene identifi cation, functional genomics, model systems, and comparative/evolutionary studies.
This course was supported with funding from the Nancy Lurie Marks Family Foundation.
PARTICIPANTS
Akimoto, Y., Ph.D., RIKEN Brain Science Institute,  
Wako-shi, Saitama, Japan
Bergelson, E., Ph.D., University of Rochester, New York
Chesters, J., D.Phil., University of Oxford, United Kingdom
Fraley, E., Ph.D., University of California, Los Angeles
Getz, H., Ph.D., Georgetown University, Washington, D.C.
Guidi, L., D.Phil., University of Oxford, United Kingdom
Hayes, R., M.S., University of Pittsburgh, Pennsylvania
Hobson, H., D.Phil., University of Oxford, United Kingdom
Kavaklioglu, T., M.S., Max-Planck Institute for 
Psycholinguistics, Nijmegen, The Netherlands
Krishnan, S., Ph.D., Birkbeck, University of London, United 
Kingdom
Martinez Alvarez, A., M.A., University of Barcelona, Spain
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Mody, M., Ph.D., Lurie Center for Autism, Lexington, 
Massachusetts
Nora, A., M.Psych., Brain Research Unit, Finland
Oseki, Y., M.A., New York University, New York
Pagliarini, E., M.A., University of Milarno-Bicocca, Milan, 
Italy
Payne, H., Ph.D., University of College, London, United 
Kingdom
Rendall, A., Ph.D., University of Connecticut, Storrs
Riva, V., Ph.D., Scientifi c Institute “Eugenio Medea,” Bosiso 
Parini (Lecco), Italy
Swanson, M., Ph.D., University of North Carolina, Chapel 
Hill
Williams, A., M.A., New York University, New York
Yablonski, M., M.Sc., Bar-Ilan University, Ramat Gan, Israel
Zhang, L., Ph.D., New York University, New York
SEMINARS
Aslin, R., University of Rochester, New York: Speech 
perception and work recognition in infants and adults.
Werker, J., University of British Colombia, Vancouver, 
Canada: Mechanisms of development and plasticity in 
speech perception.
McAllister Byun, T., New York University, New York: 
Perception-production relations in speech acquisition and 
disorders: A view from American English.
Watkins, K., Oxford University. United Kingdom: 
Similarities and differences in the neural correlates of 
developmental disorders of speech and language.
Rice, M., The University of Kansas, Kansas City: Growth of 
language in children with and without SLI: Moving toward 
epigenetic models of growth strengths and weaknesses.
Emmorey, K., San Diego State University, California: 
The impact of distinct sensory-motor systems on the 
neurobiology of language: Signed versus spoken language.
MacSweeney, M., University College London, United 
Kingdom: The impact of deafness on the neurobiology of 
spoken language.
Pylkkanen, L., New York University, New York: Combinatory 
semantics in the cognitive neuroscience of language.
Fedorenko, E., Massachusetts Institute of Technology, 
Cambridge: The language network and its place within the 
broader architecture of the human mind and brain.
Dronkers, N., University of California, Davis: What has the 
study of adult aphasia taught us about language?
Davis, M., MRC Cognition and Brain Sciences Unit, 
Cambridge, United Kingdom: The neurobiology of spoken 
word recognition.
Bishop, D., University of Oxford, United Kingdom: Using 
genetics as a tool to explore relations between language and 
other domains.
Fisher, S., Max-Planck Institute for Psycholinguistics, 
Nijmegen, The Netherlands: Genes, speech, and language: 
Translating the genome in human neuroscience.
Vernes, S., Max-Planck Institute for Psycholinguistics, 
Nijmegen, The Netherlands: The building blocks of 
language: From molecules to neuronal circuits.
Poeppel, D., New York University, New York: How 
can we develop linking hypotheses between genetics, 
computational neuroscience, and language research?
Hagoort, P., Max-Planck Institute for Psycholinguistics, 
Nijmegen, The Netherlands: The neurobiology of language 
beyond the information given.
Paracchini, S., University of St Andrews, Fife, United 
Kingdom: Dyslexia and laterality: Is there a link?
Enard, W., Ludwig-Maximilians University, Munich, 
Germany: Mice, chimpanzees, and the molecular basis of 
speech.
Scharff, C., Freie Universitat Berlin, Germany: FoxPs in birds 
and insects.
Kayser, C., University of Glasgow, Scotland: The neural 
mechanisms of speech encoding: From oscillations to 
neural populations.
Fitch, T., University of Vienna, Austria: A comparative 
approach to the neurobiology of language.
Arnold, K., University of St Andrews, Fife, United Kingdom: 
The search for language in nonhuman primates.
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Brain Tumors
August 6–12
INSTRUCTORS C. Gladson, Cleveland Clinic, Ohio
 A. Lasorella, Columbia University, New York
 S. Majumder, University of Texas MD Anderson Cancer Center, Houston
ASSISTANT A. Marisetty, University of Texas MD Anderson Cancer Center, Houston
This 1-week discussion course provided a clinical overview of brain tumors and emphasized mo-
lecular mechanisms involved in their growth. Special emphasis was placed on neural differentia-
tion, signaling mechanisms, DNA replication, chromatin modulation, stem cells, mouse models, 
genomics, imaging techniques, genetically modifi ed mouse techniques, nanotechnology, mech-
anism-based therapeutic strategies, and biobanks and ethical concerns. Attendees were able to 
interact with senior investigators one-to-one in an informal environment. All nonfaculty students 
were considered for a generous stipend depending on stated need. Applications were invited from 
medical and graduate students, postdoctoral fellows, faculty, and clinicians and scientists.
This course was supported with funding from the American Brain Tumor Association.
PARTICIPANTS
Badeaux, M., Ph.D., Massachusetts General Hospital, Boston
Braun, S., Ph.D., Lund University, Sweden
Dhruv, H., Ph.D., Translational Genomics Research 
Institute, Phoenix, Arizona
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Ferraro, G., Ph.D., Harvard Medical School, Charlestown, 
Massachusetts
Garrós-Regúlez, L., Ph.D., Biodonostia Institute, San 
Sebastián, Spain
Kaur, A., M.Sc., University of Turku, Finland
Kloepper, J., Ph.D., Massachusetts General Hospital, Boston
Lu, L., M.D., MD Anderson Cancer Center Genetics, 
Houston, Texas
Rraklli, V., Ph.D., Karolinska Institutet, Stockholm, Sweden
Seano, G., Ph.D., Harvard Medical School/Massachusetts 
General Hospital, Boston
Selvadurai, H., Ph.D., The Hospital for Sick Children, 
Toronto, Canada
Shahzad, U., Ph.D., The Hospital for Sick Children, Toronto, 
Canada
Wang, C.-L., Ph.D., Cold Spring Harbor Laboratory
Weissmann, S., Ph.D., University of Copenhagen, 
Denmark
SEMINARS
Sawaya, R., MD Anderson Cancer Center, Houston, Texas: 
Extent of resection and survival in glioblastoma: Why and 
how?
Fuller, G., MD Anderson Cancer Center, Houston, Texas: 
Clinical aspects of brain tumors: Oncologic surgical 
neuropathology.
Bondy, M., Baylor College of Medicine, Houston, Texas: 
Epidemiology of glioma: Current state of the science.
Reilly, K., National Cancer Institute, Bethesda, Maryland: 
Mouse models of brain cancer to study genetic risk 
factors.
Mietz, J., National Cancer Institute, Bethesda, Maryland.
Sawaya, R., MD Anderson Cancer Center, Houston, Texas: 
The comprehensive neuro-oncology center: Challenges and 
opportunities.
Wechsler-Reya, R., Duke University Medical Center, 
Durham, North Carolina.
Baker, S., St. Jude Children’s Research Hospital, Memphis, 
Tennessee: Molecular and clinical subgroups of pediatric 
high-grade glioma.
Eberhart, C., Johns Hopkins University School of Medicine, 
Baltimore, Maryland: The role of notch signaling in brain 
tumors.
Jabado, N., McGill University Health Center, Montreal, 
Quebec.
Roussel, M., St. Jude Children’s Research Hospital, 
Memphis, Tennessee: Pediatric medulloblastoma.
Rakesh Jain, R., Massachusetts General Hospital, Boston.
Gladson, C., Cleveland Clinic, Ohio.
Pieper, R., University of California, San Francisco: The 
deceptively complicated story of mutant IDH-mediated 
drug resistance.
James, C.D., Northwestern University, Evanston, Illinois: 
Therapeutic hypothesis testing using brain tumor 
engraftment models.
Holland, E., Fred Hutchinson Cancer Research Center, Seattle, 
Washington: The evolution of non-CIMP GBM subtypes.
Gutmann, D., Washington University School of Medicine, 
St. Louis, Missouri: Leveraging neurofi bromatosis-1 to 
understand pediatric glioma pathogenesis.
Enikolopov, G., Cold Spring Harbor Laboratory: Modes of 
division and differentiation of neural stem cells.
Dirks, P., Hospital for Sick Children/University of Toronto, 
Canada.
Kornblum, H., University of California Molecular and 
Medical Pharmacology, Los Angeles: Neurospheres: 
Making a mess of the data.
Rich, J., Cleveland Clinic, Ohio: Brain tumor stem cells.
Snyder, E., Sanford/Burnham Institute, La Jolla, California.
Lasorella, A., Columbia University, New York.
Majumder, S., University of Texas MD Anderson Cancer 
Center, Houston: Cellular fl exibility regulates both normal 
development and cancer.
Furnari, F., University of California, San Diego: EGF 
receptors in glioma biology: Therapeutic targets and 
multifaceted drivers of pathogenicity.
Berger, M., University of California, San Francisco.
Aldape, K., The University of Texas, Houston.
Brennan, C., Memorial Sloan-Kettering Cancer Center, 
New York.
Iavarone, A., Columbia University Medical Center, New 
York: The master regulators and drivers of oncogenesis of 
glioblastoma.
Gilbert, M., MD Anderson Cancer Center, Houston, Texas.
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X-Ray Methods in Structural Biology
October 13–28
INSTRUCTORS W. Furey, V.A. Medical Center and University of Pittsburgh, Pennsylvania
 G. Gilliland, Janssen R&D, LLC, Johnson & Johnson, Radnor, Pennsylvania
 A. McPherson, University of California, Irvine
 J. Pfl ugrath, The Woodlands, Texas
ASSISTANTS A. Armstrong, Janssen R&D, LLC, Spring House, Pennsylvania
 B. Hintze, Duke University Medical Center, Durham, North Carolina
Crystallography and X-ray diffraction yield a wealth of structural information unobtainable 
through other methods. This intense laboratory/computational course focused on the major tech-
niques used to determine the three-dimensional structures of macromolecules. It was designed 
for scientists with a working knowledge of protein structure and function, but who are new to 
macromolecular crystallography. Topics covered included basic diffraction theory, crystallization 
(proteins, nucleic acids, and complexes), crystal characterization, X-ray sources and optics, syn-
chrotrons, cryocrystallography, data collection, data reduction, heavy atom substructure determi-
nation, multiple isomorphous replacement, single and multiwavelength anomalous diffraction, 
molecular replacement, solvent fl attening, noncrystallographic symmetry averaging, electron den-
sity interpretation, molecular graphics, structure refi nement, structure validation, coordinate de-
position, and structure presentation. Participants learned through extensive hands-on experiments 
in fully equipped labs. They crystallized multiple proteins and determined their crystal structures 
by several methods while learning through extensive lectures on crystallogrpahic theory and in-
formal discussions behind the techniques.
Applicants were familiar with the creation and editing of simple text fi les on Linux worksta-
tions using a screen-based editor (either vi or emacs).
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This course was supported with funds provided by the National Institute of General Medical 
Sciences.
PARTICIPANTS
Arturo, E., B.S., Drexel University College of Medicine, 
Philadelphia, Pennsylvania
Chandrasekarar, V., Ph.D., University of Utah, Salt Lake 
City
Coey, A., Ph.D., Stanford University, California
Doyle, L., B.S., Fred Hutchinson Cancer Research Center, 
Seattle, Washington
Feng, J., Ph.D., Pfi zer, Inc., San Diego, California
Henderson-Stull, M.N., Ph.D., Augsburg College, 
Minneapolis, Minnesota
Hermida Aponte, D., M.S., University of Copenhagen, 
Denmark
Jones, J., B.S., Idaho State University, Meridian
Lizak, C., Ph.D., University of British Columbia, Vancouver, 
Canada
Lofgren, M., Ph.D., Harvard Medical School, Boston, 
Massachusetts
Mansoor, S., Ph.D., Oregon Health & Science University, 
Portland
Nag, S., Ph.D., Yale University, New Haven, Connecticut
Mayclin, S., Ph.D., National Institutes of Health/New York 
University, Bethesda, Maryland
Parthasarathy, G., M.S., Merck and Company, West Point, 
Pennsylvania Massachusetts
Sorensen, A., M.S., Aalborg University and Novo Nordisk 
A/S, Aalborg, Denmark
Wasmuth, E., B.S., Gerstner Sloan-Kettering Graduate 
School, New York
SEMINARS
McPherson, A., University of California, Irvine: 
Crystallization of macromolecules I. Crystallization 
of macromolecules II. Symmetry, periodicity, unit 
cells, space groups, Miller planes, and lattices. Waves, 
vectors, and complex numbers. Fundamental diffraction 
relationships and Bragg’s Law. Diffraction patterns, 
reciprocal space, and Ewalds’s Sphere. Fourier transforms 
and the electron density equation. Patterson methods. 
The art of capillary crystal mounting. Heavy atoms and 
anomalous scatterers.
Perrakis, A., Netherlands Cancer Institute, Amsterdam: 
Automated model building and rebuilding: From 
ARP/WARP to PDB_REDO.
Thorn, A., MRC Laboratory of Molecular Biology, 
Cambridge, United Kingdom: An introduction to 
SHELXC/D/E. The basics of twinning in crystals of 
macromolecules.
Smith, C., Stanford University, California: Synchrotron data 
collection and femtosecond crystallography.
Tronrud, D., Oregon State University, Corvalis: 
Macromolecular refi nement I. Macromolecular 
refi nement II.
Gilliland, G., Janssen R&D, LLC, Johnson & Johnson, 
Radnor, Pennsylvania: Course overview: The structure 
determination of biological macromolecules.
Kleywegt, G., European Bioinformatics Institute, Hinxton, 
Cambridge, United Kingdom: Just because it’s in Nature, 
doesn’t mean it’s true. . .(macromolecular structure 
validation).
Holton, J., University of California, San Francisco: Tips and 
tricks for improving diffraction.
Pfl ugrath, J., The Woodlands, Texas, and Borek, D., 
University of Texas Southwestern Medical Center at Dallas: 
X-ray data collection and processing. Cryocrystallography. 
Cryocrystallography and beyond. Scaling and merging 
synchrotron data.
Richardson, J., and Hintze, B., Duke University Medical 
Center, Durham, North Carolina: Detection and 
repair of model errors using Mo1 probity. Structure 
presentation.
Westbrook, J., Rutgers University, Piscataway, New Jersey: 
Automating PDB deposition.
Caffrey, M., Trinity College Dublin, Ireland: Crystallizing 
membrane proteins for structure-function studies using 
lipidic mesophases.
Adams, P., University of California, Berkeley: Structure 
refi nement. PHENIX overview.
Emsley, P., MRC Laboratory of Molecular Biology, 
Cambridge, United Kingdom: Model-building tools in 
Coot.
Read, R., University of Cambridge, United Kingdom: 
Using SAD data in Phaser. Molecular replacement: New 
structures from old.
Sweet, R., Brookhaven National Laboratory, Upton, 
New York: A slightly different view of fundamental 
crystallography. X-ray sources and optics.
Jackson, R., Montana State University, Bozeman: Crystal 
structure of the CRISPR RNA-guided surveillance complex 
from Escherichia coli.
Terwilliger, T., Los Alamos National Laboratory, New 
Mexico: Automated structure solution and model 
building.
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Hendrickson, W., Columbia University, New York: MAD 
and SAD phasing.
Furey, W., V.A. Medical Center and University of Pittsburgh, 
Pennsylvania: Anomalous data collection considerations. 
Patterson group therapy. Isomorphous replacement 
and anomalous scattering. Solvent fl attening/phase 
combination. MAD phasing: A classical approach. The 
role of direct methods in macromolecular crystallography. 
Noncrystallographic symmetry averaging.
Ji, X., National Cancer Institute, Frederick, Maryland: 
Structural view of double-stranded RNA processing, 
mechanism, and evolution of RNase III.
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Programming for Biology
October 13–28
INSTRUCTOR S. Prochnik, DOE–Joint Genome Institute, Walnut Creek, California
CO-INSTRUCTOR S. Robb, Stowers Institute for Medical Research, Kansas City, Missouri
ASSISTANTS S. Ahrendt, University of California, Riverside
 D. Messina, Cofactor Genomics, St. Louis, Missouri
 S. Rynearson, University of Utah, Salt Lake City
 D. Triant, University of Virginia, Charlottesville
 K. Youens-Clark, University of Arizona, Tucson
Web-based tools are no longer enough for today’s biologist who needs to access and analyze large 
data sets from myriad sources in disparate formats. The need to design and program custom 
analysis pipelines is becoming ever more important as new technologies increase the already ex-
ponential rate at which biological data are generated. Because this 2-week course was designed 
for lab biologists with little or no programming experience, students were able to complete it with 
the bioinformatics and scripting skills necessary to exploit the abundance of biological data. The 
prerequisite for the course was basic knowledge of UNIX; some scripting experience was helpful, 
but not necessary. Lectures and problem sets from previous years that covered this material were 
available online for students to study before starting the course.
The course taught Perl, a scripting language that is easy to learn and effi cient to use. Perl 
also has a vast array of ready-built modules (such as Bioperl) that are designed to solve common 
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biological problems. We started with a week of introductory coding and continued with a survey 
of available biological libraries and practical topics in bioinformatics, taught by invited experts, 
and ended with a fi nal group project. Formal instruction was provided on every topic. Students 
also worked to solve problem sets covering common scenarios in the acquisition, validation, in-
tegration, analysis, and visualization of biological data. For their fi nal projects, which ran during 
the second week of the course, students proposed problems using their own data and worked with 
each other and the faculty to solve them. They learned how to design, construct, and run power-
ful and extensible analysis pipelines in a straightforward manner. Final projects have formed the 
basis of publications as well as public biological websites (see, for example, http://bio.perl.org/
wiki/Deobfuscator). The students were provided with a library of reference books that they took 
home with them. Note that the primary focus of this course was to provide students with practical 
programming experience, rather than to present a detailed description of the algorithms used in 
computational biology.
This course was supported by the National Human Genome Research Institute.
PARTICIPANTS
Alaba, O., M.S., International Institute of Tropical 
Agriculture, Ibadan, Nigeria
Beaudoin, J.-D., Ph.D., Yale University, New Haven, 
Connecticut
del Campo, J., Ph.D., Institut de Ciencies del Mar–CSIC, 
Barcelona, Spain
Gayden, T., Ph.D., McGill University, Montreal, Canada
Gogakos, T., B.S./M.S., The Rockefeller University, 
New York
Gryganskyi, A., P.hD., Lambert Spawn Co., Coatesville, 
Pennsylvania
Hafner, M., Ph.D., NIAMS/National Institutes of Health, 
Bethesda, Maryland
Hehenberger, E., Ph.D., University of British Columbia, 
Vancouver, Canada
Hernandez, M., Icahn School of Medicine at Mount Sinai, 
New York
Irisarri, I., Ph.D., University of Konstanz, Germany
Jackson, S., Ph.D., National Institute of Standards and 
Technology, Gaithersburg, Maryland
Kepler, R., Ph.D., United States Department of Agriculture-
ARS, Beltsville, Maryland
Kosova, G., Ph.D., Massachusetts General Hospital, Boston
McLaughlin, P., Ph.D., Drexel University, Philadelphia, 
Pennsylvania
Monahan, K., Ph.D., Columbia University, New York
Orkin, J., Ph.D., Washington University, St. Louis, Missouri
Schwessinger, B., Ph.D., University of California, Davis
Ann Sutton, L., Ph.D., Uppsala University, Sweden
Tavera-Mendoza, L., Ph.D., Dana-Farber Cancer Institute/
Harvard Medical School, Boston, Massachusetts
Yue, M., Ph.D., University of Pennsylvania, Philadelphia
Zhao, B., B.A., University of Cambridge, United Kingdom
SEMINARS
Moore, B., University of Utah, Salt Lake City: VAAST.
Haas, B., Broad Institute, Cambridge, Massachusetts: RNA 
transcript reconstruction.
Robinson, J., Broad Institute, Cambridge, Massachusetts: 
IGV.
Stajich, J., University of California, Riverside: Introduction 
to NGS.
Schatz, M., Cold Spring Harbor Laboratory: Genome assembly.
Thomas, P., University of Southern California, Los Angeles: 
Protein function annotation.
Cain, S., Ontario Institute for Cancer Research, Toronto, 
Canada: Jbrowse.
Marques-Bonet, T., Universitat Pompeu Fabra, Barcelona, 
Spain: Structural variation.
Pearson, W., University of Virginia, Charlottesville: Sequence 
similarity searching.
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Computational and Comparative Genomics
October 29–November 4
INSTRUCTORS W. Pearson, University of Virginia, Charlottesville
 L. Stubbs, University of Illinois, Urbana
ASSISTANTS D. Miller, Stowers Institute for Medical Research, Kansas City, Missouri
 L. Mills, University of Virginia, Charlottesville
This course presented a comprehensive overview of the theory and practice of computational 
methods for the identifi cation and characterization of functional elements from DNA sequence 
data. The course focused on approaches for extracting the maximum amount of information from 
protein and DNA sequence similarity through sequence database searches, statistical analysis, and 
multiple sequence alignment. Additional topics included alignment and analysis of “next-gen” se-
quencing data, with applications from metagenomic, RNA-Seq, and CHiP-Seq experiments; the 
Galaxy environment for high-throughput analysis; regulatory element and motif identifi cation 
from conserved signals in aligned and unaligned sequences; integration of genetic and sequence 
information in biological databases; genome browsers; and genome features. The course com-
bined lectures with hands-on exercises; students were encouraged to pose challenging sequence 
analysis problems using their own data. The course was designed for biologists seeking advanced 
training in biological sequence and genome analysis, computational biology core resource direc-
tors and staff, and individuals in other disciplines (e.g., computer science) who wish to survey 
current research problems in biological sequence analysis. Advanced programming skills were 
not required. The primary focus of this course was the theory and practice of algorithms in 
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computational biology, with the goals of using current methods more effectively for biological 
discovery and developing new algorithms
This course was supported by the National Human Genome Research Institute.
PARTICIPANTS
Abbas, H., Ph.D., University of Texas MD Anderson Cancer 
Center, Houston
Ai-Yin Liu, I., Ph.D., Duke University, Durham, North 
Carolina
Alvarez, C., M.D., Universidad Nacional Autonoma de 
Mexico, Mexico City
Ball, R., Ph.D., The Jackson Laboratory, Bar Harbor, Maine
Brady, L., Ph.D., University of Pennsylvania, Philadelphia
Engin, H.B., Ph.D., University of California, San Diego
Garrett, E., Ph.D., Washington University, St. Louis, Missouri
Guerra Amorim, C.E., Ph.D., Columbia University, New York
Jain, R., M.D., University of Pennsylvania School of 
Medicine, Philadelphia
Jain, R., Ph.D., Yale University, New Haven, Connecticut
Josefowicz, S., Ph.D., The Rockefeller University, New York
Lee, A., Ph.D., University of British Columbia, Vancouver, 
Canada
Lee, J., Ph.D., University of Minnesota Medical School, 
Duluth
Livnat, A., Ph.D., Virginia Tech, Blacksburg
Mazutis, L., Ph.D., Harvard University, Cambridge, 
Massachusetts
McGee, W., B.A., Northern University, Chicago, Illinois
McKeithen-Mead, S., M.S., Yale University, New Haven, 
Connecticut
Megquier, K., B.A., Broad Institute, Cambridge, 
Massachusetts
Memi, F., Ph.D., University of Connecticut Health Center, 
Farmington
Moir, R., Ph.D., Albert Einstein College of Medicine, Bronx, 
New York
Savitskaya, E., Ph.D., Skolkovo Institute of Science and 
Technologies, Moscow, Russia
Taffner, S., M.S., Washington University, St. Louis, 
Missouri
Weishaupt, H., Ph.D., Uppsala University, Uppsala, 
Sweden
Williams, J., B.S., Cold Spring Harbor Laboratory
SEMINARS
Mackey, A., University of Virginia, Charlottesville: Genome 
annotation (HMM Basics). SNP discovery and variation. 
RNA-Seq. Gene lists to pathways. Assembling genomes and 
transcriptomes.
Miller, D., Stowers Institute for Medical Research, Kansas 
City, Missouri: Unix command line.
Hawkins, D., Ludwig Institute for Cancer Research, La 
Jolla, California: Chromatin states 1: Analysis of histone 
modifi cations.
Stormo, G., Washington University School of Medicine, St. 
Louis, Missouri: Modeling motifs: Collecting data. From 
motifs to regulatory networks.
Taylor, J., Emory University, Atlanta, Georgia: Galaxy for 
high-throughput analysis. Galaxy visualization. Probing 
higher-dimension chromatin structure.
Mills, L., University of Virginia, Charlottesville: 
Introduction to galaxy/genomics fi le formats. Genome 
browsers.
Stubbs, L., University of Illinois, Urbana: Introduction 
to genome biology. Integrating genomics data sets for 
biological inference.
Hardison, R., Pennsylvania State University, State College: 
Genomics of gene regulation 1: Epigenomic features and 
assays. Genomics of gene regulation 2: Epigenomic features 
and assays.
Pearson, W., University of Virginia, Charlottesville: 
Introduction and Overview. Protein evolution and sequence 
similarity searching. Practical sequence similarity searching. 
Multiple sequence alignment. PSSMs, HMMs, and Pfam. 
PSSMs to phenotype.
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Antibody Engineering and Phage Display
November 5–18
INSTRUCTORS D. Siegel, University of Pennsylvania School of Medicine, Philadelphia
 G. Silverman, New York University School of Medicine, New York
SENIOR ASSISTANT S. Kacir, University of Pennsylvania School of Medicine, Philadelphia
ASSISTANTS S. Gilgunn, Dublin City University, Dublin, Ireland
 K. Noren, New England Biolabs, Ipswich, Massachusetts
 M.A. Pohl, Oncobiolgics, Cranbury, New Jersey
Recent advances in the generation and selection of antibodies from combinatorial libraries allow 
the rapid production of antibodies from immune and nonimmune sources. This intensive labo-
ratory/lecture course focused on the construction of combinatorial antibody libraries expressed 
on the surface of phage and selection of desired antibodies from the library. Students learned 
the theoretical and practical aspects of constructing combinatorial libraries from immune and 
nonimmune sources as well as the construction of synthetic antibody libraries. Antibodies were 
selected from the library by panning. Production, purifi cation, and characterization of Fab frag-
ments expressed in Escherichia coli were also covered. Epitopes were selected from peptide librar-
ies and characterized.
The lecture series, presented by a number of invited speakers, emphasized polymerase chain 
reaction (PCR) of immunoglobulin genes, the biology of fi lamentous phage and the utility of 
surface expression libraries, expression of antibodies in E. coli and mammalian cells, antibody 
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structure and function, the immunobiology of the antibody response, and recent results on the 
use of antibodies in therapy. The theory and practical implications for selection from phage-
displayed libraries of random peptides, cDNA products, and semisynthetic proteins were also 
explored.
This course was supported with funds provided by the Howard Hughes Medical Institute.
PARTICIPANTS
Adams, R., Ph.D., Cold Spring Harbor Laboratory
Åstrand, M., M.S., KTH Royal Institute of Technology, 
Stockholm, Sweden
Elias, M., Ph.D., Inventox, Inc., Wynnewood, Pennsylvania
Gordon, S., B.S., Stanford University, California
Günaydin, G., Ph.D., Karolinska Institutet, Stockholm, 
Sweden
Hernandez, D., M.S., Sackler Institute of Biomedical Science 
at NYU, New York
Koti, M., Ph.D., Queen’s University, Kingston, Canada
Maier, N., Dipl., University of Potsdam, Germany
Moran, K., M.Sc., Dublin City University, Ireland
Pelzek, A., M.S., New York University School of Medicine-
Sackler, New York
Robinson, M.P., B.S., Cornell University, Ithaca, New York
Santich, B., B.A., Gerstner Sloan-Kettering Graduate School, 
New York
Stephenson, H., B.S., Sutro Biopharma, S. San Francisco, 
California
Suzuki, M., M.D., Memorial Sloan-Kettering Cancer Center, 
New York
Theunissen, J.-W., Ph.D., IGENICA, Burlingame, California
Vierira-Pires, R., Ph.D., Centro de Neurociências e Biologia 
Celular, Coimbra, Portugal
SEMINARS
Payne, A., University of Pennsylvania, Merion Station: 
Shared autoantibody VH gene usage in pemphigus 
vulgaris: Implications for disease development.
Rader, C., The Scripps Research Institute-Florida, Jupiter: 
Cancer and approaches to therapeutic antibody development.
Noren, C., New England Biolabs, Beverly, Massachusetts: 
Peptide display libraries.
Siegel, D., University of Pennsylvania Medical Center, 
Philadelphia: Human phage display libraries, cell-surface 
panning, translational medicine applications, and Ilamas. 
Phage display, metastatic cancer, and personalized 
medicine.
Silverman, G.J., New York University Medical Center, 
New York: Human repertoire evolution and microbial 
infl uences.
Wilson, I., Scripps Research Institute, La Jolla, California: 
Broad neutralization of viral pathogens: Implications for 
vaccine design.
Boyd, S., Stanford University, California: B-cell repertoire 
sequencing in human vaccine responses.
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Advanced Sequencing Technologies and Applications
November 11–23
INSTRUCTORS E. Mardis, Washington University School of Medicine, St. Louis, Missouri
 G. Marth, University of Utah School of Medicine, Salt Lake City
 W. McCombie, Cold Spring Harbor Laboratory
 A. Quinlan, University of Virginia, Charlottesville
 M. Schatz, Cold Spring Harbor Laboratory
ASSISTANTS B. Ainscough, Washington University, St. Louis, Missouri
 A. Farrell, University of Utah, Salt Lake City
 T. Garvin, Cold Spring Harbor Laboratory
 M. Griffi th, Washington University School of Medicine, St. Louis, Missouri
 O. Griffi th, Washington University School of Medicine, St. Louis, Missouri
 J. Gurtowski, Cold Spring Harbor Laboratory
 V. Magrini, Washington University School of Medicine, St. Louis, Missouri
 S. McGrath, Washington University School of Medicine, St. Louis, Missouri
 J. Walker, Washington University School of Medicine, St. Louis, Missouri
 A. Ward, University of Utah School of Medicine, Salt Lake City
During the last decade, large-scale DNA sequencing has markedly impacted the practice of mod-
ern biology and is beginning to affect the practice of medicine. With the introduction of several 
advanced sequencing technologies, costs and timelines have been reduced by orders of magnitude, 
enabling investigators to conceptualize and perform sequencing-based projects that heretofore 
were prohibitive. Furthermore, the application of these technologies to answer questions previ-
ously not experimentally approachable is broadening their impact and application.
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This intensive 2-week course explored applications of next-generation sequencing technolo-
gies, with a focus on commercially available methods. Students were instructed in the detailed 
operation of several revolutionary sequencing platforms, including sample preparation procedures, 
general data handling through pipelines, and in-depth data analysis. A diverse range of the types 
of biological questions enabled by next-generation sequencing technologies was explored including 
DNA resequencing of known cancer genes to compare tumor and normal DNA, de novo DNA 
sequencing and assembly of bacterial genomes, RNA sequencing, and others that were tailored to 
the student’s research areas of interest. Guest lecturers highlighted their own applications of these 
revolutionary technologies.
We encouraged applicants from a diversity of scientifi c backgrounds including molecular evo-
lution, development, neuroscience, cancer, plant biology, and microbiology.
This course was supported by the National Human Genome Research Institute and the How-
ard Hughes Medical Institute, with major equipment provided by Illumina and Life Technologies.
PARTICIPANTS
Broner, S., B.Sc., University of Southern Denmark, 
Sonderborg
Contreras, R., Ph.D., University of Michigan, Ann Arbor
Cottrell, C., Ph.D., Washington University School of 
Medicine, St. Louis, Missouri
Fox, P.K., B.A., University of Washington, Seattle
Gibbs, L., B.S., University of North Texas Health Science 
Center, Fort Worth
Hlouskova, P., B.C., Centre European Institute of 
Technology MU, Brno, Czech Republic
Lindblom, K., B.S., Duke University, Durham, North 
Carolina
Lum, C., M.D., University of Hawaii, Honolulu
Ngun, T., Ph.D., University of California, Los Angeles
Oliver, D., B.S., University of South Carolina, Columbia
Przybyl, J., M.Sc., Stanford University, California
Shih, A., Ph.D., Memorial Sloan-Kettering Cancer Center, 
New York
Teich, A., Ph.D., Columbia University, New York
Tnah, L.H., Ph.D., Forest Research Institute Malaysia, 
Selangor, Malaysia
Trimmer, C., Ph.D., Monell Chemical Senses Center, 
Philadelphia, Pennsylvania
Vega Melendez, C., Ph.D., University of North Carolina, 
Greensboro
Waanders, E., Ph.D., Radboud University Medical Center, 
Nijmegen, The Netherlands
Watkins, D., Ph.D., SAHMNRI, Adelaide, Australia
Wray, B., B.S., Field Museum of Natural History, Chicago, 
Illinois
Zolnik, C., M.S., Fordham University, Bronx, New York
SEMINARS
Moore, B., University of Utah, Salt Lake City: VAAST and 
pVAAST algorithms for genetic analysis.
Mardis, E., Washington University School of Medicine, 
St. Louis, Missouri: NGS-based cancer genomics.
Dewar, K., McGill University and Genome QC Innovation 
Centre, Montreal, Canada: Genome assembly of 
PacBio + Illumina data.
Elemento, O., Weill Cornell Medical College, New York: 
Introduction to epigenomics analysis.
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INSTRUCTORS E. Hodges, Cold Spring Harbor Laboratory
 G. Howell, The Jackson Laboratory
 B. King, Mount Desert Island Biological Laboratory
 J. Ward, Middlebury College
LECTURERS A. Gordon, Whitehead Institute for Biomedical Research
 M. Schatz, Cold Spring Harbor Laboratory
 M. Zody, New York Genome Center
The Genome Access Course (TGAC) is an intensive 2-day introduction to bioinformatics that 
was held three times in 2014 and trained more than 110 participants in total. Registration for 
the course is open to all on a fi rst-come, fi rst-served basis subject to basic eligibility requirements. 
The core of TGAC covers the manipulation and analysis of sequence data using publicly available 
tools. The course is broken into modules designed to give a broad overview of a given topic, with 
ample time for hands-on exercises chosen by the instructors. Each module includes three parts: 
(1) a discussion of theory and methods, (2) coverage of software and Web resources, and (3) use 
of selected tools in practice. The modular design allows the instructors to tailor the curriculum 
to the interests of the students. Modules in 2014 included Genome Sequencing and Assembly, 
Gene Prediction, the UCSC Genome Browser, Ensembl, Comparative Genome Analysis, Gene 
Set Enrichment and Pathway Analysis, High-Throughput Sequence Analysis, The Galaxy Project, 
and RNA-Seq Analysis Using R. Students were encouraged to bring questions and data from their 
own research projects to the course, and they were also encouraged to contact instructors with 
additional questions once they returned to their home institutions.
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As in 2013, one of the 2014 TGACs was held in Manhattan at the New York Genome Center 
(NYGC). It marked the second collaborative training project with the NYGC, for which CSHL 
is an institutional founding member. The Manhattan course had a very high enrollment of 42 
students, over half of whom were from local New York institutions. CSHL plans to offer the 
Manhattan course again in August/September 2015 in collaboration with the New York Genome 
Center, and annually thereafter as long as demand for the course continues.
March 31–April 2 (Cold Spring Harbor Laboratory)
Students: 35
PARTICIPANTS
Cloud, V., Stowers Institute for Medical Research
Dus, M., Skirball Institute, New York University School of 
Medicine
Ghazi, I., University of Hyderabad, India
Grobler, Y., New York University School of Medicine
Haines, A., Norfolk State University
Hrncir, T., Institute of Microbiology, Academy of Sciences CR
Huang, L., ISIS Pharmaceuticals
Kelly, T., Massachusetts Institute of Technology
Khamit-Kush, K., Human Genome Sequencing Center Pre-
Graduate Education Training, Baylor College of Medicine
Kim, J., Mayo Clinic College of Medicine
Liang, Y., The Rockefeller University
Liu, P., Booz Allen Hamilton
Lum, C., University of Hawaii, John A. Burns School of 
Medicine
Morris, L., Memorial Sloan-Kettering Cancer Center
Murray, D., Baylor College of Medicine
Okonkwo, L., Winthrop University Hospital
Orshinsky, A., University of Minnesota
Pascuzzi, P., Purdue University
Perron, G., University of Ottawa
Rebecca, V.H., Lee Moffi tt Cancer Center
Renwick, N., The Rockefeller University
Richter, S., University of Toronto
Rupp, L., University of Pennsylvania
Santiago-Vazquez, L., University of Houston, Clear Lake
Sengupta, S., North Shore University Health System
Solano, V., Montclair State University
Spinler, J., Baylor College of Medicine
Yoo, S., STCube Pharmaceuticals Inc.
Yoon, H., Mayo Graduate School
Zhu, Y., North Shore University Health System/University 
of Chicago
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September 2–4 (New York Genome Center)
Students: 42
PARTICIPANTS
Anike, F., North Carolina Agricultural and Technical State 
University
Cañas Villamar, I., Instituto Potosino de Investigacion 
Cientifi ca y Technologica
Dao, F., Memorial Sloan-Kettering Cancer Center
de Planell Saguer, M., Columbia University
Farris, H., The MITRE Corporation
Frank, M., New York Genome Center
Gnatenko, D., State University of New York, Stony Brook
Guerra Amorim, C., Columbia University
Hernandez, E., Memorial Sloan-Kettering Institute
Isikhuemhen, O., North Carolina Agricultural and Technical 
State University
Kaur, P., Georgia State University
Kim, I., Seoul National University
Kim, J., The Rockefeller University
Kolander, T., Newport Laboratories
Kwan, J., University of Illinois, Chicago
Lee, K., Pfi zer
LeFrancois, M., New York University Langone Medical 
Center
Li, Q., Memorial Sloan-Kettering Cancer Center
Liu, Y., Stony Brook University
Mallipattu, S., Stony Brook University
Moore, K., New York University Langone Medical Center
Nerbonne, J., Washington University School of Medicine
Niescierowicz, K., International Institute of Molecular and 
Cell Biology
Orange, D., The Rockefeller University
Peled, M., New York University Medical Center
Rahman, K., New York University School of Medicine
Rinehold, K., New York University Langone Medical 
Center
Rodrigues, A., Federal University of São Paulo
Sabando Eguizabal, A., Stony Brook University
Scott, D., Icahn School of Medicine, Mount Sinai
Siebert, A., University of Rochester
Singh, R., Weill Cornell Graduate School of Medical 
Sciences
Solomon, W., Maimonides Cancer Center
Sovegni,, G., Federal University of São Paulo
Still, D., California State Polytechnic University, Pomona
Taub, D., Southwestern University
Taylor, R., Northwestern University Feinberg School of 
Medicine
VanSolingen, C., New York University Langone Medical 
Center
Varma, H., Columbia University
Vogel, T., Washington University in St. Louis
Yimlamai, D., Boston Children’s Hospital
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November 12–14 (Cold Spring Harbor Laboratory)
Students: 31
PARTICIPANTS
Ang, R., Icahn School of Medicine, Mount Sinai
Barrett, T., New York University School of Medicine
Boland, J., Leidos Biomedical Research, Inc.
Byun, M., Washington University, St Louis
Calvert, M., Temasek Lifesciences Laboratories
Chaudhuri, D., Boston Children’s Hospital
Christensen, C., Dana-Farber Cancer Institute
Cullen, M., Leidos Biomedical Research, Inc.
De Maio, A., Baylor College of Medicine, Neurological 
Research Institute
Deck, K., University of Wisconsin, Madison
Elfekih, S., Commonwealth Scientifi c and Industrial 
Research Organization
Fisher, E., New York University School of Medicine
Gomes, A., Icahn School of Medicine, Mount Sinai
Gonzalez, C., Columbia University
Gorres, K., Yale University
Jeong, Y., University of Illinois at Chicago
Kataoka, A., Grocery Manufacturers Association
Khong, S., Stanford University
Lee, D.W., Yonsei University
Lim, H., Hunter College of the City University of New York
Lipatov, M., Stony Brook University
Liu, J., Sanofi  Pharmaceuticals
Meng, X., Baylor College of Medicine
OHara, J., University of Maryland School of Public Health
Paczkowska, M., Medical University of Bialystok
Picoraro, J., Columbia University Medical Center
Ramkhelawon, B., New York University Langone Medical 
Center
Spatafora, G., Middlebury College
Venkatasubramanian, M., University of Cincinnati
Vieregg, J., University of Chicago
Wiener, B., Newport Laboratories, Inc.
The Laboratory acknowledges the generosity of the following companies that loaned equipment and 
reagents to the various courses:
AB SCIEX LLC
Agilent Technologies Inc.
ALA Scientifi c Instruments
A-Systems
Andor Technology
Applied Precision
Applied Scientifi c 
Instrumentation Inc.
Berthold Technologies USA, 
LLC
BioLegend
Bioline USA
Bio-Rad Laboratories
BioTeck
BioVision
Bitplane
Carl Zeiss Inc.
Charles River Laboratories 
Inc.
Chroma Technology 
Corporation
Clontech
Coherent Laser
ConOptics
Covaris, Inc.
CrystaLaser
Crystalgen Inc.
Dage-MTI
Diagenode
Drummond Scientifi c 
Company
eBioscience
Electron Microscopy 
Science
Eppendorf North America
Fotodyne Inc.
GE Healthcare
Hamamatsu Photonic 
Systems
Hampton Research
Harlan
Harvard Apparatus Inc.
Heka Instruments
Hellma USA Inc.
Illumina Inc.
Integrated DNA 
Technologies
Invitrogen
Kapa Biosystems
Lafayette Instrument
Leica Biosystems Inc.
Leica Microsystems Inc.
Life Technologies
LI-COR
Lonza Pharma-Bioscience 
Solutions
Luigs & Neumann
Mightex
Millipore Corporation
Miltenyi Biotec Inc.
Molecular Devices
Nanodrop Technologies
NanoTemper Technologies
Narishige International 
USA Inc.
Nasco
Neta Scientifi c
New England Biolabs Inc.
Newport Corporation
Nikon Inc.
Nonlinear Dynamics
NSK America Corporation
Olympus America Inc.
Parkell
PerkinElmer Life and 
Analytical Sciences
Photometrics
Pressure Biosciences
Prior Scientifi c
Promega Corporation
Qiagen Inc.
Rapp Optoelectronic 
GmbH
RedShirt Imaging LLC
Roche Applied Science
Roche Nimblegen
Sage Science Inc.
Sakura Finetek USA Inc.
Santa Cruz Biotechnology 
Inc.
Scientifi ca Ltd.
SciGene
Singer Instruments
SONY Biotechnology Inc.
Spectra-Physics Lasers Inc.
Spectral Applied Research
Stemgent
Sutter Instruments
Taconic Farms
Tecan US, Inc.
The Jackson Laboratories
The Mathworks Inc.
Thermo Fisher Scientifi c
Thor Labs
Tokai Hit
Tonbo Biosciences
TotalLab Ltd.
Vector Laboratories Inc.
Warner Instruments
Waters Corporation
World Precision Instruments
Zymo Research Corporation
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INVITED SPEAKERS PROGRAM (“CSHL SEMINAR SERIES”)
Each year, Cold Spring Harbor Laboratory invites speakers from outside the institution to present 
their fi ndings. These weekly seminars keep the CSHL staff current on the latest scientifi c devel-
opments and broaden their perspectives. Graduate students and postdoctoral fellows meet with 
the seminar speakers for lunch immediately after the seminar, providing an opportunity for the 
exchange of ideas in an informal setting.
Speaker Title Host
January
Kenneth Zaret, Penn Institute for 
Regenerative Medicine, University of 
Pennsylvania
Nucleosomes, enhancers, and a basis for mitotic memory. Thomas Gingeras
Stephen Harrison, Harvard Medical School Antibody affi nity maturation: From molecular genealogy 
to molecular structure.
Leemor Joshua-Tor
Richard Tsien, New York University 
Langone Medical Center
Autism: Related genes and signal transduction pathways. Bo Li
February
David Liu, Ph.D., Harvard University Integrating chemistry and evolution to illuminate and 
program biology.
Gholson Lyon
March
Jay Keasling, Ph.D., University of 
California, Berkeley, Lawrence Berkeley 
National Laboratory
Synthetic biology for synthetic chemistry. Ian Peikon
Gregory Petsko, Weill Cornell Medical 
College
How Parkinson’s disease starts and how it might be 
stopped.
Leemor Joshua-Tor
Xiaowei Zhuang, Ph.D., Harvard 
University
Bioimaging at the nanoscale: Single-molecule and 
superresolution fl uorescence microscopy.
Leemor Joshua-Tor
April
Robert Malenka, M.D., Ph.D., Stanford 
University
Neural mechanisms underlying reward and aversion. Pavel Osten
Daniel Haber, M.D., Ph.D., Massachusetts 
General Hospital Cancer Center, 
Harvard Medical School
Molecular characterization of single circulating tumor 
cells.
Raffaella Sordella
October
Michael Bevan, John Innes Centre Understanding and exploiting plant genomes for crop 
improvement.
Richard McCombie
Roberto Malinow, Ph.D., University of 
California, San Diego
Synapses in health and disease. Bo Li
Fang Xu, University of British Columbia Genetic and molecular analysis of resistance protein-
mediated plant immunity.
Dave Jackson
Navdeep Chandel, Northwestern University Mitochondria as signaling organelles. Raffaella Sordella
November
Bart De Strooper, KU Leuven, The 
Netherlands
β and γ secretases: Understanding their biology and how 
this defi nes the therapeutic options in Alzheimer disease.
Linda Van Aelst
Paul Sternberg, California Institute of 
Technology
Molecular circuitry for sleep, sex, and predation. Chris Hammell
Molly Przeworski, Columbia University An evolutionary perspective on human germline mutation. Mickey Atwal
Scott Keeney, Weill Cornell Graduate 
School of Medical Sciences
A dangerous game: Controlling DNA breaks in meiosis. Bruce Stillman
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Speaker Title
January
Stephen Shea Inhibitory circuits for social communication in mice.
Chris Hammell Oscillatory gene expression and cell fate specifi cations.
Gholson Lyon Deep brain stimulation, psychiatric genetics, and iPS cell models of disease.
Chris Vakoc Chromatin regulators as cancer dependencies.
February
Florin Albeanu Feedforward and feedback signals in mammalian olfaction.
Lloyd Trotman What signals the end of signals?
March
Tom Gingeras Conservation and novel functions of noncoding RNAs.
Pavel Osten Mapping behavior and counting cells.
Camila Dos Santos Epigenetic control of normal and malignant mammary gland development.
April
Senthil Muthuswamy Cell polarity and 3D organoids: A trend becomes mainstay in cancer biology.
October
Erkan Karakas (Furukawa Lab) Structural characterization of NMDA receptor ion channels.
Mario Penzo (Li Lab) Neuronal circuits controlling the formation and recollection of fear memories.
Olga Anczukow-Camarda (Krainer Lab) Alternative-splicing misregulation in breast cancer.
November
Cora MacAlister (Lippman Lab) Life at the tip: Protein glycosylation in pollen tubes and protonema.
Keerthi Krishnan (Huang Lab) Elucidating the pathogenesis of Rett syndrome, a neurological disorder.
Wee Siong Goh (Hannon Lab) Just add human: Finding the real function of mouse piRNAs.
December
Bruce Stillman ATP-driven machines control the cell division cycle.
Gayatri Arun (Spector Lab) Probing the therapeutic potential of Malat1 in mammary tumor progression.
IN-HOUSE SEMINAR PROGRAM
Cold Spring Harbor Laboratory’s In-House Seminars were initiated to provide a semiformal avenue 
for communication among the various research groups at the Laboratory. The seminars also af-
ford a necessary opportunity for graduate students and postgraduate staff to develop their skills in 
organizing, presenting, and defending their research.
BANBURY CENTER
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We were relieved after the overwhelming program of 2013 that 2014 was a little less hectic, but we 
were nevertheless still busy dealing with 15 events and 500 participants.
Participants in the meetings were drawn from 37 states, and as usual, four states—California, 
Maryland, Massachusetts, and New York—accounted for 60% of participants. Banbury meet-
ings continue to have strong international participation, with 19% of participants coming from 
21 countries. Thirty-fi ve percent of participants were female, an unusually high percentage. The 
number of female participants has doubled over the years since 1988.
Education
The majority of the Banbury Center program is devoted to meetings dealing with research topics 
in biomedical research—meetings that might be considered as high-level continuing education for 
scientists. But each year, the Center also provides a venue for the education of young scientists who 
are in the early stages of their careers.
One such meeting was the Workshop on Leadership in BioScience, taught by Carl M. Cohen 
(Science Management Associates) and Danielle Kennedy (Worklab Consulting LLC). David 
Stewart was awarded a 4-year grant from American Express to support the program. The course 
is attended primarily by senior postdocs who are going to run their own laboratory and by young 
faculty. They receive training in, for example, the characteristics of a good manager, how to interact 
with people, and how to control the dynamics of meetings.
The Boehringer Ingelheim Fonds holds two retreats each year for its fellows, one in Europe 
and one in the United States. Rather like the Workshop on Leadership in BioScience course, the 
Boehringer fellows receive intense instruction in writing, making presentations, and the skills 
Cocktails on Robertson House patio
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needed to carry out research. The Founda-
tion fi rst came to Banbury in 2005 and in 
alternate years until 2011, and now comes 
annually. 
Finally, there was the NIMH Brain 
Camp. Tom Insel, director of the National 
Institute of Mental Health, has long been 
passionate about the need to base psychiatry 
and the treatment of psychiatric disorders on 
the fi ndings of neuroscience. To that end, 
beginning in 2009, Insel has brought 24 
of his brightest clinical psychiatric fellows 
to Banbury to expose them to the highest-
quality research and to persuade them that 
they should consider research careers. Speakers have included Eric Nestler, Karl Deisseroth, Eric 
Kandel, Steven Paul, and Huda Zoghbi.
Banbury Meetings on Health
A second meeting demonstrating the power of personal experience was Rhabdomyosarcoma: A 
Critical Review of Research and What It Means for Developing Therapies. Rhabdomyosarcoma is the 
most common soft tissue sarcoma of childhood, but despite four decades of advances in therapy, 
the outcome for metastatic or relapsed disease is particularly poor. This meeting, funded by fami-
lies determined that others should not suffer, examined all aspects of rhabdomyosarcoma biology 
with three questions in mind: What are the key areas for future research? What can be done to 
ensure funding for research? How can promising laboratory fi ndings be turned to developing 
drugs for clinical trials?
The meeting with the rather prosaic title Interpreting Personal Genomes: How Are We to Set Ap-
propriate Statistical Standards for Identifying Pathogenic Genetic Variants? dealt with a critical issue 
in personal medicine: How can we determine whether a genetic variant may be responsible for an 
observed disease phenotype? Current tools for identifying variants as potentially disease-causing are 
far from optimal, raising the risk of false clinical diagnoses. Participants in this meeting examined 
current methods and discussed how standards could be set for 
ensuring that appropriate analyses are performed.
Compared with other disorders, research on and care of 
the mentally ill is notoriously underfunded relative to the 
impact the illnesses have on society. Other disorders, such 
as AIDS, have strong advocates, but the stigma associated 
with mental illness seems to inhibit advocacy. Not so for 
Glenn Close, whose sister and nephew are affl icted with 
bipolar disorder. Close’s Bring Change 2 Mind Founda-
tion is dedicated to reducing stigma and has embarked on 
developing a “college toolbox” to eliminate stigma that can 
be implemented in a 4-year university course. This meet-
ing brought together individuals whose knowledge and 
expertise can help plan a pilot project. It was a fascinating 
meeting in which Close played a very active role.
Another meeting dealing with mental health was 
Lewy Body Dementia: Current Status, Future Directions. 
Robertson House
Sammis, Spring 2014
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This is the second most common cause of cognitive impairment after Alzheimer’s disease. 
Although a great deal is known about the molecular processes of Alzheimer’s, much less is 
known about Lewy body dementia (LBD) despite the fact that it makes up 30% of all de-
mentia cases. Participants in the meeting critically reviewed the current state of knowledge 
of the genetics of LBD and the usefulness or otherwise of current clinical, imaging, and bio-
logical markers. There was much discussion of how global research efforts on LBD could be 
delivered in conjunction with the goals of NINDS, NAPA, the G8 Summit Objectives, and 
related initiatives.
Finally, The Genetics of Pain and Pain Inhibition: Where to from Here? considered what is the 
most prevalent human health problem, with a lifetime prevalence of almost one in two. Associa-
tion studies and exome sequencing studies of chronic pain disorders are now being published, and 
rare genetic variants responsible for pain disorders have been identifi ed. Participants reviewed the 
relative merits of the association studies and single-gene approaches for the study of chronic pain, 
along with various current therapies in the fi eld.
Other Notable Meetings
Epigenetic regulation plays a pivotal role in plant development and offers a largely untapped re-
source for crop improvement strategies aimed at enhancing productivity. The Epigenetics and Ag-
riculture meeting focused on epigenetic mechanisms of gene regulation and their roles in heterosis, 
epigenetic programming of plant reproduction, transgenerational inheritance, and adaptation to 
abiotic and biotic stresses. Participants also explored the needs of agricultural biotechnology, and 
how epigenetic research can help efforts to manipulate gene expression in crops toward increasing 
sustainable food and feed production, to meet the needs of a growing population. The meeting 
brought leading researchers in plant epigenetics together with scientists representing agricultural 
biotechnology companies.
One of the more unusual meetings was Interdisciplinary Symposium on Creativity, organized by 
Suzanne Nalbantian, C.W. Post College, Westbury, New York. This was the fourth, and the third 
held at Banbury, in a series of meetings bringing together neuroscientists and scholars from the 
humanities. The neuroscientists described the functioning of the brain in creative acts of scientifi c 
discovery or aesthetic production. The comparatists described instances of creativity in the compo-
sition of major literary works, of musical compositions, or of works of visual art.
Reception at Robertson House Coffee break
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Banbury Center History
As Banbury approaches the 40th anniversary of its founding, we are trying to produce as true a 
record as possible of the activities of the Banbury Center since the fi rst meeting in 1978. The cur-
rent database goes back only to 1987 when I arrived, so we have made a second database covering 
the years 1978–1986 using the information recorded in the annual reports. However, as these 
record only those who gave talks at Banbury and not all attendees, we are going back through the 
fi les using other information such as housing lists. The historical database currently lists 7000 
participants, and the contemporary database lists more than 11,000.
A second project concerns the black-and-white photographs of Banbury meetings taken from 
1978 to 2003 when digital photography began. These images have been inaccessible because they 
exist only as negatives, and there is no catalog of them and no way of knowing whether a particular 
scientist is in an image. Now the negatives have been scanned and entered into a database. The 
diffi cult job remains—to identify every individual in more than 20,000 negatives!
The default position regarding publication of reports of Banbury Center meetings is that we do 
not do so. This is in part so as not to deter people from attending by making submission of a manu-
script a prerequisite for participating in a Banbury meeting; we also want to encourage presentation of 
unpublished material. However, if the participants choose to develop a publication, they are strongly 
encouraged to do so. With the help of Richard Sever, we have created a category called “Banbury 
White Paper” in the CSHL Press’s Perspectives series edited by Richard. Publications in 2014 included:
Erlich Y, et al. 2014. Redefi ning genomic privacy: Trust and empowerment. PLOS Biology 12: 1–5.
Hettmer S, et al. 2014. Rhabdomyosarcoma: Current challenges and their implications for 
developing therapies. Cold Spring Harb Perspect Med 4: a025650.
Lee FS, et al. 2014. Adolescent mental health—Opportunity and obligation: Emerging neuro-
science offers hope for treatments. Science 346: 547–549.
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BANBURY CENTER MEETINGS
Date Title Organizer(s)
February 23–26 Banbury Summit III: Genetics Training in the 
Genomic Era
Bruce Korf, ACMG Work Group
March 28–April 2 Communicating Science Claudia Walther, Sandra Schedler
April 6–9 Connections and Communications in the Brain Bijan Pesaran, Nicolas Brunel
April 16–18 The College Toolbox Project: Eliminating Stigma Bernice Pescosolido
April 21–23 Defeating Ovarian Cancer Ronald Buckanovich, Gordon Mills, 
David Tuveson
May 10–12 NIMH Brain Camp VI Joyce Chung, Thomas Insel
May 13–16 Rhabdomyosarcoma: A Critical Review of Research 
and What It Means for Developing Therapies
Charles Keller, Amy Wagers
June 22–25 The Genetics of Pain and Pain Inhibition: Where to 
from Here?
Jeffrey Mogil, Clifford Woolf
September 3–5 High-Performance Computing in Undergraduate 
Biology Education: Scanning the Landscape
David Micklos, Dan Stanzione
September 7–10 The Immune System and Cancer Glenn Dranoff, Douglas Fearon
September 15–18 Interpreting Personal Genomes: How Are We to Set 
Appropriate Statistical Standards for Identifying 
Pathogenic Genetic Variants?
David Goldstein, Daniel MacArthur
October 21–24 Interdisciplinary Symposium on Creativity Suzanne Nalbantian
October 26–29 ROS in Biology and Cancer Arne Holmgren, Navdeep Chandel, 
Nicholas Tonks, David Tuveson
November 9–12 Epigenetics and Agriculture Brian Hauge, Rob Martienssen
November 16–19 Lewy Body Dementia: Current Status, Future 
Directions
James Galvin, Ian McKeith
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Banbury Summit III: Genetics Training in the Genomic Era
February 23–26
FUNDED BY American College of Medical Genetics
ARRANGED BY B. Korf, University of Alabama, Birmingham and the ACMG Work Group
The fi eld of medical genetics is in a rapid state of fl ux as ge-
nomic approaches revolutionize the diagnosis of both rare 
and common genetic conditions, and insights into pathogen-
esis open possibilities for treatment of an increasing number 
of disorders. These changes not only require new approaches 
to training medical geneticists, but also raise questions about 
the scope of practice of medical geneticists versus other med-
ical specialists, as genomic tests become increasingly avail-
able and accessible. These issues may warrant changes in the 
system of training of medical geneticists. This conference 
brought together major stakeholders in the medical genet-
ics community to review current approaches to training and 
consider development of new approaches.
Introductory Remarks: J.A. Witkowski, Banbury Center, Cold 
Spring Harbor Laboratory
Welcome and Overview: B. Korf, University of Alabama, Birmingham
G. Herman, B. Korf, J. Witkowski
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SESSION 1: Medical Genetics Education and Training
Current Status of Clinical Genetics Training and Board Certifi cation
ABMG M. Blitzer, University of Maryland School of Medicine, Baltimore
ACMG B. Korf, University of Alabama, Birmingham
RRC R. Sutton, Baylor College of Medicine, Houston, Texas
AMGF M. Watson, American College of Medical Genetics, Bethesda, Maryland
APHMG L. Demmer, Carolinas Medical Center, Charlotte, North Carolina
Current Status of Laboratory Genetics Training and Board Certifi cation
ABMG M. Blitzer, University of Maryland School of Medicine, Baltimore
Cytogenetics K. Rao, University of North Carolina, Chapel Hill
  J. Gastier-Foster, Nationwide Children’s Hospital, Columbus, Ohio
Molecular Genetics J. Feldman, Wayne State University School of Medicine, Detroit, Michigan
  J. Gastier-Foster, Nationwide Children’s Hospital, Columbus, Ohio
Biochemical Genetics M. Blitzer, University of Maryland School of Medicine, Baltimore
ACMG M. Watson, American College of Medical Genetics, Bethesda, Maryland
APHMG L. Demmer, Carolinas Medical Center, Charlotte, North Carolina
ASHG C. Morton, Brigham & Women’s Hospital, Boston, Massachusetts
SESSION 2: New Opportunities and Challenges in a Genomics World
Integration of Genetics into Medical Specialties
Moderator: L. Demmer, Carolinas Medical Center, Char-
lotte, North Carolina
Cancer Genetics: W. Chung, Columbia University, New York
Cardiovascular Genetics: A. Roberts, Boston Children’s Hos-
pital, Boston, Massachusetts
Neurogenetics: B. Korf, University of Alabama, Birmingham
Genomics and Genome Sequencing
Introduction: J. Feldman, Wayne State University School of 
Medicine, Detroit, Michigan
Genetic Counseling for Genome Sequencing: Genetic Coun-
selors
 Training Medical Geneticists for Genome Sequencing: R. Sut-
ton, Baylor College of Medicine, Houston, Texas
 J. Hoskovec, A. Matthews, S. Hahn, R. Bennett
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 Should There be a Medical Genomics Training Pathway?: 
J. Feldman, Wayne State University School of Medicine, 
 Detroit, Michigan
Discussion
Training in Therapeutics and Clinical Trials
Moderator: B. Korf, University of Alabama, Birmingham
Introduction: B. Korf, University of Alabama, Birmingham
 Biochemical Genetics: G. Herman, Nationwide Children’s 
Hospital Research Institute, Columbus, Ohio
 Small-Molecule and Other Treatments for Genetic Disorders, 
e.g., Rasopathies: A. Roberts, Boston Children’s Hospital, 
Boston, Massachusetts
Discussion
Future of Laboratory Training
Moderators: J. Gastier-Foster, Nationwide Children’s Hospital, 
Columbus, Ohio, and M. Blitzer, University of Maryland, 
Baltimore
Future of Biochemical Genetics Training: R. Sutton, Baylor 
College of Medicine, Houston, Texas
Training in Laboratory Genomics: K. Rao, University of 
North Carolina, Chapel Hill
Discussion
Review of Meeting Statement
Continued discussion and action items.
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Communicating Science
March 28–April 2
FUNDED BY Boehringer Ingelheim Fonds Foundation for Basic Research in Medicine
ARRANGED BY C. Walther, Boehringer Ingelheim Fonds, Mainz, Germany
 S. Schedler, Boehringer Ingelheim Fonds, Mainz, Germany
The Boehringer Ingelheim Fonds has an international program of support for Ph.D. fellowships, 
and it fi rst brought its fellows to the Banbury Center for their annual North American retreat in 
2005. It has been a great pleasure to have them return, and their 2014 stay at Banbury was the 
seventh occasion that they have been here. At Banbury, the fellows receive intensive instruction in 
matters such as giving presentations and writing papers—topics usually learned by default (and 
often poorly) during graduate research.
Introductory Remarks: J.A. Witkowski, Banbury Center, Cold Spring Harbor Laboratory
Opening Remarks and All About BIF (Part 1): C. Walther, Boehringer Ingelheim Foundation, Mainz, Germany
K. Achenbach, Boehringer Ingelheim Foundation, Mainz, 
Germany: Communication: Why and how?
N. LeBrasseur, DNA Medical Communications, New York: 
Writing techniques and how to structure papers; Writing 
 assignment 1.
B. Tansey, Vanderbilt University, Nashville, Tennessee: Prepar-
ing and delivering a scientifi c talk; Group A: 4-min Power-
point presentations, videotaped with replay and feedback.
N. LeBrasseur, DNA Medical Communications, New York: 
Discussion of writing assignment 1; Writing assignment 2.
B. Tansey, Vanderbilt University, Nashville, Tennessee
Group B: 4-min Powerpoint presentations, videotaped with 
replay and feedback.
Group A: Time for preparing 3-min presentations.
Group B: 4-min presentations, Group A: 3-min preparation.
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Group A: 3-min Powerpoint presentations, videotaped with 
replay and feedback.
Group B: Time for preparing 3-min presentations.
N. LeBrasseur, DNA Medical Communications, New York: 
Return and discussion of writing assignment 2.
B. Tansey, Vanderbilt University, Nashville, Tennessee: Group B: 
3-min PowerPoint presentations, videotaped with replay and 
feedback.
S. Pfeiffer, Lazard Frères & Co. LLC, New York: Career 
talk.
K. Ris-Vicari, Katie Ris-Vicari Graphic Design, Bethpage, 
New York, and M. Hansen, Nature Publishing Group, New 
York: How to design fi gures.
C. Walther, Boehringer Ingelheim Foundation, Mainz, Ger-
many: All about BIF: Part 2 and feedback.
Guided Walking Tour on CSHL Campus
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Connections and Communications in the Brain
April 6–9
FUNDED BY The Swartz Foundation, Setauket, New York
ARRANGED BY B. Pesaran, New York University, New York
 N. Brunel, University of Chicago, Illinois
Over many decades, neuroscience has been deeply infl uenced by evidence that specifi c behavioral 
processes are localized to particular brain regions. Anatomical studies have revealed how the brain 
is organized into different regions. Functional studies have shown how activity in different brain 
regions is specifi c for different behavioral processes. Focal damage to the brain has been shown to 
result in remarkably precise behavioral defi cits. However, it is also clear that brain areas interact 
to guide behavior by communicating with each other, and they do so over neuronal projection 
systems formed by large populations of neurons that are not localized to specifi c brain regions. To 
understand how different areas cooperate to engage in a particular behavior, we must understand 
both the structure of the connectivity between these areas and the rules that govern the communi-
cation between them. The goal of this workshop was to encourage researchers using experimental 
and theoretical approaches to bring new data, tools, concepts, and ideas to bear on understanding 
the mechanisms and functional signifi cance of communication in the brain.
Welcoming Remarks: J.A. Witkowski, Banbury Center, Cold Spring Harbor Laboratory
Introduction: N. Brunel, University of Chicago, Illinois
B. Pesaran, New York University, New York
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SESSION 1
H. Kennedy, INSERM, Bron, France: What inconsistent data 
fail to tell you about cortical networks.
A. Burkhalter, Washington University School of Medicine, St. 
Louis, Missouri: Neuronal network of the mouse visual cortex.
H. Monyer, University of Heidelberg, Germany: GABAergic 
cells in the hippocampal–entorhinal formation and their role 
in spatial coding and memory.
G. Buzsaki, New York University, New York: Communication 
by spikes in the hippocampal–entorhinal system.
SESSION 2
X.-J. Wang, New York University, New York: Building a large-
scale model of the primate cortex: Structure and dynamics.
D. Bassett, University of Pennsylvania, Philadelphia: Probing 
human brain network dynamics during learning.
O. Jensen, Radboud University, Nijmegen, The Netherlands: 
Temporal coding organized by coupled α and γ oscillations 
prioritize visual processing.
S. Bressler, Florida Atlantic University, Boca Raton, Florida: 
Beta synchrony and top-down feedforward processing in visual 
 expectation.
General Discussion
SESSION 3
M. Siegel, University of Tuebingen, Germany: Spectral fi nger-
prints of large-scale neuronal interactions in the human brain.
P. Fries, Ernst Strungmann Institute for Neuroscience, Frank-
furt, Germany: Brain-wide and cell-type-specifi c synchroni-
zation at the service of attention.
J. Maunsell, Harvard University, Boston, Massachusetts: Ce-
rebral cortex as a look-up table.
C. Gray, Montana State University, Bozeman: Distributed 
cortical processing during visual working memory.
SESSION 4
N. Kopell, Boston University, Massachusetts: Cortical 
rhythms facilitate bottom-up and top-down processing.
T. Akam, Centro Champalimaud, Lisboa, Portugal: Neural 
codes supporting oscillatory control of effective connectivity 
among brain regions.
D. Battaglia, Institute for System Neuroscience, Marseille, 
France: Collective dynamics of multiscale circuits shape 
functional interactions.
T. Buschman, Princeton University, New Jersey: Neural dy-
namics of cognitive fl exibility.
S. Fusi, Columbia University, New York: High dimensional 
neural representations in prefrontal cortex.
General Discussion
SESSION 5
B. Pesaran, New York University, New York: A role for coher-
ent neural activity in coordination and decision making.
T. Akam, Centro Champalimaud, Lisboa, Portugal: Neural 
codes supporting oscillatory control of effective connectivity 
among brain regions.
A. Compte, IDIBAPS, Barcelona, Spain: Stimulus fl uctua-
tions and top-down feedback can account for the dynamics 
of choice probability in MT. 
General Discussion
Closing Remarks
A. Burkhalter H. Cohen
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The College Toolbox Project: Eliminating Stigma
April 16–18
FUNDED BY  Bring Change 2 Mind, Indiana University Foundation, The Margaret Clark Morgan Foundation and 
individual participants
ARRANGED BY B. Pescolsolido, Indiana University, Bloomington, Indiana
Since the mid-1990s, there has been a resurgence of research in the 
United States on the stigma attached to mental illness. That research 
has provided clear fi ndings for efforts to reduce prejudice and discrimi-
nation. “Contact”—whether face-to-face or video—has been shown to 
be the most effective means of reducing stigma. Older individuals tend 
to harbor more out-of-date notions, while younger individuals have 
become more open to discussing these issues.
As a result, to eliminate stigma, Bring Change 2 Mind (BC2M) has 
decided to embark on the development of a “college toolbox” that can 
be designed and implemented as a 4-year project that will be piloted at 
Indiana University and disseminated through a national effort.
This meeting brought together individuals whose knowledge and 
expertise can help plan a pilot project. Participants included the best 
minds in research and intervention on stigma, as well as administra-
tors, student groups, and the community. By the end of the meeting, 
it was expected that the group would have developed a clear outline of 
what the next steps should be and a timeline for their implementation.
Welcoming Remarks: J.A. Witkowski, Banbury Center, Cold Spring Harbor Laboratory, B. Pescosolido, Indiana University, 
Bloomington, and G. Close, Bring Change 2 Mind, San Francisco, California
B. Pescosolido
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SESSION 1: BC2M’s Vision
G. Close and P. Harrington, Bring Change 2 Mind, San Fran-
cisco, California: What do we know about mental illness 
and/or stigma among college students?
Group Discussion
C. Boyer, J. Lee, and B. Pescosolido, Indiana University, 
Bloomington
SESSION 2: The Foundations of the College Toolbox Program
B. Pescosolido, Indiana University, and G. Close and P. Har-
rington, Bring Change 2 Mind, San Francisco, California
SESSION 3: Basic Study Goals and Design
J. Martin, Y.Y. Ahn, B. Pescosolido, and E. Wright, Indiana 
University
SESSION 4: What Do We Know About Stigma Interventions?
B. Angell, Rutgers University, New Brunswick, New Jersey
S. Evans-Lacko, University of London, United Kingdom
N. Bonfi ne, Northeast Ohio Medical University, Rootstown, 
Ohio
H. Heimer, Schizophrenia Research Forum, Providence, 
Rhode Island
J. Macphee, The Jed Foundation, New York
R. Kellar, The Margaret Clark Morgan Foundation, Hudson, 
Ohio
S. Barnett, Indiana University, Bloomington
Group Discussion
SESSION 5: By Students, For Students
L. Fasone, M. Oppenheim, R. Green, R. Martinez, and A. 
Parrill, Indiana University, Bloomington
Group Discussion
SESSION 6: Next Steps, Action Steps
B. Pescosolido, Indiana University, Bloomington, Indiana: 
 Developing partnerships, getting permissions, setting pro-
gram rollout.
R. Green, H. Heimer, G. Close, R. Martinez, Y.Y. Ahn
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Defeating Ovarian Cancer
April 21–23
FUNDED BY Jonathan Gray; Cold Spring Harbor Laboratory Offi ce of Development
ARRANGED BY R. Buckanovich, University of Michigan, Ann Arbor
 G. Mills, MD Anderson Cancer Center, University of Texas, Houston
 D. Tuveson, Cold Spring Harbor Laboratory
This was the fi rst Cold Spring Harbor Laboratory meeting 
on ovarian cancer. The organizers thought that the time 
was right for a critical review of current research that could 
illuminate new avenues for basic and translational research. 
Among the topics discussed were the molecular pathology 
of human ovarian cancer, models of ovarian cancer, and 
the best current and investigational approaches to patient 
management: cytotoxic, targeted, epigenetic, immunologi-
cal, metabolic, and stem-cell-directed therapies.
Welcoming Remarks: J.A. Witkowski, Banbury Center, Cold 
Spring Harbor Laboratory
Introduction: D. Tuveson, Cold Spring Harbor Laboratory
R. Buckanovich, J. Carstens
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SESSION 1: Models: Cell Lines PDXs and Gemms
D. Dinulescu, Brigham and Women’s Hospital, Boston, Mas-
sachusetts: Can animal models of disease improve early de-
tection of tumors and precursor lesions?
T. Ince, University of Miami Miller School of Medicine, Flor-
ida: Novel ovarian cell culture systems.
K. Cho, University of Michigan Medical School, Ann Arbor: 
Mouse models in the context of the dualistic pathway of 
ovarian cancer pathogenesis.
SESSION 2: TME
P. Sabbatini, Memorial Sloan-Kettering Cancer Center, New 
York: Tumor vaccines in ovarian cancer.
J. Wolchok, Memorial Sloan-Kettering Cancer Center, New 
York: Immune modulators for cancer therapy: Assessing an-
tagonists and agonists.
SESSION 3: Traditional and Targeted Therapy for Ovarian 
Cancer
S. Domchek, Abramson Cancer Center, Philadelphia, Penn-
sylvania: Germline genetics and implications for ovarian 
cancer therapeutics.
U. Matulonis, Dana-Farber Cancer Institute, Boston, Mas-
sachusetts: Combinations of biologic agents + PARP inhibi-
tors and immunotherapy approaches to ovarian cancer.
D. Bowtell, Peter MacCallum Cancer Centre, East Mel-
bourne, Australia: Primary and acquired resistance in high-
grade serous cancer.
SESSION 4: Genetics/Epigenetics
D. Huntsman, BC Cancer Agency Research Centre, Vancou-
ver, British Columbia: Endometriosis-associated ovarian 
cancers.
D. Levine, Memorial Sloan-Kettering Cancer Center, New 
York: Clinically relevant genomic signatures and pathways.
J. Brenton, Li Ka Shing Centre, Cambridge, United Kingdom: 
Monitoring disease response and genomic change with cir-
culating tumor DNA.
D. Solit, Memorial Sloan-Kettering Cancer Center, New York: 
Insights from the study of extraordinary responders.
SESSION 5: CSC/Heterogeneity
S. Shah, University of British Columbia, Vancouver, Canada: 
Phylogenetic portraits of high-grade serous ovarian can-
cers.
B. Neel, Princess Margaret Research/University Health Net-
work, Toronto, Canada: Patient-derived xenografts for eval-
uating ovarian cancer drug response and tumor initiating 
cells.
R. Buckanovich, University of Michigan, Ann Arbor: An 
ovarian cancer stem-like cell hierarchy and why it matters.
SESSION 6: Circulating Tumor Cells
D. Tuveson, Cold Spring Harbor Laboratory: Discussion on 
advances.
General Discussion
D. Bowtell, C. Bales S. Shah, J. Watson
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NIMH Brain Camp VI
May 10–12
FUNDED BY National Institute of Mental Health, National Institutes of Health
ARRANGED BY J. Chung, National Institute of Mental Health, NIH, Bethesda, Maryland
 T. Insel, National Institute of Mental Health, NIH, Bethesda, Maryland
 
Cold Spring Harbor Laboratory is renowned worldwide for its education programs, from high 
school level to the highest professional levels. One of the Banbury Center’s contributions is to host 
the NIMH-sponsored “Brain Camp.” The goal of the Brain Camp is to identify areas of neurosci-
ence that are of interest and relevance to psychiatrists and to communicate these to a small group 
of outstanding psychiatry residents and research fellows. Some of the most distinguished and 
thoughtful neuroscientists in the country have come to the meetings as guest speakers. The goal of 
the series of meetings is to develop a neuroscience curriculum that can eventually be shared with 
psychiatry training programs around the country.
Introductions and Opening Session
T. Insel, National Institute of Mental Health, NIH, Bethesda, 
Maryland: Psychiatry 2024.
S. Paul, Weill Cornell Medical College, New York, New York: 
Alzheimer’s disease: A prototype for drug discovery and di-
agnostics in neuropsychiatry.
SESSION 1: New Diagnostics/New Therapeutics
M. State, University of California, San Francisco: From genes 
to therapeutics in neurodevelopmental disorders.
S. Vinogradov, University of California, San Francisco: Neu-
roscience-informed cognitive training for impaired neural 
systems in schizophrenia.
SESSION 2: New Diagnostics/New Therapeutics
C. Tamminga, Southwestern Medical Center, Dallas, Texas: 
From biomarkers to biotypes in psychosis.
S. Lisanby, Duke University School of Medicine, Durham, 
North Carolina: Device-based neuromodulation: From en-
gineering bench to bedside.
Roundtable Discussion with All Participants
SESSION 3: New Diagnostics/New Therapeutics
E. Leibenluft, National Institute of Mental Health, Bethesda, 
Maryland: From DSM Bipolar disorder to RDoC irritabil-
ity: A nosologic journey.
B. Teachman, University of Virginia, Charlottesville, Virginia: 
Regaining Control: Interventions for automatic and strategic 
cognitive biases in adult anxiety.
D. Pine, National Institute of Mental Health, Bethesda, 
 Maryland: RDoC and mechanism-based therapeutics: Atten-
tion bias modifi cation in pediatric anxiety.
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Rhabdomyosarcoma: A Critical Review of Research 
and What It Means for Developing Therapies
May 13–16
FUNDED BY Friends of the TJ Foundation, Inc., The Michelle Paternoster Foundation for Sarcoma Research
ARRANGED BY C. Keller, Oregon Health & Science University, Portland
 A. Wagers, Harvard Medical School, Boston, Massachusetts
Rhabdomyosarcoma is the most common soft tissue sarcoma 
of childhood, but despite four decades of advances in chemo-
therapy, radiation, and surgery, the outcome for metastatic or 
relapsed disease is particularly poor. Why is this? What are 
the biological characteristics of these recurring tumors? Can 
these characteristics be exploited for new therapies? This was 
an auspicious time to ask these questions. Recent changes 
to the NCI Cancer Therapy Evaluation Program and the 
Children’s Oncology Clinical Trial process, in conjunction 
with FDA incentives, are facilitating the movement of basic 
science discoveries from bench to clinical trial. The meeting 
provided an opportunity for researchers to present data, to 
review critically the state of the fi eld, to highlight areas for 
future research, and to establish new collaborations.
Welcome and Background: B. Stillman, Cold Spring Harbor Laboratory
Introduction: C. Keller, Oregon Health & Science University, Portland
 A. Wagers, Harvard University, Boston, Massachusetts
C. Keller, A. Billin
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SESSION 1
Chairperson: A. Wagers, Harvard University, Boston, Mas-
sachusetts
L. Wexler, Memorial Sloan-Kettering Cancer Center, New York: 
Sleeping Beauty, The Sequel: The search for Prince Charming.
L. Helman, National Cancer Institute, Bethesda, Maryland: 
Development of novel combination targeted therapies for 
rhabdomyosarcoma.
J. Khan, National Cancer Institute, Bethesda, Maryland: The 
application of Omics to identify novel targets and treatments 
for rhabdomyosarcoma.
P. Houghton, Nationwide Children’s Research Institute, 
 Columbus, Ohio: Exploiting the IGF-mTOR pathway for 
treatment of rhabdomyosarcoma.
C. Keller, Oregon Health & Science University, Portland: 
Three novel target-therapy pairs for potential clinical trials 
within 18 months.
SESSION 2
Chairperson: P. Houghton, Nationwide Children’s Research 
Institute, Columbus, Ohio
T.A. Partridge, Children’s National Medical Center, Wash-
ington DC: A model of reversible context-dependent rhab-
domyosarcoma in the dystrophic mouse.
B. Schaefer, University Children’s Hospital, Zurich, Switzer-
land: Cancer stem cells in RMS: Fact or fi ction?
J. Shipley, Institute of Cancer Research, Sutton, United King-
dom: Histone methylation status and differentiation therapy.
D. Cornelison, University of Missouri, Columbia: Compara-
tive medicine-Eph/eprin expression profi les in RMS samples 
from canine and human patients.
General Discussion
SESSION 3
Chairperson: D. Langenau, Massachusetts General Hospital, 
Charlestown
A. Wagers, Harvard University, Boston, Massachusetts: A 
transplant-based model for rhabdomyosarcoma in mice.
F. Barr, National Cancer Institute, Bethesda, Maryland: 
The molecular correlates of fusion status in rhabdomyo-
sarcoma.
D.C. Guttridge, Ohio State University, Columbus: Regula-
tion and function of NF-kB in rhabdomyosarcoma.
C.M. Linardic, Duke University, Durham, North Carolina: 
Hippo pathway signaling in ARMS.
General Discussion
SESSION 4
Chairperson: L. Helman, National Cancer Institute, Bethes-
da, Maryland
R. Pal, Texas Tech University, Lubbock: Predictive modeling 
of drug sensitivity.
S. Hettmer, Charite-Universitaets-Medizin Berlin, Berlin, 
Germany: Asparagine homeostasis and its contributions to 
rhabdomyosarcoma growth.
G. Pavlath, Emory University, Atlanta, Georgia: Nuclear 
transport receptors and myogenesis.
R. Rota, Ospedale Pediatrico Bambino Gesu, Rome, Italy: 
 Potential cross-talk involving Notch and epigenetic path-
ways in rhabdomyosarcoma.
A.R. Ehrlich, Focus on Rhabdo, Plainsboro, New Jersey: An 
ad hoc framework for community: Scientifi c collaboration 
for rhabdomyosarcoma survivability.
General Discussion
R. Rota P. Houghton, J. Shipley
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SESSION 5
Chairperson: B. Schaefer, University Children’s Hospital, 
Zurich, Switzerland
D. Langenau, Massachusetts General Hospital, Charlestown: 
Self-renewal mechanisms in embryonal rhabdomyosarcoma.
A. Hayes-Jordan, MD Anderson Cancer Center, Houston, 
Texas: The potential role of TOX-4 in rhabdomyosarcoma: 
Implications for metastatic disease.
Z. Li, Genomics Institute of Novartis Research Foundation, 
San Diego, California: Study and screen rhabdomyosarcoma 
in NIBR.
Discussion: Charting Future Research
• What have we learned at this meeting?
• What are the key areas for research that will advance our 
understanding of rhabdomyosarcoma?
• What can be done to ensure funding for research?
• How can we fund the development of promising laboratory 
fi ndings into drugs for clinical trials?
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The Genetics of Pain and Pain Inhibition: Where to from Here?
June 22–25
FUNDED BY The Mayday Fund
ARRANGED BY J. Mogil, McGill University, Montreal, Quebec, Canada
 C. Woolf, Harvard University, Boston, Massachusetts
Chronic pain is the most prevalent human health problem, with a lifetime prevalence of almost 
one in two. It is now 10 years since the fi rst human genetic association studies of pain began 
appearing in the literature; association studies and exome sequencing studies of chronic pain 
disorders are also now being published. At the same time, progress has been made in identifying 
rare genetic variants responsible for monogenic pain disorders, both loss-of-function congenital 
insensitivity to pain and gain-of-function (e.g., erythromelalgia).
The time was right for a meeting to address the relative merits of the association studies and 
single-gene approaches for the study of chronic pain, along with various current practices in the 
fi eld. Some of the questions that may be considered are the following: Will pain researchers ever 
be able to amass cohort sizes appropriate for replicable genome-wide association studies? What is 
the optimal way to phenotype patients and controls in pain genetics studies? Are genetic studies 
in model organisms broadly translatable to human clinical pain?
This discussion meeting reviewed the fi ndings and promise of human genetic studies of pain, 
with the primary aim to compare the usefulness of rare versus common variant approaches in 
this fi eld.
Welcoming Remarks: J.A. Witkowski, Banbury Center, Cold Spring Harbor Laboratory
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SESSION 1: Introductory Session
C. Woolf, Boston Children’s Hospital, Boston, Massachusetts: 
Why pain genes?
J. Mogil, McGill University, Montreal, Canada: History of 
pain genetics.
SESSION 2: Lessons from Other Fields
T. Grosser, University of Pennsylvania, Philadelphia: Pharma-
cogenetics.
A. Bowcock, National Heart & Lung Institute, London, United 
Kingdom: Molecular genetics of infl ammatory diseases.
General Discussion
SESSION 3: Single-Gene Pain Trait
G. Woods, Cambridge Institute for Medical Research, United 
Kingdom: SCN9A loss of function.
S. Waxman, Yale University, New Haven, Connecticut: 
SCN9A gain of function.
M. Ferrari, Leiden University, The Netherlands: FHM genes.
I. Belfer, University of Pittsburgh, Pennsylvania: COMT: A 
complex story.
General Discussion
SESSION 4: Complex Pain Genetics Session
L. Diatchenko, McGill University, Montreal, Canada: Com-
plex pain genetics: Progress so far.
M. Ferrari C. Spellman, P. Thye, C. Stebbins
I. Belfer, L. Diatchenko, A. Apkarian
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W. Maixner, University of North Carolina, Chapel Hill: 
 OPPERA update.
V. Anttila, Harvard University, Boston, Massachusetts: Mi-
graine GWAS.
SESSION 5: Translational Pain Genetics Session
A. van den Maagdenberg, Leiden University Medical Centre, 
The Netherlands: Transgenic mouse models of single-gene 
disorders: Migraine as the example.
G. Peltz, Stanford University, California: Haplotype mapping 
in mice.
M. Costigan, Harvard University, Boston, Massachusetts: Ex-
pression profi ling and target validation.
G. Neely, Garvin Institute of Medical Research, Sydney, Aus-
tralia: Pain genetics in nonmammalian organisms.
SESSION 6: Phenotyping
C. Nielsen, Norwegian Institute of Public Health, Oslo, Nor-
way: What can/should be measured in large cohorts?
V. Apkarian, Northwestern University, Chicago, Illinois: 
Brain imaging and genetic studies.
SESSION 7: Breakout Groups: What Is the Best Way Forward?
Four breakout groups 1.5 hours. Group people and give each 
a mandate?
SESSION 8: New Approaches
D. Bennett, University of Oxford, United Kingdom: Applying 
RNA-Seq to both animal and human pain models.
R. Ratan, Burke Medical Research Institute, White Plains, 
New York: Epigenetics.
Report Back to Other Groups
Group Review, Conclusion, and Summary
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High-Performance Computing in Undergraduate Biology Education: 
Scanning the Landscape
September 3–5
FUNDED BY Alfred P. Sloan Foundation and the National Science Foundation
ARRANGED BY D. Micklos, DNA Learning Center, Cold Spring Harbor Laboratory
 D. Stanzione, University of Texas, Austin
“Big data” are rapidly becoming the currency of modern biology, including 
data from DNA/RNA sequencing, ecology and range mapping, remote sens-
ing, automated phenotyping, visualization, and modeling. The generation and 
subsequent analysis of these data via high-performance computing (HPC) have 
traditionally been confi ned to research institutions. However, many underuti-
lized data sets are now freely available to anyone with an Internet connection, 
and the technology for generating local data sets is coming within reach of 
faculty and students in primarily undergraduate institutions (PUIs).
 Generating and analyzing large data sets hold the promise of bringing un-
dergraduate students up-to-the-minute with biological research and of learning 
fi rsthand the modern synthesis of biochemistry and bioinformatics. Big data 
analysis can potentially support course-based research, which scales authentic 
student research to reach into introductory biology courses. Large data analy-
sis also provides opportunities for distributed projects in which many students 
look at different aspects of the same problem. The time is right to discuss IF and 
HOW access to HPC resources can be extended to undergraduate institutions. D. Micklos
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 The meeting format alternated between “perspective briefi ngs” that presented the current state 
of knowledge, with free discussions that focused on the practicalities of extending HPC to under-
graduate education. The meeting drew together 30 leaders and stakeholders from undergraduate 
biology education, HPC, and funding agencies to set a course for the future.
Welcoming Remarks: J.A. Witkowski, Banbury Center, Cold Spring Harbor Laboratory
Introduction:
D. Micklos, DNA Learning Center, Cold Spring Harbor Laboratory: Making HPC egalitarian.
T. Woodin, National Science Foundation, Arlington, Virginia: Vision and change.
SESSION 1: The Biological Landscape
M. Schatz, Cold Spring Harbor Laboratory: Genome struc-
ture and function.
B. Heidorn, University of Arizona, Tucson: Small data sets 
and biodiversity informatics.
T. Brettin, Argonne National Laboratory, Lemont, Illinois: 
Genomics and systems analysis.
J. Watkins, University of Arizona, Tucson: Statistical model-
ing of biological phenomena.
M. Cabrera, University of Puerto Rico, Mayaquez: Mathemat-
ical modeling and optimization in biology.
SESSION 2: The HPC Landscape
D. Stanzione, Texas Advanced Computing Center, Austin: 
HPC, XSEDE, and lessons from iPlant.
P. Blood, Pittsburgh Supercomputing Center, Pennsylvania: 
Engaging genomics researchers, developers, and gateways 
through XSEDE.
B. Rekepalli, Oak Ridge National Laboratory, Knoxville, Ten-
nessee: Small cluster applications in science gateways.
S. Gordon, Ohio Supercomputer Center, Columbus: XSEDED 
education program.
K. Gaither, Texas Advanced Computing Center, Austin: Visu-
alization and girls in STEM.
SESSION 3: The Undergraduate Research/Education Land-
scape
J. Jungck, University of Delaware, Newark: BioQUEST cur-
riculum consortium and HPC.
S. Donovan, University of Pittsburgh, Pennsylvania: QUBES: 
Supporting quantitative thinking across the biology cur-
riculum.
C. Ghiban, M. Khalfan, and J. Williams, Cold Spring Harbor 
Laboratory; U. Hilgert, University of Arizona, Tucson: A 
GUI for biological HPC.
J. Brusslan, California State University, Long Beach; B. Buck-
ner, Truman State University, Kirksville, Missouri; S. Lewis, 
Prairie View A&M University, Texas; J. Seto, New York City 
College of Technology, Brooklyn, New York: iPlant tools in 
course-based research.
L. Fletcher, Austin Community College, Texas: Workforce 
development in biotechnology.
V. Byrd and L. Tanner, Clemson University, South Carolina: 
Broadening participation in next-generation computing.
B. Panoff, Shodor Education Foundation, Durham, North 
Carolina: Supporting computational thinking.
B. Barnett, National Center for Genome Analysis Support, 
Bloomington, Indiana: Support for genome analysis.
H. Neeman, Oklahoma University, Norman: HPC in plain 
english, starting from scratch.
SESSION 4: The Funding Landscape
Recommendations, Funding Priorities, Collaborations, and 
Distributed Projects
J. Williams
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G. Dranoff, A. Korman
The Immune System and Cancer
September 7–10
FUNDED BY Oliver Grace Cancer Fund
ARRANGED BY G. Dranoff, Dana-Farber Cancer Institute, Boston, Massachusetts
 D. Fearon, Cold Spring Harbor Laboratory
The recent reports that immunotherapy may induce du-
rable responses in some cancer patients prompted the or-
ganization of a meeting to discuss multiple aspects of the 
biology of the interaction between the immune system 
and cancer. The topics that were discussed included im-
aging the tumor microenvironment, monitoring tumor 
immune reactions, current immunological therapies in 
human cancer, and newer approaches to immune inter-
ventions.
Welcoming Remarks: J.A. Witkowski, Banbury Center, Cold Spring 
Harbor Laboratory
Introduction: G. Dranoff, Dana-Farber Cancer Institute, Boston, Massachusetts
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SESSION 1
Chairperson: S. Topalian, Johns Hopkins University, Balti-
more, Maryland
A. Korman, Bristol-Myers Squibb, Redwood City, California; 
Antitumor activity of immunomodulatory antibodies.
S. Topalian, Johns Hopkins University, Baltimore, Maryland: 
PD-1 pathway blockade in cancer therapy.
T. Mempel, Harvard Medical School, Boston, Massachusetts: 
Local regulation of the T-cell response in the tumor micro-
environment.
S. Riddell, Fred Hutchinson Cancer Research Center, Seattle, 
Washington: Adoptive cellular therapy.
General Discussion
SESSION 2
Chairperson: D. Felsher, Stanford University School of Medi-
cine, California
D. Bar-Sagi, New York University School of Medicine, New 
York: Mapping the immune landscape during early pancre-
atic neoplasia.
S. Leach, Memorial Sloan-Kettering Cancer Center, New 
York: IL-17, gut microbiome, and pancreatic cancer.
E. Sahai, Cancer Research UK, London, United Kingdom: 
Imaging the tumor microenvironment and localized re-
sponses to therapy.
D. Felsher, Stanford University School of Medicine, Califor-
nia: MYC inactivation elicits an innate and adaptive im-
mune response.
B. Van den Eynde, Ludwig Institute for Cancer Research, Brus-
sels, Belgium: Tumor-induced apoptosis of tumor- specifi c 
T lymphocytes in an autochthonous melanoma model.
General Discussion
SESSION 3
Chairperson: R. Schreiber, Washington University School of 
Medicine, St. Louis, Missouri
R. Schreiber, Washington University School of Medicine, St. 
Louis, Missouri: The importance of tumor-specifi c mutant 
antigens in endogenous and therapeutically induced im-
mune responses to cancer.
M. Krummel, University of California, San Francisco: The dy-
namics of tumor surveillance at primary and metastatic sites.
D. Irvine, Koch Institute for Integrative Cancer, Cambridge, 
Massachusetts: Engineering cancer vaccine potency through 
lymph node targeting.
G. Dranoff, Dana-Farber Cancer Institute, Boston, Massa-
chusetts: Engineering improved cancer vaccines.
G. Nolan, Stanford University School of Medicine, California: 
Single-cell proteomics and genomics at high scale.
General Discussion
SESSION 4
Chairperson: E. Vivier, Centre d’Immunologie de Marseille-
Luminy, Marseille, France
E. Vivier, Centre d’Immunologie de Marseille-Luminy, Mar-
seille, France: Natural killer cells: Development, regulation, 
and treatment.
L. Lanier, University of California, San Francisco: Immune 
evasion mediated by tumor-derived lactate dehydrogenase 
induction of NKG2D ligands on myeloid cells in can-
cer patients.
K. Wucherpfenning, Dana-Farber Cancer Institute, Boston, 
Massachusetts: Isolation of antibodies from patients respond-
ing to cancer immunotherapy.
D. Bar-Sagi G. Trinchieri, E. Vivier
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A. Rudensky, Memorial Sloan-Kettering Cancer Center, New 
York: Regulatory T cells in cancer.
A. Prevost-Blondel, Cochin Institute, INSERM, Paris, France: 
Immunoregulatory properties of NOS2: Impact on gd T cells 
and PMN-MDSC.
General Discussion
SESSION 5
Chairperson: G. Trinchieri, National Cancer Institute, Fred-
erick, Maryland
G. Trinchieri, National Cancer Institute, Frederick, Mary-
land: Microbiota and cancer therapy.
M. Egeblad, Cold Spring Harbor Laboratory: Cancer cells 
 hijack neutrophils’ pathogen eradicating function to pro-
mote metastasis.
D. Fearon, Cold Spring Harbor Laboratory: T-cell exclusion: 
A dominant means for tumoral immune suppression.
Wrap-Up Discussion
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Interpreting Personal Genomes: How Are We to Set Appropriate 
Statistical Standards for Identifying Pathogenic Genetic Variants?
September 15–18
FUNDED BY Cold Spring Harbor Laboratory Corporate Sponsor Program
ARRANGED BY D. Goldstein, Center for Human Genome Variation, Duke University, Durham, North Carolina
 D. MacArthur, Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston
Genome-scale sequencing—both exome and whole-genome 
sequencing—are already being used in the clinical setting 
for both molecular diagnosis and gene discovery in severe 
disease patients. Current sequencing methods produce vast 
amounts of data that must be sifted for variants, but appro-
priate standards are still lacking for the robust identifi cation 
of pathogenic variants and for assessing the evidence for new 
disease-linked genes. There is increasing concern that this 
lack of standards may lead to a proliferation of false positive 
claims, contaminating the literature and mutation databases 
and infl uencing clinical decisions.
 The meeting had two aims. First, the participants reviewed 
the different approaches taken to assess potential for pathoge-
nicity, including statistical and population genetic evidence, 
functional evaluation, and assessment of clinical “similarity” among patients with similar presentations.
 Second, the meeting reviewed how to ensure that the highest standards are maintained both in 
the published literature and in any evaluations that infl uence clinical decision making. Although 
D. Goldstein, D. Valle
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many elements of what was covered have been addressed in other settings, a Banbury meeting 
affords a unique environment to review the central questions in detail. Moreover, the meeting 
ensured that the full range of relevant expertise was represented.
Introduction: J.A. Witkowski, Banbury Center, Cold Spring Harbor Laboratory
SESSION 1
Chairperson: R. Myers, HudsonAlpha Institute for Biotech-
nology, Huntsville, Alabama
Topic 1: Interpreting Patient Genomes: Real World Experi-
ences
A. Beaudet, Baylor College of Medicine, Houston, Texas: 
Challenges in clinical implementation.
M. Bamshad, University of Washington, Seattle: Mendelian 
Disease Center.
D. Valle, The Johns Hopkins School of Medicine, Baltimore, 
Maryland: Mendelian Disease Center 2.
W. Chung, Columbia University, New York: Lessons learned 
from clinical implementation of exome sequencing.
General Discussion
Topic 2: Framing the Discussion
T. Manolio, National Human Genome Research Institute, 
Rockville, Maryland: NHGRI programs relevant to variant 
interpretation.
H. Rehm, Brigham and Women’s Hospital, Cambridge, Mas-
sachusetts: The new ACMG guidelines for interpreting se-
quence variants: Where are we today and what’s next?
D. MacArthur, Massachusetts General Hospital, Boston: Les-
sons from previous efforts.
General Discussion
SESSION 2
Chairperson: J. Hirschhorn, Boston Children’s Hospital, 
Massachusetts
Topic 3: Evaluating Evidence for Variant Pathogenicity De-
termination
D. Conrad, Washington University School of Medicine, St. 
Louis, Missouri: Statistical approaches for the n = 1 problem.
S. Petrovski, Duke University, Durham, North Carolina: Bio-
informatic approaches for prioritizing variants.
D. MacArthur, Massachusetts General Hospital, Boston: Re-
sources for assessing variant frequency and likely pathogenicity.
A. Allen, Duke University, Durham, North Carolina: Statisti-
cal approaches for identifying statistical anomalies in patient 
genomes.
K. Samocha, Massachusetts General Hospital, Boston: Assess-
ing de novo mutations and gene constraint.
General Discussion
Topic 4: What Is the Best Model for Sharing Genomic and 
Phenotypic Data?
R. Sever, Cold Spring Harbor Laboratory: Molecular case 
studies journal.
SESSION 3
Chairperson: H. Rehm, Brigham and Women’s Hospital, 
Cambridge, Massachusetts
Topic 5: Evaluating Evidence for Implicating Genes in Disease
M. Daly, Massachusetts General Hospital, Boston: Classes of 
evidence for implicating new genes in human disease.
J.-L. Casanova, The Rockefeller University, New York: The 
value of single families in identifying new disease genes.
Topic 6: Computational Tools
G. Cooper, HudsonAlpha Institute for Biotechnology, Hunts-
ville, Alabama: Overview of bioinformatics tools for variant 
classifi cation.
C. Bustamante, Stanford School of Medicine, California: 
Machine-learning algorithms and other high-throughput 
approaches to variant assessment.
Topic 7: Use of Phenotype to Inform Pathogenicity
D. Adams, National Human Genome Research Institute, 
Bethesda, Maryland: Using deep phenotyping to inform 
DNA-sequence-variant classifi cation: Practical challenges.
L. Biesecker, National Human Genome Research Institute, 
Rockville, Maryland: POST-HOC phenotyping and patho-
genicity.
General Discussion
SESSION 4
Chairperson: D. MacArthur, Massachusetts General Hospi-
tal, Boston
Topic 8: Functional Assessment of Genetic Variation
L. Pennacchio, Lawrence Berkeley National Laboratory, 
Berkeley, California: Beyond exomes: Noncoding in vivo 
function and human disease.
R. Xavier, Broad Institute, Boston, Massachusetts: Genes to 
biology.
Topic 9: Systems to Support Variant and Case Data Aggregation
H. Rehm, Brigham and Women’s Hospital, Cambridge, Mas-
sachusetts: Advances in variant databases.
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M. Brudno, University of Toronto, Ontario, Canada: Pheno-
typing tools and the matchmaker exchange project.
Topic 10: Approaches to Support Variant and Gene Curation
M. Lebo, Brigham and Woman’s Hospital, Cambridge, Mas-
sachusetts: Clinical approaches to variant interpretation.
C. Cassa, Brigham and Women’s Hospital, Boston, Massachu-
setts: Literature mining.
B. Funke, Massachusetts General Hospital, Cambridge: Clini-
cal approaches to gene evidence evaluation.
General Discussion
SESSION 5
Chairperson: L. Biesecker, National Human Genome Re-
search Institute, Bethesda, Maryland
Topic 11: Striking the Right Balance in Interpreting Personal 
Genomes
E. Worthey, Medical College of Wisconsin, Wauwatosa: A 
review of our 2014 lessons learned and the challenges and 
opportunities for 2015.
D. Goldstein, Duke University, Durham, North Carolina: 
Lessons from 150 diagnostic exomes.
Topic 12: The Way Forward: Discussion and Summary
Discussion Leaders:
D. Goldstein, Duke University, Durham, North Carolina
H. Rehm, Brigham and Women’s Hospital, Cambridge, Mas-
sachusetts
D. MacArthur, Massachusetts General Hospital, Boston
H. Rehm A. Allen
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Interdisciplinary Symposium on Creativity
October 21–24
FUNDED BY The Daniel & Joanna S. Rose Foundation; Mr. & Mrs. Howard Phipps
ARRANGED BY S. Nalbantian, Long Island University, Brookville, New York
This conference brought together a small group of com-
paratist scholars from the humanities with neuroscien-
tists for an interdisciplinary investigation of creativity. 
The neuroscientists described the functioning of the 
brain in creative acts of scientifi c discovery or aesthetic 
production. The comparatists described instances of 
creativity that they analyze in the composition of major 
literary works, of musical compositions, or of works of 
visual art.
The conference covered such topics as mechanisms of 
creativity: How creativity is linked to brain structure and 
function; MRI tracking creativity in the brain; Inputs of 
specifi c brain regions; Components of creativity—memory, 
emotion, decision making, and intelligence; Pathology and 
creativity; Creativity and its reception: Empathy with reader, viewer, collaborator.
Introduction: J.A. Witkowski, Banbury Center, Cold Spring Harbor Laboratory
S. Nalbantian
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SESSION I: Mechanisms of Creativity in the Brain
S. Nalbantian, Long Island University, Brookville, New York: 
Introduction to the symposium.
J.-P. Changeux, Kavli Brain-Mind Institute, La Jolla, Califor-
nia: Creativity in art: A neuronal hypothesis.
R. Stickgold, Harvard Medical School, Boston, Massachu-
setts: The roles of REM sleep, dreaming, and quiet wake in 
the creative process.
R. Jung, University of New Mexico, Albuquerque: Interacting 
networks of creative cognition: Perspectives from structural 
neuroimaging.
SESSION II: Components of Creativity in the Arts
S. Nalbantian, Long Island University, Brookville, New York: 
Creativity in modernist literary writers: Acts of mental trans-
formation.
E. Fiorentini, Humboldt University, Berlin, Germany: The 
mind’s eye?: Questions about imaging and creativity.
M. Hussey, Pace University, New York: Signifi cant form and the 
“aesthetic emotion”: Clive Bell, Roger Fry, and Virginia Woolf.
J. Wirtz, Hunter College, New York: Interdisciplinary conver-
gence on writerly invention.
SESSION III: Outlier Cases for Studying Creativity: From 
Pathology to Genius
P. Matthews, Imperial College, London, United Kingdom: In-
sights into creativity from diseases of the brain.
S. Henke, University of Louisville, Kentucky: Posttraumatic 
fi ction: Twentieth-century pathological writers and their 
creativity.
N. Andreasen, University of Iowa, Iowa City: The creative 
brain: The neuroscience of genius.
SESSION IV: Moments of Creativity; Methodologies for the 
Study of Creativity
M. Beeman, Northwestern University, Evanston, Illinois: Eu-
reka: The “aha” moments in the creative process.
Discussion by Participants of Useful Methodologies for 
Studying Creativity
Creativity in Music, Film, and Neuroscience
Talks by B. Adolphe and A. Gambis, introduced by S. Nalban-
tian, Grace Auditorium
SESSION V: Creativity: Its Reception, Its Reduction
P. Schneck, University of Osnabruck, Germany: Henry James 
and the creative process: Demons, nuggets, and the stewpot 
of the imagination.
D. Wehrs, Auburn University, Alabama: Literary innovation 
and re-imagining memory: Chivalric romance, renaissance 
genre, and plasticity.
J. Bickle, Mississippi State University, Starkville: Are creative 
humans poor recallers? A functional hypothesis suggested by 
ruthlessly reductive molecular neuroscience.
Concluding Round Table Discussion of All Participants
Includes discussion of plans for a volume on creativity to be 
edited by S. Nalbantian and P. Matthews.
E. Fiorentini D. Wehrs J. Bickle
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ROS in Biology and Cancer
October 26–29
FUNDED BY Oliver Grace Cancer Research Fund
ARRANGED BY A. Holmgren, Karolinska Institute, Stockholm, Sweden
 N. Chandel, Northwestern University, Chicago, Illinois
 N. Tonks, Cold Spring Harbor Laboratory
 D. Tuveson, Cold Spring Harbor Laboratory
This meeting delved more deeply into the biology of reactive oxygen species (ROS) to explore its 
role in cancer genesis and relevance for therapeutics than did the 2013 Banbury meeting. In addi-
tion to ROS’s ability to stimulate cancer initiation, it is now apparent that the cellular anti-oxidant 
machinery has important roles in protecting cancer cells from oxidative damage. Furthermore, 
the anti-oxidant machinery can be up-regulated in response to oncogenes and may confer drug 
resistance and “stemness.” Such observations suggest that redox modulation may offer a novel ap-
proach for selective targeting of cancer cells. Participants explored the chemical, biochemical, and 
genetic facets of ROS biology in relation to cancer, with the goal of determining whether ROS 
can be manipulated in vivo to alter cancer pathogenesis and the response of cancer cells to therapy.
Welcoming Remarks: J.A. Witkowski, Banbury Center, Cold Spring Harbor Laboratory
Introduction: D. Tuveson, Cold Spring Harbor Laboratory
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WHAT ARE ROS AND WHERE IS THE ROS COMING FROM?
SESSION 1: Redox Biology
M. Ristow, Swiss Federal Institute of Technology, Zurich, 
Switzerland: Mitohormesis: How mitochondrial ROS pro-
duction promotes metabolic health and life span.
M. Haigis, Harvard Medical School, Boston, Massachusetts; 
Posttranslational control of mitochondria.
G. Shadel, Yale University School of Medicine, New Haven, 
Connecticut: Novel roles for mitochondrial ROS in signaling 
and disease pathology and potential roles for mitochondria 
in activating the immune system in the context of cancer.
SESSION 2: ROS Biology and Chemistry
C. Winterbourn, University of Otago, Christchurch, New 
Zealand: Identifying cellular targets for reactive oxidants 
and the infl uence of peroxiredoxins.
Y. Janssen-Heininger, University of Vermont, Burlington: 
Targeting S-glutathionylation chemistry in lung cancer.
T. Miller, IC MedTech Corporation, El Cajon, California: Can 
targeted ROS = affordable new anti-neoplastics?
CAN TARGETED ROS MODULATION = AFFORDABLE NEW ANTINEOPLASTICS?
SESSION 3: ROS Pathways and Redox
M. Murphy, MRC Mitochondrial Biology Unit, Cambridge, 
United Kingdom: Complex I as a source of superoxide dur-
ing ischaemia-reperfusion injury.
H. McNeil, Lunenfeld-Tanenbaum Research Institute, Mount 
Sinai Hospital, Toronto, Ontario, Canada: Fat cadherins 
regulation of mitochondrial function.
P. Puigserver, Dana-Farber Cancer Institute, Boston, Massa-
chusetts: The PGC1 pathway programs mitochondrial and 
ROS detoxifi cation in tumor cells.
SESSION 4: ROS Methods and Therapeutic Development
T. Dick, German Cancer Research Center, Heidelberg, Ger-
many: Mechanisms of regulatory protein thiol oxidation.
E. White, The Cancer Institute of New Jersey, New Bruns-
wick: Role of mitochondria quality control in cancer.
General Discussion
Moderator: M. Espey, National Cancer Institute, NIH, 
Rockville, Maryland
WHAT IS ROS DOING?
SESSION 5: Exogenous and Endogenous Anti-Oxidants and 
Cancer
A. Holmgren, Karolinska Institute, Stockholm, Sweden: 
Thioredoxin and peroxiredoxin in ROS signaling.
C. Neumann, University of Pittsburgh Cancer Institute, 
Pennsylvania: Prdx1.
N. Chandel, Northwestern University, Chicago, Illinois: Tar-
geting redox for cancer therapy.
SESSION 6: NRF2 and ROS Regulation
D. Tuveson, Cold Spring Harbor Laboratory: Nrf2 in pancre-
atic cancer.
E. Schmidt, Montana State University, Bozeman: Functional 
antagonism of Nrf2 activity by the disulfi de reductase sys-
tems.
D. Zhang, University of Arizona, Tucson: Nrf2 regulation and 
its dual role in cancer.
SESSION 7: ROS Signaling
D. Pappin, Cold Spring Harbor Laboratory: A double-labeling 
approach for quantitative cysteine proteomics.
P. Schumacker, Northwestern University, Chicago, Illinois: 
Mitochondrial ROS in cancer: Initiators, facilitators, or in-
nocent bystanders?
T. Dick, C. Neumann
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SESSION 8: ROS Sensors
N. Hay, University of Illinois, Chicago: Selective targeting of 
cancer cells with ROS inducers: The Achilles’ heel of Akt.
A. Kimmelman, Dana-Farber Cancer Institute, Boston, Mas-
sachusetts: Redox balance in pancreatic cancer.
General Discussion
Moderators: D, Tuveson, Cold Spring Harbor Laboratory; 
N. Chandel, Northwestern University, Chicago, Illinois; 
A. Holmgren, Karolinska Institute, Stockholm, Sweden.
SESSION 9: ROS and Therapies I
J. Doroshow, National Cancer Institute, Bethesda, Maryland: 
NADPH oxidases and cancer.
P. Huang, MD Anderson Cancer Center, Houston, Texas: 
ROS in cancer therapeutics.
M. Bergo, University of Gothenburg, Sweden: Antioxidants 
and lung cancer progression.
SESSION 10: ROS and Therapies II
L. Trotman, Cold Spring Harbor Laboratory: Redox therapy 
in prostate cancer.
B. Stockwell, Columbia University, New York: Metabolic con-
trol of lipid peroxidation and cell death.
Discussion
Moderator: S. Biller, Agios Pharmaceuticals, Cambridge, 
Massachusetts
Final Meeting Summary
N. Chandel, Northwestern University, Chicago, Illinois
A. Holmgren, Karolinska Institute, Stockholm, Sweden
D. Tuveson, Cold Spring Harbor Laboratory
C. Winterbourn H. McNeil, M. Murphy T. Miller
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Epigenetics and Agriculture
November 9–12
FUNDED BY Cold Spring Harbor Laboratory Corporate Sponsor Program
ARRANGED BY B. Hauge, Monsanto Company, Chesterfi eld, Missouri
 R. Martienssen, Cold Spring Harbor Laboratory
Epigenetic regulation has a pivotal role in plant development, the response to the signals from 
the environment, and natural variation of gene expression. Epigenetics therefore offers a largely 
untapped resource for crop improvement strategies aimed at enhancing productivity through the 
selection of favorable epialleles, plant adaptation to abiotic and biotic stresses, and strategies for 
durable effi cacious expression of transgenes. The goal of this meeting was to explore these op-
portunities by bringing together leading researchers in the plant epigenetics fi eld with scientists 
representing agricultural biotechnology companies.
The meeting focused on epigenetic mechanisms of gene regulation and their roles in heterosis, 
epigenetic programming of plant reproduction, transgenerational inheritance, and adaptation to 
abiotic and biotic stresses.
Participants also explored the needs of agricultural biotechnology, and how epigenetic research 
can help efforts to manipulate gene expression in crops toward enhancing sustainable food and 
feed production, to meet the needs of a growing population.
Welcoming Remarks: J.A. Witkowski, Banbury Center, Cold Spring Harbor Laboratory
Introduction: V. Shukla, The Bill & Melinda Gates Foundation, Seattle, Washington
From Insight to Impact: How Do We Translate Epigenetics Research into Developing World Agriculture?
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SESSION 1: Epialleles: Utility and Transgenerational Inheri-
tance
Chairperson: R. Martienssen, Cold Spring Harbor Laboratory
D. Weigel, Max-Planck Institute for Developmental Biology, 
Tubingen, Germany: Computational methods for detection 
of DNA methylation differences and their application to the 
study of natural and spontaneous variation.
V. Colot, Institut de Biologie de l’Ecole Normale Superieure, 
Paris, France: Stability and potential of transgenerational 
epigenetics in plant breeding.
S. Jacobsen, University of California, Los Angeles: Epigenetic 
mechanisms in Arabidopsis.
E. Richards, Boyce Thomas Institute, Ithaca, New York: 3D 
epigenetics and stress responses.
R. Schmitz, University of Georgia, Athens: Exploring genome-
wide patterns of DNA methylation throughout the plant 
kingdom.
J. Hollick, Ohio State University, Columbus: Paramutation in 
Zea mays.
SESSION 2: Heterosis, Polyploidy, and Chromosome Dosage
Chairperson: D. Jackson, Cold Spring Harbor Laboratory
E. Dennis, CSIRO Plant Industry, Canberra, Australia: Het-
erosis and the role of epigenetics.
D. Baulcombe, University of Cambridge, United Kingdom: 
Paramutation in hybrid tomato.
Z. Lippman, Cold Spring Harbor Laboratory: Optimization 
of crop productivity using induced mutations in the fl origen 
fl owering pathway.
J. Chen, University of Texas, Austin: Maternal small RNAs 
and seed development.
N. Springer, University of Minnesota, St. Paul: Variation for 
DNA methylation patterns in maize populations.
C. Pikaard, Indiana University, Bloomington: Epigenetic in-
heritance and RNA silencing.
SESSION 3: GxE Epigenetic Contribution to Stress Adap-
tation
Chairperson: D. Ware, Cold Spring Harbor Laboratory
J. Paszkowski, University of Cambridge, United Kingdom: 
Genetic determinants of epiallelic switches.
J. Gutierrez-Marcos, University of Warwick, Coventry, Unit-
ed Kingdom: Myths and facts about transgenerational epi-
genetic inheritance in plants.
U. Grossniklaus, University of Zurich, Switzerland: Selection 
of epigenetic variation in Arabidopsis.
O. Mittelsten Scheid, Gregor Mendel Institute, Vienna, Aus-
tria: Epigenetics and genetics: A complex relationship.
J.-K. Zhu, Purdue University, West Lafayette, Indiana: Epi-
genetic antisilencing mechanisms in plants.
General Discussion
SESSION 4: Gametogenesis, Apomixis, and Imprinting
Chairperson: P. Schnable, Iowa State University, Ames 
R. Martienssen, Cold Spring Harbor Laboratory: Genome re-
programming and epigenetic inheritance.
M. Gehring, Whitehead Institute for Biomedical Research, 
Cambridge, Massachusetts: Epigenetics and seed development.
D. Grimanelli, Institut Recherche pour le Developpement, 
Montpellier, France: Epigenome dynamics and reproductive 
development.
F. Berger, Gregor Mendel Institute of Molecular Plant Biology, 
Vienna, Austria: Higher-order chromatin structure and its 
impact on genome activities in plants.
General Discussion
V. Colot, D. Weigel E. Dennis
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SESSION 5: Agricultural Applications and Translational 
Epigenetics
Chairperson: T. Osborn, Monsanto, Chesterfi eld, Missouri
F. Van Ex, Bayer CropScience, Zwijnaarde, Belgium: Explor-
ing the epigenetic potential of crops.
S. Mackenzie, University of Nebraska, Lincoln: Heritable epi-
genomic reprogramming in crop species by plastid perturbation.
P. Schnable, Iowa State University, Ames: How well does 
DNA variation predict phenotypes in maize? Can we im-
prove these predictions?
J. Reinders, DuPont Experimental Station, Johnston, Iowa: 
Assessing the impact of epigenetic variation on phenotypic 
variation in maize.
Conclusion and Future Work
S. Mackenzie E. Richards, D. Baulcomb
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Lewy Body Dementia: Current Status, Future Directions
November 16–19
FUNDED BY The Dana Foundation; Prothena Biosciences, Inc.; Sandy and Nelson DeMille
ARRANGED BY J. Galvin, New York University, New York
 I. McKeith, Newcastle University, Newcastle upon Tyne, United Kingdom
Lewy body dementia (LBD) is the second most common cause of cognitive impairment after 
Alzheimer’s disease (AD), affecting more than 1.3 million Americans and perhaps over 4 million 
people worldwide. However, much less is known about LBD despite the fact that the prevalence 
rate of LBD approaches 5% in the elderly population and makes up 30% of all dementia cases.
We are only just beginning to understand the genetics of LBD. A family history of dementia 
may be more common in LBD compared with healthy older adults, suggesting some form of in-
heritance pattern. Mutations in at least four genes are now associated with LBD—α-synuclein, 
β-synuclein, glucocerebrosidase, and new candidate loci linked to chromosome 2. There is in-
creasing evidence that although MRI may have a limited role in discriminating LBD from AD, 
nuclear imaging studies using novel markers with single photon emission computerized tomogra-
phy (SPECT) and positron emission tomography (PET) scans may be able to improve diagnoses 
and be used as outcomes for clinical trials.
Participants in the meeting critically reviewed the current state of knowledge of the genetics of 
LBD and the usefulness or otherwise of current clinical, imaging, and biological markers. There 
was much discussion of how global research efforts on LBD could be delivered in conjunction 
with the goals of NINDS, NAPA, the G8 Summit Objectives, and related initiatives.
Welcoming Remarks: J.A. Witkowski, Banbury Center, Cold Spring Harbor Laboratory
Introductions and Work Plan:
I. McKeith, Newcastle University, Newcastle upon Tyne, United Kingdom
J. Galvin, New York University, New York
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SESSION 1
Chairperson: J. Leverenz, Cleveland Center for Brain Health, 
Ohio
A. Singleton, National Institute on Aging, Bethesda, Mary-
land: DLB genetics: Progress and priorities.
J. Bras, University College London, United Kingdom: Genetic 
risk for DLB: A genome-wide assessment of genetic variabil-
ity in DLB.
J. Leverenz, Cleveland Center for Brain Health, Ohio: Genet-
ics of cognition in the Lewy body disorders.
SESSION 2
Chairperson: D. Dickson, Mayo Clinic, Jacksonville, Florida
D. Dickson, Mayo Clinic, Jacksonville, Florida: Neuropatholo-
gy of diffuse Lewy body disease: Familial and sporadic forms.
G. Halliday, University of New South Wales and Neurosci-
ence Research, Australia: The dynamics of Lewy body for-
mation in Lewy body diseases.
SESSION 3
Chairperson: O. El-Agnaf, HBK University, Doha, United 
Arab Emirates
P. Brundin, Van Andel Institute, Grand Rapids, Michigan: 
What is the possible role of cell-to-cell transfer of α-synuclein 
in the pathogenesis of Lewy body dementia?
J. Duda, Philadelphia VA Medical Center, Pennsylvania: Ol-
factory dysfunction in sporadic and genetic forms of Lewy 
body disorders.
O. El-Agnaf, HBK University, Doha, United Arab Emirates: 
Detection of α-synuclein pathogenic conformations as a 
strategy for biomarker development for Lewy body diseases.
General Discussion: Genetics and Pathology
SESSION 4: Coordination of DLB Research Initiatives to 
Include NAPA/ADRD, ADC-DLB Module, JPND, G8, and 
Others
Chairpersons: T. Montine, University of Washington, Seattle, 
and D. Aarsland, Karolinska Institute, Huddinge, Sweden
SESSION 5
Chairperson: J. O’Brien, University of Cambridge, United 
Kingdom
D. Arsland, Karolinska Institute, Huddinge, Sweden: Progno-
sis of DLB and the potential of predictive biomarkers in DLB.
J.-P. Taylor, Institute of Neuroscience, Newcastle, United King-
dom: Neurophysiological biomarkers in Lewy body dementia.
J. O’Brien, University of Cambridge, United Kindgom: Neu-
roimaging biomarkers for Lewy body dementia.
E. Masliah, University of California, La Jolla: Novel therapeu-
tics for Lewy body disease in transgenic models: Bridging 
the gap.
General Discussion
SESSION 6
Chairperson: D. Weintraub, University of Pennsylvania, 
Philadelphia
A. Muhs, AC Immune SA, Lausanne, Switzerland: Identifi ca-
tion of small-molecule inhibitors of α-synuclein aggregate 
toxicity.
R. Mills, ACADIA Pharmaceuticals, Inc. San Diego, Califor-
nia: Novel antipsychotics in Lewy body disease.
E. Mori, Tohoku University, Sendai, Japan: Cholinesterase 
 inhibitors in Lewy body dementia.
D. Weintraub, University of Pennsylvania, Philadelphia: De-
sign and conduct of clinical trials in Lewy body dementia.
Discussion: Management Strategies for LBD
J. O’Brien, University of Cambridge, United Kingdom
J.-P. Taylor, Institute of Neuroscience, United Kingdom
SESSION 7
Chairperson: J. Galvin, New York University, New York
B. Boeve, Mayo Clinic, Rochester, Minnesota: REM sleep be-
havior disorder as an early manifestation of evolving demen-
tia with Lewy bodies.
E. Mori
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J. Galvin, New York University, New York: Improving the de-
tection and diagnosis of LBD in the offi ce setting.
I. McKeith, Newcastle University, Newcastle upon Tyne, 
United Kingdom: Prodromal DLB: Diagnosing, managing, 
and trialling it.
A. Taylor, Lewy Body Dementia Association, Inc., Lilburn, 
Georgia: The role of the nonprofi t in LBD education and 
research.
SESSION 8
Chairperson: B. Boeve, Mayo Clinic, Rochester, Minnesota
Proposal for DLB 6 Consortium Meeting
B. Boeve, D. Dickson, J. Leverenz, and I. McKeith
Wrap-Up Discussion
J. O’Brien E. Masliah, O. El-Agnaf
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Lauren Correri Elna Carrasco Amanda McBrien Cornel Ghiban
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 Melissa Lee Xiaoqun Catherine Zhang
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 Kathleen McAuley
A fall meeting of computer scientists and undergraduate biology educators at CSHL’s Banbury 
 Center came to a surprising conclusion: There is plenty of compute time available on high- 
performance computers for undergraduate research projects, but most teaching faculty do not know 
how to access or use it. Representatives of the National Science Foundation’s (NSF) supercomputer 
system, XSEDE (Extreme Science and Engineering Discovery Environment), along with two major 
cyberinfrastructure projects—NSF’s iPlant Collaborative and the Department of Energy’s Knowl-
edgeBase (KBase)—agreed that they would make increased efforts to reach faculty at primarily 
undergraduate institutions.
High-performance computing (HPC) generally refers to supercomputers composed of hun-
dreds of thousands of individual processors (identical to a high-end desktop processor) linked in 
a parallel system that optimizes communication speed between the individual processors. HPC 
involves splitting a job into tasks that are performed by different processors (parallelization) and 
also assigns repeated, or looped, tasks (vectorization). Extremely intensive calculations may engage 
a large proportion of the available processors; however, smaller jobs are assigned to one or a few 
nodes, or clusters, of processors. Thus, HPC begins with clusters of parallel processors—often 
including some “cloud” services—that can perform in minutes or hours complex calculations that 
would take a desktop computer days or weeks to fi nish, if at all.
Biology is awash with data from genome sequencing. The cost of DNA sequencing—and, 
by extension, of producing a sequenced genome—has decreased 10,000-fold since 2007. Beijing 
Genomics Institute, a genome sequencing “factory” in Shenzhen and Hong Kong, China, can 
sequence several hundred eukaryotic genomes per day, including a human genome for as little 
as $3000. Mike Schatz, a genome informaticist at CSHL, said that within a decade, the “data 
tsunami” of DNA sequences will grow to an exabyte (1 billion gigabytes) annually—equivalent 
to the information carried by 200 million DVDs. Indeed, 95% of graduate students, postdoctoral 
fellows, and research faculty we have surveyed at workshops and professional meetings say that 
they are currently analyzing large data sets or expect to in the near future.
At least DNA data makes use of a standard fi le format, called FastQ. Unfortunately, there are 
few standards for many other types of biological data—from phenotyping, fi eld studies, remote 
sensing, range mapping, modeling, and visualization. According to Bryan Heidorn of the Univer-
sity of Arizona, 80% of biological data is being created by smaller projects—without computational 
infrastructure, data standards, or data federation. These data are often “trapped” in lab notebooks 
or in Word, Excel, or PDF fi les that cannot readily be accessed. For these reasons, only about 8% 
of nongenomic ecological data is shared. This creates a massive amount of biological “dark data.” 
Like the dark matter of the universe, “we know it is there or used to be there, but we can’t see it.”
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Unlike the physical sciences, which have a long tradition of large-scale, computationally inten-
sive projects, biology has only recently entered the HPC world. Henry Neeman of the University 
of Oklahoma said, “The undergraduate biology education community is in the same position 
today as the physical science education community was some years ago—aware of the value and 
potential of HPC, but still fi guring out what resources and capabilities are available, and how to 
use them.”
Neeman explained that there are “owners and orphans” in the HPC world. The “owners” 
are high-level research programs with annual allocations of hundreds of millions of core hours. 
Owner jobs, which may command thousands of compute nodes at once, get priority scheduling. 
The “orphans” are small-scale users who use nodes that are not scheduled by owners. Orphans can 
access XSEDE through a gateway—such as Galaxy, a popular bioinformatics web-based graphical 
interface, or iPlant—or can formally request an education allocation. A “start-up” education al-
location of 150,000 core hours is enough to process at least 200 RNA sequence (RNA-Seq) experi-
ments capable of yielding publishable results. So, although HPC resources are oversubscribed by 
owners, there is ample orphan bandwidth for undergraduate biology faculty. However, biological 
projects only account for 10% of educational allocations on XSEDE.
Amid calls to make undergraduate biology education more engaging, data sets from genomics, 
phenomics, range mapping, modeling, and visualization can provide authentic research oppor-
tunities for large numbers of undergraduate courses. Although the nation’s supercomputers have 
enough capacity to support a major expansion in undergraduate biology research, faculty need to 
be made aware of computational resources and trained to use them to analyze big data.
Answering the Call for RNA Sequence Analysis
RNA-Seq analysis is viewed as an “entry level” analysis of a whole eukaryotic genome, providing 
a snapshot of genes expressed by an organism that can be used to annotate new genes and gene 
variants or to document differential gene expression. Tools for RNA-Seq analysis are the most 
frequently requested genome applications at the iPlant Collaborative and Galaxy. The biochemical 
expertise for extracting RNA needed for RNA-Seq analysis is available at virtually any under-
graduate institution and sequencing costs under $3000.
Mike Schatz speaks with the RNA-Seq Working Group.
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The computational challenge of analyzing 
even a modest RNA-Seq experiment, how-
ever, is daunting. The simplest RNA-Seq ex-
periment—two experimental conditions and 
biological replicates—generates 30–50 million 
sequence “reads,” each of 75–150 nucleotides. 
Aligning these reads to a sequenced genome, 
assembling the reads into gene models, and cal-
culating differences in gene expression would 
take 27 days for a laptop computer with a single 
processor. Thus, we have made a major commit-
ment to develop a simple way for biology fac-
ulty and students to access the HPC resources 
to analyze RNA-Seq data sets.
As part of the iPlant Collaborative, a 10-year 
NSF project to develop computer infrastruc-
ture to support biological research, the DNALC developed DNA Subway with several “lines” to 
simplify the analysis of genes and genomes. In 2014, we completed the Green Line of our DNA 
Subway as an educational workfl ow for RNA-Seq analysis that taps into the XSEDE national 
high-performance computing infrastructure. Based on the popular Tuxedo Protocol, the Green 
Line stages faculty and student jobs on the Stampede supercomputer at the Texas Advanced Com-
puting Center, where an average RNA-Seq experiment takes about 40 hours on 16 processors 
(cores), or 640 core hours. This represents 0.015% of available computational power on this su-
percomputer!
This iPlant infrastructure coordinates with our $537,000 NSF grant, “Infrastructure and 
Training to Bring NGS Analysis into Undergraduate Education,” under which we are helping un-
dergraduate faculty to develop novel RNA-Seq data sets for use in course-based and independent 
student research. In June 2014, faculty members from predominantly undergraduate teaching in-
stitutions (PUI) in 10 states convened at CSHL for a Working Group Retreat. With support from 
Illumina and sequencing services performed by the CSHL Genome Center, faculty obtained 50 
RNA-Seq transcriptomes covering ~4.2 billion paired-end DNA sequencing reads. Projects were 
diverse, included eight different species, and examined gene expression changes in (1) Apis mel-
lifera fl ight muscle during life-stage transitions; (2) leaf development and senescence in Arabidopsis 
thaliana; (3) retina development in Gallus gallus; (4) caprine testes during juvenile development 
to puberty; (5) maize in response to cold stress; (6) retinas of mice with retinitis pigmentosa; (7) 
differentiation of rat neural precursors during maternal immune activation; (8) seed abscission 
in Sorghum bicolor; (9) fl oral infl orescence genes in banana/plantains; and (10) Brassica rapa gib-
berellic acid (gad) mutants upon gibberellic acid exposure. The beta version of the Green Line was 
rigorously tested during the retreat; 837 jobs were submitted to TACC, consuming 695 hours’ 
total CPU time.
Also during the Retreat, Working Group members planned classroom implementation and 
contributed content to a new website, RNA-Seq for the Next Generation (www.rnaseqforthenext 
generation.org), which was launched in December. The site already features a Profi le section, 
where each Working Group member has a dedicated page that includes a video introduction 
and abstract, experimental details and data access information, and course descriptions and 
resources. The RNA-Seq data and profi le page content can serve as a foundation and refer-
ence for other undergraduate faculty as they incorporate RNA-Seq analysis into their teaching. 
Post-retreat, we have conducted monthly videoconferences (utilizing Adobe Connect meeting 
rooms) to update Working Group faculty on data analysis progress and changes to the website 
and to share evolving instructional strategies. A multifaceted evaluation program will assess 
Eric Antoniou gives a tour of the CSHL Genome Center to RNA-Seq faculty.
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effects on student learning, interests, and attitudes across different classroom and student re-
search settings. By year’s end, Working Group members had already used their RNA-Seq data 
sets with more than 1000 students in a variety of classes—including introductory biology, 
anatomy and physiology, genetics, cell and molecular biology, genomics, agricultural breeding, 
and independent research.
iPlant Collaborative
The iPlant Collaborative cyberinfrastructure includes high-performance computing, data stor-
age, software, and human resources. iPlant’s mission is to empower researchers and educators 
to use cyberinfrastructure to solve grand challenges in biology—large questions that integrate 
large-scale data from genomes, phenotypes, and environments to predict how organisms and 
ecosystems function. iPlant’s second 5-year plan was ratifi ed by the National Science Board 
in fall 2014, bringing total funding to $100 million. As lead for the Education, Outreach, 
and Training (EOT) component, the DNALC is involved with a number of activities that are 
transitioning iPlant from infrastructure development to widespread use and sustainability into 
the future.
In addition to the release of the Green Line for RNA-Seq analysis, we continued to improve 
the usefulness of DNA Subway. Blue Line, used primarily for DNA barcoding, received an up-
graded alignment viewer that shows the quality scores of polymorphisms, and phylogenetic tree 
building was improved with an easy toggle to designate outgroups. We made signifi cant progress 
in integrating WebApollo, a faster and easier-to-use version of the Apollo gene annotation tools. 
There were 20,832 site users and 3782 new registrations in 2014, a 37% and 44% increase, 
respectively. This increase in traffi c gave us a grand total of 28,934 projects for 2014, a 58% 
increase over 2013!
We continued to deliver two-day training workshops at sites nationwide, reaching 124 re-
searchers at fi ve Tools & Services workshops and 60 faculty at three Genomics in Education 
workshops. One-hour monthly “Get Started with iPlant” webinars reached 168 attendees, and 
Livestream feeds from in-person workshops reached an additional 96 participants. Realizing 
that we can only reach a fraction of iPlant’s 20,000 registered users with in-person training, we 
initiated a train-the-trainers program to extend our reach. Working with 29 faculty at work-
shops at the University of California, Davis, and the U.S. Department of Agriculture’s Big Data 
Initiative, we devised a model curriculum that will be expanded in 2015. Our goal will be to 
develop networks of “iPlant Helpers” that can act as local campus “experts” to help others get 
started with iPlant.
The EOT team presented papers and posters to a number of different audiences. DNA 
Subway: Making Genome Analysis Egalitarian, presented at XSEDE14, showcased the Green 
Line’s use of the Stampede supercomputer—currently the world’s seventh most powerful 
computer. Cyberinfrastructure for Life Sciences: iAnimal Resource for Genomics and Other Data 
Driven Biology and DNA Subway: An Educational Bioinformatics Platform for Gene and Ge-
nome Analysis were presented at the World Congress of Genetics Applied to Livestock Produc-
tion. Participation in the European Conference on Computational Biology and organization 
of CSHL meetings on Biological Data Science and High-Performance Computing in Under-
graduate Education (described earlier) advanced the DNALC’s leadership in link biology and 
computation.
We also developed online materials for asynchronous learning. The new Online Learning Cen-
ter (www.iplantcollaborative.org/learning-center) features more than 50 tutorials and 100 You-
Tube videos. These help users get started with applications and analysis tools available in the 
iPlant Discovery Environment and iPlant cloud computing service, Atmosphere. The new iPlant 
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Academy is a place for biology faculty to exchange lesson plans, present case studies of how they 
use iPlant tools in their teaching, and showcase student projects.
Evaluation continues to guide and inform EOT efforts and document our success in reach-
ing our intermediate audience of biological researchers who do not have specialized expertise 
in computation. Our preworkshop surveys in 2014 indicated that 49% of attendees classify 
themselves at the beginner’s level of bioinformatics skills, whereas surveys across a wide variety 
of meetings and conferences now indicate a whopping 95% of researchers currently work with 
or anticipate working with large data sets involving genome sequencing and RNA-Seq. This 
great interest in analysis of these specialized data sets underscores the need for increased access 
to training and help.
New Developments around t he World
Following 3 years of collaboration, in May, we established Beijing 166 High School as a licensed 
DNA Learning Center. The project is funded by the Dongcheng School District, which serves 
100,000 students in the ancient core of Beijing, adjacent to the Forbidden City and Tiananmen 
Beijing Dave teaching. Dave Micklos leads students in a PCR lab.
Beijing Peking Man. Catherine Zhang leads Beijing 
students on a trip to see the Peking Man site.
Beijing 166 High School course graduation.
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Square. The licensing agreement is part of Principal Wang Lei’s master plan in strengthening the 
leadership of Beijing 166 as the city’s only designated high school of biology.
Under the contract, we increased the number of summer training weeks from three to 10—
and added student and teacher training workshops in Beijing—with the objective of providing 
260 student-weeks of training. Seventy-two middle and high school students attended four 2- 
or 3-week courses at the DNALC in the summer. Middle school students completed modules 
on Fun with DNA, World of Enzymes, and Forensic Detectives. High school students completed 
modules on DNA Science plus DNA Barcoding Research or Human Genomics. Eighteen students 
designed and conducted independent research projects exploring the biodiversity of Cold Spring 
Harbor’s ecosystem using DNA barcoding, including fi eldwork, lab work, computer analyses, 
and a presentation of research fi ndings. Some summer camp students met Dr. James Watson 
during a special media event in August, which was covered by journalists from more than ten 
media agencies.
In October, we taught two 4-day student courses on Human Genomics at Beijing 166 School. 
Sixty-three students used polymerase chain reaction (PCR) to look at DNA variations in their 
own DNA, highlighting concepts in population genetics, genotype–phenotype analysis, and 
human evolution. The courses culminated with a fi eld trip to the Peking Man World Heritage site 
outside of Beijing. We also conducted 2-day teacher training workshops for 340 biology teachers 
from the Beijing area.
We rigorously evaluated the students who participated in courses conducted at the DNALC 
and at the Beijing 166 School—and we compared their genetic content knowledge and literacy 
with New York students taking the same courses. The results of these studies support our conten-
tion that the DNALC courses provide Chinese students with an exposure to biology practice and 
concept development that is largely missing from even the best Chinese schools. The results of 
this study suggest that Beijing high school students are less “scientifi cally mature” than their Long 
Island counterparts—with less general biological knowledge and less exposure to the scientifi c 
process, critical thinking, and “soft” skills of scientifi c collaboration and communication. The 
results also suggest that science enrichment programs—such as the DNALC courses—can bolster 
Chinese students’ familiarity with science process and enquiry, and prepare them for science study 
at American universities.
In November, we initiated serious negotiations with Suzhou Industrial Park (SIP) to establish 
a licensed DNALC in its BioBay biotechnology park. SIP mayor Barry Yang offered his strong 
support for the development of eight teaching labs and support spaces plus exhibit and cafeteria 
facilities in three existing buildings in a grassy park in the center of BioBay. The agreement will 
build upon the existing relationship with SIP, with which the Laboratory currently operates CSH 
Asia Conferences. Like the CSHL conferences, the DNALC at SIP would be directly operated 
by CSHL. However, due to the ongoing liberalization in China and strong support from the SIP 
mayor and Communist Party secretary, the DNALC at SIP will be set up as a nongovernmental 
organization (NGO). In addition to being tax exempt, the NGO designation should make mon-
etary transfers between SIP and CSHL much easier. The NGO will share core management and 
accounting services with CSH Asia Conferences. We expect to sign a formal agreement in spring 
2015, with the objective of bringing the facility into operation in late 2015.
We also worked with a high-level consortium on plans for two licensed centers in Mexico 
due to open in late 2015 and 2016. One center will be a major attraction of the “Codes of 
Life Health Park,” an EPCOT-like exposition in Chapultepec Park—Mexico City’s “Central 
Park”—and the largest urban green space in the western hemisphere. The Mexico City Proj-
ect is headed by Armando Barriguete, a world expert on nutrition, Jose Cordova, Minister of 
Health under former President Felipe Calderone, and Hugo Scherer, the campaign manager for 
current President Enrique Peña Nieto. The other licensed DNALC will be located in the new 
“ Agri-food Research Center” (CIDAM) in Morelia, the capital of Michoacán State. Michoacán 
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is the most important agricultural region in Mexico—the world’s largest producer of avoca-
dos—and the Ministry of Agriculture has invested $10 million to develop CIDAM as a biotech-
nology research center to buttress the local agricultural sector. The DNALC project has strong 
support from Antonio Jara, a physicist who was president of the University of Michoacán and 
now is governor of the state.
DNA Center NYC
The success of the Harlem DNA Lab and DNALC-inspired centers around the world provided the 
impetus to establish a dedicated center in New York City. This will allow us to further extend the 
DNALC “brand” to NYC, using a successful formula of academic year fi eld trips, in-school in-
struction and teacher training, and follow-up support—perfected over 25 years. The development 
of DNALC NYC is a $25 million goal of CSHL’s current $250 million 125th Anniversary Cam-
paign. The catalyst for the venture came in April 2012 with a $6 million lead gift from CSHL 
Trustee Laurie Landeau. This was followed in 2013 by a $10 million gift from the Thompson 
Family Foundation and a $3 million grant from the Alfred P. Sloan Foundation. An additional 
$750,000 of support has come from the Hearst Foundation, the Booth Ferris Foundation, and the 
Achelis Foundation. The strategy is to use $3 million for renovation, with drawdown from a $22 
million endowment funding about half of annual operating costs and providing scholarships for 
at least half of the student participants.
During the year, we worked intensively with Cushman & Wakefi eld Realtors to identify a 
7,000–10,000 square foot facility with good street visibility and easy access to public transport. 
VVA and Gilman Consulting reviewed the complicated New York City Department of Buildings 
codes. We visited and reviewed approximately 20 properties, ultimately developing preliminary 
plans or offers on six. Safety zoning, cost, or landlord issues scuttled all of the best prospects. So, 
we were heartened when we re-opened negotiations with City University of New York (CUNY) 
Chief Operating Offi cer Allan Dobrin, Vice Chancellor for Research Gillian Small, and New 
York City College of Technology President Russell Hotzler for space on their City Tech Campus 
in Brooklyn.
The DNA Center NYC leadership team was signifi cantly strengthened in April with the hiring 
of Annie Greengard as Manager of Science Education Partnerships. Annie reports to the CSHL 
Vice President of Development, Charlie Prizzi, and is charged to work closely with the DNALC 
to help establish, sustain, and operate a Manhattan location. Annie is working to establish a donor 
base in NYC by identifying, cultivating, and soliciting individuals, foundations, and corporations. 
A major effort is to build the DNALC NYC Council, whose objective is to help integrate the Cen-
ter into the life of NYC. The Council will be challenged to raise funds to support the Center on 
an annual basis to complement the Center’s endowment. Members are introducing the initiative 
to opinion leaders in business, government, education, and science who can help advance CSHL’s 
mission to bring New Yorkers into the gene age. Annie is also spearheading efforts to grow our 
network of Partner Member (previously Charter Member) schools, whose prepayment for activities 
eases annual budgeting.
Genomic Approaches in BioSciences
During the year, we wound down on NSF’s Advanced Technological Education project to train 
college faculty members to implement experiments that integrate four major technologies of the 
genome era: PCR, DNA sequencing, RNA interference (RNAi), and bioinformatics. DNALC 
staff taught a workshop on the CSHL campus in August, bringing the workshop total to 13 and 
exceeding our goal of providing direct training to 288 faculty. Underrepresented minorities com-
posed 21.7% of participants, and 67.2% were females. We maintained a mix of educators from 
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three educational levels: about one-fourth high school, one-half community college, and one-
fourth 4-year college or university.
We concentrated primarily on supporting second-round workshops that were taught by fac-
ulty trained by us in the initial term of the grant. Six summer workshops were taught by col-
laborators at Universidad del Turabo (Gurabo, Puerto Rico), Bluegrass Community and Tech-
nical College (Lexington, Kentucky), Madison Area Technical College (Madison, Wisconsin), 
and Kennedy-King College (Chicago, Illinois). A preliminary analysis of surveys of teachers 
trained in fi rst- and second-round workshops offers support for the “train-the-trainer” model. 
Post-workshop knowledge gains and confi dence in teaching lab methods and bioinformatics 
were strikingly similar for participants instructed by DNALC staff at primary workshops and 
those instructed by faculty trainers at supplementary workshops. Slight differences for certain 
categories are most likely due to differences in emphasis at the supplementary workshops, which 
were customized according to local instructional needs. Most importantly, the follow-up sur-
vey conducted 9–12 months later showed that similar or higher proportions of supplementary 
workshop participants reported having incorporated workshop labs, bioinformatics, and biotech 
careers into their teaching.
As part of a collaboration with Stony Brook University, doctoral student Caren Gough is mea-
suring the impact of the Genomic Approaches workshops on faculty confi dence over time. The 
Genomic Approaches in Biosciences Workshops are unique in that they, by design, include a mix 
of educators from high schools, community colleges, and 4-year universities. In a preliminary 
analysis, Ms. Gough found that there were signifi cant gains (with medium to large effect sizes) in 
both knowledge and confi dence pre- to post-workshop. Statistical comparisons revealed similar 
gains across the three teacher groups. High school, community college, and university faculty had 
similar outcomes, indicating that the benefi ts were comparable for all participants. High school 
teachers felt as confi dent as teachers from other levels—even for diffi cult bioinformatics computer 
labs. Importantly, 75% of respondents to a refl ection survey agreed that having teachers from 
Genomic Approaches in Biotechnology locations of home institutions.
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multiple education levels working together was a positive aspect of the workshop. Focus groups 
corroborated that participants benefi tted from sharing their learning experience with teachers 
from the other levels.
Genomic Approaches in Biotechnology Participant Home Institutions
DNA Barcoding
DNA barcoding programs at the 
DNALC have now expanded into three 
separate programs. The newest is Bar-
code Long Island: Exploring Biodiversity 
in a Unique Urban Landscape (BLI), 
which is funded by a $1.2 million Na-
tional Institutes of Health (NIH) Sci-
ence Education Partnership Award. In 
collaboration with Stony Brook Uni-
versity (SBU), Brookhaven National 
Laboratory (BNL), and the American 
Museum of Natural History (AMNH), 
BLI will provide students with real and 
relevant research experience while they 
contribute to our knowledge of Long 
Island biodiversity.
After advertising to our extensive 
network of school districts and hold-
ing several information sessions, we held two BLI training workshops for 73 teachers planning 
to mentor student teams. By the end of the year, 24 teams with 71 students from 10 Long 
Island schools had submitted research proposals. The two schools from Nassau County and 
eight schools from Suffolk are diverse, with minority enrollment ranging from 5% to 91% 
(24% average). The students have proposed DNA barcoding projects on animals (six), plants 
(six) and fungi (one) and will present their fi ndings at a symposium in spring 2015. A web-
site to support all aspects of the project has been developed that allows for project proposal 
submission, review, revision, and acceptance—features that are necessary to make distributed 
barcoding feasible.
BLI builds upon our experience with two student research programs in New York City: the 
Urban Barcode Project competition (UBP) and the Urban 
Barcode Research Program (UBRP). In the UBP, students 
work with teacher mentors on DNA barcoding projects 
during the school year and compete for a grand prize. In 
the UBRP, students complete summer workshops and 
then conduct 55+ hours of research directly with scientist 
mentors.
Thirty-eight UBP teams—145 students, 53% Afri-
can American or Latino—presented research posters at 
the American Museum of Natural History (AMNH) on 
May 27. These projects were supported by 14 footlocker 
kits and 42 weekend or after-school “open labs” at Har-
lem DNA Lab and Genspace. The students’ projects in-
cluded mapping wildlife found in NYC, detecting food 
Antonia Florio demonstrates DNA isolation during a Barcode Long Island teacher workshop.
Barcode Long Island teacher using a pestle to grind his plant sample 
for DNA barcoding.
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fraud, determining biodiversity of NYC green spaces, identifying traded plant and animal 
species, and exploring the effects of biodiversity on human health. When asked to compare 
the experience with other research experiences —mostly eighth grade exit projects or school 
science fairs—UBP students (n = 145) feel that the DNA barcoding programs provide more 
“real world” science (82% of students), more chance for hands-on experience (84%) and to 
learn science (75%), more opportunity to develop critical thinking (71%) and independent 
inquiry skills (73%), and more understanding of the scientifi c process (68%). DNA barcoding 
increases students’ interest in studying science or pursuing a career in science (72%), while still 
being more fun than other research experiences (69%).
A jury of 21 experts in biodiversity, conservation biology, DNA barcoding, and education 
selected the top six fi nalist teams (13 students) who gave oral presentations at AMNH on 
June 2. Mark Stoeckle, Senior Research Associate in the Program for the Human Environ-
ment at The Rockefeller University, gave the keynote address: “DNA Barcoding: The Thrill 
of Discovery.” The UBP grand prize winner was Eric Bovee, from The High School for En-
vironmental Studies, under the direction of mentors J.T. Boehm and Marissa Bellino. Their 
project studied the international and domestic seahorse trade to see if vendors abide by trade 
regulations. After measuring and extracting DNA from hundreds of seahorses, Eric found that 
several vulnerable species are sold and most domestically traded seahorses are under the 10-cm 
size limit. Both of these fi ndings suggest more work needs to be done to protect vulnerable 
seahorse populations.
Twenty UBRP teams (38 students) presented their projects as posters and oral presentations 
on April 29 at the AMNH. These students were selected from the 130 high-achieving NYC 
high school students who completed UBRP preparatory courses in Conservation Genetics and 
DNA Barcoding. The students worked with scientist mentors from institutions all over NYC, 
including the AMNH, CUNY, Fordham University, and Albert Einstein Medical Center. The 
UBRP projects spanned studies of food fraud, biodiversity, conservation genetics, phylogenet-
ics (evolution), behavior, and the fi rst DNALC microbiome studies. The UBRP was the fi rst 
science fair for 32% of students. Of those who had previously participated in a science fair or 
competition (68%), the vast majority felt that the UBRP experience increased their interest in a 
career in science (86%).
The NYC teams collected and processed more than 1000 samples for DNA sequencing—
an average of 17 samples per team—with more than 1600 single sequences provided by 
GENEWIZ, Inc. and 600,000 sequence reads produced by next-generation sequencing meth-
ods. Importantly, UBP and UBRP students produced an additional 12 novel DNA sequences 
that did not match existing data in the international database, GenBank. These are being pub-
lished to GenBank with the students as authors, which will make the data freely available for use 
by other researchers.
During the summer, 48 middle school students attended the Backyard Barcoding camp, and 39 
high school students stepped up to DNA Barcoding Research. The advanced students explored the 
aquatic biodiversity of the intertidal zone of CSHL’s campus, collecting 158 samples that produced 
30 novel sequences to be published to GenBank. The students developed project proposals, col-
lected samples from Cold Spring Harbor, extracted and amplifi ed specimen DNA, and analyzed 
DNA sequences. We also partnered with the NYC Department of Education to offer two DNA 
barcoding courses at the Environmental Study Center, where teams from four public high schools 
assessed the biodiversity of Brooklyn’s Marine Park. The NYC students collected 115 samples, 
with 15 novel sequences to be published to GenBank. Each barcoding workshop closed with 
oral presentations of student fi ndings. Most of the barcoding sequences came from small aquatic 
invertebrates, species that are hard to classify using traditional taxonomy, highlighting the power 
of DNA barcoding.
Executive Director’s Report  469
High School Research Programs
In 2014, 19,298 students attended fi eld trips at our three facilities: Dolan DNALC, DNALC 
West, and Harlem DNA Lab. We reached an additional 9046 students through in-school in-
struction by DNALC staff, and more than 1300 students attended week-long DNALC summer 
camps. Grants from Bank of America and National Grid Foundation supported programs for 
more than 2000 underserved students from Long Island school districts including Brentwood, 
Uniondale, William Floyd, Central Islip, and Valley Stream public schools. An additional 15 
students from IS 59 in Queens participated in an ongoing collaboration with NSLIJ at DNALC 
West, which culminated at the New York Hall of Science’s STEMtastic day where students show-
cased their lab skills.
Of the 2314 students who visited Harlem DNA Lab, 85% received scholarships from the 
 William Townsend Porter Foundation, including students from two schools co-located within 
the John S. Roberts Educational Complex: Coalition School for Social Justice and Harlem Vil-
lage Academy Leadership School. Supported by the New York City Department of Education 
(NYC DOE) Offi ce of School Programs and Partnerships, 83 high school and 71 middle school 
students attended camps at the Harlem DNA Lab and the NYC DOE Environmental Study Cen-
ter during school breaks. The footlocker kit rental program at the Harlem DNA Lab continued 
to provide teachers with equipment and reagents to implement basic genetics, biotechnology, and 
DNA barcoding labs. Footlocker kits were used by 1032 students, 117 of whom were conduct-
ing independent research under the UBP and UBRP. Sixty-four percent were underrepresented 
minorities.
The Partner Membership (formerly Charter Membership) program continues to fl ourish in 
NYC. Founding member Chapin School is now in the second year of an advanced elective, Mo-
lecular Genetics, which included a pilot project using metabarcoding to investigate the diversity 
of bacteria in their school. The third-prize UBP team from Convent of the Sacred Heart School 
presented Nice to Meat You: Using DNA Barcoding to Detect Mislabeling in the Meat Industry. St. 
David’s School fi nished its fi rst year in the program with 5th grade poster presentations, includ-
ing a few DNA barcoding projects. Marymount School began their fi rst year with in-school labs 
for upper and middle school girls, as well as DNALC participation in the Upper School after-
school program.
We continued to collaborate with Cold Spring Harbor High School (CSHHS) to deliver Mo-
lecular and Genomic Biology. Students devote two class periods per day to this college-level labora-
tory course co-instructed by DNALC staff and CSHHS faculty Jaak Raadsepp. The 2013–2014 
cohort focused on hands-on experimentation and independent projects across a range of biological 
systems, including units on eugenics, DNA barcoding, RNAi, human and plant genomics, micro-
biomes, and protein structure. The 2014–2015 cohort, our tenth class, began the year with classic 
DNA Science labs in recombinant DNA technology and a survey of plant diversity at the Nature 
Conservancy.
The second year of partnership with St. Dominic High School in Oyster Bay progressed with 
the independent research component of a 5-month course, Molecular and Genomic Biology Re-
search. Several students chose to develop projects using DNA barcoding to study local biodiversity. 
A new group of high school juniors began year three in September. The fall curriculum includes 
labs in bacterial genetics, genomics, bioinformatics, and RNAi.
Our newest collaboration with the Nassau BOCES Doshi STEM School entered its second 
year of programming with two cohorts of students in grades nine and ten. Students in Living 
Environment and research electives began the school year with DNA barcoding projects that in-
cluded surveys of biological diversity in pristine and polluted environments, combined with an 
investigation of abiotic factors that might affect biodiversity in each location. This culminated in 
the presentation of posters at a small poster session and at the Barcode Long Island symposium.
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Monthly Saturday DNA! sessions drew 215 participants, with parents and grandparents joining 
children for classes on forensics, human evolution, the central dogma, and experimental design. 
An additional 4183 visitors viewed fi lms in the Multitorium, including Cablevision’s multimedia 
presentation Long Island Discovery, and/or viewed the exhibition The Genes We Share. The annual 
Great Moments in DNA Science seminar series drew 50 Long Island high school students to three 
presentations by researchers. Dr. Michael Feigin, CSHL, discussed how genomic data are used to 
fi nd gene targets in breast cancer; Dr. Daniel Bogenhagen, SBU, explained how the mitochondria 
became an essential part of eukaryotic cells; and Dr. Danielle Engle, CSHL, talked about efforts 
to improve survival in patients with pancreatic cancer by developing early detection strategies and 
identifying better biomarkers for this type of cancer.
Graduate Training
Our collaboration with the CSHL Watson School of Biological Sciences continues to provide 
graduate students with the opportunity to learn skills necessary for communicating with non-
biologists. During a 3-month training program, graduate students of the WSBS work together 
with seasoned DNALC instructors to develop effective teaching techniques. When they have 
completed the training, the graduate students will be prepared to quickly assess any audience and 
structure quality lessons accordingly.
In the fi rst phase, the WSBS students observe a DNALC instructor teaching a laboratory and 
then must organize lesson plans integrating their own experiences. In the second phase of train-
ing, the graduate students co-teach with the DNALC teachers to conduct a lesson. The DNALC 
instructors then provide feedback, discussing strengths and appropriate preparation for an inde-
pendent lesson. The fi nal phase requires the graduate students to teach a lesson under DNALC 
instructor observation. When both middle and high school rotations have been completed, the 
WSBS students select three additional lessons to demonstrate mastery of instruction and class 
management skills.
Our successful collaboration with the New York Academy of Sciences (NYAS) continues to 
improve the science literacy among high-needs students throughout New York City. DNALC in-
structors provided training to graduate students and postdoctoral researchers who serve as mentors 
in the Academy’s after-school mentoring program. Each received 6 hours of training in effective 
strategies to provide hands-on laboratories to middle school students.
BioMedia Visitation and Projects
We had a record number of visitors to our suite 
of multimedia resources in 2014. Google Analytics 
counted 5,202,881 visits to 22 DNALC websites. 
Our YouTube videos received 873,881 views, and 
the 3D Brain, Weed to Wonder, and Gene Screen 
apps were downloaded 668,396 times. Total web-
site, YouTube, and smartphone/tablet apps visita-
tion reached 6.75 million, a 7.7% increase over 
2013.
Developed under a grant from the Dana Foun-
dation, the 3D Brain app continues to be suc-
cessful, with 2.72 million downloads to date on 
Apple, Windows, and Android devices worldwide. 
In late 2013, we released an update for the Apple 
version of the 3D Brain app that included an 
Chun-hua Yang ﬁ lms Olympia Davison explaining how to perform a DNA 
extraction.
Executive Director’s Report  471
“in-app” purchase of 3D Brain HQ, 
which includes higher-resolution im-
ages and a redesigned user interface 
for $0.99. In 2014, there were 25,343 
downloads of the HQ version, netting 
$17,600 after Apple took its share. 
Proceeds from in-app purchases sup-
port the educational programs of the 
DNALC.
Although reduced in size by almost 
half, the BioMedia Group continued 
to support the DNALC’s educational 
programs with website development 
and maintenance; videography and 
postproduction for webinars, special 
events, and offsite workshops; pro-
gram promotion through email cam-
paigns; fl yer, poster, and backdrop 
design for professional meetings; mu-
seum development; photo documen-
tation of events and barcoding speci-
mens; social media management; and 
creation of architectural concept plans for potential DNALC venues in NYC and China. The 
Laurie J. Landeau Multimedia Studio hosted several events, including: monthly bioinformat-
ics webinars for iPlant and the CSHL Gramene project; mtDNA sequencing fi eld trip follow-up 
webinars; remote hands-on laboratory instruction; and seminars to remote student and faculty 
audiences. We also routinized our traveling Livestream studio setup at several events, including 
meetings at CSHL, Stony Brook University, University of Nebraska, and the USDA; and for UBP 
and UBRP symposia.
As part of the EOT Group of iPlant Collaborative, we developed and implemented a new design 
for the iPlant website that launched in May. The new site incorporates several improvements over 
the previous iPlant site: increased focus on and easier access to iPlant’s tools; simplifi ed structure 
eliminating embedded and redundant content; integration of the iPlant Learning Center; and 
modifi ed color palette and updated imagery.
In the summer, we worked with high school 
student Olympia Davison to create short videos 
that give a student’s perspective on hands-on 
laboratories and research careers. Olympia inter-
viewed CSHL neuroscientist Dr. Anne Church-
land, and demonstrated “How to Load a Gel” 
and a “DNA Extraction” from strawberries. The 
videos were uploaded to YouTube, where they 
have had more than 1,200 views.
In September, we installed BOLD (named 
for the acronym for the Barcode of Life Data 
Systems), an art exhibition on DNA barcod-
ing displayed in the front and side halls of the 
DNALC. Seattle-based artist Joseph Rossano 
partnered with biologists to engage the pub-
lic around the science of DNA barcoding and 
BOLD exhibition artwork inspired by life in coral reefs in French Polynesia.
Artist Joseph Rossano discusses his artwork with students during the installation 
of his show in the DNALC halls.
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how it is being used to catalog the world’s vast and threatened biodiversity. The work is in-
spired by specimens barcoded by Daniel Janzen from the Area de Concervación Guanacaste 
(ACG) in Costa Rica and by researchers for the University of California, Berkeley, Moorea 
Biocode Project being carried out at the Richard B. Gump South Pacifi c Research Station in 
Moorea. All of the pieces deliberately represent the specimens as fuzzy, obscured, or out of 
scale, making it diffi cult to identify the organism. However, on closer inspection the viewer 
discovers that each piece includes the DNA barcode sequence and a link to the BOLD da-
tabase, where the species identity is revealed. This underscores the reality that identifying 
species with certainty requires more than taxonomic methods. Our educators are developing 
interpretive activities for visiting students, many of whom will take part in a barcoding labo-
ratory during their visit.
As the evolution of our museum continues, plans are in place to include a one-of-a-kind 
reproduction of the 5300-year-old natural mummy discovered in the melting ice of the Öetzal 
Alps in 1991. Gary Staab, artist and life modeler, will create the “Otzi” replica (named for the 
region where the mummy was found) using CAT scans of the mummy and three-dimensional 
printing technology. Working with the South Tyrol Museum of Archeology in Italy (where the 
iceman’s body is currently kept), the project is planned to start in early 2015 and installation is 
projected for late spring. The iceman’s unique story will give us a platform to create a central 
theme on forensic biology and human origins. The publication of Ötzi’s genome provides a 
unique opportunity to refl ect on the meaning of becoming and being human. Written in each 
person’s DNA is a record of our shared ancestry, the information that makes us both similar 
and unique, and information that could foreshadow each person’s future health. This exhibit 
aims to encourage people to consider where we came from, who we are, and where we are 
going.
Staff and Interns
In 2014, we said goodbye to several staff members. Although it happens rarely, two design posi-
tions were phased out due to a lack of funding. Eun Sook Jeong, Multimedia Designer, is origi-
nally from South Korea and began as an intern in 2001. With a personality and design style 
tagged as “Zen” by our director, she has left a beautiful legacy as lead designer on several DNALC 
websites, as well as making signifi cant contributions to all of our sites. She also applied her interior 
design training in our unique upstairs kitchen/lounge area. Chris Weidler, Junior Designer, began 
as a college intern in the BioMedia Group in 2007. Initially assigned the tedious jobs that freed 
up the senior designers, he quickly proved that he could take on more intensive tasks. He soaked 
up knowledge in the Visual Communications major at Farmingdale State College and became a 
skilled Flash animator, print designer, video editor, and web designer who fi nalized a redesign of 
the iPlant Collaborative website just before departing.
Jermel Watkins, Ph.D., Staff Molecular Biologist and Educator, began his time with the 
DNALC as a high school intern from 1994 to 2000. After earning his Ph.D. in molecular and 
cellular pharmacology at Stony Brook University, he returned to us as a high school instructor in 
2007. He pioneered new workshops, managed interns, mentored research projects, and managed 
prep for workshops taught at all levels. Jermel accepted a position as an Assistant Professor and a 
Cancer and Neuroscience Research Scientist in the Department of Biological Sciences at Hamp-
ton University.
In 2007, Jennifer Galasso joined us as a Middle School Educator, and helped produce new 
workshops and labs in barcoding, personalized medicine, and epigenetics. Jenn also managed 
middle school lab preparation and the intern staff. She is now teaching Introduction to Research 
and Living Environment to ninth grade students at the Doshi STEM Institute of Nassau BOCES 
down the road in Syosset.
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Amy Nisselle, Ph.D, Multimedia and Evaluation Manager, learned about the DNALC at a 
2003 congress on human genetics in Melbourne, Australia, where she saw a presentation on our 
multimedia content. Amy then chose to pursue a Ph.D. in multimedia genetics education. As part 
of her thesis, she assisted with the evaluation of our Genes to Cognition website in 2008. She joined 
the DNALC in 2010 in her dual evaluation/producer role, and we miss her evaluation abilities and 
her big-picture perspective on multimedia projects. She returned to Australia to be with family 
and so her son (just beginning to speak) will form an Australian accent. Amy continued to consult 
with us for several months as we searched for her replacement.
The DNALC welcomed several new staff members in 2014. Emily Harrison joined us from the 
CSHL campus as a middle school educator. After receiving her Bachelor’s degree in Biology and 
a Master’s in Secondary Education from Adelphi University, she became a lab technician in Greg 
Hannon’s lab. She recently returned to Adelphi University for her Master of Science in biology and 
is completing her Master’s thesis research on laser-activated transcription.
Ashleigh Jackobel, a native Long Islander and graduate of Northport High School, began 
her time at the DNALC when she was hired as a college intern. After graduating from SUNY 
Farmingdale with a Bachelor of Science in Bioscience and a minor in Chemistry, Ashleigh jumped 
at the opportunity to join our team as a middle school and high school instructor. She is hoping 
to pursue a Ph.D. in Virology.
Shreya Shah, a new high school educator, developed an interest in bacteria during an episode 
of bubonic plague near her village in India, where she volunteered in a public awareness campaign 
to control the spread of plague. This fascination with microorganisms led her to earn a Master of 
Science in Microbiology at the University of Kansas. Her recent experience at Dowling College 
Microbiology Research Laboratory on soil microbial diversity in Long Island ecosystems makes 
her an excellent choice to help lead BLI.
Dr. Mona Spector became the project coordinator for the DNALC’s 3-year NSF project bring-
ing RNA-Seq to undergraduate education. Mona also joins us from the CSHL campus, where her 
impressive contributions to elucidating the genetic causes of cancer include key discoveries in the 
fi eld of programmed cell death (published in the journal Nature) and helping to develop a new 
three-dimensional culture system used to examine pancreatic cancer.
Anne Greengard started in the spring as Manager of Science Education Partnerships. Annie is 
a New York City native who received her B.A. from Dartmouth College. She moved on to Nash-
ville to attend law school at Vanderbilt University, then landing a place at a large law fi rm in NY. 
Annie’s family roots in science and her passion for education make her well-suited for her role 
working on development efforts for the DNA Center NYC.
We welcomed back Cornel Ghiban after a brief hiatus as a Perl programmer at Estée Lauder. 
He develops and maintains the expanding suite of DNALC websites and applications and plays a 
central role in the development of DNA Subway.
Christine Marizzi and Antonia Florio each received well-deserved promotions this year. First a sci-
ence educator, and now Manager, DNALC West, Christine instructs the majority of the 3000 students 
who attend fi eld trips there each year, as well as teaches offsite in local schools. Christine also played 
an integral role in the development of DNA barcoding programs. Since joining our staff in March 
2013 as Conservation Genetics Instructor, Antonia has the signifi cant task of managing the UBP and 
UBRP, and she provides instruction at all three DNALC locations. Now Manager, Research, Antonia 
also applies for funding, facilitates student evaluation, and plays a guiding role for BLI.
Since the DNALC opened, we have relied on high school and college interns to support our day-
to-day operations. In addition to laboratory prep work, interns may take on independent or team 
projects mentored by DNALC staff members, which translate current research into classroom labs. 
The BioMedia Group also welcomes interns for summer or longer-term roles. An internship offers stu-
dents the unique opportunity to gain real laboratory or design experience in an educational environ-
ment. We gathered an amazing group of interns this year and said farewell as others left for college:
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Sites of Major Faculty Workshops
Program Key: Middle School High School College
High School Interns
Kayla Bianco, St. Anthony’s High School Andrew Micklos, Ward Melville High School
Abigail Buckley, Oceanside High School Nicholas Nicolia, St. Anthony’s High School
Kenneth Collado, George W. Hewlett High School Gabrielle Ramirez, Walt Whitman High School
Liam Gensel, Harborfi elds High School Gavrielle Rood, Roslyn High School
Emily Gruber, Syosset High School Breanna Tahany, Kellenberg Memorial High School
Joshua Gruber, Half Hollow Hills High School East Maria Urbina, Oyster Bay High School
Omotayo Ikuomenisan, Huntington High School Scott Venturino, Huntington High School
Aiseosa Irowa, Hempstead High School Diana Vizza, North Shore High School
Serena Jones, Portledge High School Blakelee Woods, Glen Cove High School
Lenni Joya Amaya, Huntington High School
High School Interns Departing for College
Gabriella Blazich, Fordham University Jack Manzi, Binghamton University
Brittany Coscio, College of the Holy Cross Anant Mehrotra, Rochester Institute of Technology
Michaela Lee, SUNY Oneonta Jonathan Paris, Johns Hopkins University
College Interns
Kathryn Bellissimo, The College of New Jersey William McBrien, Suffolk Community College
Anne Bode, University of Notre Dame Pauline McGlone, CUNY Hunter College
Marie Jean Francois, CUNY City College Alec Micklos, University of Tampa
Nella Hauser, SUNY Stony Brook Arvind Rajabhathor, New York University
Ashleigh Jackobel, Farmingdale State College Robert Scott, Sage College of Albany
Karoline Lake, Columbia University Shenika Shah, New York Institute of Technology
ALABAMA University of Alabama, Tuscaloosa 1987–1990
Hudson Alpha Institute, Huntsville 2014
ALASKA University of Alaska, Anchorage 2012
University of Alaska, Fairbanks 1996
ARIZONA Arizona State University, Tempe 2009
Tuba City High School 1988
University of Arizona, Tucson 2011
United States Department of Agriculture, Maricopa 2012
ARKANSAS Henderson State University, Arkadelphia 1992
University of Arkansas, Little Rock 2012
CALIFORNIA California State University, Dominguez Hills 2009
California State University, Fullerton 2000
California Institute of Technology, Pasadena 2007
Canada College, Redwood City 1997
City College of San Francisco 2006
City College of San Francisco 2011, 2013
Community College of Denver 2014
Contra Costa County Offi ce of Education, Pleasant Hill 2002, 2009
Foothill College, Los Altos Hills 1997
Harbor-UCLA Research & Education Institute, Torrance 2003
Los Angeles Biomedical Research Institute (LA Biomed), Torrance 2006
Laney College, Oakland 1999
Lutheran University, Thousand Oaks 1999
Oxnard Community College, Oxnard 2009
Pasadena City College 2010
Pierce College, Los Angeles 1998
Salk Institute for Biological Studies, La Jolla 2001, 2008
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San Francisco State University 1991
San Diego State University 2012
San Jose State University 2005
Santa Clara University 2010
Southwestern College, Chula Vista 2014
Stanford University, Palo Alto 2012
University of California, Berkeley 2010, 2012
University of California, Davis 1986
University of California, Davis 2012, 2014
University of California, Northridge 1993
University of California, Riverside 2011
University of California, Riverside 2012
COLORADO Aspen Science Center 2006
Colorado College, Colorado Springs 1994, 2007
Colorado State University, Fort Collins 2013
United States Air Force Academy, Colorado Springs 1995
University of Colorado, Denver 1998, 2009–2010, 2014
CONNECTICUT Choate Rosemary Hall, Wallingford 1987
DISTRICT OF 
COLUMBIA
Howard University, Washington 1992, 1996, 2009–2010
FLORIDA Armwood Senior High School, Tampa 1991
Florida Agricultural & Mechanical University, Tallahassee 2007–2008
Florida Agricultural & Mechanical University, Tallahassee 2011
North Miami Beach Senior High School 1991
Seminole State College, Sanford 2013–2014
University of Miami School of Medicine 2000
University of Western Florida, Pensacola 1991
GEORGIA Fernbank Science Center, Atlanta 1989, 2007
Gwinnett Technical College, Lawrenceville 2011, 2012
Morehouse College, Atlanta 1991, 1996–1997
Spelman College, Atlanta 2010
HAWAII Kamehameha Secondary School, Honolulu 1990
University of Hawaii at Manoa 2012
ILLINOIS Argonne National Laboratory 1986–1987
iBIO Institute/Harold Washington College, Chicago 2010
Illinois Institute of Technology, Chicago 2009
Kings College, Chicago 2014
University of Chicago 1992, 1997, 2010
INDIANA Butler University, Indianapolis 1987
Purdue University, West Lafayette 2012
IDAHO University of Idaho, Moscow 1994
IOWA Drake University, Des Moines 1987
KANSAS University of Kansas, Lawrence 1995
KENTUCKY Bluegrass Community & Technical College, Lexington 2012–2014
Murray State University 1988
University of Kentucky, Lexington 1992
Western Kentucky University, Bowling Green 1992
LOUISIANA Bossier Parish Community College 2009
Jefferson Parish Public Schools, Harvey 1990
John McDonogh High School, New Orleans 1993
Southern University at New Orleans 2012
MAINE Bates College, Lewiston 1995
Southern Maine Community College 2012–2013
Foundation for Blood Research, Scarborough 2002
MARYLAND Annapolis Senior High School 1989
Bowie State University 2011
Frederick Cancer Research Center 1995
McDonogh School, Baltimore 1988
Montgomery County Public Schools 1990–1992
National Center for Biotechnology Information, Bethesda 2002
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St. John’s College, Annapolis 1991
University of Maryland, School of Medicine, Baltimore 1999
MASSACHUSETTS Arnold Arboretum of Harvard University, Roslindale 2011
Beverly High School 1986
Biogen Idec, Cambridge 2002, 2010
Boston University 1994, 1996
CityLab, Boston University School of Medicine 1997
Dover-Sherborn High School, Dover 1989
Randolph High School 1988
The Winsor School, Boston 1987
Whitehead Institute for Biomedical Research, Cambridge 2002
MICHIGAN Athens High School, Troy 1989
Schoolcraft College, Livonia 2012
MINNESOTA Minneapolis Community and Technical College, Madison 2009
Minneapolis Community and Technical College, Madison 2013
University of Minnesota, St. Paul 2005
University of Minnesota, St. Paul 2010
MISSISSIPPI Mississippi School for Math & Science, Columbus 1990–1991
Rust College, Holly Springs 2006–2008, 2010
MISSOURI St. Louis Science Center 2008–2010
Stowers Institute for Medical Research, Kansas City 2002, 2008
University of Missouri, Columbia 2012
Washington University, St. Louis 1989, 1997, 2011
MONTANA Montana State University, Bozeman 2012
NEBRASKA University of Nebraska, Lincoln 2014
NEVADA University of Nevada, Reno 1992, 2014
NEW HAMPSHIRE Great Bay Community College, Portsmouth 2009
New Hampshire Community Technical College, Portsmouth 1999
St. Paul’s School, Concord 1986–1987
NEW JERSEY Coriell Institute for Medical Research, Camden 2003
Raritan Valley Community College, Somerville 2009
NEW MEXICO Biolink Southwest Regional Meeting, Albuquerque 2008
NEW YORK Albany High School 1987
American Museum of Natural History, New York 2007
Bronx High School of Science 1987
Canisius College, Buffalo 2007
Canisius College, Buffalo 2011
City College of New York 2012
Cold Spring Harbor High School 1985, 1987
Cold Spring Harbor Laboratory 2014
Columbia University, New York 1993
Cornell University, Ithaca 2005
DeWitt Middle School, Ithaca 1991, 1993
Dolan DNA Learning Center 1988–1995, 2001–2004, 
2006–2009
Dolan DNA Learning Center 1990, 1992, 1995, 
2000–2011
Dolan DNA Learning Center 1990–1992
DNA Learning Center West 2005
Fostertown School, Newburgh 1991
Harlem DNA Lab, East Harlem 2008–2009, 2011–2013
Huntington High School 1986
Irvington High School 1986
John Jay College of Criminal Justice 2009
Junior High School 263, Brooklyn 1991
Lindenhurst Junior High School 1991
Mount Sinai School of Medicine, New York 1997
Nassau Community College, Garden City 2013
New York Botanical Garden, Bronx 2013
New York City Department of Education 2007, 2012
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New York Institute of Technology, New York 2006
New York Institute of Technology, New York 2006
Orchard Park Junior High School 1991
Plainview-Old Bethpage Middle School 1991
State University of New York, Purchase 1989
State University of New York, Stony Brook 1987–1990, 2014
Stuyvesant High School, New York 1998–1999
The Rockefeller University, New York 2003
The Rockefeller University, New York 2010
Titusville Middle School, Poughkeepsie 1991, 1993
Trudeau Institute, Saranac Lake 2001
Union College, Schenectady 2004
United States Military Academy, West Point 1996
Wheatley School, Old Westbury 1985
NORTH CAROLINA CIIT Center for Health Research, Triangle Park 2003
North Carolina Agricultural & Technical State University, 
Greensboro
2006–2007, 2009–2011
North Carolina School of Science, Durham 1987
North Carolina State University, Raleigh 2012
NORTH DAKOTA North Dakota State University, Fargo 2012
OHIO Case Western Reserve University, Cleveland 1990
Cleveland Clinic 1987
Langston University, Langston 2008
North Westerville High School 1990
OKLAHOMA Oklahoma City Community College 2000
Oklahoma City Community College 2006–2007, 2010
Oklahoma Medical Research Foundation, Oklahoma City 2001
Oklahoma School of Science and Math, Oklahoma City 1994
Tulsa Community College, Tulsa 2009
Tulsa Community College, Tulsa 2012–2014
OREGON Kaiser Permanente-Center for Health Research, Portland 2003
Linfi eld College, McMinnville 2014
PENNSYLVANIA Duquesne University, Pittsburgh 1988
Germantown Academy 1988
Kimmel Cancer Center, Philadelphia 2008
RHODE ISLAND Botanical Society of America, Providence 2010
SOUTH CAROLINA Clemson University 2004
Medical University of South Carolina, Charleston 1988
University of South Carolina, Columbia 1988
TENNESSEE NABT Professional Development Conference, Memphis 2008
TEXAS Austin Community College–Rio Grande Campus 2000
Austin Community College–Eastview Campus–Roundrock 
Campus
2007–2009, 2013
Austin Community College–Roundrock Campus 2012
Houston Community College Northwest 2009–2010
J.J. Pearce High School, Richardson 1990
Langham Creek High School, Houston 1991
University of Lone Star College, Kingwood 2011
Midland College 2008
Southwest Foundation for Biomedical Research, San Antonio 2002
Taft High School, San Antonio 1991
Texas A&M University, College Station 2013
Texas A&M University, Prairie View 2013
Texas A&M, AG Research and Extension Center, Weslaco 2007
Trinity University, San Antonio 1994
University of Texas, Austin 1999, 2004, 2010, 2012
University of Texas, Brownsville 2010
UTAH Brigham Young University, Provo 2012
University of Utah, Salt Lake City 1993
University of Utah, Salt Lake City 1998, 2000
478  DNA Learning Center
Utah Valley State College, Orem 2007
VERMONT University of Vermont, Burlington 1989
VIRGINIA Eastern Mennonite University, Harrisonburg 1996
Jefferson School of Science, Alexandria 1987
Mathematics and Science Center, Richmond 1990
Mills Godwin Specialty Center, Richmond 1998
Virginia Polytechnic Institute and State University, Blacksburg 2005, 2008–2009
WASHINGTON Fred Hutchinson Cancer Research Center, Seattle 1999, 2001, 2008
Shoreline Community College 2011, 2012
University of Washington, Seattle 1993, 1998, 2010
WEST VIRGINIA Bethany College 1989
WISCONSIN Blood Center of Southeastern Wisconsin, Milwaukee 2003
Madison Area Technical College/Madison Area College 1999, 2009, 2011–2014
Marquette University, Milwaukee 1986–1987
University of Wisconsin, Madison 1988–1989
University of Wisconsin, Madison 2004, 2012
WYOMING University of Wyoming, Laramie 1991
PUERTO RICO Universidad del Turabo, Gurabo 2011, 2012, 2014
University of Puerto Rico, Mayaguez 1992
University of Puerto Rico, Mayaguez 1992
University of Puerto Rico, Rio Piedras 1993
University of Puerto Rico, Rio Piedras 1994
AFRICA Godfrye Okoye University, Enugu, Nigeria 2013
AUSTRALIA Walter and Eliza Hall Institute and University of Melbourne 1996
AUSTRIA Vienna Open Lab, Vienna 2007, 2012
CANADA Red River Community College, Winnipeg, Manitoba 1989
CHINA Beijing No. 166 High School, Beijing 2013, 2014
Ho Yu College, Hong Kong 2009
DENMARK Faroe Genome Project, Torshavn, Faroe Islands 2013
GERMANY Urania Science Center, Berlin 2008
ITALY International Institute of Genetics and Biophysics, Naples 1996
Porto Conte Research and Training Laboratories, Alghero 1993
MEXICO ASPB Plant Biology, Merida 2008
PANAMA University of Panama, Panama City 1994
RUSSIA Shemyakin Institute of Bioorganic Chemistry, Moscow 1991
SINGAPORE National Institute of Education 2001–2005
Singapore Science Center 2013
SWEDEN Kristineberg Marine Research Station, Fiskebackskil 1995
Uppsala University 2000
THE 
NETHERLANDS
International Chromosome Conference, Amsterdam 2007
Wageningen University and Research Center, Wageningen 2014
UNITED KINGDOM Wellcome Trust Conference Center, Hinxton 2012–2013
University of Warwick, Coventry 2013
Workshops, Meetings, Collaborations, and Site Visits
Jan 6–Feb 13 Pinkerton Foundation Bi-Weekly Urban Barcode Research Program, “DNA Detectives,” American Museum of 
Natural History, New York
January 8 Site visit by Tatiana Nikolenko, RUSNANO, Moscow, Russia
January 9–14 NSF ATE Professional Development, Genomic Approaches in BioSciences Supplemental Workshop, Universidad del 
Turabo, Gurabo, Puerto Rico
January 10 Site visit by Suzhou Industrial Park and bioBAY Delegation, Suzhou, China
January 11–15 NSF iPlant Collaborative pre-PAG Half-Day Workshop, International Plant and Animal Genome Conference 
XXIII, “A Simple Bioinformatics Workfl ow for RNA-Seq Analysis and Distributed Genome Annotation,” 
San Diego, California
January 23 Urban Barcode Project/Urban Barcode Research Program Open Lab, Harlem DNA Lab
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January 24 Urban Barcode Project “A Practical Introduction to DNA Barcoding,” University of Delaware, Newark, Delaware
January 25 KidCreate, O’Shea Educational Complex, New York
January 28 Urban Barcode Project/Urban Barcode Research Program Open Lab, Harlem DNA Lab
January 29 NSF iPlant Collaborative Webinar, “Getting Started with iPlant,” DNALC
January 30 Urban Barcode Project/Urban Barcode Research Program Open Lab, Harlem DNA Lab
Jan 31–Feb 1 NSF iPlant Collaborative Professional Development Tools and Services Workshop, Linfi eld College, McMinnville, 
Oregon
Feb 3–Mar 7 DNA Barcoding Research Mentoring Program, “DNA Detectives,” American Museum of Natural History, 
New York
February 4 Urban Barcode Project/Urban Barcode Research Program Open Lab, Harlem DNA Lab
February 6 Urban Barcode Project/Urban Barcode Research Program Open Lab, Harlem DNA Lab
February 8 Saturday DNA! “Got Milk?” DNALC
February 8 Urban Barcode Project/Urban Barcode Research Program Open Lab, Harlem DNA Lab
February 10, 11 Human Mitochondrial Sequencing Laboratory Follow-up Webinar, Oceanside High School, DNALC
February 11 Urban Barcode Project/Urban Barcode Research Program Open Lab, Harlem DNA Lab
February 11 Urban Barcode Project/Urban Barcode Research Program Open Lab, Genspace, Brooklyn, New York
February 15 STEM Mentor Training Workshop, New York Academy of Sciences, New York
February 17–24 DNA Science Workshop, Harlem DNA Lab
February 18 Urban Barcode Project/Urban Barcode Research Program Open Lab, Genspace, Brooklyn, New York
February 19 PCR Workshop, Rockefeller University, New York
February 24 Pinkerton Foundation Urban Barcode Research Program, “Barcode of Life,” American Museum of Natural History 
After-School Program, New York
February 25 Urban Barcode Project/Urban Barcode Research Program Open Lab, Harlem DNA Lab
February 25 Urban Barcode Project/Urban Barcode Research Program Open Lab, Genspace, Brooklyn, New York
February 26 Pinkerton Foundation Urban Barcode Research Program, “Barcode of Life,” American Museum of Natural History 
After-School Program, New York
February 27 Urban Barcode Project/Urban Barcode Research Program Open Lab, Harlem DNA Lab
February 28 NSF iPlant Collaborative Seminar, “The iPlant Collaborative—Community Cyberinfrastructure for Life Science,” 
Genome Analysis Centre, Norwich, United Kingdom
March 3 Pinkerton Foundation Urban Barcode Research Program, “Barcode of Life,” American Museum of Natural History 
After-School Program, New York
March 3–4 NSF iPlant Collaborative Tools & Services Workshop, Wageningen University and Research Centre, Wageningen, 
The Netherlands
March 4 Urban Barcode Project/Urban Barcode Research Program Open Lab, Harlem DNA Lab
March 5 Pinkerton Foundation Urban Barcode Research Program, “Barcode of Life,” American Museum of Natural History 
After-School Program, New York
March 5 “DNA Barcoding,” Queensborough Community College, Bayside, New York
March 5 Site visit by The Hearst Foundation, New York
March 5 Site visit by Dr. Jose Cordova and Dr. J. Armando Barriguete, Mexico City, Mexico
March 6 Great Moments in DNA Science Honors Seminar, “The Search for New Drug Targets in Breast Cancer,” 
Dr. Michael Feigin, CSHL
March 8 Urban Barcode Project/Urban Barcode Research Program Open Lab, Harlem DNA Lab
March 10 NSF iPlant Collaborative Webinar, “Getting Started with iPlant,” DNALC
March 10 Pinkerton Foundation Urban Barcode Research Program, “Barcode of Life,” American Museum of Natural History 
After-School Program, New York
March 11 Urban Barcode Project/Urban Barcode Research Program Open Lab, Harlem DNA Lab
Mar 12–Apr 11 Pinkerton Foundation DNA Barcoding Research Mentoring Program, “DNA Barcoding,” Queensborough 
Community College, Bayside, New York
March 13 Urban Barcode Project/Urban Barcode Research Program Open Lab, Harlem DNA Lab
March 13–16 NSF iPlant Collaborative Tools & Services Half Workshop, 56th Maize Genetics Conference, Beijing, China
March 14 “Women in STEM Careers,” Panel Discussion, The Chapin School, New York, New York
March 15 Saturday DNA! “Silencing Genes,” DNALC
March 17 Pinkerton Foundation Urban Barcode Research Program, “Barcode of Life,” American Museum of Natural History 
After-School Program, New York
March 18 Urban Barcode Project/Urban Barcode Research Program Open Lab, Harlem DNA Lab
March 18 Great Moments in DNA Science Honors Seminar, “Mitochondrial DNA, Our Second Genome,” Dr. Daniel 
Bogenhagen, Stony Brook University, Stony Brook, New York
March 19 Pinkerton Foundation Urban Barcode Research Program, “Barcode of Life,” American Museum of Natural History 
After-School Program, New York
March 20 Urban Barcode Project/Urban Barcode Research Program Open Lab, Harlem DNA Lab
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March 22 Urban Barcode Project/Urban Barcode Research Program Open Lab, Harlem DNA Lab
March 22 Cold Spring Harbor Schools 3rd & 4th Grade Program, DNALC
March 24 Pinkerton Foundation Urban Barcode Research Program, “Barcode of Life,” American Museum of Natural History 
After-School Program, New York
March 25–27 NSF iPlant Collaborative Train the Trainers/Tools and Services Workshop, University of California-Davis, Davis, 
California
March 26 “DNA Extraction,” Presentation, Port Jefferson Science Fair, Edna Louise Spear Elementary School, Port Jefferson, 
New York
March 26 Pinkerton Foundation Urban Barcode Research Program, “Barcode of Life,” American Museum of Natural History 
After-School Program, New York
March 26–27 NSF iPlant Collaborative Mission Critical Bioinformatics Workshop, University of California, Davis
March 27 Great Moments in DNA Science Honors Seminar, “Using Sugars to Detect Pancreatic Cancer,” Dr. Dannielle 
Engle, CSHL
March 27 Urban Barcode Project/Urban Barcode Research Program Open Lab, Harlem DNA Lab
March 28–29 Interview with Lior Patchley, “Tuxedo RNASeq,” University of California, Berkeley
March 29 NSF ATE Professional Development, Genomic Approaches in BioSciences Workshop, Seminole State College, 
Sanford, Florida
March 29 Tour by Renaissance Technologies, East Setauket, New York, DNALC
March 31 Pinkerton Foundation Urban Barcode Research Program, “Barcode of Life,” American Museum of Natural History 
After-School Program, New York
Mar 31–Apr 2 NSF Conference on Course-Based Undergraduate Research Experiences (CUREnet), Host and “Infrastructure 
and Data for Large-Scale Collaborations” Plenary Panel, CSHL
April 1 Urban Barcode Project/Urban Barcode Research Program Open Lab, Harlem DNA Lab
April 2 Pinkerton Foundation Urban Barcode Research Program, “Barcode of Life”, American Museum of Natural History 
After-School Program, New York
April 3–4 National Science Teachers Association National Conference 2014, “Detecting Epigenetic DNA Methylation in 
Arabidopsis Thaliana,” “DNA Subway: Bringing Cutting Edge Bioinformatics into the Classroom,” and “DNA 
Barcoding Independent Research in the Classroom,” Boston, Massachusetts
April 8 Urban Barcode Project/Urban Barcode Research Program Open Lab, Harlem DNA Lab
April 10 Urban Barcode Project/Urban Barcode Research Program Open Lab, Harlem DNA Lab
April 11 NSF iPlant Collaborative Webinar, “Getting Started with iPlant,” DNALC
April 12 NSF ATE Professional Development Genomic Approaches in BioSciences Follow-up Workshop, Tulsa Community 
College, Tulsa, Oklahoma
April 12 Saturday DNA! “Transcription and Translation: What Does DNA Actually Do?” DNALC
April 12 Urban Barcode Project/Urban Barcode Research Program Open Lab, Harlem DNA Lab
April 14–18 Genome Science Workshop, Harlem DNA Lab
April 17–18 NSF Research Collaboration Network: Integrating Bioinformatics into Life Sciences Education, “The iPlant 
Collaborative—Community Cyberinfrastructure for Life Sciences,” Omaha, Nebraska
April 22 “Glowing Genes,” Remote Instruction Webinar, Berean Christian Jr. Academy, Atlanta, Georgia
April 24 Urban Barcode Project/Urban Barcode Research Program Open Lab, Harlem DNA Lab
April 25 Site visit by Dr. Jose Angel Cordova, Mme. Lia Limon, Dr. J. Armando Barriguete, and M. Hugo Scherer, 
Mexico City, Mexico
April 25 DNA Day Scavenger Hunt, DNALC and Cold Spring Harbor, New York
April 26 Urban Barcode Project/Urban Barcode Research Program Open Lab, Harlem DNA Lab
April 26 Fun with DNA, Forensic Detectives and DNA Barcoding Teacher Training Workshops, DNALC
April 29 Pinkerton Foundation Urban Barcode Research Program Symposium, American Museum of Natural History, 
New York
May 1 Urban Barcode Project/Urban Barcode Research Program Open Lab, Harlem DNA Lab
May 6 Site visit by Joseph Rossano, Arlington, Washington
May 8 Urban Barcode Project/Urban Barcode Research Program Open Lab, Harlem DNA Lab
May 10 Urban Barcode Project/Urban Barcode Research Program Open Lab, Harlem DNA Lab
May 12–13 NSF iPlant Collaborative Professional Development Software Carpentry Workshop, CSHL
May 14 NSF iPlant Collaborative Webinar, “Getting Started with iPlant,” DNALC
May 16 Site visit by Dr. J. Armando Barriguete, Mexico City, Mexico
May 17 Saturday DNA! “Human Origins: What DNA Says About Our Ancestry,” DNALC
May 21–22 NSF iPlant Collaborative Professional Development Genomics in Education Workshop, University of Nevada, Reno
May 27 Urban Barcode Project Poster Session, American Museum of Natural History, New York
May 27–28 NSF iPlant Collaborative Professional Development Tools and Services Workshop, Stony Brook, New York
May 30 Site visit by The Wall Street Journal, Harlem DNA Lab
June 2 Urban Barcode Project Symposium, American Museum of Natural History, New York
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June 2–3 Site visit by Amy Stark, University of Notre Dame, Indiana
June 2–6 NSF ATE Professional Development Genomic Approaches in BioSciences Supplemental Workshop, Bluegrass 
Community and Technical College, Lexington, Kentucky
June 3–4 Bio-Link Summer Fellows Forum, Bioinformatics in the Classroom Workshop, University of California-Berkeley, 
San Francisco
June 5 Site visit by Peter Dworkin, Regeneron, Tarrytown, New York
June 5 Ana Almeida, CSHL, Biology Career Webinar for Portuguese students
June 6 NSF iPlant Collaborative New Release Previews Webinar, DNALC
June 7 Saturday DNA! “Exploring Evolution,” DNALC
June 9–13 NSF ATE Professional Development Genomic Approaches in BioSciences Supplemental (English and Spanish) 
Workshop, Bluegrass Community and Technical College, Lexington, Kentucky
June 9–20 NSF Professional Development Infrastructure Training Bringing Next-Generation Sequence (NGS) Analysis into 
Undergraduate Education Workshop, CSHL
June 9–23 Forensics Workshop, Convent of the Sacred Heart, Greenwich, Connecticut
June 16–20 World of Enzymes Workshop, St. David’s School, New York
June 19–20 DNA Barcoding Workshop, Cabrini College, Radnor, Pennsylvania
June 23–24 NSF iPlant Collaborative Professional Development Tools and Services Workshop, Understanding GWAS Workshop, 
Lincoln, Nebraska
June 23–27 NSF ATE Professional Development Genomic Approaches in BioSciences Supplemental Workshop, Universidad del 
Turabo, Gurabo, Puerto Rico
June 27–28 NSF iPlant Collaborative Professional Development Genomics in Education Workshop, Community College of 
Denver, Denver, Colorado
June 30–July 4 Pinkerton Foundation Urban Barcode Research Program “DNA Detectives” Workshop, Harlem DNA Lab
June 30–July 4 Fun with DNA Workshops, DNALC (2 sessions)
Green Genes Workshop, DNALC
World of Enzymes Workshop, DNALC
Fun with DNA Workshop, DNA Learning Center West
July 7–11 Pinkerton Foundation Urban Barcode Research Program “Barcode of Life” Workshop, Harlem DNA Lab
July 7–11 DNA Science Workshops, DNALC (2 sessions)
Forensic Detectives Workshop, DNALC
World of Enzymes Workshop, DNALC
World of Enzymes Workshop, DNA Learning Center West
July 7–11 NSF ATE Professional Development Genomic Approaches in BioSciences Supplemental Workshop, Madison Area 
Technical College, Madison, Wisconsin
July 9 NSF iPlant Collaborative Webinar, “Getting Started with iPlant,” DNALC
July 12–16/17–18 American Association of Plant Biologists 2014, “The iPlant Collaborative: Scalable Infrastructure for Life Science” 
Seminar / The iPlant Collaborative Software Carpentry Workshop, Portland, Oregon
July 15 NSF Extreme Science and Discovery Environment (XSEDE) 2014 Conference, “DNA Subway: Making Genome 
Analysis Egalitarian,” Atlanta, Georgia
July 14–18 DNA Science Workshop, DNALC
Fun with DNA/World of Enzymes Workshop with Beijing, China students, DNALC
Fun with DNA Workshop, DNALC
Genome Science Workshop, DNALC
DNA Science Workshop, DNA Learning Center West
Fun with DNA Workshop, Harlem DNA Lab
July 14–18 NSF ATE Professional Development, Genomic Approaches in BioSciences Supplemental Workshop, Kennedy–King 
College, Chicago, Illinois
July 14–25 DNA Barcoding Workshop, Anthony J. Genovesi Center, St. Francis College, Brooklyn, New York
July 17–18 NSF iPlant Collaborative Professional Development Software Carpentry Workshop, Portland, Oregon
July 19–21 DNA Barcoding Workshop, Marine Park at the Environmental Science Center, Brooklyn, New York
July 21–22 DNA Barcoding Workshop, Rockefeller University, New York
July 21–25 BioCoding Workshop, DNALC
DNA Barcoding Workshop, DNALC
DNA Science Workshop, DNALC
Green Genes Workshops, DNALC (2 sessions)
Green Genes Workshop, DNA Learning Center West
July 23–24 “GOALS for Girls” Workshop, Rockefeller University, New York
July 26–30 Botanical Society of America, Botany 2014, The iPlant Collaborative Tools and Services/Genomics in Education 
Workshop, Boise, Idaho
July 28–Aug 1 DNA Barcoding Workshop, DNALC
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DNA Barcoding Research Workshop, DNALC
Forensics Workshop, DNALC
World of Enzymes Workshop, DNALC
Fun with DNA Workshop, DNA Learning Center West
Green Genes Workshop, Harlem DNA Lab
July 28–Aug 8 DNA Barcoding Workshop, Environmental Science Center, Brooklyn, New York
July 30 DNA Barcoding Webinar, Madison High School, San Antonio, Texas, DNALC
August 4–8 DNA Barcoding Research Workshop, DNALC
DNA Science Workshop, DNALC
Fun with DNA Workshop, DNALC
Fun with DNA/World of Enzymes Workshop with Beijing, China students, DNALC
DNA Science Workshop, DNA Learning Center West
Forensic Detectives Workshop, Harlem DNA Lab
August 6 Site visit by Elizabeth Benjamin and Elena Chon, New York City Department of Education, New York, 
Harlem DNA Lab
August 11–15 DNA Science Workshop, DNALC
Green Genes Workshops, DNALC (2 sessions)
Human Genomics Workshop, DNALC
Genome Science Workshop, DNA Learning Center West
DNA Science Workshop, Harlem DNA Lab
August 13 NSF iPlant Collaborative Webinar, “Getting Started with iPlant,” DNALC
August 13–14 NSF iPlant Collaborative Professional Development Genomics in Education Workshop, Hudson Alpha Institute, 
Huntsville, Alabama
August 17–22 10th World Congress of Genetics Applied to Livestock Production, “DNA Subway—An Educational 
Bioinformatics Platform for Gene and Genome Analysis, DNA Barcoding and RNA-Seq,” Vancouver, 
British Columbia, Canada
August 18–22 NSF ATE Professional Development, Genomic Approaches in BioSciences Workshop, CSHL
August 18–22 Backyard Barcoding Workshop, DNALC
Fun with DNA Workshop, DNALC
Silencing Genomes Workshop, DNALC
World of Enzymes Workshop, DNALC
DNA Science Workshop, Delbrµck Laboratory, CSHL
Fun with DNA Workshop, DNA Learning Center West
August 18–22 Pinkerton Foundation Urban Barcode Research Program Workshops, “Conservation Genetics,” “DNA Barcoding,” 
Harlem DNA Lab
August 25–29 DNA Science Workshop, DNALC
Forensic Detectives Workshop, DNALC
Fun with DNA Workshop, DNALC
World of Enzymes Workshop, DNALC
Green Genes Workshop, Hershey Laboratory, CSHL
World of Enzymes Workshop, DNA Learning Center West
August 25–29 Urban Barcoding Project Teacher Training Workshop, Harlem DNA Lab
September 3 National Plant Genome Initiative Postdoctoral Research Fellows Annual Awardee Meeting, “Computational 
Resources for Young Investigators: How Can iPlant Help?” Arlington, Virginia
September 3 Professional Development Workshop, “Bacterial Transformation,” Progress High School, Brooklyn, New York
September 3–5 Banbury Meeting Presentation: “High Performance Computing (HPC) in Undergraduate Biology Education, 
“DNA Subway—GUI to HPC for Undergraduates,” CSHL
September 6 Forensic Detectives Teacher Training Workshop, New York Academy of Science, New York
September 7–10 European Conference on Computational Biology, “The iPlant Collaborative—Scalable Infrastructure for Life 
Science,” Strasbourg, France
September 15 NSF iPlant Collaborative Webinar, “Getting Started with iPlant,” DNALC
September 17–19 Molecular Biology Class, Marymount College, Tarrytown, New York
September 18–19 USDA/ARS Workshop on Arthropod Genomics, “The iPlant Collaborative–Scalable Infrastructure for Life 
Science,” Beltsville, Maryland
September 21–24 Genomic Informatics 2014 Conference, “DNA Subway: An HPC-Powered, User-Friendly Workfl ow for RNA-Seq 
Analysis” Presentation, Churchill College, Cambridge, England
September 25 Site visit by Datuk Seri Idris Jusoh, Kuala Lumpur, Malaysia
September 26 Site visit by Dr. J. Armando Barriguette, Mexico City, Mexico
October 8 NSF iPlant Collaborative Webinar, “Getting Started with iPlant,” DNALC
October 13–15 Human Genome Science Workshop, Beijing 166 Middle School, Beijing, China
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October 15 Barcode Long Island Information Session, Brookhaven National Laboratory, Upton, New York
October 17 “Using an Alu Insertion Polymorphism to Study Human Populations,” Beijing 166 Middle School, Beijing, China
October 18 Saturday DNA! “Bananas for DNA!” DNALC
October 18 Urban Barcode Project Teacher Training Workshop, Harlem DNA Lab
October 20 Site visit by Wanda Rosado, Unity Center for Urban Technologies, New York, Harlem DNA Lab
October 20–22 Human Genome Science Workshop, Beijing 166 Middle School, Beijing, China
October 22 21st National ATE Principal Investigators Conference, ATE Evaluation Practice—Lessons from the Field Pre-
Conference Workshop, Washington D.C.
October 23 Barcode Long Island Information Session, DNA Learning Center West
October 24 “CSHL DNALC Lab Class Design and Implementation,” Beijing 166 Middle School, Beijing, China
October 24 21st National ATE Principal Investigators Conference, Genomic Approaches to BioSciences Presentation, Washington 
D.C.
October 30 Barcode Long Island Information Session, DNALC
November 1 Metropolitan Association of College and University Biologists Annual Meeting, “Experiments in Gene and 
Genome Analysis,” Dowling College, Oakdale, NY
November 4 CEI-PEA Teacher Network, “Short Fingerprinting Lab” and “Bacterial Transformation Lab,” East Harlem, 
New York
November 4 Barcode Long Island Teacher Training Workshop, DNALC
November 5–8 Biological Data Science Meeting, “Unleash Your Inner Data Scientist—Enabling Scalable Data Driven 
Collaborations with iPlant Cyberinfrastructure,” CSHL
November 8 Saturday DNA! “Food for Thought,” DNALC
November 10 NSF iPlant Collaborative Webinar, “Getting Started with iPlant,” DNALC
November 13–15 2014 NABT Professional Development Conference, “DNA Barcoding: Independent Student-Driven Inquiry,” 
“What DNA Says About Our Human Family,” “Analyzing DNA Sequences to Understand Evolutionary 
Relationships,” Cleveland Convention Center, Cleveland, Ohio
November 16 CureNET Workshop, “Scalable Experiments in Gene and Genome Analysis,” Bowie State University, Baltimore, 
Maryland
November 19 Barcode Long Island Information Session, Midwood High School, Brooklyn, New York
November 24 Barcode Long Island Information Session, Benjamin N. Cardozo High School, Bayside, New York
December 3 NSF iPlant Collaborative Webinar, “Getting Started with iPlant,” DNALC
December 4 Urban Barcode Project/Urban Barcode Research Program Open Lab, Harlem DNA Lab
December 4 Site visit by Gary Staab, Staab Studios, Kansas City, Missouri
December 5 Site visit by Dr. J. Armando Barriguete with Mexican Scientifi c Delegation, Mexico City, Mexico
December 6 Saturday DNA! “Hairy Tales,” DNALC
December 6 Urban Barcode Project/Urban Barcode Research Program Open Lab, Harlem DNA Lab
December 6 Barcode Long Island Teacher Training Workshop, DNALC
December 7–10 iPlant Collaborative Professional Development Train-the-Trainers Workshop, USDA/ARS Big Data: RNA-Seq, 
CSHL
December 9 Urban Barcode Project/Urban Barcode Research Program Open Lab, Harlem DNA Lab
December 11 Site visit to Regeneron, Tarrytown, New York
December 12 Site visit by Ni Shuang, Wancheng Bao and Chuansen Zhao, Qilu Company, Shanghui, China
December 13 KidCreate, O’Shea Educational Complex, New York, New York
December 16 Urban Barcode Project/Barcode Long Island Information Session, Math for America, New York
December 18 Urban Barcode Project/Urban Barcode Research Program Open Lab, Harlem DNA Lab
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2014 PRESS PUBLICATIONS
Serials
Genes & Development, Vol. 28 (www.genesdev.org)
Genome Research, Vol. 24 (www.genome.org)
Learning & Memory, Vol. 21 (www.learnmem.org)
RNA, Vol. 20 (www.rnajournal.org)
Cold Spring Harbor Symposia in Quantitative Biology, Vol. 78:
Immunity and Tolerance, edited by Anne O’Garra, 
Michel Nussenzweig, Stephen Smale, David Stewart, and 
Bruce Stillman
Cold Spring Harbor Protocols (www.cshprotocols.org)
Cold Spring Harbor Perspectives in Biology (www.cshperspectives.org)
Cold Spring Harbor Perspectives in Medicine
(www.perspectivesinmedicine.org)
Laboratory Manuals
Molecular Neuroscience: A Laboratory Manual, edited by 
Rusty Lansford
Subcellular Fractionation: A Laboratory Manual, edited 
by Paul R. Pryor
Textbooks
Signal Transduction: Principles, Pathways, and Processes, edited by 
Lewis C. Cantley, Tony Hunter, Richard Sever, and 
Jeremy Thorner
Quickstart Molecular Biology: An Introduction for 
Mathematicians, Physicists, and Computational Scientists, 
by Philip N. Benfey
Human Variation: A Genetic Perspective on Diversity, Race, 
and Medicine, by Aravinda Chakravarti
Navigating Metabolism, by Navdeep S. Chandel
Monographs (Topic Collections from 
Perspectives in Biology and Perspectives 
in Medicine)
Endocytosis, edited by Sandra L. Schmid, Alexander Sorkin, and 
Marino Zerial
The Origin and Evolution of Eukaryotes, edited by Patrick J. 
Keeling and Eugene V. Koonin
MYC and the Pathway to Cancer, edited by Chi V. Dang and 
Robert N. Eisenman
The Skin and Its Diseases, edited by Anthony E. Oro and Fiona 
M. Watt
The Genetics and Biology of Sexual Confl ict, edited by William R. 
Rice and Sergey Gavrilets
Tuberculosis, edited by Stefan H.E. Kaufmann, Eric J. Rubin, 
and Alimuddin Zumla
Innate Immunity and Infl ammation, edited by Ruslan Medzhitov
Human Fungal Pathogens, edited by Arturo Casadevall, Aaron 
P. Mitchell, Judith Berman, Kyung J. Kwon-Chung, John R. 
Perfect, and Joseph Heitman
The Biology of Heart Disease, edited by Margaret E. Buckingham, 
Christine L. Mummery, and Kenneth R. Chien
History
Father to Son: Truth, Reason, and Decency, by James D. Watson
Other
Connecting with Companies: A Guide to Consulting Agreements 
for Biomedical Scientists, by Edward Klees and H. Robert 
Horvitz
A Bioinformatics Guide for Molecular Biologists, by Sarah J. Aerni 
and Marina Sirota
Experimental Design for Biologists, Second Edition, by David J. 
Glass
Career Options for Biomedical Scientists, edited by Kaaren Janssen 
and Richard Sever
CSHL Annual Report 2013, Yearbook Edition
Banbury Center Annual Report 2013
E-books (Kindle editions)
Father to Son: Truth, Reason, and Decency, by James D. Watson
Connecting with Companies: A Guide to Consulting Agreements 
for Biomedical Scientists, by Edward Klees and H. Robert 
Horvitz
Websites
Cold Spring Harbor Monographs Archive Online
(www.cshmonographs.org)
Cold Spring Harbor Symposium on Quantitative Biology
Archive (symposium.cshlp.org)
Lab Math: A Handbook of Measurements, Calculations, and 
Other Quantitative Skills for Use at the Bench, Second Edition, 
author’s blog (www.labmath.org)
Connecting with Companies: A Guide to Consulting Agreements for 
Biomedical Scientists, sample chapter, glossary, and additional 
information (www.bioagreements.org)
Father to Son: Truth, Reason, and Decency, timeline and excerpts 
(www.fathertosonbook.org)
Services
bioRxiv, the preprint server for biology (www.bioRxiv.org)
BioSupplyNet, scientifi c supply directory (www.biosupplynet.com)
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Cold Spring Harbor Laboratory Press creates publications and services that help scientists achieve 
success, while supporting the Laboratory’s reputation and goals in research, revenue, education, 
and communication. Rooted in the publication of the fi rst Cold Spring Harbor Symposium on 
Quantitative Biology in 1933, the Press now has an internationally respected program of seven 
journals, 200 books, and two online services. It produces and distributes content digitally, but it 
also deploys long-established expertise and the latest technologies to create attractive print books 
when market demand warrants.
The year 2014 was another successful one for the Press in which its publications maintained or 
enhanced their reputation for quality, its bioRxiv preprint service made an excellent start, and its 
fi nancial goals were exceeded, resulting in a signifi cant contribution to the Laboratory. In addi-
tion, the groundwork was laid for the launch of a new research journal in 2015.
Genes & Development and Genome Research remained two of the world’s four most highly cited 
genetics journals, and the more specialized research journals RNA and Learning & Memory con-
tinued to hold their own. There was strong growth for the newer journals, Cold Spring  Harbor 
 Protocols, Cold Spring Harbor Perspectives in Biology, and Cold Spring Harbor Perspectives in 
Medicine, each of which represents a strategic transformation of content previously available only 
as print manuals and monographs into successful web-based publications with all the benefi ts of 
online discovery and indexing and a sustainable business model. Total downloads of Press journal 
articles worldwide reached a new record level of 13 million.
In its fi rst full year, the preprint service bioRxiv made a signifi cant mark. More than 1000 man-
uscripts in 25 subject categories were posted, and authors received much feedback through on-site 
comments, social media, and private email. More than 300 of the posted articles were published in 
fi nal form in more than 100 journals, and many journals changed their editorial policies to allow 
consideration of manuscripts previously made available as preprints. In this respect, and from the 
frequency with which posted manuscripts are revised and updated, it is clear that the existence of 
bioRxiv is changing the way research biologists are communicating their work.
The Press also published 21 new book titles in 2014, including Jim Watson’s family memoir 
Father to Son. There was keen anticipation of the handbook Career Options for Life Scientists in 
response to the widening awareness that long-term opportunities for postdoctoral researchers in 
academia are lessening. The best-sellers remained the classic lab manual Molecular Cloning and the 
enormously popular career development handbooks At the Bench and At the Helm. The appetite 
for books in research science has shrunk substantially in recent years, but by reducing staff, cut-
ting costs, and developing targeted marketing approaches, the Press has retained a book program 
with both print and electronic capabilities that continues to support its mission to the Laboratory 
and the scientifi c community at large.
Staff
The business strategy of the Press in recent years has succeeded owing to investment in new proj-
ects with growing revenues and a strong focus on cost control, including staff numbers. At the 
end of the year, two more positions were eliminated, resulting in the departure of two long-time 
colleagues. Kaaren Janssen was one of our best developmental editors, and the long list of books 
her skills improved since she arrived in 1996 includes many that defi ned Cold Spring Harbor as 
a place of excellence in publishing. Geraldine Jaitin joined us in 2000 and expertly headed our 
488  Cold Spring Harbor Laboratory Press
Fulfi llment Department until its operations were outsourced. During the year, we also said fare-
well to Rena Steuer after 11 years of service as a Production Editor and Jacqueline Beggins, Assis-
tant Production Editor. We welcomed Maria Ebbets as a replacement Assistant Production Editor. 
A full list of Press staff members as of December 31, 2014, is included elsewhere in this volume.
To fulfi ll the mission of the Press, we engage in our work some of the world’s most accom-
plished scientists. They respect the Laboratory’s uniqueness and drive for excellence, but ulti-
mately these relationships are made possible by the skills and professionalism of the Press staff. 
We are fortunate to have such able and dedicated individuals in all the operations of the Press. 
I particularly wish to thank those who have leadership roles in our expanding and diversifying ac-
tivities: Assistant Director Richard Sever, journal editors Terri Grodzicker and Hillary Sussman, 
and department directors Jan Argentine, Wayne Manos, Stephen Nussbaum, Marcie Siconolfi , 
and Linda Sussman. And I also thank my Executive Assistant, Mala Shwe Mazzullo, whose quiet 
effi ciency and personal warmth support this organization in countless important ways.
John Inglis
Executive Director 
and Publisher
Genome Research Assistant Editor Laura DeMare and Press Executive 
Director and Publisher John Inglis with book authors Marina Sirota and 
George Asimenos at the American Society of Human Genetics Annual 
Meeting, San Diego, California.
Press Executive Director and Publisher John Inglis presenting during a 
panel on Industry Directions at the National Press Club, Washington, D.C.
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 2014 2013
Assets:
 Cash and cash equivalents $  56,309,959 65,258,594
 Grants receivable 10,551,528 8,506,168
 Contributions receivable, net 58,786,259 110,387,860
 Publications inventory 1,673,595 2,187,157
 Investments 442,830,529 384,070,487
 Restricted use assets 5,127,815 4,504,767
 Other assets 15,126,525 16,226,007
 Land, buildings, and equipment, net  231,650,890 231,988,575
Total assets $  822,057,100 823,129,615
Liabilities and net assets:
 Liabilities:
 Accounts payable and accrued expenses $   12,510,995 10,437,314
 Deferred revenue 5,509,689 5,209,891
 Interest rate swap 33,623,553 18,613,481
 Bonds payable     97,200,000     97,200,000
    Total liabilities  148,844,237  131,460,686
 Net assets:
 Unrestricted 325,723,978 294,223,173
 Temporarily restricted 236,314,595 290,273,304
 Permanently restricted  111,174,290  107,172,452
    Total net assets  673,212,863  691,668,929
Total liabilities and net assets $      822,057,100 823,129,615
FINANCIAL STATEMENTS
CONSOLIDATED BALANCE SHEET 
December 31, 2014
(with comparative ﬁ nancial information as of December 31, 2013)
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  Temporarily Permanently 2014 2013
 Unrestricted Restricted Restricted Total Total
Revenue and other support:
Public support—contributions and 
 nonfederal grant awards  $ 14,658,668 20,623,012 4,001,838 39,283,518 45,095,768)
Federal grant awards 27,176,257 –-  ---- –  ---- 27,176,257 26,766,266)
Indirect cost allowances 23,710,599 –   ---- –  ---- 23,710,599 23,228,697)
Investment return utilized 15,695,747 801,735 –  ---- 16,497,482 14,837,880)
Program fees 6,896,378 –   ---- –  ---- 6,896,378 7,752,249)
Publications sales 10,030,061 –   ---- –  ---- 10,030,061 10,174,394)
Dining services 4,322,717 –   ---- –  ---- 4,322,717 4,715,566)
Rooms and apartments 3,638,654 –   ---- –  ---- 3,638,654 3,859,785)
Miscellaneous 6,632,532 –   ---- –  ---- 6,632,532 2,579,049)
Net assets released from restrictions   74,581,721  (74,581,721)           –  ----               –----                 –---)
Total revenue and other support  187,343,334 (53,156,974)     4,001,838   138,188,198   139,009,654)
Expenses:
Research 85,732,121 –   ---- –  ---- 85,732,121 85,776,617)
Educational programs 17,213,213 –   ---- –  ---- 17,213,213 17,388,667)
Publications 9,466,527 –   ---- –  ---- 9,466,527 9,412,728)
Banbury Center conferences 1,486,354 –   ---- –  ---- 1,486,354 1,571,105)
DNA Learning Center programs 1,973,519 –   ---- –  ---- 1,973,519 1,623,885)
Watson School of Biological Sciences 
 programs 3,422,312 –   ---- –  ---- 3,422,312 3,370,964)
General and administrative 16,603,749 –   ---- –  ---- 16,603,749 18,110,232)
Dining services      5,704,911             –   ----            –  ----       5,704,911       5,591,701)
Total expenses 141,602,706             –   ----            –  ----   141,602,706   142,845,899)
Excess (defi ciency) of revenue and other 
support over (under) expenses 45,740,628 (53,156,974) 4,001,838 (3,414,508) (3,836,245))
Other changes in net assets:
Investment return excluding 
amount utilized 770,249 (801,735) –  ---- (31,486) 36,766,285
Change in fair value of interest 
rate swap  (15,010,072)           –   ----            –  ----    (15,010,072)     16,942,866)
Increase (decrease) in net assets 31,500,805 (53,958,709) 4,001,838 (18,456,066) 49,872,906)
Net assets at beginning of year 294,223,173   290,273,304  107,172,452    691,668,929   641,796,023)
Net assets at end of year $ 325,723,978   236,314,595  111,174,290   673,212,863   691,668,929)
CONSOLIDATED STATEMENT OF ACTIVITIES
Year ended December 31, 2014
(with summarized ﬁ nancial information for the year ended December 31, 2013)
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   2014 2013
Cash fl ows from operating activities:
Change in net assets  $    (18,456,066) 49,872,906
Adjustments to reconcile change in net assets to
 net cash provided by operating activities:
Change in fair value of interest rate swap  15,010,072 (16,942,866)
Depreciation and amortization  13,942,830 14,816,411
Net appreciation in fair value of investments  (12,908,048) (47,898,692)
Contributions restricted for long-term investment  (5,020,506) (5,308,027)
Changes in assets and liabilities:
Grants receivable  (2,045,360) 1,506,233
Contributions receivable, net of fi nancing activities  48,392,029 16,062,486
Publications inventory  513,562 580,270
Other assets  1,909,996 (283,358)
Restricted use assets  (623,048) (906,921)
Accounts payable and accrued expenses, net of fi nancing activities  959,182 268,487
Deferred revenue           299,798          (48,634)
Net cash provided by operating activities     41,974,441)    11,718,295)
Cash fl ows from investing activities:
Capital expenditures  (13,605,145) (6,179,654)
Proceeds from sales and maturities of investments  75,649,786 119,019,919
Purchases of investments  (121,501,780) (158,580,385)
Net change in investment in employee residences         (810,514)          (50,707)
Net cash used in investing activities    (60,267,653)   (45,790,827)
Cash fl ows from fi nancing activities:
 Contributions restricted for long-term investment  4,001,838 2,121,977
 Contributions restricted for investment in capital  1,018,668 3,186,050
 Decrease in contributions receivable  3,209,572 18,839,280
 Increase (decrease) in accounts payable relating 
  to capital expenditures        1,114,499          (287,585)
Net cash provided by fi nancing activities        9,344,577 )    23,859,722 
Net decrease in cash and cash equivalents  (8,948,635) (10,212,810)
Cash and cash equivalents at beginning of year      65,258,594 )    75,471,404   
Cash and cash equivalents at end of year  $      56,309,959 )      65,258,594 
Supplemental disclosure:
 Interest paid   $       4,013,111 )       4,016,854 
Noncash investing and fi nancing activity:
 Contributed property  $                  –    )          641,995 
CONSOLIDATED STATEMENT OF CASH FLOWS
Year ended December 31, 2014
(with comparative ﬁ nancial information for the year ended December 31, 2013)
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FEDERAL GRANTS
NATIONAL INSTITUTES OF HEALTH
Program Project and Center Support Drs. Hannon/Krainer/Spector/Stillman 05/25/12 12/31/16 $4,221,622.00
Dr. Stillman—Cancer Center Core 08/17/11 07/31/16 4,608,416.00
Cooperative Research Agreement Support2 Dr. Gingeras 09/21/12 07/31/16 2,087,649.00
Dr. Hannon 09/26/14 06/30/17 452,400.00 *
Drs. Osten/Albeanu/Mitra 09/26/14 06/30/17 1,245,306.00 *
Drs. Powers/Krasnitz/Sordella/Tuveson 05/01/12 04/30/17 570,972.00
Dr. Tuveson 06/12/14 02/28/19 258,623.00 *
Research Support Dr. Albeanu 07/01/13 06/30/18 472,500.00
Dr. Churchland 03/01/13 02/28/18 463,050.00
Drs. Enikolopov/Koulakov 09/15/11 05/31/16 492,558.00
Dr. Furukawa 03/01/10 02/28/15 467,775.00
Dr. Furukawa 05/08/14 03/31/18 359,100.00 *
Dr. Hannon 09/01/13 08/31/18 406,350.00
Dr. Hannon 04/01/13 03/31/15 220,956.00
Dr. Huang 07/01/11 03/31/16 565,050.00
Dr. Huang 07/01/13 06/30/18 748,793.00
Drs. Huang/Wigler 03/01/14 01/31/19 716,097.00 *
Dr. Kepecs 04/01/14 03/31/19 450,250.00 *
Drs. Kepecs/Huang 07/01/11 05/31/16 409,303.00
Drs. Koulakov/Zador 07/01/13 03/31/18 425,250.00
Dr. Krainer 04/01/12 03/31/17 734,358.00
Dr. Li 07/01/10 03/31/15 564,518.00
Dr. Li 03/01/14 02/28/19 472,500.00 *
Dr. Martienssen 09/15/11 08/31/15 346,085.00
Dr. Martienssen 01/20/12 11/30/15 400,837.00
Dr. McCombie 07/23/10 02/28/15 347,879.00
Dr. McCombie 08/16/13 06/30/16 622,428.00
Dr. Mills 04/01/14 01/31/16 283,500.00 *
Dr. Mills 09/16/14 08/31/19 634,545.00 *
Dr. Mitra 03/15/13 01/31/16 250,003.00
Dr. Osten 04/01/12 03/31/17 514,900.00
Dr. Siepel 09/01/14 12/31/17 34,270.53 *
Dr. D. Spector 04/01/11 03/31/15 746,284.00
Dr. Stillman 06/01/12 05/31/16 700,725.00
1Includes direct and indirect costs
2Cooperative research agreement funding amounts include only CSHL portion of award
*New or competing renewal grants awarded in 2014
FINANCIAL SUPPORT OF THE LABORATORY
Cold Spring Harbor Laboratory, Banbury Center, and the Dolan DNA Learning Center receive 
a substantial portion of their funding through grants from the federal government and through 
grants, capital gifts, and annual contributions from New York State, private foundations, corpo-
rations, and individuals. The following section summarizes funding that occurred during 2014.
GRANTS January 1–December 31, 2014
COLD SPRING HARBOR LABORATORY
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Dr. Tonks 07/01/10 04/30/15 $  745,634.00
Dr. Trotman 07/30/14 06/30/19 392,175.00 *
Dr. Turner 07/15/10 06/30/15 457,380.00
Drs. Tuveson/C. Hammell/Hicks/Pappin 09/22/14 08/31/18 555,711.00 *
Dr. Vakoc 04/01/13 03/31/18 532,576.00
Dr. Van Aelst 08/01/13 05/31/18 524,106.00
Dr. Van Aelst 04/01/13 03/31/18 477,000.00
Dr. Zador 09/27/10 05/31/15 467,775.00
Dr. Zador 09/01/12 08/31/17 401,625.00
Dr. Zador 04/01/13 03/31/15 236,250.00
Dr. Zador 07/01/14 04/30/19 413,438.00 *
Dr. Zhong 01/01/14 12/31/18 401,625.00 *
Research Subcontracts
NIH/Brandeis University Consortium 
Agreement
Dr. Mitra 09/26/14 06/30/17 301,141.00 *
NIH/Certerra, Inc. Consortium 
Agreement
Dr. Koulakov 01/03/13 12/31/14 124,996.00
NIH/Cornell University Consortium 
Agreement
Dr. Enikolopov 03/01/13 02/29/16 354,936.00
NIH/Emory University Consortium 
Agreement
Dr. Huang 04/01/14 02/28/18 84,746.00 *
NIH/Georgia Institute of Technology 
Consortium Agreement
Dr. D. Spector 09/30/06 07/31/15 200,000.00
NIH/New York University Consortium 
Agreement
Dr. Koulakov 06/01/14 05/31/19 176,715.00 *
NIH/Scripps Research Institute 
Consortium Agreement
Dr. Osten 09/30/12 08/31/17 35,923.00
NIH/Sloan-Kettering Institute for Cancer 
Research Consortium Agreement
Dr. Sordella 09/12/12 08/31/17 150,455.00
NIH/The Research Foundation for the 
State University of New York - Stony 
Brook Consortium Agreement
Dr. Wigler 05/01/14 04/30/19 130,599.00 *
NIH/Thomas Jefferson University 
Consortium Agreement
Dr. Enikolopov 03/15/14 02/28/15 17,834.00 *
NIH/University of California - Los 
Angeles Consortium Agreement
Dr. Wigler 09/26/14 06/30/16 626,027.50 *
NIH/University of Minnesota 
Consortium Agreement
Dr. Tuveson 07/01/12 06/30/15 85,397.00
NIH/University of Texas Consortium 
Agreement
Dr. Furukawa 09/30/11 05/31/15 18,700.00
Fellowship/Career Development Support Dr. Anczukow 09/01/13 08/31/15 106,008.00
Dr. Bhagwat 07/16/14 07/15/17 26,676.00 *
S. Kelly 07/16/13 07/15/16 26,676.00
J. Tucciarone 09/17/12 09/16/15 26,676.00
Institutional Training Program Support Dr. Gann/Watson School of Biological 
Sciences
07/01/12 06/30/17 270,804.00
Dr. Mills 09/01/11 08/31/16 178,855.00
Course Support Advanced Immunocytochemistry: In Situ 
Hybridization and Live Cell Imaging
09/01/10 08/31/15 100,323.00
Advanced Sequencing Technologies and 
Applications
04/10/12 03/31/15 52,816.00
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Cell and Developmental Biology of 
Xenopus
05/05/14 03/31/19 $  76,284.00 *
Cellular Biology of Addiction 03/01/11 02/29/16 74,500.00
Computational and Comparative 
Genomics
08/01/14 06/30/17 52,816.00 *
Eukaryotic Gene Expression 04/01/12 03/31/17 107,205.00
Mouse Development, Stem Cells & 
Cancer
04/01/12 03/31/17 106,419.00
Neurobiology of Drosophila 07/15/12 06/30/17 35,000.00
Programming for Biology 09/01/14 08/31/17 80,120.00 *
Protein Purifi cation and Characterization 04/01/12 03/31/17 106,289.00
Proteomics 08/01/12 04/30/17 110,695.00
Statistical Methods for Functional 
Genomics
08/05/13 07/31/17 105,657.00
X-Ray Methods in Structural Biology 09/01/12 08/31/17 81,540.00
Meeting Support Axon Guidance, Synapse Formation and 
Regeneration
08/01/14 07/31/15 26,694.00 *
The Biology of Genomes 04/01/13 03/31/18 54,600.00
Blood Brain Barrier 09/30/14 09/29/15 20,000.00 *
Germ Cells 07/01/14 06/30/19 6,000.00 *
Glia Health and Disease 09/30/13 08/31/14 10,000.00
Mechanisms and Models of Cancer 08/06/14 07/31/15 7,000.00 *
Molecular Chaperones and Stress 
Response
04/01/14 03/31/15 30,101.00 *
Molecular Genetics of Aging 03/15/14 02/28/19 30,972.00 *
Neurodegenerative Diseases: Biology and 
Therapeutics
09/30/14 09/29/15 10,000.00 *
Nuclear Receptors and Disease 09/23/14 08/31/15 23,000.00 *
PTEN Pathways and Targets 03/17/14 02/28/15 6,000.00 *
Retroviruses 03/15/12 02/28/17 36,645.00
Systems Biology: Global Regulation of 
Gene Expression
03/01/10 02/28/15 5,000.00
The PARP Family and Friends: Gene 
Regulation and Beyond
03/01/14 02/28/15 5,000.00 *
Wiring the Brain 09/30/14 08/31/15 20,000.00 *
Library Support Human Genome Project Documentary 
History: An Annotated Scholarly 
Guide to the Human Genome Project
02/01/14 01/31/16 44,685.00 *
NATIONAL SCIENCE FOUNDATION
Multiple Project Award Support Dr. Jackson 10/01/10 09/30/15 1,162,296.00
Drs. Lippman/Schatz 11/01/12 10/31/15 879,736.00
Dr. Mitra 10/01/13 09/30/16 312,534.00
Dr. Ware 06/01/12 05/31/17 2,392,521.00
Research Support Dr. Albeanu 09/15/14 08/31/16 145,428.00 *
Dr. Mitra 09/01/14 08/31/16 152,243.00 *
Dr. Schatz 06/01/14 05/31/19 293,574.00 *
Drs. Timmermans/M. Hammell 05/01/12 04/30/16 282,768.00
Dr. Timmermans 08/01/14 07/31/18 302,892.00 *
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Research Subcontracts
NSF/Cornell University Consortium 
Agreement
Dr. Timmermans 02/01/13 01/31/18 $  415,537.00
NSF/Cornell University Consortium 
Agreement
Dr. Ware 05/15/13 04/30/18 146,823.00
NSF/Iowa State University Consortium 
Agreement
Dr. Jackson 03/01/13 02/28/18 390,389.00
NSF/North Carolina State University 
Consortium Agreement
Dr. Martienssen 03/01/11 02/29/16 469,871.00
NSF/University of Arizona Consortium 
Agreement
Drs. Ware/Micklos/Schatz 09/01/13 08/31/18 1,844,316.00
Fellowship Support C. Carlston 08/18/14 07/31/19 44,000.00 *
D. Lambert 08/15/14 07/31/19 44,000.00 *
Undergraduate Training Program Support Drs. Schatz/Churchland/Ware 04/01/12 03/31/15 118,922.00
Course Support Advanced Bacterial Genetics 01/15/14 12/31/16 85,000.00 *
Computational Cell Biology 08/01/12 07/31/15 70,000.00
Frontiers and Techniques in Plant 
Science
05/15/12 04/30/15 103,124.00
Yeast Genetics and Genomics 07/15/14 06/30/17 85,000.00 *
UNITED STATES DEPARTMENT OF AGRICULTURE
Research Support Dr. Jackson 01/15/11 01/14/15 130,834.00
Dr. Jackson 12/01/13 11/30/17 123,319.00
Dr. McCombie 09/01/14 08/31/15 500,000.00 *
UNITED STATES DEPARTMENT OF THE ARMY
Research Support Dr. Egeblad 06/15/14 06/14/19 794,485.00 *
Dr. Hannon 09/15/12 09/14/17 1,072,791.00
Dr. Trotman 09/22/14 09/21/17 229,412.00 *
Dr. Tuveson 09/30/14 09/29/16 270,914.00 *
UNITED STATES DEPARTMENT OF ENERGY
Research Subcontracts
DOE/Brookhaven National Laboratory 
Consortium Agreement
Drs. Ware/Schatz 11/29/11 09/30/16 1,050,000.00
UNITED STATES DEPARTMENT OF THE NAVY
Course Support Synthetic Biology 07/01/14 06/30/15 50,000.00 *
MISCELLANEOUS SOURCES OF FUNDING
Program Project Support
David and Fanny Luke Farm Support/Dr. Stillman 10/01/14 09/30/15 250,000.00 *
Pfi zer Inc. Dr. Stillman 01/01/12 12/31/15 2,050,000.00
Pioneer Hi-Bred International, Inc. Drs. Jackson/Lippman/Martienssen/ 
Timmermans/Ware
07/01/12 09/30/14 400,000.00
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The Simons Foundation/Autism Dr. Wigler 01/01/12 12/31/16 $4,000,000.00
The Simons Foundation Center for 
Quantitative Biology
Dr. Wigler 09/01/08 08/31/15 1,000,000.00
The Stanley Medical Research Institute Drs. Watson/McCombie 07/01/14 06/30/16 5,000,000.00 *
St. Giles Foundation Cancer Center Support/Dr. Stillman 01/01/14 12/31/15 100,000.00 *
Research Support
Alex’s Lemonade Stand Dr. Vakoc 01/01/13 12/31/15 125,000.00
Rita Allen Foundation Dr. C. Hammell 09/01/12 08/31/17 110,000.00
Dr. M. Hammell 09/01/14 08/31/19 110,000.00 *
American Cancer Society Dr. Trotman 07/01/14 06/30/18 198,000.00 *
Anonymous Dr. Tuveson 12/01/14 11/30/16 250,000.00 *
Asothera Pharmaceuticals, Inc. Dr. Krainer 10/24/14 04/30/15 440,997.00 *
Caroline E. Bassett Dr. Tonks 05/19/14 05/18/15 5,000.00 *
Boehringer Ingelheim RCV GmbH & 
Co KG
Dr. Vakoc 11/01/13 10/31/15 228,196.00
Brain Research Foundation Dr. Zador 01/01/14 12/31/15 75,000.00 *
The Breast Cancer Research Foundation Drs. Wigler/Hicks 10/01/14 09/30/15 250,000.00 *
Burroughs Wellcome Fund Dr. Furukawa 06/23/14 12/31/15 10,000.00 *
Dr. Vakoc 09/01/11 08/31/16 151,250.00
Cedar Hill Foundation Dr. Fearon 11/25/14 11/24/15 60,000.00 *
Columbia University/The Simons 
Foundation
Dr. Krainer 09/01/14 08/31/15 49,908.00 *
Dart Neuroscience LLC Dr. Dubnau 12/01/13 11/20/14 250,000.00
Families of S.M.A. Dr. Hua 07/01/13 06/30/15 75,000.00
The Clark Gillies Foundation Dr. Vakoc 09/16/14 09/15/15 50,000.00 *
Global Prostate Cancer Research 
Foundation
Dr. Wigler 09/01/13 08/31/15 25,000.00
Glen Cove C.A.R.E.S., Inc. Dr. Trotman 02/01/14 01/31/15 5,000.00 *
Halozyme, Inc. Dr. Tuveson 05/20/14 05/19/16 200,000.00 *
The Irving A. Hansen Memorial Fund Dr. Tonks 08/01/14 07/31/15 25,000.00 *
Hearts for Cancer Dr. Diermeier 12/04/14 12/03/15 9,713.33 *
Robert and Cindy Higginson Dr. Mills 01/15/14 01/16/15 1,000.00 *
F. Hoffman-LaRoche Ltd Dr. Krainer 05/06/13 05/05/15 50,860.87
Howard Hughes Medical Institute - 
Gordon and Betty Moore Foundation
Dr. Martienssen 12/01/11 11/30/16 333,333.00
IC-MedTech Corporation Dr. Trotman 03/12/14 10/05/15 63,658.50 *
The Esther A. & Joseph Klingenstein 
Fund, Inc.
Dr. Churchland 07/01/14 06/30/17 75,000.00 *
The Susan G. Komen Breast Cancer 
Foundation, Inc.
Dr. Hicks 10/22/13 10/21/17 254,107.00
Mara and Thomas Lehrman Charitable 
Fund
Dr. Tollkuhn 01/15/14 01/14/15 50,000.00 *
The Lustgarten Foundation Dr. Egeblad 01/01/13 12/31/15 163,152.00
Dr. Fearon 07/01/14 06/30/19 1,000,000.00 *
Drs. Tuveson/Pappin 09/01/12 08/30/17 1,000,000.00
Dr. Tuveson 01/01/14 01/01/15 140,357.00 *
Dr. Tuveson 06/15/12 06/30/17 50,000.00
Dr. Tuveson 10/16/14 10/15/15 50,000.00 *
Carol Marcincuk Fund Dr. Tonks 09/25/14 09/24/15 9,585.00 *
The G. Harold and Leila Y. Mathers 
Charitable Foundation
Dr. Mitra 01/01/14 12/31/16 330,000.00 *
Breast Cancer Awareness Day in Memory 
of Elizabeth McFarland
Dr. Wigler 01/01/14 12/31/15 81,592.00 *
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The McKnight Endowment Fund for 
Neuroscience
Dr. Churchland 07/01/12 06/30/15 $  75,000.00
Dr. Kepecs 02/01/14 01/31/17 100,000.00 *
The John Merck Fund Dr. Churchland 06/01/11 05/31/15 75,000.00
The Don Monti Memorial Research 
Foundation
Drs. Stillman/Tonks 03/01/08 02/28/16 500,000.00
Louis Morin Charitable Trust Dr. Tuveson 12/01/14 11/30/15 115,000.00 *
State of New York Department of Health/ 
Empire State Stem Cell Fund
Dr. Enikolopov 06/01/14 05/31/17 358,948.00 *
Nimbus Discovery, Inc. Dr. Tuveson 12/15/14 12/14/15 75,000.00 *
In Memory of Jack O’Brien Dr. Hicks 08/01/14 07/31/15 10,010.00 *
Omicia, Inc. Dr. G. Lyon 11/17/14 11/16/15 10,000.00 *
Pancreatic Cancer UK Dr. Tuveson 10/23/12 10/22/15 65,000.00
Mr. Joe Paternoster Dr. Vakoc 09/16/14 09/15/15 10,000.00 *
Mr. Paul J. Paternoster Dr. Vakoc 09/16/14 09/15/15 10,000.00 *
Pershing Square Sohn Cancer Research 
Alliance
Dr. Trotman 07/01/14 06/30/17 200,000.00 *
The Pew Charitable Trusts Dr. Albeanu 08/01/12 07/31/17 60,000.00
Dr. Churchland 08/01/14 07/31/19 60,000.00 *
Dr. Hannon 01/01/11 12/31/15 355,063.00
Phi Beta Psi Sorority Dr. Egeblad 08/15/14 08/14/15 54,130.00 *
Pioneer Hi-Bred International, Inc. Dr. Ware 03/15/12 06/30/15 54,873.00
The Hazen Polsky Foundation Dr. Vakoc 01/01/12 12/31/15 50,000.00
Precision Medicine Research Associates, 
LLC
Dr. Tuveson 03/20/14 03/19/15 157,836.00 *
Dr. Tuveson 12/01/14 11/30/15 268,390.00 *
Prostate Cancer Foundation Dr. Hicks 09/01/13 08/31/15 184,325.00
Christina Renna Foundation Inc. Dr. Van Aelst 02/01/14 01/31/15 20,000.00 *
Marie Robertson Memorial Fund CSHL Neuroscience Program Support 01/01/14 12/31/14 34,375.00 *
Diane Emdin Sachs Memorial Fund Dr. Sordella 09/01/12 08/31/15 1,233.00
Eleanor Schwartz Charitable Foundation Dr. Tuveson 08/01/14 07/31/17 200,000.00 *
Mr. Doug Shorenstein Dr. Tuveson 03/01/13 02/28/15 25,000.00
The Simons Foundation Dr. Churchland 07/01/14 06/30/17 200,000.00 *
Dr. Huang 08/01/14 07/31/17 82,473.00 *
Dr. Mills 08/01/14 07/31/15 212,100.00 *
Dr. Shea 01/01/14 12/31/14 81,970.00 *
The Sontag Foundation Dr. Zheng 10/01/13 09/30/17 150,000.00
Starr Cancer Consortium Drs. Hannon/Atwal 01/01/14 12/31/15 396,000.00 *
Dr. Tuveson 01/01/14 12/31/15 192,000.00 *
The Swartz Foundation Dr. Zador 01/01/14 12/31/14 75,000.00 *
Friends of the TJ Foundation Inc. Dr. Vakoc 09/16/14 09/15/15 50,000.00 *
Joan & Sanford I. Weill Medical College Dr. Fearon 07/01/14 06/30/19 165,061.90 *
Whitehall Foundation, Inc. Dr. Albeanu 01/01/12 12/31/14 75,000.00
Dr. Shea 09/01/11 08/31/15 70,740.00
Women’s Partnership for Science Dr. Joshua-Tor 01/01/14 12/31/14 174,631.64 *
Dr. Timmermans 01/01/14 12/31/14 162,659.44 *
Elisabeth R. Woods Foundation Inc. Dr. Sordella 09/27/13 09/26/15 9,000.00
The WTFC Organization, Inc. Dr. Tonks 07/15/14 07/14/15 5,500.00 *
The Bradley Zankel Foundation, Inc. Dr. Zheng 01/22/14 01/21/15 15,000.00 *
Fellowship Support
Agricultural Biotechnology Center Dr. Benkovics 05/01/13 07/04/15 18,862.00
American Cancer Society Dr. Ardito 07/01/13 06/30/16 50,000.00
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Boehringer Ingelheim Fonds M. Delas Vives 08/01/13 07/31/15 $  60,000.00
A. Hohmann 08/01/13 07/31/15 60,000.00
J. Kebschull 08/01/13 07/31/15 60,000.00
Brain and Behavior Research 
Foundation
Dr. Ahrens 01/15/14 01/14/16 30,000.00 *
Dr. Horev 01/15/14 01/14/16 30,000.00 *
Dr. Y. Kim 01/15/14 01/14/16 30,000.00 *
Dr. K. Krishnan 01/15/14 01/14/16 30,000.00 *
Dr. J. Lu 01/15/13 01/14/15 30,000.00
Dr. Paul 01/15/13 01/14/15 30,000.00
Terri Brodeur Breast Cancer Fund Dr. Anczukow 01/01/13 12/31/14 50,000.00
Marie Curie International Outgoing 
Fellowships for Career Development
Dr. Hangya 01/01/13 12/31/14 100,718.98
Dr. Benkovics 05/01/13 04/04/15 84,460.00
European Molecular Biology 
Organization
Dr. Claeys 07/01/14 04/30/16 43,765.00 *
Genentech Foundation Watson School of Biological Sciences 10/01/12 09/30/15 58,751.00
German Research Foundation Dr. Knauer 05/01/14 04/30/16 27,000.00 *
Dr. Kuettner 09/01/14 08/31/16 12,160.00 *
Lola A. Goldring Dr. Stillman 10/01/14 09/30/15 85,000.00 *
Hope Funds for Cancer Research Dr. Knott 07/01/12 06/30/15 50,500.00
Human Frontier Science Program Dr. Elyada 04/01/14 03/31/17 61,080.00 *
Dr. Huilgol 04/01/14 03/31/17 51,720.00 *
Dr. Livneh 01/01/14 12/31/16 52,500.00 *
Dr. Malinauskas 04/01/14 03/31/17 51,720.00 *
International Rett Syndrome Foundation Dr. He 02/01/13 08/15/14 27,083.61
International Society of Computational 
Biology
Dr. Ballouz 06/04/14 06/03/15 900.00 *
Dr. Verleyen 06/04/14 06/03/15 900.00 *
Annette Kade Charitable Trust Watson School of Biological Sciences 10/15/14 10/14/15 25,000.00 *
Mr. and Mrs. John Phelan Watson School of Biological Sciences 09/01/10 08/31/15 100,000.00
Damon Runyon Cancer Research 
Foundation
Dr. Chio 10/01/13 09/30/17 52,000.00
Dr. Sabin 01/01/12 12/31/15 52,000.00
Sass Foundation for Medical Research Inc. Dr. Roe 06/01/13 05/31/15 50,000.00
Lauri Strauss Leukemia Foundation Dr. Roe 12/01/14 11/30/15 12,500.00 *
The Swartz Foundation Drs. Albeanu/Anselmi 01/01/14 12/31/14 55,000.00 *
Drs. Churchland/Kaufman 01/01/14 12/31/14 55,000.00 *
Drs. Koulakov/Ferrente 01/01/14 12/31/14 55,000.00 *
Dr. Zador 01/01/14 12/31/14 15,000.00 *
Umea University Dr. Olund 12/01/12 11/30/14 12,520.00
Vasterbottens Lans Landsting/Swedish 
Research Council
Dr. Olund 01/01/14 12/31/14 22,140.00 *
Vasterbottens Lans Landsting Dr. Olund 01/01/14 12/31/14 19,581.85 *
Training Support
New York State Department of Economic 
Development
Dr. Mills, Postdoctoral Cancer 
Research Training
11/01/12 10/31/17 144,301.00
The Lita Annenberg Hazen Foundation Undergraduate Research Support 05/01/08 04/30/18 10,000.00
William Townsend Porter Foundation Undergraduate Research Support 04/01/14 03/31/15 13,500.00 *
University of Maryland Undergraduate Research Support 06/01/14 05/31/15 8,700.00 *
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Meeting Support
Anonymous Plasmids: History & Biology 07/08/14 07/07/15 $  15,000.00 *
Bethyl Laboratories, Inc. The Cell Cycle 05/20/14 05/19/15 13,000.00 *
Calico Life Sciences LLC Molecular Genetics of Aging 07/24/14 07/23/15 5,000.00 *
The Company of Biologists LTD Avian Model Systems 02/01/14 01/31/15 6,448.40 *
Dr. Gerald J. Cordani Meeting Support 03/26/14 03/25/15 1,000.00 *
Forest Research Institute, Inc. 79th CSHL Symposium on Quantitative 
Biology Cognition
04/24/14 04/23/15 50,000.00 *
Gilead Sciences Inc. Retroviruses 05/01/14 04/30/15 12,500.00 *
GlaxoSmithKline, LLC Molecular Genetics of Aging 11/11/13 11/19/14 5,000.00
Illumina, Inc. Avian Model Systems 02/01/14 01/31/15 3,000.00 *
The Lalor Foundation, Inc. Germ Cells 08/06/14 08/05/15 8,000.00 *
Life Sciences Foundation Plasmids: History & Biology 07/08/14 07/07/15 2,500.00 *
March of Dimes Foundation Germ Cells 05/28/14 05/27/15 7,500.00 *
Medimmune, LLC Plasmids: History & Biology 07/08/14 07/07/15 2,500.00 *
Merck Sharp & Dohme Corp. Neurodegenerative Diseases: Biology & 
Therapeutics
10/15/14 10/14/15 5,000.00 *
Monsanto Company Plasmids: History & Biology 07/08/14 07/07/15 2,500.00 *
Mr. Richard P. Novick Plasmids: History & Biology 07/08/14 07/07/15 5,000.00 *
Regeneron Pharmaceuticals Inc Personal Genomes: Discovery, Treatment 
& Outcomes
10/15/14 10/14/15 10,000.00 *
Society for Developmental Biology Avian Model Systems 02/25/14 02/24/15 4,000.00 *
Society for General Microbiology Plasmids: History & Biology 07/08/14 07/07/15 10,155.54 *
The Swartz Foundation 79th CSHL Symposium on Quantitative 
Biology Cognition
05/01/14 04/30/15 25,000.00 *
University of Arizona Avian Model Systems 02/01/14 01/31/15 1,000.00 *
Course Support
American Brain Tumor Association Brain Tumors 02/01/14 01/31/15 25,000.00 *
Howard Hughes Medical Institute Course Support 08/01/11 07/31/15 600,000.00
Illumina, Inc. Advanced Sequencing Technologies and 
Applications
11/01/13 10/31/14 10,000.00
Nancy Lurie Marks Foundation Genetics and Neurobiology of Language 07/01/12 06/30/16 50,000.00
Library Support
The Ellen Brenner Memorial Fund 12/15/14 12/14/15 2,000.00 *
Howard Hughes Medical Institute 10/01/14 09/30/15 110,812.00 *
The New York State Education 
Department
07/01/14 06/30/15 3,804.00 *
Library Meeting Support
Lexogen GmbH Messenger RNA: From Discovery to 
Synthesis and Regulation in Bacteria 
and Eukaryotes
03/18/14 03/17/15 778.20 *
Life Sciences Foundation Messenger RNA: From Discovery to 
Synthesis and Regulation in Bacteria 
and Eukaryotes
03/18/14 03/17/15 2,500.00 *
New England Biolabs, Inc. Messenger RNA: From Discovery to 
Synthesis and Regulation in Bacteria 
and Eukaryotes
03/18/14 03/17/15 10,000.00 *
The Rockefeller University Messenger RNA: From Discovery to 
Synthesis and Regulation in Bacteria 
and Eukaryotes
03/18/14 03/17/15 40,000.00 *
DNA LEARNING CENTER GRANTS
Grantor Program
Duration 
of Grant
2014 
 Funding†
FEDERAL GRANTS
National Institutes of Health Barcode Long Island 7/14–3/19 48,628
National Science Foundation Infrastructure and Training to Bring Next-Generation Sequence (NGS) 
Analysis into Undergraduate Education
9/13–8/16 198,670
National Science Foundation Gramene, Cereal Comparative Genomics 6/12–9/14 28,460
National Science Foundation, 
University of Arizona
iPlant Collaborative: Cyberinfrastructure for the Life Sciences 9/13–8/18 873,877
National Science Foundation Advanced Technology Education (ATE) Genomic Approaches in BioSciences 4/11–3/15 239,397
NONFEDERAL GRANTS
Beijing No. 166 High School Chinese Collaboration Agreement 5/14–4/15 16,780
Alfred P. Sloan Foundation DNA Center NYC start-up 12/13–11/16 138,993
Alfred P. Sloan Foundation High-Performance Computing in Undergraduate Biology Education 5/14–9/14 11,207
National Grid Foundation Scholarships for Minority and Underserved Students in the Central 
Islip Union Free School District
10/14–10/15 15,000
Pinkerton Foundation Urban Barcode Research Program 1/13–5/15 156,535
The Bank of America 
Charitable Foundation
Genetics and Biotechnology Lab 11/14–11/15 20,000
William Townsend Porter 
Foundation
Harlem DNA Lab for Underprivileged Students 4/14–3/15 13,500
The following schools and school districts each contributed $1,000 or more for participation in the Curriculum Study program:
Bellmore–Merrick Central High School District 1,500 Levittown Union Free School District 1,500
East Meadow Union Free School District 1,500 Long Beach City School District 1,500
East Williston Union Free School District 2,750 North Shore Central School District 1,500
Elwood Union Free School District 1,500 North Shore Hebrew Academy 1,500
Fordham Preparatory School 1,500 Oceanside Union Free School District 1,500
Garden City Union Free School District 1,500 Oyster Bay–East Norwich Central School District 1,500
Great Neck Union Free School District 1,500 Plainedge Union Free School District 1,500
Green Vale School 1,500 Plainview–Old Bethpage Central School District 1,500
Half Hollow Schools Central School District 1,500 Portledge School 1,500
Harborfi elds Central School District 1,500 Port Washington Union Free School District 1,500
Herricks Union Free School District 1,500 Ramaz Upper School 1,500
Huntington Union Free School District 1,500 Roslyn Union Free School District 1,500
Island Trees Union Free School District 3,000 Syosset Central School District 1,500
Jericho Union Free School District 3,000
The following schools and school districts each contributed $1,000 or more for participation in the Genetics as a Model for 
Whole Learning program:
Bais Yaakov Academy for Girls 1,200 Locust Valley Central School District 9,582
Bellmore Union Free School District 2,400 Merrick Union Free School District 3,900
Bellmore–Merrick Union Free School District 4,200 M.S. 447, Brooklyn 1,800
Berkeley Carroll School 1,300 North Bellmore Union Free School District 2,600
Cold Spring Harbor Central School District 12,600 North Shore Central School District 1,050
East Meadow Union Free School District 3,828 Oceanside Union Free School District 1,625
East Williston Union Free School District 2,900 Oyster Bay–East Norwich Central School District 3,175
Elwood Union Free School District 3,725 Portledge School 2,400
Floral Park–Bellerose Union Free School District 7,500 Port Washington Union Free School District 10,300
Franklin lakes Public Schools, NJ 1,300 Redeemer Lutheran School 1,300
Friends Academy 3,300 Rockville Centre Union Free School District 6,240
Friends Seminary of New York 1,100 Roslyn Union Free School District 5,250
Garden City Union Free School District 11,655 Saint Dominic Elementary School 4,200
Great Neck Union Free School District 8,250 Saint Joseph School 2,400
Half Hollow Hills Union Free School District 1,284 Saint Patrick School 5,000
Herricks Union Free School District 2,275 Scarsdale Union Free School District 6,300
Hicksville Public Schools 1,400 Smithtown Union Free School District 1,680
Hofstra STEP 1,500 Syosset Union Free School District 38,800
Holy Child Academy 1,600 Three Village Central School District 2,800
Huntington Union Free School District 8,275 Valley Stream Union Free School District 13 1,050
Jericho Union Free School District 9,450 YBH of Passaic 1,400
Lawrence Union Free School District 2,100 Yeshiva Darchei Torah 2,775
Lindenhurst Union Free School District 1,000
†Includes direct and indirect costs.
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BANBURY CENTER GRANTS
Grantor Program
Duration 
of Grant
2014 
Funding
FEDERAL SUPPORT
National Institute of Mental Health Brain Camp VI 2014 $ 26,500
National Science Foundation High Performance Computing in Undergraduate Biology 
Education: Scanning the Landscape
2014 29,000
NONFEDERAL SUPPORT
American College of Medical Genetics 
and Genomics (ACMG)
Genetics Training in the Genomic Era 2014 33,920
Boehringer Ingelheim Fonds Science—Get It Across! 2014 60,967
Bring Change 2 Mind The College Toolbox Project: Eliminating Stigma 2014 7,500
Cold Spring Harbor Laboratory 
Corporate Sponsor Program
Interpreting Personal Genomes: How Are We to Set 
Appropriate Statistical Standards for Identifying 
Pathogenic Variants?
2014 52,362
Cold Spring Harbor Laboratory 
Corporate Sponsor Program
Epigenetics and Agriculture 2014 59,398
Cold Spring Harbor Laboratory Offi ce 
of Development
Defeating Ovarian Cancer 2014 10,000
Dana Foundation Lewy Body Dementia: Current Status, Future Directions 2014 10,000
Friends of TJ Foundation Rhabdomyosarcoma: A Critical Review of Research and What 
It Means for Developing Therapies
2014 20,000
Nelson DeMille Lewy Body Dementia: Current Status, Future Directions 2014 5,000
Jonathan Gray Defeating Ovarian Cancer 2014 25,000
Indiana University Foundation The College Toolbox Project: Eliminating Stigma 2014 7,500
Indiana University The College Toolbox Project: Eliminating Stigma 2014 6,360
The Margaret Clark Morgan Foundation The College Toolbox Project: Eliminating Stigma 2014 2,120
The Mayday Fund Genetics of Pain and Pain Inhibition 2014 56,250
Oliver Grace Cancer Fund The Immune System and Cancer 2014 40,852
Oliver Grace Cancer Fund ROS in Biology and Cancer 2014 53,801
Oliver Grace Fund Lewy Body Dementia: Current Status, Future Directions 2014 20,700
Michelle Paternoster Foundation for 
Sarcoma Research
Rhabdomyosarcoma: A Critical Review of Research and 
What It Means for Developing Therapies
2014 20,000
Mr. & Mrs. Howard Phipps Interdisciplinary Symposium on Creativity 2014 15,000
Prothena Biosciences Inc. Lewy Body Dementia: Current Status, Future Directions 2014 10,000
The Daniel & Joanna S. Rose Fund Interdisciplinary Symposium on Creativity 2014 15,000
Alfred P. Sloan Foundation High Performance Computing in Undergraduate Biology 
Education: Scanning the Landscape
2014 15,500
Society of Biological Psychiatry Brain Camp VI 2014 710
The Swartz Foundation Connections and Communications in the Brain 2014 44,337
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CORPORATE SPONSOR PROGRAM 
FOR MEETINGS SUPPORT
The Corporate Sponsor Program continues to provide critical funding for the vigorous meetings 
program held at Cold Spring Harbor Laboratory, whether at Grace Auditorium on the main 
Laboratory campus or at the Banbury Center. Without the strong foundation provided by the 
Program, we could neither plan with confi dence for the year’s meetings nor introduce new and 
unusual topics.
Raising funds for this program continues to be challenging even as the economy improves. We 
are thus especially grateful to the companies that joined us in 2014.
The members of the Program receive special privileges in acknowledgment of their contribu-
tions. We waive all on-site fees for eight representatives of the Corporate Sponsors at our meetings. 
Three scientists from Sponsors may attend meetings at the Banbury Center, where attendance is 
otherwise only by invitation of the organizers. Member companies also receive gratis copies of 
Cold Spring Harbor Laboratory Press publications, including the journals Genes & Development, 
Genome Research, and RNA.
We acknowledge our Sponsors in all relevant publications, including the books of abstracts 
given to each of the 7,000 participants who come to the meetings each year. The names of the 
sponsoring companies are listed on the poster describing the meetings, and this is mailed to ap-
proximately 17,000 scientists throughout the world. In addition, the companies are listed on the 
Cold Spring Harbor Laboratory website on the Meetings Offi ce and Banbury Center pages. Mem-
bers in 2014 were as follows.
CORPORATE SPONSORS PLANT CORPORATE SPONSORS
Agilent Technologies, Inc. Monsanto Company
Bristol-Myers Squibb Company 
Genentech, Inc. FOUNDATIONS
Life Technologies  Hudson-Alpha Institute for Biotechnology
(part of Thermo Fisher Scientifi c) 
New England BioLabs, Inc. 
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DEVELOPMENT
In celebration of the 125th anniversary of Cold Spring Harbor Laboratory (CSHL), we refl ect 
on the many people who have shaped this great institution and helped it become one of the most 
revered scientifi c organizations in the world. As Vice President for Development, I have had the 
privilege to work closely with our dedicated donors and friends, including Marilyn and Jim Si-
mons, Cathy Soref, Ginny Knott, Mary Lindsay, Kristina Davison, and so many others.
The Laboratory not only has a long history of world-class science, it also has a legacy of in-
volvement among on the part of and their families. One example is the Davenport/Spire family. 
In 1969, newly appointed Director of Cold Spring Harbor Laboratory Jim Watson expressed his 
hope to fi nd an “angel” donor to support CSHL’s new cancer research program in an article in the 
Long Island Press. John and Edna Davenport responded to his plea, donating more than $100,000 
of Pfi zer stock for building an extension to James Laboratory. This extraordinary gift provided 
critical support for the tumor virus program, enabling the Laboratory to establish itself as a world 
leader in cancer research. Over the years, John and Edna’s family has stayed involved, support-
ing the Laboratory’s education and research programs. In 2014, through a friendship with John’s 
grandson Bill, the Laboratory received a $3 million pledge to name “the Edna and John Davenport 
Genetic Screening Facility,” an invaluable shared resource critical to many of our scientists’ work.
In 2014, we raised almost $6.7 million in unrestricted funding, largely due to the overwhelm-
ing success of the Double Helix Medal Dinner. This year, we proudly honored Matt Meselson, 
Andrew Solomon, and Marlo Thomas for their uncompromising passion and hard work toward 
improving human health and changing the world for the better.
This is truly a year to celebrate both Cold Spring Harbor Laboratory and our generous support-
ers. Thank you for always believing in the work we do and partnering with us on this incredible 
journey toward a healthier world.
  Charles V. Prizzi, Vice President for Development and Community Relations
Bill and Heather Spire at CSHL’s President’s Council receptionEdith Seligson, Kate Friedman, and Kristina Perkin Davison with 
Alan Alda at the Double Helix Medal Dinner
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Cold Spring Harbor Laboratory Association
The Cold Spring Harbor Laboratory Association (CSHLA) continues to be instrumental in its 
support of CSHL. Members continue to generously host outreach events and introduce friends 
and colleagues to the Laboratory to raise awareness of CSHL’s cutting-edge research and educa-
tion programs. The year 2014 saw more unrestricted funding raised than ever before. With events 
spearheaded by directors of the Association with new president Frank O’Keefe at the helm, more 
than $7 million were raised. Some of this important funding resulted from events that were sup-
ported by the Association, its directors, community members, major donors, foundations, and 
corporate sponsors, including the 13th annual Women’s Partnership for Science luncheon, the 
21st annual golf tournament at Piping Rock Club, and the 9th annual Double Helix Awards din-
ner honoring Matt Meselson, Andrew Solomon, and Marlo Thomas for their efforts in bringing 
awareness to disease research.
Directors
2014 Directors
Frank O’Keefe, President
James A. Woods, Treasurer
Virginia Knott, Secretary
Honorary Directors
Mary D. Lindsay
Anne R. Meier
Cathy Cyphers Soref
Pearl F. Staller
Elizabeth Ainslie
Lori Bahnik
Hans E.R. Bosch
Edward A. Chernoff
Susan A. Cohen
Maria de Lesseps
Nelson DeMille
Carolyn Gulotta
Nancy Lippman Israeli, M.D.
Joel J. Kassimir, M.D.
Kassahun Kebede
Laureen Stanton Knutsen
Suzanne Leeds
Jeffrey A. Nagel
Timothy Q. O’Neill
Olga Pharr
Whitney F. Posillico
Charles S. Ryan, Ph.D.
Caroline Monti Saladino
Tracey DeMatteis Serko
Lonnie Shoff
Hope Geier Smith
Heather Lane Spehr
Nancy Szigethy
Peter S. Tilles
Lara S. Trafelet
Marjorie J. van de Stouwe, M.D.
2014 CSHLA Directors
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Cold Spring Harbor Laboratory Corporate Advisory Board
The Corporate Advisory Board (CAB) is comprised of prominent business leaders from the 
tristate community and is a vital source of funding and outreach for Cold Spring Harbor Labo-
ratory. Board members are the driving force behind the Laboratory’s annual golf outing at Pip-
ing Rock Club, which raises critical unrestricted funding for research and education programs. 
CAB president Eddie Chernoff graciously chaired his 10th CSHL outing, which honored CSHL 
Trustee, CAB member, and longtime friend to the Lab, Ed Travaglianti, and more than $175,000 
was raised.
Corporate Advisory Board
Edward A. Chernoff, MARS, Chairperson
Michael Aboff, Aboff ’s Inc.
Paul Amoruso, Oxford & Simpson Realty
Rocco S. Barrese, Dilworth & Barrese
Edward Blaskey, TD Bank
Thomas J. Calabrese, Daniel Gale Sotheby’s International Realty
Christopher Callaghan, GFI Group
Jeffrey Carstens, Capital One
Richard A. Catalano, KPMG, LLP
Jonathan Connors, Wells Fargo
Marian Conway, New York Community Bank Foundation
J. Daniel Decker, Eppendorf North America
Robert Dickstein, Ph.D., Pall Corporation
Kevin Foley, Fidelity
Brian Fox, McKinsey & Company
Brian Goldstein, M.D.
Lawrence Goodman, Curtis, Mallet-Prevost, 
Colt & Mosle LLP
Mary Jane Helenek, Luitpold Pharmaceuticals
Diana Hoadley, JP Morgan
Richard W. Humann, H2M
Robert Isaksen, Bank of America
M. Patricia Janco, Wells Fargo
Neil M. Kaufman, Abrams Fensterman
John C. Kean III, Kean Development Corporation
Norman Kelker, Enzo Life Sciences
Robert Keller, National Grid Foundation
Amy Koreen, M.D.
Laurie J. Landeau, V.M.D.
Victoria Meagher
Rob Palatnick, DTTC
John G. Passarelli, M.D.
David Peikon
Patricia Petersen, Daniel Gale Sotheby’s International Realty
Stephen Ross, Ph.D., Nikon Instruments
Raju Sarwal, M.D.
Nancy Szigethy, NMS Management
Edward Travaglianti, TD Bank
Andrew Whiteley, Enzo Life Sciences
Joseph M. Willen, Advantage Title
Hans Zobel
CAB Chairman Eddie Chernoff (right) with Bryan McMillen, Pat Petersen, and 
Brando Casalicchio
CSHL Board Member and Golf Honoree Ed Travaglianti 
(left) with Paul Amoruso and Chris Giamo
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Honor Roll of Donors
Contributions of $5 million+ lifetime
Anonymous
Estate of Donald E. Axinn
The Arnold and Mabel Beckman 
Foundation
Jamie Nicholls and Fran Biondi
David Boies, Chairman of Boies, Schiller 
& Flexner LLP
The Breast Cancer Research Foundation
Mr. and Mrs. Landon T. Clay
The Dana Foundation
Mr. and Mrs. Norris W. Darrell
Dart Neurosciences LLC
Estate of Kathryn W. Davis
DeMatteis Family Foundation
Mr. and Mrs. Charles F. Dolan—Dolan 
Family Foundation
The William Stamps Farish Fund
Estate of Robert B. Gardner, Jr.*
Gen*NY*Sis grant from New York State 
Dormitory Authority
Kate Medina Guthart and Leo A. Guthart
Howard Hughes Medical Institute
W.M. Keck Foundation
Mr. and Mrs. David H. Koch
Laurie J. Landeau, V.M.D. and the Laurie 
J. Landeau Foundation
Mr. and Mrs. Robert D. Lindsay and 
Family
Estate of Elisabeth Sloan Livingston
The Lustgarten Foundation
Lucille P. Markey Charitable Trust
Nancy Abeles Marks
The Don Monti Memorial Research 
Foundation
New York State Empire State 
Development Corporation
Pershing Square Foundation
The Honorable and Mrs. Leon Polsky—
Hazen Polsky Foundation
The Quick Family
The Robertson Family—Banbury Fund
The Seraph Foundation
Drs. Marilyn and James Simons
The Simons Foundation
Alfred P. Sloan Foundation
St. Giles Foundation
Theodore R. Stanley—Stanley Medical 
Research Institute
The Starr Foundation
Thompson Family Foundation
Dr. and Mrs. James D. Watson
Mr. and Mrs. Henry Wendt III
The Roy J. Zuckerberg Family Foundation
Contributions of $1 million+ lifetime 
or $100,000 in 2014
Paul G. Allen Foundation
Angel Foundation
Anonymous (4)
Gonzalo Río Arronte Foundation
Lalit and Kavita Bahl
BioBay of Suzhou Venture Capital Group
Booth Ferris Foundation
Bristol-Myers Squibb Company
Burroughs Wellcome Fund
The Mary K. Chapman Trust
Cutler Family Education and Animal 
Welfare Fund
Michel David-Weill
Ira W. DeCamp Foundation
Edward P. Evans Foundation
Charitable Lead Annuity Trust—Will of 
Louis Feil
Samuel Freeman Charitable Trust
Coleman Fung Foundation
Robert L. Garland*
Mr. and Mrs. Robert A. Gay
Genentech, Inc.
Kenyon Gillespie
Jacob Goldfi eld
Lola Goldring
The Florence Gould Foundation
The Grace Family
The Harrison Foundation and The Mary 
Anderson Harrison Foundation
Thomas Hartman Foundation for 
Parkinson’s Research
Janet Strauss and Jeff Hawkins
Jo-Ellen and Ira Hazan
William Randolph Hearst Foundation
The Karches Foundation
Walter B. Kissinger
Mr. and Mrs. John Klingenstein—The 
Esther A. and Joseph Klingenstein 
Fund, Inc.
Elise H. Knight
Mr. and Mrs. David M. Knott
The Forrest C. and Frances H. Lattner 
Foundation
Betsy and Bryan H. Lawrence
Mara and Thomas Lehrman
The Lehrman Institute
Mr. and Mrs. Stephen M. Lessing
Mary D. Lindsay
The Litchfi eld Charitable Trust
Louis Morin Charitable Trust
Lisa Lourie
Dr. Robert W. Lourie
Mr. and Mrs. David L. Luke III*
Josiah Macy, Jr. Foundation
Manhasset Women’s Coalition Against 
Breast Cancer
The G. Harold and Leila Y. Mathers 
Charitable Foundation
Gillian and Eduardo Mestre
Mr. and Mrs. William R. Miller
Dr. and Mrs. Howard L. Morgan
Estate of Dr. Thomas C. Nelson
OSI Pharmaceuticals, LLC
David and Lucile Packard Foundation
The Pew Charitable Trusts
Amy and John Phelan
William and Maude Pritchard Charitable 
Trust
Fannie E. Rippel Foundation
The Robertson Foundation
Mr. and Mrs. David M. Rubenstein
Raymond and Beverly Sackler Foundation
Eleanor Schwartz Charitable Foundation
Edith and Alan Seligson
Jeanne and Herbert J. Siegel
Mr. and Mrs. Howard Solomon
Mr. and Mrs. Erwin P. Staller
Dr. and Mrs. James M. Stone
Dr. Jerome Swartz—The Swartz 
Foundation
CSHL President Bruce Stillman with the 2014 Double Helix Medals honorees Matt Meselson, 
Marlo Thomas, and Andrew Solomon
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Waclaw T. Szybalski, D.Sc.
Mr. and Mrs. Paul J. Taubman
Whitehall Foundation, Inc.
Contributions of $50,000+ 
The Achelis Foundation
Anonymous
Cedar Hill Foundation
Mr. and Mrs. Edward A. Chernoff—
MARS
Ellen and Casey Cogut
Claire Friedlander Family Foundation
Genentech Foundation
The Clark Gillies Foundation
Joni Gladowsky Breast Cancer Foundation
Mr. and Mrs. Jeffrey E. Kelter
Breast Cancer Awareness Day in Memory 
of Elizabeth McFarland
Mr. and Mrs. Douglas P. Morris
Nimbus Discovery, Inc.
The Sass Foundation for Medical 
Research
Hope Geier Smith and Theodore 
Smith III
Swim Across America Nassau/Suffolk
The Friends of T.J. Foundation
Wodecroft Foundation
Contributions of $25,000+ 
Annette Kade Charitable Trust
Ashley and Frank O’Keefe
Dr. and Mrs. Mark S. Ptashne—The Joe 
Lewis Jefferson Foundation, Inc.
Dr. and Mrs. Stuart T. Weisbrod
Dr. and Mrs. Thomas P. Maniatis
Drs. Maria and Charles Ryan—Forest 
Laboratories, Inc.
Drs. Nancy and Ron Israeli
Francis Goelet Charitable Lead Trusts
Hearts for Cancer
Ike, Molly and Steven Elias Foundation
John and Laura Desmarais
Jon and Mindy Gray Family Foundation
Life Technologies
Long Island Real Estate Group, Inc.
Loren Eng and Dinakar Singh
Louise Parent and John Casaly
Mr. and Mrs. Claudio Del Vecchio
Mr. and Mrs. Douglas W. Shorenstein
Mr. and Mrs. Francis J. Ingrassia
Mr. and Mrs. Geoffrey de Lesseps—
Alpha/Omega Charitable 
Foundation
Mr. and Mrs. Harry Slatkin
Mr. and Mrs. James F. Stebbins
Mr. and Mrs. Louis Moore Bacon
Mr. and Mrs. Oliver R. Grace, Jr.—
OBX, Inc.
Mr. and Mrs. Ronald A. Gottlieb
Mr. and Mrs. Thomas A. Saunders III
Pall Corporation
Pamela Hurst-Della Pietra and Stephen 
Della Pietra
Paul J.R. Paternoster
Pfi zer, Inc.
Pien and Hans Bosch
Susan T. Harris
Susan Wasserstein and George Sard
The Bahnik Foundation
The Carson Family Charitable Trust
The Irving A. Hansen Memorial 
Foundation
The Marc Haas Foundation
The Morningside Foundation
The Rockefeller University Banbury 
Meeting
Thomas C. Quick
Wilhelmus Johannes Van der Goes
William Townsend Porter Foundation
Contributions of $10,000+ 
Elizabeth and Lee Ainslie
The Bank of America Charitable 
Foundation
Caroline E. Bassett
Blavatnik Family Foundation
Broad Hollow Bioscience Park, Inc.
David P. Brown
Mr. and Mrs. George W. Carmany III
Dr. and Mrs. Bayard D. Clarkson
Dr. Stanley N. Cohen—Banbury 
Meeting
Susan and Glenn Cohen
Samara P. Cohen
Patricia Petersen—Daniel Gale Sotheby’s 
International Realty
Barbara Amonson and Vincent Della 
Pietra
Sandy and Nelson DeMille
Miriam and David Donoho
Eppendorf North America
F.A.C.T. Breast Cancer Foundation
The Fascitelli Family Foundation
Fortunato Sons Contracting, Inc.
Mr. and Mrs. Stephen C. Freidheim
Masthead Cove Yacht Club presents a check to CSHL scientist Dr. Nick Tonks for the Carol 
Marcincuk Fund
Nelson DeMille, Bruce Stillman, Ed Travaglianti, and Sandy DeMille at CSHL’s annual Golf Tournament
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Dr. Alexander Gann
Goddard Family Charitable Foundation
Kappa Alpha Order-University of 
Maryland
Dr. and Mrs. Joel Kassimir
Thomas L. Kempner, Jr. and Katheryn C. 
Patterson
Andrea B. and Peter D. Klein
Laureen and Ragnar M. Knutsen
Mitchell and Karen Kufl ik Charitable 
Foundation
Long Island 2 Day Walk to Fight Breast 
Cancer
Bridget and John Macaskill
Robert L. Marcus
Edward E. Matthews
Marcia Kramer Mayer
Mirus Bio LLC
National Grid Foundation
North Shore-LIJ Health System
Susanne C. Olin
Mr. and Mrs. George D. O’Neill
Wendy O’Neill
Robert and Lauryl Palatnick
Joe Paternoster
Michael Peluso
Mrs. Richardson Pratt, Jr. and Family—
Spionkop Charitable Trust
Mr. and Mrs. Preston V. Pumphrey
Rauch Foundation, Inc.
Mr. and Mrs. John R. Reese
Christina Renna Foundation
Lonnie and Michael Shoff
Deborah K. Solbert
St. Jude Children’s Research Hospital
Grace and Bruce Stillman
Nancy M. Szigethy
TD Bank
Mr. and Mrs. Peter S. Tilles
Joan P. Tilney
Mr. and Mrs. Edward Travaglianti
Sandy and Howard Tytel
Dr. and Mrs. Roy Vagelos
Dr. and Mrs. Fredrick Valauri
West Islip Breast Cancer Coalition for 
Long Island
Elisabeth R. Woods Foundation
Ann Eden Woodward Foundation
The Bradley Zankel Foundation
Karen E. Zoller
Contributions of $5,000+ 
Arlene and Alan Alda
Mr. and Mrs. W. Dillaway Ayres, Jr.
Fred H. Baron
Geoffrey Beene Foundation
Frank and Nancy Bynum—The Bynum 
Family Foundation
Trudy and Tom Calabrese
Mr. and Mrs. Christopher C. Callaghan
Mr. and Mrs. Frank Castagna
Michele and Jim Celestino
Centerbrook Architects and Planners, 
LLC
Rita Cleary
Nancy Parmet Cook and Jim Cook
Milton Cooper
Ide and David Dangoor
Dau Family Foundation
Panera Bread
Dr. Lee MacCormick Edwards Charitable 
Foundation
Diane and Bob Fagiola
Stephen F. Melore, Esq.—Farrell Fritz, P.C.
Michael Focazio-Carissa Maringo Fund
Mr. and Mrs. Roger Fradin
The Deane A. and John D. Gilliam 
Foundation
Glen Cove C.A.R.E.S.
H2M Architects + Engineers
The Randall and Mary Hack Foundation
Robin Hadley
Harvest Real Estate Services, Inc.
Mr. and Mrs. Mark Hoffman
Joan M. Hutchins
J. Fallon’s Tap Room
Kean Development Company, Inc.
The Kebede Family Foundation
The Kleinknecht Family Foundation
Drs. Amy and Roger Koreen
Dan Levy
Mr. and Mrs. Thomas H. Lister
Luitpold Pharmaceuticals, Inc.
Mrs. David J. Mahoney
Carol Marcincuk Fund
Mr. and Mrs. Edward C. Meagher
The Elena Melius Foundation
Mickie and Jeff Nagel
New York Community Bank Foundation
Indra K. Nooyi
Oxford & Simpson Realty Services
David P. Pearson
Amy Falls and Hartley Rogers
Pamela and Richard Rubinstein 
Foundation
Mr. and Mrs. Phillip Satow
Israel Scheut
Mr. and Mrs. Jonathan R. Serko
Mary F. Smith Family Foundation
Mr. and Mrs. Douglas S. Soref
Mr. and Mrs. Richard A. Spehr
Stand Up for Suzanne
The Hastings Foundation
Thermo Fisher Scientifi c
Drs. Marjorie J. van de Stouwe and Scott 
Ratner
Dr. and Mrs. George F. Vande Woude
Mr. and Mrs. Paul A. Vermylen, Jr.
J.B. Vermylen
W.F. Whitman Family Foundation
Deedee and Michael Wigler
Mr. and Mrs. Richard H. Witmer, Jr.
The WTFC Organization
Olivia Flatto, Frank Wisner, Fran Biondi, and Judy Cormier at the 2014 Double Helix Medals
Barbara Buckley of Manhasset Women’s 
Coalition Against Breast Cancer presents a 
check to Dr. Sarah Diermeier for her breast 
cancer research. Also pictured are CSHL 
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